<SEC-DOCUMENT>0001213900-25-097465.txt : 20251008
<SEC-HEADER>0001213900-25-097465.hdr.sgml : 20251008
<ACCEPTANCE-DATETIME>20251008170048
ACCESSION NUMBER:		0001213900-25-097465
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		100
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20251008
DATE AS OF CHANGE:		20251008

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Advanced Biomed Inc.
		CENTRAL INDEX KEY:			0001941029
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			NV

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42548
		FILM NUMBER:		251383010

	BUSINESS ADDRESS:	
		STREET 1:		401 RYLAND ST
		STREET 2:		STE 200-A
		CITY:			RENO
		STATE:			NV
		ZIP:			89502
		BUSINESS PHONE:		86-21-20510823

	MAIL ADDRESS:	
		STREET 1:		401 RYLAND ST
		STREET 2:		STE 200-A
		CITY:			RENO
		STATE:			NV
		ZIP:			89502
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ea0257629-10k_advanced.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Oct 08 20:28:35 UTC 2025 -->
<html xmlns:advb="http://www.advanbiomed.com/20250630" xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-16389">10-K</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="ixv-34"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric>
<b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-16390"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-16391">June 30</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-16392">2025</ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="ixv-49"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric>
<b>TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from _____________ to
___________________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-60"><b>001-42548</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-66"><b>Advanced Biomed Inc.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-76"><span style="font-size: 10pt"><b>Nevada</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-81"><span style="font-size: 10pt"><b>87-2177170</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of<br/>
incorporation or organization)</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">(I.R.S. Employer <br/>
Identification No.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-16393">No. 689-85 Xiaodong Road</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-16394">Yongkang District</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-16395">Tainan City</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-16396">Taiwan</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Telephone: <ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-16397">+ 886</ix:nonNumeric>-<ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-16398">6-3121716</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section 12(b)
of the Act:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Title of Each Class:</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s):</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Name of Each Exchange on Which Registered:</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-132"><span style="font-size: 10pt">Common Stock</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-136"><span style="font-size: 10pt">ADVB</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-16399">Nasdaq</ix:nonNumeric> Stock Market LLC</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section 12(g)
of the Act:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-16400">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-16401">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-16402">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-16403">Yes</ix:nonNumeric>
<span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 25%"><span style="font-size: 10pt">Large accelerated filer</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%"><span style="font-size: 10pt">Accelerated filer</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-192"><span style="font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Smaller reporting company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-199"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td><span style="font-size: 10pt">Emerging growth company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-207"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="ixv-213"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="ixv-219"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-225"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-237"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the shares of Common
Stock, par value $0.001 per share, held by non-affiliates of the registrant as of June 30, 2025, was approximately $<ix:nonFraction contextRef="c1" decimals="-4" name="dei:EntityPublicFloat" scale="6" unitRef="usd" id="ixv-16404">4.43</ix:nonFraction> million, based
on the closing sale price per share of the registrant&#8217;s common stock as reported by the Nasdaq Capital Market on such date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of October 8, 2025, Advanced Biomed Inc. had
<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-16405">21,640,000</ix:nonFraction> shares of outstanding Common Stock, par value $0.001 per share.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 1; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; width: 8%">&#160;</td>
    <td style="vertical-align: bottom; width: 84%; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><a href="#a_001"><span style="font-size: 10pt">PART I</span></a></td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 1.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><a href="#a_002">Business</a></span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Item 1A.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_003"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">43</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 1B.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_004"><span style="font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">83</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Item 1C</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_005"><span style="font-size: 10pt">Cybersecurity</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">83</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 2.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_006"><span style="font-size: 10pt">Properties</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">84</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Item 3.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_007"><span style="font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">84</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 4.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><a href="#a_008">Mine Safety Disclosures</a></span></td>
    <td style="text-align: center"><span style="font-size: 10pt">84</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#a_009"><span style="font-size: 10pt">PART II</span></a></td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 5.</span></td>
    <td style="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"><a href="#a_010"><span style="font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">85</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 6.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_011"><span style="font-size: 10pt">Reserved</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">86</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Item 7.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_012"><span style="font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">86</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 7A.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><a href="#a_013">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="text-align: center"><span style="font-size: 10pt">101</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Item 8.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_014"><span style="font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td style="text-align: center">101</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 9.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_015"><span style="font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="text-align: center">101</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Item 9A.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_016"><span style="font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="text-align: center">101</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 9B.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_017"><span style="font-size: 10pt">Other Information</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">102</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Item 9C.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_018"><span style="font-size: 10pt">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">102</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><a href="#a_019"><span style="font-size: 10pt">PART III</span></a></td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 10.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_020"><span style="font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">103</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Item 11.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_021"><span style="font-size: 10pt">Executive Compensation</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">107</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 12.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_022"><span style="font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">108</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Item 13.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_023"><span style="font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">110</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 14.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><a href="#a_024"><span style="font-size: 10pt">Principal Accounting Fees and Services</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">112</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#a_025"><span style="font-size: 10pt">PART IV</span></a></td>
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Item 15.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><a href="#a_026">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Item 16.</span></td>
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><a href="#a_027">Form 10-K Summary</a></span></td>
    <td style="text-align: center"><span style="font-size: 10pt">113</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INTRODUCTION </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this annual report on Form
10-K, or this annual report, except where the context otherwise requires and for purposes of this annual report only, references to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">&#8220;Advanced Biomed Taiwan&#8221; refers to Advanced Biomed Inc. (Taiwan);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">&#8220;Advanced Biomed HK&#8221; refers to Advanced Biomed HK Limited;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">&#8220;China&#8221; or &#8220;PRC&#8221; refer to the People&#8217;s Republic of China, including Hong Kong, Macau and Taiwan; however the only time such jurisdictions are not included in the definition of PRC and China is when we reference to the specific laws that have been adopted by the PRC; The term &#8220;Chinese&#8221; has a correlative meaning for the purpose of this Report; The term &#8220;Mainland China&#8221; refers to the People&#8217;s Republic of China, excluding Hong Kong, Macau and Taiwan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">&#8220;CRO&#8221; refers to contract research organization, a type of third-party entity that is engaged by medical device research and manufacturing companies to conduct all or part of the required scientific or medical trials before a medical device can be sold to the public;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span>Common Stock&#8221; refers to shares of our common stock, par value US$0.001 per share</span>;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">&#8220;NMPA&#8221; refers to National Medical Products Administration, formerly known as China Food and Drug Administration;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">&#8220;NTD&#8221; or &#8220;NT$&#8221; refers to New Taiwan Dollar, the legal currency of Taiwan</span><span style="font-size: 10pt">;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;<span>RMB&#8221; or &#8220;Renminbi&#8221; refers to the legal currency of the People&#8217;s Republic of China</span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">&#8220;Initial Public Offering&#8221; refers to the initial primary underwritten public offering of 1,640,000 shares of common stock, par value $0.001 per share, of Advanced Biomed Inc. at US$4.00 per share, completed on March 7, 2025;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">&#8220;Shanghai Sglcell&#8221; or &#8220;Shanghai subsidiary&#8221; refers to Shanghai Sglcell Biotech Co., Ltd., a company incorporated in the People&#8217;s Republic of China and our wholly foreign owned entity 100% owned by Advanced Biomed HK. Shanghai subsidiary is our only subsidiary in Mainland China; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">&#8220;Taiwan&#8221; refers to Taiwan, Penghu, Kinmen, Matsu, and any other areas under the effective control of the government of Republic of China;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;US$,&#8221; &#8220;$&#8221; or &#8220;U.S. dollars&#8221; refers to the legal currency of the United States; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;our company,&#8221; and &#8220;our group&#8221; refer to Advanced Biomed Inc., a Nevada company and its subsidiaries.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
10-K (this &#8220;Report&#8221;) contains forward-looking statements that involve risks and uncertainties. You should not place undue
reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in the forward-looking
statements for many reasons, including the reasons described in our &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management
Discussion and Analysis of Financial Condition and Result of Operations&#8221; sections, as well as those discussed elsewhere in this
Report. In some cases, you can identify these forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;continue,&#8221; &#8220;could,&#8221; &#8220;depends,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;intend,&#8221;
&#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221;
&#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms or other similar expressions, although not all forward-looking
statements contain those words.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations and business
prospects are always subject to risks and uncertainties including, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may fail to develop or bring early cancer detection devices, chips, or kits to market on time or at all, and may not remain competitive. Regulatory approvals may be delayed, limited, or never obtained, significantly impairing our ability to generate revenue;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Disruptions at production sites, regulatory compliance issues, or cybersecurity breaches could delay commercialization, raise costs, or harm our reputation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our ability to obtain and maintain intellectual property protection for our products; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our estimates of expenses, future revenue, capital requirements and our needs for, or ability to obtain, additional financing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The forward-looking statements
in this Report represent our views as of the date of this Report. We anticipate that subsequent events and developments will cause our
views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current
intention to do so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements
as representing our views as of any date subsequent to the date of this Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MARKET DATA AND FORECASTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Report includes estimates
regarding market and industry data. Unless otherwise indicated, information concerning our industry and the markets in which we operate,
including our general expectations, market position, market opportunity, and market size, are based on our management&#8217;s knowledge
and experience in the markets in which we operate, together with currently available information obtained from various third-party sources,
including publicly available information, industry reports and publications, surveys, our customers, trade and business organizations,
and other contacts in the markets in which we operate. Some data is also based on our good faith estimates. The industry in which we operate
is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section entitled &#8220;Risk
Factors.&#8221; These and other factors could cause results to differ materially from those expressed in these publications. If any one
or more of the assumptions underlying the market data turns out to be incorrect, actual results may differ from the projections based
on these assumptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview and Recent Developments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a holding company incorporated
in the State of Nevada. We operate through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the
main operation and the design and development of the company&#8217;s primary technologies and products. Since our establishment in 2014,
we have been focusing on the integration of multiple interdisciplinary technologies and established our own microfluidic technology platform.
Utilizing the physical and molecular biological characteristics of tumor cells, we have developed various advanced and original research
through the joint application of semiconductor technology and biotechnology. This includes complex precision structures, dielectric detection,
functional microfluidic biochips, microfluidic integrated semiconductor sensors, related application modules, and key components of medical
testing equipment. We have also developed a series of medical testing equipment and related products by integrating various functions
of microfluidic modules, automation software, and hardware. Our technologies and products can be used for early screening and detection,
diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers in blood samples,
capture of single circulating tumor cells, and single-cell sorting and determination. These products provide assistance in treatment selection
and patient prognosis intervention once the required licenses and approvals have been obtained. Advanced Biotech HK is our first localized
operation company, mainly responsible for market operation and management in China, localized production, product registration, and future
local market sales of our products in accordance with relevant local regulations in China. Our Shanghai subsidiary owns some of our R&amp;D
equipment and patents and will be responsible for operations related to clinical trials in Mainland China through CROs. In the future,
we also plan to establish operation centers in countries and regions in North America and Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our devices, A<sup>+</sup>Pre,
AC-1000, A<sup>+</sup>CellScan, and A<sup>+</sup>SCDrop, and three corresponding microfluidic biochips, A<sup>+</sup>Pre Chip and AC-1000
CTC Enrichment Chip and A<sup>+</sup>CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer
patients. Among them, A<sup>+</sup>Pre is mainly used to reduce the viscosity of blood samples, and AC-1000 is used to complete the separation
and enrichment of circulating tumor cells (&#8220;CTCs&#8221;) and tumor-related targeted cells in blood samples. The A<sup>+</sup>CellScan
is mainly used for fluorescent labeling and automatic scanning judgment of targeted cells while A<sup>+</sup>SCDrop preserves the original
viability of single cells. A+PerfusC&#8482; system, our latest development, is a compact, all in one perfusion-based 3D cell culture incubator
engineered to replicate human physiological conditions to form 3D tumor spheroids/organoids in vitro. The system supports up to 12 days
of continuous, hands-free culture, reducing the risk of human error and contamination. By maintaining uniform nutrient delivery and preventing
waste accumulation, the platform promotes tumor spheroid and organoid formation, enhancing cell viability, growth, and drug response predictability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we have finished the research and
development stage for four matching immunostaining kits, A<sup>+</sup>CTCE, A<sup>+</sup>CTCM, A<sup>+</sup>EMT and A<sup>+</sup>CM, and
submitted registration applications in China. The immunostaining kit use antibodies combined with fluorescent groups of different colors
to bind to specific proteins on the cell surface or inside the cells. The presence and intensity of fluorescent signals can be observed
through a separate fluorescent imaging system, and the expression of the target protein and the cell type can be judged and determined
accordingly. Different cell types can be distinguished using multiplexed combined staining with different antibodies. The A<sup>+</sup>CTCE
kit is mainly used to identify epithelial circulating tumor cells, the A<sup>+</sup>CTCM kit is used to identify mesenchymal circulating
tumor cells, the A<sup>+</sup>EMT kit is mainly used to identify epithelial-to-mesenchymal circulating tumor cells, and the A<sup>+</sup>CM
kit is used to identify tumor-associated macrophages (cancer-associated macrophage-like cells).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also developed a product
for early screening of lung cancer, the A<sup>+</sup>LCGuard Lung Cancer Early Screening Kit (&#8220;A<sup>+</sup>LCGuard&#8221;), which
is used to assist in the determination of benign and malignant pulmonary nodules. From August 2020 to September 2022, we finalized the
research, design, and development of A<sup>+</sup>LCGuard. A<sup>+</sup>LCGuard is a Class III medical device and is required to conduct
clinical trials before completing the registration process, and we plan to begin A+LCGuard&#8217;s clinical research in November 2025.
We believe clinical research serves as the foundation for clinical trials, bridging the gap between preclinical studies and large-scale
clinical trials. We believe clinical trials enables an understanding of subject recruitment, facilitates the development of appropriate
inclusion and exclusion criteria for later stages, and helps verify trial procedures. Additionally, we believe it increases familiarity
with the trial products. In June 2025, the Company and the CRO began collaborating on drafting the clinical research protocol and started
preparing the necessary equipment, consumables, reagent kits, and other materials for the study. We expect that the clinical research
protocol may pass ethical review and receive ethics committee approval by the end of October 2025. Thereafter, we plan to initiate the
trial stage of the clinical research, with completion anticipated within six months of November 2025. We believe the results of the clinical
research will inform the work plan for future large-scale clinical trials, minimizing waste from an excessively large sample size or insufficient
statistical power due to a sample size that is too small. We recognize that the clinical research results may differ from expectations
and may not support our expected progression to clinical trials. If so, we plan to promptly optimize the product, adjust participant group
selection, and modify the final protocol for large-scale clinical trials. However, we cannot guarantee that any clinical research or trial
will meet our anticipated outcomes. Furthermore, delays in obtaining ethical approval or recruiting participants could prevent the clinical
research from being completed on schedule. Such delays could subsequently postpone the large-scale clinical trial and ultimately the product
launch date.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our products must go
through three steps to receive the required clearance from the NMPA before they can be sold to customers. The three steps are research
and development, registration application, and registration review, which must be done in that order. At the registration application
stage, we have to assemble all the required application materials, complete clinical trials (if required by NMPA), and work with an NMPA
accredited third-party organization to examine our products in accordance with NMPA rules. NMPA will review our application during the
registration review period and may request additional information before officially approving or denying our applications. Currently,
A<sup>+</sup>Pre and AC-1000 and their corresponding chips have been cleared by the NMPA; A<sup>+</sup>SCDrop, A<sup>+</sup>CellScan,
A<sup>+</sup>CellScan Chip, and A<sup>+</sup>LCGuard are at the registration application stage; the four matching immunostaining kits
are under registration review. A<sup>+</sup>LCGuard is a Class III medical device and is required to conduct clinical trials before completing
the registration process. As of the date of this Report, we have not applied for similar clearances from other jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We participated in a scientific
research project at Shanghai Pulmonary Hospital from July 17, 2019 to December 2021, and completed a total of 123 case studies to test
A+Pre, AC-1000 and A<sup>+</sup>LCGuard. In the study, we selected 123 individuals, and among them, 75 were surgical patients with nodular
changes or shadows in the lungs reported by imaging studies and 48 healthy patients without lung nodules reported by imaging studies.
7ml blood samples were taken from test subjects either before the clinical operation (for cancer patients) or after the physical examination
(for healthy individuals), and A<sup>+</sup>Pre, AC-1000, and A<sup>+</sup>LCGuard kits were used to determine whether there were circulating
tumor cells and other tumor markers in the blood samples. Finally, the pathological and physical examination results of the tested individuals
were compared with the test results of our products. Our test results achieved 96% sensitivity and 99.9% specificity, which provides the
research and development basis for our products. Specifically, A+Pre and AC-1000 were at the research and development stage, and we completed
their effectiveness and performance indicators testing through this project. At the same time, A<sup>+</sup>LCGuard finished its feasibility
and functional verification testing. All three products were tested together throughout the entire project.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our products must be
approved by applicable regulatory authorities before being sold to customers. A<sup>+</sup>Pre and A<sup>+</sup>CellScan can work with
third-party products to achieve their designed objectives. AC-1000 and A<sup>+</sup>SCDrop may be used together with other devices according
to different application scenarios below. For the A<sup>+</sup>LCGuard early screening kit, it has to be used in combination with A<sup>+</sup>Pre
and AC-1000. Our four staining kits, A<sup>+</sup>CTCE, A<sup>+</sup>CM, A<sup>+</sup>CTCM, and A<sup>+</sup>EMT, can be used independently
or with third-party products. A<sup>+</sup>Pre, AC-1000, and A<sup>+</sup>CellScan require the use of our supporting microfluidic chips.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">For the analysis of high-viscosity blood samples: A<sup>+</sup>Pre can be independently used for pretreatment, retaining the original cell activity while preventing blood samples from clogging the equipment pipeline after entering the detection equipment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">For the identification and counting application of circulating tumor cells: blood samples are diluted with A<sup>+</sup>Pre, and then AC-1000 is used to separate and enrich circulating tumor cells and related tumor markers. The enriched samples are stained, calibrated, and finally identified and counted. We can provide this service to the public if using third-party staining reagents already on the market in China. However, we plan to officially roll out this service once our in-house developed staining reagents, A<sup>+</sup>CTCE, A<sup>+</sup>CTCM, A<sup>+</sup>EMT and A<sup>+</sup>CM, complete the registration process. The identification and counting of circulating tumor cells and related tumor marker cells can provide auxiliary references for relevant clinical applications.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The capture of circulating tumor cells: we follow the same process as the identification of circulating tumor cells to obtain enriched samples with A<sup>+</sup>Pre and AC-1000, and then the samples are captured and separated by A<sup>+</sup>SCDrop to isolate single circulating tumor cells. This service can provide tumor cells with high purity and high activity.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">For early screening of lung cancer: peripheral blood samples of the subjects are first obtained, and the target cells are enriched and captured sequentially by A<sup>+</sup>Pre and AC-1000. After that, A<sup>+</sup>LCGuard performs cell fluorescence staining on the enriched samples to determine the number of targeted cells, and finally makes a judgment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the different regulatory
requirements for the marketing of medical device products and in-vitro diagnostics (&#8220;IVD&#8221;) products in various regions/countries,
it is necessary to complete the registration application and obtain the corresponding license in accordance with the local regulations
before engaging in commercial activities in the respective regions/countries (&#8220;localization registration&#8221;). Afterward, marketing
and sales can be carried out. We follow the principle of modularization when design and develop all of our products and equipment so that
products and equipment can be produced locally to meet different regulatory requirements. Based on the current development of the early
tumor screening and preventive treatment industry and the characteristics of the products we are planning to register and apply in the
future, we have adopted the operation model of centralized research and development and localized management. We have started the registration
process with the NMPA in China for all of our products. Later on, the Company may establish subsidiaries in the United States and Europe
to produce products and carry out product registration. To achieve that, our products must be cleared by the United States Food and Drug
Administration and go through the conformity assessment process to obtain the Conformite Europeenne marking (&#8220;CE marking&#8221;)
from competent authority in each European Union member state.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are looking for suitable
locations in the states of California and Washington for our planned expansion to the North America market. We aim to complete site selection
and personnel recruitment in the United States by the end of December 2025 and start product registration, testing and production afterward.
Our US subsidiary will be responsible for the production and registration of our equipment and related products in the US. Production,
testing, and clinical trials in our US market will be conducted in accordance with US regulations, and clinical data from trials conducted
in China will not be used to establish product standards. In addition, we plan to break into the European market in 2025 and conduct localized
management and operations in accordance with European regulations. In 2025, we also plan to start the localized registration of our IVD
products in Europe. As of the date of this Report, we have not conducted any clinical trials for our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, as of the date of
this Report, we have not commenced sales of our products nor have any revenue-generating products and do not expect sales of revenue-generating
product candidates until we have completed clinical development, submitted regulatory filings, and received applicable regulatory approvals
for candidate products. Due to differences in regulatory and clinical registration requirements, we may not be able to obtain device and
product approvals or provide product service on time. We expect to be in a state of continuous loss for the next two to three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq Notification Letter</i></b>s</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 18, 2025, we received
a written notification from the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying us that we were not in compliance with the minimum
bid price requirement set forth in Nasdaq rules for continued listing on the Nasdaq, and we were provided 180 calendar days, or until
January 14, 2026, to regain compliance (the &#8220;Compliance Period&#8221;). If we do not regain compliance by the end of the Compliance
Period, we may be eligible for an additional 180 calendar day compliance period, provided that we meet the continued listing requirement
for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market (except for the bid price
requirement), and provides written notice to Nasdaq of its intent to cure the deficiency during the second compliance period, including,
if necessary, by effecting a reverse stock split. We intend to monitor the closing bid price of our common stock and will consider all
available options to regain compliance with the Minimum Bid Price Requirement within the Compliance Period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Registration Statement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 23, 2025, we filed
with the SEC a registration statement on Form S-1 (File No. 333-288907) to register under the Securities Act an aggregate of up to 40,000,000
shares of our common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), which represents the shares available for issuance
under the ELOC Agreement (as defined below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Entry into A Material Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 6, 2025, we entered
into a purchase agreement (the &#8220;ELOC Agreement&#8221;) with HELENA GLOBAL INVESTMENT OPPORTUNITIES I LTD. (the &#8220;Investor&#8221;
or &#8220;Selling Stockholder&#8221;), pursuant to which we have the right to issue and sell to the Investor, from time to time as provided
therein, and the Investor is obligated to purchase from us, up to Twenty-Five Million United States Dollars ($25,000,000) of our Common
Stock, subject to terms and conditions set forth in the ELOC Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate History and Corporate Structure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in Nevada
in July 2021 as a holding company. We started operations in 2014 through Advanced Biomed Taiwan as a research and development center for
technology research and product development. In August 2021, we established Advanced Biomed HK as the wholly owned subsidiary of Advanced
Biomed Taiwan to integrate market development and commercialization in the PRC. On January 1, 2022, Advanced Biomed HK acquired 100% equity
interest of Shanghai Sglcell from its stockholders for a consideration of RMB12 million. In March 2022, Advanced Biomed HK established
Sglcell (Huangshan) Biotech Co., Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2022, we consummated
a reorganization pursuant to which we acquired 100% equity interest of Advanced Biomed Taiwan, making it our wholly owned subsidiary.
On November 7, 2022, we obtained the approval of Taiwan Investment Commission for the reorganization, the Issue No. of which is &#8220;<span style="font-family: Times New Roman, Times, Serif">&#32147;&#23529;&#19968;&#23383;&#31532;</span>11100116890<span style="font-family: Times New Roman, Times, Serif">&#34399;</span>&#8221;.
Additionally, the Bureau of Economic Development of Tainan City Government has also approved the reorganization in accordance with the
Taiwan Company Act on December 26, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 8, 2023, pursuant
to the Share Transfer Agreement entered into by Ting Wang and Haifeng Zhang, who are independent third-party individuals, and Shanghai
Sglcell on June 2, 2023, Shanghai Sglcell transferred its wholly owned subsidiary, Nanjing Yitian Biotech Co., Ltd. and its subsidiary,
Beijing Yitan Jiarui Technology Co., Ltd., to Ting Wang and Haifeng Zhang at aggregate consideration of RMB500,000 (approximately US$72,780)
without any other obligations arising from the transfers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 9, 2023, pursuant
to the Share Transfer Agreement entered into by Ting Wang and Haifeng Zhang, who are independent third-party individuals, and Shanghai
Sglcell on May 31, 2023, Shanghai Sglcell transferred its wholly owned subsidiary, Shandong Sglcell Medical Devices Co., Ltd., to Ting
Wang and Haifeng Zhang at zero consideration without any other obligations arising from the transfers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2023, pursuant
to the Share Transfer Agreement entered into by Quantum Capital (Hong Kong) Limited, who is an independent third-party corporation, and
Advanced Biomed HK on June 9, 2023, Advanced Biomed HK transferred its wholly owned subsidiary, Sglcell (Huangshan) Biotech Co., Ltd.,
to Quantum Capital (Hong Kong) Limited at zero consideration without any other obligations arising from the transfers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this Report,
our Shanghai subsidiary is the only operating entity we have in the PRC and owns all of our patents and some of our R&amp;D equipment
while the rest of our R&amp;D equipment are owned by Advanced Biomed Taiwan. Our Shanghai subsidiary will also be responsible for operations
related to clinical trials in Mainland China through CROs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The chart below depicts the
corporate structure of the Company as of the date of this Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC maintains a website
at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically
with the SEC using its EDGAR system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 8 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Oncology Detection Solutions</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current market uses positive
antibody-labeling selection to capture CTCs out of the blood by a specific epithelial cell adhesion molecule (EpCAM). This method could
detect tumor cells in the patient&#8217;s blood for diagnosing lung, prostate, pancreatic, and breast cancers. However, this technology
costs approximately $1,000 per chip, and the processing time per patient is up to 12 hours. Besides, antibody-based methods such as immunomagnetic
methods are highly dependent on antigen expression of CTC. Some CTCs may show low or no EpCAM expression on the cell membrane, and thus
cannot be effectively captured using the proposed biomarkers and makes it difficult to detect cancer in the early stage. More importantly,
the capture of dying or dead CTCs cannot provide meaningful information to doctors for diagnosis or treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products use pure physical
mechanisms (antigen-independent) and can effectively enrich and detect the CTCs with high or low antigen expressions with high viability.
Among them, A<sup>+</sup>Pre is mainly used to reduce the viscosity of blood samples, and AC-1000 is used to complete the separation and
enrichment of circulating tumor cells (&#8220;CTCs&#8221;) and tumor-related targeted cells in blood samples. The A<sup>+</sup>CellScan
is mainly used for fluorescent labeling and automatic scanning judgment of targeted cells while A<sup>+</sup>SCDrop preserves the original
viability of single cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For three corresponding microfluidic
biochips, A<sup>+</sup>Pre Chip and AC-1000 CTC Enrichment Chip have been cleared by NMPA and can be mass-produced and sold to customers.
A<sup>+</sup>CellScan Chip is expected to start the registration application by the end of 2025. The A<sup>+</sup>CellScan Chip and A<sup>+</sup>CellScan
will enrich our product chain by upgrading our immunochromogenic kits to tumor cell assay equipment. Specifically, A<sup>+</sup>CellScan,
together with A<sup>+</sup>Pre and AC-1000, can serve as a liquid biopsy IVD product to accelerate downstream assay and reduce the amount
of labor required for assaying tumor cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use our own product features
combined with different application scenarios to achieve the corresponding work objectives. To identify CTCs in liquid biopsy, blood samples
are first diluted through equipment A<sup>+</sup>Pre, then AC-1000 is used to separate and enrich circulating tumor cells, and then the
obtained cells are stained for identification and counting. We have been cleared by NMPA to provide this service to customers in China
and plan to do so once our matching immunostaining kits pass the NMPA&#8217;s registration review. The counting of circulating tumor cells
can provide auxiliary reference for clinical diagnosis, treatment evaluation, prognosis evaluation, recurrence, and metastasis detection,
etc. In the future, we can also use our A<sup>+</sup>LCGuard early screening kit combined with two devices, A<sup>+</sup>Pre and AC-1000,
for early screening of lung cancer. In addition, we use A<sup>+</sup>SCDrop together with A<sup>+</sup>Pre and AC-1000 to complete the
capture of a single circulating tumor cell, which retains the original activity of the cell and can provide high-purity, high-activity
tumor cells for relevant clinical applications. It can be applied to various applications such as single-cell sequencing, whole gene sequencing,
protein sequencing, new drug development, cancer biomarker research, individualized diagnosis, and individualized drug sensitivity testing.
The above product applications need to be approved by the local regulatory authorities before they can be provided to customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A<sup>+</sup>Pre</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A<sup>+</sup>Pre is a fully
automated sample preparation system that enables to pre-concentrate diluted blood sample and it is able to deplete approximately 90 %
blood cells in 10 minutes and reduce sample volume with a lower blood cell density (hematocrit approximately 4%). A<sup>+</sup>Pre provides
dual channels to simultaneously process two patients&#8217; samples per run, and 8 samples could be done in an hour. A<sup>+</sup>Pre
is easy to operate with two simple steps: (1) dilute the samples by 10-fold; (2) insert the samples and A<sup>+</sup>Pre chips into A<sup>+</sup>Pre
system and press &#8220;START.&#8221; Our A<sup>+</sup>Pre sample-pretreatment could provide clotting-free and clogging-free samples for
downstream microfluidic applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A<sup>+</sup>Pre Chip</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Blood sample includes several
billions blood cells and millions white blood cells with a hematocrit of approximately 45% (&#8220;Hct&#8221;). The high-density blood
cells in microfluidic chip typically induces clotting or clogging in microchannel and microstructs, causing trail failure or unstable
system. Sample dilution can effectively reduce the clotting and clogging. However, dilution may increase sample volume and prolong the
processing time for downstream precise separation and makes analysis more difficult.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A<sup>+</sup>Pre chip utilizes
microfluidic inertial forces to rapidly pre-enrich (deplete approximately 90% blood cells) and pre-concentrate (reduce over 90% sample
volume) the diluted blood sample in 10 minutes. We can dilute a 5ml blood sample with approximately 45% by a factor of 10 and obtain a
50ml blood sample. After concentration and enrichment using the A<sup>+</sup>Pre chip, the total volume of the 50ml blood sample can be
reduced by 10-13 times to around 4 ml while maintaining low red blood cell density (Hct approximately 4.5%), and we can recover more than
90% of the targeted tumor cells. It reduces blood cell density of oncology patients to make it possible for clotting-free downstream precise
separation, A<sup>+</sup>Pre treated sample provide AC-1000 with high purity rare tumor cells in 20 minutes (12 mL/hour). A<sup>+</sup>Pre
chip plays an important role to reduce sample volume and density to make downstream applications much faster and more stable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: center"><img alt="" src="image_002.jpg"/></td>
    <td style="width: 50%; text-align: center"><img alt="" src="image_003.jpg"/></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>Pre</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>Pre Chip</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>AC-1000</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AC-1000 is a rare cell enrichment
device to solve the problem of detection of hypercoagulable state samples of tumor patients. Our rare cell enrichment system uses semiconductor
fabrication method to implant high-aspect-ratio functional microstructures inside the microchannel and patented microfluidic chip technology
to separate rare cells with complete cell activity. The system is convenient and efficient. We take 5 mL of blood from a patient and the
whole process takes only 20 minutes. Compatible to A<sup>+</sup>Pre, AC-1000 also provides dual channels to simultaneously process two
patients&#8217; samples per run, and 8 samples could be done with high-purity enrichment of tumor cells in one and half hours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The blood sample enriched
by AC-1000 can maintain the capture rate of 76-90% of the targeted cells, and the isolated product after blood sample separation can achieve
a leukocyte removal rate of 99.9%, which is convenient for downstream detection. Because the rare cell enrichment system is non-destructive,
highly active and label-free, it can carry out pure physical and high-purity enrichment, completely maintain the original characteristics
of the desired target cells and improve accuracy. What we get is highly active cells, which can be used for different applications in
the future, and can be used for tumor screening, auxiliary diagnosis, treatment evaluation, prognosis evaluation, recurrence and metastasis
detection, individualized medication guidance, and companion diagnosis. Our rare cell enrichment system is low-cost, and the cost will
be further reduced after mass production. It has great potential to be applied to routine liquid biopsy and companion diagnostic platforms
in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>AC-1000 CTC Enrichment Chip</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AC-1000 chip utilizes a hybrid
mechanism with microfluidics induced lateral displacement to combine the difference in cell deformability and to remove all of red blood
cells (&#8220;RBCs&#8221;) and deplete over three logs White Blood Cell (&#8220;WBCs&#8221;). The remaining cells, including few WBCs
and rare cell-based cancer biomarkers, are all sorted out.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 50%"><img alt="" src="image_004.jpg"/></td>
    <td style="vertical-align: bottom; text-align: center; width: 50%"><img alt="" src="image_005.jpg"/></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A<sup>+</sup>SCDrop</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A<sup>+</sup>SCDrop is a CTCs
single cell capture device. It preserves the original viability of single cells. The polymer microfluidic chip combines the cell dielectric
sensing technology, without the need for antibody fluorescence calibration and image recognition. CTC sorting combined with AC-1000 achieves
tandem for complete label-free live cell sorting. A<sup>+</sup>SCDrop can sort single circulating tumor cells into nanoliter droplet collection
samples while maintaining single cell biological activity: a. Precise counting of CTCs while separating and capturing single cells; b.
In vitro culture and expansion of non-destructive Single-CTC; drug sensitivity test; c. Single-CTC encapsulated in oil droplets, single-cell
sequencing or genetic screening d. Single CTCs were independently sorted into 96-well plates in suspension liquid mode for CTC proteomic
study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_006.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 11 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A<sup>+</sup>CellScan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, A<sup>+</sup>CellScan
are developed as an analyzer with immunostaining chip for reducing hands-on time, manual discrimination, and accelerating immunostaining/analysis
of the AC-1000 product. A<sup>+</sup>CellScan provides a novel approach for rapid on-chip immunofluorescence staining, which may take
approximately 30 minutes, and artificial intelligence analysis of enriched sample for detecting, identification, and counting of rare
CTCs/clusters from white blood cells with four color immune-fluorescent images. The prototype we designed can (a) autofocus for capturing
and analyzing images of four colors fluoresces in A<b><i><sup>+</sup></i></b>CellScan chip, (b) perform on-chip immunostaining, and (c)
automatically count tumor cells and labeling them on each image. We also completed A<b><i><sup>+</sup></i></b>CellScan&#8217;s performance
study, which examine (i) its autofocus ability and precision for automatically capturing and analyzing cell images, (ii) whether it can
detect and analyze 3-1000 cancer cells in &lt;106 WBCs, and (iii) its maximum on-chip immunostaining ability. Performance study (i) to
(iii) were completed in December 2022, January 2023, and March 2023, respectively. During the performance study, we have thoroughly evaluated
A<b><i><sup>+</sup></i></b>CellScan&#8217;s autofocus precision in capturing cell images. Out of 6,400 cell pictures that were captured
through a non-stop and fully automated process, less than 2 pictures were found to be out-of-focus. We also analyzed the presence of 3-1,000
cancer cells stained with fluorescence within samples containing 104, 105, and 106 WBCs, resulting in reliable detection of cancer cells.
We have optimized the antibody concentrations for CK+, DAPI, and CD14/45 combination, resulting in a maximum on-chip immunostaining ability
with high specificity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A<sup>+</sup>CellScan Chip</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Conventional immuno-staining
is labor-intensive with multiple processes, and its reaction is based on diffusion-dominated mechanism, thus causing a long operating
time (about 4-5 hours per sample). A<sup>+</sup>CellScan chip consists of fluid device and 5 &#956;m micro-pores membrane that is used as
a filter to trap nucleated cells on the membrane surface form the through-flow. Only fluid and RBCs are allowed to pass through the pores.
Captured cells are kept in wells during flowing staining and washing. The active through-flow plays two important roles: 1. carrying antibodies
to cells rapidly, thus accelerating the reaction rate of specific binding between reporting antibody and cells; 2. simplifying the operation
processes in reagent spiking and repeated washing steps. A<sup>+</sup>CellScan chip stains rare cells such as CTCs and CTC clusters without
cell loss during fixation, permeabilization, blocking, incubation and washing. The device provides flexibility to process up to eight
samples per run. On-chip immunostaining only need 30 minutes for one sample, and batch process for eight samples can be completed in one
and half hours. After cell staining, A<sup>+</sup>CellScan and A<sup>+</sup>CellScan chips automatically captures cell images and analyses
the stained cells in 30 minutes. Compared to conventional methods, A<sup>+</sup>CellScan chip significantly reduces the total detection
time by 4-5 hours per 1 sample.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: center"><img alt="" src="image_007.jpg"/></td>
    <td style="width: 50%; text-align: center"><img alt="" src="image_008.jpg"/></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 12 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following diagrams illustrate
the procedures using our devices for diagnostic detection of blood samples from oncology patients:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Diagram 1: A<sup>+</sup>Pre reduces blood
density of oncology patients.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_009.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the analysis of high-viscosity
blood samples, the A<sup>+</sup>Pre equipment can be used for pretreatment, retaining the original cell activity while preventing blood
samples from clogging the equipment pipeline after entering the detection equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Diagram 2: AC-1000 completes targeted cell
enrichment work.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_010.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A<sup>+</sup>Pre and AC-1000
equipment can be combined for the identification and counting application of circulating tumor cells purposes. First, blood samples are
diluted with A<sup>+</sup>Pre, and then AC-1000 is used to separate and enrich circulating tumor cells and related tumor markers. The
enriched samples are stained, calibrated, and finally identified and counted. A<sup>+</sup>Pre combined with AC-1000 provide the purified
solution of cell-based cancer biomarkers, which can be easily identified, analyzed and tested. The total purification process can be completed
in only 40 minutes. A<sup>+</sup>Pre combined with AC-1000 capture multi-cell-based cancer markers simultaneously with a high recovery
rate (76~90%), and therefore making it possible to diagnose cancer and predict cancer progression in very early stage. This application
service can already be commercialized in the Chinese market. Calibration and staining currently use staining reagents that are already
on the market. Once our products are registered, we will start using our own developed reagents. The identification and counting of circulating
tumor cells and related tumor marker cells can provide auxiliary reference for relevant clinical applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Diagram 3: A<sup>+</sup>SCDrop completes
single targeted cell capture.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_011.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The capture of circulating
tumor cells requires the use of A<sup>+</sup>Pre, AC-1000, and A<sup>+</sup>SCDrop in combination. First, the user needs to follow the
same process as the identification of circulating tumor cells to obtain enriched samples, and then the samples are captured and separated
by A<sup>+</sup>SCDrop equipment to isolate single circulating tumor cells. This combined application can provide tumor cells with high
purity and high activity.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Products</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Four Immunochromogenic Kits</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The four immunochromogenic
kits, A<sup>+</sup>CTCE, A<sup>+</sup>CM, A<sup>+</sup>CTCM and A<sup>+</sup>EMT, are currently under NMPA registration review.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_012.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the four immunochromogenic
kits, the basic principle is to use antibodies combined with different colored fluorophores to bind to specific proteins on the cell surface
or inside the cells and observe the presence or absence of fluorescent signals through a fluorescent imaging system (to be obtained separately).
Afterwards, the expression of the target protein can be examined, and the cell type can be determined accordingly. Different cell types
can be distinguished using multiplexed combined staining with different antibodies. The A<sup>+</sup>CTCE kit is mainly used to identify
epithelial circulating tumor cells, and is determined by immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies. The A<sup>+</sup>CTCM
kit is used to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies.
A<sup>+</sup>EMT is mainly used to identify epithelial-to-mesenchymal circulating tumor cells, which are determined by immunochromogenicity
of Cell-Surface Vimentin (CSV), CD45 antibody, and CD14 antibody. A<sup>+</sup>CM is used to identify tumor-associated macrophages (cancer-associated
macrophage-like cells) based on immunochromogenicity of PD-L1, CD45, and CD14 antibodies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the assistance of the
four kits, targets are stained using antibodies conjugated with different fluorophores that specifically bind to antigens in cells. In
immunohistochemical reaction or in situ hybridization reaction, it is combined with the primary antigen antibody, and the target is marked
by staining. It is suitable for the staining of blood cells enriched by A<sup>+</sup>Pre and AC-1000 hemocytometer. We transfer the cell
suspension separated and obtained by A<sup>+</sup>Pre and AC-1000 into a centrifuge tube, use the kits to stain the cell suspension, and
observe and count the fluorescently stained cells under a fluorescence microscope or a fluorescence scanner. Observed under a fluorescence
microscope, all nuclei are stained blue, and the cell membrane of leukocytes is red, and the color of the cell membrane we observe under
the fluorescence microscope is the marked color, which is the target cell we want to obtain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our 3D Cell Culture Platform</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Conventional cell culture
equipment is bulky and requires frequent manual intervention. In addition, in static culture, nutrients are unevenly distributed and waste
products from cell metabolism tend to accumulate. This can negatively affect cell growth, viability, and experimental consistency. In
addition, unlike 2D cultures, 3D cell culture better mimics the structural and functional complexity of human tissues. It enables more
physiologically relevant cell-cell and cell-matrix interactions, leading to improved accuracy in drug response prediction and disease
modeling. Notably, in certain high-density culture scenarios, particularly within multi-microwell 3D culture devices, metabolic waste
can rapidly accumulate inside the micro-grooves.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our A+PerfusC<sup>&#8482;</sup>
is a compact All-in-One 3D cell culture system that integrates automated perfusion with environmental control in a compact format. A+PerfusC<sup>&#8482;</sup>
ensures a more uniform supply of nutrients while simultaneously removing metabolic waste, thereby reducing cellular stress and enhancing
viability over extended periods, providing more accurate drug response and disease modeling.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>A+PerfusC</i></b><i><sup>&#8482;</sup> <b>System</b></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A+PerfusC<sup>&#8482;</sup>
an automatic perfusion 3D cell culture system revolutionizes in vitro 3D cell culture by integrating automated perfusion and environmental
control to closely replicate human physiological conditions. This system ensures uniform nutrient delivery, prevents waste accumulation,
and promotes spheroid/organoid formation, significantly enhancing cell viability, growth, and drug response predictability. The system
designed to mount directly onto a microscope for real-time observation, it supports up to 12 days of hands-free culture, reducing human
error and contamination risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36.05pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The system is characterized and proved by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">8 independent channel/patient source per plate</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">600 tumor spheroids per row for one patient</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">4,800 tumor spheroids per plate</span></td></tr></table><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Easy to transfer into 96 or 384 well plate for high-throughput drug screening</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span>&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Easy to mount on microscopy platforms for real-time analysis</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_013.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A+PerfusC<sup>&#8482;</sup>&#160;system
and its perfusion-based 3D culture plate (consumable) have passed internal testing and validation with design finalized. Currently we
are advancing its mass-production development. The commercialization can be achieved following mass-production development finalized,
quality control standards established, and system electrical safety verification (IEC 61010-1).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Product in the Pipeline</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our A<sup>+</sup>LCGuard was
designed for early screening of lung cancer. In order to detect lung cancer, peripheral blood samples of the subjects are first obtained,
and the target cells are enriched and captured sequentially by A<sup>+</sup>Pre and AC-1000. Then, A<sup>+</sup>LCGuard performs cell
fluorescence staining on the enriched samples to determine the number of targeted cells, and finally makes a judgment. We completed A<sup>+</sup>LCGuard&#8217;s
research and development in China between August 2020 and September 2022. A<sup>+</sup>LCGuard is a Class III medical device and is required
to conduct clinical trials before completing the registration process. We plan to begin A+LCGuard&#8217;s clinical research in November
2025. Specifically, in June 2025, the Company and the CRO began collaborating on drafting the clinical research protocol and started preparing
the necessary equipment, consumables, reagent kits, and other materials for the study. We expect that the clinical research protocol may
pass ethical review and receive ethics committee approval by the end of October 2025. Thereafter, we plan to initiate the trial stage
of the clinical research, with completion anticipated within six months of November 2025. Based on the results of clinical research, we
plan to formulate a work plan for large-scale clinical trials and proceed with the clinical trial. We believe the registration declaration
will be made after we complete the clinical trials.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following diagrams illustrate
the procedures using our detection solutions for CTC enriched samples:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_014.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 16 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We participated in scientific
research projects at Shanghai Pulmonary Hospital from July 17, 2019 to December 2021, and completed a total of 123 case studies. In the
study, we selected 123 individuals, and among them, 75 were surgical patients with nodular changes or shadows in the lungs reported by
imaging studies and 48 healthy patients without lung nodules reported by imaging studies. 7ml blood samples were taken from test subjects
either before the clinical operation (for cancer patients) or after the physical examination (for healthy individuals), and A<sup>+</sup>Pre,
AC-1000, and A<sup>+</sup>LCGuard kits were used to determine whether there were circulating tumor cells and other tumor markers in the
blood samples. Finally, the pathological and physical examination results of the tested individuals were compared with the test results
of our products. Our test results achieved 96% sensitivity and 99.9% specificity, which provides the research and development basis for
our kit products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Below are two comparable blood
testing methods in the current market. We have not tested the sensitivity of our products against these two comparable blood testing products
in head-to-head comparisons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Universal Diagnostics (UDX),
a Spanish vitro diagnostic company, announced the preliminary research data of its liquid biopsy method for early detection of lung cancer
at the International Association for the Study of Lung Cancer 2020 World Conference. In a preliminary study, UDX detected 37 lung cancer
patients and 71 asymptomatic control subjects with a panel of 10 methylation sites. The results showed that lung cancer patients could
be detected with a sensitivity of 73% (27/37) with 90% (64/71) specificity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The &#8220;Aifeiming&#8221;
gene methylation detection kit (P)R-fluorescent probe method) by Beijing Akron Medical Technology Co., Ltd. won the NMPA Class III certification.
The clinical sensitivity of this product is 86.83%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Quality Control System</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have established quality
control system in accordance with the following regulations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Medical Device Quality Management System for Regulatory Requirements</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Quality Management System Requirements</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Regulations on the Supervision and Administration of Medical Devices</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Measures for the Supervision and Administration of Medical Device Production</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Appendix of Good Manufacturing Practice for Medical Devices In Vitro Diagnostic Reagents</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Guiding Principles for Clinical Trial of In Vitro Diagnostic Reagents</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our quality control system
includes quality manuals specifically designed for each product, procedure documents, supporting documents and quality records. We implement,
maintain and improve the quality control system to ensure that product quality can be effectively and compliantly controlled throughout
the entire process of procurement, production, formation and realization. Specifically, our quality control team (&#8220;QC&#8221;) consists
of three members who are responsible to examine the entire production process from raw materials to finished products. QC also collaborate
with various internal departments of the Company to conduct periodic review on all aspects of our research, development, and production
process and provide their recommendations to the management to ensure our products and processes adhere to the regulations apply to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Commercialization Preparation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are committed to the development
of microfluidic chips, reagents and detectors for capturing circulating tumor cells in blood. We have integrated various complex precision
structures, dielectric detection and functional microfluidic biochips. Our devices include a variety of expensive semiconductor manufacturing
and precision micro-manufacturing related equipment. We signed a research project equipment use contract with TSRI and used their semiconductor
manufacturing equipment and precision micro-nano processing equipment for chip technology research and development such as concept presentation
of each R&amp;D process, cross-scale composite structure production, rapid wafer trial production, material testing, and thin film production.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The contract between Advanced
Biomed Taiwan and TSRI was executed on August 1, 2022 and expired on July 31, 2023. The total cost of the study, including tax, is NTD
1,300,000. Advanced Biomed Taiwan will pay the research fee to the National Institute of Experimental Research in two installments. The
first installment of NTD 650,000 was paid on September 23, 2022, and the second installment of NTD650,000 was paid on April 18, 2023.
The agreement can be unilaterally terminated only if a party fails to fulfil its obligations, if Advanced Biomed Taiwan declares bankruptcy,
or if its business activities are disrupted by the government. The agreement can only be terminated by mutual agreement in all other circumstances.
The parties agree to take the Taiwan Taipei District Court as the jurisdiction court of first instance for any disputes arising from the
execution of this agreement, which shall be subject to the laws of Taiwan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As for the designed microfluidic
detector, since 2020, we have developed various functional microfluidic biomedical testing devices for microfluidic modules, automation
software, and hardware. We also designed, manufactured and processed an increasing number of key components of our testing devices. All
of our products must go through three steps to receive the required clearance from the NMPA before they can be sold to customers. The
three steps are research and development, registration application, and registration review, which must be done in that order. At the
registration application stage, we have to assemble all the required application materials, complete clinical trials (if required by NMPA),
and work with an NMPA accredited third-party organization to examine our products in accordance with NMPA rules. NMPA will review our
application during the registration review period and may request additional information before officially approving or denying our applications.
Currently, A<sup>+</sup>Pre and AC-1000 and their corresponding chips have been cleared by the NMPA; A<sup>+</sup>SCDrop, A<sup>+</sup>CellScan,
A<sup>+</sup>CellScan Chip, and A<sup>+</sup>LCGuard are at the registration application stage; the four matching immunostaining kits
are under registration review. A<sup>+</sup>LCGuard is a Class III medical device and is required to conduct clinical trials before completing
the registration process. As of the date of this Report, we have not applied for similar clearances from other jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although none of the chips
has been mass produced as of the date of this Report, we have been cooperating with the injection molding machine manufacturer Riva and
the mold manufacturer Unimold to conduct pre-mass production trial test for our A<sup>+</sup>Pre Chip and AC-1000 Enrichment Chip. During
the mass production trial test, we examine the following factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">whether the tested chip can work with its corresponding product, and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">whether chips&#8217; flatness, roughness, water leakage, critical size and thickness match the original design.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Chip is ready for mass-production
if each individual production line can produce at least 2,500 pieces per month and pass the quality control examination. During the quality
control examination, one chip out of every 48 chips will be randomly selected for verification and must achieve designed objectives when
working with their corresponding products and meet all the product specifications to pass the examination. The product specifications
are listed in the table below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Flatness</b></span></td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Roughness</b></span></td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>No Water leakage</b></span></td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Critical size<br/>
compared with<br/>
original design</b></span></td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Thickness</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 25%; text-align: justify"><span style="font-size: 10pt">A<sup>+</sup>Pre Chip</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center"><span style="font-size: 10pt">&#916;F &lt; 0.1 mm</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center"><span style="font-size: 10pt">&#916;R&lt;1.5 um /mm<sup>2</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center"><span style="font-size: 10pt">Under 2 bar</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center"><span style="font-size: 10pt">within 5%</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center"><span style="font-size: 10pt">2 mm &#177;10%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">AC-1000 Enrichment Chip</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#916;F &lt; 0.3 mm</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#916;R &lt; 1.5 um/mm<sup>2</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Under 2 bar</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">within 5%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">1.5 mm &#177;10%</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon completion of the pre-mass
production trial test, all of the randomly selected A<sup>+</sup>Pre Chips and AC-1000 Enrichment Chips can work with their corresponding
A<sup>+</sup>Pre and AC-1000 products and meet or exceed the production specifications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of every 48 chips was
randomly selected and tested for performance verification by using A549 lung cancer cells spiked into human blood. In May 2023, a total
of 20 A+Pre chips were tested, with a result of average tumor cell recovery rate of 94%, which exceeded the target rate of 90%, with the
highest and lowest rates of 99% and 91.6%, respectively. The liquid and blood cells removal rate by A+Pre chip was between 90-92.5%, which
is in line with the target rate of 90-94%. A total of 12 AC-1000 chips were examined and the average recovery rate is 79.5%, which exceeded
the target rate of 75%, with the highest and lowest recovery rates of 88.6% and 76.8%, respectively. The blood cells depletion rate was
&gt;2.5 logs, exceeding the target rate of 2 logs, with the highest and lowest rate of 4 and 2.5 logs, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The specifications of the
randomly selected A<sup>+</sup>Pre and AC-1000 chips produced during the pre-mass production trial test can be found in the table below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Flatness</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Roughness</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>No Water leakage</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Critical size<br/>
compared with<br/>
original design</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Thickness</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 25%; text-align: justify"><span style="font-size: 10pt">A<sup>+</sup>Pre Chip</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center"><span style="font-size: 10pt">&#916;F &lt; 0.05 mm</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center"><span style="font-size: 10pt">&#916;R&lt;1.5 um /mm<sup>2</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center"><span style="font-size: 10pt">Under 2 bar</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center"><span style="font-size: 10pt">within 3%</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 14%; text-align: center"><span style="font-size: 10pt">2 mm &#177;5%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">AC-1000 Enrichment Chip</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#916;F &lt; 0.08 mm</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">&#916;R &lt; 1 um/mm<sup>2</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Under 2 bar</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">within 5%</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">1.5 mm &#177;10%</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Riva is a mold manufacturing
and injection molding machine manufacturer. We have purchased a Riva injection molding machine at the end of October 2022 and completed
the mass production trial test for AC-1000 chips, and the production samples met our product specifications. The special structure mold
core we made combined with the Riva injection molding machine has repeatedly produced hundreds of pieces of AC-1000 chips. The quality
of the products is consistent and meet the product specifications of the microstructure characteristics. The operation on the equipment
has achieved the expected efficiency and cell enrichment efficiency. Each equipment is expected to produce 2,000 pieces AC-1000 chips
per month.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unimold is a mold manufacturer
and an ISO9001 plastic injection molding foundry. We cooperate with Unimold to embed our specially manufactured mold core for A+Pre Chip
into the mold cavity, which will be employed at our future production facility. Although there is no formal cooperation agreement between
Unimold and us, Unimold produces custom-made molds for us on a make-to-order basis. Each time, we first discuss the mold specification
with a Unimold representative, then receive an offer from Unimold with the price, and Unimold will produce the customized mold for us
to test. To protect our intellectual property, Unimold and us entered into a Non-Disclosure Agreement (the &#8220;NDA&#8221;) with a term
of three years. The NDA prohibits both parties from disclosing confidential information without authorization and hiring the other party&#8217;s
employees during the term of the NDA or within two years of the termination of the NDA. The NDA is governed by the laws of Taiwan, and
any disputes arising from the NDA must be resolved before Taiwan Tainan District Court. The chips produced by Unimold&#8217;s mold have
met the specifications set by us, and a batch of small-scale trial production of 5,000 pieces was carried out in October 2022. Our A<sup>+</sup>Pre
is operating to expected efficacy and performance specifications using the in-house produced A<sup>+</sup>Pre Chip. One injection-type
production equipment is expected to produce 50,000 pieces of A<sup>+</sup>Pre Chip per month.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Platform</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have built our microfluidic
technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines
our patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor
fabrication technology, and integrated application patented technology. Each geographic territory will establish clean rooms for chip
production in compliance with local regulations to meet local market demand. While performing its designed duties, our microfluidic technology
platform can provide customized services to third parties for a fee. We envision providing services such as OEM production of microfluidic
chips, micro-electromechanical components, biochips, sensors, and other components, customized product design, and commissioned development
and research services to customers. Different from the general IC wafer OEM production, our production is based on our micro-nano manufacturing
technology platform developed by professionals in various fields that integrates cross-field knowledge, including Micro Electro Mechanical
Systems (MEMS), lithography-assisted micromachining (LIGA), semiconductor process, and soft materials such as silicone gel and polydimethylsiloxane.
We boast the ability to develop, design, and manufacture micro-electromechanical components and sensors, including three-dimensional microstructures
or micro-optical-electromechanical integrated components. The material of the microstructure can be multi-layer stacking of alloys and
insulating materials, which may be used in a wide range of fields, such as pressure or environment detection, MEMS oscillators, optical
actuators, biomedical components, passive components, silicon optical integration platforms, and microfluidic structures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The platform integrates our
AC-1000 and A<sup>+</sup>SCDrop devices. Our rare cell enrichment device AC-1000 integrates the A<sup>+</sup>Pre chip and AC-1000 CTC
enrichment chip. AC-1000 uses semiconductor nano ultra-sensitive biosensors and patented microfluidic chip technology to isolate rare
cells with complete cell activity. It has great potential to be applied to routine liquid biopsy and companion diagnosis in the future.
AC-1000 can satisfy different applications with corresponding special chip products. Our products also have the potential to provide application
services in tumor screening, auxiliary diagnosis, treatment evaluation, prognosis evaluation, recurrence and metastasis detection, individualized
medication guidance, and companion diagnosis. In terms of tumor screening, we have developed a complete set of service models for early
screening of lung cancer, and plan to begin the clinical research in November 2025. Our application services for the identification of
CTCs have matured, and the identification of CTCs can be used for tumor screening, auxiliary diagnosis, and treatment evaluation, etc.
Our CTCs single cell capture device A<sup>+</sup>SCDrop is used in combination with A<sup>+</sup>Pre and AC-1000. It preserves the original
activity of single cells and polymer microfluidic chips combined with cell dielectric sensing technology. With the technical advantages
combined with our IVD kit products, A<sup>+</sup>SCDrop can be used in a variety of applications, such as single-cell sequencing, whole
gene sequencing, protein sequencing, new drug development, cancer biomarker research, individualized diagnosis, individualized drug susceptibility
testing, and other aspects of individualized precision medicine. We are also working on prognosis assessment, recurrence and metastasis
detection, individualized medicine, and companion diagnosis.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although no services have
been provided to customers yet, we believe the application services using our products and devices will be an essential part of our future
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competitive Strengths</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we have not received
any regulatory approvals necessary to commercialize our products, we believe that the following competitive strengths enable us to compete
effectively in and capitalize on the growing oncology detection market:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Our Microfluidic Technology Platform.</b> We can quickly complete the product development and improvement we need on our own platform.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Proprietary Ultra-Sensitive Biosensor Technology. </b>Our self-developed proprietary semiconductor nano ultra-sensitive biosensor technology integrates various composite precision structures, dielectric detection and functional microfluidic biochips to complete the microfluidic chips and reagents for capturing circulating tumor cells in a patient&#8217;s blood. Our technology also enables a fast and inexpensive method for early cancer diagnosis because we mainly rely on self-developed equipment and products, including the microfluidic chips and the related reagents. Specifically, with the start and expansion of mass-production, the cost and price of microfluidic chips will drop multiple times. Also, since we estimate that we will enrich all the targeted cells, the amount of reagents required in the process will decrease correspondingly. Additionally, we are able to complete the detection and analysis in a short period of time while ensuring the accuracy of the results and reducing the death number of targeted cells throughout the process because we have a complete microfluidic technology platform, which uses self-developed microfluidic chips to separate and detect CTCs. By using automatic and efficient microfluidic chips, we can reduce human errors when capturing, releasing, counting, and detecting CTCs. For example, AC-1000 and its corresponding chip can achieve high throughput (800-1000 drops/s) and high flow rate (&gt;0.7ml/hr) while completely removing red blood cells in peripheral blood samples within 30 minutes. Due to the non-destructive nature of the rare cell enrichment system, it can maintain the original characteristics of the desired target cells through purely physical and high-purity enrichment processes, improving the accuracy of the results and reducing the number of target cells that die during the entire process.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>On Track to Commercialization.</b> All of our products must go through three steps to receive the required clearance from NMPA before they can be sold to customers. The three steps are research and development, registration application, and registration review, which must be done in that order. Currently, A+Pre and AC-1000 and their corresponding chips have been cleared by the NMPA; A+SCDrop, A+CellScan, A+CellScan Chip, and A+LCGuard are at the registration application stage; the four matching immunostaining kits are under registration review. We expect to submit the A+CellScan, and A+CellScan Chip&#8217;s registrations to the NMPA in December 2024 while completing preliminary works for A+SCDrop&#8217;s application. We have been cooperating with the injection molding machine manufacturer Riva Machinery Co., Ltd. (&#8220;Riva&#8221;) and the mold manufacturer Unimold Technology Inc. (&#8220;Unimold&#8221;) to conduct mass production mode testing and trial production. Although none of the chips has been mass-produced as of the date of this Report, we have purchased a Riva injection molding machine at the end of October 2022 and completed the mass production trial test of AC-1000 CTC Enrichment chip. We also cooperate with Unimold to embed our specially manufactured mold core for A+Pre Chip into the mold cavity made by Unimold. The chips produced have met the specifications set by us, and a batch of small-scale trial production of 5,000 pieces has been carried out in October 2022. Our equipment is operating to expected efficacy and performance specifications using in-house produced chips. Moreover, the prototype of A+CellScan and its corresponding chip have completed the performance study. You can find more information on page 8 under the heading &#8220;A+CellScan.&#8221; We are refining the production method of A+CellScan chip and have submitted the results of our medical device safety test to a third party for independent evaluation. In addition, we have completed the mass production trial test using the mold manufactured by Unimold in December 2023, and an independent third-party is evaluating the test result. The A+CellScan and its corresponding chip will enrich our product chain by upgrading our immunochromogenic kits to tumor cell assay equipment. Specifically, A+CellScan, together with A+Pre and AC-1000, can serve as a liquid biopsy IVD product to accelerate downstream assay time and reduce the amount of labor required for assaying tumor cells. In addition, we are actively carrying out registration application for our A+LCGuard kit products, as well as work related to research programs.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Multi-Disciplinary Management Team.</b> We have a multi-disciplinary management team, an R&amp;D team and strategic cooperation units composed of interdisciplinary and cross-field professionals and well-known experts. The R&amp;D team has the ability to combine semiconductor/integrated circuits and biomedical expertise. Our team has accumulated valuable experience from chip development and design, manufacturing, mass production, design and development of detectors, research and development of system modules, and the operation of clinical laboratory personnel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Growth Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will strive to be a leading
provider of precision oncology detection solutions by the following growth strategies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Increase the market penetration </b>of our oncology auxiliary products and expand our product portfolio to actively focus on in vitro early diagnosis, rapid evaluation of chemotherapy drugs, individualized treatment including clinical screening of drugs, detection of drug resistance, and monitoring of tumor recurrences.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Develop cancer screening market in China and further expand to other regions.</b> We plan to initially focus on developing our cancer screening market in China. We also plan to expand to North American and European market by setting up subsidiaries and localize production and operation to meet specific market demand and compliance requirements in the relevant market.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Expand our R&amp;D</b> to strength and develop pipeline products. In the future, we will actively promote the research and development, application and registration of other cancer early screening products.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2025 we had
registered or applied with China Patent and Trademark Office 8 patents on novel separation technologies for antibody-free and label-free
enrichment of rare cell-based cancer biomarkers (such as CTC, CTC cluster, tumor marker expressed cells) from very dense blood cells,
6 patents on high throughput droplet microfluidic chips for nano-liter scale reagent preparation and single-cell, 3 patents for the device
of water phase single-cell isolation and capturing for single cell applications, 6 patents on single-CTC detection/discrimination and
delivery for single-CTC sorting and downstream single-CTC analysis, and 3 patents on target cells pre-concentration and enrichment. Meanwhile,
we also applied 2 of abovementioned patents with PCT and 2 of abovementioned patents with the U.S., and one of the U.S. application has
been granted on October 11, 2022. As of June 30, 2025, we own a total of 20 patents and an additional patent application is pending. Several
smart and key chip fabrication techniques/methods with mass production level are protected by commercial confidential to reduce exposed
risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our ability to obtain and maintain proprietary or intellectual property protection for our detection solutions and other commercially
important products, technologies, invention and&#160;know-how,&#160;to operate without infringing, misappropriating or otherwise violating
the proprietary or intellectual property rights of others and to prevent others from infringing, misappropriating or otherwise violating
our proprietary or intellectual property rights. Our patent strategy is focused on seeking coverage for our core technologies and specific&#160;follow-on&#160;applications,
implementations for detecting and monitoring cancer by determining genomic alterations and evaluating the status of specific biomarkers
in liquid biopsy or tissue samples. In addition, we file for patent protection on our&#160;on-going&#160;research and development, particularly
into early-stage cancer screening.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on trade secrets,&#160;know-how&#160;and
continuing technological innovation to develop and maintain our proprietary and intellectual property position. We generally require our
R&amp;D personnel to enter into confidentiality agreements. These agreements provide that all confidential information developed or made
known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed
to third parties except under specific circumstances. In the case of our R&amp;D personnel, the agreements provide that all of the technology
which is conceived by the individual during the course of employment is our exclusive intellectual property. Furthermore, as a matter
of company policy, our R&amp;D personnel have entered into agreements that generally require disclosure and assignment to us of ideas,
developments, discoveries and inventions made by them which relate to their employment with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 22%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Patent Number</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center">&#160;</td>
    <td style="white-space: nowrap; width: 14%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Patent Type*</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center">&#160;</td>
    <td style="white-space: nowrap; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Patent Description</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center">&#160;</td>
    <td style="white-space: nowrap; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Jurisdiction</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center">&#160;</td>
    <td style="white-space: nowrap; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Status</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center">&#160;</td>
    <td style="white-space: nowrap; width: 11%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Expiration <br/>
Date</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center">&#160;</td>
    <td style="white-space: nowrap; width: 14%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Product <br/>
Application</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201821544689.4</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Utility Models</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Target cells pre-concentration and enrichment</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">09/20/2028</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>Pre</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201811418768.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Invention</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Target cells pre-concentration and enrichment</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">11/26/2038</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>Pre</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201811098975.7</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Invention</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Target cells pre-concentration and enrichment</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">09/20/2038</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>Pre</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">PCT/CN2018/103116</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Invention</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Single-CTC detection/discrimination</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">International</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">N/A</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>SCDrop chip</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">US11467081B216/639,117</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Invention</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Single-CTC detection/discrimination</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">USA</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">08/30/2038</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>SCDrop chip</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201821544716.8</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Utility Models</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Single-CTC detection/discrimination</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">09/20/2028</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>SCDrop chip</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201821544498.8</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Utility Models</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Single-CTC detection/discrimination</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">09/20/2028</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>SCDrop chip</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">PCT/CN2018/103171</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Invention</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Separation technologies</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">International</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">N/A</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">AC-1000</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">US20200086320A1<br/>
16/617,634</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Invention</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Separation technologies</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">USA</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10/31/2040</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">AC-1000</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201821544718.7</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Utility Models</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Separation technologies</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">09/20/2028</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">AC-1000</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201821544717.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Utility Models</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Separation technologies</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">09/20/2028</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">AC-1000</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201810169100.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Invention</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Separation technologies</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">02/28/2038</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">AC-1000</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201810381143.X</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Invention</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Single-CTC detection/discrimination</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">04/25/2038</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>SCDrop chip</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201921425592.6</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Utility Models</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Droplet microfluidics</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">08/29/2029</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>SCDrop</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201910807870.2 </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Invention</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Droplet microfluidics</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">08/30/2038</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>SCDrop</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201821961715.3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Utility Models</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Droplet microfluidics</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">11/26/2028</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>CellScan Chip &amp; A<sup>+</sup>SCDrop</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201821544526.6</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Utility Models</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Droplet microfluidics</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">09/20/2028</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>SCDrop</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201811470094.3 </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Invention</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Droplet microfluidics</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">11/26/2038</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>SCDrop chip&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201811099052.3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Invention</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Droplet microfluidics</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">09/20/2038</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>SCDrop&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">ZL201821562851.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Utility Models</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Single-cell isolation and capturing</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Granted</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">09/20/2028</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>Pre Chip, AC-1000 CTC Enrichment Chip, and A<sup>+</sup>CellScan Chip</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">202310325582.X</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Invention</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Separation technologies</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">China</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Pending</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">03/29/2043</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">A<sup>+</sup>CellScan reagent</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chinese Patent Law defines three different types of patents for protecting invention-creation: invention, utility model, and design. &#8220;Invention&#8221; means any new technical solution proposed for a product, a process or the improvement thereof. &#8220;Utility Model&#8221; means any new technical solution proposed for the shape, the structure, or their combination, of a product, which is fit for practical use. &#8220;Design&#8221; means, with respect to an overall or partial product, any new design of the shape, the pattern, or their combination, or the combination of the colour with shape or pattern, which is rich in an aesthetic appeal and is fit for industrial application.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 22 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2025, we had
registered 12 trademarks in China, including <span style="font-family: Times New Roman, Times, Serif">&#27427;&#25096;&#36187;</span>
and sglcell.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also own 1 registered domain
name in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Item</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Trademarks</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 8%"><span style="font-size: 10pt">1</span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 91%; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#27427;&#25096;&#36187;</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">sglcell</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 5.4pt; text-align: center"><img alt="" src="image_015.jpg"/></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 8%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Item</b></span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 91%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Domain Names</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">sglcell.com</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">www.advanbiomed.com</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2025, we had 31 employees. The following table sets
forth the number of our employees by function as of June 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As&#160;of&#160;June 30, <br/>
2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% &#160;of&#160;Total <br/> Employees</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Functions:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Technology, Research and Development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">58</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Medical Affairs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operations and Quality Assurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sales and Marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and Administration</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt">Total number of employees</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">31</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 23 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our R&amp;D personnel are
imperative to our technological development. They are responsible for the early stage of biochip design and production, design improvement
and optimization, self-developed microfluidic system, design and development of biomedical testing instruments, and establishment of biochip
mass production mode. They also test the electrical safety of our medical devices, assist us to prepare FDA medical device regulatory
certification and registration application documents. The R&amp;D personnel are also responsible for the training of clinical laboratory
personnel, the training of assembly, testing and maintenance of medical equipment production line personnel, and future chip mass production
and packaging production.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Shanghai subsidiary is
required by law to make contributions equal to certain percentages of each employee&#8217;s salary for his or her pension insurance, medical
insurance, unemployment insurance and other statutory benefits and a housing provident fund. Our Shanghai subsidiary also enters into
standard labor contracts with its employees. The labor contract typically includes a confidentiality covenant that requires employees
to protect the company confidential information during their employment. In addition, employees are prohibited from entering into another
employment relationship with a third party, which may adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Advisors and Industry-Academia Cooperation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We focus on the research and
development of various advanced and original microfluidic biochips and strive to provide tumor precision diagnosis and treatment technology
and early cancer detection service. In order to strengthen our strategic development and research, we have worked with the following advisors
(&#8220;Advisors&#8221;) and the National Taiwan University (the &#8220;NTU&#8221;) pursuant to certain advisory agreements and industry-academia
cooperation agreements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advisors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Lin Jianhuang</i></b>
is currently President of Taipei Medical University, Director of National Applied Research Laboratory, Director of Biotechnology and Pharmaceutical
Industry Research Institute, Executive Director of Taiwan Pharmacological Society, and Director of International Cooperation Foundation.
Dr. Lin is mainly engaged in the field of molecular pharmacology signal transduction new drug development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Zhou Caicun</i></b>
Director of the Institute of Oncology, Tongji University School of Medicine, Director of the Department of Oncology. Director of Oncology
Department of Shanghai Pulmonary Hospital, Director of Lung Cancer Immunology Research Office, Director of Clinical Pharmacology Institute.
Mainly engaged in early diagnosis of lung cancer, comprehensive treatment, targeted therapy and individualized therapy, molecular imaging
of tumor, phage vaccine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Advisors attend quarterly
meetings and provide professional advice to the Company. Advisors make recommendations and offer guidance on the Company&#8217;s long-term
development strategy and major decisions, including providing consultation and suggestions on the Company&#8217;s development plans, research
directions, scientific partnerships, and academic exchanges based on their abundant clinical experience to help the Company stay on the
right track. For example, we used to focus on counting tumor cells, and our Advisors suggested to capture active single cells for further
clinical application. Based on the suggestion, we eventually developed A<sup>+</sup>SCDrop. Furthermore, our Advisors suggested that we
adopt the method of taking blood samples at multiple times, as the number of targeted cells contained in samples at different times is
different, so as to ensure the accuracy of the obtained results. Accordingly, we adjusted our clinical plan regarding our prospective
clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 24 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Below are the material terms
of the advisory agreements (the &#8220;Advisory Agreement&#8221;):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Terms</i></b>. The Advisory
Agreement for Mr. Lin Jianhuang went into effect on November 1, 2022, and will end on October 31, 2025, unless terminated earlier in accordance
with the provisions of the Advisory Agreement. The Advisory Agreement for Mr. Lin Jianhuang may be renewed if the parties start the renewal
process three months prior to the end of this agreement and agree on the terms and conditions of the new agreement. The Advisory Agreement
with Mr. Zhou Caicun went into effect on July 1, 2022, and was originally scheduled to end on June 30, 2025. On June 20, 2025, we renewed
the Advisory Agreement with Mr. Zhou under the same terms and conditions, with a new expiration date of June 19, 2026. The Advisory Agreement
may be renewed again if the parties initiate the renewal process at least one month prior to the expiration date and agree on the terms
and conditions of the new agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Services</i></b>. The
Advisor is hired by us as its advisor (&#8220;Advisor&#8221;) and provide consulting service to us regarding our development plans and
strategies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Compensation</i>.</b>
We will reimburse Mr. Zhou Caicun any work-related expenses. We will reimburse Mr. Lin Jianhuang any work-related expenses and we agreed
to grant Mr. Lin 0.5% of the total number of shares of the Initial Public Offering. The Common Stock will be distributed evenly among
Mr. Lin&#8217;s three years of service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Termination</i></b>.
This Advisory Agreement can only be modified by both parties&#8217; written consents and will remain in effect if either Party does not
agree on the proposed modification. This Advisory Agreement is terminated once the end date has been reached or in accordance with the
terms and conditions of this Advisory Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Industry-Academia Cooperation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advanced Biomed Taiwan entered
into two industry-academia cooperation agreements with the National Taiwan University under identical terms and conditions for identifying
novel biomarkers for early detection of lung cancer (together the &#8220;Cooperation Agreements&#8221;). Advanced Biomed Taiwan renewed
one of the two Cooperation Agreements on November 30, 2024 (the &#8220;Renewed Cooperation Agreement&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Below are the material terms
of the Cooperation Agreements&#160;and the Renewed Cooperation Agreement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Terms.</i></b> The Cooperation
Agreements went into effect on April 15, 2023 and expired on October 14, 2024. The Renewed Cooperation Agreement went into effect on December
1, 2024 and will expire on November 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Scopes</i>.</b> Research
and development works stipulated in the Cooperation Agreements and the Renewed Cooperation Agreement focus on improving the accuracy of
early lung cancer detection and exploring more novel biomarkers in that regard.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Payment</i>.</b> Under
the Cooperation Agreements, Advanced Biomed Taiwan is required to pay the NTU NTD 6 million in two equal installments, with the first
one been paid on April 24, 2023. The second installment of NTD 3 million was paid in February 2024. Under the Renewed Cooperation Agreement,
Advanced Biomed Taiwan is required to pay the NTU NTD 3 million in two installments, with the first one due on December 15, 2024. We received
the required invoice from the NTU for the first installment and made the payment on January 24, 2025. The second installment of NTD 1.5
million was paid on June 23, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Ownership</i>.</b> The
parties recognize that the services provided by the advisor are advisory and consulting in nature and do not involve actual research activities.
The NTU shall own the copyrights of any and all reports and works produced under the Cooperation Agreements, while Advanced Biomed Taiwan
has the license to use any and all reports and works produced under the Cooperation Agreements freely.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Renewed Cooperation Agreement
does not permit Advanced Biomed Taiwan to use any results or products under that agreement directly for profit. We do not believe this
negatively impacts the development and commercialization of our products because this agreement focuses on studying the effect of certain
proteins, unrelated to our products. Instead, the purpose of our involvement under the Renewed Cooperation Agreement is to support the
NTU with funds and equipment for the separation and enrichment of target cells. Our participation under the Renewed Cooperation Agreement
is aimed at demonstrating a potential application of our product to other research institutions, who could be our customers in the future.
Therefore, the results of this research under the Renewed Cooperation Agreement and the patentability and commercialization of such proteins,
do not affect the commercialization of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Termination</i>.</b>
Either party to the Cooperation Agreements and the Renewed Cooperation Agreement has the power to terminate such agreement if the NTU
cannot perform its duties and obligations due to force majeure events or if Advanced Biomed Taiwan cannot perform its duties and obligations,
provided that the NTU shall refund Advanced Biomed Taiwan any portion of the payment to the extent not actually spent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Licenses and Approvals</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
licenses and approvals that our subsidiaries are required to obtain for our operations in Taiwan and China as of the date of this Report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="white-space: nowrap; vertical-align: bottom; width: 29%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 24%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Licenses and <br/>
Approvals</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 24%; border-bottom: black 1.5pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PRC and Taiwan Regulatory</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Authority</b></p></td>
    <td style="white-space: nowrap; width: 1%; text-align: center">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Expiration Date</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">Advanced Biomed Taiwan</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Business Registration Certificate</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Tainan City Government</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">indefinite</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Advanced Biomed HK</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Certificate of Incorporation</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Registrar of Companies, Hong Kong Special Administrative
    Region</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">indefinite</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Business Registration Certificate</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrar of Companies, Hong Kong Special
    Administrative Region</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">August 9, 2026&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Shanghai Sglcell</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Business License</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Shanghai Administration for Market Regulation</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">indefinite</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Insurance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and our subsidiaries do
not currently maintain any commercial insurance. As such, we are susceptible to losses including property damage, accidents, or liabilities.
In the event that such damages are substantial, we may experience materially negative impact on our business operations, financial condition,
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This section summarizes the
principal Taiwan and PRC laws, rules and regulations related to our business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulations in Taiwan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations Relating to Taiwan Companies
Going to The Mainland to Engage in Technical Cooperation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 1, 1993, the Ministry
of Economic Affairs promulgated the Regulations Governing the Examination of Investment or Technical Cooperation in Mainland China (&#8220;Examination
of Investment or Technical Cooperation&#8221;) which became effective immediately. The regulations were amended and took effect on December
30, 2020. On March 1, 1993, the Ministry of Economic Affairs also promulgated the Regulations Governing the Approval of Investment or
Technical Cooperation in Mainland China (&#8220;Approval of Investment or Technical Cooperation&#8221;). The regulations were amended
and took effect on April 21, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a Taiwan company intends
to go to Mainland China for technical cooperation, in principle, it must submit an application to the Taiwan Investment Commission in
advance. According to the instructions of the Taiwan Investment Commission, the average review time for each case is 15-30 days. During
the review, the competent authority will consider factors such as the impact on the core competitiveness of other Taiwanese companies,
the layout of R&amp;D and innovation, and the infringement of intellectual property rights of other companies to comprehensively determine
whether to approve or not. If a Taiwan company and a Chinese company engage in technical cooperation without permission, the competent
authority may impose a fine of not less than NTD 50,000 but not more than NTD 25,000,000 in accordance with Paragraph 1 of Article 86
of the Taiwan -Mainland People&#8217;s Relations Act, and may terminate it within a time limit, or require the companies to make corrections.
Those who do not comply or make corrections within the time limit may be punished continuously. However, if a Taiwan company goes to Mainland
China to engage in technical cooperation that does not involve substantial technology outflow, for example, if the Chinese company has
no substantial involvement in product design and related R&amp;D processes, it is not necessary to apply to the Investment Review Committee
in advance. The competent authority may make alterations to the general and prohibited technical cooperation projects either by conducting
regular reviews annually or by conducting special reviews on a case-by-case basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations Relating to Exchange Control
or Currency Regulations or any Registration Requirements Under Anti-Money Laundering Laws</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 23, 1996, the Ministry
of Justice promulgated the Money Laundering Control Act (the &#8220;Act&#8221;), which became effective on April 23, 1997. The Act was
amended and became effective on November 7, 2018. The Act is enacted to prevent money laundering activities and combat-related crimes;
bolster anti-money laundering systems; maintain financial stability; increase transparency in money flows; and strengthen international
cooperation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Act, inward
and outward remittances involving currency exchange between NTD and another foreign currency are subject to an annual ceiling of: USD
5 million for individuals and USD 50 million for businesses. Any total annual remittance exceeding these thresholds requires approval
by the Central Bank of the Republic of China (CBC). Individual foreign exchange transactions over NTD 500,000 must be reported to the
CBC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no other foreign
exchange controls on trade, insurance, and authorized investment transactions, and no limit on repatriation of capital or profits from
portfolio investments. There are also no registration requirements under anti-money laundering laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations Relating to Anti-bribery or
Corruption</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bribery and corruption of
public officials in Taiwan are mainly regulated by the Anti-Corruption Act. The Anti-Corruption Act was promulgated by the Ministry of
Justice and took effect on July 15, 1963. It was later amended on June 22, 2016 and became effective on July 1, 2016. The Anti-Corruption
Act lists various behaviors that constitute bribery of public officials. Public officials who commit bribery may be punished by up to
life imprisonment together with a fine of up to NTD 100 million. Any private individual who commits bribery of public officials may be
punished by up to seven years of imprisonment together with a fine of up to NTD 3 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Hospitality accepted by a
public official is only allowed under limited circumstances specified in the Integrity and Ethics Directions for Civil Servants. The value
of gifts received by a public official cannot exceed NTD500. Gifts received due to visits to companies cannot exceed NTD 3,000. The total
value of gifts received from the same source in one year cannot exceed NTD 10,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Ethical Corporate Management
Best Practice Principles were promulgated by the Taipei Exchange and became effective on September 3, 2010. The principles were amended
and took effect on May 23, 2019. These principles are applicable to companies, their subsidiaries, any foundation to which the companies&#8217;
direct or indirect contribution of funds exceeds 50 percent of the total funds received, and other institutions or juridical persons which
are substantially controlled by such companies. The purpose of the principles is to foster a corporate culture of ethical management and
sound development and offer a reference framework for establishing good commercial practices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations Relating to employment relationships</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Employment Service Act
was promulgated by the Ministry of Labor and became effective on May 8, 1992. It was amended and became effective on November 28, 2018.
The Act is enacted to promote the employment of nationals with a view to enhance social and economic development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Labor Standards Act was promulgated
by the Ministry of Labor and became effective on July 30, 1984. It was amended and took effect on June 10, 2020. The Act is enacted to
provide minimum standards for working conditions, protect workers&#8217; rights and interests, strengthen employee-employer relationships
and promote social and economic development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 27 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations Relating to Intellectual Property</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Patents</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Patent Act was promulgated
by the Ministry of Economic Affairs and took effect on May 29, 1944. It was amended and took effect on May 4, 2022. The Patent Act is
formulated to encourage, protect and utilize the creations of invention, utility model and design in order to promote industrial development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Trademarks</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Trademark Act was promulgated
by the Ministry of Economic Affairs and became effective on May 6, 1930. Articles 68, 70, 95, 96 and 97 were amended on May 4, 2022, which
shall take effect on the date designated by Executive Yuan. This Act is enacted for protection of the rights of trademark, certification
mark, collective membership mark, collective trademark and the interests of consumers, maintenance of fair competition, and promotion
of development of the industry and commerce.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Copyright</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Copyright Act was promulgated
by the Ministry of Economic Affairs and took effect on May 14, 1928. It was amended and took effect on June 15, 2022. This Act is specifically
enacted for the purposes of protecting the rights and interests of authors with respect to their works, balancing different interests
for the common good of society, and promoting the development of national culture. Matters not provided for herein shall be governed by
the provisions of other acts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Trade Secrets</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Trade Secrets Act was
promulgated by the Ministry of Economic Affairs and became effective on January 17, 1996. It was amended and took effect on January 15,
2020. This Act is enacted to protect trade secrets, maintain industrial ethics and order in competition, and balance societal and public
interests. Matters not provided for in this Act shall be governed by other laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Regulations Relating to Data Protection</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Personal Data Protection
Act was promulgated by the National Development Council on August 11, 1995 and became effective on January 17, 1996. It was amended on
December 30, 2015, and became effective on March 15, 2016. The Personal Data Protection Act (hereinafter, the &#8220;PDPA&#8221;) is enacted
to regulate the collection, processing and use of personal data so as to prevent harm on personality rights, and to facilitate the proper
use of personal data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations on Taxation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Income Tax Act was promulgated
by the Ministry of Finance and became effective on February 17, 1943. It was amended on April 28, 2021 and became effective on July 1,
2021. Income tax is classified into consolidated income tax and profit-seeking enterprise income tax. For any individual having income
from sources in the Republic of China, consolidated income tax shall be levied in accordance with this Act on his income derived from
sources in the Republic of China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Tax Collection Act was
promulgated by the Ministry of Finance and became effective on October 22, 1976. It was amended on December 17, 2021 and became effective
on January 1, 2022. Collection of taxes shall be governed by this Act. Where a profit-seeking enterprise ceases to exist after a merger,
the surviving or newly incorporated profit-seeking enterprise shall pay in full the taxes originally payable by the dissolved enterprise
prior to the merger. Major taxes on corporations include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Corporate income tax (&#8220;CIT&#8221;)</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the total taxable income
of a profit-seeking enterprise is NTD120,000 or less, the profit-seeking enterprise is exempt from tax. If the total taxable income of
a profit-seeking enterprise is more than NTD120,000 but not more than NTD 200,000, the income tax payable is computed based on the following
formula: (Profit-NTD120,000) x 50%. As for a profit-seeking enterprise with the total taxable income of more than NTD200,000, the income
tax rate shall be: Profit x 20%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Profit retention tax</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An additional profit retention
tax of 5% is imposed on any current earnings of a corporation that remain undistributed by the end of the following year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations Relating to Bio Industry in
Taiwan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Act for the Development of Biotech and
Pharmaceutical Industry</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2007, Act for the Development
of Biotech and Pharmaceutical Industry (the &#8220;Statute&#8221;) was enacted in order to promote the development of the biotech and
pharmaceutical industry in Taiwan so that it can bring about changes in the economic structure of the country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By 2022, the scope of the
Statute covers industries that deals in new drugs, new dosage forms, high-risk medical devices, regenerative medicine, precision medicine,
digital medicine, innovative technology platforms dedicated to biotech and pharmaceutical industry and other strategic biotech and pharmaceutical
products used by human beings, animals and plants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Statute permits biotech
and new pharmaceutical companies to offset up to 30% of their expenses for personnel training and R&amp;D against enterprise income tax
over a period of five years. Up to five percent (5%) of the annual investment amount may be credited against the profit-seeking enterprise
income tax payable by it in the then current year from the first year the biotech and pharmaceutical company has payable profit-seeking
income tax; or up to three percent (3%) of the annual investment amount may be credited against the profit-seeking enterprise&#8217;s
income tax payable in each of the three years from the first year the biotech and pharmaceutical company has payable profit-seeking income
tax. In addition, based on Article 5, up to 25% of the research and development investment of the biotech companies that engage in research,
development, and manufacturing may be deducted from the amount of profit-seeking enterprise income tax payable for each year within five
years from the year in which the payable profit-seeking enterprise income tax is incurred with the annual deduction capped at 50% of the
tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Statute provides for tax
incentives to high-level professionals and technology investors to participate in company operations and R&amp;D (Art. 7), to elaborate,
up to 20% of the price paid for the shares may be deducted from the payable profit-seeking enterprise income tax for each year within
five years from the year a payable profit-seeking enterprise income tax is incurred with the annual deduction capped at 50% of the tax.
Moreover, if the senior professional staff or technology investors of the biotech companies receive newly issued stock or stock options
as a result of reward or due to technology invested as capital stock and have held shares or stock options, been employed, or provided
technical services cumulatively for two years, they may choose to be taxed at the lower of the &#8220;transfer price&#8221; or the &#8220;current
price or price at which the stock was acquired.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, researchers of schools
and institutions who are the main technology providers of the start-up biotech companies are exempted from the prohibitions against business
operation and part-time employment and the restrictions on shareholding percentage under Article 34 of the Act Governing the Appointment
of Educators and Articles 13 and 14 of the Civil Servants Work Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulations in the PRC</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations Relating to Medical Devices
in the PRC</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Regulations Relating to Classification
of Medical Devices</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Regulations
on the Supervision and Administration of Medical Devices promulgated on January 4, 2000, effective on June 1, 2014, amended by the State
Council on May 4, 2017 and now effective, and then amended on February 9, 2021 but not yet effective until June 1, 2021 (&#8220;Regulation
on Supervision and Administration of Medical Devices&#8221;), the China Food and Drug Administration (&#8220;CFDA&#8221;) of the State
Council shall be responsible for the national administration and supervision of medical devices of the PRC and its local counterparts
take charge of the local administration and supervision of medical devices of the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under this regulation, medical
devices have been classified into three categories based on the degree of risk. Class I medical devices shall refer to those devices with
low level of risks and whose safety and effectiveness can be ensured through routine administration. Class II medical devices shall refer
to those devices with moderate risks that must be strictly controlled and regulated to ensure their safety and effectiveness. Class III
medical devices shall refer to those devices with relatively high risks that must be strictly controlled and regulated through special
measures to ensure their safety and effectiveness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, the products we
are approved by NMPA to manufacture and sell are Class I medical device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Registration and Filings of Medical Devices</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Regulations
on the Supervision and Administration of Medical Devices (&#8220;the Supervision and Administration of Medical Devices&#8221;), which
was amended and came into effect on May 4, 2017. Then it was amended on February 9, 2021 and came into effect on June 1, 2021, Class I
medical devices are subject to filing administration, and Class II and Class III medical devices are subject to pre-approval registration
administration. A registration certificate for Class II and Class III medical devices are issued upon approval, which is valid for five
years and may be renewed six months prior to its expiration date. In addition, a registrant or record-filing party of medical devices
may manufacture medical devices on its own or entrust enterprises that meet the provisions hereof and have corresponding conditions to
manufacture medical devices. In the event of entrusted manufacture of medical devices, the registrant or record-filing party of medical
devices shall be responsible for the quality of medical devices manufactured under entrustment, and strengthen management of the manufacturing
activities of the entrusted manufacturers to ensure that they carry out manufacturing in accordance with statutory requirements. The registrant
or record-filing party of medical devices shall enter into an entrustment agreement with the entrusted manufacturer to specify the rights,
obligations and responsibilities of both parties. The entrusted manufacturer shall organize manufacture of medical devices in accordance
with laws and regulations, GMP, compulsory standards, product technical requirements and the entrustment agreement, be responsible for
the manufacturing activities and accept the supervision of the entrusting party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials are not required
for the filing of the Class I medical devices, but necessary for the registration of Class II and Class III medical device with certain
exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among our products, A<sup>+</sup>Pre
and AC-1000 are Class I medical devices and have passed NMPA registration review. A<sup>+</sup>CellScan, A<sup>+</sup>CellScan Chip, and
A<sup>+</sup>SCDrop are Class II medical devices but do not need to conduct clinical trials. A<sup>+</sup>LCGuard is Class III medical
device and is required to conduct clinical trials before completing the registration process. We have already started the registration
process and plan to begin the clinical research in November 2025. Specifically, in June 2025, the Company and the CRO began collaborating
on drafting the clinical research protocol and started preparing the necessary equipment, consumables, reagent kits, and other materials
for the study. We expect that the clinical research protocol may pass ethical review and receive ethics committee approval by the end
of October 2025. Thereafter, we plan to initiate the trial stage of the clinical research, with completion anticipated within six months
of November 2025. Based on the results of clinical research, we plan to formulate a work plan for large-scale clinical trials and proceed
with the clinical trial. We anticipate that we will obtain the required registration certificate by October 2027.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Production License for Medical Devices</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Regulation
on the Supervision and Administration of Medical Devices promulgated on July 30, 2014 and came into effect on October 1, 2014, as amended
in 2017 and came into effect on May 4, 2017 (amended on February 9, 2021, came into effect on June 1, 2021), and the Administrative Measures
on the Production Supervision of Medical Devices promulgated on July 30, 2014 and came into effect on October 1, 2014, as amended in March
10, 2022 and came into effect on May 1, 2022, manufacturers engaged in the manufacturing of Class I medical devices are subject to production
filing administration and receive production filing certificates upon satisfaction of filing requirements; while those engaged in the
manufacturing of Class II and Class III medical devices are subject to pre-approval licensing administration and receive medical device
production licenses upon receipt of approval for licensing. A medical device production license is valid for five years and may be renewed
six months prior to its expiration date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 30 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before obtaining production
licenses from local government authorities, our product must pass NMPA&#8217;s registration review. Among our products, A<sup>+</sup>Pre
and AC-1000 and their corresponding chips have passed NMPA registration review, A<sup>+</sup>CellScan, A<sup>+</sup>CellScan Chip, and
A<sup>+</sup>SCDrop are at the registration application stage, the four matching immunostaining kits are under NMPA registration review.
A<sup>+</sup>LCGuard is required to conduct clinical trials before completing the registration process. We have already started the registration
process and plan to begin clinical research in November 2025. Specifically, in June 2025, the Company and the CRO began collaborating
on drafting the clinical research protocol and started preparing the necessary equipment, consumables, reagent kits, and other materials
for the study. We expect that the clinical research protocol may pass ethical review and receive ethics committee approval by the end
of October 2025. Thereafter, we plan to initiate the trial stage of the clinical research, with completion anticipated within six months
of November 2025. Based on the results of clinical research, we plan to formulate a work plan for large-scale clinical trials and proceed
with the clinical trial. We anticipate that we will obtain the required registration certificate by October 2027.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a manufacturer
of medical devices shall satisfy the following conditions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="width: 24px; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">possessing production sites, environmental conditions, production equipment and professional technicians that are suitable for such medical device produced;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">possessing organizations or professional examination staff and examination equipment that carry out quality examination for such medical device produced;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">formulating a management system which ensures the quality of such medical device;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">having capability of after-sale services that is suitable for such medical device produced; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">satisfying the requirements as prescribed in production R&amp;D and production technique documents.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this Report,
we have obtained the license for the production of the Class I medical device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Production and Quality Management of
Medical Devices</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Administrative
Measures on the Supervision of the Production of Medical Devices promulgated on December 29, 2014 and came into effect on March 1, 2015,
as amended in March 10, 2022 and came into effect on May 1, 2022, and the Standards on Production and Quality Management of Medical Devices
promulgated by the CFDA on December 29, 2014 and came into effect on March 1, 2015, an enterprise engaged in the production of medical
devices shall establish and effectively maintain a quality control system in accordance to the requirements of the Standards on Production
and Quality Management of Medical Devices. The enterprise engaged in the production of medical devices shall regularly conduct comprehensive
self-inspection on the operation of quality management system and submit this report to the local food and drug supervision and administration
authorities before the end of every year. The enterprise shall also establish its procurement control procedure and assess its suppliers
by establishing an examination system to ensure the purchased products are in compliance with the statutory requirements. The enterprise
shall apply risk management to the whole process of design and development, production, sales and after-sale services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to The Notice of
Four Guidelines including On-site Inspection Guidelines for the standards on Production and Quality Management of Medical Devices promulgated
by the CFDA on September 25, 2015 and came into effect on September 25, 2015, during the course of on-site verification of the registration
of medical devices and on-site inspection of production license t(including change production license), the inspection team shall, in
accordance with the guidelines, issue recommended conclusions for on-site inspections, which shall be divided into &#8220;Passed,&#8221;
&#8220;Failed&#8221; and &#8220;Reassessment after rectification.&#8221; During the supervision and inspection, if it is found that the
requirements of the key items or ordinary items that may have direct impact on product quality are not satisfied, the enterprise shall
suspend production and go through rectification. If it is found that the requirements of the ordinary items are not satisfied, and it
does not directly affect product quality, the enterprise shall rectify in a prescribed time. The regulatory authorities will examine and
verify the recommended conclusions and on-site inspection materials submitted by the inspection group and issue the final inspection results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Good Clinical Practice for Medical Devices</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 24, 2022, the CFDA
and the National Health and Family Planning Commission jointly promulgated the Good Clinical Practice for Medical Devices, which became
effective as of May 1, 2022. The regulation includes full procedures of clinical trial of medical devices, including, among others, the
protocol design, conduction, monitoring, verification, inspection, and data collection, recording, analysis and conclusion and reporting
procedure of a clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">For conducting clinical trials
of medical devices, an applicant shall organize to formulate scientific and reasonable clinical trial protocol based on the categories,
risks and intended use of the medical devices for the clinical study. The applicant shall be responsible for organizing to develop and
revise of the researcher&#8217;s manual, clinical trial protocol, informed consent form, case report form, relevant standard operating
procedures and other relevant documents, and shall be responsible for organizing necessary trainings for the clinical trials. The applicant
shall select the clinical trial institutions and its researchers from the qualified medical device clinical trial institutions according
to the characteristics of the medical devices to be used in the clinical study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an applicant for clinical
trials of medical devices, we are responsible for initiating, applying, organizing and monitoring such clinical trials, and shall be responsible
for the authenticity and reliability of the clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Operation License for Medical Device</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Supervision
and Administration of Medical Devices, filing and licensing are not required for the operation of Class I medical devices. Operators engaged
in the operation of Class II medical devices are subject to filing administration and will receive medical device operation filing certificate
upon satisfaction of filing requirement, while operators engaged in the operation of Class III medical devices are subject to pre-approval
licensing administration and will receive medical device operation license upon receipt of approval for licensing. A medical device operation
license is valid for five years and may be renewed six months prior to its expiration date</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To engage in business operations
of medical devices, the following requirements shall be met:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Having a quality control institution or staff corresponding to the business scope and scale, and the staff shall have relevant education or professional titles certified by the state;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Having an operation and storage premises corresponding to the business scope and scale;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Having storage conditions corresponding to the business scope and scale; warehouses are not required if all storage is commissioned to other operators of medical devices;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Having a quality control system corresponding to the medical devices concerned; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Possessing the capability of professional guidance, technical training and after-sale service corresponding to the medical devices it operates; or it has come into an agreement on technical support with a relevant institution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An enterprise to be engaged
in business operations of Category III medical devices shall also have a computerized information management system compliant with quality
standards to ensure traceability of products. An enterprise to be engaged in business operations of Category I or Category II medical
devices is encouraged to set up such a system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Special Procedures for Examination and
Approval of Innovative Medical Devices</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 2017, the General
Office of the CPC Central Committee and the General Office of the State Council issued the Opinions on Deepening the Reform of the Evaluation
and Approval Systems and Encouraging Innovation on Drugs and Medical Devices, which aims to encourage the innovation for medical devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Opinions,
the priority review and approval will be applicable to innovative medical devices supported by the National Science and Technology Major
Projects and the National Key R&amp;D Program of China, and the clinical trials of which having been conducted by the National Clinical
Research Center and approved by the management department of National Clinical Research Center. Pursuant to the Special Procedures for
Examination and Approval of Innovative Medical Devices which were promulgated by the NMPA on November 2, 2018 and came into effect on
December 1, 2018, special procedures shall be applicable to the examination and approval for medical devices in the following circumstances:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">if the applicant legally owns the invention patent of the core technology of the product through its technological innovation activities in the PRC, or legally obtained the invention patent or the right of use thereof through transfer in the PRC, and that the interval between the date of application for the special examination and approval of innovative medical devices to the date of authorized publication should not exceed five years; or the patent administration department of the State Council has disclosed the application for the invention patent of the core technology and the Patent Search and Consultation Center of the National Intellectual Property Administration of the PRC has issued the patent search report setting out the novelty and innovation of the core technology solution of the product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the applicant has developed the prototype product and completed the preliminary research under a true and controllable process that generated complete and traceable data; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the product has major working mechanism or mechanism of action which is the first of its kind in the PRC, has fundamental improvement in product performance or safety compared with similar products, is of an internationally leading standard in terms of techniques and has significant clinical value. The Center for Medical Device Evaluation of the NMPA should give priority to the innovative medical devices in their technical review upon receiving the registration application, after which the NMPA will give priority to the product in their administrative approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Advertisements of Medical Devices</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Regulations
on Tentative Measures for the Censorship of Advertisement for Drugs, Medical Devices, Dietary Supplements, Food Formula for Special Medical
Purpose promulgated by SAMR on December 24, 2019 and came into effect on March 1, 2020, the State Administration for Market Regulation
is responsible for organizing and guiding the review of advertisements for drugs, medical devices, health foods and formula foods for
special medical purposes. The administrations for market regulation and drug administrations (hereinafter referred to as the &#8220;advertisement
review authorities&#8221;) of all provinces, autonomous regions and centrally administered municipalities shall be responsible for the
review of advertisements for drugs, medical devices, health food and formula food for special medical purposes, and may entrust other
administrative authorities to implement review of advertisements pursuant to the law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity period of the
advertisement approval number for drugs, medical devices, health food and formula food for special medical purposes shall be consistent
with the shortest validity period of the product registration certificate, filing certificate or production license. If no valid period
is prescribed in the product registration certificate, filing certificate or production license, the valid period of the advertisement
approval number shall be two years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advertisements for drugs,
medical devices, health food and formula food for special medical purposes shall be true and legitimate and shall not contain any false
or misleading contents. Advertisers shall be responsible for the veracity and legitimacy of the contents of advertisements for drugs,
medical devices, health food and formula food for special medical purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">National Medical Insurance Program</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The National Medical Insurance
Program (NMIP) was adopted pursuant to the Decision of the State Council on the Establishment of the Urban Employee Basic Medical Insurance
Program issued by the State Council on December 14, 1998, under which all employers in urban cities are required to enroll their employees
in the Urban Employee Basic Medical Insurance Program and the insurance premium is jointly contributed by the employers and employees.
Pursuant to the Opinions on the Establishment of the New Rural Cooperative Medical System forwarded by the General Office of the State
Council on January 16, 2003, China launched the New Rural Cooperative Medical System to provide medical insurance for rural residents
in selected areas which has since spread to the whole nation. The State Council promulgated the Guiding Opinions of the State Council
about the Pilot Urban Resident Basic Medical Insurance on July 10, 2007, under which urban residents of the pilot district, rather than
urban employees, may voluntarily join Urban Resident Basic Medical Insurance. In 2015, the PRC government announced the Outline for the
Planning of the National Medical and Health Service System (2015-2020) which aims to establish a basic medical and health care system
that covers both rural and urban citizens by 2020. On January 3, 2016, the State Council issued the Opinions on Integrating the Basic
Medical Insurance Systems for Urban and Rural Residents to integrate the Urban Resident Basic Medical Insurance and the New Rural Cooperative
Medical System and the establishment of a unified Basic Medical Insurance for Urban and Rural Residents, which will cover all urban and
rural non-working residents expect for rural migrant workers and persons in flexible employment arrangements who participate in the basic
medical insurance for urban employees. The National Healthcare Security Administration (NHSA) is the responsible agency that makes the
final determination on whether a product may be covered by the NMIP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With regard to reimbursement
for medical devices and diagnostic tests, the Notice of Opinion on the Diagnosis and Treatment Management, Scope and Payment Standards
of Medical Service Facilities Covered by the National Urban Employees Basic Medical Insurance Scheme (Lao She Bu Fa [1999] No. 22) prescribes
the coverage of diagnostic and treatment devices and diagnostic tests where part of the fees is paid through the basic medical insurance
scheme. It also includes a negative list that precludes certain devices and medical services from governmental reimbursement, which includes
(i) examination and treatment items by applying large medical devices such as positron emission tomography (PET), electron beam CT, ophthalmic
excimer laser therapy instruments, etc.; (ii) rehabilitation appliances such as spectacles, artificial dentures, artificial eyes, artificial
limbs and hearing aids, etc.; (iii) medical devices for health care, massage, physical examination and treatment for own use; and (iv)
disposable materials for medical use that cannot be charged separately as stipulated by price authorities of all provinces. Detailed reimbursement
coverage and rate for medical devices and medical services (including diagnostic tests and kits) are subject to each province&#8217;s
local policies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therefore, every covered individual
is eligible to request reimbursement from the NMIP for medical expenses, but the reimbursement rate and coverage are determined on a case-by-case
basis. Based on our understanding of applicable PRC laws and regulations, the reimbursement rate and coverage for certain products are
different for each individual and are subject to the following factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Whether the product is covered by the NMIP or whether the product is part of a procedure or service that is covered by the NMIP. If not covered, the NMIP may deny the request for reimbursement or reduce the reimbursement rate and coverage;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The region and status of individuals seeking reimbursement. NMIP varies in different regions and types, leading to different reimbursement ratios. For instance, the basic medical insurance for urban employees generally covers around 50% to 80% of basic medical expenses, while the rural resident medical insurance typically covers around 60% to 80%;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Hospital level. The reimbursement ratio of NMIP is related to the level and grade of hospitals performing services. For example, a level 3 hospital&#8217;s service is generally more expensive than primary healthcare institutions, and the reimbursement ratio for level 3 hospitals is lower than for primary healthcare institutions. Typically, an individual who received services from a primary care provider can get a relatively high reimbursement rate and coverage for medical expenses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 3pt"></p><div>

</div><!-- Field: Page; Sequence: 34 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Individual payment status. The reimbursement ratio of NMIP is also related to the individual payment status. If an individual contributes more and for a longer period of time, the reimbursement ratio will correspondingly increase; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Special diseases or major illnesses. For certain special diseases or major illnesses, the reimbursement ratio of medical insurance may be correspondingly increased, or special medical subsidies or assistance may be provided to alleviate the financial burden on patients by NHSA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this Report,
our products are not covered by any national or provincial medical insurance programs. Currently, A+LCGuard is the only product we are
applying for NMIP coverage. There is no fixed timeline to get a product covered by NMIP, as the application process involves multiple
procedures and interactions with NHSA that are beyond the applicant&#8217;s control. To our knowledge, the application process may take
one to two years to complete. Currently, A+LCGuard is the only product we are applying for NMIP coverage. Although we strive to make our
products covered by the NMIP in the future, there is no guarantee that the NHSA will approve our applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Export Registration</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Administrative
Measures on the Supervision of the Production of Medical Devices promulgated on December 29, 2014 and came into effect on March 1, 2015,
as amended in March 10, 2022 and came into effect on May 1, 2022, in accordance with the spirit of the Notice of Guo Ban Fa [94] No. 66
of the State Council, conducts inspections of safety and legality of the exported products manufactured by domestic enterprises, grants
legitimate production license in China (if these products are sold within Chinese territory) and files the relevant product information
by its branches at the level of a districted city for recordation. In accordance with international practice, the quality of exported
medical devices is mainly supervised by the importing countries. However, some importing countries/regions may require exporting enterprises
to provide Medical Device Product Export Sales Certificates issued by the CFDA. Pursuant to Announcement on Issuing the Provisions on
the Administration of Medical Device Product Export Sales Certificates, promulgated by the CFDA and effective on September 1, 2015, such
exporting enterprises may apply to the provincial departments of the CFDA at the places where enterprises are located for Medical Device
Product Export Sales Certificates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The premise of obtaining Medical
Device Product Export Sales Certificates is that the relevant production enterprises have obtained medical device product registration
certificates and production licenses or have undergone the formalities for recordation and production recordation of medical device products
in China. The valid period of Medical Device Product Export Sales Certificates, except being specified for one time use, shall not expire
after the earliest deadline of any certificate among various certificates submitted by the enterprise amid the application materials,
and shall be no longer than two years. Where the relevant materials submitted by an enterprise change, the enterprise shall report to
the certificate issuing department in a timely manner. Where the relevant materials change, or the Medical Device Product Export Sales
Certificate still needs to be used after its expiration, the enterprise shall apply for a new Medical Device Product Export Sales Certificate.
Where the CFDA find that any relevant enterprises fail to meet the requirements of relevant regulations on production, they shall downgrade
the credit ratings of such enterprises to lower levels; or, when any enterprises are considered failing to meet the requirements for issuance
of certificates anymore, or the relevant materials submitted by the enterprises change, the provincial CFDA departments shall notify the
relevant information in a timely manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations Relating to M&amp;A Rules and
Overseas Listings</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2006, six PRC
regulatory agencies, including the China Securities Regulatory Commission, or the CSRC, adopted the Regulations on Mergers of Domestic
Enterprises by Foreign Investors, or the M&amp;A Rules, which became effective on September 8, 2006 and was amended on June 22, 2009.
Foreign investors shall comply with the M&amp;A Rules when they purchase equity interests of a domestic company or subscribe the increased
capital of a domestic company, thus changing the nature of the domestic company into a foreign-invested enterprise; or when the foreign
investors establish a foreign-invested enterprise in the PRC, purchase the assets of a domestic company and operate the assets; or when
the foreign investors purchase the asset of a domestic company, establish a foreign-invested enterprise by injecting such assets and operate
the assets. The M&amp;A Rules purport, among other things, to require offshore special purpose vehicles formed for overseas listing purposes
through acquisitions of PRC domestic companies and controlled by PRC companies or individuals, to obtain the approval of the CSRC prior
to publicly listing their securities on an overseas stock exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 35 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Anti-Monopoly
Law which took effect as of August 1, 2008, where the concentration of business operators reaches the filing thresholds stipulated by
the State Council, business operators shall file a declaration with the SAMR, and no concentration shall be implemented until the SAMR
clears the anti-monopoly filing. Pursuant to the Notice of the General Office of the State Council on the Establishment of the Security
Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors and the Security Review Rules issued by the General
Office of the State Council on February 3, 2011 and became effective on March 3, 2011, mergers and acquisitions by foreign investors that
raise &#8220;national defense and security&#8221; concerns, and mergers and acquisitions through which foreign investors may acquire de
facto control over domestic enterprises that raise &#8220;national security&#8221; concerns, are subject to strict review by the PRC government
authorities. On August 25, 2011, the MOFCOM issued the Provisions of the Ministry of Commerce for the Implementation of the Security Review
System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, which provides that if a foreign investor&#8217;s merger
or acquisition of a domestic enterprise falls within the scope of security review specified in the Notice of the General Office of the
State Council on the Establishment of the Security Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors,
the foreign investor shall file an application with MOFCOM for security review. Whether a foreign investor&#8217;s merger or acquisition
of a domestic enterprise falls within the scope of security review or not shall be determined based on the substance and actual influence
of the merger or acquisition transaction. No foreign investor is allowed to substantially avoid the security review in any way, including
but not limited to, holding shares on behalf of others, trust arrangements, multi-level reinvestment, leasing, loans, contractual control,
or overseas transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 17, 2023, the
CSRC released Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (the &#8220;Trial Measures&#8221;)
which came into effect on March 31, 2023. Pursuant to Trial Measures, a PRC domestic company that seeks to offer and list securities in
overseas markets, either in direct or indirect overseas offering, shall fulfil the filing procedure with the CSRC per requirement of the
Trial Measures, submit relevant materials that contain a filing report and a legal opinion, and provide truthful, accurate and complete
information on the shareholder and etc. Direct overseas offering and listing by domestic companies refers to such overseas offering and
listing by a joint-stock company incorporated domestically. Any overseas offering and listing made by an issuer that meets both the following
conditions will be determined as indirect offering and listing in overseas market and, therefore, be subject to filing requirement: (i)
50% or more of the issuer&#8217;s operating revenue, total profit, total assets or net assets as documented in its audited consolidated
financial statements for the most recent accounting year is accounted for by domestic companies; and (ii) the main parts of the issuer&#8217;s
business activities are conducted in the Mainland China, or its main places of business are located in the Mainland China, or the senior
managers in charge of its business operation and management are mostly Chinese citizens or domiciled in the Mainland China. The determination
as to whether or not an overseas offering and listing by domestic companies is indirect, shall be made on substance over form basis. In
addition, initial public offerings or listings in overseas markets or subsequent securities offerings and listing of an issuer in overseas
market other than where it has offered and listed shall be filed with the CSRC within 3 working days after the relevant application is
submitted overseas. Subsequent securities offerings of an issuer in the same overseas market where it has previously offered and listed
securities shall be filed with the CSRC within 3 working days after such offering is completed. A PRC domestic company that seeks to directly
or indirectly list its domestic assets in overseas markets through single or multiple acquisitions, share swaps, transfers of shares or
other means, shall also fulfil the filing procedure as prescribed above. Furthermore, upon the occurrence of any of the material events
specified below after an issuer has offered and listed securities in an overseas market, the issuer shall submit a report thereof to CSRC
within 3 working days after the occurrence and public disclosure of the event: (i) change of control; (ii) investigations or sanctions
imposed by overseas securities regulatory agencies or other relevant competent authorities; (iii) change of listing status or transfer
of listing segment; (iv) voluntary or mandatory delisting. Where an issuer&#8217;s main business undergoes material changes after overseas
offering and listing, and is therefore beyond the scope of business stated in the filing documents, such issuer shall submit to the CSRC
an ad hoc report and a relevant legal opinion issued by a domestic law firm within 3 working days after occurrence of the changes. However,
the PRC Companies already listed overseas before effectiveness of Trial Measures are not required to submit any records with the CSRC
until they have successive refinancing demand or other filing requirement. A six-month transition will be given to PRC domestic enterprises
that have obtained the approval of overseas regulatory bodies or exchanges since implementation date of the Trial Measure but have not
completed the overseas listing. If they fail to complete the overseas listing within six months, they should file records with CSRC according
to the requirements. The Trial Measure further stipulate that CSRC may order rectification, issue warnings, and impose a fine between
RMB1 million and RMB10 million if an applicant fails to fulfill the filing requirements with the CSRC or conducts an overseas offering
or listing in violation of the Trial Measure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 24, 2023, the
CSRC, together with other PRC government authorities, released the Provisions on Strengthening the Confidentiality and Archives Administration
Related to the Overseas Securities Offering and Listing by Domestic Enterprises (the &#8220;Confidentiality and Archives Administration
Provisions&#8221;), which came into effect on March 31, 2023. The Confidentiality and Archives Administration Provisions require, among
others, that PRC domestic enterprises seeking to offer and list securities in overseas markets, either directly or indirectly, shall establish
the confidentiality and archives system, and shall complete approval and filing procedures with competent authorities, if such PRC domestic
enterprises or their overseas listing entities provide or publicly disclose documents or materials involving state secrets and work secrets
of PRC government agencies to relevant securities companies, securities service institutions, overseas regulatory agencies and other entities
and individuals. It further stipulates that providing or publicly disclosing documents and materials which may adversely affect national
security or public interests, and accounting files or copies of important preservation value to the state and society shall be subject
to corresponding procedures in accordance with relevant laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations Relating to Foreign Investment</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investment activities in the
PRC by foreign investors are principally governed by the Industry Guidelines of Encouraged Foreign Investment, or the Industry Guidelines,
effective on January 27, 2021, and the Special Administrative Measures for Entrance of Foreign Investment (Negative List), or the Negative
List, most recently amended on April 8, 2024 and effective on September 6, 2024, and together with the PRC Foreign Investment Law, which
took effect on January 1, 2020, and its respective implementation rules and ancillary regulations. The Industry Guidelines and the Negative
List lay out the basic framework for foreign investments in China, classifying businesses into three categories with regard to foreign
investments: &#8220;encouraged&#8221;, &#8220;restricted&#8221; and &#8220;prohibited&#8221;. Industries not listed in the Industry Guidelines
or the Negative List are generally deemed as falling into a fourth category &#8220;permitted&#8221; unless specifically restricted by
other PRC laws. The Negative List specifies that Investment in Internet news service, Internet publishing service, Internet audio-visual
program service, cyber culture operation (except for music) and Internet information dissemination service (except for contents opened
up in China&#8217;s WTO commitments) shall be prohibited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the PRC Foreign
Investment Law, foreign investments shall enjoy pre-entry national treatment, except for those foreign-invested entities that operate
in industries deemed to be either &#8220;restricted&#8221; or &#8220;prohibited&#8221; in the &#8220;negative list.&#8221; While foreign
investors shall refrain from investing in any of the foreign &#8220;prohibited&#8221; industries, foreign-invested entities operating
in foreign &#8220;restricted&#8221; industries shall require market entry clearance and other approvals from relevant PRC governmental
authorities. Furthermore, the PRC Foreign Investment Law provides that foreign-invested enterprises that have been established before
the implementation of PRC Foreign Investment Law according to the then existing laws regulating foreign investments may maintain their
structure and corporate governance within five years after the implementation of the PRC Foreign Investment Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 19, 2020, MOFCOM
and NDRC released the Measures for the Security Review of Foreign Investments, which took effect on January 18, 2021. For foreign investments
within the following scope, foreign investors or the relevant parties in China (hereinafter referred to collectively as the &#8220;parties
concerned&#8221;) shall take the initiative to declare to the office of the working mechanism prior to implementation of the investments:&#8230;(II)
investments in important agricultural products, important energy and resources, important equipment manufacturing, important infrastructure,
important transport services, important cultural products and services, important information technology and Internet products and services,
important financial services, key technologies and other important fields relating to national security, and obtaining the actual controlling
stake in the investee enterprise. Prior to a decision made by the office of the working mechanism, the parties concerned shall not make
the investment. The parties concerned shall not make the investment unless the office of the working mechanism decides that security review
is not required. Where the declared foreign investment affects national security, a decision on prohibiting the investment shall be made.
Foreign-invested entities of the group have businesses that conduct Internet services, but not related to national security within the
scope of the regulations above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 37 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 26, 2019, the
State Council promulgated the Regulations for Implementing the PRC Foreign Investment Law, which took effect on January 1, 2020. The implementation
regulations further clarified that the State encourages and promotes foreign investments, protects the lawful rights and interests of
foreign investors, regulates foreign investment administration, continues to optimize foreign investment environment, and advances a higher-level
opening.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 30, 2019, MOFCOM
and SAMR jointly promulgated the Measures for Information Reporting on Foreign Investment, which became effective on January 1, 2020.
Pursuant to the Measures for Information Reporting on Foreign Investment, where a foreign investor carries out investment activities in
China directly or indirectly, the foreign investor or the foreign-invested enterprise shall submit the investment information to the competent
commerce department.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations relating to Anti-Monopoly and
Competition</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 11, 2020, the
Anti-Monopoly Commission of the State Council issued Anti-Monopoly Compliance Guideline for Business Operators, which requires business
operators to establish anti-monopoly compliance management systems under the PRC Anti-Monopoly Law to manage anti-monopoly compliance
risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 17, 2021, the State
Administration for Market Regulation, or the SAMR, issued a discussion draft of Provisions on the Prohibition of Unfair Competition on
the Internet, under which business operators should not use data or algorithms to hijack traffic or influence users&#8217; choices, or
use technical means to illegally capture or use other business operators&#8217; data. Furthermore, business operators are not allowed
to (i)&#160;fabricate or spread misleading information to damage the reputation of competitors, or (ii)&#160;employ marketing practices
such as fake reviews or use coupons or &#8220;red envelopes&#8221; to entice positive ratings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 7, 2021, the Anti-Monopoly
Commission of the State Council published Anti-Monopoly Guidelines for the Internet Platform Economy Sector that specified circumstances
where an activity of an internet platform will be identified as monopolistic act as well as concentration filing procedures for business
operators. According to the PRC Anti-Monopoly Law, if a business operator carries out a concentration in violation of the law, the relevant
authority shall order the business operator to terminate the concentration, dispose of the shares or assets or transfer the business within
a specified time limit, or take other measures to restore the pre-concentration status, and impose a fine of up to RMB500,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 23, 2021, the Standing
Committee of the National People&#8217;s Congress issued a discussion draft of the amended Anti-Monopoly Law, which proposes to increase
the fines for illegal concentration of business operators to no more than ten&#160;percent of its last&#160;year&#8217;s sales revenue
if the concentration of business operator has or may have an effect of excluding or limiting competitions, or a fine of up to RMB5 million
if the concentration of business operator does not have an effect of excluding or limiting competition. The draft also proposes that the
relevant authority shall investigate a transaction where there is any evidence that the concentration has or may have the effect of eliminating
or restricting competitions, even if such concentration does not reach the filing threshold.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations Relating to Cybersecurity and
Privacy Protection</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC Constitution states
that PRC law protects the freedom and privacy of communications of citizens and prohibits infringement of these rights. In recent years,
PRC government authorities have enacted legislation on the Internet use to protect personal information from any unauthorized disclosure.
Under the Several Provisions on Regulating the Market Order of Internet Information Services which was promulgated by MIIT on December
29, 2011, an Internet content service operator may not collect any user personal information or provide any such information to third
parties without the consent of a user, unless otherwise stipulated by laws and administrative regulations. An Internet content service
operator must expressly inform the users of the method, content and purpose of the collection and processing of such user personal information
and may only collect such information necessary for the provision of its services. An Internet content service operator is also required
to properly keep the user personal information, and in case of any leak or likely leak of the user personal information, the Internet
content service operator must take immediate remedial measures and, in severe circumstances, to make an immediate report to the telecommunication
regulatory authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Decision
on Strengthening Network Information Protection, which was promulgated by the Standing Committee of NPC on December 28, 2012, provides
that electronic information that is able to identify personal identities of citizens or is concerned with personal privacy of citizens
is protected by law and shall not be unlawfully obtained or provided. Internet content service operators collecting or using personal
electronic information of citizens shall specify purposes, manners and scopes of information collection and use, obtain the consent of
citizens concerned, and strictly keep confidential personal information collected. Internet content service operators are prohibited from
disclosing, tampering with, damaging, selling or illegally providing others with personal information collected. Technical and other measures
are required to be taken by Internet content service operators to prevent personal information collected from unauthorized disclosure,
damage or being lost. Internet content service operators are subject to legal liability, including warnings, fines, confiscation of illegal
gains, revocation of licenses or filings, closing of websites concerned, public security administration punishment, criminal liabilities,
or civil liabilities, if they violate relevant provisions on Internet privacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Order for
the Protection of Telecommunication and Internet User Personal Information which was promulgated by MIIT on July 16, 2013, any collection
and use of users&#8217; personal information must be subject to the consent of the users, abide by the principles of legality, rationality
and necessity and be within the specified purposes, methods and scopes. Pursuant to the Ninth Amendment to the Criminal Law which was
issued by the Standing Committee of NPC on August 29, 2015 and became effective on November 1, 2015, any Internet service provider that
fails to fulfil obligations to manage information and network security as required by applicable laws and refuses to rectify upon orders
from government authorities, will be subject to the criminal penalty if such failure (i) causes dissemination of illegal information in
large scale; (ii) causes user information leaks resulting in severe consequences; (iii) causes serious loss of evidence to criminal investigations;
or (iv) implicates other severe circumstances. Moreover, any individual or entity that (i) sells or provides personal information to others
in violation of applicable laws, or (ii) steals or illegally obtains any personal information, in either case implicating severe circumstances,
will be subject to the criminal penalty. The PRC government, however, has the power and authority to order Internet content service operators
to turn over personal information if an Internet user posts any prohibited content or engages in illegal activities on the Internet.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To further regulate cybersecurity
and privacy protection, the PRC Cybersecurity Law which was promulgated by the Standing Committee of NPC on November 7, 2016 and took
effect on June 1, 2017, provides that: subject to certain exceptions, (i) to collect and use personal information, network operators must
follow the principles of legitimacy, rightfulness, and necessity, disclose their rules of data collection and use, clearly express the
purposes, means, and scope of collecting and using the information, and obtain the consent of the persons whose data is gathered; (ii)
network operators can neither gather personal information unrelated to the services they provide, nor gather or use personal information
in violation of the provisions of laws and administrative regulations or the scopes of consent given by the persons whose data is gathered,
and must dispose of personal information they have saved in accordance with the provisions of laws and administrative regulations and
agreements reached with users; (iii) network operators cannot divulge, tamper with, or damage the personal information they have collected,
and cannot provide the personal information to others without the consent of persons whose data is collected. According to the PRC Cybersecurity
Law, personal information refers to all kinds of information that are recorded electronically or that can otherwise be used to independently
identify or be combined with other information to identify natural persons&#8217; personal information, including but not limited to natural
persons&#8217; names, dates of birth, identification numbers, biologically identified personal information, addresses, and telephone numbers.
Any Internet information services provider that violates these privacy protection requirements under the PRC Cybersecurity Law and related
laws and regulations may be ordered to turn in illegal gains generated from unlawful operations and pay a fine of no less than one but
no more than ten times of the illegal gains and may be ordered to cease the relevant business operations when the violation is serious.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 28, 2016, the CAC
issued the Administrative Provisions on Mobile Internet Applications Information Services, which became effective on August 1, 2016, to
further strengthen the regulation of the mobile app information services. Pursuant to these provisions, owners or operators of mobile
apps that provide information services are required to be responsible for information security management, establish and improve the protective
mechanism for user information, observe the principles of legality, rightfulness and necessity, and expressly state the purpose, method
and scope of, and obtain user consent to, the collection and use of users&#8217; personal information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 8, 2017, the Supreme
People&#8217;s Court and the Supreme People&#8217;s Procuratorate issued the Interpretations of the Supreme People&#8217;s Court and the
Supreme People&#8217;s Procuratorate on Several Issues Concerning the Application of Law in the Handling of Criminal Cases Involving Infringement
of Citizens&#8217; Personal Information, or the Personal Information Interpretations, which became effective on June 1, 2017. The Personal
Information Interpretations provides more practical conviction and sentencing criteria for the infringement of citizens&#8217; personal
information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 23, 2019, the PRC
Office of the Central Cyberspace Affairs Commission and other three authorities jointly issued the Circular on the Special Campaign of
Correcting Unlawful Collection and Usage of Personal Information via Apps. Pursuant to this circular, (i) app operators are prohibited
from collecting any personal information irrelevant to their services; (ii) information collection and usage policy should be presented
in a simple and clear way, and such policy should be consented by the users voluntarily, and; (iii) authorization from users should not
be obtained by coercing users with default or bundling clauses or making consent a condition of service. App operators violating these
rules can be ordered by authorities to correct their noncompliance within a given period of time, be publicly reported, or ordered to
quit its operation or cancel its business license or operational permits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 10, 2019, the Ministry
of Public Security promulgated the Guidelines for Internet Personal Information Security Protection, which establishes the management
mechanism, security technical measures and business workflows for personal information security protection. On August 22, 2019, the CAC
promulgated the Provisions on the Cyber Protection of Children&#8217;s Personal Information which requires, among others, that network
operators who collect, store, use, transfer and disclose personal information of children under the age of 14 shall establish special
rules and user agreements for the protection of children&#8217;s personal information, inform the children&#8217;s guardians in a noticeable
and clear manner, and shall obtain the consent of the children&#8217;s guardians.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 28, 2019, the
CAC, MIIT, the Ministry of Public Security and SAMR jointly promulgated the Measures for the Determination of the Collection and Use of
Personal Information by Apps in Violation of Laws and Regulations, which provides guidance for the regulatory authorities to identify
the illegal collection and use of personal information through mobile apps, and for the app operators to conduct self-examination and
self-correction and social supervision by citizens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 28, 2020, the NPC approved
the Civil Code of the PRC or the Civil Code, which came into effect on January 1, 2021. Pursuant to the Civil Code, the personal information
of a natural person shall be protected by the law. Any organization or individual that needs to obtain personal information of others
shall obtain such information legally and ensure the safety of such information, and shall not illegally collect, use, process or transmit
personal information of others, or illegally purchase or sell, provide or make public personal information of others. Furthermore, information
processors shall not divulge or tamper with personal information collected or stored by them; without the consent of a natural person,
information processors shall not illegally provide personal information of such person to others, except for information that has been
processed so that specific persons cannot be identified and that cannot be restored. In addition, an information processor shall take
technical measures and other necessary measures to ensure the security of the personal information that is collected and stored and to
prevent the information from being divulged, tampered with or lost; where personal information has been or may be divulged, tampered with
or lost, the information processor shall take remedial measures in a timely manner, inform the natural person concerned in accordance
with the provisions and report the case to the relevant competent department.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 20, 2021, the SCNPC
adopted the Personal Information Security Law, which took effect on November 1, 2021. The Personal Information Protection Law includes
the basic rules for personal information processing, the rules for cross-border provision of personal information, the rights of individuals
in personal information processing activities, the obligations of personal information processors, and the legal responsibilities for
illegal collection, processing, and use of personal information. As the first systematic and comprehensive law specifically for the protection
of personal information in the PRC, the Personal Information Protection Law provides, among others, that (i) an individual&#8217;s consent
shall be obtained to use sensitive personal information, such as biometric characteristics and individual location tracking, (ii) personal
information operators using sensitive personal information shall notify individuals of the necessity of such use and impact on the individual&#8217;s
rights, and (iii) where personal information operators reject an individual&#8217;s request to exercise his or her rights, the individual
may file a lawsuit with a People&#8217;s Court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 14, 2021, the
CAC published the Regulations of Internet Data Security Management (Draft for Comments), which further regulate the internet data processing
activities and emphasize the supervision and management of network data security, and further stipulate the obligations of internet platform
operators, such as to establish a system for disclosure of platform rules, privacy policies and algorithmic strategies related to data.
Specifically, the draft regulations require data processors to, among others, (i) adopt immediate remediation measures when finding that
network products and services they use or provide have security defects and vulnerabilities, or threaten national security or endanger
public interest, and (ii) follow a series of detailed requirements with respect to processing of personal information, management of important
data and proposed overseas transfer of data. In addition, the draft regulations require data processors handling important data or the
data processors to be listed overseas to complete an annual data security assessment and file a data security assessment report to applicable
regulators. Such annual assessment, as required by the draft regulations, would encompass areas including, but not limited to, the status
of important data processing, data security risks identified and the measures adopted, the effectiveness of data protection measures,
the implementation of national data security laws and regulations, data security incidents that occurred and their handling, and a security
assessment with respect to sharing and provision of important data overseas. As of the date of this Report, the draft regulations have
been released for public comment only and have not been formally adopted. The final provisions and the timeline for its adoption are subject
to changes and uncertainties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, our business does not involve the collection of user data,
implicate cybersecurity, or involve any other type of foreign investment restricted industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations Relating to Intellectual Property
Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Patent</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents in the PRC are principally
protected under the Patent Law of the PRC. The duration of a patent right is either 10 years or 15 year or 20 years from the date of application,
depending on the type of patent right. The Patent Law of the PRC and its implementation rules provide for three types of patents, namely,
&#8220;invention&#8221;, &#8220;utility model&#8221; and &#8220;design&#8221;. Invention patents are valid for twenty years, utility model
patents are valid for fifteen years, while design patents are valid for ten years, from the date of application. The Chinese patent system
adopts a &#8220;first-to-file&#8221; principle, which means that where more than one person files a patent application for the same invention,
a patent will be granted to the person who files the application first. To be patentable, invention or utility models must meet three
criteria: novelty, inventiveness and practicability. A third party must obtain consent or a proper license from the patent owner to use
the patent. Otherwise, the use constitutes an infringement of the patent rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Copyright</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Copyright in the PRC, including
copyrighted software, is principally protected under the Copyright Law of the PRC and related rules and regulations. Under the Copyright
Law, promulgated in September 1990, implemented in June 1991, amended in October 2001, February 2010 and November 2020, and effective
on June 1, 2021 the term of protection for copyrighted software is 50 years. The Regulation on the Protection of the Right to Communicate
Works to the Public over Information Networks, as most recently amended on January 30, 2013, provides specific rules on fair use, statutory
license, and a safe harbor for use of copyrights and copyright management technology and specifies the liabilities of various entities
for violations, including copyright holders, libraries and Internet service providers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Trademark</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Registered Trademarks are
protected by the PRC Trademark Law which was adopted by the Standing Committee of NPC on August 23, 1982 and most recently amended on
April 23, 2019 as well as the Implementation Regulation of the PRC Trademark Law which was adopted by the State Council on August 3, 2002
and amended on April 29, 2014. The Trademark Office of the National Intellectual Property Administration under SAMR handles trademark
registrations and grants a term of ten years to registered trademarks which may be renewed for consecutive ten-year periods upon request
by the trademark owner. For licensed use of a registered trademark, the licensor shall file record of the licensing of the said trademark
with the Trademark Office, otherwise it may not defend against a bona fide third party. The PRC Trademark Law has adopted a &#8220;first-to-file&#8221;
principle with respect to trademark registration. Where a trademark for which a registration has been made is identical or similar to
another trademark which has already been registered or been subject to a preliminary examination and approval for use on the same kind
of or similar commodities or services, the application for registration of such trademark may be rejected. Any person applying for the
registration of a trademark may not prejudice the existing right first obtained by others, nor may any person register in advance a trademark
that has already been used by another party and has already gained a &#8220;sufficient degree of reputation&#8221; through such party&#8217;s
use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under PRC law, any of the
following acts will be deemed as an infringement to the exclusive right to use a registered trademark: (i) use of a trademark that is
the same as or similar to a registered trademark for identical or similar goods without the permission of the trademark registrant; (ii)
sale of any goods that have infringed the exclusive right to use any registered trademark; (iii) counterfeit or unauthorized production
of the label of another&#8217;s registered trademark, or sale of any such label that is counterfeited or produced without authorization;
(iv) change of any trademark of a registrant without the registrant&#8217;s consent, and selling goods bearing such replaced trademark
on the market; or (v) other acts that have caused any other damage to another&#8217;s exclusive right to use a registered trademark.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the PRC Trademark
Law, in the event of any of the foregoing acts, the infringing party will be ordered to stop the infringement immediately and may be imposed
a fine; the counterfeit goods will be confiscated. The infringing party may also be held liable for the right holder&#8217;s damages,
which will be equal to the losses suffered by the right holder as a result of the infringement, including reasonable expenses incurred
by the right holder for stopping the infringement, or the gains obtained by the infringing party if the losses are difficult to be ascertained.
If both gains and losses are difficult to be ascertained, the damages may be determined by referring to the amount of royalties for the
license of such trademarks, which will be one to five times of the royalties in the case of any serious infringement with malicious intent.
If the gains, losses and royalties are all difficult to be ascertained, the court may render a judgment awarding damages no more than
RMB5 million. Notwithstanding the above, if a distributor does not know that the goods it sells infringe another&#8217;s registered trademark,
it will not be liable for infringement provided that the seller shall prove that the goods are lawfully obtained and identify its supplier.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Domain Name</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Domain names are protected
under the Administrative Measures on Internet Domain Names promulgated by the MIIT on August 24, 2017 and effective as of November 1,
2017. Domain name registrations are handled through domain name service agencies established under the relevant regulations, and applicants
become domain name holders upon successful registration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations on Foreign Currency Exchange</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal regulations
governing foreign currency exchange in China are the Foreign Exchange Administration Regulations, most recently amended on August 5, 2008.
Under PRC foreign exchange regulations, payments of current account items, such as profit distributions, interest payments and trade and
service-related foreign exchange transactions, can be made in foreign currencies without prior approval from the State Administration
of Foreign Exchange, or SAFE, by complying with certain procedural requirements. By contrast, approval from or registration with appropriate
government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital account
items, such as direct investments, repayment of foreign currency-denominated loans, repatriation of investments and investments in securities
outside of China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 19, 2012, SAFE
promulgated the Circular of Further Improving and Adjusting Foreign Exchange Administration Policies on Foreign Direct Investment, or
Circular 59, which substantially amends and simplifies the current foreign exchange procedure. Pursuant to Circular 59, the opening of
various special purpose foreign exchange accounts, such as pre-establishment expenses accounts, foreign exchange capital accounts and
guarantee accounts, the reinvestment of RMB proceeds derived by foreign investors in the PRC, and remittance of foreign exchange profits
and dividends by a foreign-invested enterprise to its foreign stockholders no longer require the approval or verification of SAFE, and
multiple capital accounts for the same entity may be opened in different provinces, which was not possible previously. In 2013, SAFE specified
that the administration by SAFE or its local branches over direct investment by foreign investors in the PRC must be conducted by way
of registration and banks must process foreign exchange business relating to the direct investment in the PRC based on the registration
information provided by SAFE and its branches. In February 2015, SAFE promulgated the Notice on Further Simplifying and Improving the
Administration of the Foreign Exchange Concerning Direct Investment, or SAFE Notice 13. Instead of applying for approvals regarding foreign
exchange registrations of foreign direct investment and overseas direct investment from SAFE, entities and individuals may apply for such
foreign exchange registrations from qualified banks. The qualified banks, under the supervision of SAFE, may directly review the applications
and conduct the registration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 42 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2015, SAFE promulgated
the Circular of the SAFE on Reforming the Management Approach regarding the Settlement of Foreign Capital of Foreign-invested Enterprise,
or Circular 19, which expands a pilot reform of the administration of the settlement of the foreign exchange capitals of foreign-invested
enterprises nationwide. Circular 19 replaced both the Circular of the SAFE on Issues Relating to the Improvement of Business Operations
with Respect to the Administration of Foreign Exchange Capital Payment and Settlement of Foreign-invested Enterprises, or Circular 142,
and the Circular of the SAFE on Issues concerning the Pilot Reform of the Administrative Approach Regarding the Settlement of the Foreign
Exchange Capitals of Foreign-invested Enterprises in Certain Areas, or Circular 36. Circular 19 allows all foreign-invested enterprises
established in the PRC to settle their foreign exchange capital on a discretionary basis according to the actual needs of their business
operation, provides the procedures for foreign invested companies to use RMB converted from foreign currency-denominated capital for equity
investments and removes certain other restrictions that had been provided in Circular 142. However, Circular 19 continues to prohibit
foreign-invested enterprises from, among other things, using RMB funds converted from their foreign exchange capital for expenditure beyond
their business scope and providing entrusted loans or repaying loans between non-financial enterprises. SAFE promulgated the Notice of
the State Administration of Foreign Exchange on Reforming and Standardizing the Foreign Exchange Settlement Management Policy of Capital
Account, or Circular 16, effective June 2016, which reiterates some of the rules set forth in Circular 19. Circular 16 provides that discretionary
foreign exchange settlement applies to foreign exchange capital, foreign debt offering proceeds and remitted foreign listing proceeds,
and the corresponding RMB capital converted from foreign exchange may be used to extend loans to related parties or repay inter-company
loans (including advances by third parties). However, there are substantial uncertainties with respect to Circular 16&#8217;s interpretation
and implementation in practice. Circular 19 or Circular 16 may delay or limit us from using the proceeds of offshore offerings to make
additional capital contributions to our Shanghai subsidiary and any violations of these circulars could result in severe monetary or other
penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2017, SAFE promulgated
the Circular on Further Improving Reform of Foreign Exchange Administration and Optimizing Genuineness and Compliance Verification, or
Circular 3, which stipulates several capital control measures with respect to the outbound remittance of profits from domestic entities
to offshore entities, including (i) banks must check whether the transaction is genuine by reviewing board resolutions regarding profit
distribution, original copies of tax filing records and audited financial statements, and (ii) domestic entities must retain income to
account for previous years&#8217; losses before remitting any profits. Moreover, pursuant to Circular 3, domestic entities must explain
in detail the sources of capital and how the capital will be used, and provide board resolutions, contracts and other proof as a part
of the registration procedure for outbound investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 23, 2019, SAFE
issued Circular of the State Administration of Foreign Exchange on Further Promoting the Facilitation of Cross-border Trade and Investment,
or the Circular 28, which took effect on the same day. Circular 28 allows non-investment foreign-invested enterprises to use their capital
funds to make equity investments in China, provided that such investments do not violate the effective special entry management measures
for foreign investment (negative list) and the target investment projects are genuine and in compliance with laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulation on Foreign Debt</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A loan made by a foreign entity
as direct or indirect shareholder in a FIE is considered to be foreign debt in China and is regulated by various laws and regulations,
including the Regulation of the People&#8217;s Republic of China on Foreign Exchange Administration, the Interim Provisions on the Management
of Foreign Debts, the Statistical Monitoring of Foreign Debts Tentative Provisions, the Detailed Rules for the Implementation of Provisional
Regulations on Statistics and Supervision of External Debt, and the Administrative Measures for Registration of Foreign Debts. Under these
rules and regulations, a shareholder loan in the form of foreign debt made to a PRC entity does not require the prior approval of SAFE.
However, such foreign debt must be registered with and recorded by SAFE or its local branches within fifteen (15) business days after
entering into the foreign debt contract. Pursuant to these rules and regulations, the maximum amount of the aggregate of (i) the outstanding
balance of foreign debts with a term not longer than one year, and (ii) the accumulated amount of foreign debts with a term longer than
one year, of a FIE shall not exceed the difference between its registered total investment and its registered capital, or Total Investment
and Registered Capital Balance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 12, 2017, the People&#8217;s
Bank of China, or PBOC, promulgated the Notice of the People&#8217;s Bank of China on Matters concerning the Macro-Prudential Management
of Full-Covered Cross-Border Financing, or PBOC Circular 9, which sets forth an upper limit for PRC entities, including FIEs and domestic
enterprises, regarding their foreign debts. Pursuant to PBOC Circular 9, the outstanding cross-border financing of an enterprise (the
outstanding balance drawn, here and below) shall be calculated using a risk-weighted approach, or Risk-Weighted Approach, and shall not
exceed the specified upper limit, namely: risk-weighted outstanding cross-border financing &#163; the upper limit of risk-weighted outstanding
cross-border financing. Risk-weighted outstanding cross-border financing =&#8721; outstanding amount of RMB and foreign currency denominated
cross-border financing * maturity risk conversion factor * type risk conversion factor +&#8721; outstanding foreign currency denominated
cross-border financing * exchange rate risk conversion factor. Maturity risk conversion factor shall be 1 for medium- and long-term cross-border
financing with a term of more than one year and 1.5 for short-term cross-border financing with a term of one year or less than one year.
Type risk conversion factor shall be 1 for on-balance-sheet financing and 1 for off-balance-sheet financing (contingent liabilities) for
the time being. Exchange rate risk conversion factor shall be 0.5. The PBOC Circular 9 further provides that the upper limit of risk-weighted
outstanding cross-border financing for enterprises, or Net Asset Limits, shall be 200% of its net assets. The PBOC Circular 9 does not
supersede the Interim Provisions on the Management of Foreign Debts, but rather serves as a supplement to it. PBOC Circular 9 provided
for a one-year transitional period, or the Transitional Period, from its promulgation date for FIEs, during which period FIEs could choose
to calculate their maximum amount of foreign debt based on either (i) the Total Investment and Registered Capital Balance, or (ii) the
Risk-Weighted Approach and the Net Asset Limits. Under the PBOC Circular 9, after the Transitional Period ends on January 11, 2018, the
PBOC and SAFE will determine the cross-border financing administration mechanism for the foreign-invested enterprises after evaluating
the overall implementation of PBOC Circular 9. In addition, according to PBOC Circular 9, a foreign loan must be filed with SAFE through
the online filing system of SAFE after the loan agreement is signed and at least three business days prior to the borrower withdraws any
amount from such foreign loan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations Relating to Dividend Distributions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the PRC Company
Law and Foreign Investment Law, each of our Shanghai subsidiary, as a foreign invested enterprise, or FIE, is required to draw 10% of
its after-tax profits each year, if any, to fund a common reserve, which may stop drawing its after-tax profits if the aggregate balance
of the common reserve has already accounted for over 50% of its registered capital. These reserves are not distributable as cash dividends.
Furthermore, under the EIT Law, which became effective in January 2008, the maximum tax rate for the withholding tax imposed on dividend
payments from PRC foreign invested companies to their overseas investors that are not regarded as &#8220;resident&#8221; for tax purposes
is 20%. The rate was reduced to 10% under the Implementing Regulations for the EIT Law issued by the State Council. However, a lower withholding
tax rate might be applied if there is a tax treaty between China and the jurisdiction of the foreign holding companies, such as tax rate
of 5% in the case of Hong Kong companies that holds at least 25% of the equity interests in the foreign-invested enterprise, and certain
requirements specified by PRC tax authorities are satisfied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations Relating to Employment, Social
Insurance and housing fund</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Labor Law and The Labor
Contract Law provide requirements concerning employment contracts between an employer and its employees. If an employer fails to enter
into a written employment contract with an employee within one year from the date on which the employment relationship is established,
the employer must rectify the situation by entering into a written employment contract with the employee and pay the employee twice the
employee&#8217;s salary for the period from the day following the lapse of one month from the date of establishment of the employment
relationship to the day prior to the execution of the written employment contract. All employers must comply with local minimum wage standards.
The Labor Contract Law and its implementation rules also require compensation to be paid upon certain terminations, which significantly
affects the cost of reducing workforce for employers. In addition, if an employer intends to enforce a non-compete provision with an employee
in an employment contract or non-competition agreement, it has to compensate the employee on a monthly basis during the term of the restriction
period after the termination or ending of the labor contract. Employers in most cases are also required to provide a severance payment
to their employees after their employment relationship are terminated. Violations of the PRC Labor Contract Law and the PRC Labor Law
may result in the imposition of fines and other administrative and criminal liability in the case of serious violations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Enterprises in China are required
by PRC laws and regulations to participate in certain employee benefit plans, including social insurance funds, namely a pension plan,
a medical insurance plan, an unemployment insurance plan, a work-related injury insurance plan and a maternity insurance plan, and a housing
provident fund, and contribute to the plans or funds in amounts equal to certain percentages of salaries, including bonuses and allowances,
of the employees as specified by the local government from time to time at locations where they operate their businesses or where they
are located. According to the Social Insurance Law, an employer that fails to make social insurance contributions may be ordered to pay
the required contributions within a stipulated deadline and be subject to a late fee. If the employer still fails to rectify the failure
to make social insurance contributions within the stipulated deadline, it may be subject to a fine ranging from one to three times the
amount overdue. According to the Regulations on Management of Housing Fund, an enterprise that fails to make housing fund contributions
may be ordered to rectify the noncompliance and pay the required contributions within a stipulated deadline; otherwise, an application
may be made to a local court for compulsory enforcement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulations on Taxes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Enterprise Income Tax</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Enterprise Income
Tax Law of the PRC, or the EIT Law, which became effective on January 1, 2008 and was subsequently amended on February 24, 2017 and December
29, 2018, and its implementing rules, enterprises are classified as resident enterprises and non-resident enterprises. PRC resident enterprises
typically pay an enterprise income tax at the rate of 25% while non-PRC resident enterprises without any branches in the PRC should pay
an enterprise income tax in connection with their income from the PRC at the tax rate of 10%. An enterprise established outside of the
PRC with its &#8220;de facto management bodies&#8221; located within the PRC is considered a &#8220;resident enterprise,&#8221; meaning
that it can be treated in a manner similar to a PRC domestic enterprise for enterprise income tax purposes. The implementing rules of
the EIT Law define a de facto management body as a managing body that in practice exercises &#8220;substantial and overall management
and control over the production and operations, personnel, accounting, and properties&#8221; of the enterprise. Enterprises qualified
as &#8220;High and New Technology Enterprises&#8221; are entitled to a 15% enterprise income tax rate rather than the 25% uniform statutory
tax rate. The preferential tax treatment continues as long as an enterprise can retain its &#8220;High and New Technology Enterprise&#8221;
status.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The EIT Law and the implementation
rules provide that an income tax rate of 10% should normally be applicable to dividends payable to investors that are &#8220;non-resident
enterprises,&#8221; and gains derived by such investors, which (a) do not have an establishment or place of business in the PRC or (b)
have an establishment or place of business in the PRC, but the relevant income is not effectively connected with the establishment or
place of business to the extent such dividends and gains are derived from sources within the PRC. Such income tax on the dividends may
be reduced pursuant to a tax treaty between China and other jurisdictions. Pursuant to the Arrangement Between the Mainland of China and
the Hong Kong Special Administrative Region for the Avoidance of Double Taxation on Income, or the Double Tax Avoidance Arrangement, and
other applicable PRC laws, if a Hong Kong resident enterprise is determined by the competent PRC tax authority to have satisfied the relevant
conditions and requirements under such Double Tax Avoidance Arrangement and other applicable laws, the 10% withholding tax on the dividends
the Hong Kong resident enterprise receives from a PRC resident enterprise may be reduced to 5% upon receiving approval from in-charge
tax authority. However, based on the Notice on Certain Issues with Respect to the Enforcement of Dividend Provisions in Tax Treaties issued
on February 20, 2009 by the SAT, if the relevant PRC tax authorities determine, in their discretion, that a company benefits from such
reduced income tax rate due to a structure or arrangement that is primarily tax-driven, such PRC tax authorities may adjust the preferential
tax treatment; and based on the Announcement on Relevant Issues Concerning the &#8220;Beneficial Owners&#8221; in Tax Treaties issued
on February 3, 2018 by the SAT and effective from April 1, 2018, which replaces the Notice on the Interpretation and Recognition of Beneficial
Owners in Tax Treaties and the Announcement on the Recognition of Beneficial Owners in Tax Treaties by the SAT, comprehensive analysis
based on the stipulated factor therein and actual circumstances shall be adopted when recognizing the &#8220;beneficial owner&#8221; and
agents and designated wire beneficiaries are specifically excluded from being recognized as &#8220;beneficial owners.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 17, 2019, the State
Taxation Administration issued the notice on the scope of small-scale and low-profit corporate income tax preferential policies of the
Ministry of Finance and the State Administration of Taxation (&#8220;MOF and SAT&#8221;), [2019] No. 13 for small-scale and low-profit
enterprises whose annual taxable income is less than RMB1,000,000 (including RMB1,000,000), approximately $142,209, their income is reduced
by 25% to the taxable income, and enterprise income tax is paid at 20% tax rate, which is essentially resulting in a favorable income
tax rate of 5%. While for the portion of annual taxable income exceeding RMB1,000,000, approximately $142,209, but not more than RMB3,000,000,
approximately $426,627, the income is reduced by 50% to the taxable income, and enterprise income tax is paid at 20% tax rate, which is
essentially resulting in a favorable income tax rate of 10%. On April 9, 2021, MOF and SAT issued [2021] No.12 which provides an enterprise
income tax rate of 2.5% on a small-scale and low-profit enterprises whose annual taxable income less than RMB1,000,000, approximately
$142,209, from January 1, 2021 to December 31, 2022. MOF and SAT [2022] No.13, issued on May 29, 2023, also provides an enterprise income
tax rate of 5% on a small-scale and low-profit enterprises whose annual taxable income more than RMB1,000,000, approximately $142,209,
but not more than RMB3,000,000, approximately $426,627, from January 1, 2022 to December 31, 2024. The qualifications of small-scale and
low-profit enterprises were examined annually by the Tax Bureau. All of the Company&#8217;s Shanghai subsidiary met the criteria of small-scale
and low-profit enterprises.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Value-added Tax</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to applicable PRC
tax regulations, any entity or individual conducting business in the service industry used to be generally required to pay a business
tax at the rate of 5% on the revenues generated from providing such services. However, if the services provided are related to technology
development and transfer, such business tax may be exempted subject to approval by the relevant tax authorities. Whereas, pursuant to
the Provisional Regulations on Value-Added Tax of the PRC and its implementation regulations, unless otherwise specified by relevant laws
and regulations, any entity or individual engaged in the sales of goods, provision of processing, repairs and replacement services and
importation of goods into China is generally required to pay a value-added tax, or VAT, for revenues generated from sales of products,
while qualified input VAT paid on taxable purchase can be offset against such output VAT.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2011, the Ministry
of Finance and the State Administration of Taxation promulgated the Pilot Plan for Imposition of Value-Added Tax to Replace Business Tax.
In March 2016, the Ministry of Finance and the State Administration of Taxation further promulgated the Notice on Fully Promoting the
Pilot Plan for Replacing Business Tax by Value-Added Tax, which became effective on May 1, 2016. Pursuant to the pilot plan and relevant
notices, VAT is generally imposed in lieu of business tax in the modern service industries, including the VATS, on a nationwide basis.
VAT of a rate of 6% applies to revenue derived from the provision of some modern services. Certain small taxpayers under PRC law are subject
to reduced value-added tax at a rate of 3%. Unlike business tax, a taxpayer is allowed to offset the qualified input VAT paid on taxable
purchases against the output VAT chargeable on the modern services provided.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 4, 2018, the Ministry
of Finance and the State Administration of Taxation issued the Notice on Adjustment of VAT Rates, which came into effect on May 1, 2018.
According to the abovementioned notice, the taxable goods previously subject to VAT rates of 17% and 11%, respectively, become subject
to lower VAT rates of 16% and 10%, respectively, starting from May 1, 2018. Furthermore, according to the Announcement on Relevant Policies
for Deepening Value-added Tax Reform jointly promulgated by the Ministry of Finance, the State Administration of Taxation and the General
Administration of Customs, which became effective on April 1, 2019, the taxable goods previously subject to VAT rates of 16% and 10%,
respectively, become subject to lower VAT rates of 13% and 9%, respectively, starting from April 1, 2019. Under Provisional Regulations
of the People&#8217;s Republic of China on Value-added Tax, amended and effective on November 19, 2017, for entities that are VAT small
taxpayers, VAT is levied at a levy rate of 3%. On February 29, 2020, the State Administration of Taxation issued the Announcement on Taxation
Matters to Support Individual Businesses in Resumption of Business, during the COVID-19, the small taxpayers are allowed to enjoy the
preferred tax policy, tax rate from 3% to 1% for the period from March 1, 2020 to December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 46 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1A. Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Investing in our securities
involves a high degree of risk. Before making any investment decision, you should consider carefully the following risks and other information
in this Report, including our consolidated financial statements and related notes. The risks and uncertainties we describe are not the
only ones facing us. Additional risks and uncertainties that we are unaware of or that we believe are not material at the time could also
materially adversely affect our business, financial condition or results of operations. In any case, the value of our Common Stock could
decline, and you could lose all or part of your investment. Please also see the section entitled &#8220;Cautionary Note Regarding Forward-Looking
Statements.&#8221;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Business and Industry</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are an early stage cancer diagnostics
company with a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are at the early stage
of commercializing our business. We have not started manufacturing or sales of any products or services. Our limited operating history
may make it difficult to evaluate our current business and predict our future performance. Any assessment of our profitability or prediction
about our future success or viability is subject to significant uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Taiwan and China&#8217;s precision
oncology detection market is still in its early stage of development and rapidly evolving, and companies operating in this industry face
a variety of risks. We may not have sufficient experience or resources to address risks frequently encountered in this industry, which
include, among other things, our potential failure to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">acquire and retain customers and increase adoption of our precision oncology detection products and services by hospitals, physicians, patients, pharmaceutical companies and others in the medical community;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">timely respond to changing market conditions and keep up with evolving industry and technological standards and regulatory developments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">obtain and maintain the regulatory approvals required for us to further market and sell our precision oncology detection products and services and commercialize our early cancer detection products and services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">manage our relationships with our suppliers, customers and research partners;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">protect proprietary technologies and intellectual property rights; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">attract, train, motivate and retain research and development and other qualified personnel.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unsuccessful in
addressing any one or more of these risks, our business, financial condition and results of operations could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to develop and commercialize
our early cancer detection devices, chips or immunochromogenic kits on a timely basis, or at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing early cancer
detection products and may develop and commercialize our cancer diagnostics products from time to time in the future. Developing early
cancer detection and new cancer diagnostics products is a lengthy and complex process. New products may take time to commercialize, and
their launch could be delayed or may not be successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product development process
involves various risks, and we may not be able to develop and commercialize any early cancer detection products or new precision oncology
detection products on a timely basis, or at all. A product candidate that appears promising in the early phases of development may fail
to reach the market for a number of reasons. For example:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our product candidates may fail to demonstrate clinical utility, or the development process may produce negative or inconclusive results, and we may decide, or regulators may require us to conduct additional clinical trials or we may decide to abandon our development programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our employees, or third-party clinical investigators, medical institutions and CROs, may fail to comply with their contractual duties or obligations or meet expected deadlines, and if the quality, completeness or accuracy of the clinical data they obtain are compromised due to any failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may fail to obtain approvals for our product candidates from relevant regulatory authorities; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">failure to generate additional data and insights from our existing products to advance the research and development of new products as quickly, or at all.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our competitors
may develop and commercialize competing products faster than we are able to, in which case our results of operations could be adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to keep up with industry and
technology developments in a timely and cost-effective manner, we may be unable to compete effectively and our business and prospects
could suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cancer early detection market
is characterized by rapid changes, including technological and scientific breakthroughs, increasing amounts of data, frequent introductions
of new tests, constant emergence of alternative diagnostic methods, and evolving industry standards. If we are not able to keep pace with
these advances and increased customer expectations as a result of these advances and capture new market opportunities that develop as
a result of these advances, our proprietary technologies could be rendered obsolete, our existing products and services and products and
services we are developing could be rendered less clinically effective, and our future operations and prospects could suffer. To remain
competitive, we must continuously upgrade our existing products and services and launch new products and services, to keep pace with these
developments. We cannot assure you that these efforts will be successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we must expend
significant resources in order to continuously upgrade our existing products and services or launch new ones to keep pace with industry
and technological advances. We may never realize a return on investment on these efforts, especially if the improved or new products and
services fail to perform as expected, in which case our business, financial condition and results of operations could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our products or services do not perform
as expected, our operating results, reputation and business could suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends on the
market confidence that we can provide reliable, high-quality cancer early detection products and services that will provide physicians
with real-time clinically actionable diagnostic information. However, there is no assurance that our products and services will perform
as expected at all times. Our tests may fail to accurately detect gene variants or incompletely or incorrectly identify the significance
of genomic alterations, or contain other errors or mistakes due to a variety of reasons (such as malfunction of our laboratory equipment
and degraded liquid biopsy or tissue samples provided by our delivery service providers), which may result in negative perception of our
tests. In addition, inaccurate results or misunderstandings of, or inappropriate reliance on, the diagnostic information our tests provide
could lead to, or be associated with, side effects or adverse events in patients who use our tests, including treatment-related death,
and could lead to termination of our services or claims against us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face risks related to natural disasters,
health epidemics, civil and social disruption and other outbreaks, which could significantly disrupt our operations. In particular, the&#160;COVID-19&#160;outbreak
in China and worldwide has adversely affected, and may continue to adversely affect, our business, results of operations and financial
condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are vulnerable to social
and natural catastrophic events that are beyond our control, such as natural disasters, health epidemics, and other catastrophes, which
may materially and adversely affect our business. Since December 2019, a novel strain of coronavirus, or&#160;COVID-19,&#160;has become
widespread in China and around the world. In March 2020, the World Health Organization declared&#160;COVID-19&#160;a pandemic, given its
threat beyond a public health emergency of international concern that the organization had declared in January 2020. Since the beginning
of 2020, China, Taiwan and many other countries have taken various restrictive measures to contain the virus&#8217; spread, such as quarantines,
travel restrictions and home office policies to avoid large-scale population movement and gathering. These restrictions had certain degree
of impact on our research and development and production plan in Taiwan and China. COVID-19 has reduced the availability of labor and
led to difficulties for employees to return to work and constraints of service chain interruption. Because of the uncertainty surrounding
the COVID-19 outbreak, the business disruption and the related financial impact related to the outbreak of and response to the coronavirus
cannot be reasonably estimated at this time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently, the COVID-19 situation
has improved in Taiwan and China. With Taiwan relaxing its mask mandate on April 17, 2023, and China no longer enforcing the &#8220;zero-COVID&#8221;
policy, our research and development have started to recover. However, the potential downturn brought by the COVID-19 outbreak is difficult
to assess or predict and the full impact of the virus on our operations will depend on many factors beyond our control. The extent to
which the&#160;COVID-19 outbreak impacts our business, results of operations and financial condition&#160;remains uncertain, and we are
closely monitoring its impact on us. Our business, results of operations, financial conditions and prospects could be materially adversely
affected to the extent that&#160;COVID-19&#160;harms the Chinese and global economy in general, and the trading price of our shares of
Common Stock may be adversely affected. To the extent the&#160;COVID-19&#160;pandemic and the outbreak of other health epidemics adversely
affect our business and financial results, they may also have the effect of heightening many of the other risks described in this &#8220;Risk
Factors&#8221; section.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we cannot compete successfully with our
competitors, we may be unable to increase or sustain our revenue or achieve and sustain profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cancer early detection and
screening market has become increasingly competitive, and we expect this competition to intensify further in the future. Some of our existing
and potential future competitors may have longer operating histories, larger customer bases, more expansive brand recognition and deeper
market penetration, substantially greater financial, technological and research and development resources and selling and marketing capabilities,
and more favorable terms from suppliers. As a result, they may be able to respond more quickly to changes in customer requirements or
preferences, develop faster, better and more expansive advancements for their technologies and tests, create and implement more successful
strategies for the promotion and sale of their tests, adopt more aggressive pricing policies for their tests, secure supplies from vendors
on more favorable terms or devote substantially more resources to infrastructure and system development. In addition, competitors may
be acquired by, receive investments from or enter into other commercial relationships with larger, well-established and well-financed
companies as the use of precision oncology detection increases. In addition, if we expand into international markets in the future, we
could face competition from the companies in these markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to compete
successfully with current and future competitors for these or any other reasons, we may be unable to increase market acceptance and sales
volume of our tests, which could prevent us from maintaining or increasing our revenue levels or achieving or sustaining profitability
or could otherwise negatively affect our performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future success depends on our ability
to promote our brand and protect our reputation. If we are unable to effectively promote our brand, our business may be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that enhancing
and maintaining awareness of our trademarks <span style="font-family: Times New Roman, Times, Serif">&#27427;&#25096;&#36187;</span> and
sglcell are critical to achieving widespread acceptance of our microfluidic biochip products, gaining trust for our testing devices and
attracting customers. Successful promotion of our brand depends largely on the quality of the products and services we offer and the effectiveness
of our branding and marketing efforts. Currently, we rely primarily on our own sales and marketing team to promote our brand and our precision
oncology detection products and testing services. We expect that our branding and marketing efforts will require us to incur significant
expenses and&#160;devote substantial resources. We cannot guarantee that our sales and marketing efforts will be successful. Brand promotion
activities may not lead to increased revenue in the near term, and, even if they do, any revenue increases may not offset the expenses
we incur to promote our brand. Our failure to establish and promote our brand and any damage to our reputation will hinder our growth.
In addition, our reputation may be undermined as a result of the negative publicity about our company or our industry in general. If precision
oncology detection products or services provided by us or our competitors do not perform to customers&#8217; expectations, it may result
in lower confidence in precision oncology detection in general, which may in turn impair our operating results and our reputation. You
can find more information regarding our intellectual properties in &#8220;Business &#8211; Intellectual Property.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 49 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to attract and retain our senior
management and other key employees could adversely affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success is significantly
dependent upon the continued service of our senior management, such as Dr.&#160;Yi Lu, our chairman of the board of directors and chief
executive officer. If we lose their services, we may not be able to locate suitable or qualified replacements, and we may incur additional
expenses to recruit new senior management team members, which could severely disrupt our business and growth. In addition, if these personnel
join our competitors or form a competing business, our business and prospects could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
activities and laboratory operations depend upon our ability to attract and retain highly skilled scientists and technicians. We are also
in strong need of sales and marketing personnel with the relevant technology background and industry expertise in order to effectively
conduct our sales and marketing activities and increase our hospital network. We face intense competition for qualified individuals from
numerous biotechnology and pharmaceutical companies, universities, governmental entities and other research institutions. We may be unable
to attract and retain suitably qualified individuals, and our failure to do so could adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we experience difficulties in recruiting
subjects for clinical trials, our clinical development activities may be delayed or otherwise adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Completion of a clinical trial
on time according to the trial plan depends, among other things, on our ability to recruit a sufficient number of subjects to participate
in the trial until the end of the trial. We may encounter difficulties in recruiting subjects for clinical trials for a variety of reasons,
including the base and nature of the subject population and the eligibility criteria for subjects defined in the trial plan. Our clinical
trials will likely compete with other clinical trials, which will reduce the number and categories of subjects we can recruit, as some
subjects who may choose to participate in our trials may instead choose to participate in trials conducted by other companies. Due to
the limited number of qualified clinical investigators and clinical trial sites, we expect that some of our clinical trials will be conducted
at the same clinical trial sites used by some of our competitors, which will result in subjects eligible to participate in our clinical
trials at those clinical trial sites decrease in the number of people. Even if our clinical trials are able to enroll a sufficient number
of subjects, delays in enrolling subjects may increase costs or affect the timing or outcomes of planned clinical trials, hindering the
completion of those trials and hindering our progress adversely affect the ability of product candidates to develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we do not launch new products in a timely
manner, our products may become obsolete and our results of operations may suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Technology in the cancer screening
industry is constantly changing, new products are emerging, and industry standards continue to evolve. If new and improved products are
not introduced in a timely manner, our products may become technologically obsolete or vulnerable to competition, and our revenue and
results of operations could be impaired. Even if we develop new or improved products, our ability to bring those products to market may
be limited by a variety of factors, including regulatory approvals and market demand. We invest significant financial and other resources
in our research and development activities. The research and development process are lengthy and uncertain. The products we are currently
developing may not be able to complete the development process or obtain the regulatory or other approvals required to bring such products
to market in a timely manner or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Technological innovations
often require significant time and investment before their commercial viability can be determined. We may not have the necessary financial
resources to fund all such projects. In addition, even if we are able to successfully develop new or improved products, those products
may not generate revenue in excess of development costs or achieve desirable financial returns and may become obsolete or due to changes
in customer preferences or the introduction of advanced technology or functionality by competitors. Products or other factors resulting
in a decline in competitiveness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As of the date of this Report, we have not
conducted any clinical trials for our products. Uncertainties or failures in clinical trials of our product candidates could materially
and adversely affect our business operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We must conduct various clinical
trials to demonstrate the sensitivity and specificity of our test prior to regulatory approval for marketing of our product candidates
and depending on the type of our relevant product candidates, clinical trials may require large-scale prospective clinical studies, and
such studies are far more rigorous and expensive than other existing tests or auxiliary diagnostic products. We have planned to conduct
a multicenter registry trial in China to evaluate the performance of the pulmonary nodule benign and malignant determination kit. We may
encounter a variety of contingencies while conducting or as a result of clinical trials that may delay or prevent us from obtaining regulatory
approval or commercializing our product candidates, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Regulatory agencies, institutional review boards or ethics committees may refuse to authorize us or investigators to conduct clinical trials or conduct clinical trials at the intended trial site;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We are unable to reach agreement on admissible terms with prospective CROs and hospitals (as trial centers), which may require extensive negotiation and may vary significantly between different CROs and hospitals (as trial centers);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Production issues, including issues with the quality of production, supply, or obtaining sufficient quantities of the product candidate for use in clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Insufficient testing capacity to meet the needs of clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our products fail to demonstrate superior results than competitors&#8217; or alternative products (if applicable);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Clinical trials of our product candidates may fail to demonstrate the expected cancer screening sensitivity and specificity, and we may decide or regulatory authorities may require us to conduct additional clinical trials or abandon product development programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The number of subjects required for clinical trials of our product candidates may be larger than expected, recruitment may be insufficient or slower than we expect, or the rate of subjects dropping out of trials may be higher than expected;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Our third-party contractors may fail to comply with regulatory requirements or perform in a timely manner or at all of their contractual obligations to us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We may have to suspend or terminate clinical trials of our product candidates for a variety of reasons, including the discovery of a lack of clinical response or other unexpected characteristics; and preliminary or interim results of clinical trials may not be indicative of final results.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
such trials will be completed in a timely or cost-effective manner, or that they will result in a commercially viable product. If clinical
trials of any of our product candidates are delayed or terminated, the commercial prospects of that product candidate will be impaired
and our ability to generate revenue from any such product candidate will be delayed. In addition, any delay in the completion of our clinical
trials would increase our costs, slow down the development and approval process of our product candidate, and impair our ability to initiate
product sales and generate related revenue for that product candidate. The occurrence of any of the above events could materially damage
our business, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have contracts with third parties for
the future manufacturing, supply and registration applications of certain of our products, which supply could become limited or interrupted
or may not be of satisfactory quality and quantity.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently rely on third
parties in the PRC for certain supplying, registration applications and future manufacturing of certain of our products. Any such reliance
may increase the risk that we will not have sufficient quantities of our products, or such quantities at an acceptable cost or quality,
which could delay, prevent or impair our development or commercialization efforts. Furthermore, all the contract manufacturers in the
PRC for our products are subject to extensive PRC laws and regulations. These PRC laws and regulations govern manufacturing processes
and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of
investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants,
or to inadvertent changes in the properties or stability of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Associated with Government Regulations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be adversely affected by uncertainties
and changes in China&#8217;s regulations on the cancer screening industry, and the lack of necessary approvals, licenses, registrations
or filings in relation to our business may adversely affect our business, results of operations and prospects material adverse effects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the relatively short
history of the cancer screening industry in China, a comprehensive regulatory framework to regulate the industry has not yet been established.
The possibility cannot be ruled out that certain industry practices, which we have also adopted, may be deemed to fail to fully comply
with the existing laws and regulations in the PRC. As China&#8217;s laws and regulations on medical devices are still developing, and
it is uncertain whether new laws, regulations or interpretations will be promulgated or adopted in the future, we cannot assure you that
our early stage cancer detection devices will not be construed as non-compliance with applicable laws and regulations in the future. If
the PRC government issues clear requirements for the approval of our devices, we intend to take the necessary steps to comply with those
requirements. Our business and results of operations may be adversely affected if we fail to comply with existing or future requirements
or are found to be otherwise non-compliant in the conduct of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to obtain, complete or maintain
the required regulatory approvals, licenses, registrations or filings, or if there is a delay in obtaining, complete or maintain the required
regulatory approvals, licenses, registrations or filings, we will not be able to commercialize our product candidates change, and our
ability to generate revenue will be significantly compromised.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the relatively short
history of the cancer screening industry in China, a comprehensive regulatory framework to regulate the industry has not yet been established.
However, the significant aspects of the development and commercialization of our products have been strictly regulated in China. The process
of obtaining regulatory approvals and complying with applicable laws and regulations requires significant time and financial resources.
Applicants may face administrative or judicial sanctions if they fail to comply with applicable regulations during the product development
process, the approval process, or at any time after approval. Such sanctions may include regulatory refusals to approve pending applications,
revocation of approvals, revocation of licenses, clinical restrictions, voluntary or compulsory product recalls, product seizures, suspensions
of production or distribution in whole or in part, injunctions, fines, refusals to government contracts, compensation, Hand over money
or civil or criminal penalties. Failure to comply with these regulations may affect our business, financial business conditions and prospects
are materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 52 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before obtaining regulatory
approval for commercial sale of some of our products, we must demonstrate its effectiveness in a well-controlled clinical trial and, for
approval in China, must be satisfied by NMPA that the product candidate is safe and effective for its intended use, and appropriate manufacturing
and testing facilities, procedures and controls are in place. For now, only A<sup>+</sup>LCGuard is required by NMPA to complete clinical
trial. Obtaining regulatory approval is a long, expensive and uncertain process, and approval may not be obtained. When we submit a registration
application to NMPA, it will decide whether to accept or reject the submitted registration application. We cannot be certain that any
submission will be approved by NMPA for registration review. NMPA may also slow down, suspend or terminate the review of our application,
and any such circumstance will prolong the registration process for our products. Our product candidates may not receive regulatory approval
for a number of reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The clinical trial results cannot reach the level of statistical significance required for approval or the clinical trial cannot be conducted in accordance with regulatory regulations or clinical trial plan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Approval policy or regulatory changes that make our preclinical and clinical data insufficient to obtain approval or require us to revise our clinical trial plan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Regulatory requirements requiring additional analysis, reporting, data, non-clinical studies and clinical trials, or questions regarding interpretation of data and results and the emergence of new information about our product candidates or other products; and/or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The relevant authority refuses to approve a pending application submitted by us or a supplementary application to an approved application, or suspends, withdraws or withdraws the approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory requirements and
guidelines may also change, and we may, among other things, need to revise clinical trial plans submitted to applicable regulatory authorities
to reflect such changes. We may make revisions that necessitate resubmission of the clinical trial proposal to the Institutional Review
Board or Ethics Committee for reconsideration, which may affect the outcome of the clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of developing,
obtaining regulatory approval, and commercializing medical device candidates is long, complex, and costly, both within China and abroad.
Even if our product candidates are successful in obtaining regulatory approval, such approval may impose significant restrictions on the
approved use, or require product labels to contain precautions or warnings, or require expensive and time-consuming post-approval clinical
trials or surveillance as approval conditions of. If we are unable to obtain regulatory approvals for our product candidates in one or
more jurisdictions, or any approvals come with significant restrictions, our target market will be reduced and our ability to realize
the full market potential of our product candidates will be impaired. In addition, we may not be able to obtain sufficient financing or
generate sufficient revenue and cash flow to continue developing any other product candidates in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products and any future products will
be subject to ongoing regulatory obligations and ongoing regulatory scrutiny, which may result in significant additional expenses, and
if we fail to comply with regulatory requirements or if there are unexpected issues with our products and/or product candidates, we may
be punished.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our regulatory agency-approved
testing services, products and any other product candidates are subject to and will be subject to compliance with manufacturing, testing,
labelling, packaging, storage, advertising, promotion, sampling, record keeping, post-marketing studies, submission of safety, efficacy
and other ongoing regulatory requirements for post-listing materials, and other requirements from regulatory authorities in the PRC and/or
other jurisdictions. Our testing and manufacturing facilities are subject to numerous regulatory requirements from the China Food and
Drug Administration (&#8220;CFDA&#8221;) and/or other similar authorities. Accordingly, we have been and will be subject to ongoing scrutiny
and inspection by regulatory agencies to assess our compliance with applicable laws and regulations and our commitments made in any application
materials submitted to the CFDA or other authorities. Therefore, we must continue to invest time, money and effort in all aspects of regulatory
compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory approvals for our
products and any approvals we obtain for product candidates are subject to and may be limited by the use of our marketable products. Our
approvals may also be subject to other conditions that may result in the need for potentially costly post-market testing and surveillance
to monitor the safety and efficacy of our products or product candidates. Such restrictions and conditions may adversely affect the commercial
potential of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After our product candidates
are approved for commercialization, certain changes to the products, such as changes in manufacturing processes and additional claims,
may require additional review and approval by the CFDA and/or similar regulatory authorities. Regulatory approval of any of our product
candidates may also be withdrawn. If we fail to maintain compliance with these ongoing regulatory requirements or if problems arise after
the product is launched, the CFDA or similar regulatory authorities may seek to enforce a consent order or withdraw marketing approval.
Late discovery of our products or product candidates or issues previously unknown to us in our manufacturing process may lead to revisions
to approved labels or regulations to add new safety information; conduct clinical studies to evaluate new safety risk; or impose distribution
restrictions or other restrictions. Other potential consequences include (among others):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Restrictions on the listing or manufacture of our products, withdrawal of products from the market, or voluntary or mandatory product recalls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Fines, untitled letters or warning letters, or suspension of clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The CFDA or similar regulatory authorities refuse to approve our pending applications or supplements to approved applications, or suspend or revoke licensing approval or withdraw approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Product seizure or detention, or denial of permission to import or export our products and candidate products; and/or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Injunction or Civil or Criminal Penalty</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CFDA and other regulatory
authorities strictly supervise the listing, labelling, advertising and promotion of medical products and services introduced to the market.
Our products and testing services may only be marketed for their approved uses in accordance with approved labels. The CFDA and other
regulatory authorities actively enforce laws and regulations that prohibit the promotion of off-label uses, and companies found to improperly
promote off-label uses may bear significant responsibility. The policies of the CFDA and other regulatory authorities may change and other
government regulations may be issued to prevent, limit or delay regulatory approval of our product candidates. Given the changing regulatory
environment, we cannot predict the likelihood, nature or scope (whether in China or abroad) of government policies or regulations that
may result from future legislative or administrative actions. If we are slow or unable to adapt to changes in existing regulations or
adopt new regulations or policies, or if we are unable to maintain regulatory compliance, we may lose any regulatory approvals we have
obtained and may not be able to achieve or maintain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our existing and new products fail to
meet the quality standards required by applicable laws, our business and reputation could be damaged, and our revenue and profitability
could be materially and adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our production and manufacturing
processes are subject to certain quality standards. We have established quality control and assurance systems and adopted standardized
operating procedures to prevent quality issues related to our products and operating processes. For further details of our quality control
and assurance system, please refer to &#8220;Business &#8212; Quality Control System&#8221;. Although we have quality control and assurance
systems and procedures, we cannot eliminate the risk of product defects or malfunctions. Quality defects may not be detected or remedied
due to a number of factors, many of which are beyond our control, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Manufacturing error;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Technical or mechanical failures in the manufacturing process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Human error or malfeasance by our quality control personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Third party intervention; and/or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The raw materials we produce or purchase have quality problems.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our failure to
detect quality defects in our products or to prevent such defective products from being delivered to end users may result in injury or
death, product recalls or withdrawals, revocation of licenses or fines by regulatory agencies, product and professional liability or other
problems, which could seriously damage our reputation and business, expose us to the risk of liability, and materially and adversely affect
our revenue and profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>In addition to the Chinese market, we are
planning to expand to North American and European markets. We cannot give any assurance that any of our products will receive regulatory
approval in North America or Europe, which is necessary before they can be commercialized.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain that
any of our product candidates will be successful in clinical studies or receive regulatory approval. Applications for our products could
fail to receive regulatory approval for many reasons, including but not limited to the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the Food and Drug Administration (FDA), the competent authority of individual member states of the European Union where we plan to offer our products, or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the FDA, the competent authority of individual member states of the European Union where we plan to offer our products, or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical or clinical studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the data collected from clinical studies of our products in China may not be sufficient or accepted to obtain regulatory approval in the U.S. or elsewhere;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">we may be unable to demonstrate to the FDA, the competent authority of individual member states of the European Union where we plan to offer our products, or comparable foreign regulatory authorities that a product&#8217;s benefit-risk ratio for its proposed indication is acceptable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the FDA, the competent authority of individual member states of the European Union where we plan to offer our products, or other regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the approval policies or regulations of the FDA, the competent authority of individual member states of the European Union where we plan to offer our products, or comparable foreign regulatory authorities may change significantly in a manner rendering our clinical data&#160;insufficient for approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, we plan to seek
regulatory approval to commercialize our product candidates in the U.S., the EU and in additional countries where we obtain commercial
and IP rights. To obtain regulatory approval in other countries, we must comply with numerous and varying regulatory requirements of such
other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales, pricing, marketing
and distribution of our products. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain
approval in any other jurisdictions. Failure to obtain marketing authorization for our products will result in our being unable to market
and sell such products, which would materially adversely affect our business, financial condition and results of operations. If we fail
to obtain approval in any jurisdiction, the geographic market for our products could be limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to obtain the broad market acceptance
or maintain a good reputation necessary for our current products and any future products could materially and adversely affect our results
of operations and profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
our current and future products depends on their market acceptance, especially among customers, hospitals and physicians. As a diagnostic
method recently developed and introduced into the Chinese market, our products may not be widely recognized by the intended target customers,
doctors or end users. If our products and any future approved product candidates fail to gain sufficient market acceptance from physicians,
end users, third-party payers and other industry players, our product sales will be adversely affected. In addition, customers, physicians,
end users and third-party payers may prefer other new products over our products. If our products and product candidates fail to achieve
an adequate level of recognition, we may not generate significant revenue and may not be profitable. The failure of our products, product
candidates and our testing services to achieve an adequate level of recognition or to increase market visibility could adversely affect
our financial condition, business and results of operations. Once approved for commercial sale, the market acceptance of our products
and product candidates and their services will depend on a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Physicians, end users and hospitals consider our products and product candidates to be safe and effective;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Potential and visible advantages of our products and product candidates over other alternatives;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Our continuous cooperation with existing commercialization channels;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We further validate the product&#8217;s capabilities through clinical studies and accompanying publications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The timing and scope of the approval of our other cancer screening products by the CFDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Our ability to maintain laboratory accreditation, accreditation and regulatory approval and to complete required inspections;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Defects or errors that lead to negative reports about our or our competitors&#8217; testing and technology influences;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Changes in government policies or guidelines regarding cancer screening;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Development of cancer treatments that may diminish or reduce the need for cancer screening;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Our competitors accelerate R&amp;D progress;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The effectiveness of our sales and marketing efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our commercialized
products and services fail to gain market acceptance among doctors, end users, hospitals or other customers, or if we fail to maintain
good relationships with them, we will not be able to generate significant revenue. Our ability to market our products and product candidates
may be limited by regulatory approval requirements, restrictions on approved uses, inherent patterns of clinical practice, uncertainty
about third-party compensation or other factors. Even if our products gain market acceptance, we may not be able to maintain market acceptance
all the time if new products or technologies are introduced that are more popular, cost-effective or make our products obsolete. We believe
that maintaining and enhancing our brand image and increasing the market awareness of our company and our products are critical to gaining
broad recognition for our services and products, strengthening our relationships with existing customers and our ability to attract new
customers. The successful promotion of our brand will largely depend on our ability to continue to provide high-quality products, as well
as our research and development efforts. However, there is no guarantee that our branding activities and research and development efforts
will be successful or contribute to our growth. In addition, even if such activities increase revenue, such revenue may not be sufficient
to offset the increase in expenses we incur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There is no guarantee that our products
will be covered by the National Medical Insurance Program in China.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China maintains a National
Medical Insurance Program that can reimburse certain residents in urban cities and rural areas for, among other things, fees associated
with diagnostic and treatment devices and diagnostic tests covered by such Program through the basic medical insurance scheme.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this Report,
our products are not covered by any national or provincial medical insurance programs. Although we strive to make our products covered
by the national medical insurance programs in the future, there is no guarantee that the responsible government agency, the National Healthcare
Security Administration, will approve our applications. Furthermore, even if our products may be covered by the Program in the future,
uncertainties still exist around reimbursement coverage and rates as we need to negotiate such terms with government entities in the PRC,
and we cannot guarantee that we will receive favorable coverage and rates. In the absence of reimbursement or favorable coverage and rates
from the National Medical Insurance Program, end users have to bear all or the majority part of their expenses to use our products, which
may reduce consumers&#8217; interest in our products or cause our products to be less competitive when compared with other products that
are covered by such Program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have relatively limited experience in
product promotion and sales. There is no assurance that we will be able to successfully commercialize our products and, as a result, our
revenue and profitability could be materially and adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have relatively limited
experience in launching and commercializing product candidates and in the sales and marketing of products, and limited experience in market
analysis or managing sales teams for product candidates. As a result, our ability to successfully commercialize our product candidates
may involve more inherent risks, require more time and cost more than would be the case if we were a company with extensive experience
in launching product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market size of existing and future products
has not been precisely established and may be lower than our estimates, and we may not fully grasp the target population of our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our estimates of the total
addressable market and target population for our existing products and product candidates are based on a number of internal and third-party
estimates, including but not limited to the size of the target population, the number of people at higher risk of developing cancer, and
the availability of the hypothetical price at which the established market sells the relevant candidate product. Although we believe that
our assumptions and data relating to estimates are reasonable, such assumptions and estimates may not be correct, and the conditions supporting
our assumptions or estimates may change at any time, reducing the accuracy of forecasts for these relevant factors. Accordingly, our estimates
of the total addressable market for current or future products may prove to be incorrect. If the target population that will benefit from
our products, the price at which we can sell our products or the total addressable market for our products is lower than our estimates,
it could harm our sales growth and adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Associated with Our Testing and the Manufacture
and Supply of Our Products</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Delays in the completion and obtaining regulatory
approvals of our manufacturing facilities, or damage, destruction or interruption of production at such facilities may delay our development
plans or commercialization efforts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future manufacturing facilities
will be global. The facility may incur unanticipated expenses due to a number of factors including regulatory requirements. Our manufacturing
facilities are subject to ongoing periodic inspections by various NMPA or other comparable regulatory agencies to ensure compliance with
current drug manufacturing practices. Failure to comply with applicable regulations may also result in us being subject to penalties,
including fines, injunctions, civil penalties, requests to suspend or stop one or more of our clinical trials, failure to obtain regulatory
approvals for our product candidates, delays, Suspension or withdrawal of approvals, supply interruptions, revocation of licenses, seizure
or recall of products or product candidates, operational restrictions and criminal prosecutions, any of which can cause harm to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 57 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our facilities may be damaged
or rendered inoperable due to physical damage caused by fire, flood, earthquake, typhoon, tornado, power outage, telecommunications failure,
intrusion and similar events. If our production facilities or equipment are damaged or destroyed, we may not be able to replace our production
capacity quickly or cheaply or at all. In the event of temporary or long-term damage to facilities or equipment, we may not be able to
transfer manufacturing to third parties. Even if we could transfer manufacturing to a third party, that transfer could be expensive and
time-consuming, especially since the new facility has to meet the necessary regulatory requirements and we have to obtain regulatory approvals
before selling any products manufactured at that facility. This event could delay our clinical trials or reduce sales of our products.
Any disruption to our manufacturing operations at our manufacturing facilities may result in us being unable to meet our clinical trial
or commercialization needs. Any disruption to our ability to manufacture products or product candidates in a timely manner could materially
damage our business, financial condition and results of operations. We currently insure against damage to our property and equipment for
an amount we believe is reasonable. However, our insurance coverage may not compensate us or may not be sufficient to cover any expenses
or losses we may incur. In the event of a catastrophic event or the failure of our production facilities or processes, we may not be able
to meet our requirements for products and product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The manufacturing and testing process of
our products is complex and subject to strict quality control. If we or any of our suppliers or logistics partners experience manufacturing,
logistics or quality problems, including as a result of natural disasters, our business may be damaged.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Partly due to stringent regulatory
requirements, the manufacturing and testing process for products is complex and subject to strict quality control. Additionally, quality
is paramount as product or test defects can have serious and costly consequences. Manufacturing and testing processes can go wrong for
a number of reasons, including equipment failure, non-compliance with codes and procedures, raw material issues, software issues, sample
contamination or human error. In addition, if contaminants are found in our product or product candidate supply, or in our production
and testing facilities, such production and testing facilities may need to be shut down for an extended period of time to investigate
the contamination and remediate it. Stability and other issues may arise in the future related to the manufacture and testing of our products
or product candidates. While well-managed, disruptions can occur during the introduction of new equipment and systems to replace aging
equipment, as well as production line transfers and expansions. As we increase market penetration, we may face unexpected surges in demand
for our products, which could put pressure on our production capacity or testing capabilities. If these problems arise, or if we otherwise
fail to meet our internal quality standards or the standards of the CFDA or other applicable regulatory agencies, including detailed record-keeping
requirements, our reputation may be damaged and we Safety warnings or recalls may apply, we may incur product and professional liability
and other costs, product approvals may be delayed, and our business may otherwise be adversely affected. In addition, our manufacturing,
testing and warehousing facilities, as well as those of our suppliers and logistics partners, may be severely damaged by earthquakes,
hurricanes, volcanoes, fires and other natural disasters or catastrophic circumstances, could materially and adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Security threats to our information technology
infrastructure and unauthorized use of data by third parties could expose us to liability or damage our reputation and business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our information technology
systems store and process a variety of sensitive data, including our proprietary business information, as well as patients&#8217; personal
data such as health information and personally identifiable information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is essential that our information
technology infrastructure remains secure and is perceived by hospitals, patients and our research partners to be secure. Despite our security
measures, we may face cyber-attacks that attempt to penetrate our network security, sabotage or otherwise disable our research, tests
and services, misappropriate our proprietary business information or cause interruptions of our internal systems and services. Any cyber-attacks
could negatively affect our reputation, damage our network infrastructure and our ability to deploy our products and services, harm our
relationship with customers and research partners, and expose us to significant financial liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, we may not be able
to prevent third parties from illegally obtaining and misappropriating personal data of the tested patients that we collect. Concerns
about data leakage or unauthorized use of data by third parties, even if unfounded, could damage our reputation and negatively affect
our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to effectively protect
our intellectual property, our business and competitive position would be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on patents, software
copyrights, trademarks, trade secrets and other intellectual property rights protection and contractual restrictions to protect our products,
services and technologies. We have registered a number of patents and trademarks in China and the United States. However, such protection
is limited and may not adequately protect our rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also be subject to
infringement claims by third parties. We may be subject to fines and other legal or administrative sanctions, and it may also be costly
to defend such claims. In addition, competitors could purchase our products and attempt to replicate and/or improve some or all of the
competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, and design their devices
and tests around our protected technologies or develop their own competitive technologies that fall outside of our intellectual property
rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Monitoring unauthorized disclosure
and uses of our trade secrets is difficult, and we do not know whether the steps we have taken to prevent such disclosure and uses are,
or will be, adequate. If we resort to litigation to enforce or protect our intellectual property rights, such litigation could result
in substantial costs and a diversion of our managerial and financial resources, while the outcome would be unpredictable, and any remedy
may be inadequate. Our contractual agreements may be breached by our counterparties, and there may not be adequate remedies available
to us for any such breach. In addition, our trade secrets may be leaked or otherwise become available to, or be independently discovered
by, our competitors, and we would have no right to prevent others from using them. Moreover, if a party having an agreement with us has
an overlapping or conflicting obligation to a third party, our rights in and to certain intellectual property could be undermined. If
we fail to effectively protect our intellectual property, our competitive position and prospects could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to intellectual property
infringement or misappropriation claims by third parties, which may force us to incur substantial legal expenses and, if determined adversely
against us, could disrupt our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain that
our products, tests and technologies do not or will not infringe patents, software copyrights, trademarks or other intellectual property
rights held by third parties, especially when they are in China, as the validity, enforceability and scope of intellectual property rights
protection in China are uncertain and still evolving. From time to time, we may be subject to legal proceedings and claims alleging infringement
of patents, trademarks or copyrights, or misappropriation of creative ideas or formats, or other infringement of proprietary intellectual
property rights. Any such proceedings and claims could result in significant costs to us and divert the time and attention of our management
and technical personnel from the operation of our business. These types of claims could also potentially adversely impact our reputation
and our ability to conduct business and raise capital, even if we are ultimately absolved of all liability. Moreover, third parties making
claims against us may be able to obtain injunctive relief against us, which could block our ability to offer one or more devices or tests
and could result in a substantial award of damages against us. In addition, since we sometimes indemnify our customers or collaboration
partners, we may have additional liability in connection with any infringement or alleged infringement of third-party intellectual property.
Intellectual property litigation can be very expensive, and we may not have the financial means to defend ourselves or our customers or
collaboration partners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because patent applications
can take many years to issue, there may be pending applications, some of which are unknown to us, that may result in issued patents upon
which our products, tests or proprietary technologies may infringe. Moreover, we may fail to identify issued patents of relevance or incorrectly
conclude that an issued patent is invalid or not infringed by our technology or any of our devices or tests. There is a substantial amount
of litigation involving patents and other intellectual property rights in our industry. If a third-party claims that we infringe upon
a third-party&#8217;s intellectual property rights, we may have to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">seek to obtain licenses that may not be available on commercially reasonable terms, if at all;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">abandon any product alleged or held to infringe, or redesign our products or processes to avoid potential assertion of infringement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 59 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">pay substantial damages including, in exceptional cases, treble damages and attorneys&#8217; fees, if a court decides that the device, test or proprietary technology at issue infringes upon or violates the third-party&#8217;s rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">pay substantial royalties or fees or grant cross-licenses to our technology; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">defend litigation or administrative proceedings that may be costly whether we win or lose, and which could result in a substantial diversion of our financial and management resources.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to litigation and other
claims and legal proceedings, and may not always be successful in defending ourselves against these claims or proceedings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to lawsuits
and other claims in the ordinary course of our business. We may from time to time be subject to lawsuits and other legal proceedings brought
by our customers, competitors, employees, business partners, investors, other shareholders of the companies we invest, or other entities
against us in the ordinary course of our business. We may also be subject to regulatory proceedings in the ordinary course of our business.
We may not be successful in defending ourselves, and the outcomes of these lawsuits and proceedings may be unfavorable to us. Lawsuits
and regulatory proceedings against us may also generate negative publicity that significantly harms our reputation, which may adversely
affect our customer base, market position and our relationships with our research partners and other business partners. In addition to
the related costs, managing and defending litigation and other legal proceedings and related indemnity obligations can significantly divert
our management&#8217;s attention from operating our business. We may also need to pay damages or settle lawsuits or other claims with
a substantial amount of cash, negatively affecting our liquidity. As a result, our business, financial condition and results of operations
could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Relating to Our Financial Prospects and
Need for Additional Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We incurred net losses for the years ended
June 30, 2025 and 2024 and may not be able to generate sufficient operating cash flows and working capital to continue as a going concern.
Failure to manage our liquidity and cash flows may materially and adversely affect our financial condition and results of operations.
As a result, we may need additional capital, and financing may not be available on terms acceptable to us, or at all.</i></b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incurred net losses of
$3,258,969 and $2,782,278 for the years ended June 30, 2025 and 2024, respectively. Our ability to continue as a going concern depends
upon our ability to develop, register and obtain regulatory approval for commercial sell of our products to generate positive operating
cash flows. The Company had net cash outflows of $5,825,055 and $2,126,340 from operating activities for the years ended June 30, 2025
and 2024, respectively. These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going
concern. The Company certain related parties have waived off the amount due to them as of June 30, 2024 amounted to $2,820,624 in order
to improve the Company&#8217;s working capital. The Company completed its initial public offering. In the initial public offering, the
Company issued 1,640,000 shares of common stock at a price of US$4.00 per share. The Company received gross proceeds in the amount of
US$6.56 million before deducting any underwriting discounts or expenses. On June 6, 2025, the Company entered into a purchase agreement
(the &#8220;ELOC Agreement&#8221;) with HELENA GLOBAL INVESTMENT OPPORTUNITIES I LTD. (the &#8220;Investor&#8221; or &#8220;Selling Stockholder&#8221;),
pursuant to which the Company have the right to issue and sell to the Investor, from time to time as provided therein, and the Investor
is obligated to purchase from us, up to Twenty-Five Million United States Dollars ($25,000,000) of the Company&#8217;s Common Stock, subject
to terms and conditions set forth in the ELOC Agreement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We can offer no assurance
that we will operate profitably or that we will generate positive cash flows in the next twelve months, given our substantial expenses
in relation to our revenue at this stage of our Company. Inability to collect our accounts receivable in a timely and sufficient manner,
or the inability to offset our expenses with adequate revenue, may adversely affect our liquidity, financial condition and results of
operations. Although we believe that our cash on hand will be sufficient to meet our anticipated working capital requirements and capital
expenditures in the ordinary course of business for the next 6 months, we cannot assure you this will be the case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If and when we are unable
to meet our working capital requirements and various operating needs, we may need to raise additional funds for our operations and such
funds may not be available on commercially acceptable terms, if at all. If we are unable to raise funds on acceptable terms, we may not
be able to execute our business plan, take advantage of future opportunities, or respond to competitive pressures or unanticipated requirements.
This may seriously harm our business, financial condition and results of operations. If we are unable to achieve or maintain profitability,
the market price of our shares may significantly decrease. In the event that the Company requires additional funding to finance its operations,
the Company&#8217;s major stockholders have indicated their intent and ability to provide such financial support, however, there is no
assurance such funding will be available when the Company needs it in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have recorded negative cash flows from
operating activities historically and may have a current liabilities position in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have experienced significant
cash outflow from operating activities since our inception. We had net cash outflow in operating activities of $5.8 million and $2.1 million
for the years ended June 30, 2025 and 2024, respectively. The cost of continuing operations could further reduce our cash position, and
an increase in our net cash outflow from operating activities could adversely affect our operations by reducing the amount of cash available
to meet the cash needs for operating our business and to fund our investments in our business expansion.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
had net current asset (liabilities) of $3.1 million and $0.3 million as of June 30, 2025 and 2024, respectively. We cannot guarantee that
we will remain in a net current assets position in future, which would expose us to liquidity risk. Our future liquidity and ability to
make additional capital investments necessary for our operations and business expansion will depend primarily on our ability to maintain
sufficient cash and to obtain adequate external financing. There can be no assurance that we will be able to obtain any sources of financing.</span>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We require substantial funding for our operations.
If we cannot raise sufficient additional capital on acceptable terms, our business, financial condition and prospects may be adversely
affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We require substantial capital
to fund our existing operations, commercialize new products, expand our business and pursue strategic investments. In particular, we require
substantial capital to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">advance our early cancer detection technologies and develop early cancer detection product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">increase our sales and marketing efforts to drive market adoption of our products and services and address competitive developments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">seek regulatory and marketing approvals for our tests;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">maintain, expand and protect our intellectual property portfolio;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">hire and retain additional personnel, such as scientists and sales and marketing personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">develop, acquire and improve operational, financial and management information systems;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">add equipment and physical infrastructure to support our research and development programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">finance general and administrative expenses; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">operate as a public company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our available cash balances
are insufficient to satisfy our liquidity requirements, in particular, for the development and commercialization of our products, we may
seek to obtain further funding through public or private equity offerings, debt financings or other sources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further financing may not
be available to us on acceptable terms, or at all. If we fail to raise capital as and when needed it would have a negative impact on our
financial condition and our ability to pursue our business strategy. In addition, if we raise funds by issuing debt securities or incurring
additional borrowings, the terms of debt securities issued or borrowings could impose significant restrictions on our operations, and
we may be unable to repay the indebtedness when due. If we raise funds by issuing equity securities, your investment in our company could
be diluted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raising additional capital may lead to dilution
of shareholdings by our existing stockholders, restrict our operations, and may further result in fair value loss adversely affecting
our financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional funding
through a combination of equity and debt financings and collaborations. To the extent that we raise additional capital through the sale
of equity or convertible debt securities, the ownership interest of existing holders of our shares will be diluted, and the terms may
include liquidation or other preferences that adversely affect the rights of our existing stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The incurrence of additional
indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in
certain additional restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations
on our ability to acquire or license IP rights and other operating restrictions that could adversely impact our ability to conduct our
business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have only a limited accounting personnel
and have corrected an error in application of the accounting principle for business combinations accounted for an acquisition of an entity
during the year ended June 30, 2022.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the completion of
the Initial Public Offering, we had been a private company with limited accounting personnel mainly engage in financial reporting. On
January 1, 2022, the Company, through Advanced Biomed HK, acquired 100% equity interest of Shanghai Sglcell. The Company carefully considered
the appropriate accounting guidance in accordance with its application of the accounting principle related to accounting for business
combinations. However, we did not engage outside experts to assist in the detailed analysis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon further assessment, the
Company has corrected an error in its application of the accounting principle for business combinations where the Company previously incorrectly
accounted for an acquisition of an entity as a business combination; the Company has amended its consolidated financial statements for
the year ended June 30, 2022 to account for the transaction as purchase of assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management concluded that
the above correction identified in connection with the accounting treatment for the acquisition was a significant deficiency that did
not rise to the level of a material weakness. The deficiency identified was narrow as it focused on the interpretation of accounting literature
to a specific transaction structure which is not expected to be recurring nature. For future material acquisitions, the Company will engage
outside experts to assist in the transaction, including legal and accounting advisors, to advise on complex accounting issues in order
to prevent potential differences in the accounting for business combinations. As a result, the Company does not believe that the significant
deficiency rose to the level of a material weakness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Doing Business in Taiwan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advanced Biomed Taiwan does not currently
own any trademark or patent.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No trademark or patent has
been registered by Advanced Biomed Taiwan so far in Taiwan. It also has no pending intellectual property right contracts, including license,
transfer or sublicense. Its primary business is research and development of various advanced and innovative microfluidic biochip technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on Article 7 of Taiwan&#8217;s
Patent Act, where a fund provider appoints another party to conduct research and development, the ownership of the right to apply for
a patent and the patent right in connection with the outcome of such research and development shall be vested in the party as mutually
agreed upon in an agreement between both parties, or such rights shall be vested in the inventor, utility model creator or designer in
the absence of such agreement. However, the fund provider shall be entitled to exploit such invention, utility model or design. Advanced
Biomed Taiwan signed a research project equipment use contract with TSRI and used their semiconductor manufacturing equipment and precision
micro-nano processing equipment for chip technology research and development such as concept presentation of each R&amp;D process, cross-scale
composite structure production, rapid wafer trial production, material testing, and thin film production. Both parties agree to keep the
test data, process and materials confidential. Advanced Biomed Taiwan agrees that TSRI may quote the test data in its research paper with
the consent of Advanced Biomed Taiwan. The contract also provides that any intellectual property rights of one party should only be used
in the test by licensing to the other party and that any intellectual property rights derived from the test will belong to the developer.
Both parties will jointly own the intellectual property right if it cannot be clearly identified who the developer is. The ownership of
patent application rights and patent rights may be obscure in such practice and raise disputes on who the developers are. We cannot assure
you that the patents owned or applied by Advanced Biomed Taiwan will not be subject to disputes under Taiwan&#8217;s Patent Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face economic and political risks associated
with doing business in Taiwan, particularly due to the geopolitical tension between Taiwan and China that could negatively affect our
business and hence the value of your investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, we rely on Advanced
Biomed Taiwan for microfluidic biochip technology and its application in precision medicine in the field of oncology. Accordingly, our
business, financial condition and results of operations and the market price of our securities may be affected by changes in governmental
policies, taxation, growth rate, inflation rate or interest rates and by social instability and diplomatic and social developments in
or affecting Taiwan. In particular, the unique political status of Taiwan and its internal political movement cause sustained tension
between China and Taiwan. Past developments related to the interactions between China and Taiwan, especially in relation to trade activities
such as bans on exports of goods from time to time, have on occasions depressed the transactions and business operations of certain Taiwanese
companies and overall economic environment. We cannot predict whether there will be escalation of the tensions between China and Taiwan
which would lead to new bans or tariffs on exports or even conflict. Any conflict which threatens the military, political or economic
stability in Taiwan could have a material adverse effect on our current or future business and financial conditions and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advanced Biomed Taiwan is subject to restrictions
on paying dividends or making other payments to us, which may restrict our ability to satisfy its liquidity requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company incorporated
under the laws of the State of Nevada structured as a holding company, we may need dividends and other distributions on equity from our
Taiwan subsidiary to satisfy our liquidity requirements. Current Taiwan regulations permit our Taiwan subsidiary to pay dividends to its
shareholders only out of its accumulated profits, if any, which shall first make up previous losses and set aside at least 10% of its
accumulated profits each year. These reserves are not distributable as cash dividends. Furthermore, if our Taiwan subsidiary incurs debt
on its own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other payments
to us. Any limitation on the ability of our Taiwan subsidiary to distribute dividends or to make payments to us may restrict our ability
to satisfy our liquidity requirements. In addition, the dividend payments by our Taiwan subsidiary to us shall be subject to the withholding
tax of 21% since January&#160;1, 2018.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advanced Biomed Taiwan is subject to foreign
exchange control imposed by Taiwan authorities, which may affect the paying dividends, repatriating the interest or making other payments
to us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently Taiwan regulates
only those foreign exchange transactions that involve the conversion of the New Taiwan Dollar into foreign currencies. Pursuant to the
relevant provisions of Taiwan Foreign Exchange Control Act, foreign exchange transactions of a value of NTD 500,000 or more shall be declared
to the Central Bank of Republic of China (Taiwan). Further, for a remittance by a company as follows, relevant testimonials shall be submitted
and such remittance shall be subject to the approval of the Central Bank of Taiwan: (i)&#160;a single remittance of an amount over USD1&#160;million;
or (ii)&#160;annual accumulated settlement amount of foreign exchange purchased or sold has exceeded USD50&#160;million. Nevertheless,
Taiwan government may impose further foreign exchange restrictions in certain emergency situations, where Taiwan government experiences
extreme difficulty in stabilizing the balance of payments or where there are substantial disturbances in the financial and capital markets
in Taiwan. If the dividend payments or other payments by our Taiwan subsidiary and branches to us involves the currency conversion from
New Taiwan Dollar to US&#160;Dollar, such conversion would be subject to the foregoing foreign exchange control imposed by Taiwan authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 63 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taiwan laws and regulations of loans to
and direct investment in Taiwan entities by offshore holding companies may delay or prevent us from using the credits of the ELOC Agreement
or any future financing acitivies to make loans or additional contributions to Advanced Biomed Taiwan, which could materially and adversely
affect our ability to fund and expand our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an offshore holding
company conducting our R&amp;D operations substantially in Taiwan through our Advanced Biomed Taiwan. We may make loans to Advanced Biomed
Taiwan, or we may make additional capital contributions to Advanced Biomed Taiwan, or we may establish new Taiwan subsidiaries and make
capital contributions to these new Taiwan subsidiaries, or we may acquire offshore entities with business operations in Taiwan in an offshore
transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most of these ways are subject
to Taiwan regulations and approvals or registration. For example, investment, including lending long-term loans, in Taiwan entities require
Foreign Investment Approval (as defined below) from the Taiwan Investment Commission. Furthermore, foreign entities are prohibited from
investing in some industries which are relating to national security and environmental protection, as specified in the negative list provided
by Taiwan authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advanced Biomed Taiwan will collaborate
and share its R&amp;D efforts with us and our Shanghai subsidiary and is subject to Taiwan regulations on investment or technical cooperation
in China. It may affect its technical cooperation with the Shanghai subsidiary and more seriously its acquisition by Advanced Biomed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the cross-strait relations
become more and more sensitive recently, Taiwan authorities incline to prohibit Taiwan technology companies from selling their subsidiaries
or assets to mainland Chinese investors to prevent leak of sensitive technologies, including semiconductors. Pursuant to the Taiwan Permission
Regulations for Investment or Technical Cooperation in the PRC and the Review Principles for Investments or Technical Cooperation in China
(&#8220;Permission Regulations&#8221;), an investment or technical cooperation made by a Taiwanese investor in China is subject to the
restrictions thereunder and requires the approval by the competent Taiwan authority, Taiwan Investment Commission. The restrictions under
the Permission Regulations include a negative list in which investment or technical cooperation is prohibited. Currently, Advanced Biomed
Taiwan&#8217;s technical cooperation with the Shanghai subsidiary is not on such negative list. However, we cannot preclude the possibility
that the negative list will be amended to restrict Advanced Biomed Taiwan&#8217;s cooperation with the Shanghai subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taiwanese investors holding more than 10%
of Advanced Biomed Common Stock will be subject to Taiwan regulations on investment or technical cooperation in China for its investment
or technical cooperation in China.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Permission Regulations,
for an investment made by a Taiwanese individual or entity (&#8220;Taiwanese Investor&#8221;) in a &#8220;third region&#8221; company
which conducts the investments or technical cooperation in China defined therein and such Taiwanese Investor (i)&#160;acts as director,
supervisor, manager or equivalent position or (ii)&#160;has a shareholding or capital contribution of 10% or more in such third region
company, the investment in such a third region company would also be deemed a defined investment in China and therefore be subject to
the Permission Regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therefore, for our future
investment or technical cooperation in China, our Taiwanese shareholders holding 10% or more of our Common Stock will need to apply for
the foreign investment approval with the competent Taiwan authority, the Taiwan Investment Commission in accordance with the Permission
Regulations (the &#8220;Foreign Investment Approval&#8221;). There are restrictions on the investment or technical cooperation with China,
including, without limitation, the annual investment amount in China shall be capped at USD5 million per year for Taiwan individuals or
NTD 80 million or 60% of the higher of its stand-along net worth or consolidated net worth for a Taiwan small-medium enterprise. Your
indirect investment in the PRC via the Company under the Permission Regulations will be calculated on the portion of your shareholdings
in the Company. If your aggregate investments in the PRC exceed the annual ceiling amount, the Taiwan Investment Commission will reject
your application for the exceeding investment in the PRC. If the Taiwanese Investor fails to obtain applicable approvals from the Taiwan
Investment Commission in respect of its investment in China, an administrative fine ranging NTD 50 thousand to 25 million or imprisonment
may be imposed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The imposition of foreign exchange restrictions
in Taiwan may have an adverse effect on foreign investors&#8217; abilities to acquire securities of a Taiwan company, including the shares
of our subsidiaries in Taiwan, or to repatriate the interest, dividends or sale proceeds from those securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Taiwan government may
impose foreign exchange restrictions in certain emergency situations, including situations where there are sudden fluctuations in interest
rates or exchange rates, where the Taiwan government experiences extreme difficulty in stabilizing the balance of payments or where there
are substantial disturbances in the financial and capital markets in Taiwan. These restrictions may require foreign investors to obtain
the Taiwan government&#8217;s approval before acquiring securities of a Taiwan company, including the shares of our subsidiaries in Taiwan,
repatriating the interest or dividends from those securities or repatriating the proceeds from the sale of those securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our operations are subject to the effects
of a rising rate of inflation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Taiwan experienced historically
high levels of inflation in 2022 and 2023. Although the inflation rate peaked in June 2022 at 3.59%, there is no guarantee that the inflation
will not accelerate again. If the inflation rate continues to remain at a relatively high level or increases drastically, for example,
due to increases in the costs of labor and supplies, it will affect our expenses, such as employee compensation and research and development
charges. Additionally, Taiwan is experiencing an acute workforce shortage, which, in turn, has created a very competitive wage environment
that may increase our operating costs. To the extent inflation results in rising interest rates and has other adverse effects on the market,
it may adversely affect our consolidated financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You may experience difficulties in effecting
service of legal process, enforcing foreign judgments, or bringing actions in Taiwan against us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company incorporated
under the laws of the State of Nevada, it may be difficult for you to enforce judgments obtained in U.S. courts based on civil liability
provisions of the U.S. federal securities laws against us in Taiwan. In addition, there is uncertainty as to whether the courts of Taiwan
would recognize or enforce judgments of U.S. courts against us or such persons predicated upon the civil liability provisions of the securities
laws of the U.S. or any state, if the following circumstances occurs:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Where the foreign court lacks jurisdiction pursuant to the Taiwan laws;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Where a default judgment is rendered against the losing defendant, except in the case where the notice or summons of the initiation of action had been legally served in a reasonable time in the foreign country or had been served through judicial assistance provided under the Taiwan laws;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Where the performance ordered by such judgment or its litigation procedure is contrary to Taiwan public policy or morals; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Where there exists no mutual recognition between the foreign country and the Taiwan.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Doing Business in China</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A downturn in China or global economy, and
economic and political policies of the PRC could materially and adversely affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the different regulatory
requirements for the marketing of medical device products and invitro diagnosis (&#8220;IVD&#8221;) products in different regions/countries,
it is necessary to complete the registration application and obtain the corresponding license in accordance with the local regulations
before engaging in commercial activities in the respective regions/countries (&#8220;localization registration&#8221;). Afterwards, marketing
and sales can be carried out. All the products and equipment we research and develop are designed following the principle of modularization
so that products and equipment can be produced locally to meet different regulatory requirements. The Chinese market has a great potential
and is our one of the main markets in the future. At present, we have applied for product registration in China in accordance with relevant
Chinese laws and regulations. Meanwhile, we have established subsidiaries in Mainland China and Hong Kong. Accordingly, our business,
prospects, financial condition and results of operations may be influenced by political, economic and social conditions in the PRC generally
and by continued economic growth in the PRC as a whole. The Chinese economy differs from the economies of most developed countries in
many respects, including the amount of government involvement, level of development, growth rate, control of foreign exchange and allocation
of resources. While the Chinese economy has experienced significant growth over the past decades, growth has been uneven, both geographically
and among various sectors of the economy, and we cannot assure you that such growth is sustainable. The Chinese government has implemented
various measures to encourage economic growth and guide the allocation of resources. Some of these measures may benefit the overall Chinese
economy but may have a negative effect on us. For example, the Chinese government may direct resources to industries other than the one
we operate in and potentially reduce the investors&#8217; interest in our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 65 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Economic conditions in China
are sensitive to global economic conditions. Any prolonged slowdown in the global or Chinese economy may affect potential clients&#8217;
confidence in financial market as a whole and have a negative impact on our business, results of operations and financial condition. Additionally,
continued turbulence in the international markets may adversely affect our ability to access the capital markets to meet liquidity needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in the policies, regulations, rules,
and the enforcement of laws of the PRC government may be quick with little advance notice and could have a significant impact upon our
ability to operate profitably in the Mainland China and Hong Kong.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since we have our subsidiaries
in Shanghai and Hong Kong, economic, political and legal developments in the PRC will affect our business, financial condition, results
of operations and prospects. Policies, regulations, rules, and the enforcement of laws of the PRC government can have significant effects
on economic conditions in the PRC and the ability of businesses to operate profitably. Our ability to operate profitably in the PRC may
be adversely affected by changes in policies by the PRC government, including changes in laws, regulations or their interpretation, particularly
those dealing with the Internet, including censorship and other restriction on material which can be transmitted over the Internet, security,
intellectual property, money laundering, taxation and other laws that affect our ability to operate business in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Chinese government may intervene in
or influence our operations in the Mainland China or Hong Kong at any time or may exert more control over offerings conducted overseas
and/or foreign investment in us, which could result in a material change in our operations and and/or the value of the securities we are
registering for sale.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Chinese government has
significant oversight and discretion over the conduct of our business and may intervene or influence our operations in the Mainland China
or Hong Kong as the government deems appropriate to further regulatory, political and societal goals. The Chinese government has recently
published new policies that significantly affected certain industries such as the education and Internet industries, and we cannot rule
out the possibility that it will in the future release regulations or policies regarding our industry that could require us to seek permission
from Chinese authorities to commence to operate our business, which may adversely affect our business, financial condition and results
of operations. Furthermore, recent statements made by the Chinese government have indicated an intent to increase the government&#8217;s
oversight and control over offerings of companies with significant operations in China that are to be conducted in foreign markets, as
well as foreign investment in PRC-based issuers. There is no guarantee that we will not be subject to such direct influence or intervention
in the future due to changes in laws or other unforeseeable reasons. There is always a risk that the Chinese government may, in the future,
seek to affect operations of any company with any level of operations in the Mainland China and Hong Kong. Any such action, once taken
by the Chinese government, could cause the value of our Common Stock to significantly decline or become worthless. In addition, if we
were to become subject to the direct intervention or influence of the PRC government at any time due to changes in laws or other unforeseeable
reasons, it may require a material change in our operations and/or result in increased costs necessary to comply with existing and newly
adopted laws and regulations or penalties for any failure to comply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the Chinese government chooses to exert
more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers, such action could
significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such
securities to significantly decline or be worthless.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We face risks arising from
China including risks and uncertainties regarding the enforcement of laws and that rules and regulations in China can change quickly with
little advance notice. The Chinese government may intervene or influence the operations of our subsidiaries in Shanghai and Hong Kong
at any time, or may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could
result in a material change in the operations of our subsidiaries in Shanghai and Hong Kong and/or the value of our Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Chinese government has
exercised and continues to exercise substantial control over virtually every sector of the Chinese economy through regulation and state
ownership. Our ability to operate in China through our subsidiaries in Shanghai and Hong Kong may be harmed by changes in laws and regulations
in China, including those relating to securities regulation, data protection, cybersecurity and mergers and acquisitions and other matters.
The PRC central or local governments may impose new, stricter regulations or interpretations of existing regulations that would require
additional expenditures and efforts on our part to ensure our and our subsidiaries&#8217; compliance with such regulations or interpretations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government actions in the
future could significantly affect economic conditions in China or particular regions thereof, and could require our subsidiaries in Shanghai
and Hong Kong to materially change their operating activities or divest ourselves of any interests we hold in Chinese assets. Our subsidiaries
in Shanghai and Hong Kong may be subject to various government and regulatory interference. We may incur increased costs necessary to
comply with existing and newly adopted laws and regulations or penalties for any failure to comply. Such subsidiaries&#8217; operations
could be adversely affected, directly or indirectly, by changes to existing laws or implementation of future laws and regulations relating
to their business or industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this Report,
we and our subsidiaries in the Mainland China and Hong Kong (1) are not required to obtain permissions from any PRC authorities to operate
or issue our Common Stock to foreign investors, (2) are not subject to permission requirements from the CSRC, CAC or any other entity
that is required to approve their operations in the Mainland China and Hong Kong, and (3) have not received or were denied such permissions
by any PRC authorities. Nevertheless, the General Office of the Central Committee of the Communist Party of China and the General Office
of the State Council jointly issued the &#8220;Opinions on Severely Cracking Down on Illegal Securities Activities According to Law,&#8221;
which were made available to the public on July 6, 2021. The Opinions emphasized the need to strengthen the administration over illegal
securities activities, and the need to strengthen the supervision over overseas listings by Chinese companies. The regulatory agencies
like CSRC or CAC may impose fines and penalties on our operations in the Mainland China or Hong Kong, limit our ability to pay dividends
outside of the Mainland China or Hong Kong, limit our operations in the Mainland China or Hong Kong, delay or restrict the repatriation
of the credits from the ELOC Agreement or any future financing activities into the Mainland China or Hong Kong or take other actions that
could have a material adverse effect on our business, financial condition, results of operations and prospects, as well as the trading
price of our securities. The CSRC, the CAC, or other PRC regulatory agencies also may take actions requiring us, or making it advisable
for us, to halt future offerings before settlement and delivery of our Common Stock. Consequently, if you engage in market trading or
other activities in anticipation of and prior to settlement and delivery, you do so at the risk that settlement and delivery may not occur.
In addition, if the CSRC, the CAC or other regulatory PRC agencies later promulgate new rules requiring that we obtain their approvals
for future offerings, we may be unable to obtain a waiver of such approval requirements, if and when procedures are established to obtain
such a waiver. Any uncertainties and/or negative publicity regarding such an approval requirement could have a material adverse effect
on the trading price of our securities.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any actions by the Chinese
government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers
could significantly limit or complete hinder our ability to offer or continue to offer our securities and cause the value of such securities
to significantly decline or be worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 67 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the Chinese government were to exert
more oversight and control over or impose new requirements for approval from the PRC authorities to issue our Common Stock to foreign
investors or list on a foreign exchange, such action could significantly limit or completely hinder our ability to offer or continue to
offer securities to investors and cause the value of such securities to significantly decline or be worthless.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recent statements by the Chinese
government have indicated an intent to exert more oversight and control over offerings that are conducted overseas and/or foreign investments
in PRC based issuers. PRC has recently promulgated new rules that require companies collecting or holding large amounts of data to undergo
a cybersecurity review prior to listing in foreign countries, a move that will significantly tighten oversight over PRC-based internet
giants. The Measures for Cybersecurity Review (2021 version) was promulgated on December 28, 2021 and became effective on February 15,
2022. These measures specify that any &#8220;online platform operators&#8221; controlling the personal information of more than one million
users which seek to list on a foreign stock exchange are subject to prior cybersecurity review.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 24, 2024, the
State Council promulgated the Regulation on Network Data Security Management (the &#8220;Network Data Regulation&#8221;), which became
effective as of January 1, 2025. The Network Data Regulation restates and further specifies the legal requirements for personal information,
important data, cross-border data transfer, network platform services, and data security. Among others, if the network data processing
activities have or may have impacts on national security, such activities shall be subject to national security review in accordance with
relevant laws and regulations. Any failure to comply with such requirements may subject us to, among others, suspension of services, fines,
revoking relevant business permits or business licenses and penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC Data Security Law,
which was promulgated by the Standing Committee of the National People&#8217;s Congress (the &#8220;SCNPC&#8221;) on June 10, 2021 and
took effect on September 1, 2021, requires data collection to be conducted in a legitimate and proper manner, and stipulates that, for
the purpose of data protection, data processing activities must be conducted based on data classification and hierarchical protection
system for data security.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 20, 2021, the SCNPC
promulgated the Personal Information Protection Law of the People&#8217;s Republic of China, or the Personal Information Protection Law,
which integrates the scattered rules with respect to personal information rights and privacy protection and took effect on November 1,
2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business does not involve the collection of user data, implicate
cybersecurity, or involve any other type of foreign investment restricted industry. As of the date of this Report, we have not received
any notice from any authorities identifying the operating entities as CIIOs or requiring us to go through cybersecurity review or network
data security review by the CAC. Uncertainties still exist, however, due to the possibility that laws, regulations, or policies in the
PRC could change rapidly in the future. Any future action by the PRC government expanding the categories of industries and companies whose
foreign securities offerings are subject to review by the CAC could significantly limit or completely hinder our ability to offer or continue
to offer securities to investors and could cause the value of such securities to significantly decline or be worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 17, 2023, the CSRC released Trial Administrative Measures
of Overseas Securities Offering and Listing by Domestic Companies with five interpretive guidelines (the &#8220;Trial Measures&#8221;),
which came into effect on March 31, 2023. Pursuant to the Trial Measures, a PRC domestic company that seeks to offer and list securities
in overseas markets, either in direct or indirect overseas offering, shall fulfill the filing procedure with the CSRC and report relevant
information to the CSRC. Direct overseas offering and listing by domestic companies refers to such overseas offering and listing by a
joint-stock company incorporated domestically. Any overseas offering and listing made by an issuer that meets both the following conditions
will be determined as indirect offering and listing in overseas market and, therefore, be subject to filing requirement: (i) 50% or more
of the issuer&#8217;s operating revenue, total profit, total assets or net assets as documented in its audited consolidated financial
statements for the most recent accounting year is accounted for by domestic companies; and (ii) the main parts of the issuer&#8217;s business
activities are conducted in the Mainland China, or its main places of business are located in the Mainland China, or the senior managers
in charge of its business operation and management are mostly Chinese citizens or domiciled in the Mainland China. The determination as
to whether or not an overseas offering and listing by domestic companies is indirect, shall be made on substance over form basis. As of
the date of this Report, we believe we do not meet the explicit conditions set out in the Trial Measures to determine whether an overseas
offering shall be deemed as an indirect overseas offering and listing by a domestic company and thus we believe we are not required to
complete the filing with the CSRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 68 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, as the Trial Measures
was newly published and the determination as to whether or not an overseas offering and listing by domestic companies is indirect, shall
be made on a substance over form basis, there are substantial uncertainties as to the implementation and interpretation, and the CSRC
may take a view that is contrary to our understanding of the Trial Measures. If we are required by the CSRC to submit and complete the
filing procedures of future offering and listing, we cannot assure you that we will be able to complete such filings in a timely manner,
or even at all. Any failure by us to comply with such filing requirements under the Trial Measures may result in rectification, warnings,
and a fine between RMB1 million and RMB10 million on our Shanghai subsidiary, which could adversely and materially affect our business
operations and financial outlook, and significantly limit or completely hinder our ability to offer or continue to offer our Common Stock
to investors and could cause the value of our Common Stock to significantly decline or such shares to become worthless.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 24, 2023, the
CSRC, together with other PRC government authorities, released the Provisions on Strengthening the Confidentiality and Archives Administration
Related to the Overseas Securities Offering and Listing by Domestic Enterprises (the &#8220;Confidentiality and Archives Administration
Provisions&#8221;), which came into effect on March 31, 2023. The Confidentiality and Archives Administration Provisions require, among
others, that PRC domestic enterprises seeking to offer and list securities in overseas markets, either directly or indirectly, shall establish
the confidentiality and archives system, and shall complete approval and filing procedures with competent authorities, if such PRC domestic
enterprises or their overseas listing entities provide or publicly disclose documents or materials involving state secrets and work secrets
of PRC government agencies to relevant securities companies, securities service institutions, overseas regulatory agencies and other entities
and individuals. It further stipulates that providing or publicly disclosing documents and materials which may adversely affect national
security or public interests, and accounting files or copies of important preservation value to the state and society shall be subject
to corresponding procedures in accordance with relevant laws and regulations. As of the date of this Report, our Shanghai subsidiary has
established the confidentiality and archives system and we are not subject to the approval to the competent authorities since we do not
possess any documents or materials involving state secrets and work secrets of PRC government agencies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this Report, we believe we and our subsidiaries in
the Mainland China and Hong Kong, (1) are not required to obtain permissions from any PRC authorities to operate or issue our Common Stock
to foreign investors, (2) are not subject to permission requirements from the CSRC, CAC or any other entity that is required to approve
of our PRC Subsidiaries&#8217; operations, and (3) have not received or were denied such permissions by any PRC authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been closely monitoring
regulatory developments in PRC regarding any necessary approvals from the CSRC or other PRC governmental authorities required for overseas
listings. As of the date of this Report, we have not received any inquiry, notice, warning, sanctions or regulatory objection to our offering
of securities from the CSRC or other PRC governmental authorities. However, there remains significant uncertainty as to the enactment,
interpretation and implementation of regulatory requirements related to overseas securities offerings and other capital markets activities.
Given the current PRC regulatory environment, it is uncertain when and whether we or our subsidiaries in Shanghai and Hong Kong will be
required to obtain permission from the PRC government to list on U.S. exchanges in the future, and even when such permission is obtained,
whether it will be denied or rescinded. Such significant uncertainty could materially and adversely impact our business and financial
outlook and may impact our ability to accept foreign investments, or continue to list on a U.S. or other foreign exchange.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Uncertainties in the interpretation and
enforcement of PRC laws and regulations could limit the legal protections available to you and the Company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are subject
to various PRC laws and regulations generally applicable to companies in the PRC because we have subsidiaries in Shanghai and Hong Kong.
The PRC legal system is based on written statutes. Unlike common law systems, it is a system in which legal cases have limited value as
precedents. In the late 1970s, the PRC government began to promulgate a comprehensive system of laws and regulations governing economic
matters in general. The overall effect of legislation over the past four decades has significantly increased the protections afforded
to various forms of foreign or private-sector investment in the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, the PRC has not developed
a fully integrated legal system and recently enacted laws and regulations may not sufficiently cover all aspects of economic activities
in the PRC. In particular, the interpretation and enforcement of these laws and&#160;regulations involve uncertainties. In addition, the
PRC legal system is based in part on government policies and internal rules (some of which are not published on a timely basis or at all)
that may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until sometime after
the violation. Such uncertainties, including uncertainty over the scope and effect of our contractual, property (including intellectual
property) and procedural rights, and any failure to respond to changes in the regulatory environment in the PRC could materially and adversely
affect our business and impede our ability to continue our operation in the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if certain PRC
laws and regulations were to become applicable to us in the future, the application of such laws and regulations may have a material adverse
impact on our business, financial condition and results of operations, any of which may cause the value of our securities to significantly
decline or become worthless. In addition, the laws and regulations in the PRC are evolving, and their enactment timetable, interpretation
and implementation involve significant uncertainties. To the extent any PRC laws and regulations become applicable to our business, it
may be subject to the risks and uncertainties associated with the legal system in the PRC, including with respect to the enforcement of
laws and the possibility of changes of rules and regulations with little or no advance notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You may experience difficulties in effecting
service of legal process, enforcing foreign judgments, or bringing actions in PRC against us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company incorporated
under the laws of the State of Nevada, it may be difficult for you to enforce judgments obtained in U.S. courts based on civil liability
provisions of the U.S. federal securities laws against us in the PRC. In addition, there is uncertainty as to whether the courts of the
PRC would recognize or enforce judgments of U.S. courts against us or such persons predicated upon the civil liability provisions of the
securities laws of the U.S. or any state.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The recognition and enforcement
of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce foreign judgments in accordance
with the requirements of the PRC Civil Procedures Law based either on treaties between PRC and the country where the judgment is made
or on principles of reciprocity between jurisdictions. PRC does not have any treaties or other forms of written arrangement with the United
States that provide for the reciprocal recognition and enforcement of foreign judgments. In addition, according to the PRC Civil Procedures
Law, the PRC courts will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates
the basic principles of PRC laws or national sovereignty, security, or public interest. As a result, it is uncertain whether and on what
basis a PRC court would enforce a judgment rendered by a court in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-compliance with the PRC Labor Contract
Law and other labor-related regulations in the PRC may adversely affect our business and our results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been subject to stricter
regulatory requirements in terms of entering into labor contracts with our employees and paying various statutory employee benefits, including
pensions, housing fund, medical insurance, work-related injury insurance, unemployment insurance and childbearing insurance to designated
government agencies for the benefit of our employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the PRC Labor
Contract Law, or the Labor Contract Law, which was released on January&#160;1, 2008, was amended on December&#160;28, 2012 and became
effective on July 1, 2013 employees have the right, among others, to enter into written labor contracts, minimum wages, paying remuneration,
determining the term of employees&#8217; probation and unilaterally terminating labor contracts. In the event that we decide to terminate
some of our employees or otherwise change our employment or labor practices, the Labor Contract Law and its implementation rules may limit
our ability to effect those changes in a desirable or cost-effective manner, which could adversely affect our business and results of
operations. In addition, according to the PRC Social Insurance Law, which was released on July&#160;1, 2011, amended on December&#160;29,
2018 and became effective on the same day, and the Administrative Regulations on the Housing Provident Funds, which was released on April
3, 1999, amended on March 24, 2019 and became effective on the same day, companies operating in the PRC are required to participate in
pension insurance, work-related injury insurance, medical insurance, unemployment insurance, maternity insurance and housing provident
fund plans, and the employers must pay all or a portion of the social insurance premiums and housing provident funds for their employees.&#160;We
believe our current practice complies with the Labor Contract Law and its amendments. However, the relevant governmental authorities may
take a different view and impose fines on us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interpretation and
implementation of these laws and regulations are still evolving, our employment practices may not at all times be deemed in compliance
with the new laws and regulations. If we incur significant liabilities in connection with labor disputes or investigations, our businesses
and results of operations may be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in the PRC&#8217;s economic, political
or social conditions or government policies could have a material adverse effect on our businesses and operations in Mainland China and
Hong Kong.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC&#8217;s economy differs
from the economies of the PRC&#8217;s counterpart countries in many respects, including the level of government involvement, level of
development, growth rate, control of foreign exchange and allocation of resources. Although the PRC government has implemented measures
since the late 1970s emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive
assets, and the establishment of improved corporate governance in business enterprises, which are generally viewed as a positive development
for foreign business investment, a substantial portion of productive assets in the PRC is still owned by the PRC government. In addition,
the PRC government continues to play a significant role in regulating industry development by imposing industrial policies. The PRC government
also exercises significant control over the PRC&#8217;s economic growth through allocating resources, controlling payments of foreign
currency-denominated obligations, setting monetary policy and providing preferential treatment to particular industries or companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the PRC&#8217;s economy
has experienced significant growth over the past decades, such growth has been uneven, both geographically and among various sectors of
the economy, and the rate of growth has been slowing down. In addition, in the past, the PRC government has implemented certain measures
to control the pace of economic growth. These measures may cause decreased economic activity, which in turn could lead to a low demand
for our products and services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Shanghai subsidiary is subject to restrictions
on paying dividends or making other payments to us, which may restrict our ability to satisfy our liquidity requirements in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, we may need
dividends and other distributions on equity from our Shanghai subsidiary to satisfy our liquidity requirements. Current PRC regulations
permit our Shanghai subsidiary to pay dividends to their respective shareholders only out of their accumulated profits, if any, determined
in accordance with PRC accounting standards and regulations. In addition, such companies are required to set aside at least 10% of its
accumulated profits each year, if any, to fund certain reserve funds until the total amount set aside reaches 50% of its registered capital.
Our Shanghai subsidiary may also, at the respective subsidiary&#8217;s discretion, allocates a portion of its&#160;after-tax profits based
on its articles of association and PRC accounting standards to certain reserve funds. These reserves are not distributable as cash dividends.
Furthermore, if our Shanghai subsidiary incur debt on their own behalf in the future, the instruments governing the debt may restrict
their ability to pay dividends or make other payments to us. Any limitation on the ability of our Shanghai subsidiary to distribute dividends
or to make payments to us may restrict our ability to satisfy our future liquidity requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Enterprise
Income Tax Law and its implementation rules provide that a withholding tax rate of up to 10% will be applicable to dividends payable by
PRC companies to&#160;non-PRC-resident&#160;enterprises unless otherwise exempted or reduced according to treaties or arrangements between
the PRC central government and governments of other countries or regions where the&#160;non-PRC-resident&#160;enterprises are incorporated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 71 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are deemed by the PRC
tax authorities as a PRC tax resident enterprise for tax purposes, any dividends we pay to our non-PRC resident stockholders may be regarded
as China-sourced income and as a result, may be subject to PRC withholding tax at a rate of up to 10%. Pursuant to the Arrangement between
Mainland China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Tax Evasion on Income, or the
Double Tax Avoidance Arrangement, the 10% withholding tax rate may be reduced to 5% if a Hong Kong resident enterprise owns no less than
25% of a PRC entity. However, the 5% withholding tax rate does not automatically apply and certain requirements must be satisfied, including,
without limitation, that (a) the Hong Kong entity must be the beneficial owner of the relevant dividends; and (b) the Hong Kong entity
must directly hold no less than 25% share ownership in the PRC entity during the 12 consecutive months preceding its receipt of the dividends.
In practice, a Hong Kong entity must obtain a tax resident certificate from the Hong Kong tax authority to apply for the 5% lower PRC
withholding tax rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case basis, we cannot be
certain that we will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority and enjoy the preferential
withholding tax rate of 5% under the Double Taxation Arrangement with respect to any dividends to be paid by our Shanghai subsidiary to
our Hong Kong subsidiary, Advanced Biomed HK. Moreover, Advanced Biomed HK may be subject to additional restrictions and government regulations
if the Chinese government were to impose new laws and regulations or exert more control over Hong Kong&#8217;s business activities. Our
Shanghai subsidiary currently does not have any plan to declare and pay dividends, and we have not applied for the tax resident certificate
from the relevant Hong Kong tax authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We can give no assurance that
we will declare dividends of any amounts, at any rate or at all in the future. The declaration of future dividends, if any, will be at
the discretion of our board of directors and will depend upon our future operations and earnings, capital requirements, general financial
conditions, legal and contractual restrictions and other factors that our board of directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PRC regulation on loans to, and direct investment
in, PRC entities by offshore holding companies and governmental control in currency conversion may delay or prevent us from making loans
to or making additional capital contributions to our Shanghai subsidiary.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any funds we transfer to the
Shanghai subsidiary, either as a shareholder loan or as an increase in registered capital, are subject to approval by or registration
with relevant governmental authorities in China. According to the relevant PRC regulations on foreign invested enterprises in China, capital
contributions to our Shanghai subsidiary are subject to the registration with the State Administration for Market Regulation or its local
counterpart and registration with a local bank authorized by the SAFE. In addition, (i) any foreign loan procured by our Shanghai subsidiary
is required to be registered with the SAFE or its local branches and (ii) any of our Shanghai subsidiary may not procure loans which exceed
the difference between its total investment amount and registered capital or, as an alternative, only procure loans subject to the calculation
approach and limitation as provided by the People&#8217;s Bank of China. Additionally, any medium or long-term loans to be provided by
us to the Shanghai subsidiary must be registered with the National Development and Reform Commission and SAFE or its local branches. We
may not be able to obtain these government approvals or complete such registrations in a timely manner, or at all, with respect to future
capital contributions or loans by us to our Shanghai subsidiary. Moreover, Advanced Biomed HK may be subject to additional restrictions
and government regulations if the Chinese government were to impose new laws and regulations or exert more control over Hong Kong&#8217;s
business activities. If we fail to receive such approvals or complete such registration or filing, our ability to use the proceeds of
future offerings to capitalize our PRC operations may be negatively affected, which could adversely affect our liquidity and our ability
to fund and expand our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SAFE promulgated the Notice
of the State Administration of Foreign Exchange on Reforming the Administration of Foreign Exchange Settlement of Capital of Foreign-invested
Enterprises, or SAFE Circular 19, effective on June&#160;1, 2015 and was amended on December 30, 2019, in replacement of the Circular
on the Relevant Operating Issues Concerning the Improvement of the Administration of the Payment and Settlement of Foreign Currency Capital
of Foreign-Invested Enterprises, the Notice from the State Administration of Foreign Exchange on Relevant Issues Concerning Strengthening
the Administration of Foreign Exchange Businesses, and the Circular on Further Clarification and Regulation of the Issues Concerning the
Administration of Certain Capital Account Foreign Exchange Businesses. According to SAFE Circular 19, the flow and use of the RMB capital
converted from foreign currency-denominated registered capital of a foreign-invested company is regulated such that RMB capital may not
be used for the issuance of RMB entrusted loans, the repayment of inter-enterprise loans or the repayment of bank loans that have been
transferred to a third party. Although SAFE Circular 19 allows RMB capital converted from foreign currency-denominated registered capital
of a foreign-invested enterprise to be used for equity investments within the PRC, it also reiterates the principle that RMB converted
from the foreign currency-denominated capital of a foreign-invested company may not be directly or indirectly used for purposes beyond
its business scope. Thus, it is unclear whether the SAFE will permit such capital to be used for equity investments in the PRC in actual
practice. The SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing the Foreign Exchange
Settlement Management Policy of Capital Account, or SAFE Circular 16, effective on June&#160;9, 2016, which reiterates some of the rules
set forth in SAFE Circular 19, but changes the prohibition against using RMB capital converted from foreign currency-denominated registered
capital of a foreign-invested company to issue RMB entrusted loans to a prohibition against using such capital to grant loans to&#160;non-associated
enterprises. Violations of SAFE Circular 19 and SAFE Circular 16 could result in administrative penalties. SAFE Circular 19 and SAFE Circular
16&#160;may significantly limit our ability to transfer any foreign currency it holds, including the net proceeds from the offering to
our Shanghai subsidiary, which may adversely affect our liquidity and our ability to fund and expand our business in the PRC.&#160;On
October 23, 2019, SAFE issued the Notice of the State Administration of Foreign Exchange on Further Facilitating Cross-border Trade and
Investment, or &#8220;SAFE Circular 28,&#8221; which, among other things, expanded the use of foreign exchange capital to domestic equity
investment area. Non-investment foreign-funded enterprises are allowed to lawfully make domestic equity investments by using their capital
if (i) such investments do not violate the current Negative List and (ii) the domestic investment projects are authentic and are in compliance
with relevant regulations. However, since SAFE Circular 28 is newly promulgated, it is unclear how SAFE and competent banks will carry
it out in practice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 72 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the various requirements
imposed by PRC regulations on loans to, and direct investment in, PRC entities by offshore holding companies, we cannot assure you that
we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if
at all, with respect to future loans or future capital contributions by us to our Shanghai subsidiary. If we fail to complete such registrations
or obtain such approvals, our ability to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially
and adversely affect our liquidity and our ability to fund and expand our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PRC regulations relating to offshore investment
activities by PRC residents may subject our PRC resident beneficial owners or our Shanghai subsidiary to liability or penalties, limit
our ability to inject capital into our Shanghai subsidiary, limit our Shanghai subsidiary&#8217;s ability to increase its registered capital
or distribute profits to us, or may otherwise adversely affect us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2014, SAFE promulgated
the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and
Roundtrip Investment Through Special Purpose Vehicles, or SAFE Circular 37, to replace the Notice on Relevant Issues Concerning Foreign
Exchange Administration for Domestic Residents&#8217; Financing and Roundtrip Investment Through Offshore Special Purpose Vehicles, or
SAFE Circular 75, which ceased to be effective upon the promulgation of SAFE Circular 37. SAFE Circular 37 requires PRC residents (including
PRC individuals and PRC corporate entities) to register with SAFE or its local branches in connection with their direct or indirect offshore
investment activities. SAFE Circular 37 may be applicable to any offshore acquisitions that we make in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under SAFE Circular 37, PRC
residents who make, or have prior to the implementation of SAFE Circular 37 made, direct or indirect investments in offshore special purpose
vehicles, or SPVs, will be required to register such investments with SAFE or its local branches. In addition, any PRC resident who is
a direct or indirect shareholder of an SPV is required to update its filed registration with the local branch of SAFE with respect to
that SPV, to reflect any material change. Moreover, any subsidiary of such SPV in China is required to urge the PRC resident stockholders
to update their registration with the local branch of SAFE. If any PRC shareholder of such SPV fails to make the required registration
or to update the previously filed registration, the subsidiary of such SPV in China may be prohibited from distributing its profits or
the proceeds from any capital reduction, share transfer or liquidation to the SPV, and the SPV may also be prohibited from making additional
capital contributions into its subsidiary in China. On February 13, 2015, the SAFE promulgated a Notice on Further Simplifying and Improving
Foreign Exchange Administration Policy on Direct Investment, or SAFE Notice 13, which became effective on June 1, 2015. Under SAFE Notice
13, applications for foreign exchange registration of inbound foreign direct investments and outbound overseas direct investments, including
those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE. The qualified banks will directly examine the
applications and accept registrations under the supervision of SAFE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 73 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this Report,
none of our stockholders are subject to the SAFE Circular 37. We may not be informed of the identities of all the PRC residents holding
direct or indirect interest in our company, however, and we have no control over any of our future beneficial owners. Thus, we cannot
provide any assurance that our current or future PRC resident beneficial owners will comply with our request to make or obtain any applicable
registrations or continuously comply with all registration procedures set forth in these SAFE regulations. Such failure or inability of
our PRC residents beneficial owners to comply with these SAFE regulations may subject us or our PRC resident beneficial owners to fines
and legal sanctions, restrict our cross-border investment activities, or limit our Shanghai subsidiary&#8217;s ability to distribute dividends
to or obtain foreign-exchange-dominated loans from us, or prevent us from being able to make distributions or pay dividends, as a result
of which our business operations and our ability to distribute profits to you could be materially and adversely affected. Moreover, Advanced
Biomed HK may be subject to additional restrictions and government regulations if the Chinese government were to impose new laws and regulations
or exert more control over Hong Kong&#8217;s business activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Chinese government may exert more control
over Hong Kong business or impose new laws or regulations on business activities in Hong Kong.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although Advanced Biomed HK
is a holding company with no operations and is in compliance with current Mainland China and Hong Kong laws and regulations, it may be
subject to similar risks faced by our Shanghai subsidiary in the future if the Chinese government were to exert more control over Hong
Kong business or impose new laws or regulations on business activities in Hong Kong, which often comes with little advance notice. In
that case, we cannot guarantee you that we can timely comply with any new laws and regulations, which could materially affect our operations
and significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of
such securities to significantly decline or be worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent joint statement by the SEC and the
PCAOB, rule changes by Nasdaq, and the Holding Foreign Companies Accountable Act all call for additional and more stringent criteria to
be applied to emerging market companies upon assessing the qualification of their auditors, especially the non-U.S. auditors who are not
inspected by the PCAOB. These developments could add uncertainties to our continued listing or future offerings of our securities in the
U.S.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 21, 2020, SEC Chairman
Jay Clayton and PCAOB Chairman William D. Duhnke III, along with other senior SEC staff, released a joint statement highlighting the risks
associated with investing in companies based in or have substantial operations in emerging markets including China. The joint statement
emphasized the risks associated with lack of access for the PCAOB to inspect auditors and audit work papers in China and higher risks
of fraud in emerging markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 18, 2020, Nasdaq filed
three proposals with the SEC to (i) apply minimum offering size requirement for companies primarily operating in &#8220;Restrictive Market&#8221;,
(ii) adopt a new requirement relating to the qualification of management or board of director for Restrictive Market companies, and (iii)
apply additional and more stringent criteria to an applicant or listed company based on the qualifications of the company&#8217;s auditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 20, 2020, the U.S.
Senate passed the Holding Foreign Companies Accountable Act requiring a foreign company to certify it is not owned or controlled by a
foreign government if the PCAOB is unable to audit specified reports because the company uses a foreign auditor not subject to PCAOB inspection.
If the PCAOB is unable to inspect the company&#8217;s auditors for three consecutive years, the issuer&#8217;s securities are prohibited
to trade on a national exchange. On December 2, 2020, the U.S. House of Representatives approved the Holding Foreign Companies Accountable
Act. On December 18, 2020, the Holding Foreign Companies Accountable Act was signed into law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 24, 2021, the SEC
announced the adoption of interim final amendments to implement the submission and disclosure requirements of the Holding Foreign Companies
Accountable Act. In the announcement, the SEC clarifies that before any issuer will have to comply with the interim final amendments,
the SEC must implement a process for identifying covered issuers. The announcement also states that the SEC staff is actively assessing
how best to implement the other requirements of the Holding Foreign Companies Accountable Act, including the identification process and
the trading prohibition requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 74 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 22, 2021, the U.S.
Senate passed the AHFCAA, which, if passed by the U.S. House of Representatives and signed into law, would reduce the number of consecutive
non-inspection years required for triggering the prohibitions under the Holding Foreign Companies Accountable Act from three years to
two. On December 29, 2022, a legislation entitled &#8220;Consolidated Appropriations Act, 2023&#8221; (the &#8220;Consolidated Appropriations
Act&#8221;), was signed into law by President Biden. The Consolidated Appropriations Act contained, among other things, an identical provision
to HFCAA, which reduces the number of consecutive non-inspection years required for triggering the prohibitions under the HFCAA from three
years to two.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 22, 2021, the
PCAOB adopted a final rule implementing the Holding Foreign Companies Accountable Act, which provides a framework for the PCAOB to use
when determining, as contemplated under the Holding Foreign Companies Accountable Act, whether the board of directors of a company is
unable to inspect or investigate completely registered public accounting firms located in a foreign jurisdiction because of a position
taken by one or more authorities in that jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 2, 2021, the SEC
issued amendments to finalize rules implementing the submission and disclosure requirements in the Holding Foreign Companies Accountable
Act. The rules apply to registrants that the SEC identifies as having filed an annual report with an audit report issued by a registered
public accounting firm that is located in a foreign jurisdiction and that PCAOB is unable to inspect or investigate completely because
of a position taken by an authority in foreign jurisdictions. The final amendments are effective on January 10, 2022. The SEC will begin
to identify and list Commission-Identified Issuers on its website shortly after registrants begin filing their annual reports for 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 16, 2021, PCAOB
announced the PCAOB Holding Foreign Companies Accountable Act determinations (the &#8220;PCAOB determinations&#8221;) relating to the
PCAOB&#8217;s inability to inspect or investigate completely registered public accounting firms headquartered in China of the PRC or Hong
Kong, a Special Administrative Region and dependency of the PRC, because of a position taken by one or more authorities in the PRC or
Hong Kong.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 26, 2022, PCAOB
signed a Statement of Protocol with the CSRC and the Ministry of Finance of the People&#8217;s Republic of China governing inspections
and investigations of audit firms based in Mainland China and Hong Kong.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 15, 2022, the
PCAOB announced in the 2022 Determination its determination that the PCAOB was able to secure complete access to inspect and investigate
accounting firms headquartered in Mainland China and Hong Kong, and the PCAOB Board voted to vacate previous determinations to the contrary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should the PCAOB again encounter
impediments to inspections and investigations in Mainland China or Hong Kong as a result of positions taken by any authority in either
jurisdiction, including by the CSRC or the MOF, the PCAOB will make determinations under the HFCAA as and when appropriate. The inability
of the PCAOB to conduct inspections of auditors in PRC makes it more difficult to evaluate the effectiveness of these accounting firm&#8217;s
audit procedures or quality control procedures as compared to auditors outside of PRC that are subject to the PCAOB inspections, which
could cause investors and potential investors in our Common Stock to lose confidence in our audit procedures and reported financial information
and the quality of our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our auditor WWC, P.C., the
independent registered public accounting firm that issues the audit report included elsewhere in this Report, as an auditor of companies
that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States pursuant to
which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards Our auditor, WWC, P.C.
is headquartered in San Mateo, California and has been inspected by the PCAOB on a regular basis, with the last inspection conducted in
December 2021. It is not subject to the determinations announced by the PCAOB on December 16, 2021 or the Statement of Protocol with the
China Securities Regulatory Commission and the Ministry of Finance of the People&#8217;s Republic of China on August 26, 2022. However,
if the PCAOB is unable to inspect our accounting firm in the future, our Common Stock may be delisted from or prohibited from trading
on a national securities exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 75 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The recent developments would
add uncertainties to our offering and we cannot assure you whether Nasdaq or regulatory authorities would apply additional and more stringent
criteria to us since we are an emerging growth company and substantially all of our operations are conducted in China. The Holding Foreign
Companies Accountable Act, which requires that the PCAOB be permitted to inspect an issuer&#8217;s public accounting firm within three
years, may result in the delisting of our Company or prohibition of trading in our Common Stock in the future if the PCAOB is unable to
inspect our accounting firm at such future time. Further, the AHFCAA which was later signed into law in the Consolidated Appropriations
Act, reduces the period for foreign companies to comply with PCAOB audits to two consecutive years instead of three, thus reducing the
time period for triggering the prohibition on trading, and this ultimately could result in our Common Stock being delisted by an exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The M&amp;A Rules and certain PRC regulations
may make it more difficult for us to pursue growth through acquisitions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among other things, the Regulations
on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&amp;A Rules, adopted by six PRC regulatory agencies
in 2006 and amended in 2009, and some other regulations and rules concerning mergers and acquisitions, established&#160;additional procedures
and requirements that could make merger and acquisition activities by foreign investors more time-consuming and complex. Such regulation
requires, among other things, that the Ministry of Commerce of the PRC, or the MOFCOM, be notified in advance of any&#160;change-of-control
transaction in which a foreign investor acquires control of a PRC domestic enterprise or a foreign company with substantial PRC operations,
if certain thresholds under the Provisions on Thresholds for Prior Notification of Concentrations of Undertakings, issued by the State
Council in 2008, are triggered. Moreover, the Anti-Monopoly Law promulgated by the Standing Committee of the National People&#8217;s Congress
which became effective in 2008 requires that transactions which are deemed concentrations and involve parties with specified turnover
thresholds must be cleared by the Anti-Monopoly Bureau of State Administration for Market Regulation, or the Anti-Monopoly Bureau, before
they can be completed. Therefore, our acquisitions of other entities that we make in the future (whether by ourselves or our subsidiaries)
and that meets the thresholds for clearance, may be required to be report to and approved by the anti-monopoly law enforcement agency
in the PRC, and we may be subject to penalty including but not limited to a fine of no more than RMB500,000 if we fail to comply with
such requirement. In addition, PRC national security review rules which became effective in September 2011 require acquisitions by foreign
investors of PRC companies engaged in military related or certain other industries that are crucial to national security be subject to
security review before consummation of any such acquisition. On December 19, 2020, the Measures for the Security Review for Foreign Investment
was jointly issued by National Development and Reform Commission (&#8220;NDRC&#8221;) and MOFCOM and took effect from January 18, 2021.
The Measures for the Security Review for Foreign Investment specified provisions concerning the security review mechanism on foreign investment,
including the types of investments subject to review, review scopes and procedures, among others.&#160;We may pursue potential strategic
acquisitions that are complementary to our business and operations in the future. Complying with the requirements of these regulations
to complete such transactions could be time-consuming, and any required approval processes, including obtaining approval or clearance
from the MOFCOM or the Anti-Monopoly Bureau or its local counterparts or other relevant governmental authorities, may delay or inhibit
our ability to complete such transactions, which could affect our ability to expand our business or maintain our market share. Moreover,
Advanced Biomed HK may be subject to additional restrictions and government regulations if the Chinese government were to impose new laws
and regulations or exert more control over Hong Kong&#8217;s business activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Enhanced scrutiny over acquisition transactions
by the PRC tax authorities may have a negative impact on potential acquisitions we may pursue in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Notice on
Strengthening Administration of Enterprise Income Tax for Share Transfers by&#160;Non-PRC&#160;Resident Enterprises, or SAT Circular 698,
issued by the PRC&#8217;s State Administration of Taxation (&#8220;SAT&#8221;) on December&#160;10, 2009, where a foreign investor transfers
the equity interests of a resident enterprise indirectly via disposition of the equity interests of an overseas holding company, or an
&#8220;indirect transfer,&#8221; and such overseas holding company is located in a tax jurisdiction that (i)&#160;has an effective tax
rate less than 12.5% or (ii)&#160;does not tax foreign income of its residents, the foreign investor shall report the indirect transfer
to the competent PRC tax authority. The PRC tax authority will examine the true nature of the indirect transfer, and if the tax authority
considers that the foreign investor has adopted an &#8220;abusive arrangement&#8221; to avoid PRC tax, it may disregard the existence
of the overseas holding company and&#160;re-characterize&#160;the indirect transfer and as a result, gains derived from such indirect
transfer may be subject to PRC withholding tax at a rate of up to 10%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February&#160;3, 2015,
the SAT issued the Announcement of the State Administration of Taxation on Several Issues Concerning the Enterprise Income Tax on Indirect
Property Transfer by&#160;Non-Resident&#160;Enterprises, or SAT Bulletin 7, to supersede existing provisions in relation to the &#8220;indirect
transfer&#8221; as set forth in SAT Circular 698, while the other provisions of SAT Circular 698 remain in force. Pursuant to SAT Bulletin
7, where a&#160;non-resident&#160;enterprise indirectly transfers properties such as equity in PRC resident enterprises without any justifiable
business purposes and aiming to avoid the payment of enterprise income tax, such indirect transfer must be reclassified as a direct transfer
of equity in PRC resident enterprise. To assess whether an indirect transfer of PRC taxable properties has reasonable commercial purposes,
all arrangements related to the indirect transfer must be considered comprehensively and factors set forth in SAT Bulletin 7 must be comprehensively
analyzed considering the actual circumstances. SAT Bulletin 7 also provides that, where a&#160;non-PRC&#160;resident enterprise transfers
its equity interests in a resident enterprise to its related parties at a price lower than the fair market value, the competent tax authority
has the power to make a reasonable adjustment to the taxable income of the transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October&#160;17, 2017,
the SAT issued the Announcement of the State Administration of Taxation on Matters Concerning Withholding of Income Tax of&#160;Non-resident&#160;Enterprises
as Source, or SAT Bulletin 37, which repealed the entire SAT Circular 698 and the provision in relation to the time limit for the withholding
agent to declare to the competent tax authority for payment of such tax of SAT Bulletin 7. Pursuant to SAT Bulletin 37, the income from
a property transfer, as stipulated in the second item under Article 19 of the Enterprise Income</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tax Law, shall include the
income derived from transferring such equity investment assets as stock equity. The balance of deducting the equity&#8217;s net value
from the total income from equity transfer shall be taxable income from equity transfer. Where a withholding agent enters into a business
contract, involving the income specified in the third paragraph of Article 3 in the Enterprise Income Tax Law, with a&#160;non-resident&#160;enterprise,
the&#160;tax-excluding&#160;income of the&#160;non-resident&#160;enterprise will be treated as the&#160;tax-including&#160;income, based
on which the tax payment will be calculated and remitted, if it is agreed in the contract that the withholding agent shall assume the
tax payable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the effective period
of SAT Circular 698 and by the application of SAT Bulletin 7 and SAT Bulletin 37, some intermediary holding companies were looked through
by the PRC tax authorities, and consequently the&#160;non-PRC&#160;resident investors were deemed to have transferred the PRC Subsidiary
and PRC corporate taxes were assessed accordingly. It is possible that we or our&#160;non-PRC&#160;resident investors may at some point
be at risk of being taxed under SAT Bulletin 7 and SAT Bulletin 37 and may be required to expend valuable resources to comply with SAT
Bulletin 7 and SAT Bulletin 37 or to establish that we or our&#160;non-PRC&#160;resident investors should not be taxed under SAT Bulletin
7 and SAT Bulletin 37, which may have an adverse effect on our financial condition and results of operations or such&#160;non-PRC&#160;resident
investors&#8217; investment in the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It may be difficult for overseas stockholders
and/or regulators to conduct investigations or collect evidence within the PRC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholder claims or regulatory
investigation that are common in the United States generally are difficult to pursue as a matter of law or practicality in the PRC. For
example, in the PRC, there are significant legal and other obstacles to providing information needed for regulatory investigations or
litigation initiated outside the PRC or otherwise with respect to foreign entities. Although the authorities in the PRC may establish
a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border supervision
and administration, such cooperation with the securities regulatory authorities in the Unities States may not be efficient in the absence
of mutual and practical cooperation mechanism. Furthermore, according to Article 177 of the PRC Securities Law, which became effective
in March 2020, or Article 177, the securities regulatory authority of the State Council may collaborate with securities regulatory authorities
of other countries or regions in order to monitor and oversee cross border securities activities. Article 177 further provides that no
overseas securities regulator is allowed to directly conduct investigation or evidence collection activities within the territory of the
PRC, and that PRC entities and individuals are not allowed to provide documents or materials related to securities business activities
to overseas agencies without prior consent of the securities regulatory authority of the State Council and the competent departments of
the State Council. While detailed interpretation of or implementation rules under Article 177 have yet to be promulgated, the inability
for an overseas securities regulator to directly conduct investigation or evidence collection activities within the PRC may further increase
difficulties faced by you in protecting your interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Regulation and censorship of information
disseminated over the Internet in the PRC may adversely affect our business, and we may be liable for content that is displayed on our
website.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PRC has enacted laws and
regulations governing internet access and the distribution of products, services, news, information, audio-video programs and other content
through the Internet. In the past, the PRC government has prohibited the distribution of information through the Internet that it deems
to be in violation of PRC laws and regulations. If any of our Internet information is deemed by the PRC government to violate any content
restrictions, we would not be able to continue to display such content and could become subject to penalties, including confiscation of
income, fines, suspension of business and revocation of required licenses, which could materially and adversely affect our PRC businesses,
financial condition and results of operations. We may also be subject to potential liability for any unlawful actions of our customers
or users of our website or for content we distribute that is deemed inappropriate. It may be difficult to determine the type of content
that may result in liability to us, and if we are found to be liable, we may be prevented from operating our website in the PRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Additional factors outside of our control
related to doing business in the Mainland China and Hong Kong could negatively affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional factors that could
negatively affect our business include a potential significant revaluation of the RMB, which may result in an increase in the cost of
operating in the PRC. Natural disasters or health pandemics impacting the PRC can also have a significant negative impact on our PRC businesses.
Further, the imposition of trade sanctions or other regulations against products imported by us from, exported by us into, or the loss
of &#8220;normal trade relations&#8221; status with the PRC could significantly increase our cost of products exported outside of or imported
into the PRC and harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Payment of dividends
is subject to restrictions under PRC laws.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Because
of a variety of rules applicable to our operations in the PRC and the regulations on foreign investments as well as the applicable tax
law, we may be subject to limitations on our ability to declare and pay dividends to our stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a holding company, we may
rely on dividends and other distributions from our Shanghai subsidiary for cash requirements. If our Shanghai subsidiary incurs any debts,
the instruments governing such debts may restrict its ability to pay dividends to us. To the extent cash or assets in the business is
in the PRC or the Shanghai subsidiary, the cash or assets may not be available to fund operations or for other use outside of the PRC
due to interventions in or the imposition of restrictions and limitations on our or Shanghai subsidiary&#8217;s ability by the PRC government
to transfer cash or assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Current PRC regulations permit
Chinese operating subsidiaries to pay dividends to foreign parent companies only out of their accumulated profits, if any, determined
in accordance with Chinese accounting standards and regulations. In addition, our subsidiary in China is required to set aside at least
10% of its after-tax profits each year, if any, to fund a statutory reserve until such reserve reaches 50% of its registered capital.
The Shanghai subsidiary is also required to further set aside a portion of its after-tax profits to fund the employee welfare fund, although
the amount to be set aside, if any, is determined at the discretion of its board of directors. While the statutory reserves can be used,
among other ways, to increase the registered capital and eliminate future losses in excess of retained earnings of the respective companies,
the reserve funds are not distributable as cash dividends except in the event of liquidation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash dividends, if any, on
our Common Stock will be paid in U.S. dollars. The PRC government also imposes restrictions on the conversion of RMB into foreign currencies
and the remittance of currencies out of the PRC. As such, we may experience difficulties in completing the administrative procedures necessary
to obtain and remit foreign currency for the payment of dividends from our profits, if any. Furthermore, if the Shanghai subsidiary incurs
any debts, the existence of debts evidenced by the debt instruments may significantly limit its ability to pay dividends or make other
payments. If we are unable to receive earnings distributions from the operating subsidiary in China, we would be unable to pay dividends
on our shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 78 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are deemed by the PRC
tax authorities as a PRC tax resident enterprise for tax purposes, any dividends we pay to our non-PRC resident stockholders may be regarded
as China-sourced income and as a result, may be subject to PRC withholding tax at a rate of up to 10%. Pursuant to the Arrangement between
Mainland China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Tax Evasion on Income, or the
Double Tax Avoidance Arrangement, the 10% withholding tax rate may be reduced to 5% if a Hong Kong resident enterprise owns no less than
25% of a PRC entity. However, the 5% withholding tax rate does not automatically apply and certain requirements must be satisfied, including,
without limitation, that (a) the Hong Kong entity must be the beneficial owner of the relevant dividends; and (b) the Hong Kong entity
must directly hold no less than 25% share ownership in the PRC entity during the 12 consecutive months preceding its receipt of the dividends.
In practice, a Hong Kong entity must obtain a tax resident certificate from the Hong Kong tax authority to apply for the 5% lower PRC
withholding tax rate. As the Hong Kong tax authority will issue such a tax resident certificate on a case-by-case basis, we cannot be
certain that we will be able to obtain the tax resident certificate from the relevant Hong Kong tax authority and enjoy the preferential
withholding tax rate of 5% under the Double Taxation Arrangement with respect to any dividends to be paid by our Shanghai subsidiary to
our Hong Kong subsidiary, Advanced Biomed HK. Moreover, Advanced Biomed HK may be subject to additional restrictions and government regulations
if the Chinese government were to impose new laws and regulations or exert more control over Hong Kong&#8217;s business activities. Our
Shanghai subsidiary currently does not have any plan to declare and pay dividends, and we have not applied for the tax resident certificate
from the relevant Hong Kong tax authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this Report,
we have not paid, and do not anticipate paying in the foreseeable future, dividends or other distributions to our stockholders. Our Shanghai
subsidiary has never paid any dividends or distributions outside of China. We presently intend to retain all earnings to fund our operations
and business expansions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We can give no assurance that
we will declare dividends of any amounts, at any rate or at all in the future. The declaration of future dividends, if any, will be at
the discretion of our board of directors and will depend upon our future operations and earnings, capital requirements, general financial
conditions, legal and contractual restrictions and other factors that our board of directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Nevada Corporate Laws</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Nevada law and our charter documents provide our directors and
officers with broad protection from liability, which could reduce stockholder rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
the laws of the State of Nevada. Nevada law provides directors and officers with broader discretion in the discharge of their duties,
and greater protection from liability, than directors and officers of corporations incorporated in many other states. Except in cases
of intentional misconduct, fraud, or a knowing violation of law, Nevada law generally provides that directors and officers are not personally
liable to the corporation or its stockholders. As a result, stockholders may have more limited rights to challenge actions of our directors
and officers, even when they believe those actions are not in their best interests. This limitation on liability could reduce the likelihood
of derivative litigation against our directors and officers and may discourage or prevent stockholders from bringing a lawsuit, even in
instances where they believe that directors or officers have acted improperly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We indemnify our officers and directors
against liability to us and our security holders, and such indemnification could increase our operating costs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our articles of incorporation
and bylaws require us to indemnify our officers and directors against claims associated with carrying out the duties of their offices.
We are also required to advance the costs of certain legal defenses upon the indemnitee undertaking to repay such expenses to the extent
it is determined that such person was not entitled to indemnification of such expenses. Insofar as indemnification for liabilities arising
under the&#160;Securities Act&#160;may be permitted to our officers, directors, or control persons, the SEC has advised that such indemnification
is against public policy and is therefore unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions in our articles of incorporation,
our bylaws, and Nevada law might discourage, delay or prevent a change in control of our Company or changes in our management and, therefore,
depress the trading price of our Common Stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of our articles
of incorporation, our bylaws, and Nevada law may have the effect of deterring unsolicited takeovers or delaying or preventing a change
in control of our Company or changes in our management, including transactions in which our stockholders might otherwise receive a premium
for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions
that they may deem to be in their best interests. These provisions include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the ability of stockholders to call special meetings only upon request of
stockholders holding 80% of the shares entitled to vote at the meeting; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the &#8220;business combinations&#8221; and &#8220;control share acquisitions&#8221;
provisions of Nevada law (discussed below), to the extent applicable, could discourage attempts to acquire our stockholders&#8217; stock
even on terms above the prevailing market price.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The existence of the forgoing
provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our Common
Stock. They could also deter potential acquirers of our company, thereby reducing the likelihood that you could receive a premium for
your Common Stock in an acquisition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Nevada&#8217;s anti-takeover statutes could make it more difficult
for a third party to acquire us, even if doing so would benefit our stockholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">As a Nevada corporation, we are subject to provisions of the Nevada
Revised Statutes (&#8220;NRS&#8221;) that may have the effect of discouraging, delaying, or preventing a change of control that stockholders
may consider favorable. In particular, Nevada&#8217;s &#8220;business combination&#8221; statute (NRS 78.411&#8211;78.444) restricts certain
transactions between a Nevada corporation and an &#8220;interested stockholder&#8221; (generally a person who owns 10% or more of the
corporation&#8217;s voting shares) for up to two years after the person becomes an interested stockholder, unless certain conditions are
met. Nevada&#8217;s &#8220;control share&#8221; statute (NRS 78.378&#8211;78.3793) also limits the voting rights of a person acquiring
a &#8220;controlling interest&#8221; (generally 20% or more of a corporation&#8217;s voting shares), unless approved by the disinterested
stockholders. These statutes, and similar provisions in our articles of incorporation and bylaws, may make it more difficult for a third
party to acquire control of us without the approval of our board of directors and may discourage potential takeover attempts that stockholders
might consider in their best interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Risks Related to our
Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Common Stock may not develop an active
trading market and the price and trading volume of our shares may fluctuate significantly.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock is currently
listed on the Nasdaq Capital Market. We cannot predict whether investor interest in us will lead to the development of an active and liquid
trading market. If an active trading market does not develop, holders of our shares of Common Stock may have difficulty selling our shares
that may now be owned or may be purchased later. Even if an active trading market develops for our shares, the market price of our shares
may be highly volatile and could be subject to wide fluctuations. In addition, the trading volume of our shares may fluctuate and cause
significant price variations to occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We do not anticipate
paying cash dividends on our Common Stock in the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
do not anticipate paying cash dividends in the foreseeable future. Presently, we intend to retain all our earnings, if any, to finance
development and expansion of our business. Consequently, your only opportunity to achieve a positive return on your investment in us will
be if the market price of our Common Stock appreciates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Our Chairman Dr.
Yi Lu owns a substantial portion of our outstanding shares of Common Stock and could significantly influence the outcome of our corporate
matters.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
Chairman and Chief Executive Officer, Dr. Yi Lu, beneficially owns 31.00% of our outstanding shares of Common Stock. As a result, Mr.
Lu is able to exercise significant influence over all matters that require us to obtain stockholder approval, including the election of
directors to our board and approval of significant corporate transactions that we may consider, such as a merger or sale of our company
or its assets. This concentration of ownership in our shares by Mr. Lu will limit other stockholders&#8217; ability to influence corporate
matters and may have the effect of delaying or preventing a third party from acquiring control over us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 80 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The price of our Common Stock may be volatile
or may decline regardless of our operating performance, and stockholders may not be able to resell their shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of our stock
may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">actual or anticipated fluctuations in our revenue and other operating results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">actions of securities analysts who initiate or maintain coverage of us, changes in financial estimates by any securities analysts who follow our company, or our failure to meet these estimates or the expectations of investors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">announcements by us or our competitors of significant products, acquisitions, strategic partnerships, joint ventures, or capital commitments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">price and volume fluctuations in the overall stock market, including as a result of trends in the economy as a whole;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">lawsuits threatened or filed against us; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">other events or factors, including those resulting from health pandemics, war or incidents of terrorism, or responses to these events.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the stock markets
have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of securities of many
companies. Stock prices of many companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those
companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to the ELOC Agreement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>It is not possible
to predict the actual number of shares of our Common Stock, if any, we will sell under the ELOC Agreement, or the actual gross proceeds
resulting from those sales or the dilution to you from those sales. Further, we may not have access to the full amount available under
the ELOC Agreement.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Pursuant
to the ELOC Agreement, the Selling Stockholder will purchase from us, from time to time, up to 4,325,836 Common Stock (the &#8220;Resale
Shares&#8221;), which equal to 19.99% of the total number of shares of Common Stock outstanding immediately prior to the execution of
the ELOC Agreement (the &#8220;Exchange Cap&#8221;), until such time as we obtain stockholder approval to issue in excess of 19.99% of
our Common Stock upon the terms and subject to the conditions and limitations set forth in the ELOC Agreement; provided, however, that
such limitations will not apply if we obtain stockholder approval to issue additional shares of Common Stock. In no event shall the number
of shares of Common Stock issuable to the Selling Stockholder pursuant to an advance under the ELOC Agreement cause the aggregate number
of shares of Common Stock beneficially owned (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder) by the Selling Stockholder and its affiliates as a result of previous issuances
and sales of Common Stock to the Selling Stockholder under the ELOC Agreement to exceed 4.99% of the then issued and outstanding Common
Stock (the &#8220;Ownership Limitation).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
shares of our Common Stock that may be issued under the ELOC Agreement may be sold by us to the Selling Stockholder at our discretion
from time to time until the earliest to occur of (i) the 24-month anniversary of the effective date of the ELOC Agreement or (ii) the
date on which the Selling Stockholder has purchased the total Commitment Amount pursuant to the ELOC Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 81 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
ELOC Agreement provides that we may sell up to an aggregate of $25,000,000 of shares of our Common Stock to the Selling Stockholder, and
we have therefore agreed to register shares of Common Stock with an aggregate offering price of up to $25,000,000 for resale under one
or more registration statements, which includes the up to 10,000,000 shares of Common Stock registered offered by a registration statement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
generally have the right to control the timing and amount of any sales of our Common Stock to the Selling Stockholder under the ELOC Agreement
(the &#8220;Resale Offering&#8221;). Sales of our Common Stock, if any, to the Selling Stockholder under the ELOC Agreement will depend
upon market conditions and other factors to be determined by us. We may ultimately decide to sell to the Selling Stockholder all, some
or none of the Common Stock that may be available for us to sell pursuant to the ELOC Agreement. Accordingly, we cannot guarantee that
we will be able to sell all of the Commitment Amount or how much in proceeds we may obtain under the ELOC Agreement. If we cannot sell
securities under the ELOC Agreement, we may be required to utilize more costly and time-consuming means of accessing the capital markets,
which could have a material adverse effect on our liquidity and cash position.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Because
the purchase price per share of Common Stock to be paid by the Selling Stockholder for the Common Stock that we may elect to sell to under
the ELOC Agreement, if any, will fluctuate based on the market prices of our Common Stock at the time we make such election, it is not
possible for us to predict, as of the date of this Report and prior to any such sales, the number of shares of Common Stock that we will
sell to the Selling Stockholder under the ELOC Agreement, the purchase price per share that the Selling Stockholder will pay for shares
of Common Stock purchased from us under the ELOC Agreement, or the aggregate gross proceeds that we will receive from those purchases
by the Selling Stockholder under the ELOC Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
actual number of shares of our Common Stock issuable will vary depending on the then current market price of shares of our Common Stock
sold to the Selling Stockholder in the Resale Offering and the number of shares of our Common Stock we ultimately elect to sell to the
Selling Stockholder under the ELOC Agreement. The Company shall not issue or sell any Common Stock pursuant to the ELOC Agreement, and
the Selling Stockholder shall not purchase or acquire any Common Stock under the ELOC Agreement, if such shares, when aggregated with
all other Common Stock issued pursuant to the ELOC Agreement and the transactions contemplated thereby, exceed the Exchange Cap. In no
event shall the number of shares of Common Stock issuable to the Selling Stockholder pursuant to an advance under the ELOC Agreement cause
Selling Stockholder to exceed the Ownership Limitation. Our inability to access a portion or the full amount available under the ELOC
Agreement, in the absence of any other financing sources, could have a material adverse effect on our business or results of operation.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Investors who buy
shares of Common Stock from the Selling Stockholder at different times will likely pay different prices.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Pursuant
to the ELOC Agreement, we have discretion, to vary the timing, price and number of shares of Common Stock we sell to the Selling Stockholder.
If and when we elect to sell shares of Common Stock to the Selling Stockholder pursuant to the ELOC Agreement, after the Selling Stockholder
has acquired such shares, the Selling Stockholder may resell all, some or none of such shares at any time or from time to time in its
sole discretion and at different prices. As a result, investors who purchase shares from the Selling Stockholder in the Resale Offering
at different times will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases
substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares
they purchase from the Selling Stockholder in the Resale Offering as a result of future sales made by us to the Selling Stockholder at
prices lower than the prices such investors paid for their shares in the Resale Offering. In addition, if we sell a substantial number
of shares to the Selling Stockholder under the ELOC Agreement, or if investors expect that we will do so, the actual sales of shares or
the mere existence of our arrangements with the Selling Stockholder may make it more difficult for us to sell equity or equity-related
securities in the future at a time and at a price that we might otherwise wish to effect such sales.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 82 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Future resales
and/or issuances of shares of Common Stock, or the perception that such sales may occur, may cause the market price of our shares to drop
significantly.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
shares of our Common Stock that may be issued under the ELOC Agreement may be sold by us to the Selling Stockholder at our discretion
from time to time from the date of effectiveness of the registration statement on Form S-1 (File No. 333-288907) until the earliest to
occur of (i) the 24-month anniversary of the effective date of the ELOC Agreement, or (ii) the date on which the Selling Stockholder has
purchased the aggregate Commitment Amount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
purchase price for shares of our Common Stock that we may sell to the Selling Stockholder under the ELOC Agreement will fluctuate based
on the trading price of shares of our Common Stock. Depending on market liquidity at the time, sales of shares of our Common Stock may
cause the trading price of shares of our Common Stock to decrease. We generally have the right to control the timing and amount of any
future sales of shares of our Common Stock to the Selling Stockholder. Additional sales of shares of our Common Stock, if any, to the
Selling Stockholder will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to the
Selling Stockholder all, some or none of the additional shares of our Common Stock that may be available for us to sell pursuant to the
ELOC Agreement. If and when we do sell shares of our Common Stock to the Selling Stockholder, after the Selling Stockholder has acquired
shares of our Common Stock, the Selling Stockholder may resell all, some or none of such shares of our Common Stock at any time or from
time to time in its discretion and at different prices. Therefore, sales to the Selling Stockholder by us could result in substantial
dilution to the interests of other holders of shares of our Common Stock. In addition, if we sell a substantial number of shares of our
Common Stock to the Selling Stockholder under the ELOC Agreement, or if investors expect that we will do so, the shares held by the Selling
Stockholder will represent a significant portion of our public float and may result in substantial decreases to the price of our Common
Stock. The actual sales of shares of our Common Stock or the mere existence of our arrangement with the Selling Stockholder may also make
it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish
to effect such sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
market price of shares of our Common Stock could drop significantly if the Selling Stockholder sells shares of Common Stock or is perceived
by the market as intending to sell them. These factors could also make it more difficult for us to raise additional funds through future
offerings of shares of our Common Stock or other securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We may use proceeds
from sales of our Common Stock made pursuant to the ELOC Agreement in ways with which you may not agree or in ways which may not yield
a significant return.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
will have broad discretion over the use of proceeds from sales of our Common Stock made by Helena pursuant to the ELOC Agreement, including
for any of the purposes described in the section entitled &#8220;Use of Proceeds&#8221; of our S-1, and you will not have the opportunity,
as part of your investment decision, to assess whether the proceeds are being used appropriately. Because of the number and variability
of factors that will determine our use of the net proceeds, their ultimate use may vary substantially from their currently intended use.
While we expect to use the net proceeds from the Resale Offering as set forth in &#8220;Use of Proceeds,&#8221; we are not obligated to
do so. The failure by us to apply these funds effectively could harm our business, and the net proceeds may be used for corporate purposes
that do not increase our operating results or enhance the value of our Common Stock.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>You will experience
dilution if we issue additional equity securities in future financing transactions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">If
we issue additional shares of Common Stock, or securities convertible into or exchangeable or exercisable for Common Stock, our stockholders,
including investors who purchase shares of Common Stock in the Resale Offering, may experience dilution, and any such issuances may result
in downward pressure on the price of our Common Stock. We also cannot assure you that we will be able to sell shares or other securities
in any future offering at a price per share that is equal to or greater than the price per share paid by investors in the Resale Offering,
and investors purchasing shares or other securities in the future could have rights superior to existing stockholders.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 83 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq may apply additional and more stringent
criteria for our continued listing because we had a small Initial Public Offering and insiders hold a large portion of our listed securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nasdaq Listing Rule 5101 provides
Nasdaq with broad discretionary authority over the continued listing of securities in Nasdaq, and Nasdaq may use such discretion to apply
additional or more stringent criteria for the continued listing of particular securities, or suspend or delist particular securities based
on any event, condition, or circumstance that exists or occurs that makes continued listing of the securities on Nasdaq inadvisable or
unwarranted in the opinion of Nasdaq, even though the securities meet all enumerated criteria for initial or continued listing on Nasdaq.
In addition, Nasdaq has used its discretion to deny continued listing or to apply additional and more stringent criteria in the instances,
including but not limited to: (i) where the company engaged an auditor that has not been subject to an inspection by the Public Company
Accounting Oversight Board (&#8220;PCAOB&#8221;), an auditor that PCAOB cannot inspect, or an auditor that has not demonstrated sufficient
resources, geographic reach, or experience to adequately perform the company&#8217;s audit; (ii) where the company planned a small public
offering, which would result in insiders holding a large portion of the company&#8217;s listed securities. Nasdaq was concerned that the
offering size was insufficient to establish the company&#8217;s initial valuation, and there would not be sufficient liquidity to support
a public market for the company; and (iii) where the company did not demonstrate sufficient nexus to the U.S. capital market, including
having no U.S. stockholders, operations, or members of the board of directors or management. Our offering will be relatively small, and
our company&#8217;s insiders will hold a large portion of the company&#8217;s listed securities. Nasdaq might apply the additional and
more stringent criteria for our continued listing, which might cause delay or even denial of our continued listing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we cannot continue to satisfy the listing
requirements and other rules of Nasdaq Capital Market, our securities may be delisted, which could negatively impact the price of our
securities and your ability to sell them.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our securities are
listed on the Nasdaq Capital Market, we cannot assure you that our securities will continue to be listed on the Nasdaq Capital Market.
In order to maintain our listing on the Nasdaq Capital Market, we will be required to comply with certain rules of Nasdaq Capital Market,
including those regarding minimum stockholders&#8217; equity, minimum share price, and certain corporate governance requirements. Even
if we initially meet the listing requirements and other applicable rules of the Nasdaq Capital Market, we may not be able to continue
to satisfy these requirements and applicable rules. If we are unable to satisfy the Nasdaq Capital Market criteria for maintaining our
listing, our securities could be subject to delisting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 18, 2025, we received
a written notice (the &#8220;Deficiency Notice&#8221;) from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying
us that, for the last 32 consecutive business days, the bid price for our Common Stock had closed below the minimum $1.00 per share requirement
for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price Requirement&#8221;).
The Notice has no immediate effect on the listing or trading of our Common Stock, which will continue to trade on the Nasdaq Capital Market
under the symbol &#8220;ADVB.&#8221; In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided a compliance period of
180 calendar days, or until January 14, 2026 (the &#8220;Compliance Period&#8221;), to regain compliance with the Minimum Bid Price Requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not regain compliance
by the end of the Compliance Period, we may be eligible for an additional 180 calendar day compliance period, provided that we meet the
continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital
Market (except for the bid price requirement), and provides written notice to Nasdaq of our intent to cure the deficiency during the second
compliance period, including, if necessary, by effecting a reverse stock split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to monitor the closing
bid price of our Common Stock and will consider all available options to regain compliance with the Minimum Bid Price Requirement within
the compliance period. However, if we do not regain compliance by the end of the Compliance Period and any additional compliance period,
our Common Stock will be subject to delisting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Nasdaq Capital Market
subsequently delists our securities from trading, we could face significant consequences, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">limited availability for market quotations for our securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">reduced liquidity with respect to our securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 84 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a determination that our Common Stock is a &#8220;penny stock,&#8221; which will require brokers trading in our Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our Common Stock;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">limited amount of news and analyst coverage; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">a decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price of our Common Stock may
be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the public
offering price.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently, there have been
instances of extreme stock price run-ups followed by rapid price declines and strong stock price volatility with a number of recent initial
public offerings, especially among companies with relatively smaller public floats. If you purchase our Common Stock in the Resale Offering,
you may not be able to sell those shares at or above the Initial Public Offering price or the Resale Offering price. In particular, our
Common Stock may be subject to rapid and substantial price volatility, low volumes of trades and large spreads in bid and ask prices,
given that we will have relatively small public floats after the Resale Offering, and the Selling Stockholder is offering Resale Shares
through this Resale Offering. Such volatility, including any stock price run-ups, may be unrelated to our actual or expected operating
performance, financial condition or prospects.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
the market price following the Resale Offering will equal or exceed prices in privately negotiated transactions of our shares that have
occurred from time to time prior to the Resale Offering. The market price of our Common Stock may fluctuate significantly in response
to numerous factors, many of which are beyond our control, including:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">actual or anticipated fluctuations in our revenue and other operating results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the sale of Resale Shares by the Selling Stockholder in the open market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">actions of securities analysts who initiate or maintain coverage of us, changes in financial estimates by any securities analysts who follow our company, or our failure to meet these estimates or the expectations of investors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">announcements by us or our competitors of significant services or features, technical innovations, acquisitions, strategic relationships, joint ventures, or capital commitments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">price and volume fluctuations in the overall stock market, including as a result of trends in the economy as a whole;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">lawsuits threatened or filed against us; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">other events or factors, including those resulting from war or incidents of terrorism, or responses to these events.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. Stock prices of many companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have filed securities class action litigation following periods of market volatility. In the event that we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business, and adversely affect our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 85 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our Common Stock
may also not be able to readily liquidate their investment or may be forced to sell at depressed prices due to low volume trading. Broad
market fluctuations and general economic and political conditions may also adversely affect the market price of our Common Stock. As a
result of this volatility, investors may experience losses on their investment in our Common Stock. Furthermore, the potential extreme
volatility may confuse the public investors of the value of our stock, distort the market perception of our stock price and our company&#8217;s
financial performance and public image, negatively affect the long-term liquidity of our Common Stock, regardless of our actual or expected
operating performance. If we encounter such volatility, including any rapid stock price increases and declines seemingly unrelated to
our actual or expected operating performance and financial condition or prospects, it will likely make it difficult and confusing for
prospective investors to assess the rapidly changing value of our Common Stock and understand the value thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The purchase price of our Common Stock in
the Resale Offering could be higher or lower than the IPO.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock was initially
offered in a primary underwritten offering in March 2025 (the &#8220;IPO&#8221;). Although our Common Stock was offered at a fixed price
in the IPO determined by the underwriters and us, we cannot guarantee that the Selling Stockholder will also offer their shares at the
same price. As a result, if you participate in the Resale Offering, you could pay more or less than the price in our IPO, depending on
the actual price of the Resale Shares at the time of the sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shares eligible for future sale may adversely
affect the market price of our Common Stock, as the future sale of a substantial amount of outstanding Common Stock in the public marketplace
could reduce the price of our Common Stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The market price of our shares
could decline as a result of sales of substantial amounts of our shares in the public market or the perception that these sales could
occur, including the sale of Resale Shares by the Selling Stockholder. In addition, these factors could make it more difficult for us
to raise funds through future offerings of our Common Stock. 21,640,000 shares of our Common Stock are outstanding immediately before
the Resale Offering. All of the shares sold in the Resale Offering will be freely transferable without restriction or further registration
under the Securities Act. Certain Common Stock are &#8220;restricted securities&#8221; as defined in Rule 144, as they are subject to
lock-up in connection with our Initial Public Offering. These shares may be sold in the future without registration under the Securities
Act to the extent permitted by Rule 144 or other exemptions under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will not receive any proceeds
from the Resale Offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will incur additional costs as a result
of becoming a public company, which could negatively impact our net income and liquidity.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We became a public company
in March 2025. As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private
company. In addition, Sarbanes-Oxley and rules and regulations implemented by the SEC and the Nasdaq Capital Market require significantly
heightened corporate governance practices for public companies. We expect that these rules and regulations will increase our legal, accounting
and financial compliance costs and will make many corporate activities more time-consuming and costly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not expect to incur
materially greater costs as a result of becoming a public company than those incurred by similarly sized U.S. public companies. In the
event that we fail to comply with these rules and regulations, we could become the subject of a governmental enforcement action, investors
may lose confidence in us and the market price of our Common Stock could decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The obligation to disclose information publicly
may put us at a disadvantage to competitors that are private companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a publicly listed company
in the United States. As a publicly listed company, we will be required to file quarterly and annual reports with the Securities and Exchange
Commission. In some cases, we will need to disclose material agreements or results of financial operations that we would not be required
to disclose if we were a private company. Our competitors may have access to this information, which would otherwise be confidential.
This may give them advantages in competing with our company. Similarly, as a U.S.-listed public company, we will be governed by U.S. laws
that our competitors, which are mostly private Chinese companies, are not required to follow. To the extent compliance with U.S. laws
increases our expenses or decreases our competitiveness against such companies, our public listing could affect our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1B. Unresolved Staff Comments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1C. Cybersecurity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-6795"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize the importance
of identifying, assessing, and managing material risks from cybersecurity threats, as defined in Item 106(a) of Regulation S-K. Our risk
management program is designed to detect, evaluate, and mitigate cybersecurity risks, and is informed by applicable laws, regulations,
and industry best practices.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="ixv-6801"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Chief Executive Officer
oversees our cybersecurity program and leads our incident response efforts. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="ixv-16406">The incident response team is cross-functional, drawing members
from cybersecurity, IT support, mining operations, software engineering, compliance, legal, contractors, and partners.</ix:nonNumeric></p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When a potential incident
is detected, the cybersecurity team validates it before escalating to the incident response team for triage. Significant incidents are
escalated to executive management. Response actions such as allocating resources, setting priorities, creating action plans, and notifying
external parties are directed by the Chief Executive Officer in coordination with the cross-functional working group. We also consult
outside counsel on materiality assessments and disclosure decisions, with executive management making the final determinations.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="ixv-16407">In 2025, <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="ixv-16408">we did not identify
any cybersecurity threats that materially affected, or are reasonably likely to materially affect</ix:nonNumeric>, our strategy, operations, or financial
condition.</ix:nonNumeric> However, no program can eliminate all risks, and we cannot guarantee that undetected incidents have not occurred. See Part
I, Item 1A. &#8220;Risk Factors&#8221; of this Annual Report for further details.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 87 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. Properties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">We currently lease three properties
for our Taiwan R&amp;D center, which covers an area of 450 square meters. The lease of Haihuan Street expires on May 29, 2026;&#160;the
lease of 689-86 Xiaodong Street expires on July 14, 2027; and the lease of 689-85 Xiaodong Road expires on July 14, 2026. Pursuant to
an equipment use contract with the adjacent TSRI, Taiwan R&amp;D center can use the TSRI&#8217;s various semiconductor manufacturing equipment
manufacturing and precision micro-nano processing equipment to carry out concept presentation and cross-scale composite structure of each
R&amp;D process, chip technology research and development, rapid chip trial production, material testing, and thin film production. We
believe that we will be able to obtain adequate facilities, principally through leasing, to accommodate our future expansion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shanghai office is located
in Shanghai Bay Valley Science and Technology Park (&#8220;Bay Valley&#8221;), adjacent to Shanghai Pulmonary Hospital and Fudan University
Life Research Institute. The leased area is 1267.98 square meters, and the lease term is from October 16, 2024 to October 15, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The geographic location of
our Taiwan R&amp;D center provides access to supply of graduates from the local Chenggong University for R&amp;D personnel. Its vicinity
to Taiwan Semiconductor Research Center, Yongkang Industrial Zone, and Chengda Hospital enables us to form a good research and development
ecosystem for biomedical testing of our devices and chips. The location also enables us to integrate nearby resources of the semiconductor
micro-manufacturing related facilities, precision processing industry community, hospital biological treatment and preservation facilities
and other resources required for our research and development process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 3. Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may from time to time be
subject to legal and administrative proceedings and claims that arise in the ordinary course of business. We are not aware of any pending
or threatened material legal or administrative proceedings against us. We do not believe that any claims exist where the outcome of such
matters would have a material adverse effect on our consolidated financial position, operating results or cash flows. However, there can
be no assurance such legal proceedings will not have a material impact on future results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4. Mine and Safety Disclosure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. Market for Registrant&#8217;s Common Equity, Related Stockholder
Matters and Issuer Purchases of Equity Securities </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock trades on
the Nasdaq Stock Market under the symbol &#8220;ADVB.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Holders of Record</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2025, we had
approximately 11 holders of record of our Common Stock, including CEDE &amp; CO. The number of beneficial owners may be substantially
greater than the number of stockholders of record because our Common Stock may be held in &#8220;street name&#8221; by brokers, banks,
and other financial institutions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our Common Stock, and we do not anticipate paying any cash dividends on our shares in the foreseeable future.
It is presently intended that we will retain our earnings for future operations and expansion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Within the organization, investor
cash inflows have all been received by Advanced Biomed Inc., the parent Nevada entity. Cash to fund our operations is transferred from:
(i) the Nevada parent to its operating companies through capital contributions; and (ii) operating companies to other operating companies
through capital contributions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a holding company, Advanced
Biomed Inc. may rely on dividends and other distributions on equity paid by its subsidiaries for its cash and financing requirements.
If any of our subsidiaries incur debt on its own behalf in the future, the instruments governing such debt may restrict their ability
to pay dividends to us. As of the date of this Report, neither we nor any of our subsidiaries have ever paid dividends or made distributions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had a net loss in fiscal
years 2025 and 2024 does not expect to distribute earnings in the near future. Going forward, Advanced Biomed intends to continue to invest
profit generated from its business operations to invest in new markets or business lines.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Sales of Unregistered Securities </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Purchases of Equity Securities by the Issuer
and Affiliated Purchasers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 89 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. Reserved</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 7. Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following discussion
and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements
and related notes included elsewhere in this Report. This discussion and analysis and other parts of this Report contain forward-looking
statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results and
the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several
factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this Report. You should carefully read the &#8220;Risk
Factors&#8221; section of this Report to gain an understanding of the important factors that could cause actual results to differ materially
from our forward-looking statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a holding company incorporated
in the State of Nevada. We operate through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the
main operation and the design and development of the company&#8217;s primary technologies and products. Since our establishment in 2014,
we have been focusing on the integration of multiple interdisciplinary technologies and established our own microfluidic technology platform.
Utilizing the physical and molecular biological characteristics of tumor cells, we have developed various advanced and original research
through the joint application of semiconductor technology and biotechnology. This includes complex precision structures, dielectric detection,
functional microfluidic biochips, microfluidic integrated semiconductor sensors, related application modules, and key components of medical
testing equipment. We have also developed a series of medical testing equipment and related products by integrating various functions
of microfluidic modules, automation software, and hardware. Our technologies and products can be used for early screening and detection,
diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers in blood samples,
capture of single circulating tumor cells, and single-cell sorting and determination. These products provide assistance in treatment selection
and patient prognosis intervention once the required licenses and approvals have been obtained. Advanced Biotech HK is our first localized
operation company, mainly responsible for market operation and management in China, localized production, product registration, and future
local market sales of our products in accordance with relevant local regulations in China. Our Shanghai subsidiary owns some of our R&amp;D
equipment and patents and will be responsible for operations related to clinical trials in Mainland China through CROs. In the future,
we plan to also establish operation centers in countries and regions in North America and Europe.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our devices, A<sup>+</sup>Pre,
AC-1000, A<sup>+</sup>CellScan, and A<sup>+</sup>SCDrop, and three corresponding microfluidic biochips, A<sup>+</sup>Pre Chip and AC-1000
CTC Enrichment Chip and A<sup>+</sup>CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer
patients. Among them, A<sup>+</sup>Pre is mainly used to reduce the viscosity of blood samples, and AC-1000 is used to complete the separation
and enrichment of circulating tumor cells (&#8220;CTCs&#8221;) and tumor-related targeted cells in blood samples. The A<sup>+</sup>CellScan
is mainly used for fluorescent labeling and automatic scanning judgment of targeted cells while A<sup>+</sup>SCDrop preserves the original
viability of single cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A+PerfusC&#8482; system,
our latest development, is a compact, all in one perfusion-based 3D cell culture incubator engineered to replicate human physiological
conditions to form 3D tumor spheroids/organoids in vitro. The system supports up to 12 days of continuous, hands-free culture, reducing
the risk of human error and contamination. By maintaining uniform nutrient delivery and preventing waste accumulation, the platform promotes
tumor spheroid and organoid formation, enhancing cell viability, growth, and drug response predictability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we have finished
the research and development stage for four matching immunostaining kits, A<sup>+</sup>CTCE, A<sup>+</sup>CTCM, A<sup>+</sup>EMT and A<sup>+</sup>CM,
and submitted registration applications in China. The immunostaining kit use antibodies combined with fluorescent groups of different
colors to bind to specific proteins on the cell surface or inside the cells. The presence and intensity of fluorescent signals can be
observed through a separate fluorescent imaging system, and the expression of the target protein and the cell type can be judged and determined
accordingly. Different cell types can be distinguished using multiplexed combined staining with different antibodies. The A<sup>+</sup>CTCE
kit is mainly used to identify epithelial circulating tumor cells, the A<sup>+</sup>CTCM kit is used to identify mesenchymal circulating
tumor cells, the A<sup>+</sup>EMT kit is mainly used to identify epithelial-to-mesenchymal circulating tumor cells, and the A<sup>+</sup>CM
kit is used to identify tumor-associated macrophages (cancer-associated macrophage-like cells).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 90 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also developed a product
for early screening of lung cancer, the A<sup>+</sup>LCGuard Lung Cancer Early Screening Kit (&#8220;A<sup>+</sup>LCGuard&#8221;), which
is used to assist in the determination of benign and malignant pulmonary nodules. From August 2020 to September 2022, we finalized the
research, design, and development of A<sup>+</sup>LCGuard. A<sup>+</sup>LCGuard is Class III medical devices and is required to conduct
clinical trials before completing the registration process. We plan to begin A+LCGuard&#8217;s clinical research in November 2025. Specifically,
in June 2025, the Company and the CRO began collaborating on drafting the clinical research protocol and started preparing the necessary
equipment, consumables, reagent kits, and other materials for the study. We expect that the clinical research protocol may pass ethical
review and receive ethics committee approval by the end of October 2025. Thereafter, we plan to initiate the trial stage of the clinical
research, with completion anticipated within six months of November 2025. We believe the results of the clinical research will inform
the work plan for future large-scale clinical trials, minimizing waste from an excessively large sample size or insufficient statistical
power due to a sample size that is too small. We recognize that the clinical research results may differ from expectations and may not
support our expected progression to clinical trials. If so, we plan to promptly optimize the product, adjust participant group selection,
and modify the final protocol for large-scale clinical trials. However, we cannot guarantee that any clinical research or trial will
meet our anticipated outcomes. Furthermore, delays in obtaining ethical approval or recruiting participants could prevent the clinical
research from being completed on schedule. Such delays could subsequently postpone the large-scale clinical trial and ultimately the
product launch date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our products must go through three steps to receive the required clearance from the NMPA before they can be sold to customers. The
three steps are research and development, registration application, and registration review, which must be done in that order. At the
registration application stage, we have to assemble all the required application materials, complete clinical trials (if required by
NMPA), and work with an NMPA accredited third-party organization to examine our products in accordance with NMPA rules. NMPA will review
our application during the registration review period and may request additional information before officially approving or denying our
applications. Currently, A<sup>+</sup>Pre and AC-1000 and their corresponding chips have been cleared by the NMPA; A<sup>+</sup>SCDrop,
A<sup>+</sup>CellScan, A<sup>+</sup>CellScan Chip, and A<sup>+</sup>LCGuard are at the registration application stage; the four matching
immunostaining kits are under registration review. As of the date of this Report, we have not applied for similar clearances from other
jurisdictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
participated in a scientific research project at Shanghai Pulmonary Hospital from July 17, 2019 to December 2021, and completed a total
of 123 case studies to test A+Pre, AC-1000 and A<sup>+</sup>LCGuard. In the study, we selected 123 individuals, and among them, 75 were
surgical patients with nodular changes or shadows in the lungs reported by imaging studies and 48 healthy patients without lung nodules
reported by imaging studies. 7ml blood samples were taken from test subjects either before the clinical operation (for cancer patients)
or after the physical examination (for healthy individuals), and A<sup>+</sup>Pre, AC-1000, and A<sup>+</sup>LCGuard kits were used to
determine whether there were circulating tumor cells and other tumor markers in the blood samples. Finally, the pathological and physical
examination results of the tested individuals were compared with the test results of our products. Our test results achieved 96% sensitivity
and 99.9% specificity, which provides the research and development basis for our products. Specifically, A+Pre and AC-1000 were at the
research and development stage, and we completed their effectiveness and performance indicators testing through this project. At the
same time, A<sup>+</sup>LCGuard finished its feasibility and functional verification testing. All three products were tested together
throughout the entire project.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our products must be approved by applicable regulatory authorities before being sold to customers. A<sup>+</sup>Pre and A<sup>+</sup>CellScan
can work with third-party products to achieve their designed objectives. AC-1000 and A<sup>+</sup>SCDrop may be used together with other
devices according to different application scenarios below. For the A<sup>+</sup>LCGuard early screening kit, it has to be used in combination
with A<sup>+</sup>Pre and AC-1000. Our four staining kits, A<sup>+</sup>CTCE, A<sup>+</sup>CM, A<sup>+</sup>CTCM, and A<sup>+</sup>EMT,
can be used independently or with third-party products. A<sup>+</sup>Pre, AC-1000, and A<sup>+</sup>CellScan require the use of our supporting
microfluidic chips.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the
    analysis of high-viscosity blood samples: A<sup>+</sup>Pre can be independently used for pretreatment, retaining the original cell
    activity while preventing blood samples from clogging the equipment pipeline after entering the detection equipment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the
    identification and counting application of circulating tumor cells: blood samples are diluted with A<sup>+</sup>Pre, and then AC-1000
    is used to separate and enrich circulating tumor cells and related tumor markers. The enriched samples are stained, calibrated, and
    finally identified and counted. We can provide this service to the public if using third-party staining reagents already on the market
    in China. However, we plan to officially roll out this service once our in-house developed staining reagents, A<sup>+</sup>CTCE,
    A<sup>+</sup>CTCM, A<sup>+</sup>EMT and A<sup>+</sup>CM, complete the registration process. The identification and counting of circulating
    tumor cells and related tumor marker cells can provide auxiliary references for relevant clinical applications.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 91 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The capture
    of circulating tumor cells: we follow the same process as the identification of circulating tumor cells to obtain enriched samples
    with A<sup>+</sup>Pre and AC-1000, and then the samples are captured and separated by A<sup>+</sup>SCDrop to isolate single circulating
    tumor cells. This service can provide tumor cells with high purity and high activity.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For early
    screening of lung cancer: peripheral blood samples of the subjects are first obtained, and the target cells are enriched and captured
    sequentially by A<sup>+</sup>Pre and AC-1000. After that, A<sup>+</sup>LCGuard performs cell fluorescence staining on the enriched
    samples to determine the number of targeted cells, and finally makes a judgment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the different regulatory requirements for the marketing of medical device products and in-vitro diagnostics (&#8220;IVD&#8221;) products
in various regions/countries, it is necessary to complete the registration application and obtain the corresponding license in accordance
with the local regulations before engaging in commercial activities in the respective regions/countries (&#8220;localization registration&#8221;).
Afterward, marketing and sales can be carried out. We follow the principle of modularization when design and develop all of our products
and equipment so that products and equipment can be produced locally to meet different regulatory requirements. Based on the current
development of the early tumor screening and preventive treatment industry and the characteristics of the products we are planning to
register and apply in the future, we have adopted the operation model of centralized research and development and localized management.
We have started the registration process with the NMPA in China for all of our products. Later on, the Company may establish subsidiaries
in the United States and Europe to produce products and carry out product registration. To achieve that, our products must be cleared
by the United States Food and Drug Administration and go through the conformity assessment process to obtain the Conformite Europeenne
marking (&#8220;CE marking&#8221;) from competent authority in each European Union member state.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are looking for suitable locations in the states of California and Washington for our planned expansion to the North America market.
We aim to complete site selection and personnel recruitment in the United States in January 2026 and start product registration, testing
and production afterward. Our US subsidiary will be responsible for the production and registration of our equipment and related products
in the US. Production, testing, and clinical trials in our US market will be conducted in accordance with US regulations, and clinical
data from trials conducted in China will not be used to establish product standards. In addition, we plan to break into the European
market in January 2026 and conduct localized management and operations in accordance with European regulations. In 2026, we plan to also
start the localized registration of our IVD products in Europe. As of the date of this Report, we have not conducted any clinical trials
for our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
as of the date of this Report, we have not commenced sales of our products nor have any revenue-generating products and do not expect
sales of revenue-generating product candidates until we have completed clinical development, submitted regulatory filings, and received
applicable regulatory approvals for candidate products. Due to differences in regulatory and clinical registration requirements, we may
not be able to obtain device and product approvals or provide product service on time. We expect to be in a state of continuous loss
for the next two to three years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended June 30, 2025 and 2024, the Company conducted its business through Advanced Biomed Taiwan and Shanghai Sglcell&#8217;s
subsidiaries as research and development centers for technology research and product development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 92 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of Results of Operations for the Fiscal Years Ended June 30, 2025 and 202</b></span><b>4</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(909,771</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(880,193</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(29,578</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,111,265</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,661,379</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">(449,886</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">27</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,021,036</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,541,572</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(479,464</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,915</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(28,580</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(53</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(262,848</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(294,201</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">31,353</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">(11</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss before tax expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,258,969</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,782,278</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(476,691</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nm</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(3,258,969</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(2,782,278</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">(476,691</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">17</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we do not have any products approved for sale, we have not generated any revenue from the sale of products, and we do
not expect to generate revenue from the sale of our product candidates until we complete clinical development, submit regulatory filings
and receive approvals from the applicable regulatory bodies for such product candidates, if ever. Our main activities through June 30,
2025 have been re-organizational and capital raising activities and the research and development of three automated devices A<sup>+</sup>Pre,
AC-1000 and A<sup>+</sup>SCDrop.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses are primarily related to research and development of microfluidic biochip technology and its application
in precision medicine in the field of oncology, including early cancer screening and detection, diagnosis and staging, treatment selection,
and patient prognosis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended June
30, 2025 and 2024, we incurred research and development expenses of $910 thousand and $880 thousand, respectively. The research and development
expenses slight increased by approximately $30 thousand or 3% for the year ended June 30, 2025 mainly due to increase in clinical development
activities. We plan to begin the clinical research for A<sup>+</sup>LCGuard in November 2025, and we anticipate the clinical research
will end in May 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses primarily consist of (i) staff cost; (ii) depreciation and amortization; (iii) office supplies and
upkeep expenses; (iv) travelling and entertainment; (v) legal and professional fees; (vi) property and related expenses; and (vii) miscellaneous
expenses. The following table sets forth the breakdown of our general and administrative expenses for the years ended June 30, 2025 and
2024:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">$</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Staff costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">503,788</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">761,257</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(257,469</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(34</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">343,830</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399,602</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,772</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Travelling and entertainment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,843</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Legal and professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,003,489</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">653,489</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,150</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(64</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office supplies and upkeep expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,984</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Miscellaneous expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">85,114</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,381</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">38,733</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">84</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,111,265</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,661,379</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">449,886</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">27</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended June 30,
2025 and 2024, our general and administrative expenses amounted to $2.1 million and $1.7 million, respectively. The increase in administrative
expenses by approximately $0.4 million or 27% for the year ended June 30, 2025, is mainly attributable to the decrease in the staff costs,
depreciation and amortization, and property and related expenses which offset by the increase in travelling and entertainment expenses,
legal and professional fees, office supplies and upkeep expenses and miscellaneous expenses.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended June 30, 2025 and 2024, our other expense, net
amounted to $(0.3) million and $(0.3) million, respectively. There&#8217;s no significant change from the year ended June 30, 2024 to
2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss for the Year</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the foregoing, our net loss for the year ended June
30, 2025 was $3.3 million, compared to a loss from operations of $2.8 million for the year ended June 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off
Balance Sheet Arrangements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources
that is material to investors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
liquidity and working capital requirements are primarily related to our research and development and operating expenses. Historically,
we have met our working capital and other liquidity requirements primarily through a combination of cash generated from stockholders&#8217;
advances to the company. Going forward, we expect to fund our working capital and other liquidity requirements from various sources,
including but not limited to cash generated from our operations, loans from banking facilities, the net proceeds from the Initial Public
Offering and other equity and debt financings as and when appropriate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s ability
to continue as a going concern depends upon its ability to develop, register and obtain regulatory approval for commercial sell of its
products to generate positive operating cash flows. For the financial year ended June 30, 2025 and 2024, the Company reported net loss
of $3,258,969 and $2,782,278, respectively. As of June 30, 2025 and 2024, the Company&#8217;s working capital surplus was $3,143,443 and
$318,650 respectively. In addition, the Company had net cash outflows of $5,825,055 and $2,126,340 from operating activities for the financial
year ended June 30, 2025 and 2024, respectively. These conditions give rise to substantial doubt as to whether the Company will be able
to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
circumstances warrant and to sustain its ability to support the Company&#8217;s operating activities, the Company may consider supplementing
its available sources of funds through the following sources:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">raise additional capital; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash generated from upcoming operations; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial support from the Company&#8217;s related party and stockholders as well as third parties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management has commenced strategies
to raise debts from related parties and stockholders and equity. The Company certain related parties have waived off the amount due to
them as of June 30, 2024 amounted to $2,820,624 in order to improve the Company&#8217;s working capital. The Company completed its initial
public offering in 2025. In the initial public offering, the Company issued 1,640,000 shares of common stock at a price of US$4.00 per
share. The Company received gross proceeds in the amount of US$6.56 million before deducting any underwriting discounts or expenses.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 94 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 6, 2025, the Company
entered into a purchase agreement (the &#8220;ELOC Agreement&#8221;) with HELENA GLOBAL INVESTMENT OPPORTUNITIES I LTD. (the &#8220;Investor&#8221;
or &#8220;Selling Stockholder&#8221;), pursuant to which the Company have the right to issue and sell to the Investor, from time to time
as provided therein, and the Investor is obligated to purchase from us, up to Twenty-Five Million United States Dollars ($25,000,000)
of the Company&#8217;s Common Stock, subject to terms and conditions set forth in the ELOC Agreement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we acknowledge that unforeseen circumstances or changes in market conditions could impact our liquidity, we remain committed to monitoring
our financial health and will take necessary actions to secure additional financing if needed. In the event of unforeseen circumstances
that disrupt the above-mentioned financial projection and strategies, the Company believes that our existing cash $2,903,915 as of June
30, 2025 will be sufficient to meet our research and development and operating expenditures for a minimum period of approximately twelve
months from the date of this Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
there can be no certainty that these additional financings will be available on acceptable terms or at all. If management is unable to
execute this plan, there would likely be a material adverse effect on the Company&#8217;s business. All of these factors raise substantial
doubt about the ability of the Company to continue as a going concern. The consolidated financial statements for the financial years
ended June 30, 2025 and 2024 have been prepared on a going concern basis and do not include any adjustments to reflect the possible future
effects on the recoverability and classifications of assets or the amounts and classifications of liabilities that may result from the
inability of the Company to continue as a going concern.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Material
Cash Requirements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cash requirements consist primarily of day-to-day operating expenses, research and development expenses, capital expenditures and contractual
obligations with respect to facility leases and other operating leases. We lease our R&amp;D center and office. We expect to make future
payments on existing leases from cash generated from operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had the following contractual obligations and lease commitments as of June 30, 2025:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual
    Obligations</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than <br/> 1 year</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-3
    years</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-5
    years</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
    than <br/> 5 years</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease commitment</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,690</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,811</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,879</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    obligations</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,690</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,811</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,879</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Working
Capital</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Total current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,032,571</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,051,110</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,981,461</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,889,128</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,732,460</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(156,668</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Net current assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,143,443</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">318,650</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,824,793</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 30, 2025 and 2024,
the Company&#8217;s working capital surplus was $3,143,443 and $318,650, respectively. Management has commenced a strategy to raise debt
and equity, including financial supports from the Company&#8217;s related party and stockholders as well as third parties, which will
enable that we have sufficient working capital for our requirements for at least the next two months from the date of this Report, in
the absence of unforeseen circumstances, taking into account the cash and financial resources presently available to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
flows</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows for the fiscal years ended June 30, 2025 and 2024:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-style: italic">&#160;</td>
    <td colspan="2" style="font-style: italic; text-align: center">$</td><td style="font-style: italic">&#160;</td><td style="font-style: italic">&#160;</td>
    <td colspan="2" style="font-style: italic; text-align: center">$</td><td style="font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Cash at beginning of the year</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,607,973</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,622,279</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,825,055</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,126,340</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31,650</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(74,110</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,934,301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,866,820</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign currency effect</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">218,346</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">319,324</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Net increase (decrease) in cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">295,942</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(14,306</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Cash at end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,903,915</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,607,973</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify; text-indent: 27pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flow from Operating Activities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended June 30, 2025 and 2024, the operating activities were primarily comprised the research and development activities, staff
costs and administrative expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net cash used in operating activities primarily reflected our net loss, as adjusted for non-operating items, such as non-cash depreciation
and amortization and effects of changes in working capital such as decrease in prepaid expenses and other current assets and increase
or decrease in accounts payables, accruals and other current liabilities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30, 2025, our net cash used in operating activities
was approximately $5.8 million, which primarily reflected our net loss of approximately $3.3 million, as primarily adjusted by the (i)
non-cash depreciation and amortization of approximately $0.3 million, positively offset by (ii) increase in prepaid expenses and other
current assets of approximately $2.7 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended June 30, 2024, our net cash used in operating activities was approximately $2.1 million, which primarily reflected our
net loss of approximately $2.8 million, as primarily adjusted by the (i) non-cash depreciation and amortization of approximately $0.4
million positively offset by (ii) increase in accounts payable, accrual and other current liabilities of approximately $0.5 million and
negatively impacted by increase in prepaid expenses and other current assets of approximately $0.3 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 96 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flow from Investing Activities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cash flows used in investing activities primarily consisted of (i) the purchase of intangible assets; (ii) the purchase of equipment,
furniture and fixtures and leasehold improvements; and (iii) acquisition of assets of the subsidiaries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended June 30, 2025, our net cash used in investing activities was approximately $0.03 million, primarily attributable to the
purchase of equipment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended June 30, 2024, our net cash used in investing activities was approximately $0.08 million, primarily attributable to the
purchase of equipment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flow from Financing Activities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cash flows from financing activities primarily consists of proceeds from issuance of shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended June 30, 2025, our Company recorded net cash generated
from financing activities of approximately $5.9 million, which was mainly attributable to the proceeds from issuance of shares of approximately
$5.5 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended June 30, 2024, our Company recorded net cash generated from financing activities of approximately $1.9 million, which
was mainly attributable to the initial public offering costs and certain expenditures paid on behalf by the related parties and loans
from the related parties totaling approximately $1.9 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements
and accompanying notes requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues
and expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various
other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis of making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. We have identified certain accounting
policies that are significant to the preparation of our financial statements. These accounting policies are important for an understanding
of our financial condition and results of operation. Critical accounting policies are those that are most important to the portrayal
of our financial conditions and results of operations and require management&#8217;s difficult, subjective, or complex judgment, often
as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods.
Certain accounting estimates are particularly sensitive because of their significance to financial statements and because of the possibility
that future events affecting the estimate may differ significantly from management&#8217;s current judgments. While our significant accounting
policies are more fully described in Note 3 to the consolidated financial statements included elsewhere in this Report, we believe the
following critical accounting policies involve the most significant estimates and judgments used in the preparation of our financial
statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company&#8221; as defined under the federal securities laws and, as such, will be subject to reduced public
company reporting requirements. Section 107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage
of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting
standards. We have elected to take advantage of the extended transition period for complying with new or revised accounting standards
and acknowledge such election is irrevocable pursuant to Section 107 of the JOBS Act. As a result of our election, our financial statements
may not be comparable to those of companies that comply with public company effective dates.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 97 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates and Assumptions</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated
financial statements and the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical
experience, when available, and on other various assumptions that are believed to be reasonable under the circumstances. Actual results
could differ significantly from those estimates under different assumptions and conditions. Significant accounting estimates reflected
in our consolidated financial statements include the useful lives for equipment and intangible assets, fair value of financial instruments,
assumptions used in assessing right of use assets, impairment of equipment and intangible assets. We continue to evaluate these estimates
and assumptions that we believe to be reasonable under the circumstances. We rely on these evaluations as the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. Since the use of estimates is an
integral component of the financial reporting process, actual results could differ from these estimates. Some of our accounting policies
require higher degrees of judgment than others in their application. We believe critical accounting policies as disclosed in this Report
reflect the more significant judgments and estimates used in preparation of our consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following accounting policies are significant to the preparation of our consolidated financial statements. The areas involving a higher
degree of judgement or complexity, or areas where estimates and assumptions are significant to the financial statements are disclosed
in Critical, Accounting Judgements and Key Sources of Estimation Uncertainty.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intangible
assets, net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s intangible assets are stated at cost less accumulated amortization and impairment, if any, and amortized on a straight-line
basis over the estimated useful lives of the assets. The Company also re-evaluates the periods of depreciation to determine whether subsequent
events and circumstances warrant revised estimates of useful lives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; width: 88%; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Category</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
    <br/> useful lives</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 years</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software
represents purchased software and is amortized straight-line over the Company&#8217;s estimates to generate economic benefits from such
software, generally three years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents represent the estimated fair value assigned to finite-lived
intangible assets acquired in a transaction that is accounted for as an acquisition of assets rather than a business combination are initially
recognized in accordance with other application GAAP. Any consideration transferred in excess of the fair value of the assets acquired
is allocated to each asset acquired on a relative fair value basis. Amortization is computed using the straight-line method over the estimated
useful lives of the respective finite-lived intangible assets, generally six years. Intangible assets are reviewed for impairment at least
annually or more frequently if indicators of potential impairment exist. The Company reviews finite-lived intangible assets for impairment
at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be
recoverable. The Company had previously recognized an impairment loss on certain intangible assets in prior years. The remaining intangible
assets were assessed for impairment as of the balance sheet date, and management concluded that no further impairment was required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an impairment is determined, the actual impairment recognized is the difference between the carrying amount and the fair value as estimated
using one of the following approaches: income, cost and/or market. Assets which are to be disposed of are reported at the lower of the
carrying amount or fair value less costs to sell.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amount of a long-lived asset or asset group is considered
impaired when the anticipated undiscounted cash flows from such asset or asset group is less than its carrying amount. In that event,
a loss is recorded in &#8220;Impairment of long-lived assets&#8221; on our Consolidated Statements of Operations and Comprehensive Income
(Loss) based on the amount by which the carrying amount exceeds the fair value of the long-lived asset or asset group. Fair value, using
the income approach, is determined primarily using a discounted cash flow model that uses the estimated cash flows associated with the
asset or asset group under review, discounted at a rate commensurate with the risk involved. Fair value, utilizing the cost approach,
is determined based on the replacement cost of the asset reduced for, among other things, depreciation and obsolescence. Fair value, utilizing
the market approach, benchmarks the fair value against the carrying amount. As of June 30, 2025 and 2024, the Company had no remaining
carrying amount of finite-lived intangible related to purchased patents from the acquisition of Shanghai Sglcell Biotech Co., Ltd. as
the assets were fully impaired in 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equipment,
net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment,
net are stated at cost less accumulated depreciation and impairment, if any, and depreciated on a straight-line basis over the estimated
useful lives of the assets. Cost represents the purchase price of the asset and other costs incurred to bring the asset into its intended
use. The estimated useful lives are as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 91%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Category</b></span></td>
    <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
    <br/>
    useful lives</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab equipment</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 to 5 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer equipment</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 to 5 years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 to 5 years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditure
for repair and maintenance costs, which do not materially extend the useful lives of the assets, are charged to expenses as incurred,
whereas the expenditure for major renewals and betterment that substantially extends the useful lives of property and equipment are capitalized
as additions to the related assets. Retirements, sales and disposals of assets are recorded by removing the costs, accumulated depreciation
and impairment with any resulting gain or loss recognized in the consolidated statements of income. The Company also re-evaluates the
periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
consist of cash on hand, the Company&#8217;s demand deposit placed with financial institutions, which have original maturities of less
than three months and unrestricted as to withdrawal and use. Deposits are held at highly liquid and well capitalized financial institutions.
As of June 30, 2025, cash balances of $2,836,037 and $14,306 were maintained at financial institutions in Taiwan and the PRC, respectively.
PRC and Taiwan laws and regulations impose certain restrictions on our ability to transfer cash between countries and between our subsidiaries.
ash may be transferred within our organization in the following manners: (i) Advanced Biomed may transfer funds to our subsidiaries,
including our Shanghai subsidiary, by way of capital contributions or loans, through intermediate holding subsidiaries or otherwise;
(ii) we and our intermediate holding subsidiaries may provide loans to our operating subsidiaries and vice versa; and (iii) our subsidiaries,
including our Shanghai subsidiary, may make dividends or other distributions to us through intermediate holding companies or otherwise.
As of the date of this Report, Advanced Biomed made fourteen capital contributions to Advanced Biomed Taiwan and Advanced Biomed HK to
support their research and development.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receiving
    Entity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount<br/>
    (US$)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
                                            29, 2022</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 55%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed
    Taiwan</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,500,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
                                            11, 2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed Taiwan</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
                                            24, 2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed HK</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
                                            26, 2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed HK</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
                                            7, 2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed Taiwan</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
                                            2, 2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed HK</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
                                            14, 2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed Taiwan</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
                                            10, 2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed HK</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
                                            5, 2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed HK</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
                                            9, 2024</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed HK</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
                                            22, 2024</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed HK</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
                                            13, 2025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed HK</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
                                            20, 2025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed Taiwan</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
                                            20, 2025</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed HK</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">550,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 99 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than the transfers in
the table above, we have not made any distribution of dividends or assets, cash transfers, capital contributions or loans among the holding
company or any of our subsidiaries. Any loans from us or our holding subsidiaries outside of Mainland China to our Shanghai subsidiary,
which is treated as a FIE under PRC law, are subject to PRC regulations and foreign exchange loan registrations. Such loans to our FIE
subsidiary to finance its activities must be registered with the SAFE or its local counterparts. PRC laws, regulations and judicial interpretations
thereof do not prohibit using cash generated from one subsidiary to fund another subsidiary&#8217;s operations by way of short term interest
free loans as long as they comply with relevant laws and procedures. In the future, cash proceeds raised from overseas financing activities,
including any securities offerings, may be transferred by us to our Taiwan and Hong Kong subsidiaries and Shanghai subsidiary via capital
contributions or shareholder loans. As of the date of this Report, Advanced Biomed has not made dividend or other distributions to our
stockholders. Advanced Biomed may pay dividends to our stockholders subject to our ability to service our debts as they become due and
provided that our assets will exceed our liabilities after the payment of such dividends. As a holding company, Advanced Biomed may rely
on dividends and other distributions on equity paid by our subsidiaries for our cash and liquidity requirements, including payment of
any debt we may incur outside of China and our expenses. If any of our subsidiaries incurs debt on its own behalf in the future, the instruments
governing such debt may restrict their ability to pay dividends to us. To the extent cash or assets in the business is in the PRC or the
Shanghai subsidiary, the cash or assets may not be available to fund operations or for other use outside of the PRC due to interventions
in or the imposition of restrictions and limitations on our or our subsidiaries&#8217; ability by the PRC government to transfer cash
or assets or distribute earnings within our group or to U.S. investors. PRC laws and regulations applicable to our Shanghai subsidiary
permit payments of dividends only out of their retained earnings, if any, determined in accordance with applicable accounting standards
and regulations. Our Shanghai subsidiary may pay dividends only out of their respective accumulated after-tax profits as determined in
accordance with PRC accounting standards and regulations. In addition, our subsidiaries are required to set aside at least 10% of its
accumulated after-tax profits each year, if any, to fund certain statutory reserve funds, until the aggregate amount of such funds reaches
50% of its registered capital. At its discretion, a wholly foreign-owned enterprise may allocate a portion of its after-tax profits to
discretionary funds. These reserve funds and discretionary funds are not distributable as cash dividends. Furthermore, dividends paid
by our Shanghai subsidiary to its parent companies will be subject to a 10% withholding tax, which can be reduced to 5% if certain requirements
are met. The PRC government also imposes restrictions on the conversion of RMB into foreign currencies and the remittance of currencies
out of the PRC. As such, we may experience difficulties in completing the administrative procedures necessary to obtain and remit foreign
currency for the payment of dividends from our profits, if any, or transfer cash within our group, across border, or to U.S. investors.
Additionally, current Taiwan regulations only permit our Taiwan subsidiary to pay dividends to its shareholders out of its accumulated
profits, and Advanced Biomed Taiwan must set aside at least 10% of its accumulated profits each year and use it to make up previous losses,
if any. The statutory reserve cannot be distributed as cash dividends. As of the date of this Report, no dividends, transfers, or distributions
have been made within our group or to stockholders. We presently intend to retain all earnings to fund our operations and business expansions
and have no plan to distribute earnings to stockholders. We do not anticipate paying dividends or other distributions to our stockholders,
including U.S. investors, in the foreseeable future. See the relevant discussions in Risk Factors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
of loss is not expected by management. A hypothetical 10% change in average interest rates during 2025 would not have a material impact
in annual interest income.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of long-lived assets</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets, including equipment and intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances
(such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying
value of an asset may not be recoverable. We assess the recoverability of the assets based on the undiscounted future cash flows the
assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from
the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset.
If an impairment is identified, we would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash
flows approach or, when available and appropriate, to comparable market values. As of June 30, 2025 and 2024, except for the impairment
loss on intangible assets recognized, no further impairment of long-lived assets was recognized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an impairment is determined, the actual impairment recognized is the difference between the carrying amount and the fair value as estimated
using one of the following approaches: income, cost and/or market. Assets which are to be disposed of are reported at the lower of the
carrying amount or fair value less costs to sell.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amount of a long-lived asset or asset group is considered impaired when the anticipated undiscounted cash flows from such asset
or asset group is less than its carrying amount. In that event, a loss is recorded in &#8220;Impairment of long-lived assets&#8221; on
our Consolidated Statements of Operations and Comprehensive Income (Loss) based on the amount by which the carrying amount exceeds the
fair value of the long-lived asset or asset group. Fair value, using the income approach, is determined primarily using a discounted
cash flow model that uses the estimated cash flows associated with the asset or asset group under review, discounted at a rate commensurate
with the risk involved. Fair value, utilizing the cost approach, is determined based on the replacement cost of the asset reduced for,
among other things, depreciation and obsolescence. Fair value, utilizing the market approach, benchmarks the fair value against the carrying
amount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
leases</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASC 842 on July 1, 2020. The Company determines if an arrangement is a lease at inception. Operating leases are included
in operating lease right-of-use (&#8220;ROU&#8221;) assets, operating lease liability, and operating lease liability, non-current in
the Company&#8217;s consolidated balance sheets. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease
term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU
assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. When determining
the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that it will exercise that
option, if any. As the Company&#8217;s leases do not provide an implicit rate, the Company used an incremental borrowing rate based on
the information available at commencement date in determining the present value of lease payments. The Company has elected to adopt the
following lease policies in conjunction with the adoption of ASU 2016-02: (i) for leases that have lease terms of 12 months or less and
does not include a purchase option that is reasonably certain to exercise, the Company elected not to apply ASC 842 recognition requirements;
and (ii) the Company elected to apply the package of practical expedients for existing arrangements entered into prior to July 1, 2020
to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification applied to existing leases, and(c) initial
direct costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Measurement</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and
requires disclosure of the fair value of financial instruments held by the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance
disclosure requirements for fair value measures. The three levels are defined as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 inputs to the valuation
    methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 inputs to the valuation
    methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets
    or liability, either directly or indirectly, for substantially the full term of the financial instruments.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 inputs to the valuation
    methodology are unobservable and significant to the fair value.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost,
which approximate fair value because of the short period of time between the origination of such instruments and their expected realization
and their current market rates of interest.&#160;The Company accounts for bank loans and lease payables at amortized cost and has elected
NOT to account for them under the fair value hierarchy. Fair value estimates are made at a specific point in time based on relevant market
information about the financial instrument. These estimates are subjective in nature and involve uncertainties and matters of significant
judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect the estimates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025 and 2024, the carrying amount for cash and cash equivalents, trade accounts receivable (net of allowance for credit
losses) and current liabilities (excluding the &#8220;Current portion of long-term debt and finance lease obligations&#8221;) was equal
to or approximated fair value due to their short-term nature or proximity to current market rates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair values of private debt are based on, among other things, available trade information, and/or an analysis in which we evaluate market
conditions, related securities, various public and private offerings, and other publicly available information. In performing this analysis,
we make various assumptions regarding, among other things, credit spreads, and the impact of these factors on the value of the debt securities.
See Note 10 for the fair value of our long-term debt.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration
of Credit Risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to credit risk consist of cash on hand, the Company&#8217;s demand deposit placed with
financial institutions and other receivables. Bank and cash balances are maintained with high credit quality institutions, the composition
and maturities of which are regularly monitored by management. As of June 30, 2025 and 2024, bank and cash balances of $2.9 million and
$2.6 million, respectively were maintained at financial institutions in Taiwan and China, of which approximately $2.9 million and $2.6
million, respectively, was subject to credit risk. While management believes that these financial institutions are of high credit quality,
it also continually monitors their credit worthiness. The maximum exposure to credit risk is the carrying amounts of cash and bank balances
presented on the consolidated statements of financial position.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
Risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company&#8217;s policy is
to ensure that it has sufficient cash to meet its liabilities when they become due, under both normal and stressed conditions, without
incurring unacceptable losses or risking damage to the Company&#8217;s reputation. A key risk in managing liquidity is the degree of
uncertainty in the cash flow projections. If future cash flows are fairly uncertain, the liquidity risk increases.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impact
of Inflation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
types of inflationary pressures that affected the Company has primarily related to research and development costs, staff salaries and
related costs. Inflation in Taiwan and China has not materially affected our profitability and operating results. However, we can provide
no assurance that we will be unaffected by higher inflation rates in Taiwan and China or globally in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Seasonality</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not observed any significant seasonal trends. Our directors believe that there is no apparent seasonality factor affecting the industry
that our Company is operating in.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Trend
Information</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as disclosed elsewhere in this Report, we are not aware of any trends, uncertainties, demands, commitments, or events that are reasonably
likely to have a material effect on our profitability, liquidity, or capital resources, or that would cause reported financial information
not necessarily indicative of future operating results or financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 102 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quantitative
and Qualitative Disclosures about Market Risk</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Rate Risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not exposed to interest rate risk while we have no bank loans outstanding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2025 and 2024, bank and cash balances of approximately $2.9 million and $2.6 million, respectively, were maintained at financial
institutions. A hypothetical 10% decrease in average interest rates during 2025 would not have a material impact in annual interest income.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Credit
Risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
risk is the potential financial loss to the Company resulting from the failure of a customer or a counterparty to settle its financial
and contractual obligations to the Company, as and when they fall due. As the Company does not hold any collateral, the maximum exposure
to credit risk is the carrying amounts of other receivables (exclude prepayments), financial instrument and cash presented on the consolidated
statements of financial position. The Company has no other financial assets which carry significant exposure to credit risk.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Foreign
Exchange Risk</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reporting currency is the United States Dollar. The Company cannot guarantee that the current exchange rate will remain steady; therefore,
there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating
exchange rate actually post higher or lower profit depending on exchange rate of NT$ and RMB converted to US$ on that date. The exchange
rate could fluctuate depending on changes in political and economic environments without notice. However, the Company assessed that a
hypothetical 10% decrease in exchange rates during 2025 would not have a material impact in exchange gain/loss.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical,
Accounting Judgements and Key Sources of Estimation Uncertainty</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no critical judgements, apart from those involving estimation (see below) that the management has made in the process of applying
the Group&#8217;s accounting policy and that has the most significant effect on the amounts recognized in the financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Key
sources of estimation uncertainty</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period, that have a
significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are
disclosed below:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration:underline">Impairment
of intangible assets</span></i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews finite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances
indicate that the carrying value of the assets might not be recoverable. Accounting standards require that if the sum of the future cash
flows expected to result from a company&#8217;s asset, undiscounted and without interest charges, is less than the reported value of
the asset, an asset impairment must be recognized in the financial statements. The amount of impairment to recognize is calculated by
subtracting the fair value of the asset from the reported value of the asset. As disclosed in note 6 to the consolidated financial statements
for the years ended June 30, 2025 and 2024, the intangible asset related to acquired patents are carried forward through the acquisition
of Shanghai Sglcell since the year ended June 30, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believe that the accounting estimate related to asset impairment is a &#8220;critical accounting estimate&#8221; because: (1)
it is susceptible to change from period to period because it requires company management to make assumptions about future sales and cost
of sales over the life of the products arising from the patents acquired (generally six years); and (2) the impact that recognizing an
impairment would have on the assets reported on our balance sheet as well as our net loss would be material. Management&#8217;s assumptions
about future sales prices and future sales volumes of the products arising from the patents acquired require significant judgment because
actual sales prices and volumes have fluctuated in the past and are expected to continue to do so. Management has discussed the development
and selection of this critical accounting estimate with our board of directors and the board has reviewed the Company&#8217;s disclosure
relating to it in this MD&amp;A. In estimating future sales, we use our internal budgets. We develop our budgets based on estimated sales
data for new products, planned timing of new product launches, customer commitments related to newly developed products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 103 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company had previously
recognized an impairment loss on certain intangible assets in prior years. The remaining intangible assets were assessed for impairment
as of the balance sheet date, and management concluded that no further impairment was required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The management has assessed
that risk related to using different assumptions and analyze their sensitivity to change based on outcomes that are deemed reasonably
likely to occur and concluded any change would not have affected our liquidity and capital resources with the impairment recognized as
of June 30, 2025 and 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
accounting pronouncements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2023, the FASB
issued ASU 2023-06, &#8220;Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification
Initiative.&#8221; This amendment incorporates certain U.S. Securities and Exchange Commission (SEC) disclosure requirements into the
FASB Accounting Standards Codification. The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements
of a variety of Codification Topics, allow users to more easily compare entities subject to the SEC&#8217;s existing disclosures with
those entities that were not previously subject to the requirements, and align the requirements in the Codification with the SEC&#8217;s
regulations. For entities subject to the SEC&#8217;s existing disclosure requirements and for entities required to file or furnish financial
statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual
restrictions on transfer, the effective date for each amendment will be the date on which the SEC removes that related disclosure from
its rules. For all other entities, the amendments will be effective two years later. However, if by June 30, 2027, the SEC has not removed
the related disclosure from its regulations, the amendments will be removed from the Codification and not become effective for any entity.
The Company does not expect the adoption of ASU 2023-06 to have a material impact on its consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the FASB
issued ASU 2023-09, Income Taxes (Topic 740)&#160;&#8212;&#160;Improvements to income Tax Disclosures. The amendment in this update are
effective for annual periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective
for annual periods beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been
issued or made available for issuance. The Company has adopted ASU 2023-09 on July 1, 2024 and the adoption of the standard did not have
a material impact to the overall financial presentation. See Note 10 for further information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2024, the FASB issued ASU 2024-01, Compensation &#8212; Stock
Compensation (Topic 718)&#160;&#8212;&#160;Scope Application of Profits Interest and Similar Award. For public business entities, the
amendments in this Update are effective for annual periods beginning after December 15, 2024, and interim periods within those annual
periods. For all other entities, the amendments are effective for annual periods beginning after December 15, 2025, and interim periods
within those annual periods. Early adoption is permitted for both interim and annual financial statements that have not yet been issued
or made available for issuance. If an entity adopts the amendments in an interim period, it should adopt them as of the beginning of the
annual period that includes that interim period. The Company believes the future adoption of this ASU is not expected to have a material
impact on its consolidated financial statements.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 104 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March&#160;2024, the FASB
issued ASU&#160;2024-02, &#8220;Codification Improvements&#160;&#8212;&#160;Amendments to Remove References to the Concepts Statements&#8221;.
This update contains amendments to the Codification that remove references to various FASB Concepts Statements. These issues to remove
references to various Concepts Statements and the amendments apply to all reporting entities within the scope of the affected accounting
guidance. The amendments in this Update are effective for public business entities for fiscal&#160;years beginning after December&#160;15,
2024. Early application of the amendments in this Update is permitted for any fiscal year or interim period for which financial statements
have not yet been issued (or made available for issuance). The Company is currently evaluating the impact of adoption on the Company&#8217;s
related disclosures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November&#160;2024, the
FASB issued ASU&#160;2024-03, Income Statement&#160;&#8212;&#160;Reporting Comprehensive Income&#160;&#8212;&#160;Expense Disaggregation
Disclosures (Subtopic&#160;220-40): Disaggregation of Income Statement Expenses and in January&#160;2025, the FASB issued ASU&#160;2025-01,
Income Statement&#160;&#8212;&#160;Reporting Comprehensive Income&#160;&#8212;&#160;Expense Disaggregation Disclosures (Subtopic&#160;220-40):
Clarifying the Effective Date (&#8220;ASU&#160;2025-01&#8221;). The ASU requires a public business entity to provide disaggregated disclosures
of certain categories of expenses on an annual and interim basis including purchases of inventory, employee compensation, depreciation,
and intangible asset amortization for each income statement line item that contains those expenses. ASU&#160;2024-03, as clarified by
ASU&#160;2025-01 is effective for annual reporting periods beginning after December&#160;15, 2026, and interim periods beginning after
December&#160;15, 2027, with prospective or retrospective application permitted. The Company is currently evaluating the impact of adoption
on the Company&#8217;s related disclosures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as mentioned above, the Company does not believe other recently
issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&#8217;s consolidated
balance sheets, statements of operations and comprehensive loss and statements of cash flows.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
7A. Quantitative and Qualitative Disclosure About Market Risk</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a &#8220;smaller reporting company&#8221; we are not required to provide information required by this Item.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
8. Financial Statements and Supplementary Data </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
is made to pages F-1 through F-23 comprising a portion of this Report, which are incorporated herein by reference.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
9A. Controls and Procedures</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded,
processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is
accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons
performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 105 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the participation
of our chief executive officer and chief financial officer, has performed an evaluation of the effectiveness of our disclosure controls
and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report, as required by
Rule 13a-15(b) under the Exchange Act. Based on that evaluation, our management has concluded that, as of December 31, 2023, our disclosure
controls and procedures were effective to ensure that the information required to be disclosed by us in reports that we file or submit
under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and
forms, and that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated
to our management, including our chief executive officer and chief financial officer, to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Management&#8217;s Annual Report on Internal
Control over Financial Reporting </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under
the Securities Exchange Act of 1934, as amended. Our internal control over financial reporting is a process designed to provide reasonable
assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance
with Generally Accepted Accounting Principles (GAAP) in the United States of America and includes those policies and procedures that (1)&#160;pertain
to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets
of our company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated
financial statements in accordance with GAAP, and that receipts and expenditures of our company are being made only in accordance with
authorizations of our management and directors; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of
the unauthorized acquisition, use or disposition of our company&#8217;s assets that could have a material effect on the consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of its inherent limitations,
internal control over financial reporting may not prevent or detect all potential misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As required by Section&#160;404
of the Sarbanes-Oxley Act of 2002 and related rules as promulgated by the SEC, our management, including our chief executive officer and
chief financial officers, assessed the effectiveness of internal control over financial reporting as of June 30, 2025 using the criteria
set forth in the report &#8220;Internal Control&#8212;Integrated Framework (2013)&#8221; published by the Committee of Sponsoring Organizations
of the Treadway Commission. Based on this evaluation, the management concluded that our internal control over financial reporting was
ineffective as of June 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The material weaknesses identified
relate to (i)&#160;our lack of a sufficient number of finance and accounting personnel or sufficiently trained finance and accounting
personnel, as well as comprehensive accounting policies in accordance with U.S.&#160;GAAP financial reporting; and (ii)&#160;our internal
control policy does not have a proper approval mechanism, and our lack of internal controls on performing periodic reviews of user accounts
and their level of authorization in the financial systems. We plan to implement a number of measures to remedy these material weaknesses.
To remedy the identified material weakness and the other control deficiencies, we have implemented and will continue to implement initiatives
to improve our internal control over financial reporting to address the material weaknesses that have been identified, including: (i)&#160;obtain
additional resources, including experienced staff with U.S.&#160;GAAP and SEC reporting knowledge, to strengthen the financial reporting
function and to set up financial and system control framework; (ii)&#160;conducting regular and continuous U.S.&#160;GAAP accounting and
financial reporting training programs for our accounting and financial reporting personnel, including sending our financial staff to attend
external U.S.&#160;GAAP training courses; and (iii)&#160;optimizing our financial systems by establishing a proper approval mechanism
and performing periodic reviews of users accounts and their level of authorization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9B. Other Information </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-16409"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-16410"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-16411"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-16412">Not</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> Applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9C. Disclosure Regarding Foreign Jurisdictions That Prevent
Inspections</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not Applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 106 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 10. Directors, Executive Officers and Corporate Governance
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Listed below are the names
of the directors and executive officers of the Company, their ages as of the date of this Report, their positions held and the year they
commenced service with the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 30%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 7%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 61%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt"><b>Position with the Company</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">Yi Lu, Ph.D.</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">59</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chairman of the Board and Chief Executive Officer </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Mingze Yin</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">35</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">Steven I-Fang Cheng, Ph.D.</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">44</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director and Chief Technology Officer</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Jing Zhang</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">46</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Independent Director and Chair of the Audit Committee</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-size: 10pt">Cheang I Kei</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">29</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Independent Director and Chair of the Compensation Committee</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Mingyue Cai</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">47</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Independent Director and Chair of the Nominating and Corporate Governance Committee</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Dr. Yi Lu </i></b>has
served as our Chairman of the Board since November 2022 and as our Chief Executive Officer since March 2024. He has been the Chairman
and Chief Science Officer of Advanced Biomed Taiwan since June 2014. He was the Chairman of HFC Semiconductor from January 2020 to October
2022 and was responsible for the company&#8217;s strategic development. Dr.&#160;Lu previously served as Chairman of Nextchip Semiconductor
Corporation, a semiconductor foundry specializing in integrated circuit production, from February 2016 to December 2019 and led the company
to launch the first 12-inch integrated circuit production line in Anhui Province with an investment of RMB20 billion. From January 2004
to December 2007, he was the senior executive of Cypress Semiconductor, overseeing the company&#8217;s business operation. From May 2001
to January 2004, he was the founder, Chairman and CEO of Cascade Semiconductor, which was acquired by Cypress Semiconductor Corporation
(Nasdaq: CY), and managed the overall operations of the company. Dr.&#160;Lu received a Doctor of Philosophy from the University of Florida
in 1994. Dr. Lu has a wealth of experience in successful entrepreneurship and has extensive experience in the fields of technology management,
market management, and operations. He has a clear strategic orientation and has established a clear strategic plan for us. We believe
Dr.&#160;Lu&#8217;s significant experience in the United States and China qualifies him to serve as a member of our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Mr. Mingze Yin </i></b>has
served as our Chief Financial Officer since November 2022. He has over 11 years of experience in the financial and investment banking
industry. He has been the Chief Financial Officer of Shanghai Sglcell Biotech Co., Ltd. since January 2021 and oversees its finance department.
From March 2017 to December 2021, Mr. Yin was Director of Shanghai Guangdian Asset Management Co., Ltd., where he participated in all
major corporate decisions and financial compliance matters. From February 2020 to November 2020, he was an independent director of TMSR
Holding Company Limited (Nasdaq: TMSR) and a member of its Audit Committee, Nominating and Governance Committee, and Compensation Committee.
From February 2018 to November 2018, Mr. Yin was the investors relations manager of Planet Green Holdings Corp. (NYSE: PLAG). From November
2015 to February 2017, Mr. Yin was a senior manager of the Investment Banking Department of Zhongshan Securities Co., Ltd. From October
2012 to October 2015, he was the senior audit manager of BDO China Shu Lun Pan Certified Public Accountants LLP. Mr. Yin is a certified
internal auditor and obtained his Bachelor of Management from Jiangsu Haiyang University in 2011.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Dr. Steven I-Fang Cheng</i></b>
has served as our Chief Technology Officer since November 2022 and as our director since May 2025, respectively. In 2014, Dr. Cheng joined
Advanced Biomed Taiwan. as a co-founder and CTO. Since 2013, he was an associate research fellow (Principal Investigator) in TSRI. His
professional research expertise includes biomicrofluidics, biosensors, cancer diagnosis and infectious detection, micro/nano fabrication
technology, on-chip drug screening, electrokinetics/electrical analysis and their biomedical applications, patent design and implantation.
He received his Master of Science degree from Department of Biomedical Engineering of National Cheng Kung University in Taiwan in 2007
and received his Ph.D. degree from Institute of Nanotechnology &amp; Microsystems Engineering at National Cheng Kung University in 2010.
He has great experience in cross-disciplinary integration development and novel techniques/products creation on biomedical research. He
also has great professional capability and personality characteristic to lead and co-operate with our top researchers from many different
fields.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 107 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Jing Zhang</i></b> has
served as our independent director and the Chair of the Audit Committee since February 2025. Ms. Zhang has more than 25 years of working
experience in financial management. Since July 2013, Ms. Zhang has been the Chief Financial Officer of Shanghai Xun Yang Network Technology
Co., Ltd. From September 2022 to February 2023, Ms. Zhang served as an independent director and the chair of the audit committee of Code
Chain New Continent Limited Co., Ltd. (NASDAQ: CCNC). From March 2009 to July 2013, Ms. Zhang served as the financial manager of Shanghai
Branch of Jiangsu Zi Guang Intelligence Co., Ltd. From March 1999 to February 2009, Ms. Zhang served as the accountant and financial director
of the Finance Department of the Eight Five Hospital. Ms. Zhang graduated from Zaozhuang University in 1999.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Cheang I Kei</i></b>
has served as our independent director and the Chair of the Compensation Committee since February 2025. Ms. Cheang has been the legal
senior manager at Luso International Banking Ltd. since October 2022. She served as the legal manager at Bank of China (Macau) from May
2019 to October 2022. She was the legal assistant at Luso International Banking Ltd. between August 2016 and May 2019. Ms. Cheang is experienced
in corporate governance matters and day to day administrative affairs, which we believe makes her a suitable member to our Board. Ms.
Cheang received her bachelor&#8217;s degree in Chinese-English translation and interpretation from Macau Polytechnic University in 2016.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Mingyue Cai</i></b>
has served as our independent director and the Chair of the Nominating and Corporate Governance Committee since February 2025. Mr. Cai
has been the Vice President at Yitu Safety Technology (Shenzhen) Co., Ltd., a PRC company engages in artificial intelligence development
and application. From February 2020 to April 2024, Mr. Cai worked as an independent director and the chair of compensation committee of
GD Culture Group Limited (NASDAQ: GDC). From November 2009 to August 2017, he was an administrative director at Rugao Port Group Co.,
Ltd., a PRC company that focuses on port logistics, industrial park construction and timber, coal and ore trade. From June 2004 to October
2009, Mr. Cai worked as a manager at Shanghai Rishan Environmental Protection Technology Co., Ltd., a PRC company that distribute and
retail environmentally friendly cleaning products. Mr. Cai graduated from China Central Radio &amp; TV University in 2015 with a major
in administration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships,
or other arrangements or understandings between or among any of the directors or executive officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All directors hold office
until the next annual meeting of stockholders and until their successors have been duly elected and qualified. Directors are elected at
the annual meetings to serve for one-year terms. Officers are elected by, and serve at the discretion of, the board of directors. Our
board of directors shall hold meetings on at least a quarterly basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors has
determined to comply with the Nasdaq Listing Rules with respect to certain corporate governance matters. We also intend to comply with
the requirements of Rule 10A-3 under the Securities Exchange Act of 1934 within the applicable time frame.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors has
reviewed the independence of our directors, applying the Nasdaq independence standards. Based on this review, the board of directors determined
that Jing Zhang, Cheang I Kei, and Mingyue Cai are independent within the meaning of the Nasdaq rules. In making this determination, our
board of directors considered the relationships that each of these non-employee directors has with us and all other facts and circumstances
our board of directors deemed relevant in determining their independence. As required under applicable Nasdaq rules, we anticipate that
our independent directors will meet on a regular basis as often as necessary to fulfil their responsibilities, including at least annually
in executive session without the presence of non-independent directors and management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 108 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Committees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors established
standing committees in connection with the discharge of its responsibilities in February 2025. These committees include an Audit Committee,
a Compensation Committee and a Corporate Governance and Nominating Committee. Our board of directors will adopt written charters for each
of these committees. Our board of directors may establish other committees as it deems necessary or appropriate from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Audit Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee is composed
of three of our independent directors: Jing Zhang (Chair), Cheang I Kei and Mingyue Cai. The Board has determined that Jing Zhang qualifies
as the Audit Committee financial expert as defined in Item 407(d)(5) of Regulation S-K promulgated under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to its charter,
the Audit Committee consists of at least three members, each of whom shall be a non-employee director who has been determined by the Board
to meet the independence requirements of Nasdaq, and also Rule 10A-3(b)(1) of the SEC, subject to the exemptions provided in Rule 10A-3(c).
The Audit Committee Charter describes the primary functions of the Audit Committee, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Oversee the Company&#8217;s accounting and the financial reporting processes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Oversee audits of the Company&#8217;s financial statements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Review and discuss with management the Company&#8217;s audited financial statements and review with management and the Company&#8217;s independent registered public accounting firm the Company&#8217;s financial statements prior to the filing with the SEC of any report containing such financial statements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Discuss policies with respect to risk assessment and risk management, and discuss the Company&#8217;s major financial risk exposures and the steps management has taken to monitor and control such exposures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Review major changes to the Company&#8217;s auditing and accounting principles and practices as suggested by the Company&#8217;s independent registered public accounting firm, internal auditors or management; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Take, or recommend that the board take, appropriate action to oversee and ensure the independence of the Company&#8217;s independent registered public accounting firm.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee
is composed of three of our independent directors: Cheang I Kei (Chair), Jing Zhang, and Mingyue Cai. The Compensation Committee will
be responsible for, among other matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing and approving employment agreements and other similar arrangements between us and our executive officers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing and approving, or recommending to the board of directors to approve the compensation of our CEO and other executive officers and directors reviewing key employee compensation goals, policies, plans and programs; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">appointing and overseeing any compensation consultants or advisors.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Governance and Nominating Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate governance and
nominating committee is composed of three of our independent directors: Mingyue Cai (Chair), Jing Zhang, and Cheang I Kei. The Corporate
Governance and Nominating Committee will be responsible for, among other matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing and making recommendations regarding the structure and composition of our board and the board committees;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">evaluating the independence of directors and director nominees;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">developing and recommending to the board corporate governance principles and practices;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing and monitoring the Company&#8217;s code of business conduct; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">overseeing the evaluation of the Company&#8217;s management.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Ethics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted our code of
business conduct (the &#8220;code of business conduct&#8221;) that applies to all directors, executive officers and employees, which is
available on our website. Our code of business conduct is a &#8220;code of ethics,&#8221; as defined in Item 406(b) of Regulation&#160;S-K.&#160;Copies
of the code of business conduct and charters for each of our board committees will be provided without charge upon request from us and
will be posted on our company website. We will make any legally required disclosures regarding amendments to, or waivers of, provisions
of our code of ethics on our Internet website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recovery of Erroneously Awarded Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted an executive
incentive compensation recovery policy pursuant to Section 10D of the Exchange Act, Rule 10D-1 promulgated under the Exchange Act (&#8220;Rule
10D-1&#8221;), and Listing Rule 5608 adopted by Nasdaq (the &#8220;Listing Standards&#8221;) to provide for the recovery of certain incentive-based
compensation in the event of an accounting restatement, which became effective in February 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Involvement in Certain Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, there are
no material proceedings to which any of our directors, officers or affiliates of the Company is a party adverse to the Company or has
a material interest adverse to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no outstanding
equity awards as of June 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Role of Board in Risk Oversight Process</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodically, our board of
directors assesses these roles and the board of directors leadership structure to ensure the interests of the Company and our stockholders
are best served. Our board of directors has determined that its current leadership structure is appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While management is responsible
for assessing and managing risks to the Company, our board of directors is responsible for overseeing management&#8217;s efforts to assess
and manage risk. This oversight is conducted primarily by our full board of directors, which has responsibility for general oversight
of risks, and standing committees of our board of directors. Our board of directors satisfies this responsibility through full reports
by each committee chair regarding the committee&#8217;s considerations and actions, as well as through regular reports directly from officers
responsible for oversight of particular risks within our company. Our board of directors believes that full and open communication between
management and the board of directors is essential for effective risk management and oversight.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 110 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation Committee Interlocks and Insider
Participation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our executive officers
serves, or in the past has served, as a member of the board of directors or compensation committee, or other committee serving an equivalent
function, of any entity that has one or more executive officers who serve as members of our board of directors or our compensation committee.
None of the members of our compensation committee is, or has ever been, an officer or employee of our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Section 16(a) Beneficial Ownership Reporting
Compliance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 16(a) of the Exchange
Act requires our directors, executive officers and ten percent stockholders to file initial reports of ownership and reports of changes
in ownership of our Common Stock with the Commission. Directors, executive officers and ten percent stockholders are also required to
furnish us with copies of all Section 16(a) forms that they file. Based solely on our review of such forms furnished to us and written
representations from certain reporting persons, we believe that during the year ended June 30, 2025, all reports applicable to our executive
officers, directors and greater than 10% beneficial owners were not filed in a timely manner in accordance with Section 16(a) of the Exchange
Act.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 11. Executive Compensation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This section discusses the
material components of the executive compensation program for our named executive officers for the years ended June 30, 2025 and 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Summary Compensation Table</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
the compensation awarded to or earned by or paid to our named executive officers during the fiscal years ended June 30, 2025 and 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year <br/> (FY)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option <br/> Awards <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Equity <br/> Incentive <br/> Plan <br/> Compensation <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nonqualified <br/> Deferred <br/> Compensation <br/> Earnings <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other <br/> Compensation <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Yi Lu</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 6%; text-align: center">2025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Mingze Yin</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161,743</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Steven I-Fang Cheng</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at Fiscal Year End</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no outstanding
equity awards as of June 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share Incentive Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective March 30, 2023,
our Stock Incentive Plan (the &#8220;2023 Plan&#8221;) was approved by our Board of Directors. Under the 2023 Plan, the Board of Directors
may grant options or purchase rights to purchase Common Stock to officers, employees, and other persons who provide services to us or
any related company. The participants to whom awards are granted, the type of awards granted, the number of shares covered for each award,
and the purchase or exercise price, conditions and other terms of each award are determined by the Board of Directors, except that the
term of the options shall not exceed 10 years. A total of 15 million shares of our Common Stock are subject to the 2023 Plan and maybe
either a qualified or non-qualified stock option. The shares issued for the 2023 Plan may be either treasury or authorized and unissued
shares. As of June 30, 2025, we have granted no stock options to purchase any shares of our Common Stock under the 2023 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreements with Our Named Executive
Officers and Potential Payments Upon Termination or Change in Control</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Compensations</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the fiscal year ended June
30, 2025, we and our subsidiaries paid aggregate cash compensation of approximately $8,000 to our executive and non-executive directors
as a group. Our Chief Executive Officer and Chief Technology Officer are executive directors whose compensation were disclosed under &#8220;<b>Item
11 - Executive Compensation </b>- <b><i>Summary Compensation Table</i></b>.&#8221; We do not pay or set aside any amounts for pensions,
retirement or other benefits for directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table shows
the compensation paid to our non-employee directors during the year ended June 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees<br/> Earned<br/> or Paid<br/> in&#8239;Cash<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock<br/> Awards<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<br/> Awards <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nonequity<br/> incentive<br/> plan<br/> compensation <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nonqualified<br/> deferred<br/> compensation<br/> earnings <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All other<br/> compensation <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Cheang I Kei</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">8,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">8,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 12. Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
certain information concerning the ownership of our Common Stock as of the date of this Report, with respect to: (i) each person, or group
of affiliated persons, known to us to be the beneficial owner of more than five percent of our Common Stock; (ii) each of our directors;
(iii) each of our named executive officers; and (iv) all of our current directors and executive officers as a group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Applicable percentage ownership
is based on an aggregate of 21,640,000 shares of Common Stock outstanding as of June 30, 2025. The following table sets forth certain
information known to us with respect to the beneficial ownership of Common Stock as of that date by (i) each of our directors, (ii) each
of our executive officers, (iii) all of our directors and executive officers as a group, and (iv) each person, or group of affiliated
persons, whom we know to beneficially own more than 5% of our Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have determined beneficial
ownership in accordance with the rules of the SEC, which generally define beneficial ownership to include any shares over which a person
exercises sole or shared voting or investment power. Such determination is not necessarily indicative of beneficial ownership for any
other purpose. Unless otherwise indicated, we believe, based on the information furnished to us, that all persons named in the table have
sole voting and investment power with respect to all shares beneficially owned by them. None of the stockholders listed in the table are
a broker-dealer or an affiliate of a broker dealer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 112 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">&#160;<b>Name and Address of Beneficial Owner<sup>(1)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount<br/> and<br/> Nature of<br/> Beneficial<br/> Ownership</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Approximate Percentage of<br/> Outstanding<br/> Shares<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Directors and Officers</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Yi Lu</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,708,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">31.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Mingze Yin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Steven I-Fang Cheng<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">742,560</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.43</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Jing Zhang</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cheang I Kei</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Mingyue Cai</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">All officers and directors as a group (four persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,450,560</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.43</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">5% Stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Hung To Pau</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,524,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.28</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Advance On Ventures Limited<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,184,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.09</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Yimin Jin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,755,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.10</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Xiaoyuan Luo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,398,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.46</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Nanzhen Shen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,209,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.59</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Unless otherwise indicated, the business address of each of the individuals is 689-85 Xiaodong Road, Yongkang District, Tainan, Taiwan. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Based on 21,640,000 shares issued and outstanding as of June 30, 2025. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Represents 742,560 shares beneficially owned by Mr. Steven I-Fang Cheng through Advance On Ventures Limited, a company incorporated in the British Virgin Islands, in which Mr. Cheng owns 34% equity interests. The registered address of Advance on Ventures Limited is Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chen-Yi Lee is the sole director and a 25% shareholder of Advance On Ventures Limited. Ms. Lee is the controlling person and has sole voting and dispositive power over shares beneficially owned by Advance on Ventures Limited.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 6, 2022, we entered
into an investment agreement with Hanyu Assets Co., Ltd. (&#8220;Hanyu&#8221;). Under this agreement, Hanyu will invest US$2.5 million
in the Company to acquire a 2.5% equity interest in the Company after the transaction, and Hanyu must pay US$2.5 million before June 30,
2022 to the Company&#8217;s designated bank account. Hanyu transferred US$2.5 million to us on June 29, 2023. This agreement can only
be terminated by mutual agreement in writing. The formation, validity, interpretation, performance, and settlement of disputes arising
from this agreement will be governed by the laws of the State of New York.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 6, 2022, we entered
into an investment agreement with Newlink Technology Inc. (&#8220;Newlink&#8221;). Under this agreement, Newlink will invest HK$8,000,000
to acquire a 1% equity interest in the Company after the transaction, and Newlink must pay HK$8,000,000 before September 10, 2022, to
the Company&#8217;s designated bank account. We received the payment from Newlink on September 13, 2022. This agreement can only be terminated
by mutual agreement in writing. The formation, validity, interpretation, performance, and settlement of disputes arising from this agreement
will be governed by the laws of the State of New York.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After receiving the fund from
Newlink and Hanyu, we issued 625,000 shares to Hanyu Assets Co. Ltd. and 250,000 shares to Newlink Technology Inc. on October 25, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2022, we entered
into a Debt-for-Equity Exchange Agreement with Pau Hung To, Jin Yimin, Luo Xiaoyuan, Shen Nanzhen, Wang Jian, and Chen Qiang (collectively,
the &#8220;Creditors&#8221;) to settle certain debts owed to the Creditors. Pursuant to the agreement, we issued 12,644,375 Common Stock
to the Creditors to completely settle the debt between the Creditors and us. Any disputes arising from this agreement must be submitted
to China International Economic and Trade Arbitration Commission&#8217;s Shanghai Office for arbitration. The agreement cannot be amended
unless all parties agree in writing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our existing stockholders
have different voting rights from other stockholders. To our knowledge, we are not owned or controlled, directly or indirectly, by another
corporation, by any foreign government or by any other natural or legal persons, severally or jointly. We are not aware of any arrangement
that may, at a subsequent date, result in a change of control of our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our best knowledge, as
of June 30, 2025, we had 21,640,000 Common Stock issued and outstanding and 11 holders of record of our Common Stock, including CEDE &amp;
CO. The number of beneficial owners may be substantially greater than the number of stockholders of record because our Common Stock may
be held in &#8220;street name&#8221; by brokers, banks, and other financial institutions.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Control</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"></p><div>

</div><!-- Field: Page; Sequence: 113 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 13. Certain Relationships and Related
Transactions, and Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since July 1, 2019, there
has not been any transaction or series of similar transactions to which we were, or will be, a party in which the amount involved exceeded,
or will exceed, the lesser of (i) $120,000 or (ii) one percent of the average of our total assets for the last two completed fiscal years,
and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate
family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest except
for the followings:-</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 35%; border-bottom: black 1.5pt solid; padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt"><b>Name of Related Party</b></span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 64%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt"><b>Relationship to Us</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Yi Lu, Ph.D.</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chairman of the Board and Chief Executive Officer of the Company</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Hung To Pau, Ph.D.</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Stockholder of the Company</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Steven I-Fang Cheng, Ph.D.</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director and Chief Technology Officer of the Company</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Chen-Yi Lee</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chen-Yi Lee is the sole director and the controlling person of Advance On Ventures Limited, which owns 10.09% equity interest in the Company and has sole voting and dispositive power over shares beneficially owned by Advance On Ventures Limited. </span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Advance On Ventures Limited</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Stockholder of the Company</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Well Fancy Development Ltd</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Hung To Pau is the director and stockholder of the entity</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"><span style="font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd.</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Hung To Pau is the legal person and stockholder of the entity</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 16, 2021, the Company
issued 8,000,000 shares to Dr. Hung To Pau. On March 15, 2022, Dr. Hung To Pau transferred all of his 8,000,000 shares to Sglcell Ltd.,
an exempted company incorporated under the law of Cayman Islands, the sole stockholder of which is Dr. Hung To Pau for a total consideration
of $8,000. On June 8, 2022, Sglcell Ltd. transferred all of its 8,000,000 shares to Dr. Yi Lu for a total consideration of $8,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Shares Issued to Advanced Biomed Taiwan Holders/Employees</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 12, 2022, we issued
additional 385,000 shares to Dr. Yi Lu, and 257 shares to Chen-Yi Lee while Dr. Yi Lu and Chen-Yi Lee transferred 2,998,000 shares and
2,000 shares owned by them respectively in Advanced Biomed Taiwan, representing in aggregate 100% of the issued share capital of Advanced
Biomed Taiwan, to the Company pursuant to the share exchange agreement the Company entered into with Dr. Yi Lu and Chen-Yi Lee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 24, 2022, we issued
365,352 shares for no consideration to Chen-Yi Lee, who is an employee of Advanced Biomed Taiwan, for past services to Advanced Biomed
Taiwan. On October 24, 2022, we also issued 2,730,000 shares for no consideration to Advance On Ventures Limited, a company incorporated
under the law of British Virgin Islands (the &#8220;Ventures Limited&#8221;), the beneficial owners of which are employees of Advanced
Biomed Taiwan for past services to Advanced Biomed Taiwan. We issued 4,405,625 shares, 2,193,750 shares, 2,060,000 shares, 1,511,250 shares,
1,243,750 shares, 1,230,000 shares respectively to Dr. Hung To Pau, Yimin Jin, Xiaoyuan Luo, Nanzhen Shen, Jian Wang and Qiang Chen pursuant
to the Debt-For-Equity Exchange Agreement the Company entered into with the abovementioned stockholders on June 30, 2022 to settle debt
of a total amount of NTD 174,020,033 and RMB22,200,000 (approximately $9.04 million).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 114 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary course of
business, during fiscal years ended June&#160;30, 2025 and 2024, the Company was involved in certain transactions, either at cost or current
market prices, and on the normal commercial terms with related parties. The following table provides the transactions with these parties
for the&#160;years as presented (for the portion of such period that they were considered related):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Amount due to related parties &#8211; major stockholders</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"><span style="text-decoration:underline">Name of related party</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi Lu, Ph.D. <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">122,626</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">110,268</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chen-Yi Lee <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,544</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau, Ph.D. <sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,705</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">172,767</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">113,812</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Amount due to related parties &#8211; related corporations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Name of related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Fancy Development Ltd <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">211,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd. <sup>(5)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">704,953</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">674,262</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">916,036</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">674,262</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Non-Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Name of related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Fancy Development Ltd <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd. <sup>(5)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">69,797</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">139,772</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Advanced Biomed Inc.(Taiwan) entered into an unsecured, interest-free loan to Yi Lu amounting to NTD 3,578,212 (approximately US$122,626) for general working capital in January 2023. As of June 30, 2025 and 2024, the loan balance due to Yi Lu amounted to US$122,626 and US$110,268, respectively.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Payments of expenses on behalf of Advanced Biomed Inc. (Taiwan).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Advanced Biomed Inc.(HK) entered into one unsecured, interest-free loan to Hung To Pau, Ph.D. amounting to US$200,000 for general working capital in July 2024 and the amount was full settled in 2025. And Shanghai Sglcell Biotech Co., Ltd entered into three unsecured, interest-free loans to Hung To Pau, Ph.D. amounting to RMB122,566 (approximately US$17,110), RMB121,681 (approximately US$16,986) and RMB76,000 (approximately US$10,609) for general working capital in October 2024, November 2024 and December 2024. As of June 30, 2025, the loan balance due to Hung To Pau, Ph.D. totally amounted to RMB320,247 (approximately US$44,705) for general working capital.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advanced Biomed Inc.(Taiwan) entered into seven unsecured, interest-free loans to Well Fancy Development Ltd amounting to NTD 5,740,600 (approximately US$196,731), NTD 1,911,944 (approximately US$65,522), NTD 1,906,840 (approximately US$65,347), NTD 3,121,500 (approximately US$106,974), NTD 1,798,060 (approximately US$61,620), NTD 1,291,552 (approximately US$44,262) and NTD 455,992 (approximately US$15,627) for general working capital in July 2024, October 2024, November 2024, December 2024, January 2025, February 2025 and March 2025. In March 2025, Advanced Biomed Inc.(HK) paid US$550,000 to Well Fancy Development Ltd for Advanced Biomed Inc.(Taiwan)&#8217;s debt. And Advanced Biomed Inc. entered into two unsecured, interest-free loan to Well Fancy Development Ltd amounting to US$119,975 and US$205,000 for general working capital in November 2024 and March 2025. In March 2025, Advanced Biomed Inc. paid US$50,000 to Well Fancy Development Ltd for repayment. As of June 30, 2025, the loan balance due to Well Fancy Development Ltd totally amounted to NTD 177,488 (approximately US$6,083) and US$274,975 for general working capital.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Sglcell Biotech Co., Ltd entered into nine unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. amounting to RMB500,000 (approximately US$69,797) in April 2023, May 2023, June 2023 and September 2023, respectively, and RMB700,000 (approximately US$97,716), RMB1,000,000 (approximately US$139,595), RMB500,000 (approximately US$69,797), RMB700,000 (approximately US$97,716) and RMB650,000 (approximately US$90,738) in January 2024, March 2024, March 2024, June 2024 and October 2024, respectively, for general working capital. As of June 30, 2025 and 2024 the loan balance due to Shanghai Junfu Electronic Technology Co., Ltd totally amounted to RMB5,550,000 (approximately US$774,750) and RMB4,900,000 (approximately to US$674,262), respectively.</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 115 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14. Principal Accounting Fees and Services</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the aggregate fees by categories specified below in connection with certain professional services rendered by WWC, P.C., our independent
registered public accounting firm, for the periods indicated. We did not pay any other fees to our independent registered public accounting
firm during the periods indicated below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>WWC, P.C.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&#160;the&#160;Year&#160;Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">(in&#160;thousands&#160;of&#160;US$)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Audit fees<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">200,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">200,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><span style="font-size: 10pt">Audit related fees<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">Tax fees<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">All other fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">200,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">200,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Audit fees&#8221; means the aggregate fees billed for professional services rendered by our independent registered public accounting firm for the audit of our annual consolidated financial statements and the review of our comparative interim financial information.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Audit related fees&#8221; means the aggregate fees billed for related services by our principal accountant that are reasonably related to the performance of the audit or review of our financial statements and are not reported under Audit fees.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#8220;Tax fees&#8221; represents the aggregated fees billed for professional services rendered by our independent registered public accounting firm for tax compliance, tax advice, and tax planning.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Procedures For Board of Directors Pre-Approval
of Audit and Permissible Non-Audit Services of Independent Auditor</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee is responsible
for the oversight of our independent accountants&#8217; work. The policy of our audit committee is to pre-approve all audit and non-audit
services provided by WWC, P.C., including audit services, audit-related services, tax services and other services as described above,
other than those for de minimis services which are approved by the audit committee prior to the completion of the audit.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART IV</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. Exhibits and Financial Statements
Schedules</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The following documents are filed as part of this Report:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Consolidated Financial Statements</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="text-indent: -10pt; padding-left: 10pt; padding-bottom: 1.5pt; vertical-align: top; width: 90%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr>
    <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-2</span></td></tr>
  <tr>
    <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top"><span style="font-size: 10pt"><a href="#f_002">Consolidated Balance Sheets as of June 30, 2025 and 2024</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-3</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#f_003">Consolidated Statements of Operations and Comprehensive Loss for the Financial Years Ended June 30, 2025 and 2024</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr>
    <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top"><span style="font-size: 10pt"><a href="#f_004">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Financial Years Ended June 30, 2025 and 2024&#160;</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-5</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#f_005">Consolidated Statements of Cash Flows for the Financial Years Ended June 30, 2025 and 2024</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-6</span></td></tr>
  <tr>
    <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top"><span style="font-size: 10pt"><a href="#f_006">Notes to Consolidated Financial Statements</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">F-7</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 117; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;<img alt="" src="image_016.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt">To:</span></td>
    <td><span style="font-size: 10pt">The Board of Directors and Stockholders of</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Advanced Biomed Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AuditorOpinionTextBlock-c0_cont_1" escape="true" name="dei:AuditorOpinionTextBlock" id="ixv-11135"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Financial Statements</b></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:continuation id="_AuditorOpinionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Advanced Biomed Inc. and its subsidiaries (collectively the &#8220;Company&#8221;) as of June 30, 2025 and 2024, and
the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash flows in each
of the years for the two-year period ended June 30, 2025, and the related notes (collectively referred to as the consolidated financial
statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of
the Company as of June 30, 2025, and 2024, and the results of its operations and its cash flows in each of the years for the two-year
period ended June 30, 2025, in conformity with accounting principles generally accepted in the United States of America.</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Explanatory Paragraph &#8212; Substantial Doubt
about the Company&#8217;s Ability to Continue as a Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As described in Note 2, the Company has incurred significant
losses, has significant net cash outflows from operating activities and needs to raise additional funds to meet its obligations and sustain
its operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s
plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements are the
responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide
a reasonable basis for our opinion.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ WWC, P.C.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-16413">WWC, P.C.</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certified Public Accountants</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PCAOB ID No. <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-16414">1171</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-16415">San Mateo, California</ix:nonNumeric></p><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">October 8, 2025</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_017.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ADVANCED BIOMED INC. AND ITS
SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-16416">2,903,915</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-16417">2,607,973</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Prepaid expenses and other current assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-16418">3,128,656</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-16419">443,137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-16420">6,032,571</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-16421">3,051,110</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-16422">331,346</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-16423">524,528</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Right-of-use assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-16424">65,399</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-16425">126,740</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-16426">118,998</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Deferred initial public offering (&#8220;IPO&#8221;) costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCosts" scale="0" unitRef="usd" id="ixv-16427">638,871</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Other non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-16428">83,027</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-16429">479,772</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-16430">1,409,137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-16431">6,512,343</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-16432">4,460,247</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable, accruals, and other current liabilities (including amount due to related parties &#8211; major stockholders as of June 30, 2025 and 2024, with $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">172,767</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">113,812</ix:nonFraction> due to related parties &#8211; related corporations, and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">916,036</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">674,262</ix:nonFraction> due to related corporations, respectively <sup>(1)</sup>)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-16437">2,853,317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-16438">2,670,249</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Lease payable - current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-16439">35,811</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-16440">62,211</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-16441">2,889,128</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-16442">2,732,460</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; text-indent: 7.1pt">Amount due to related parties &#8211; related corporations, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-16443">139,772</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Lease payable &#8211; non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-16444">5,879</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-16445">64,529</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-16446">145,651</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-16447">64,529</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">TOTAL LIABILITIES</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-16448">3,034,779</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-16449">2,796,989</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Commitments and contingencies</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify">Stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Common stock $<ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" id="ix_12_fact" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" id="ix_13_fact" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value per share; as of June 30, 2025 and 2024; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">400,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">400,000,000</ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" id="ix_10_fact" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" id="ix_11_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">21,640,000</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">20,000,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">21,640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-16460">21,347,278</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-16461">16,493,989</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Accumulated deficits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-16462">19,233,044</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-16463">15,974,075</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-16464">1,341,690</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd" id="ixv-16465">1,123,344</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-16466">3,477,564</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-16467">1,663,258</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-16468">6,512,343</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-16469">4,460,247</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in; text-align: right"/><td style="width: 0.25in">*</td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"><sup>(1)</sup></span></td> <td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-size: 10pt">See Note 12 for disclosure of related parties amounts.</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The accompanying notes are an integral part of these consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ADVANCED BIOMED INC. AND ITS
SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-16471">909,771</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-16472">880,193</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-16473">2,111,265</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-16474">1,661,379</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-16475">3,021,036</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-16476">2,541,572</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-16477">24,915</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-16478">53,495</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd" id="ixv-16479">262,848</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd" id="ixv-16480">294,201</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-16481">237,933</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-16482">240,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss before tax expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-16483">3,258,969</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-16484">2,782,278</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-16485">3,258,969</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-16486">2,782,278</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Foreign currency translation gain, net of taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-16487">218,346</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-16488">319,324</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-16489">3,040,623</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-16490">2,462,954</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">basic and diluted*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" id="ix_14_fact" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" id="ix_15_fact" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.16</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" id="ix_16_fact" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" id="ix_17_fact" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.14</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Weighted average number of shares of common stock in computing net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">basic and diluted*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" id="ix_18_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" id="ix_19_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">20,525,699</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" id="ix_20_fact" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" id="ix_21_fact" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">20,000,000</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in">*</td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The accompanying notes are an integral part of these consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>ADVANCED BIOMED INC. AND ITS
SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217;
EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>No. of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>shares*</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>paid-in<br/>
 capital*</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>comprehensive</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>income</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Accumulated</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>deficit</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance as of July 1, 2023</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" id="ix_22_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">20,000,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" id="ix_23_fact" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">20,000</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" id="ix_24_fact" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">13,673,365</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-16503">804,020</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-16504">13,191,797</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-16505">1,305,588</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Waiver of amount due to related parties &#8211; major stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" id="ix_25_fact" name="advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" scale="0" unitRef="usd">1,233,764</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" scale="0" unitRef="usd" id="ixv-16507">1,233,764</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Waiver of amount due to related parties &#8211; related corporations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" id="ix_26_fact" name="advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" scale="0" unitRef="usd">1,586,860</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" scale="0" unitRef="usd" id="ixv-16509">1,586,860</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-16510">2,782,278</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-16511">2,782,278</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-16512">319,324</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-16513">319,324</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance as of June 30, 2024</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" id="ix_27_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">20,000,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" id="ix_28_fact" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">20,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" id="ix_29_fact" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">16,493,989</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-16517">1,123,344</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-16518">15,974,075</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-16519">1,663,258</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Balance as of July 1, 2024</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" id="ix_30_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">20,000,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" id="ix_31_fact" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">20,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" id="ix_32_fact" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">16,493,989</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-16523">1,123,344</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-16524">15,974,075</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-16525">1,663,258</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-16526">3,258,969</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-16527">3,258,969</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Issuance of stocks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="INF" format="ixt:num-dot-decimal" id="ix_33_fact" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">1,640,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" id="ix_34_fact" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">1,640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" id="ix_35_fact" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">4,853,289</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-16531">4,854,929</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-16532">218,346</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd" id="ixv-16533">218,346</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance as of June 30, 2025</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" id="ix_36_fact" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">21,640,000</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" id="ix_37_fact" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">21,640</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" id="ix_38_fact" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">21,347,278</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-16537">1,341,690</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-16538">19,233,044</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-16539">3,477,564</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The accompanying notes are an integral part of these consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ADVANCED BIOMED INC. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the years ended <br/>
June 30,</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>US$</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-16541">3,258,969</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-16542">2,782,278</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustment:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation and amortization</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-16543">343,830</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-16544">399,602</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in operating assets:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other current assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-16545">2,685,519</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-16546">279,425</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable, accruals and other current liabilities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-16547">117,661</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="0" unitRef="usd" id="ixv-16548">479,634</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease obligations, net cash</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-16549">23,709</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other non-current assets</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" unitRef="usd" id="ixv-16550">83,027</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" sign="-" unitRef="usd" id="ixv-16551">56,127</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash used in operating activities</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-16552">5,825,055</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-16553">2,126,340</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase of equipment</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-16554">31,650</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-16555">74,110</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash used in investing activities</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-16556">31,650</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-16557">74,110</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net proceeds from issuance of stock in IPO/(prepayments for IPO costs)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" unitRef="usd" id="ixv-16558">5,493,800</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" sign="-" unitRef="usd" id="ixv-16559">85,400</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from related parties &#8211; major stockholders</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-16560">296,507</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-16561">294,900</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayments to related parties &#8211; major stockholders</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-16562">237,552</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from related parties &#8211; related corporations</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-16563">981,546</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-16564">1,657,320</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayments to related parties &#8211; related corporations</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-16565">600,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash provided by financing activities</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-16566">5,934,301</ix:nonFraction></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-16567">1,866,820</ix:nonFraction></b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency effect</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-16568">218,346</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-16569">319,324</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net change in cash</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-16570">295,942</ix:nonFraction></b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-16571">14,306</ix:nonFraction></b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>)</b></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash at beginning of the year</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-16572">2,607,973</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-16573">2,622,279</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash at year end</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-16574">2,903,915</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-16575">2,607,973</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net increase (decrease) in cash</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-16576">295,942</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-16577">14,306</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supplementary Cash Flow Information:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid for interest</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash paid for taxes</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash received for interest</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1" scale="0" unitRef="usd" id="ixv-16578">24,915</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ADVANCED BIOMED INC. AND ITS SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-12902"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. ORGANIZATION AND PRINCIPAL ACTIVITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2021, Advanced Biomed Inc. (the &#8220;Company&#8221;)
was incorporated in the State of Nevada, as an investment holding company. The Company&#8217;s principal executive offices are located
in Tainan City, Taiwan. The Company has no substantive operations and assets. It is holding Company that holds all of the issued and outstanding
shares of Advanced Biomed HK Limited and Advanced Biomed Inc. (Taiwan).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2025, the Company announced the closing of its initial
public offering (the "Offering") of <ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-16579">1,640,000</ix:nonFraction> shares of common stock (the &#8220;Shares&#8221;), at a public offering price
of US$<ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-16580">4.00</ix:nonFraction> per share for total gross proceeds of US$<ix:nonFraction contextRef="c36" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" unitRef="usd" id="ixv-16581">6.56</ix:nonFraction> million. The Company raised total net proceeds of approximately US$<ix:nonFraction contextRef="c36" decimals="-4" format="ixt:num-dot-decimal" name="advb:NetProceedsFromInitialPublicOffering" scale="6" unitRef="usd" id="ixv-16582">5.49</ix:nonFraction> million,
which was reflected in the statement of cash flows, after deducting underwriting discounts and commissions and outstanding offering expenses
upon the completion of listing. The common stock of the Company began trading on the Nasdaq Capital Market under the ticker symbol &#8220;ADVB&#8221;
from March 6, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt"><i>(1)</i></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Establishment of Advanced Biomed HK Limited </i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2021, the Company incorporated a
wholly owned subsidiary, Advanced Biomed HK Limited, in Hong Kong to facilitate market development and commercialization of the Company&#8217;s
oncology products for sale and distribution in the People&#8217;s Republic of China (the &#8220;PRC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt"><i>(2)</i></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Acquisition of Shanghai Sglcell Biotech Co., Ltd. and its subsidiaries</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2022, Advanced Biomed HK Limited
acquired <ix:nonFraction contextRef="c37" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-16583">100</ix:nonFraction>% equity interest of Shanghai Sglcell Biotech Co., Ltd. Shanghai Sglcell Biotech Co., Ltd. was established in the PRC on April
12, 2019. It is engaged in the establishment and operation of medical clinics in the PRC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shanghai Sglcell Biotech Co., Ltd. owns <ix:nonFraction contextRef="c38" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-16584">100</ix:nonFraction>% equity
interest of two subsidiaries namely 1.) Shandong Sglcell Medical Devices Co., Ltd. and 2.) Nanjing Yitian Biotech Co., Ltd. Shandong Sglcell
Medical Devices Co., Ltd. was incorporated in the PRC on July 8, 2021 to carry out the establishment of medical clinics, and the supply
of medical products and services to clinics in the PRC. Nanjing Yitian Biotech Co., Ltd. was established in the PRC on January 6, 2017.
Nanjing Yitian Biotech Co., Ltd. wholly owns a subsidiary, Beijing Yitan Jiarui Technology Co. Ltd., which was established in the PRC
on October 20, 2017. Both were established to carry out marketing and clinical services in the PRC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 8, 2023, Shanghai Sglcell Biotech Co.,
Ltd. transferred its wholly owned subsidiary, Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co.,
Ltd., to independent third-party individuals at aggregate consideration of CNY<ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" unitRef="cny" id="ixv-16585">500,000</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" unitRef="usd" id="ixv-16586">71,942</ix:nonFraction>) without any other obligations
arising from the transfer. Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co., Ltd. have not commenced
business activity since it was acquired on January 1, 2022 and the Company believed the transfer will improve in operational efficiency.
The consideration is determined by the Company according to the net assets appraisal report issued by an independent third-party appraisal
company on May 31, 2023, as of the date of May 31, 2023, the net assets value of Nanjing Yitian Biotech Co., Ltd. and its subsidiary,
Beijing Yitan Jiarui Technology Co., Ltd., was CNY<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="advb:BusinessCombinationConsiderationNetAssetFairValue" scale="0" unitRef="cny" id="ixv-16587">498,587</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="advb:BusinessCombinationConsiderationNetAssetFairValue" scale="0" unitRef="usd" id="ixv-16588">71,739</ix:nonFraction>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 9, 2023, Shandong Sglcell Biotech Co.,
Ltd., the wholly owned subsidiary of Shanghai Sglcell Biotech Co., Ltd., was transferred to independent third-party individuals at <ix:nonFraction contextRef="c41" decimals="0" format="ixt:fixed-zero" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" unitRef="usd" id="ixv-16589">zero</ix:nonFraction>
consideration without any other obligations arising from the transfer. Shandong Sglcell Biotech Co., Ltd. has been inactive since it was
incorporated on July 8, 2022 and the Company believed the transfer will improve in operational efficiency. The consideration is determined
by the Company according to the net assets appraisal report issued by an independent third-party appraisal company on May 31, 2023, as
of the date of May 31, 2023, the net assets value of Shandong Sglcell Medical Devices Co., Ltd., was <ix:nonFraction contextRef="c42" decimals="0" format="ixt:fixed-zero" name="advb:BusinessCombinationConsiderationNetAssetFairValue" scale="0" unitRef="usd" id="ixv-16590">zero</ix:nonFraction>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-size: 10pt"><i>(3)</i></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><i>Subsidiary established under Advanced Biomed HK Limited</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advanced Biomed HK Limited incorporated a wholly
owned subsidiary, Sglcell (Huangshan) Biotech Co., Ltd., in the PRC on March 4, 2022; it was established for the expected future manufacturing
of medical devices in the PRC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 15, 2023, Sglcell (Huangshan) Biotech
Co., Ltd., the wholly owned subsidiary of Advanced Biomed HK Limited, was transferred to an independent third-party corporation at zero
consideration without any other obligations arising from the transfers. Sglcell (Huangshan) Biotech Co., Ltd. has been dormant since its
incorporation date from March 4, 2022 and the Company believed the transfer will improve in operational efficiency. The consideration
is determined by the Company according to the net assets appraisal report issued by an independent third-party appraisal company on May
31, 2023, as of the date of May 31, 2023, the net assets value of Shandong Sglcell Medical Devices Co., Ltd., was <ix:nonFraction contextRef="c43" decimals="0" format="ixt:fixed-zero" name="advb:BusinessCombinationConsiderationNetAssetFairValue" scale="0" unitRef="usd" id="ixv-16591">zero</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i>&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-size: 10pt"><i>(4)</i></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><i>Reorganization of Advanced Biomed Inc. (Taiwan) </i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advanced Biomed Inc. (Taiwan) was established
in Taiwan on September 1, 2014. It is primarily focused on mainly operates as a research and development of new center for technologies
in the field of oncology to help efficiently and cost-effectively identify and diagnose cancer cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On date of incorporation, <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-16592">July 16, 2021</ix:nonNumeric>, the Company
issued <ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-16593">8,000,000</ix:nonFraction> shares to Dr. Hung To Pau. On March 15, 2022, Dr. Hung To Pau transferred all of his <ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-16594">8,000,000</ix:nonFraction> shares to Sglcell Ltd,
an exempted company incorporated under the law of Cayman Islands, the sole stockholder of which is Dr. Hung To Pau for a total consideration
of $<ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" unitRef="usd" id="ixv-16595">8,000</ix:nonFraction>. The Company was dormant and has no substantive assets. On June 8, 2022, Sglcell Ltd transferred all of its <ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-16596">8,000,000</ix:nonFraction> shares
to Dr. Yi Lu for a total consideration of $<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" unitRef="usd" id="ixv-16597">8,000</ix:nonFraction>. In July 2022, the Company consummated a reorganization of Advanced Biomed Inc. (Taiwan)
under share exchange arrangement of its then existing stockholders, who collectively owned all the equity interests of Advanced Biomed
Inc. (Taiwan) prior to the reorganization, transferred their respective shares in Advanced Biomed Inc. (Taiwan) to the Company. Prior
to the re-organization, Advanced Biomed Inc. (Taiwan) was directly owned and controlled by Dr. Yi Lu and Chen-Yi Lee with <ix:nonFraction contextRef="c49" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-16598">99.93</ix:nonFraction>% and <ix:nonFraction contextRef="c50" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-16599">0.07</ix:nonFraction>%
beneficial ownership interest, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">The Share Exchange</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to a share exchange agreement (the &#8220;Agreement&#8221;)
dated July 11, 2022, Dr. Yi Lu and Chen-Yi Lee transferred their respective shares in Advanced Biomed Inc. (Taiwan) at the time of the
Agreement, representing in aggregate <ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-16600">100</ix:nonFraction>% of the issued share capital of Advanced Biomed Inc. (Taiwan), to the Company. The consideration
for the share transfers was satisfied by the allotment and issuance of an aggregate of <ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-16601">385,257</ix:nonFraction> fully paid up shares of common stock to
Dr. Yi Lu and Chen-Yi Lee. Following the completion of the share exchange and related issuances by and among the Company, Dr. Yi Lu and
Chen-Yi Lee, Advanced Biomed Inc. (Taiwan) ultimately became a wholly-owned subsidiary of the Company, and Dr. Yi Lu and Chen-Yi Lee became
the beneficial owners of the Company with percentage ownerships of <ix:nonFraction contextRef="c53" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-16602">99.99</ix:nonFraction>% and <ix:nonFraction contextRef="c54" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-16603">0.01</ix:nonFraction>% as of August 12, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequently, on October 24, 2022, the Company
issued <ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-16604">365,368</ix:nonFraction> shares to Chen-Yi Lee, and on October 24, 2022, the Company also issued <ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-16605">2,730,000</ix:nonFraction> shares to Advance On Ventures Limited,
a company incorporated under the law of British Virgin Islands (the &#8220;Ventures Limited&#8221;), the beneficial owners of which are
employees of Advanced Biomed Taiwan. The Company issued <ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-16606">4,405,625</ix:nonFraction> shares, <ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-16607">2,193,750</ix:nonFraction> shares, <ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-16608">2,060,000</ix:nonFraction> shares, <ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-16609">1,511,250</ix:nonFraction> shares, <ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-16610">1,243,750</ix:nonFraction>
shares, <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-16611">1,230,000</ix:nonFraction> shares respectively to Dr. Hung To Pau, Yimin Jin, Xiaoyuan Luo, Nanzhen Shen, Jian Wang and Qiang Chen pursuant to
the Debt-For-Equity Exchange Agreement the Company entered into with the abovementioned stockholders on June 30, 2022 to settle debt of
a total amount of NTD <ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="twd" id="ixv-16612">174,020,033</ix:nonFraction> and RMB<ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="cny" id="ixv-16613">22,200,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c63" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="6" unitRef="usd" id="ixv-16614">9.04</ix:nonFraction> million). On October 25, 2022, the Company issued <ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-16615">625,000</ix:nonFraction> shares
to Hanyu Assets Co. Ltd. pursuant to the Investment Agreement the Company entered into with Hanyu Assets Co. Ltd. on June 6, 2022, and
the Company issued <ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-16616">250,000</ix:nonFraction> shares to Newlink Technology Inc. pursuant to the Investment Agreement the Company entered into with Newlink
Technology Inc. on June 6, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of the reorganization, Dr. Yi
Lu&#8217;s percentage of ownerships of the Company became <ix:nonFraction contextRef="c66" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-16617">33.54</ix:nonFraction>% as of October 25, 2022.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 7, 2022, the Company obtained the
approval of the Investment Commission of the Ministry of Economic Affairs (&#8220;Taiwan Investment Commission&#8221;) for the reorganization,
and the issuance number of which is &#8220;<span style="font-family: Times New Roman, Times, Serif">&#32147;&#23529;&#19968;&#23383;&#31532;</span>11100116890<span style="font-family: Times New Roman, Times, Serif">&#34399;</span>&#8221;.
Additionally, the Bureau of Economic Development of Tainan City Government has also approved the reorganization in accordance with the
Taiwan Company Act on December 26, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to this reorganization, the Company
determined that Advanced Biomed Inc. (Taiwan) is the predecessor entity as the Company is an investment holding company with no business
activities carried out and all of the business of Advanced Biomed Inc. (Taiwan) acquired formed substantially all of the business of
the Company under Rule 405 of Regulation C. To reflect the real economic substance of the Company&#8217;s business under the reorganization,
the accompanying consolidated financial statements were prepared assuming that the share exchange transaction, as disclosed above has
been completed, and the Company exercises control of Advanced Biomed Inc. (Taiwan). The transaction detailed above has been accounted
for as reverse takeover and recapitalization of the Company; whereby the Company (the legal acquirer) is considered the accounting acquiree,
and Advanced Biomed Inc. (Taiwan)(the legal acquiree) is considered as the accounting acquirer. This transaction is deemed to be a continuation
of the business of Advanced Biomed Inc. (Taiwan); therefore, no goodwill has been recorded for this transaction, and the Company&#8217;s
historical financial information prior to the date of the recapitalization transaction is that of Advanced Biomed Inc. (Taiwan) and historical
changes in stockholders&#8217; deficit and its results of operations have been presented from the beginning of the first period presented.
The above-mentioned equity is before the stock split on May 16, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" id="ixv-13015"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and its subsidiaries are in the table
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="15" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Percentage of effective ownership</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date of <br/> Incorporation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold; vertical-align: top">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold; vertical-align: top">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Place of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>incorporation</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Principal <br/> Activities</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left">Advanced Biomed Inc.</td><td>&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c67" format="ixt:date-monthname-day-year-en" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" id="ixv-16618">July 16, 2021</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="vertical-align: top; text-align: right">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="vertical-align: top; text-align: right">&#160;</td><td>&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c67" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-16619">Nevada</ix:nonNumeric></td><td>&#160;</td> <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c67" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-16620">Investment holding</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; width: 25%; text-align: left">Advanced Biomed Inc. (Taiwan)</td><td style="width: 1%">&#160;</td> <td style="vertical-align: top; width: 14%; text-align: center"><ix:nonNumeric contextRef="c69" format="ixt:date-monthname-day-year-en" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" id="ixv-16621">September 1, 2014</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="vertical-align: top; width: 9%; text-align: right"><ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-16622">100</ix:nonFraction></td><td style="vertical-align: top; width: 1%; text-align: right">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="vertical-align: top; width: 9%; text-align: right"><ix:nonFraction contextRef="c70" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-16623">100</ix:nonFraction></td><td style="vertical-align: top; width: 1%; text-align: right">%</td><td style="width: 1%">&#160;</td> <td style="vertical-align: top; width: 14%; text-align: center"><ix:nonNumeric contextRef="c69" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-16624">Taiwan</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="vertical-align: top; width: 20%; text-align: left"><ix:nonNumeric contextRef="c69" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-16625">Research and development of various advanced and innovative microfluidic biochip technologies, and provide the leading application of such technologies in precision oncology detection, diagnosis and treatment</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left">Advanced Biomed HK Limited</td><td>&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c71" format="ixt:date-monthname-day-year-en" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" id="ixv-16626">August 10, 2021</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right"><ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-16627">100</ix:nonFraction></td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-16628">100</ix:nonFraction></td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c71" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-16629">Hong Kong</ix:nonNumeric></td><td>&#160;</td> <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c71" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-16630">Market development</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left">Shanghai Sglcell Biotech Co., Ltd.</td><td>&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c73" format="ixt:date-monthname-day-year-en" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" id="ixv-16631">April 12, 2019</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-16632">100</ix:nonFraction></td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-16633">100</ix:nonFraction></td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c73" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" id="ixv-16634">People&#8217;s Republic of China</ix:nonNumeric></td><td>&#160;</td> <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c73" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-16635">Clinical-related business</ix:nonNumeric></td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
are presented assuming that the Company was in existence at the beginning of the first period presented.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="ixv-13128"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. LIQUIDITY AND GOING CONCERN</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in conformity with U.S. GAAP which contemplates continuation of the Company on a going concern basis. The going concern
basis assumes that assets are realized, and liabilities are settled in the ordinary course of business at amounts disclosed in the consolidated
financial statements. The Company&#8217;s ability to continue as a going concern depends upon its ability to develop, register and obtain
regulatory approval for commercial sell of its products to generate positive operating cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To sustain its ability to support the Company&#8217;s
operating activities, the Company may have to consider supplementing its available sources of funds through the following sources:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">raise additional capital; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash generated from upcoming operations; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial support from the Company&#8217;s related party and stockholders as well as third parties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company certain related parties have waived
off the amount due to them as of June 30, 2024, which amounted to $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="advb:workingCapital" scale="0" unitRef="usd" id="ixv-16636">2,820,624</ix:nonFraction> in order to improve the Company&#8217;s working capital.
The Company completed its initial public offering. In the initial public offering, the Company issued <ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-16637">1,640,000</ix:nonFraction> shares of common stock
at a price of US$<ix:nonFraction contextRef="c76" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-16638">4.00</ix:nonFraction> per share. The Company received gross proceeds in the amount of US$<ix:nonFraction contextRef="c75" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" unitRef="usd" id="ixv-16639">6.56</ix:nonFraction> million before deducting any underwriting
discounts or expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 6, 2025, the Company entered into a purchase
agreement (the &#8220;ELOC Agreement&#8221;) with HELENA GLOBAL INVESTMENT OPPORTUNITIES I LTD. (the &#8220;Investor&#8221; or &#8220;Selling
Stockholder&#8221;), pursuant to which the Company have the right to issue and sell to the Investor, from time to time as provided therein,
and the Investor is obligated to purchase from us, up to Twenty-Five Million United States Dollars ($<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd" id="ixv-16640">25,000,000</ix:nonFraction>) of the Company&#8217;s
Common Stock, subject to terms and conditions set forth in the ELOC Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, for the financial year ended June 30,
2025, the Company reported net loss of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-16641">3,258,969</ix:nonFraction>. In addition, the Company had net cash outflows of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-16642">5,825,055</ix:nonFraction> from operating activities
for the financial year ended June 30, 2025. These conditions give rise to substantial doubt as to whether the Company will be able to
continue as a going concern. The consolidated financial statements for the financial years ended June 30, 2025 and 2024 have been prepared
on a going concern basis and do not include any adjustments to reflect the possible future effects on the recoverability and classifications
of assets or the amounts and classifications of liabilities that may result from the inability of the Company to continue as a going concern.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-13172"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-13177"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(a) Basis of presentation</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;)
and pursuant to the regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;).</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-13186"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(b) Consolidation</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ConsolidationPolicyTextBlock-c0_cont_2" id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the financial statements of the Company and its subsidiaries. All inter-company transactions, if any, and balances due to, due from, long-term
investment subsidiary, and registered paid in capital have been eliminated upon consolidation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ConsolidationPolicyTextBlock-c0_cont_3" id="_ConsolidationPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business combinations are accounted for using
the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective
fair values as of the acquisition date in the Company&#8217;s consolidated financial statements. Any excess fair value of consideration
transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection
with the business combination are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent
reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in the consolidated statements
of operations.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When the Company determines that assets acquired
do not meet the definition of a business under the acquisition method of accounting, acquired assets is expensed, no goodwill is recorded,
and any contingent consideration is recognized only when it becomes payable or is paid.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-13214"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(c) Use of estimates</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to useful lives for equipment
and intangible assets, assumptions used in assessing right of use assets, impairment of long-lived assets and uncertain tax position.
Actual results could vary from the estimates and assumptions that were used.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:nonNumeric contextRef="c0" continuedAt="advb_StockSplitPolicyTextBlock-c0_cont_1" escape="true" name="advb:StockSplitPolicyTextBlock" id="ixv-13222"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(d) Stock split and reverse share
split</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:continuation continuedAt="advb_StockSplitPolicyTextBlock-c0_cont_2" id="advb_StockSplitPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2023, the Company effected a forward
share split of all issued and outstanding shares of <ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="advb:ForwardShareSplitIssued" scale="0" unitRef="shares" id="ixv-16643"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="advb:ForwardShareSplitOutstanding" scale="0" unitRef="shares" id="ixv-16644">25,000,000</ix:nonFraction></ix:nonFraction> shares at a ratio of <ix:nonNumeric contextRef="c79" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-16645">1-to-4</ix:nonNumeric>. As a result of the forward split, the Company
now have <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="advb:ForwardShareSplitIssued" scale="0" unitRef="shares" id="ixv-16646"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="advb:ForwardShareSplitOutstanding" scale="0" unitRef="shares" id="ixv-16647">100,000,000</ix:nonFraction></ix:nonFraction> common stock issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the
above transactions on a retroactive basis similar to share split or dividend pursuant to ASC 260. All references made to share or per
share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect
the <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-16648">4</ix:nonFraction> for <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-16649">1</ix:nonFraction> share split. The shares of common stock retain a par value of $<ix:nonFraction contextRef="c82" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-16650">0.001</ix:nonFraction> per share. Accordingly, an amount equal to the par value
of the increased shares resulting from the share split was reclassified from &#8220;Additional paid-in capital&#8221; to &#8220;Common
stock&#8221;.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="advb_StockSplitPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 15, 2024, the Company effected the
reverse share split of all issued and outstanding shares of <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="advb:ForwardShareSplitIssued" scale="0" unitRef="shares" id="ixv-16651"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="advb:ForwardShareSplitOutstanding" scale="0" unitRef="shares" id="ixv-16652">100,000,000</ix:nonFraction></ix:nonFraction> shares at a ratio of <ix:nonNumeric contextRef="c84" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-16653">5:1</ix:nonNumeric>. As a result of the reverse share split,
the Company now have <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="advb:ForwardShareSplitIssued" scale="0" unitRef="shares" id="ixv-16654"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="advb:ForwardShareSplitOutstanding" scale="0" unitRef="shares" id="ixv-16655">20,000,000</ix:nonFraction></ix:nonFraction> common stock issued and outstanding as of the date hereof. Unless indicated or the context otherwise requires,
all number of common stock in this report has been retrospectively adjusted for the reverse share split, as if such reverse share split
occurred on the first day of the years presented.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-13233"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(e) Risks and uncertainties</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The main operations of the Company are located
in Taiwan and mainland China. Accordingly, the Company&#8217;s business, financial condition, and results of operations may be influenced
by political, economic, and legal environments in Taiwan and mainland China, as well as by the general state of the economy in these two
countries. The Company&#8217;s results may be adversely affected by changes in the political, regulatory and social conditions in these
two countries.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&#8217;s operations.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-13243"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(f) Foreign currency translation and transaction
and convenience translation</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
are presented in the US Dollar (&#8220;US$&#8221;), which is the reporting currency of the Company. The functional currency of the Company
is the US$. Advanced Biomed Inc. (Taiwan) uses New Taiwan dollar (&#8220;NT$&#8221;) as its functional currency. Advanced Biomed HK Limited
uses Hong Kong dollars (&#8220;HKD&#8221;) and Shanghai Sglcell Biotech Co., Ltd. uses Chinese Yuan (&#8220;CNY&#8221;) as their functional
currencies, respectively.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities denominated in currencies
other than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the balance sheet
date. Translation gains and losses are recognized in the consolidated statements of income and comprehensive income as other comprehensive
income or loss. Transactions in currencies other than the reporting currency are measured and recorded in the reporting currency at the
exchange rate prevailing on the transaction date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated
statements of income and comprehensive income as other income (other expense).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value of foreign currencies including, the
NT$, CNY and HKD, may fluctuate against the US Dollar. Any significant variations of the aforementioned currencies relative to the US
Dollar may materially affect the Company&#8217;s financial condition in terms of reporting in US Dollar. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" id="ixv-16656">The following table outlines
the currency exchange rates that were used in preparing the accompanying consolidated financial statements:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock-c0_cont_1"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">US$ to NT$ fiscal year end</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c91" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-16657">29.18</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-16658">32.45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">US$ to NT$ average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-16659">32.09</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-16660">31.83</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">US$ to CNY fiscal year end</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-16661">7.16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-16662">7.27</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">US$ to CNY average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-16663">7.21</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-16664">7.23</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">US$ to HKD fiscal year end</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-16665">7.85</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c100" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-16666">7.81</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">US$ to HKD average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c101" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-16667">7.79</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-16668">7.82</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-13354"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(g) Fair value measurement</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance defines fair value as the
price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded
at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions
that market participants would use when pricing the asset or liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance establishes a fair value hierarchy
that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
A financial instrument&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant
to the fair value measurement. Accounting guidance establishes three levels of inputs that may be used to measure fair value:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 1 applies to assets or liabilities for which there are quoted prices, in active markets for identical assets or liabilities.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical asset or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3 applies to asset or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash, other current assets, leases payable, accounts
payables, accruals and other current liabilities are financial assets and liabilities. Cash, other current assets, accounts payable, accruals
and other current liabilities are subject to fair value measurement; however, because of their being short term in nature management believes
their carrying values approximate their fair value. Financial instruments are fair value financial assets that are marked to fair value
and are accounted for under as Level 3 under the above hierarchy. The Company accounts for lease payables at amortized cost and has elected
NOT to account for them under the fair value hierarchy.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="advb_RelatedPartiesPolicyTextBlock-c0_cont_1" escape="true" name="advb:RelatedPartiesPolicyTextBlock" id="ixv-13395"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(h) Related parties</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="advb_RelatedPartiesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We adopted ASC 850, Related Party Disclosures,
for the identification of related parties and disclosure of related party transactions for the years ended June 30, 2025 and 2024.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-13417"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(i) Cash </i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash consists of cash on hand, the Company&#8217;s
demand deposit placed with financial institutions, which have original maturities of less than three months and unrestricted as to withdrawal
and use. Deposits are held at highly liquid and well capitalized financial institutions. Risk of loss is not expected by management.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="ixv-13424"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(j) Intangible assets, net</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="ixv-13428"><ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s intangible assets are stated
at cost less accumulated amortization and impairment, if any, and amortized on a straight-line basis over the estimated useful lives of
the assets.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Category</b></span></td> <td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: justify">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Estimated <br/>
useful lives</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Software</span></td> <td style="white-space: nowrap; text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c86" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-16669">3</ix:nonNumeric> years</span></td></tr> <tr style="vertical-align: top; "> <td style="width: 88%"><span style="font-size: 10pt">Patents</span></td> <td style="white-space: nowrap; width: 1%; text-align: justify">&#160;</td> <td style="text-align: center; width: 11%"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c87" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-16670">6</ix:nonNumeric> years</span></td></tr> </table></ix:continuation></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_IntangibleAssetsFiniteLivedPolicy-c0_cont_4" id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Software represents purchased software and is
amortized straight-line over the Company&#8217;s estimates to generate economic benefits from such software, generally <ix:nonNumeric contextRef="c86" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-16671">three years</ix:nonNumeric>.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_IntangibleAssetsFiniteLivedPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents represent the estimated fair value assigned to finite-lived
intangible assets acquired in a transaction that is accounted for as an acquisition of assets rather than a business combination are initially
recognized in accordance with other application GAAP. Any consideration transferred in excess of the fair value of the assets acquired
is allocated to each asset acquired on a relative fair value basis. Amortization is computed using the straight-line method over the estimated
useful lives of the respective finite-lived intangible assets, generally <ix:nonNumeric contextRef="c87" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-16672">six years</ix:nonNumeric>. Intangible assets are reviewed for impairment at least
annually or more frequently if indicators of potential impairment exist. The Company reviews finite-lived intangible assets for impairment
at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be
recoverable. If the carrying value of a finite-lived intangible asset exceeds its fair value, then it is written down to its adjusted
fair value. The Company had previously recognized an impairment loss on certain intangible assets in prior years. The remaining intangible
assets were assessed for impairment as of the balance sheet date, and management concluded that no further impairment was required.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-13462"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(k) Equipment, net</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment, net are stated at cost less accumulated
depreciation and impairment, if any, and depreciated on a straight-line basis over the estimated useful lives of the assets. Cost represents
the purchase price of the asset and other costs incurred to bring the asset into its intended use. <ix:nonNumeric contextRef="c0" continuedAt="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock-c0_cont_1" escape="true" name="advb:ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock" id="ixv-16673">Estimated useful lives are as follows:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock-c0_cont_1"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 88%"><span style="font-size: 10pt"><b>Category</b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; width: 11%"><span style="font-size: 10pt"><b>Estimated <br/>
useful lives</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Lab equipment</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c103" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-16674">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c104" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-16675">5</ix:nonNumeric> years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">Computer equipment</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c105" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-16676">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c106" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-16677">5</ix:nonNumeric> years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Furniture and fixtures</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c107" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-16678">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c108" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-16679">5</ix:nonNumeric> years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c109" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-16680">3</ix:nonNumeric> years</span></td></tr>
  </table></ix:continuation></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenditure for repair and maintenance costs,
which do not materially extend the useful lives of the assets, are charged to expenses as incurred, whereas the expenditure for major
renewals and betterment that substantially extends the useful lives of property and equipment are capitalized as additions to the related
assets. Retirements, sales and disposals of assets are recorded by removing the costs, accumulated depreciation and impairment with any
resulting gain or loss recognized in the consolidated statements of operations and comprehensive loss.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock-c0_cont_1" escape="true" name="advb:DeferredInitialPublicOfferingIPOCostsPolicyTextBlock" id="ixv-13524"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>(l) Deferred Initial Public Offering (&#8220;IPO&#8221;) costs&#160;</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation id="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company complies with the requirement of the
ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses of Offering&#8221;. Initial public
offering expense directly attributable to offering of securities are deferred and would be charged against the gross proceeds of the offering,
as a reduction in share capital. These deferred expenses mainly consist of underwriting, legal and other expenses incurred through the
balance sheet date that are directly related to the intended IPO. As of June 30, 2024, the Company capitalized US$<ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalizedComputerSoftwareNet" scale="0" unitRef="usd" id="ixv-16681">638,871</ix:nonFraction> of deferred
initial public offering costs. As of June 30, 2025, the Company had completed its Initial Public Offering, and the accumulated deferred
IPO cost was <span style="-sec-ix-hidden: hidden-fact-38">Nil</span>.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-13534"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(m) Impairment of long-lived assets</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews its long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When
these events occur, the Company measures impairment by comparing the carrying value of the long-lived assets to the estimated undiscounted
future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted
cash flow is less than the carrying amount of the assets, the Company would recognize an impairment loss, which is the excess of carrying
amount over the fair value of the assets, using the expected future discounted cash flows. As of June 30, 2025 and 2024, the Company had
<span style="-sec-ix-hidden: hidden-fact-39"><span style="-sec-ix-hidden: hidden-fact-40">no</span></span> remaining carrying amount of finite-lived intangible related to purchased patents from the acquisition of Shanghai Sglcell Biotech
Co., Ltd. as the assets were fully impaired in 2022.&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-13543"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(n) Commitments and contingencies</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the Company
is subject to commitments and contingencies, including operating lease commitments, legal proceedings and claims arising out of its business
that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes a liability for such
contingency if it determines it is probable that a loss will occur, and a reasonable estimate of the loss can be made. The Company may
consider many factors in making these assessments on liability for contingencies, including historical and the specific facts and circumstances
of each matter.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-13551"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(o) Research and development expenses</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses include costs
directly attributable to the conduct of research and development programs, including licensing fees, cost of salaries, payroll taxes and
other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing
costs and professional services. All costs associated with research and developments are expensed as incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_3" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has already started the registration
process and plans to start clinical research in November 2025, which are expected to end in May 2026, and we expect to obtain the required
registration certificate by October 2027. As of June 30, 2025, the Company has not commenced sales of the products nor have any revenue-generating
products and do not expect sales of revenue-generating product candidates until the Company has completed clinical development, submitted
regulatory filings, and received applicable regulatory approvals for candidate products.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hence, the Company incurred its research and development
cost during the years ended June 30, 2025 and 2024, which is in compliance under ASC 730-10-25.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="ixv-13566"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(p) General and administrative expenses</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses mainly consist
of staff cost, depreciation, office supplies and upkeep expenses, travelling and entertainment, legal and professional fees, property
and related expenses, other miscellaneous administrative expenses.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-13588"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(q) Operating leases</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Prior to the adoption of ASC 842 on January
1, 2019:</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases, mainly leases of factory buildings, offices
and employee dormitories, where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for
as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The
Company had no finance leases for any of the periods stated herein.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_4" id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Upon and hereafter the adoption of ASC 842
on January 1, 2019:</i></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines if an arrangement is a
lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, operating lease liability,
and operating lease liability, non-current in the Company&#8217;s consolidated balance sheets. ROU assets represent the Company&#8217;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments
arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease
payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is
reasonably certain that it will exercise that option, if any. As the Company&#8217;s leases do not provide an implicit rate, the Company
used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.
The Company has elected to adopt the following lease policies in conjunction with the adoption of ASU 2016-02: (i) for leases that have
lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Company elected not
to apply ASC 842 recognition requirements; and (ii) the Company elected to apply the package of practical expedients for existing arrangements
entered into prior to January 1, 2019 to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification
applied to existing leases, and (c) initial direct costs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-13606"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<i>(r) Income Taxes</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company
is able to realize their benefits, or future deductibility is uncertain.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 740, a tax position is recognized as
a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not
that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical
merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount
of benefits recognized in the financial statements. <ix:nonNumeric contextRef="c0" name="us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" id="ixv-16682">A tax position is measured at the largest amount of benefit that is greater than 50
percent likely of being realized upon ultimate settlement.</ix:nonNumeric> Tax positions that previously failed to meet the more-likely-than-not recognition
threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that
no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the
threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense
in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the years ended June 30, 2025
and 2024. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures
and transition.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_4" id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Valuation of Deferred Tax Assets</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is recorded to reduce the
Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results
in the period such determination was made.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-13638"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(s) Loss per share</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per share is computed by dividing net loss
attributable to common stockholders&#160;by the weighted average number of common stock outstanding during the year. Diluted earnings
per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted
into common stock.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-13646"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(t) Segment Reporting</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 280, &#8220;Segment Reporting&#8221;,
establishes standards for reporting information about operating segments on a basis consistent with the Company&#8217;s internal organizational
structure as well as information about geographical areas, business segments and major customers in financial statements for details on
the Company&#8217;s business segments.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_3" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the management approach to determine
reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#8217;s chief
operating decision maker (&#8220;CODM&#8221;) for making decisions, allocating resources and assessing performance.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s CODM has been identified as
the CEO, who reviews results when making decisions about allocating resources and assessing the performance of the Company. For the years
ended June 30, 2025 and 2024, the CODM reviewed the consolidated results when making decisions about allocating resources and assessing
performance of the Company as a whole, and the Company has only <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="pure" id="ixv-16683">one</ix:nonFraction> reportable segment.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-13661"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(u) Recent accounting pronouncements</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2023, the FASB issued ASU 2023-06,
&#8220;Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative.&#8221;
This amendment incorporates certain U.S. Securities and Exchange Commission (SEC) disclosure requirements into the FASB Accounting Standards
Codification. The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification
Topics, allow users to more easily compare entities subject to the SEC&#8217;s existing disclosures with those entities that were not
previously subject to the requirements, and align the requirements in the Codification with the SEC&#8217;s regulations. For entities
subject to the SEC&#8217;s existing disclosure requirements and for entities required to file or furnish financial statements with or
to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer,
the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. For all other
entities, the amendments will be effective two years later. However, if by June 30, 2027, the SEC has not removed the related disclosure
from its regulations, the amendments will be removed from the Codification and not become effective for any entity. The Company does not
expect the adoption of ASU 2023-06 to have a material impact on its consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740)&#160;&#8212;&#160;Improvements to income Tax Disclosures. The amendment in this update are effective for annual
periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods
beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available
for issuance. The Company has adopted ASU 2023-09 on July 1, 2024 and the adoption
of the standard did not have a material impact to the overall financial presentation. See Note 10 for further information.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2024, the FASB issued ASU 2024-01, Compensation
&#8212; Stock Compensation (Topic 718)&#160;&#8212;&#160;Scope Application of Profits Interest and Similar Award. For public business
entities, the amendments in this Update are effective for annual periods beginning after December 15, 2024, and interim periods within
those annual periods. For all other entities, the amendments are effective for annual periods beginning after December 15, 2025, and interim
periods within those annual periods. Early adoption is permitted for both interim and annual financial statements that have not yet been
issued or made available for issuance. If an entity adopts the amendments in an interim period, it should adopt them as of the beginning
of the annual period that includes that interim period. The Company believes the future adoption of this ASU is not expected
to have a material impact on its consolidated financial statements.</p></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March&#160;2024, the FASB issued ASU&#160;2024-02,
&#8220;Codification Improvements&#160;&#8212;&#160;Amendments to Remove References to the Concepts Statements&#8221;. This update contains
amendments to the Codification that remove references to various FASB Concepts Statements. These issues to remove references to various
Concepts Statements and the amendments apply to all reporting entities within the scope of the affected accounting guidance. The amendments
in this Update are effective for public business entities for fiscal&#160;years beginning after December&#160;15, 2024. Early application
of the amendments in this Update is permitted for any fiscal year or interim period for which financial statements have not yet been issued
(or made available for issuance). The Company is currently evaluating the impact of adoption on the Company&#8217;s
related disclosures.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November&#160;2024, the FASB issued ASU&#160;2024-03,
Income Statement&#160;&#8212;&#160;Reporting Comprehensive Income&#160;&#8212;&#160;Expense Disaggregation Disclosures (Subtopic&#160;220-40):
Disaggregation of Income Statement Expenses and in January&#160;2025, the FASB issued ASU&#160;2025-01, Income Statement&#160;&#8212;&#160;Reporting
Comprehensive Income&#160;&#8212;&#160;Expense Disaggregation Disclosures (Subtopic&#160;220-40): Clarifying the Effective Date (&#8220;ASU&#160;2025-01&#8221;).
The ASU requires a public business entity to provide disaggregated disclosures of certain categories of expenses on an annual and interim
basis including purchases of inventory, employee compensation, depreciation, and intangible asset amortization for each income statement
line item that contains those expenses. ASU&#160;2024-03, as clarified by ASU&#160;2025-01 is effective for annual reporting periods beginning
after December&#160;15, 2026, and interim periods beginning after December&#160;15, 2027, with prospective or retrospective application
permitted. The Company is currently evaluating the impact of adoption on the Company&#8217;s related disclosures.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as mentioned above, the Company does not
believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&#8217;s
consolidated balance sheets, statements of operations and comprehensive loss and statements of cash flows.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-13702"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>4. PREPAID EXPENSES AND OTHER CURRENT ASSETS,
NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-13707"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Tax refundable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidTaxes" scale="0" unitRef="usd" id="ixv-16684">221,889</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidTaxes" scale="0" unitRef="usd" id="ixv-16685">161,142</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-16686">10,548</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-16687">44,035</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="0" unitRef="usd" id="ixv-16688">1,782</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Prepayment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-16689">2,894,437</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-16690">237,960</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="advb:PrepaidExpensesAndOtherCurrentAssetGross" scale="0" unitRef="usd" id="ixv-16691">3,128,656</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="advb:PrepaidExpensesAndOtherCurrentAssetGross" scale="0" unitRef="usd" id="ixv-16692">443,137</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: allowance for credit losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total prepaid expenses and other current assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-16693">3,128,656</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-16694">443,137</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in">*</td><td style="text-align: justify">The amount due from a related corporation, which the Company&#8217;s major stockholders
have controlling equity interest in, as of June 30, 2025 are non-trade, unsecured, interest-free and repayable on demand.</td>
</tr></table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-13809"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>5. EQUIPMENT, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-13814"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment, net, consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-16695">1,619,480</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-16696">1,486,392</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-16697">33,917</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-16698">31,745</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-16699">36,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-16700">35,332</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-16701">204,430</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-16702">201,516</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-16703">1,894,332</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-16704">1,754,985</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-16705">1,562,986</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-16706">1,230,457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Equipment, net</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-16707">331,346</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-16708">524,528</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expenses were approximately US$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-16709">224,832</ix:nonFraction>
and US$<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-16710">268,279</ix:nonFraction> for the years ended June 30, 2025 and 2024, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="ixv-13923"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>6. INTANGIBLE ASSETS, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="ixv-13928"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the carrying amount
of the Company&#8217;s finite-lived intangible assets:</p>

<p style="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Acquired technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-16711">372,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-16712">391,016</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-16713">372,197</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-16714">272,018</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-16715">118,998</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2025 and 2024, the Company had
no remaining carrying amount of finite-lived intangible related to purchased patents from the acquisition of Shanghai Sglcell Biotech
Co., Ltd. as the assets were fully impaired in 2022.&#160;<b>&#160;</b></p></ix:nonNumeric><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-13987"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>7. ACCOUNTS PAYABLE, ACCRUALS AND OTHER CURRENT
LIABILITIES AND AMOUNT DUE TO RELATED PARTIES <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;
RELATED CORPORARIONS, NON-CURRENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-13993"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Payable, accrued expenses and other liabilities
consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Accounts payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-16716">632,697</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-16717">620,476</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Payroll payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-16718">29,216</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-16719">77,113</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Amount due to related parties &#8211; major stockholders *</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_41_fact" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">172,767</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_42_fact" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">113,812</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Amount due to related parties &#8211; related corporations**</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_43_fact" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">916,036</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" id="ix_44_fact" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">674,262</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other payable#</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" id="ix_39_fact" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">1,102,601</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_40_fact" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">1,184,586</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">&#160;Total Accounts payable, accruals, and other current liabilities</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-16726">2,853,317</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-16727">2,670,249</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Amount due to related parties &#8211; related corporations, non-current***</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" id="ix_45_fact" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" scale="0" unitRef="usd">139,772</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in; text-align: right"/><td style="width: 0.25in">*</td><td style="text-align: justify"><ix:footnote id="ix_5_footnote" xml:lang="en-US">The amount due to the Company&#8217;s major stockholders as of June 30, 2025 and 2024 is
non-trade, unsecured, interest-free and repayable on demand.</ix:footnote></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in; text-align: right"/><td style="width: 0.25in">**</td><td style="text-align: justify"><ix:footnote id="ix_6_footnote" xml:lang="en-US">The amount due to related corporations, which the Company&#8217;s major stockholders have
controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and repayable on demand.</ix:footnote></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 0pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td> <td style="padding-bottom: 0pt; text-align: justify; font-size: 10pt"><ix:footnote id="ix_7_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount due to related corporations, which the Company&#8217;s major stockholders have controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and the remaining loan term are over <ix:nonNumeric contextRef="c1" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="ixv-16731">one year</ix:nonNumeric>. The Company believes the carrying value approximates fair value.</span></ix:footnote></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in; text-align: right"/><td style="width: 0.25in">#</td><td style="text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US">The amount consists of payables owed to third party creditors, which are unsecured, interest-free
and repayable on demand, and other payables due to operational use.</ix:footnote></td>
</tr></table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" id="ixv-14148"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8.
OTHER EXPENSE, NET</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherNonoperatingExpenseByComponentTextBlock" id="ixv-14152"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expense), net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="advb:OtherNonoperatingIncomeExpenseGross" scale="0" sign="-" unitRef="usd" id="ixv-16733">29,040</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="advb:OtherNonoperatingIncomeExpenseGross" scale="0" unitRef="usd" id="ixv-16734">486</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Foreign exchange loss, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossAfterTax" scale="0" sign="-" unitRef="usd" id="ixv-16735">233,808</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossAfterTax" scale="0" sign="-" unitRef="usd" id="ixv-16736">294,687</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Other expense, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-16737">262,848</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-16738">294,201</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-14209"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>9. EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the sake of undertaking a public offering
of the Company&#8217;s common stock, the Company has performed a series of re-organizing transactions resulting in <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-16739"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-16740">20,000,000</ix:nonFraction></ix:nonFraction> of common
stock and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-16741">20,000,000</ix:nonFraction> of common stock outstanding as of December 31, 2024 and June 30, 2024 giving the retroactive effects to the <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-16742">4</ix:nonFraction> for
<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-16743">1</ix:nonFraction> share split effected on May 16, 2023 and <ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-16744">5</ix:nonFraction> for <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-16745">1</ix:nonFraction> reverse share split effected on October 15, 2024. The Company has accounted for these
shares had they been issued and outstanding at the beginning of the first period presented. The Company only has one single class of common
stock that is accounted for as permanent equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2023, the Company effected a forward
share split of all issued and outstanding shares of <ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-16746"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-16747">25,000,000</ix:nonFraction></ix:nonFraction> shares at a ratio of 1-to-4. As a result of the forward split, the Company
now have <ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-16748"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-16749">100,000,000</ix:nonFraction></ix:nonFraction> common stock issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the
above transactions on a retroactive basis similar to share split or dividend pursuant to ASC 260. All references made to share or per
share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect
the <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-16750">4</ix:nonFraction> for <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-16751">1</ix:nonFraction> share split. The shares of common stock retain a par value of $<ix:nonFraction contextRef="c82" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-16752">0.001</ix:nonFraction>&#160;per share. Accordingly, an amount equal to the par
value of the increased shares resulting from the stock split was reclassified from &#8220;Additional paid-in capital&#8221; to &#8220;Common
stock&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 15, 2024, the Company effected the
reverse share split of all issued and outstanding shares of <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-16753"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-16754">100,000,000</ix:nonFraction></ix:nonFraction> shares at a ratio of 5:1. As a result of the reverse share split,
the Company now have <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-16755"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-16756">20,000,000</ix:nonFraction></ix:nonFraction> common stock issued and outstanding as of the date hereof. Unless indicated or the context otherwise requires,
all number of common stock&#160;in this report has been retrospectively adjusted for the reverse share split, as if such reverse share
split occurred on the first day of the years presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2025, the Company completed its initial
public offering. In the initial public offering, the Company issued <ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-16757">1,640,000</ix:nonFraction> shares of common stock at a price of US$<ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-16758">4.00</ix:nonFraction> per share.
The Company received gross proceeds in the amount of US$<ix:nonFraction contextRef="c34" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" unitRef="usd" id="ixv-16759">6.56</ix:nonFraction> million before deducting any underwriting discounts or expenses. The Shares
began trading on the Nasdaq Capital Market on March 6, 2025 under the ticker symbol &#8220;ADVB.&#8221;</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-14225"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is not an operating company but a
holding company incorporated in the State of Nevada and is considered U.S. tax resident under U.S. tax laws; accordingly, it is subject
to U.S. tax laws at a statutory tax rate of <ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-16760">21</ix:nonFraction>%. The Company is subject to the State of Nevada tax laws at a tax rate of&#160;<ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure" id="ixv-16761">0</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s net deferred income tax assets
as of June 30, 2025and 2024 consist of net operating loss carry forwards. The net operating loss carry forwards for U.S. federal tax and
Taiwan, China, Hong Kong tax purposes are available for carry forward indefinitely for use in offsetting taxable income. The U.S. federal
net operating loss carry forward offset is limited to up to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="advb:NetOperatingLossCarryForwardOffset" scale="-2" unitRef="pure" id="ixv-16762">80</ix:nonFraction>% of the taxable income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2025 and 2024, the Company had
total net operating loss carry forwards of approximately $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-16763">13,167,716</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-16764">8,767,393</ix:nonFraction>, respectively, which consists of China net operating
loss carry forwards of $<ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-16765">4,896,250</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-16766">3,817,009</ix:nonFraction>, respectively, Taiwan net operating losses of $<ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-16767">5,824,336</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-16768">4,200,888</ix:nonFraction>, respectively,
Hong Kong net operating loss carry forwards of $<ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-16769">94,686</ix:nonFraction> and $<ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-16770">5,014</ix:nonFraction>, respectively, and US net operating loss carry forwards of $<ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-16771">2,352,444</ix:nonFraction>
and $<ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-16772">744,480</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Taiwan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company&#8217;s operating
subsidiary, Advanced Biomed Inc. (Taiwan) is considered Taiwan tax resident enterprises under Taiwan tax laws; accordingly, it is subject
to enterprise income tax on its taxable income as determined under Taiwan tax laws at a statutory tax rate of <ix:nonFraction contextRef="c129" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-16773">20</ix:nonFraction>%.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>China</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company&#8217;s operating
subsidiary, Shanghai Sglcell Biotech Co., Ltd. is considered PRC resident enterprises under Enterprise Income Tax Law of the PRC; accordingly,
it is subject to enterprise income tax on their taxable income as determined under Enterprise Income Tax Law of the PRC at a statutory
tax rate of <ix:nonFraction contextRef="c130" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-16774">25</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Hong Kong</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Under the current Hong&#160;Kong
Inland Revenue Ordinance, a two-tier&#160;corporate income tax system was implemented in Hong&#160;Kong, which is <ix:nonFraction contextRef="c131" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" unitRef="pure" id="ixv-16775">8.25</ix:nonFraction>% for the first
HK$<ix:nonFraction contextRef="c131" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" unitRef="hkd" id="ixv-16776">2.0</ix:nonFraction>&#160;million taxable income, and <ix:nonFraction contextRef="c131" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure" id="ixv-16777">16.5</ix:nonFraction>% for the subsequent taxable income generated from operations in Hong&#160;Kong. The Company&#8217;s
subsidiary, Advanced Biomed HK Limited is considered Hong Kong tax resident under Hong Kong Tax Law; accordingly, it is subject to corporate
income tax on its taxable income at <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" unitRef="pure" id="ixv-16778">8.25</ix:nonFraction>% with <span style="-sec-ix-hidden: hidden-fact-64">nil</span> and <span style="-sec-ix-hidden: hidden-fact-65">nil</span> for the years ended June 30, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-14271"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The income tax provision consists of the following
component:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">The following table reconciles the operating
profit to the Company&#8217;s effective tax rate:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Loss before tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-16779">3,258,969</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-16780">2,782,278</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Statutory income tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-16781">21</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-16782">21</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax expense calculated at the statutory tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effect of tax losses carry forwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="advb:EffectOfTaxLossesCarryForwards" scale="0" sign="-" unitRef="usd" id="ixv-16783">2,890,755</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="advb:EffectOfTaxLossesCarryForwards" scale="0" sign="-" unitRef="usd" id="ixv-16784">2,019,708</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of subsidiaries foreign income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" unitRef="usd" id="ixv-16785">2,890,755</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" unitRef="usd" id="ixv-16786">2,019,708</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Effective tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">%</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-14416"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The component of deferred tax assets are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating losses carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-16787">2,890,755</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-16788">2,019,708</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-16789">2,890,755</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-16790">2,019,708</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In assessing
the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred
tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income
during the periods in which those temporary differences become deductible. Management considers the cumulative earnings and projected
future taxable income in making this assessment. Recovery of substantially all of the Company&#8217;s deferred tax assets is dependent
upon the generation of future income, exclusive of reversing taxable temporary differences.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the differences between the
federal income tax rate and the effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>State of Nevada</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Tax at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-16791">21</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-16792">21</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c133" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-16793">21</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-16794">21</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Provision for taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Taiwan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Tax at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c135" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-16795">21</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c136" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-16796">21</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Different foreign subsidiary tax rate impact</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c135" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" sign="-" unitRef="pure" id="ixv-16797">1</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c136" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" sign="-" unitRef="pure" id="ixv-16798">1</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c135" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-16799">20</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c136" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-16800">20</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Provision for taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>China</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Tax at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-16801">21</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-16802">21</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Different foreign subsidiary tax rate impact</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure" id="ixv-16803">4</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure" id="ixv-16804">4</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-16805">25</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-16806">25</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Provision for taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Hong Kong</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Tax at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-16807">21</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-16808">21</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Different foreign subsidiary tax rate impact</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c139" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" sign="-" unitRef="pure" id="ixv-16809">12.75</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c140" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" sign="-" unitRef="pure" id="ixv-16810">12.75</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c139" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-16811">8.25</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c140" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-16812">8.25</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Provision for taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">%</td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 137 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-14798"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. STOCK OPTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective from March 30, 2023, the Stock Incentive
Plan (the &#8220;2023 Plan&#8221;) was approved by the Company's Board of Directors. Under the 2023 Plan, the Board of Directors may grant
options or purchase rights to purchase common stock to officers, employees, and other persons who provide services to the Company or any
related company. The participants to whom awards are granted, the type of awards granted, the number of shares covered for each award,
and the purchase or exercise price, conditions and other terms of each award are determined by the Board of Directors, except that the
term of the options shall not exceed <ix:nonNumeric contextRef="c141" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-16813">10</ix:nonNumeric> years. A total of <ix:nonFraction contextRef="c142" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" unitRef="shares" id="ixv-16814">15</ix:nonFraction> million shares of our common stock are subject to the 2023 Plan and maybe
either a qualified or non-qualified stock option. The shares issued for the 2023 Plan may be either treasury or authorized and unissued
shares. As of the date of this report, the Company has granted <span style="-sec-ix-hidden: hidden-fact-66">no</span> stock options to purchase any shares of the common stock under the 2023
Plan.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-14808"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>12. RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-14813"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These related parties of the Company with whom
transactions are reported in these financial statements are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 35%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Related Party</b></span></td> <td style="width: 1%">&#160;</td> <td style="width: 64%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship to Us</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi Lu, Ph.D.</span></td> <td>&#160;</td> <td><ix:nonNumeric contextRef="c180" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-14830"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board and Chief Executive Officer of the Company</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau, Ph.D.</span></td> <td>&#160;</td> <td><ix:nonNumeric contextRef="c181" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-14837"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder of the Company</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven I-Fang Cheng, Ph.D.</span></td> <td>&#160;</td> <td><ix:nonNumeric contextRef="c182" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-14844"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Chief Technology Officer of the Company</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chen-Yi Lee</span></td> <td>&#160;</td> <td><ix:nonNumeric contextRef="c183" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-14851"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chen-Yi Lee is the sole director and the controlling person of Advance On Ventures Limited, which owns 10.92% equity interest in the Company and has sole voting and dispositive power over shares beneficially owned by Advance On Ventures Limited. Chen-Yi Lee is also the Stockholder of the Company</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance On Ventures Limited</span></td> <td>&#160;</td> <td><ix:nonNumeric contextRef="c184" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-14858"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder of the Company</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Fancy Development Ltd</span></td> <td>&#160;</td> <td><ix:nonNumeric contextRef="c185" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-14865"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau is the director and stockholder of the entity</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd.</span></td> <td>&#160;</td> <td><ix:nonNumeric contextRef="c186" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" id="ixv-14872"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau is the legal person and stockholder of the entity</span></ix:nonNumeric></td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of business, during the&#160;fiscal
years ended June&#160;30, 2025 and 2024, the Company was involved in certain transactions, either at cost or current market prices, and
on the normal commercial terms with related parties. <ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_2" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1">The following table provides the transactions with these parties for the&#160;years
as presented (for the portion of such period that they were considered related):</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_3" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Amount due to related parties &#8211; major stockholders</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"><span style="text-decoration:underline">Name of related party</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi Lu, Ph.D. <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" id="ix_46_fact" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">122,626</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" id="ix_47_fact" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">110,268</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chen-Yi Lee <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" id="ix_48_fact" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">5,436</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" id="ix_49_fact" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">3,544</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau, Ph.D. <sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" id="ix_50_fact" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd">44,705</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-16821">172,767</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-16822">113,812</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Amount due to related parties &#8211; related corporations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Name of related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Fancy Development Ltd <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" id="ix_51_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">211,083</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd. <sup>(5)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" id="ix_53_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">704,953</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" id="ix_54_fact" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">674,262</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-16826">916,036</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-16827">674,262</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Non-Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Name of related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Fancy Development Ltd <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" id="ix_52_fact" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" unitRef="usd">69,975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd. <sup>(5)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" id="ix_55_fact" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" unitRef="usd">69,797</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-16830">139,772</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><ix:footnote id="ix_8_footnote" xml:lang="en-US"><span style="font-size: 10pt">Advanced Biomed Inc.(Taiwan) entered into an unsecured, interest-free loan to Yi Lu amounting to NTD <ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="twd" id="ixv-16831">3,578,212</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16832">122,626</ix:nonFraction>) for general working capital in January 2023. As of June 30, 2025 and 2024, the loan balance due to Yi Lu amounted to US$<ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="advb:WorkingCapitalLoan" scale="0" unitRef="usd" id="ixv-16833">122,626</ix:nonFraction> and US$<ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="advb:WorkingCapitalLoan" scale="0" unitRef="usd" id="ixv-16834">110,268</ix:nonFraction>, respectively.</span></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><ix:footnote id="ix_9_footnote" xml:lang="en-US"><span style="font-size: 10pt">Payments of expenses on behalf of Advanced Biomed Inc. (Taiwan).</span></ix:footnote></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><ix:footnote id="ix_10_footnote" xml:lang="en-US"><span style="font-size: 10pt">Advanced Biomed Inc.(HK) entered into one unsecured, interest-free loan to Hung To Pau, Ph.D. amounting to US$<ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16835">200,000</ix:nonFraction> for general working capital in July 2024 and the amount was full settled in 2025. And Shanghai Sglcell Biotech Co., Ltd entered into three unsecured, interest-free loans to Hung To Pau, Ph.D. amounting to RMB<ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16836">122,566</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16837">17,110</ix:nonFraction>), RMB<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16838">121,681</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16839">16,986</ix:nonFraction>) and RMB<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16840">76,000</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16841">10,609</ix:nonFraction>) for general working capital in October 2024, November 2024 and December 2024. As of June 30, 2025, the loan balance due to Hung To Pau, Ph.D. totally amounted to RMB<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="advb:WorkingCapitalLoan" scale="0" unitRef="cny" id="ixv-16842">320,247</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="advb:WorkingCapitalLoan" scale="0" unitRef="usd" id="ixv-16843">44,705</ix:nonFraction>) for general working capital.</span></ix:footnote></td></tr>
</table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_3"><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">4.</span></td> <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:footnote id="ix_11_footnote" xml:lang="en-US">Advanced Biomed Inc.(Taiwan) entered into seven unsecured, interest-free
loans to Well Fancy Development Ltd amounting to NTD <ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="twd" id="ixv-16845">5,740,600</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16846">196,731</ix:nonFraction>), NTD <ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="twd" id="ixv-16847">1,911,944</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16848">65,522</ix:nonFraction>), NTD
<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="twd" id="ixv-16849">1,906,840</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16850">65,347</ix:nonFraction>), NTD <ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="twd" id="ixv-16851">3,121,500</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16852">106,974</ix:nonFraction>), NTD <ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="twd" id="ixv-16853">1,798,060</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16854">61,620</ix:nonFraction>), NTD <ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="twd" id="ixv-16855">1,291,552</ix:nonFraction>
(approximately US$<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16856">44,262</ix:nonFraction>) and NTD <ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="twd" id="ixv-16857">455,992</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16858">15,627</ix:nonFraction>) for general working capital in July 2024, October 2024, November 2024,
December 2024, January 2025, February 2025 and March 2025. In March 2025, Advanced Biomed Inc.(HK) paid US$<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" unitRef="usd" id="ixv-16859">550,000</ix:nonFraction> to Well Fancy Development
Ltd for Advanced Biomed Inc.(Taiwan)&#8217;s debt. And Advanced Biomed Inc. entered into two unsecured, interest-free loan to Well Fancy
Development Ltd amounting to US$<ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="advb:WorkingCapitalLoan" scale="0" unitRef="usd" id="ixv-16860">119,975</ix:nonFraction> and US$<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="advb:WorkingCapitalLoan" scale="0" unitRef="usd" id="ixv-16861">205,000</ix:nonFraction> for general working capital in November 2024 and March 2025. In March 2025, Advanced
Biomed Inc. paid US$<ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-16862">50,000</ix:nonFraction> to Well Fancy Development Ltd for repayment. As of June 30, 2025, the loan balance due to Well Fancy Development
Ltd totally amounted to NTD 177,488(approximately US$<ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="advb:WorkingCapitalLoan" scale="0" unitRef="usd" id="ixv-16863">6,083</ix:nonFraction>) and US$<ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="advb:WorkingCapitalLoan" scale="0" unitRef="twd" id="ixv-16864">274,975</ix:nonFraction> for general working capital.</ix:footnote></p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify; font-size: 10pt"><ix:footnote id="ix_12_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Sglcell Biotech Co., Ltd entered into nine unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. amounting to RMB<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16865"><ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16866">500,000</ix:nonFraction></ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16867"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16868">69,797</ix:nonFraction></ix:nonFraction>) in April 2023, May 2023, June 2023 and September 2023, respectively, and RMB<ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16869">700,000</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16870">97,716</ix:nonFraction>), RMB<ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16871">1,000,000</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16872">139,595</ix:nonFraction>), RMB<ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16873"><ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16874">500,000</ix:nonFraction></ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16875"><ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16876">69,797</ix:nonFraction></ix:nonFraction>), RMB<ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16877">700,000</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16878">97,716</ix:nonFraction>) and RMB<ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16879"><ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16880"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16881"><ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="cny" id="ixv-16882">650,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd" id="ixv-16883">90,738</ix:nonFraction>) in January 2024, March 2024, March 2024, June 2024 and October 2024, respectively, for general working capital. As of June 30, 2025 and 2024 the loan balance due to Shanghai Junfu Electronic Technology Co., Ltd totally amounted to RMB<ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="advb:WorkingCapitalLoan" scale="0" unitRef="cny" id="ixv-16884">5,550,000</ix:nonFraction> (approximately US$<ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="advb:WorkingCapitalLoan" scale="0" unitRef="usd" id="ixv-16885">774,750</ix:nonFraction>) and RMB<ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="advb:WorkingCapitalLoan" scale="0" unitRef="cny" id="ixv-16886">4,900,000</ix:nonFraction> (approximately to US$<ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="advb:WorkingCapitalLoan" scale="0" unitRef="usd" id="ixv-16887">674,262</ix:nonFraction>), respectively.</span></ix:footnote></td></tr> </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-15160"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>13. SEGMENT INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates and manages its business
as a single reportable segment, which is consistent with how the Chief Operating Decision Maker (&#8220;CODM&#8221;), the Chief Executive
Officer, makes operating decisions and allocates resources. The CODM assesses performance and results of operations at the Company level.
The Company&#8217;s operations are centralized and integrated, with financial results reviewed and managed on a consolidated basis. Accordingly,
management has determined that the Company has <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="pure" id="ixv-16888">one</ix:nonFraction> reportable segment under ASC Topic 280, Segment Reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Measure of Segment Profit or Loss</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CODM assesses performance for the segment
and decides how to allocate resources by regularly reviewing the consolidated net income from the statement of operations, after taking
into account the Company&#8217;s strategic priorities, its cash balance, and its expected use of cash. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="ixv-16889">The following table presents the
significant expense categories in the Company&#8217;s single operating segment:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/> year ended <br/> June&#160;30, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/> year ended <br/> June&#160;30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-16890">909,771</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-16891">880,193</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-16892">2,111,265</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-16893">1,661,379</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-16894">237,933</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-16895">240,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net Loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-16896">3,258,969</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-16897">2,782,278</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="ixv-15240"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>14. CONCENTRATIONS AND RISKS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Credit Risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Credit risk is the potential financial loss to
the Company resulting from the failure of a customer or a counterparty to settle its financial and contractual obligations to the Company,
as and when they fall due. As the Company does not hold any collateral, the maximum exposure to credit risk is the carrying amounts of
other receivables (exclude prepayments) and cash and bank deposits presented on the consolidated balance sheets. The Company has no other
financial assets which carry significant exposure to credit risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidity Risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity risk is the risk that the Company will
encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another
financial asset. The Company&#8217;s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient
liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking
damage to the Company&#8217;s reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Typically, the Company ensures that it has sufficient
cash on demand to meet expected operational expenses for a period of <ix:nonNumeric contextRef="c0" format="ixt-sec:durday" name="advb:NumberOfDaysForOperationalExpenses" id="ixv-16898">60</ix:nonNumeric> days, including the servicing of financial obligations; this excludes
the potential impact of extreme circumstances that cannot reasonably be predicted, such as natural disasters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Foreign currency risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency risk is the risk that the fair
value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The company&#8217;s exposure to
the risk of changes in foreign exchange rates relates primarily to the Company&#8217;s operating activities (when expense is denominated
in a foreign currency) and the Company&#8217;s net investments in foreign subsidiaries.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="_ConcentrationRiskDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Impact of Inflation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inflation in Taiwan and PRC has not materially
affected the Company&#8217;s profitability and operating results. However, the Company can provide no assurance that we will be unaffected
by higher inflation rates in Taiwan and PRC or globally in the future.</p></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-15287"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>15. COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Contingencies</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of business, the Company
may be subject to legal proceedings regarding contractual and employment relationships and a variety of other matters. The Company records
contingent liabilities resulting from such claims, when a loss is assessed to be probable, and the amount of the loss is reasonably estimable.
In the opinion of management, there were no pending or threatened claims and litigation as of June 30, 2025 and up through October 8,
2025, the issuance date of these consolidated financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Lease commitment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines if a contract contains
a lease at inception. US GAAP requires that the Company&#8217;s leases be evaluated and classified as operating or finance leases for
financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation
includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods
when the exercise of the renewal option is reasonably certain and failure to exercise such option which results in an economic penalty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right-of-use assets relate to leases of office
premises and a dormitory for employees in the PRC and the laboratory in Taiwan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-15307"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recognized operating lease ROU assets and
lease liabilities as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease ROU asset</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-16899">65,399</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-16900">126,740</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current portion</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-16901">35,811</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-16902">62,211</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-16903">5,879</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-16904">64,529</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-16905">41,690</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-16906">126,740</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-15398"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2025, future minimum lease payments
under the non-cancellable operating leases are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Future payment</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-16907">36,532</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd" id="ixv-16908">5,929</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total future lease payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-16909">42,461</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-16910">771</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Present value of operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-16911">41,690</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease liabilities, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-16912">35,811</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease liabilities, non-current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-16913">5,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes other supplemental information
about the Company&#8217;s operating lease as of June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Weighted average discount rate</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-16914">3.40</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average remaining lease term (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c1" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-16915">1.15</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr> </table></ix:continuation></ix:nonNumeric><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-15498"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>16. SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has assessed all events from June
30, 2025 through October 8, 2025, which is the date that these consolidated financial statements are available to be issued, unless as
disclosed below, there are not any material subsequent events that require disclosure in these consolidated financial statements.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial Statement Schedules</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All schedules are omitted
because they are not applicable, not required, or the information has been otherwise included in the Consolidated Financial Statements
or Notes to Consolidated Financial Statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Index of Exhibits</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby file as part of
this Report the exhibits listed in the attached Exhibit Index. Exhibits that are incorporated herein by reference can be inspected on
the SEC website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Exhibit</b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Description</b></span></td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="7" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Incorporated by Reference</b>&#160;</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 1.5pt; vertical-align: top">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: top">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Form</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>File No.</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 8%"><span style="font-size: 10pt"><b>3</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 49%; text-align: justify"><span style="font-size: 10pt"><b>Certificate of Incorporation and Bylaws</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 8%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 8%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 13%">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex3-1_advanced.htm"><span style="font-size: 10pt">Amended and Restated Memorandum and Articles of the Company</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex3-2_advanced.htm"><span style="font-size: 10pt">Corporate Bylaws</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt"><b>4</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Instruments Defining the Rights of Security Holders, Including Indenture.</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex4-1_advanced.htm">Specimen Stock Certificate evidencing the shares of common stock</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">4.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td>4.2*</td>
    <td>&#160;</td>
    <td><a href="ea025762901ex4-2_advanced.htm">Description of Capital Stock</a></td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt"><b>10</b></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Material Contracts</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex10-1_advanced.htm"><span style="font-size: 10pt">Employment Agreement with the Chief Financial Officer</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex10-2_advanced.htm">2023 Equity Incentive Plan</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex10-3_advanced.htm"><span style="font-size: 10pt">Advisory Agreement between Advanced Biomed Inc. and Lin Chien Huang</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.3</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 8%"><span style="font-size: 10pt">10.4</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 48%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex10-4_advanced.htm">Advisory Agreement between Advanced Biomed Inc. and&#160;Zhou Caicun</a></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 7%; text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 7%; text-align: center"><span style="font-size: 10pt">10.4</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 17%; text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex10-5_advanced.htm">Industry-Academia Cooperation Agreement between National Taiwan University and Advanced Biomed Inc.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex10-6_advanced.htm">Non-Disclosure Agreement between Advanced Biomed Inc. and Unimold Technology Inc.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.6</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.7</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex10-7_advanced.htm">Industrial Cooperation Research Agreement between TSRI and Advanced Biomed Inc.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.7</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex10-8_advanced.htm">Investment Agreement between Advanced Biomed Inc. and Hanyu Assets Co., Ltd.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.8</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex10-9_advanced.htm">Investment Agreement between Advanced Biomed Inc. and Newlink Technology Inc.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.9</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex10-10_advanced.htm">Debt-for-Equity Swap Agreement</a>&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex10-12_advanced.htm">Renewed Industry-Academia Cooperation Agreement between National Taiwan University and Advanced Biomed Inc.</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025052234/ea024395301ex99-1_advanced.htm">ELOC Agreement</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">001-42548</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">June 6, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">14.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex99-1_advanced.htm">Code of Business Conduct and Ethics of the Registrant</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">99.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">19.1*</span></td>
    <td>&#160;</td>
    <td><a href="ea025762901ex19-1_advanced.htm"><span style="font-size: 10pt">Insider Trading Policies and Procedures</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">21.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex21-1_advanced.htm">Subsidiaries of the Registrant</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">21.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">31.1**</span></td>
    <td>&#160;</td>
    <td><a href="ea025762901ex31-1_advanced.htm"><span style="font-size: 10pt">Certificate of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">31.2**</span></td>
    <td>&#160;</td>
    <td><a href="ea025762901ex31-2_advanced.htm"><span style="font-size: 10pt">Certificate of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">32.1**</span></td>
    <td>&#160;</td>
    <td><a href="ea025762901ex32-1_advanced.htm"><span style="font-size: 10pt">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">32.2**</span></td>
    <td>&#160;</td>
    <td><a href="ea025762901ex32-2_advanced.htm"><span style="font-size: 10pt">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">-</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">97.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1941029/000121390025067053/ea024661301ex99-5_advanced.htm">Policy Relating to Recovery of Erroneously Awarded Compensation</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">333-288907</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">99.5</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">July 23, 2025</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; ">
    <td style="width: 8%"><span style="font-size: 10pt">101.INS</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 91%"><span style="font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (Embedded as Inline XBRL document and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Filed herewith</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Furnished herewith</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16. Form 10-K Summary.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 141; Options: NewSection; Value: 113 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="poa_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by
the undersigned, thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">October 8, 2025</span></td>
    <td colspan="2" style="text-align: justify"><span style="font-size: 10pt"><b>Advanced Biomed Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%; text-align: justify"><span style="font-size: 10pt">By:</span></td>
    <td style="white-space: nowrap; width: 36%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Yi Lu</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">Yi Lu</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in
the capacities and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 35%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 45%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Yi Lu</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Executive Officer and Chairman of the Board</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">October 8, 2025</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Yi Lu</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Mingze Yin</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">October 8, 2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Mingze Yin</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Steven I-Fang Cheng</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Technology Officer and Director</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">October 8, 2025</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Steven I-Fang Cheng</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Jing Zhang</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">October 8, 2025</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Jing Zhang</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">/s/ Cheang I Kei</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">October 8, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Cheang I Kei</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-size: 10pt">/s/ Mingyue Cai</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">October 8, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Mingyue Cai</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 142; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c1" id="hidden-fact-0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-1" name="us-gaap:DeferredCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:OtherAssetsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-3" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-4" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-7" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-8" name="advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-9" name="advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-10" name="advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-11" name="advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-12" name="advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-13" name="advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-14" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-15" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-16" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-17" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-18" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-19" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-20" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-21" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-22" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-25" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-26" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-27" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-28" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-29" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-30" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-31" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-32" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-33" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-34" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-35" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c67" id="hidden-fact-36" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-37" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-38" name="advb:DeferredInitialPublicOfferingCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-39" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c90" id="hidden-fact-40" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-41" name="us-gaap:DepositsAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-42" name="us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-43" name="us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-44" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-45" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-46" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-47" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-48" name="advb:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-49" name="advb:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-50" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-51" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-52" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-53" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c133" id="hidden-fact-54" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c134" id="hidden-fact-55" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c135" id="hidden-fact-56" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c136" id="hidden-fact-57" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c137" id="hidden-fact-58" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c138" id="hidden-fact-59" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c139" id="hidden-fact-60" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-61" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-62" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-63" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c131" id="hidden-fact-64" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c132" id="hidden-fact-65" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c143" id="hidden-fact-66" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c189" id="hidden-fact-67" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c193" id="hidden-fact-68" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c193" id="hidden-fact-69" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c195" id="hidden-fact-70" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-71" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-72" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-73" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-74" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-16993">0001941029</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-16994">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-16995">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-16996">00000</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="advb-20250630.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_4_fact ix_5_fact ix_6_fact ix_7_fact ix_8_fact ix_9_fact ix_10_fact ix_11_fact ix_12_fact ix_13_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_14_fact ix_15_fact ix_16_fact ix_17_fact ix_18_fact ix_19_fact ix_20_fact ix_21_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_22_fact ix_23_fact ix_24_fact hidden-fact-8 ix_25_fact hidden-fact-11 ix_26_fact hidden-fact-14 hidden-fact-15 hidden-fact-17 hidden-fact-18 ix_27_fact ix_28_fact ix_29_fact ix_30_fact ix_31_fact ix_32_fact hidden-fact-20 hidden-fact-21 ix_33_fact ix_34_fact ix_35_fact hidden-fact-25 hidden-fact-26 ix_36_fact ix_37_fact ix_38_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_39_fact ix_40_fact" toRefs="ix_4_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_41_fact ix_42_fact" toRefs="ix_5_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_43_fact ix_44_fact" toRefs="ix_6_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_45_fact hidden-fact-45" toRefs="ix_7_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_46_fact ix_47_fact" toRefs="ix_8_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_48_fact ix_49_fact" toRefs="ix_9_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_50_fact hidden-fact-67" toRefs="ix_10_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_51_fact hidden-fact-68 ix_52_fact hidden-fact-69" toRefs="ix_11_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_53_fact ix_54_fact ix_55_fact hidden-fact-70" toRefs="ix_12_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-10-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-01</xbrli:startDate>
    <xbrli:endDate>2025-03-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-07</xbrli:startDate>
    <xbrli:endDate>2025-03-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:BeijingYitanJiaruiTechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-08</xbrli:startDate>
    <xbrli:endDate>2023-06-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:BeijingYitanJiaruiTechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-31</xbrli:startDate>
    <xbrli:endDate>2023-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-09</xbrli:startDate>
    <xbrli:endDate>2023-06-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:ShandongSglcellMedicalDevicesCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-31</xbrli:startDate>
    <xbrli:endDate>2023-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-15</xbrli:startDate>
    <xbrli:endDate>2023-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrHungToPauMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-16</xbrli:startDate>
    <xbrli:endDate>2021-07-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:SglcellLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-15</xbrli:startDate>
    <xbrli:endDate>2022-03-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrHungToPauMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-15</xbrli:startDate>
    <xbrli:endDate>2022-03-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:SglcellLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-08</xbrli:startDate>
    <xbrli:endDate>2022-06-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrYiLuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-08</xbrli:startDate>
    <xbrli:endDate>2022-06-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrYiLuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:ChenYiLeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:AdvancedBiomedHKLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:DrYiLuMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">advb:ShareExchangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrYiLuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:ChenYiLeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-08-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:ChenYiLeeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-24</xbrli:startDate>
    <xbrli:endDate>2022-10-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:AdvanceOnVenturesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-24</xbrli:startDate>
    <xbrli:endDate>2022-10-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrHungToPauMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-24</xbrli:startDate>
    <xbrli:endDate>2022-10-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:YiminJinMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-24</xbrli:startDate>
    <xbrli:endDate>2022-10-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:XiaoyuanLuoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-24</xbrli:startDate>
    <xbrli:endDate>2022-10-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:NanzhenShenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-24</xbrli:startDate>
    <xbrli:endDate>2022-10-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:JianWangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-24</xbrli:startDate>
    <xbrli:endDate>2022-10-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:QiangChenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-24</xbrli:startDate>
    <xbrli:endDate>2022-10-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-30</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:HanyuAssetsCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-25</xbrli:startDate>
    <xbrli:endDate>2022-10-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:NewlinkTechnologyIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-06-06</xbrli:startDate>
    <xbrli:endDate>2022-06-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrYiLuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-10-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedHKLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedHKLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-06-06</xbrli:startDate>
    <xbrli:endDate>2025-06-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-16</xbrli:startDate>
    <xbrli:endDate>2023-05-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-16</xbrli:startDate>
    <xbrli:endDate>2023-05-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-16</xbrli:startDate>
    <xbrli:endDate>2023-05-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-15</xbrli:startDate>
    <xbrli:endDate>2024-10-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:TWD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:FiscalYearEndCurrencyRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:TWD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:FiscalYearEndCurrencyRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:TWD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:CurrencyExchangeAverageRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:TWD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:CurrencyExchangeAverageRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:FiscalYearEndCurrencyRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
<!-- [WMV6][yqOmLo9aTBoZIIVChHkeDEmTVjNoOSx0oVkvUQ+KqekeOxM6rtgNiFwpj8VUrG5RkppZBBdnJ3rGDmKl6JFeZ39LQXiecvm2eyrNEk/F5oBVxXcGcTlfT0VfVdROgQgEmdwfhpwR/kM9J/bK3tmc+ubjX5T1vE6bCSef4PRkt+eLMYsSzWxZfJFvKXin8iUPKkinDlenJe17qG2GVPi2uF3rTfw6Frag41TXI/olEIJAln/+6uJ4Ee46IB7UjgK57TfqAG/gej8cMKsa2SxEWn24BClYXe2EOu8tVPi1aklBN0RmRoUdHO/2SwSFSh2m9BxUjzMZC4Aoyz/tWZ5mMY1C5gUltHnuSwE=] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:FiscalYearEndCurrencyRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:CurrencyExchangeAverageRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:CurrencyExchangeAverageRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:FiscalYearEndCurrencyRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:FiscalYearEndCurrencyRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:CurrencyExchangeAverageRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:CurrencyExchangeAverageRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">advb:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">advb:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-15</xbrli:startDate>
    <xbrli:endDate>2024-10-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-15</xbrli:startDate>
    <xbrli:endDate>2024-10-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NV</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:TW</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:TW</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:TW</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NV</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NV</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TW</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TW</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advb:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advb:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advb:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:YiLuPhDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:YiLuPhDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:YiLuPhDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiJunfuElectronicTechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiJunfuElectronicTechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiJunfuElectronicTechnologyCoLtdMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:YiLuPhDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:StevenIFangChengPhDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ChenYiLeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:AdvanceOnVenturesLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ShanghaiJunfuElectronicTechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ChenYiLeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ChenYiLeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ShanghaiJunfuElectronicTechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ShanghaiJunfuElectronicTechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:RelatedCorporationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001941029</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:RelatedCorporationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="cny">
  <xbrli:measure>iso4217:CNY</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="twd">
  <xbrli:measure>iso4217:TWD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="hkd">
  <xbrli:measure>iso4217:HKD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ea025762901ex4-2_advanced.htm
<DESCRIPTION>DESCRIPTION OF CAPITAL STOCK
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
of the capital stock of Advanced Biomed Inc. (the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo;) and
certain provisions of our certificate of incorporation and bylaws, as amended from time to time, is a summary and is qualified in its
entirety by reference to the full text of our certificate of incorporation and bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advanced Biomed Inc. is authorized
to issue 400,000,000 shares of common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each share of our Common Stock
is entitled to one vote on all matters submitted to a vote of the stockholders, including the election of directors. Except as otherwise
required by law, the holders of Common Stock will possess all voting power. Generally, all matters to be voted on by stockholders must
be approved by a majority of the votes entitled to be cast by all shares of Common Stock that are present in person or represented by
proxy. Holders of Common Stock representing a majority of our capital stock issued, outstanding and entitled to vote, represented in person
or by proxy, are necessary to constitute a quorum at any meeting of our stockholders. Our Articles of Incorporation do not provide for
cumulative voting in the election of directors. Holders of Common Stock have no pre-emptive rights, no conversion rights and there are
no redemption provisions applicable to our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Non-cumulative Voting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of shares of our Common
Stock do not have cumulative voting rights; meaning that the holders of 50.1% of the outstanding shares, voting for the election of directors,
can elect all of the directors to be elected, and, in such event, the holders of the remaining shares will not be able to elect any of
our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our Common Stock
are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends
and then only at the times and in the amounts that our board of directors may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exchange Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock is listed
on the Nasdaq Capital Market under the trading symbol &ldquo;ADVB.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our Common Stock is Transhare Corporation, with an address at Bayside Center 1, 17755 North US Highway 19, Suite 140, Clearwater,
FL 33764, telephone number is (303) 662-1112.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnification of Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our Articles of
Incorporation as amended, and Bylaws, we may indemnify an officer or director who is made a party to any proceeding, including a lawsuit,
because of his position, if he acted in good faith and in a manner he reasonably believed to be in or not opposed to our best interest,
provided, however, that (i) we will not indemnify such person against expenses incurred in connection with an action if he is threatened
but does not become a party unless the incurring of such expenses was authorized by the board of directors and (ii) we will not indemnify
against any amount paid in settlement unless our board of directors has consented to such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An officer or director is
not entitled to indemnification against costs or expenses incurred in connection with any action, commenced by such person against us
or any person who is or was a director, officer, fiduciary, employee or agent of our company unless and to the extent that the officer
or directors is successful on the merits in any such proceeding as to which such person is to be indemnified, we must indemnify him against
all expenses incurred, including attorney&rsquo;s fees. With respect to a derivative action, indemnity may be made only for expenses actually
and reasonably incurred in defending the proceeding, and if the officer or directors is judged liable, only by a court order. The indemnification
is intended to be to the fullest extent permitted by the laws of the State of Nevada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted for directors, executive officers, or persons controlling us, we have
been informed that, in the opinion of the U.S. Securities and Exchange Commission, such indemnification is against public policy as expressed
in the Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>ea025762901ex19-1_advanced.htm
<DESCRIPTION>INSIDER TRADING POLICIES AND PROCEDURES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 19.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Advanced Biomed Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Insider Trading Compliance Policy</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>I. Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preventing insider trading
is necessary to comply with securities laws and to preserve the reputation and integrity of Advanced Biomed Inc. (collectively with all
of its subsidiaries, &ldquo;<B><I>ADVB</I></B>&rdquo;) as well as that of all persons affiliated with ADVB. &ldquo;Insider trading&rdquo;
occurs when any person purchases or sells a security while in possession of inside information relating to the security. As explained
in Section III below, &ldquo;inside information&rdquo; is information that is both &ldquo;material&rdquo; and &ldquo;non-public.&rdquo;
Insider trading is a crime. The penalties for violating insider trading laws include imprisonment, disgorgement of profits, civil fines,
and significant criminal fines. Insider trading is also prohibited by this Policy, and violation of this Policy may result in ADVB-imposed
sanctions, including termination of employment for cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy applies to all
officers, directors and employees of ADVB. Individuals subject to this Policy are responsible for ensuring that members of their households
also comply with this Policy. This Policy also applies to any entities controlled by individuals subject to the Policy, including any
corporations, limited liability companies, partnerships or trusts (such entities, together with all officers, directors and employees
of ADVB, are referred to as the &ldquo;<B><I>Covered Persons</I></B>&rdquo;), and transactions by these entities should be treated for
the purposes of this Policy and applicable securities laws as if they were for the individual&rsquo;s own account. This Policy extends
to all activities within and outside an individual&rsquo;s duties at ADVB. Every officer, director and employee must review this Policy.
Questions regarding the Policy should be directed to ADVB&rsquo;s compliance team at trading@advbiomedicine.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>II. Statement of Policies Prohibiting Insider Trading </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No officer, director or
employee shall purchase or sell any type of security while in possession of material, non-public information relating to the
security or its issuer, whether the issuer of such security is ADVB or any other company. For example, if a director, officer or
employee learns material non-public information about ADVB, or another company with which ADVB does business, including a business
partner, supplier, or collaborator, that person may not trade in ADVB&rsquo;s or such other company&rsquo;s securities,
respectively, until the information becomes public or is no longer material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These prohibitions do not apply to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">purchases of ADVB&rsquo;s securities by a Covered Person from ADVB (such as through ADVB&rsquo;s employee
stock purchase plan) or sales of ADVB&rsquo;s securities by a Covered Person to ADVB (such as if ADVB were to ever redeem or repurchase
its shares);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">exercises of stock options or other equity awards or the surrender of shares to ADVB in payment of the
exercise price or in satisfaction of any tax withholding obligations in a manner permitted by the applicable equity award agreement, or
vesting of equity-based awards, that in each case do not involve a market sale of ADVB&rsquo;s securities (the &ldquo;cashless exercise&rdquo;
of a ADVB stock option through a broker <U>does</U> involve a market sale of ADVB&rsquo;s securities, and therefore would not qualify
under this exception);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">sales to cover tax withholding obligations upon the vesting of restricted stock or restricted stock units,
where such sales are mandated by ADVB pursuant to a program implemented with ADVB&rsquo;s broker or stock plan administrator;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">transactions in widely-held mutual funds or exchange-traded funds (&ldquo;ETFs&rdquo;) that are invested
in ADVB&rsquo;s securities (however, this Policy does apply to transactions in widely-held mutual funds or ETFs if more than 10% of such
fund&rsquo;s portfolio consists of ADVB&rsquo;s securities);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">bona fide gifts of ADVB&rsquo;s securities, unless the person making the gift has reason to believe that
the recipient intends to sell the securities while the donor is in possession of material, non-public information about ADVB; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">purchases or sales of ADVB&rsquo;s securities made pursuant to any binding contract, specific instruction
or written plan entered into outside of a black-out period and while the purchaser or seller, as applicable, was unaware of any material,
non-public information and which contract, instruction or plan (i) meets all of the requirements of the affirmative defense provided by
Rule 10b5-1 (&ldquo;Rule 10b5-1&rdquo;) promulgated under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
(ii) was pre-cleared in advance pursuant to this Policy and (iii) has not been amended or modified in any respect after such initial pre-clearance
without such amendment or modification being pre-cleared in advance pursuant to this Policy. For more information about Rule 10b5-1 trading
plans, see Section VI below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, no officer, director
or employee shall directly or indirectly communicate (or &ldquo;<B><I>tip</I></B>&rdquo;) material, non-public information to anyone outside
of ADVB (except in accordance with ADVB&rsquo;s policies regarding the protection or authorized external disclosure of ADVB information)
or to anyone within ADVB other than on a need-to-know basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>III. Explanation of Insider Trading </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&ldquo;<B>Insider trading</B>&rdquo;</I>
refers to the purchase or sale of a security while in possession of &ldquo;material,&rdquo; &ldquo;non-public&rdquo; information relating
to the security or its issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&ldquo;<B>Securities</B>&rdquo;</I>
includes stocks, bonds, notes, debentures, options, warrants and other convertible securities, as well as derivative instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&ldquo;<B>Purchase</B>&rdquo;</I>
and <I>&ldquo;<B>sale</B>&rdquo;</I> are defined broadly under the federal securities law. <I>&ldquo;Purchase&rdquo;</I> includes not
only the actual purchase of a security, but any contract to purchase or otherwise acquire a security. <I>&ldquo;Sale&rdquo;</I> includes
not only the actual sale of a security, but any contract to sell or otherwise dispose of a security. These definitions extend to a broad
range of transactions, including conventional cash-for-stock transactions, conversions, the exercise of stock options, and acquisitions
and exercises of warrants or puts, calls or other derivative securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is generally understood
that insider trading includes the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">trading by insiders while in possession of material, non-public information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">trading by persons other than insiders while in possession of material, non-public information, if the
information either was given in breach of an insider&rsquo;s fiduciary duty to keep it confidential or was misappropriated; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">communicating or tipping material, non-public information to others, including recommending the purchase
or sale of a security while in possession of such information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">A. <U>What Facts are Material?</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The materiality of a fact
depends upon the circumstances. A fact is considered &ldquo;material&rdquo; if there is a substantial likelihood that a reasonable investor
would consider it important in making a decision to buy, sell or hold a security, or if the fact is likely to have a significant effect
on the market price of the security. Material information can be positive or negative and can relate to virtually any aspect of a company&rsquo;s
business or to any type of security, debt or equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Examples of material information
include (but are not limited to) information about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">corporate earnings or earnings forecasts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">possible mergers, acquisitions, tender offers or dispositions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">major new products or product developments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">important business developments, such as developments regarding strategic collaborations or developments
with major customers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">developments regarding ADVB&rsquo;s intellectual property portfolio;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">management or control changes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">significant financing developments including pending public sales or offerings of debt or equity securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">defaults on borrowings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">bankruptcies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">significant data breaches or other cybersecurity risks or incidents or vulnerabilities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">significant litigation or regulatory actions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, material information
does not have to be related to a company&rsquo;s business. For example, the contents of a forthcoming newspaper column that is expected
to affect the market price of a security can be material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A good general rule of thumb: <B>When in doubt,
do not trade.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">B. <U>What is Non-Public?</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information is &ldquo;non-public&rdquo;
if it is not available to the general public. In order for information to be considered public, it must be widely disseminated in a manner
making it generally available to investors through such media as <U>Dow Jones</U>, <U>Business Wire</U>, <U>Reuters</U>, <U>The Wall Street
Journal</U>, <U>Associated Press</U>, or <U>United Press International</U>, a broadcast on widely available radio or television programs,
publication in a widely available newspaper, magazine or news web site, a Regulation FD-compliant conference call, or public disclosure
documents filed with the United States Securities and Exchange Commission (&ldquo;<B><I>SEC</I></B>&rdquo;) that are available on the
SEC&rsquo;s website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The circulation of rumors,
even if accurate and reported in the media, does not constitute effective public dissemination. In addition, even after a public announcement,
a reasonable period of time must lapse in order for the market to react to the information. Generally, one should allow two full trading
days following publication as a reasonable waiting period before such information is deemed to be public. For the purposes of this Policy,
a &ldquo;trading day&rdquo; is a day on which national stock exchanges are open for trading. If, for example, ADVB were to make an announcement
on a Monday prior to 9:30 a.m. Eastern Time, the information would be deemed public after the close of trading on Tuesday. If an announcement
were made on a Monday after 9:30 a.m. Eastern Time, the information would be deemed public after the close of trading on Wednesday. If
you have any question as to whether information is publicly available, please err on the side of caution and direct an inquiry to ADVB&rsquo;s
compliance team at trading@advbiomedicine.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">C. <U>Who is an Insider?</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Insiders&rdquo; include
officers, directors and employees of a company and anyone else who has material non-public information about a company. Insiders have
independent fiduciary duties to their company and its stockholders not to trade on material, non-public information relating to the company&rsquo;s
securities. All officers, directors and employees of ADVB should consider themselves insiders with respect to material, non-public information
about ADVB&rsquo;s business, activities and securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individuals subject to this
Policy are responsible for ensuring that members of their households also comply with this Policy. This Policy also applies to any entities
controlled by individuals subject to the Policy, including any corporations, partnerships or trusts, and transactions by these entities
should be treated for the purposes of this Policy and applicable securities laws as if they were for the individual&rsquo;s own account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">D. <U>Trading by Persons Other than
Insiders</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insiders may be liable for
communicating or tipping material, non-public information to a third party (&ldquo;<B><I>tippee</I></B>&rdquo;), and insider trading violations
are not limited to trading or tipping by insiders. Persons other than insiders also can be liable for insider trading, including tippees
who trade on material, non-public information tipped to them or individuals who trade on material, non-public information that has been
misappropriated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tippees inherit an insider&rsquo;s
duties and are liable for trading on material, non-public information illegally tipped to them by an insider. Similarly, just as insiders
are liable for the insider trading of their tippees, so are tippees who pass the information along to others who trade. In other words,
a tippee&rsquo;s liability for insider trading is no different from that of an insider. Tippees can obtain material, non-public information
by receiving overt tips from others or through, among other things, conversations at social, business, or other gatherings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">E. <U>Penalties for Engaging in Insider
Trading</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Penalties for trading on or
tipping material, non-public information can extend significantly beyond any profits made or losses avoided, both for individuals engaging
in such unlawful conduct and their employers. The SEC and Department of Justice have made the civil and criminal prosecution of insider
trading violations a top priority. Enforcement remedies available to the government or private plaintiffs under the federal securities
laws include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">SEC administrative sanctions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">securities industry self-regulatory organization sanctions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">civil injunctions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">damage awards to private plaintiffs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">disgorgement of all profits;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">civil fines for the violator of up to three times the amount of profit gained or loss avoided;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">civil fines for the employer or other controlling person of a violator (i.e., where the violator is an
employee or other controlled person) of up to the greater of $2,636,135 (subject to adjustment for inflation) or three times the amount
of profit gained or loss avoided by the violator;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">criminal fines for individual violators of up to $5,000,000 ($25,000,000 for an entity); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">jail sentences of up to 20 years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, insider trading
could result in serious sanctions by ADVB, including dismissal. Insider trading violations are not limited to violations of the federal
securities laws. Other federal and state civil or criminal laws, such as the laws prohibiting mail and wire fraud and the Racketeer Influenced
and Corrupt Organizations Act (RICO), also may be violated in connection with insider trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">F. <U>Size of Transaction and Reason
for Transaction Do Not Matter</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The size of the transaction
or the amount of profit received does not have to be significant to result in prosecution. The SEC has the ability to monitor even the
smallest trades, and the SEC performs routine market surveillance. Brokers and dealers are required by law to inform the SEC of any possible
violations by people who may have material, non-public information. The SEC aggressively investigates even small insider trading violations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">G. <U>Examples of Insider Trading</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Examples of insider trading
cases include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">actions brought against officers, directors, and employees who traded in a company&rsquo;s securities
after learning of significant confidential developments of that company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">friends, business associates, family members and other tippees of such officers, directors, and employees
who traded in the securities after receiving such information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">government employees who learned of such information in the course of their employment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">other persons who misappropriated, and took advantage of, confidential information from their employers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">H. <U>Prohibition of Records Falsification
and False Statements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 13(b)(2) of the Exchange
Act requires companies subject to the Exchange Act to maintain proper internal books and records and to devise and maintain an adequate
system of internal accounting controls. The SEC has supplemented the statutory requirements by adopting rules that prohibit (1) any person
from falsifying records or accounts subject to the above requirements and (2) officers or directors from making any materially false,
misleading, or incomplete statement to any accountant in connection with any audit or filing with the SEC. These provisions reflect the
SEC&rsquo;s intent to discourage officers, directors and other persons with access to ADVB&rsquo;s books and records from taking action
that might result in the communication of materially misleading financial information to the investing public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IV. Statement of Procedures Preventing Insider Trading </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following procedures have
been established, and will be maintained and enforced, by ADVB to prevent insider trading. Every officer, director and employee of ADVB
is required to follow these procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">A. <U>Pre-Clearance of All Trades
by All Officers, Directors and Certain Employees</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To provide assistance in preventing
inadvertent violations of applicable securities laws and to avoid the appearance of impropriety in connection with the purchase and sale
of ADVB&rsquo;s securities, all transactions in ADVB&rsquo;s securities by officers, directors and such other employees as are designated
in Schedule I, as may be amended from time to time by the Board of Directors, the Chief Executive Officer or the Chief Financial Officer
as being subject to this pre-clearance process (each, a &ldquo;<I>Pre-Clearance Person</I>&rdquo;) must be pre-cleared by ADVB&rsquo;s
Chief Executive Officer or the Chief Executive Officer&rsquo;s designee. The transactions that must be pre-cleared under this Policy include,
without limitation, acquisitions and dispositions of ADVB stock, gifts, the cashless exercise of stock options and the sale of ADVB stock
issued upon exercise of stock options (except that, for individuals subject to Section 16 of the Exchange Act, any exercise of stock options
must be pre-cleared, even a cash exercise). Pre-clearance does not relieve anyone of his or her responsibility under SEC rules. For the
avoidance of doubt, any designation by the Board of Directors of the employees who are subject to pre-clearance may be updated from time
to time by the Chief Executive Officer or the Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A request for pre-clearance
must be in writing (including without limitation by e-mail or submission on the online Pre-Clearance Requests dashboard), should be made
at least two (2) business days in advance of the proposed transaction in the form of pre-clearance request attached hereto as <U>Attachment
A</U> or as otherwise approved by the Chief Executive Officer the Chief Executive Officer&rsquo;s designee and should include the identity
of the Pre-Clearance Person, the type of proposed transaction (for example, an open market purchase, a privately negotiated sale, a gift,
an option exercise, etc.), the proposed date of the transaction and the number of shares, options or other securities to be involved.
In addition, unless otherwise determined by the Chief Executive Officer or the Chief Executive Officer&rsquo;s designee, the Pre-Clearance
Person must execute a certification (in the form attached hereto as <U>Attachment A</U> or as otherwise approved by the Chief Executive
Officer or the Chief Executive Officer&rsquo;s designee) that they are not aware of material, non-public information about ADVB. The Chief
Executive Officer or C the Chief Executive Officer&rsquo;s designee shall have discretion to decide whether to clear any contemplated
transaction, provided that the Chief Financial Officer shall have sole discretion to decide whether to clear transactions by the Chief
Executive Officer or persons or entities subject to this policy as a result of their relationship with the Chief Executive Officer. All
trades that are pre-cleared must be effected within five business days of receipt of the pre-clearance unless a specific exception has
been granted by the Chief Executive Officer (or the Chief Financial Officer, in the case of the Chief Executive Officer or persons or
entities subject to this policy as a result of their relationship with the Chief Legal Officer). A pre-cleared trade (or any portion of
a pre-cleared trade) that has not been effected during the five business day period must be pre-cleared again prior to execution. Notwithstanding
receipt of pre-clearance, if the Pre-Clearance Person becomes aware of material, non-public information or becomes subject to a black-out
period before the transaction is effected, the transaction may not be completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">B. <U>Black-Out Periods</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>No officer, director or
other employee shall purchase or sell any security of ADVB during the period beginning at 1:00 p.m. Eastern Time, on the 15th calendar
day of the last month of any fiscal quarter of ADVB and ending upon the completion of the second full trading day after the public release
of earnings data for such fiscal quarter or during any other trading suspension period declared by ADVB,</B> except for purchases and
sales made pursuant to the permitted transactions described in Section II. For example, if ADVB&rsquo;s fourth fiscal quarter ends on
June 30, the corresponding blackout period would begin at 1:00 p.m. Eastern Time, on June 15. For the avoidance of doubt, any designation
by the Board of Directors of the employees who are subject to quarterly blackout periods may be updated from time to time by the Chief
Executive Officer or Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Exceptions to the blackout
period policy may be approved only by ADVB&rsquo;s Chief Executive Officer (or, in the case of an exception for the Chief Executive Officer
or persons or entities subject to this policy as a result of their relationship with the Chief Executive Officer, the Chief Financial
Officer or, in the case of exceptions for directors or persons or entities subject to this policy as a result of their relationship with
a director, the Board of Directors).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, ADVB, through
the Board of Directors, ADVB&rsquo;s disclosure committee, the Chief Executive Officer or the Chief Financial Officer, may recommend that
officers, directors, employees or others suspend trading in ADVB&rsquo;s securities because of developments that have not yet been disclosed
to the public. Subject to the exceptions noted above, all of those affected should not trade in ADVB&rsquo;s securities while the suspension
is in effect, and should not disclose to others that ADVB has suspended trading. Any trading suspension will remain effective until revoked
by the Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">C. <U>Post-Termination Transactions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an individual is in possession
of material, non-public information when his or her service terminates, that individual may not trade in ADVB&rsquo;s securities until
that information has become public or is no longer material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">D. <U>Information Relating to ADVB</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">1. <I>Access to Information</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Access to material, non-public
information about ADVB, including ADVB&rsquo;s business, earnings or prospects, should be limited to officers, directors and employees
of ADVB on a need-to-know basis. In addition, such information should not be communicated to anyone outside ADVB under any circumstances
(except in accordance with ADVB&rsquo;s policies regarding the protection or authorized external disclosure of ADVB information) or to
anyone within ADVB on an other than need-to-know basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In communicating material,
non-public information to employees of ADVB, all officers, directors and employees must take care to emphasize the need for confidential
treatment of such information and adherence to ADVB&rsquo;s policies with regard to confidential information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. <I>Inquiries From Third Parties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inquiries from third parties,
such as industry analysts or members of the media, about ADVB should be directed to the investor relations team at invest@advbiomedicine.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">E. <U>Limitations on Access to Company
Information</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following procedures are
designed to maintain confidentiality with respect to ADVB&rsquo;s business operations and activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All officers, directors and
employees should take all steps and precautions necessary to restrict access to, and secure, material, non-public information by, among
other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">maintaining the confidentiality of ADVB-related transactions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">conducting their business and social activities so as not to risk inadvertent disclosure of confidential
information. Review of confidential documents in public places should be conducted so as to prevent access by unauthorized persons;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">restricting access to documents and files (including computer files) containing material, non-public information
to individuals on a need-to-know basis (including maintaining control over the distribution of documents and drafts of documents);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">promptly removing and cleaning up all confidential documents and other materials from conference rooms
following the conclusion of any meetings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">disposing of all confidential documents and other papers, after there is no longer any business or other
legally required need, through shredders when appropriate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">restricting access to areas likely to contain confidential documents or material, non-public information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">safeguarding laptop computers, mobile devices, tablets, memory sticks, CDs and other items that contain
confidential information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">avoiding the discussion of material, non-public information in places where the information could be overheard
by others such as in elevators, restrooms, hallways, restaurants, airplanes or taxicabs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Personnel involved with material,
non-public information, to the extent feasible, should conduct their business and activities in areas separate from other ADVB activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>V. Additional Prohibited Transactions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADVB has determined that there
is a heightened legal risk and/or the appearance of improper or inappropriate conduct if the persons subject to this Policy engage in
certain types of transactions. Therefore, unless otherwise approved by the Board of Directors, officers, directors and employees shall
comply with the following policies with respect to certain transactions in ADVB securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">A. <U>Short Sales</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Short sales of ADVB&rsquo;s
securities evidence an expectation on the part of the seller that the securities will decline in value, and therefore signal to the market
that the seller has no confidence in ADVB or its short-term prospects. In addition, short sales may reduce the seller&rsquo;s incentive
to improve ADVB&rsquo;s performance. For these reasons, short sales of ADVB&rsquo;s securities are prohibited by this Policy. In addition,
Section 16(c) of the Exchange Act absolutely prohibits Section 16 reporting persons (i.e., directors, certain officers and ADVB&rsquo;s
10% stockholders) from making short sales of ADVB&rsquo;s equity securities, <I>i.e.</I>, sales of shares that the insider does not own
at the time of sale, or sales of shares against which the insider does not deliver the shares within 20 days after the sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">B. <U>Options</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A transaction in options is,
in effect, a bet on the short-term movement of ADVB&rsquo;s stock and therefore creates the appearance that an officer, director or employee
is trading based on inside information. Transactions in options, whether traded on an exchange, on any other organized market or on an
over-the-counter market, also may focus an officer&rsquo;s, director&rsquo;s or employee&rsquo;s attention on short-term performance at
the expense of ADVB&rsquo;s long-term objectives. Accordingly, transactions in puts, calls or other derivative securities involving ADVB&rsquo;s
equity securities, on an exchange, on or in any other organized market or on an over-the-counter market, are prohibited by this Policy.
For the avoidance of doubt, the sale of common stock underlying stock options granted to officers, directors and employees pursuant to
ADVB&rsquo;s equity compensation plans are not prohibited by this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">C. <U>Hedging Transactions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Purchasing financial instruments,
such as prepaid variable forward contracts, equity swaps, collars, and exchange funds, or otherwise engaging in transactions that hedge
or offset, or are designed to hedge or offset, any decrease in the market value of ADVB&rsquo;s equity securities, may cause an officer,
director, or employee to no longer have the same objectives as ADVB&rsquo;s other stockholders. Therefore, all such transactions involving
ADVB&rsquo;s equity securities, whether such securities were granted as compensation or are otherwise held, directly or indirectly, are
prohibited by this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">D. <U>Margin Accounts and Pledged Securities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities held in a margin
account as collateral for a margin loan may be sold by the broker without the customer&rsquo;s consent if the customer fails to meet a
margin call. Similarly, securities pledged as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because
a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material nonpublic information or otherwise is not
permitted to trade in ADVB&rsquo;s securities, holding ADVB&rsquo;s securities in a margin account or otherwise pledging ADVB&rsquo;s
securities as collateral for a loan, in either case, is prohibited by this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">E. <U>Partnership Distributions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing in this Policy is
intended to limit the ability of a venture capital partnership or other similar entity with which a director is affiliated to distribute
ADVB&rsquo;s securities to its partners, members or other similar persons. It is the responsibility of each affected director and the
affiliated entity, in consultation with their own counsel (as appropriate), to determine the timing of any distributions, based on all
relevant facts and circumstances and applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-size: 10pt">8</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>VI. Rule 10b5-1 Trading Plans </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">A. <U>Overview</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rule 10b5-1 presents an opportunity
for insiders to establish arrangements to sell (or purchase) ADVB&rsquo;s stock without the restrictions of trading windows and black-out
periods, even when there is undisclosed material information. Rule 10b5-1 will protect directors, officers and employees from insider
trading liability under Rule 10b5-1 for transactions under a previously established contract, plan or instruction to trade in ADVB&rsquo;s
stock entered into in good faith and in accordance with the terms of Rule 10b5-1 (a &ldquo;<B><I>Trading Plan</I></B>&rdquo;) and will
be exempt from the trading restrictions set forth in this Policy. Each such Trading Plan, and any proposed modification or termination
thereof, must be submitted to and pre-approved by ADVB&rsquo;s Chief Legal Officer or his or her designee (the &ldquo;<B><I>Authorizing
Officer</I></B>&rdquo;), who may impose such conditions on the implementation and operation of the Trading Plan as the Authorizing Officer
deems necessary or advisable. However, compliance of the Trading Plan to the terms of Rule 10b5-1 and the execution of transactions pursuant
to the Trading Plan are the sole responsibility of the person initiating the Trading Plan, not ADVB or the Authorizing Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Trading Plans do not exempt individuals subject
to Section 16 of the Exchange Act from complying with Section 16 reporting obligations or from short-swing profit rules or liability.
Furthermore, Trading Plans only provide an &ldquo;affirmative defense&rdquo; in the event there is an insider trading lawsuit. It does
not prevent someone from bringing a lawsuit.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director, officer or employee
may enter into a Trading Plan only when he or she is not in possession of material, non-public information, and only during a trading
window period outside of the trading black-out period. Although transactions effected under a Trading Plan will not require further pre-clearance
at the time of the trade, any transaction (including the quantity and price) made pursuant to a Trading Plan of a Section 16 reporting
person must be reported to ADVB promptly on the day of each trade to permit ADVB&rsquo;s filing coordinator to assist in the preparation
and filing of a required Form 4. However, the ultimate responsibility, and liability, for timely filing remains with the Section 16 reporting
person. ADVB reserves the right from time to time to suspend, discontinue or otherwise prohibit any transaction in ADVB&rsquo;s securities,
even pursuant to a previously approved Trading Plan, if the Authorizing Officer or the Board of Directors, in its discretion, determines
that such suspension, discontinuation or other prohibition is in the best interests of ADVB. Any Trading Plan submitted for approval hereunder
should explicitly acknowledge ADVB&rsquo;s right to prohibit transactions in ADVB&rsquo;s securities. Failure to discontinue purchases
and sales as directed shall constitute a violation of the terms of this Section VI and result in a loss of the exemption set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Officers, directors and employees
may adopt Trading Plans with brokers that outline a pre-set plan for trading of ADVB&rsquo;s stock, including the exercise of options.
Employees may only adopt Trading Plans with a broker that has been approved by the Legal Team. Trades pursuant to a Trading Plan generally
may occur at any time. However, the Trading Plan must include a minimum &ldquo;cooling-off period&rdquo; between the establishment of
a Trading Plan and commencement of any transactions under such plan for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">Section 16 reporting persons that extends to the later of 90 days after adoption or modification of a
Trading Plan or two business days after filing the Form 10-K or Form 10-Q covering the fiscal quarter in which the Trading Plan was adopted
or modified, as applicable, up to a maximum of 120 days; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify">employees who are not Section 16 reporting persons and any other persons, other than ADVB, that extends
to 30 days after adoption or modification of a Trading Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individuals may not adopt
more than one Trading Plan at a time except under the limited circumstances permitted by Rule 10b5-1 and subject to pre-approval by the
Authorizing Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For clarity, the requirements
of this Section VI.A do not apply to any Trading Plan entered into by an investment firm or other similar entity with which a director
is affiliated. It is the responsibility of each such investment firm or other entity, in consultation with their own counsel (as appropriate),
to comply with applicable securities laws in connection with any Trading Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">B. <U>Revocation of and Amendments to
Trading Plans</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revocation of Trading Plans
should occur only in unusual circumstances. Effectiveness of any revocation or amendment of a Trading Plan will be subject to the prior
review and approval of the Authorizing Officer. Revocation is effected upon written notice to the broker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person acting in good faith
may modify a prior Trading Plan so long as such modifications are made outside of a quarterly trading black-out period and at a time when
the Trading Plan participant does not possess material, non-public information. Modifications to a Trading Plan are subject to pre-approval
by the Authorizing Officer and modifications of a Trading Plan that change the amount, price, or timing of the purchase or sale of the
securities underlying a Trading Plan will trigger a new cooling-off period (as described in Section VI.A above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under certain circumstances,
a Trading Plan <I>must</I> be revoked. This may include circumstances such as the announcement of a merger or the occurrence of an event
that would cause the transaction either to violate the law or to have an adverse effect on ADVB. The Authorizing Officer or administrator
of ADVB&rsquo;s stock plans is authorized to notify the broker in such circumstances, thereby insulating the insider in the event of revocation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">C. <U>Reporting (if Required)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If required, an SEC Form 144
will be filled out and filed by the individual/brokerage firm in accordance with the existing rules regarding Form 144 filings. A footnote
at the bottom of the Form 144 should indicate that the trades &ldquo;are in accordance with a Trading Plan that complies with Rule 10b5-1
and was adopted on ____.&rdquo; For Section 16 reporting persons, Form 4s should be filed before the end of the second business day following
the date that the broker, dealer or plan administrator informs the individual that a transaction was executed, provided that the date
of such notification is not later than the third business day following the trade date. The Form 4 must indicate that the transaction
was made pursuant to a Trading Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">D. <U>Options</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Exercises of options utilizing
cash may be executed at any time. &ldquo;Cashless exercise&rdquo; option exercises through a broker are subject to trading windows. However,
ADVB will permit same day sales under Trading Plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">E. <U>Trades Outside of a Trading Plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During an open trading window,
trades differing from Trading Plan instructions that are already in place are allowed as long as the Trading Plan continues to be followed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">F. <U>Public Disclosure</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADVB reserves the right to
publicly disclose, announce, or respond to inquiries from the media regarding the adoption, modification, or termination of a Trading
Plan and non-Rule 10b5-1 trading arrangements, or the execution of transactions made under a Trading Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">G. <U>Prohibited Transactions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transactions prohibited
under Section V of this Policy, including among others short sales and hedging transactions, may not be carried out through a Trading
Plan or other arrangement or trading instruction involving potential sales or purchases of ADVB&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">H. <U>Limitation on Liability</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">None of ADVB,
the Chief Executive Officer, the Chief Financial Officer, the Authorizing Officer, ADVB&rsquo;s other employees or any other person will
have any liability for any delay in reviewing, or refusal of, a Trading Plan submitted pursuant to this Section VI or a request for pre-clearance
submitted pursuant to Section IV of this Policy. Notwithstanding any review of a Trading Plan pursuant to this Section VI or pre-clearance
of a transaction pursuant to Section IV of this Policy, none of ADVB, the Chief Executive Officer, the Chief Financial Officer, the Authorizing
Officer, ADVB&rsquo;s other employees or any other person assumes any liability for the legality or consequences of such Trading Plan
or transaction to the person engaging in or adopting such Trading Plan or transaction.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * * * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ea025762901ex31-1_advanced.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 302 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Yi Lu, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 10-K of Advanced Biomed Inc. for the period ended June 30,
2025;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made,
not misleading with respect to the period covered by this annual report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this annual
report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of,
and for, the periods presented in this annual report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly for the period in which this annual report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting
that occurred during the registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially
affect, the registrant&rsquo;s internal control over financial reporting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation,
to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent
function):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">all significant deficiencies and material weaknesses in the design or operation of internal controls which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">any fraud, whether material, that involves management or other employees who have a significant role in
the registrant&rsquo;s internal controls over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: October 8, 2025</TD>
    <TD STYLE="width: 3%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 37%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Yi Lu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi Lu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Chief Executive Officer<BR> (Principal Executive Officer)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ea025762901ex31-2_advanced.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 302 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Mingze Yin, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 10-K of Advanced
Biomed Inc. for the period ended June 30, 2025;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this annual report does not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this annual report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material respects the financial condition, results of operations and
cash flows of the registrant as of, and for, the periods presented in this annual report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which this
annual report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD STYLE="text-align: justify">disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent function):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">all significant deficiencies and material weaknesses in the
design or operation of internal controls which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process,
summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">any fraud, whether material, that involves management or
other employees who have a significant role in the registrant&rsquo;s internal controls over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: October 8, 2025</TD>
    <TD STYLE="width: 4%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 36%; border-bottom: black 1.5pt solid; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mingze Yin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mingze Yin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Chief Financial Officer <BR>
(Principal Financial Officer)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ea025762901ex32-1_advanced.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In connection with the Annual Report on Form 10-K of Advanced Biomed
Inc. (the &ldquo;Company&rdquo;) for the period ended June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof
(the &ldquo;Report&rdquo;), I, Yi Lu, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: October 8, 2025</TD>
    <TD STYLE="width: 4%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 36%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Yi Lu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi Lu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Chief Executive Officer <BR>
(Principal Executive Officer)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ea025762901ex32-2_advanced.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Annual Report on Form 10-K of Advanced Biomed
Inc. (the &ldquo;Company&rdquo;) for the period ended June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof
(the &ldquo;Report&rdquo;), I, Mingze Yin, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 36%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mingze Yin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mingze Yin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Chief Financial Officer <BR>
(Principal Financial Officer)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: October 8, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #H F<# 2(  A$! Q$!_\0
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M_FJH_P"&._V??^A'U'_PXOQ+_P#FJKZ?HH ^8/\ ACO]GW_H1]1_\.+\2_\
MYJJ/^&._V??^A'U'_P .+\2__FJKZ?HH ^59?V//@+)MDM_#_B[2;@*39ZAX
M>^+OQE\.:G9X[_VSHGQ#AF##^':RJ>A5N:QOA%JOCGX=?%C7?V>/'WBG6?'.
MEMX&'Q*^#/Q \2XF\9ZMX%TC7H/#WCKP7XXU103XA\2?"[7?$'@Z-/&+O;2^
M+_!WC[PH)X+CQKX3\9>,/&'V'7S'XA_Y/'^$'_9M/[0W_JSOV9* /IRBBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/$>NXTG5F\7>+_!?C/PC)X/EUV3RA(L4]O)_1I_PU'J'_1L?[5W_ (;;0?\
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M #PZ /K:BODG_AJ/4/\ HV/]J[_PVV@__/#H_P"&H]0_Z-C_ &KO_#;:#_\
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M_A>GP6_Z+!\+/_"_\(?_ "\KFO\ AE?]F3_HW7X%_P#AH/AS_P#,W1_PRO\
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M'/\ \S='_#*_[,G_ $;K\"__  T'PY_^9N@#I?\ A>GP6_Z+!\+/_"_\(?\
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M?"^XU+*Z1#\0O'G@_P %OJ952N=(C\0Z[:F0#&TB)7R1MP.37!_\-I?L>_\
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M%\4>)_'WBCP)K&@_M&?LVZSX4_X1[Q;XX\.Q:Q'HG[0/PME\<2:YI?@>6/\
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M ?3-%?,W_#:7['O_ $=?^S1_X??X8?\ S34?\-I?L>_]'7_LT?\ A]_AA_\
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M1_X??X8?_--0!],T5\S?\-I?L>_]'7_LT?\ A]_AA_\ --1_PVE^Q[_T=?\
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MIJ/^&TOV/?\ HZ_]FC_P^_PP_P#FFH ^F:*^9O\ AM+]CW_HZ_\ 9H_\/O\
M##_YIJ/^&TOV/?\ HZ_]FC_P^_PP_P#FFH ^F:*^9O\ AM+]CW_HZ_\ 9H_\
M/O\ ##_YIJ/^&TOV/?\ HZ_]FC_P^_PP_P#FFH ^F:*\R\ ?%GX;?%+3;C5O
MA=\0_ /Q&TJTG-M=:AX \8:'XSTZSD7I&\_AZXN(@S$@ &0G!W!F56P4 ?,/
M["WAKPSKG[/WPE_: U+0;"_^+7[2_P +?AY\</B=XTU.S2\\1:YXG^*?@_2/
M'$^BOK+0>>OAGP@-8A\+^!?#*D0>$_!VB6EM %1YI9OMG^SK#_GRM?\ P#_^
MM7RE_P $_P#_ ),,_8F_[-"_9P_]4SX(KZ_H S?[.L/^?*U_\ __ *U>'_'W
MXW_!S]F+X/?$#X\_&W7['P%\*/A?H=QXB\9^)5T+5]6-CIL01//ATC0-#NM>
MUEA)(ICAT"&:XE 8&,QQS,/H*OS<_P""@G[+7QI_:YTW]G3X9?#SQ_X;^&/P
MY\-_M&^$_C1\;O$VI:)H_C76KS2OA%H^O>-OA?X0T+P-XDT>?PKXAM?$OQG_
M .$$?QM#XC"K'X/T&X:,7-W>;& )?BA_P4L_8A^$&G?!35O%_P 0]3O]+_:,
M^$VI_'3X7WW@/X1?$[XHIJ/P:T&+0=8UGXGZXOPZ^'?B=?#'P_\ #47C3P_<
MOXC\2BWB23Q"SJCN99).B/\ P4 _8GMO!OQV\?1_&3PKJG@_]F[P-\,/BE\6
M]?TC2M?U72].\ _'3P9%XX^$'C'P\^D:)<GQ[H/Q.\*ZM&OA%O!K>*%N[AY_
M#$*1W+/"_P"17P9_X)N_\%#?V5O$G[.,GPND_9P^.C_LV_"7]N?]ESP+XB^)
MOQ-\:?#=?^%._M'?&GP%\5?@9XS\1:%X:^&/BR67_A56@>'8O"7C7X9^&)(8
MA;VF@1>"O&<D(D^SW+'_ ((I?%7P%XD_8"\'^#OBEX,UCX!^!/@Q\"O@]_P4
M#TC7;/6K+4_C3IG[)WQH?]ICX%#P3H<<3H^A2?&C6=>\*>-$\4R!1\']>:V5
MI9E:.@#]=M/_ &[OV1;[XC?M-_"=?B;HK?$3]CSX>Z3\1?V@O#/_  CVNRWO
M@/P'KW@^X\=+K$DL?AB6/78_^$:42>*M#\*MXCF\--+:V=W#:W;1PG&\%_\
M!1;]AKQO\/O"?Q1\.?'+P7)\./'/[/WCK]J?2?'>M:-KOAGPXWP)^$^N^&_
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MK'B#1UTO6VC6['AKQ0-&@\,^-/#,\G_",>,_"-Q+X.ND>R\O;]KU\Y?M<?\
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M,7C3,+10CEOVU?\ DT7]IC_LA/Q/_P#4*UVOJ%>@^@_E0!G?V=8?\^5K_P"
M?_UJ/[.L/^?*U_\  /\ ^M6E10!\B?M)_M:_LT?LC0?"N\_:'^(FC?#*W^-/
MQ1\+_!CX</=:#K.JQZ_\0/&;W$&B:*SZ#H=S'HD,SQ;I/$'B5[;PS;)&3<W$
M4DD:UY7X^_X*-_L3?"_]H+6?V:?'OQ*N_#7Q&\,ZQ\+O#WC&^UCX6_$Y_ASX
M1\3?%);7_A5&A>-?C5_PBC?"_P .Z[XR&KZ4/",/B7Q;$SLP,;)*Y>/Y/_X*
M2?\ !-CXV_\ !0SXGW-NWQDT'X0_!+PO^R+\9/A9X&@M?#6F^-?$NL?'3XWZ
MYI2:_P")]=TC7=#DM/#_ (?\(^'/ O@A/"GBGPG*?&J3ZOXC,4EI'*(Y/DCQ
M5_P3=_X*'?&>+]JKX:?$VY_9FT_P[^WUX$_8DTW]HKXS6GC[QGK_ (F\"ZG^
MSU\+_ 7@;XZ1_"GX7GX;QQ^*=<\6Z]H6M2^"_$?BKQEX47P:VL1R%&N((BH!
M^RGA?]M[]DOQCH7PD\2^'/B#9ZIIGQU^-'C;]G/X=6R^#?&,.J:]\8_ [_$+
M_A/?!6L:2WAR37]$;PQ_PJWQG#XR\0^*(K?PE;_\(T\MQ=[;FU9O)Q_P5/\
M^"?*?LR>+_VQ5^.GAQOV<_ /QD_X45XP^)2^"_&XT_0_B(==T/PX-$DT?_A&
M?^$G.BM'X@T66+Q0EJ?!S>$-8'C%KMO P%V/SO\ B+_P2K_:ST[]I/\ ;*^(
M7P1\=_"[2_AGXP\'_M"?$#]B[PYK.K:SI6I_";]K;]LOP/X&^$_[1?Q+UO\
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M\6?!7PW\$>$?#?A;Q+XD^(GB/Q5X"US1/$<,?@ZW\2L\1\[$;(XC^#/VH/\
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M^-] ^)VN^,_$;+,DN@>$HX/ \WAU?$\D+VS>+O$'A;PF2+CQ/"P* /NGQW\
M?@9\5K^'5?BK\%OA/\2-;MK1[.WU3QU\./!_C2_M=/)!;3;?5?$6@W4L4+-G
M;#O0#<202=YXW_ABW]CO_HU']G'_ ,,E\-/_ )FZ^FJ* /F7_ABW]CO_ *-1
M_9Q_\,E\-/\ YFZ/^&+?V._^C4?V<?\ PR7PT_\ F;KZ:HH ^9?^&+?V._\
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MU']G'_PR7PT_^9NOIJB@#YE_X8M_8[_Z-1_9Q_\ #)?#3_YFZ/\ ABW]CO\
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MPZ*^//\ A4W[8?\ T>!X2_\ $8M#_P#GET?\*F_;#_Z/ \)?^(Q:'_\ /+H
M^PZ*^//^%3?MA_\ 1X'A+_Q&+0__ )Y='_"IOVP_^CP/"7_B,6A__/+H ^PZ
M*^//^%3?MA_]'@>$O_$8M#_^>71_PJ;]L/\ Z/ \)?\ B,6A_P#SRZ /L.BO
MCS_A4W[8?_1X'A+_ ,1BT/\ ^>71_P *F_;#_P"CP/"7_B,6A_\ SRZ /L.B
MOCS_ (5-^V'_ -'@>$O_ !&+0_\ YY='_"IOVP_^CP/"7_B,6A__ #RZ /L.
MBOA6WO\ ]HGX5?%GX)^&?B-\9?"?Q>T'XQ>+_$_@VYL[3X0+\.-3T;^Q?A=\
M0/'QU72]6T7Q-XH5D>3P;I4$D%P8_OLZRPS%9(ONJ@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0E+GQO)(K '[W?\ "(_MF_\ 1P/[.?\ XB?\1_\ Z+NC_A$?VS?^C@?V<_\
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MR,^'?#'B3/VRS\-9M8IWAVA^,\*?LN_LV^!W-QX(^ 7P8\)%_%&D^-%;PO\
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M\'=$\3Z)?Z+\&O#3_M7>*3_P4#\?_M*?'/X*^"M;U]G\2_L_C_A'O&NN^)O
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M_P#G_P#V1O\ P6?&;_Y>T44 'E?MY_\ /_\ LC?^"SXS?_+VCROV\_\ G_\
MV1O_  6?&;_Y>T44 'E?MY_\_P#^R-_X+/C-_P#+VCROV\_^?_\ 9&_\%GQF
M_P#E[110 >5^WG_S_P#[(W_@L^,W_P O:/*_;S_Y_P#]D;_P6?&;_P"7M%%
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FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "S .H# 2(  A$! Q$!_\0
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MUO\ EF37!WW[1/P>TJ%;J[\<Z&[R1J/L]I+>W-RVXEXXW:U@G40YY;S'"/M
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MYCY^Z3O*@84;6V_!=AX _P""GGC72[R]U&/X._!&UA<>=;?$#Q3X>\/ZWLN
M&/\ 9]E?0ZW+,UKO*S*LB30S*45BW-2:A^Q3\7O$-A:K\0OV^-/MKV59S=>&
MO!GA/QIJUJIW(TKRZGH^IZ?IUV\V#Y+R6_E@;7"A<*']7JIMS]G3=[-U*U.+
MNK6NG)RLT^UT]-7>TOV"T>)A.UG:A2KU]'=Z2IT^2Z:M=2<6K-N*W^Y[CQIX
M6L$DN-3\0:1I-E\\<AO]3L[:W%R!OV2122H9.0,QC;LD93DYQ7E7B/\ :B^
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M\DT44<C22N)$: (T:0^23(AF8Y),T7[IL,54YSG.!<M;I\W"W<T:LH:V2-&
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M;7$YV#R':>9Q(S%E7>26QA&'[H _>FW;V)4# Z\L/,FD<Q2.%DE2-F0(J(5
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M?":P@\;^&8M9ATSXC>)+RYU_QTD6OK-%J4;ZQ<-%"B2VD\E@BVUC;+%8DVR
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M33\KM2Z)+2_4_HOAR;^J5:#>M&LVEVC52;7?2<):OJ]$K%FBBBO'/H0HHHH
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M.5520!@@ C/S,0.F17GX[B&M.]/"Q]C%.2G4E:4Y6;7N:*,+I?%9RUTLT=&
MX9P\&JN+G[>32<*:O"G&^OOV;E4:;2<;J#MKS7L78Q+>R)+=3O-(=\JO<2-\
MK%B=HB0A1$"<[<=26&#77Z?'(D*@1(9EB7#9P?*']T?>*MR<'EMJD<FLBSMH
MH\RJ0\IQ$&QO10B@EV4@*HV]2O\ =R0:ZO1;2\U"[M]+TRTNM0OKJ98+:"TM
MY+FXNY9Y$CMX+>*(--+))+*J10JFYC(JHI)%?+5JLZLG.I*523U<IR<I-^K;
MO>]DM%Y'UM&E3HP4(0C"$591A&,4EY))+9=?FV:%C;$[(R&PYWD\[RI(,A0-
MR2.Q/(7/7&*_T(?^"4OPTM?A?^P/^SOIEKJ5UJ9\5>#HOB1=R75O;VS6E[\0
MIG\4W6EPI;I&)+;3)-1^Q07$P:XNEA^T3NTDAK^:G]@__@BE\>?V@9M/\;?'
M&/4O@;\)RVFW\*:MIR-X_P#&5C)=V_V^TT/0II8V\,K-IXOX$UKQ'!YME?I:
M31^'-5M)#(?[4M$T;3O#NCZ5H.D6EO8Z5HVGVFF:=9VL$-K;6UG8P);6\,-O
M;1Q6\,<<4:JL<,4<:@81%7 'M93AJL)3KU(."E34*?-I)IM2E)1NG&-DDN9>
M]NK)7?DYQBJ4Z=/#TIJ<HS<ZJB[QBXQY81;5TY)RD_=D^79MO1:E%%%>X> %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?S1_\%A/^""/
MA;]L.^\0?M'?LM)H_@7]I&>U>[\6>"KJ2UTGP/\ &&ZM87,.H?:"D5MX7\?7
M("VMQJ\[KH>O@6TVLBPO8+C5+[^ERBAJX)V/\<CX@_#/QI\*/&OB/X;_ !$\
M+:WX2\9>$M5N- \2>']?LI]/U32-5LF:*XL;NWG1'A>-@23@I)&R3PR2121N
MW%>'98=9\0:SI1B0GP_J.DV D5B/,74;&UU8Y5@#A3<%1TQG.=Q('^E'_P %
M??\ @C=X#_X*$^$;CXD?#5=%\!?M4^%M,V:'XHFB%GHWQ*TRR1FA\&>.IK=-
MRRE 8?#GB9TEGT6Y:.WO/-T>6>.'_/W^(G[.WQ+_ &?/C3K/PQ^*_P /=;^&
M?Q"T[5M-@\2:3K-M<PSN]K9I#:ZO;22@PW6GW]E'$]I?6,DUE/&VZ*9@&5<)
MOV<:DI7:4)23O_*FWY[)K;T.JE%5)045O**E&VJYFHKM=<S6MT][VMKZ#;6D
M,*0J(0X:,Y53E42$[5 )PI4!5.21DJ%&XUT-K8EB6C0&3:A)+%R.K#"+G!&0
M<'G<0"<XKW?]G']E#X\_M3>-;3X?_!/P!KOC#5[N02W=[:P&UT/0[&.YTZVN
M]0U[6YC#INE:?9OJ=@]W/>7,0V74!C63S%5OZX/V(/\ @@7\&?@Q/I'CW]IO
M4;'XV^.(;9I1X%%LR_"_2;J=+*2,WUE.JW/BN[L"-0LY(]3!T*X$\5W'IIN+
M>WG3YJAA<1BI>XK1O:565U#N]=Y/7:*;ONT?15\50PJ_>2O)).-*-G/R\HIV
MWDTNR?7^<K]B7_@F-^TK^VKJMO=>"O#DO@_X;YGDU#XI^,;+5-,\$QBTN[NQ
MN+71;U;.1_%&I6U_:26<^FZ"MY-92JRZG+I\0\P_V%?L4?\ !)G]F+]C)8/$
M.GZ:_P 5/BIY!AG^(GC;3K,BQVZC?WD+^%O# >]T[PY-]FN;&SN;W[5J>ISM
MI5M<1:A;"26 _IQ86%AI=G;Z?IEE::=86D8BM;*QMH;2TMHE^['!;6Z1PPQC
MLD:*H["K=>[ALNH8>TFO:U5KSS2LG_<AJHVZ-\TO-'A8G,:^(O%/V5)Z<D'K
M)?WYZ2=^J7+'R84445WG %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5^&G_!<?X!_!WXB?"7]G[X@>,? .B:QXWTG]J3X%
M?#JQ\5D7EAKR>!O'_C 6/BSPM-J6EW5E<WFCZI;Q@I:7LEPNFW$D][I)L;RY
MN)Y2BLJ^M&HGK[CW^2_5FM!M5J5G;WUM\S]@?A/\'OA;\#/!FF_#[X0> _#7
MP\\':8D(MM#\,:9!I]O+-#9VNGB_U&9 UYJ^K2V=C9V]UK&K7-[JMXEM!]KO
M)VC4CTJBBM$DDDDDDK)))))=$E9)>B,VVVVVVV[MMMMM]6VVV_5A1113$%%%
,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #> ,\# 2(  A$! Q$!_\0
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M<C'R?$[M]1UMKB/P5)_D>GEN];TA^<SGXA]K+7 =I))7>)44$"+'/RYQM8G
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M@HHHH **** "BBB@!&^ZWT/\J_DLUJP:6\ORK*)#,I0 !5>1 H#MO!#$LI'
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M+C7?VRM8TR4;/.BC\4V\L$;RMM\C<L4@9XP-S,&PO/7(-=.__!83XU*8XO\
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M/\5K(+Y4<, :-@B.A,P9"5PY&/EPI)!R23D9QT^4AKK.LD<VY2BEU F#AI"
M2&4_,P8 _<Y[8Q4$NNOM>> ,HX&-P$89QSE6<D[<9P.@89QW\.EP/AH.49K$
M>]IRNI*25G=7E4;EKU5FE:R74^YJT*3Y;RY'R2I-+XHS4DVKIV?P[JR=]#ZF
M?XO)$3&J6SEY%"3/#N8 8 8AF&0.<@ 'OG&,DWQCNQ(/(EA$18(6$(0%0/\
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M>34?!.MP3 K=ZEX,O9UDO/AYXPB1FGL->\/RV@^THCW,;?>&[^UI\"/V5?\
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MV9B\^WU%XK(*TC@5\]MH>OI8Z7JDOA_Q*^E>)9+BV\.:R?#NL)IWBIH&*?\
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MWPB^-?@OP?XX^-OBBX^,OQU^''Q@\/>!_'>A:;HW@'X%Z#X3T+5=,O\ X?\
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MQE$<H955@Z[3SL#= &YR>V0/\,U^N?\ P7K\P_\ !63]JX('W._PP5 O /\
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MY5:6+C4J0CA?[0P]+$9+5FY4YWJT,PJX;W)J%6<E8\H2 _/^[6/Y4+2 *H#
M_+A6/+ G=]>N,U.D3I'P^]I"=SARJ-MSG()(&0"20!SCG@"O:M1^%.GW]W=Z
MG!KFF^%M"M8-!L[8:DTUQ]HUF\\'6?B"[>\._P ZQL)KB39%=E) \\H1(RD8
M!K6?PNM=3U!+;3/$TMOI\7@C0/&.L7VI:<T4EJ-::.U6RTJVDD6/5(([R5FF
MN$:%+:*-O-W2%5K#&>#O&]!54L#AZLH5:-%4UCL&JTYUW-TY1I<\VX.G3G*4
ME62BURNSWZL!])SPGJX;"5*N=8O#NKAL5B<1%99C\1A\//#8>AB9X;Z[AL/4
MHSQ%6.,P5+#PY4YXBM*C)0]G*2\A)5=K1@@,R[RSG,8(R!G!)R1NRO\ "0#S
M59(I)6,D:J V&!C=RBM[[B,MCYLGMVXKVG3OAC86$6JSZQKL>M(_A[XA:CH$
M6EZ5J%UI=ZOA&%X(]8OM95([?39DOE$\%A*K;XHQD!9D+>36JW$J!S\HE5-X
M11G:X!?@ #)/(R 1G'8U\IQ+P=F_".$R^MG$*5"KF3QOL\/&K2JU*4<'6PU*
M4JOLIU$E5>(O#751L]9:?;\%>*?"?B/F.=X3A?&O&0X=AEE3%8R5#%T<+B?[
M3I8RK"&#J8K"X65:="&$J0K1=.+C74Z6J49S=9AQO10& &<228 8GYOFQR?[
MJYY/%;4+%!L>-GY!^8J#R00=C=.G#<@]<=JSULI"5R9L$AMIPRL!SU&2N.,>
MN<9K2A@\Z4 L8BO(8YR ""5 /7([?B!7PM249-I/5]-;_IY]#]2I5'&%/EES
M0DY:+R;3V;OKV+<:L\JHF ?WAY!W!5R."",<<D@'/;I3C  Q ;?NS(1C*CJ,
M%^H[=NQZU+$BQ+B1XPQ11&!&Q8,P*J06^8[@223P".@!Q5R.$*45G,NWIY:^
M6%/0DD ;LXQWZ\$UPUI*#4G/1W]RW9;MW].F^ESLA6B[1Y'?7WKM=+_R]M/Q
M*D*2D[@&5D9PK%C(,*0!MV[=I]3G!Z>E=#HB3MJ5B8HG\\/.%).06^QW!DR!
MR5V9VYR<C.>M5_*A100LJH&'S-\S D'&T$>I'?IS@8KHO#H\O5[#&2_[\HRD
MXQ]CN V<[AN/';UYYJL%B$LQP*4;KZWA]4^U1>3^>YY>?/FR7.'M?+,9_P"F
M3]2_^"ZT>[_@JY^U,7+;#/\ #C"KQ@K\//#X1F/H2S \$@ $#&*_(J:T :4;
M68D<)$7+X+#"P[0'E,@^41J"<GIUK]@O^"Z<;G_@JK^U*^6 ^T_#<@%8]HS\
M/-!4$$G/!&3D<C\,_D]97E]I=U:ZG9W/V:_T^X2ZM;F/8[PS*6*,J,C(Q7(R
MK*4VG'I7N<85:+XYSI5ZTJ>'_MB4,14A[TZ=*].-6<(M>].$'*48[2G&,;I2
MNOD?"JK6I>$W"-3"0IU,7#AJF\/3J.U.I77UGV-.I+I3G-PC.6\8RE):P1TV
MG_";QD/#NH^++_3E\.Z-%:M(G]LSS6,VLR*%,5K8:4$DN+N9\HXD>-8\9SS7
MG\]C>3/&5L-0 C'RDZ?=Q(" !M"B#YD(S\QR3@$9S7U+<_M.^*;_ ,-S:9KG
MVZ/78;?&C>)/#YL8)C=(FQ4UC3+VVN+.> @@/+;"*48X4MFN"'QM^+9#$^/K
M[[JD#[#HZ)DX*JK+I[$%1P%)]<GI7W7$N$\'L+3R:.3<4\68ZG4RFG]:KU<K
MHU*]/%.LI5J=7#5<SI+#I^\H8:"G3C3A":J.4VH_&<(9SXY8EY[3SWA'@_ U
M*&=3>"PD,RJ83#PPJI3A3Q&'S"CEF(K8^2BX2G4K5(S=2I*/+RP3?BS6-_L"
M2:=?G("D):7CJ#D\JAA  8_>8@9. 0*@;2K[<K?8-1R",J]E=$8(('6'" @\
M,<@>HKW!?C?\6)I!&?&M^/E"DBPTF1GR%QC%@<YQDDX(.#])I?C#\8"VW_A-
M]261XAD+8Z1D+'T<QM8D>6!U.!S@"OE.7PUCK_K!Q1HK^_P[@&OFGG5[:]+=
M+'V<L=XL3A*W#_"E1--6CQ+CW)]TO^$A:_/N?.L^DZE#!MDT^^E;SF*AK&\<
M8''!$1R,#!(.,DCIBJ=Q!J B8OIMY!"I"F>:VN8(=X4*%W21JN2!\J$@<>N
M?;[SX[_&1+C[,GQ U$;#E,Z;HH"H>2>-.X+'&X>HQP.O,^(_BK\2_%.D7.B^
M(O%M]J^D78A6ZL)+/38/.DCD$T+++;VL$J&.5%=2" 6V!]R$@];CP+]6G+"Y
MUQ!*NXRE05;)L+0IRFTE%3C3S:KRP;NG)4YO6_)=7.*CFOB6Z].EB\AX8I86
M52,,3*EQ!CJN(A2D[572IRRJG&=11;Y$ZL%>WO*VOD"I)(?*EBE) )'SLC!Q
M@L>HR,9SR3D=?1ZP0KYFT.3E=ZAR2&;D C#'&,JV>O4^^BD <C.\!=W$C9.6
M(+'CWSGC'ICC#GM$BS.&*,HWOM48?#?(%((+/R"P.!@'/4 ?-U9J,DM4HP45
M&-3G;:4^5R;T@VW!RIJZAM=W/MJ>(Y$J/[RM"BX)1E3Y:D:,7"3HR;;]I.*]
MK'VDIWFG%R2M8A;3+@:<=3$*#3_[1&E-=#<[PW30"Z>&:)5+;#;_ #B5B(T;
M ST%,O\ 1+O3I+.UOK=%%]I5MK5LT+^;G2KP%K&\9HF+*955_-A<9B 4NXR1
M7J_@+QG8>&],GLM1;6&C3Q"^MO:V%K9R:7KUBND/ICZ+KCW"^=%9SW$BR75S
M#Y@2%%7RGD"XTM&\=Z5:+:M);ZWHEQ:Z5X6MCJ>DPV5S=7L6A0W,=QX>F^U
MQQZ%J?VA#Y@PY2,K<P3Y4+^P8/A7P\Q>38"=3C.G@,UQ&$P$\73JPG4IX;$R
MIUGF,')4'M4]A[!+FY8J>KN?S9F?B3XR99Q'G>!POA54SCAO*\YSO#X/-X5X
M8>6:Y9*EE]3A^I1A#%*3Q'UF>80Q56<*<:E&G357DI0FSQ(VT 1IMH2/Y8W9
M%+?.1\J,WW/<KNR1@XZ$11V&LZ3;:=XJLGNK&V;4[C3M-U>UNA!=1:E;VR7$
MXA$91XXWM9XRL@8HP?R_FR!7N;_$711HD]J=$G%NUI<V3>#EAM8_"-U=RZN^
MI_\ "13780:B-3AMFCL$@53Q;H4G2!C$<3XD^,+'Q?HFG:182:S=)8>(M4\0
MB/5[;3K>VTZTU;3[6W3P]I<>G!=UCIKVPCBN)0&D@"%(XGW"F^%>"<KP>-Q]
M#CZCB,50PDXX&E@Z=6&)>8+$X6GA\0I*E3E&E&A6KU).-2$U*FG&TDKY83Q)
M\4L^S7),JQ7@SBLHRC&YCAJ?$&89SB,+F>%_LF5'%5,;A5A:&*JT</6E7HX2
MA.O..-P+I8B<\/3DX-+R&77_ !"-2363JNLG6"# FIB^G:\,95@8+=\E1 0S
M^9;1JR,S;F&Y58=+97'CV^\/M96EY=GP_>?\)7JES"EZ;>34O[/L;*?Q(-4;
MSEEG2.U-N\8;][-&9(E."RUZA!\2/#T&O6^LO;:M):C19=-L=+FL+$0> )Y4
MLR&\*O#);RWT>+:6-9KJ2VG2&[=6+RAI7P[_ ,<VMS<7UPFGLOVS_A/&!M;:
MUABC?Q3I>GV.G2"T#/%"+:>T>?4/GD,HF)5F)(KZW+\)PY1A6_M'Q2Q3IXN&
M(H25&OC.:I3E[&<)U7*+E+GJ)3E>2;=/>RL?G^?Y]XA8U99A\I^C]EN%_LVO
MEV,]IC,%E.*P]+V4,51JY?3H.=.E&%%8C$../=*M5J/&SQ4J56K2A3EY/;:[
MKUO]I%KJ=Y;K?VL=G-MF=?M]I;QB.VBF>0DS1PP*(;8L6\J%/+4[0!5FUU'7
M+-].OK75M6BGTZTFM]*B6\G2XL;.>0/<6UGG+1V<KE62'#PD!BBY)([CQOKF
ME>([SPY>P6U[*--T^SL]8$D*V-M=_9WA?R-'LX7FBTF)(XW5Y%D:":=DGA@A
M4R1OW.N_%32)[RPO= L=2M;W3?"?B[0[._OK>R.JVUSKLMC)H$HN9C/#,=!B
MM[F)ID"%VF1[:&$%EKY[!X+*<3B<RIXSQ1GEN$P'U:G@ZCJ9IB?[6I5,#"M4
M=+#T*L94I4,;S4ZDU*,I5.:2NG)O[;,>(\^HX#ANM@? /"9MC,ZAF\<^P4<#
MD&&AP_B<#BHX# U*^85\,OK=+'8+"+%8+$3HQG.CBHNIA\-44:<?+M*;Q7K#
M_P!A:=K&I9UVYFQI2:E<P6MS,T<AOI+J,,L2M.B31W#.JQSE3%*&(&,+3="U
M#4K6ZO;.-Y[>TU&PTV95E13!=:I'<OI\ 3*[ED6SG+RA@B",$\'%>^Z;\4M+
M@U*?5Q;:]IMY)>P:G?+I5KI.SQ87\-P:)<6FN&X"FRAM]26YU6U-A@7#7D[2
MJL["0>>^$-5L/#]C<6EQ8S7(F\3>&=;D$+1M#)#H4>JQ74$HEY+RF_C, .Y7
M"2;MO&<\;E7 TH971S+Q!J9G&O\ VW+$8F-#&*AEJ5/ 5<#35+&>WKTWBZ[J
MQFXNI&I4H3D_9Q2OSX/C#Q9HX?B7$Y-X.83AZ-&?"<<)ED9Y7/$Y]7>-QL<]
MJU:^ E@*%.&&P2P5;#34J4HSE63C4G5DI\C#"(S&Q!13NC#"1F#.G#IR,;D&
M-V"<''KQKV]A<LT[0J2T-M+=.V0BQVL07=*V[;YB(SHIV[GW., Y->KQ^*-%
ME\+75I'+>6,]EIGAA;?PT+33VT:;4-(\1VNH:EJNGW>PW@O-9MDE-\)-J@^9
M&YEC95$5[XJ\/2W3/I>EZK-9S6OBTR)J=O:0,+KQ)>6%W:0A("P:SLA:SVJW
M*OYS0.LD21DE:\[$>'W!5+ZMBI^)&3K#XNE7<4J;]M3<5-X?FBJ#FN:4::D^
M36$I;7N>EAO&OQ3J+'8"GX'YLL;@LPR^A[:>-_V6-!N6.Q-6G.=:C"2JTJDL
M*U2=9QE3IQDVHN;X"'3)?[/BU&2 ?9Q??V6]PS!9'G%LUVH0/]Z*2$,RS1YB
M?[@.034B)'R#LC502N,.2>,?,H /!^[@X/)&:]-\3Z];>(M.@L()]9,<&L2:
MQ9VNIP:=%9:1;/IOV9-#TE;4"1["SD_X]Y9MI=,#RT<.7X2&W9OW2&0E06!$
M*$J3]YF.>%4GJ.N0,'O^5<<8+(,HS3#X3A_-XYY067X6KB\9&ZI?7JCJ3Q-.
MG&5.FXQA[L8I1^"VNZ/V3PQXAXNXER;%YIQOP^^%<REG&-P^791SQJ.&3X:G
M3^KUZ\XU*O/7Q52I42DY)I4I1:22;H0N\Z[98 8Q)C>PV88DL",;2<KCJ,>G
M?/4:!!''JMEAMQ5IPH(];2XS@Y.Y< 8)Y/S=JKPJG[M)=LJB3;RN&#G[K,0,
M*@/)R?7C/3MM$L;:75=/*J@827() X/^A76,C./4Y]?K7R&#Q:>99;%+D4L9
M05T^OM$ENKVO;HNG0^WSV4?[$S>\E;^S<8NO6E;L?I1_P7*A+?\ !5']J=\;
MB9_AR% Q_#\/=!4 #D;MV2-W![XK\G)[4",(RJ SA2PPI!/*L)-H #8(9&!Q
MC@]*_7__ (+:6K7'_!4[]JDL$91<_#Q$!;+DGX>Z V%&/E88/!R/?%?ES9V5
MN-0LTN8RUJM[;";S0,!"RM^\#$[5#$!AG.#CZ?79O@5G_BMBLA^M4, \VXLP
MV5K%XJK3HX;#/'XW#815Z]6M*-*G3I^WYY2J-0T4+IS37YMP5G4>'/ K+>(9
M83$X^.1<#8[.'@<'2JU\7B_[-P688[ZMAZ-%2JU*M9X90C&G&4DG.:35-I\%
M)I\A>!$A=F,F8U6.21Y#QA$PH61N"2%SD$''6FF"5)"J1.A8JK?*H7YE/WE(
M_@P0>=V>N#P/9K8ZL-=LO[2>>*W_ +41K01B);.+]ZZQ^4J@J<QDL&!"A2<\
MUGW>D65\(3:V*"1]>GL'0WD@MKJ$K-,TUS+D/$P8$_N\9!"*V2#7[35^CU2Q
M^&QE'(L_Q.'SG 9YCLE_LOBG*99/B<THY71P%;,,ZRN-/'5D\J_VZ'U&KB)1
MJ8V-.4Z,6G9?A-'Z5L\MQ^4_ZU<.4YY#F_#.3Y[_ &WPGFG]N83)<9GV*SG"
MY=DF?2JX+">QS"$LKI+,?82=/ ?6+8B</9N4O)(U99APL9W<L%=S,O\ "5#9
MYX[<_3%6Y+M3%&D 25W=0[@E6Q(<;6!R20.PX/7&0,>GQ>'=+>YT&.;3_LXO
M9]1AO$2>>.,BUC8V]PC7,K36Q95*AFPK-@[2"#56PT71+R[T5VL/LZW5QK%O
M>PI=RL)C81E[:X+NN^&X+/L+#Y&8@@$ 5G5^BSQ3',*N75N(^%XXZ#B\)1GB
M<6EC*$,-E>(Q.+A5I4L11AAL%+-:,:RJ5O;3C1Q#H4I2I\ITX7Z9W!V(RJ.:
MX?@SCRI@(TJRQM6.%RJ-3 8^.)SK#4,OJ4JF/@ZU7$K(<57IUJ'/0C2Q>7N=
M2,L0K^4SZ:A9Y-DCO(R@&,* 1R"!DY/S<';E<@=P*RYM+>9T1(;G(,Y98QYL
MOEIS)*H5"56)1N))*J <G.*]GM=$T6_DT=FMY;(7+ZS;W5N;V5TN/L""2T4M
MO$JRW$K")S&T2N%RGS4_1[.%-0D>WM+JPDD\.:S!=QW,$L*&01LD#VPN9I)5
M#(0CCJY4'.,@^IEOT9,YC# YIC^,>%WP]CL7AZ>$Q>%QTXXZMA,;@'C,)B98
M+,,/AGAXS<H0<<14I./LZK3NH*?E9A],;AQ8['9-EW!7&-/B7 T,;4K83,,+
MA%0PN)RS.Y93CL)4G@,1BZV+K858>O/$ULOA7PM&M6P$&YT\1*</#6T_! &U
MD!7$@5@H&W<4)^[N*\DY+=3BD>W$BB-8OD#!TRK,[,.47&,E>,AN0V,9KUSP
M[I":E8:MX:=XHS=-8ZC%)*Z[DDLY1%J&V1L>6YMF8A.,D$$D]=^]$5PC>*K:
M*W3^P[+5- B@C6+#RQD6ND2&$D,S/;2-.SD8#!6'(S5\)> F"XGX,P'&$..<
MLPF#QF"QF.GA*T*7UFE1X?QV;8?C252<\7",/]7L'A,KS2,9PY\?A,TA&A&=
M91B^KC/Z4^.X.X]S#@27A[F^,QU+$8;#QS"E.N\'.KQ#@,JQ?!;?L\%5J.7$
MN(K9W@91I3:P%?)*RK<JQ%/F^?XK2=V\D0D(A.!N(4^8?,8+D$$%ERP .35A
MK-\[F8;5)/F&1F0@G 5B#EL=B!@=.!73):/-;^5&)%8 >9(1ARP&6*<\<Y7M
MD$]<FD_LQ_)7ARRC"HX4!LG  (R2._/'4C!YK^7*^-ITZM6$*\K0J3C!>T=Y
M1C*<82=W9>TC&-1);0J03]Y-+^L:=:H\+"%:E2C.O1HUZB2OR3K4J55+97<%
M-Q=[:IW2::.4%A@2,7>4!=L@ZA$+ .22 /E4?PDL>,<<FN^G[48HC1D/M5U)
M((D.["\9SMYST'6NR73'0$DJJLJ$QG(W'I@'!RG!(R>>..I#I-*E=6A-P(O,
M8'RD;,>  06*C>I)X7:<9X/ Q4+,K:.K)+NYR:7JMO-].IK1J2IP24:3CS;.
ME&_O2BG[UKZ-W2\K;,X633=C;I0\@.4V@G#!LA=P;YF(')/3(/TJI+I\\(9H
MOG?(;#,0%4Y 55&X;@.,#IU'MZ(VF%<,T_S!0K;E;YE')&6)P?5EP>,# K,>
MQ8N44.,'(.0I/!(.#DXQT/&>?2NFGFDFFY5755K)N;25NR3Z;?/[\*\$YSBH
MP34Y)M1C[R35D]-+?IL<?#'/'$R!V4[E!WG<I5L$A5;.5!SDL0<CH*LK9,T6
MQ8HP7R6#,-Q"GY60'A%YW #N<FND-F<[I H.]!D% V%R&#@OL4JI+\ ,5^N*
MG2TRJG+2;>,JH.1C@C:<@=.>X(YIRS!-WN];_P#+R7^7W"IV@N7D@]]7"/4Y
M18_]8SQL&^1@Q9F)RPC4$'!(7:3@'H<G&*OI$%;:' 4H@8#.,#&T9!X)]^3U
M)SQ72#3-T:F.-6"'#>9G< Y'(/<+R<=0.E2G2&C<@$2;VC*L$P(QT9EQU;!^
M7/'<\\US5<PIMV=1Q:4EK-RT<==]K)W6@G5<9Q:C!*/Q145:;NFG*RTY4K*U
M]#%:R0;6CW,Y95B &%"D^8^\]2N"Q)]">PJ[9V5PAQN5P6.Q6)V. 25P<@E%
MY R<#C':NGBTM[=5_P!(=C\T8^8$C)Y)P#C<I*<9R3R<5<MM)E=XG"$ND9*'
M!()#'*,HP/E!![Y((ZUYM;,Z3@HJ=N56YI7E*7+?:3DN6^NB6EVE?<UC.5*4
MW!J2J2]HZ=2,:E.$VOBI1<4X2W4I<TN:[T5[+*BLIV82B'<0!_JWW(KY/ 5A
ME>!]T].PQTO1V#@YD'E-UV#<S@]<Y7@@Y' R/;GCLX=.9TWQHJG!\U]I4GH
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>'+GV7QHY!G*CR\M/*\:K727-[&S5NEI/1]]GU/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $- -P# 2(  A$! Q$!_\0
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M\$HOV"_B1JOPMT#0[V?PQ\7O&^A:EJ?AF^U7Q-I%G<ZY\0;K6?$VD1IX@L/
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M]P+&4[> &;>N/0*21@=AZ''0FM!;N_#!UD( &WB.,'&,8SY>>V.O3-'L_/\
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M>'\G=::A$ < K=Q.O3.=C)N(]<GTP#S1+F:]W?[M.IQ3R>M>\4K_ "3M^?\
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M]2O;5U6VN+AXVQ X+",B3/-?>MVK/%N<\*)!C(YW!1TYS^/3/!%?R&_\%1/
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MA*[6DO=>]F]5^?+Y:']($'B;6;:3]QJ=V%& %DD9L*.VV3'(^O K;M_''B!
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M\.9?'"4*F(5>59XV-";B]?9\D9I6[J7/NNQ7'3@< $GMQW[?TJ:"4QSJZ/\
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MM3BUF?1I_#&A3V<DBWJE#(D\D9E2+R]RI@OSQ7^@E=,6O;PL?G^U7'Y"9_\
M/7-?$OA#_@FS^PC\._BUX9^.GP^_9F^'_@CXI>#;RXO_  WXD\.17%@MA?3Q
M/#)?#3XI!9M<[)&6 E,)C.1D5]K.K9>5B7WL69OXBS$EB1URS$D\#K7C2G5J
M5:M2M-3G-\[>KUE=OY_?^AZ>'IQHTXT8*T*>D=+:;?I_6@P*<@8^X#NZ<$C]
M>_2J4^8TF;&T0VUU("#S@(Y![\_TK3( 7<,98'< 1D'MD]">2,9_GFL?5I4A
MT_4Y2X!CTV\.>>T$C<9 R<'/X<U-1I4JK;M^[E^157X'\_R9^;.Y7O+]R?OW
M]VX)SDYN78X_ D@=/2MFT)"G(^4<GD=#R.,^O;'/%<[$V6>1A@/-.['/'S2O
MCGT(_+O72Z3&\[L57& '4N,QX!!W-VV8#;CVZX-?$5&GS6?VG_Z4SQDGS+1[
MO=>IMHI9 -V9,J  I+ D!@NT#)++Z#_"JGB3QEH/@;2VU'6[F(>6Q2*WCD62
M:\N ,BVC5"^Y]VWS%R"HSN((Q7E'C;XR^#+'0+R'2-;N[C4[F\N-,TR;38WL
MYFOK8[+M]/N9T#$6K;X_M)7R@_"Y.,_.U];ZGXQET.T4+8:=HUD+O4;VX+2V
MFEI<LTLLL[2L3<WMR2TP))EGG; 54 %>?*HH\T>973;Y;ZZMVO\ Y7.JG!O6
MSO>RTT_K^NQWUKK>L>/;[6S80BVBOI_[0N8YIY9+335D=/.O)WD<JJ>3@Q1*
M1@Y4+S766=W9V<)TS0HV*2ILO]2D 6ZU.:([5"/P(++!)2-<;@H8DURFGZGI
M\6FMI.@)]DT""-EEGE.+_7KMSC[5J,R@'RB=YM[1<+$N V370Z/#%(5RTA,7
MEKDKA6..%&./DQ\K=QZUD[R=[-^B=CTZ"C&#4EKJU?2]_P"M#M= Q%>V/F(N
M/M,$3H4PN7F3<$()W?*.21@]:_J-_9Z2-/@?\+1$@2,^"]%<*.@,EJLC?7+,
MQ)[DYK^8C2;5GOK2*-?,E+*Z%EPJE,,N&)QD8^]D>IX&:_J;^%.C_P!@?#/P
M#HV IT[PCH%L0,$!DTVW+=./O$U[>3_\ONZ4;KU;M^"(J-6BEM[VG:[#XGVG
MVOP9JB\Y@:UN05^\/*N8\XQURK,I'=21QG(_.B1&@N9?E(V'''<YVD]<]^I^
MO:OTL\;LB>$]>DD5FCCL))75!ERD;([;0>^%)'IUK\X]2C87MT%7 65U^8D]
M&SGU(Z9/7N0,U]##9^IMAH*2G?IMIY+^O0B1R548Y()/<X'/)^@SC_ZU2HX
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M8W,=W<8&TC)_#\<>U/8[E!)&?3Z<#CZ8H=!D[7W 9Y/48[=^V#VZ]*C/&/\
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MS_JP N1G/2O:K/0;F2:2.66W6&-%9KI91*5DD7<D,2K\SRM]W RJGKT..?\
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M0_EM\U^B3_'\#%*;-RD+CH#@GDC/3T[<=_85F7T;%5X!V9*NN%7.,#>3PH/
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M_P# E_F<IK\>WPWXI( S_P (KXB)(R"?^)5,O/U[G\,5_+3JT /B?52?F?\
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MJ""..>G>FI)M+7]/S_IB]BMK_B_\CB?&)!\)^+\###PIKX!QM/.GNGS$<G@
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M^6LAZ8)89QP>YP/3_'O7RO\ &?,'[1W[$5TQ""?Q?\8=&#J,'_2O LUPJ=<
MN\(R>A Y!)%?5;(<J0<'<#VQGYMP_#M7R]\?K;R/BA^QEKQ?9#HWQTURQN&(
MRW_%0^"]4L8MJ^C2<'W(ZC%7.M!QLGU3T:>P-)[JY]%NK<[E(*@+R3SMSG.>
M^/I4>,#/<GI[>N.M:DT6QY$.6*RR(QYR2CX!('3( ^O)JHT7 .=QW'M@[>..
MI]>N.]$*T=(VE?7=))_B3R0>\5]Q4\O=ABVW(VE/4>N??..A'J#BJ31E78KD
M#/J/\_UK8VJ3R,L#E5(P=N.QSQSDGCJ./>L\(&2K;N"<G(P?3'/ _P ^E5.J
MDENM?(%"/:*,V0$[ !@KG)!'<_X$].?RJG)G>P+$X/0XQT^F?UK9*?*%(X;.
MXC.>#P<YXZ =NE9[PKCG=C)Q@'(_X%SG/;T]>E1&O[RO?Y6?HU9=Q^SC_=7H
M[?H<YXAB9O#'B_.=K>$_$&&!(82#2IO+VG.!M)R/1N>:_E)^('@?Q'=ZWK.K
M2SW$YEOYIHQ,IE?SI%"%@W\*NJJ6"@'*@\8K^LO4[9IO#_B2-2"DGAS6URRY
MVE[&55#9] ",'@\<9K^=*75=&U6^UZUM99'GM-;O+.Y2X&W8;>9T9X>.8QLR
MO8CL>:^9XCIO%QH1C-P<)57ONW&"UMTT_0[L"J<)U'*S7*K:WZONEWWZGQ;X
M5T35+._OGNK1PMO93H)%/RC8<R22A@-JXR 2<Y^H-=WJ,Q\12:8EC.+6Y;1K
M"&S;4[6>&SGE1GCFD%VJ^684Q\K< D8)YP/7O$6@VLFG36DD3B/4;^R@NI+,
M^7<26DUPHDC#+\RJZ\G SSSWKZYN_P!EGPEXJTGP98>$/&.M65]<Z7#;W']H
MV45]:Z0I@>XE+,!%<>7;W&V,IR&4\FOG\)@JD5-0DIU-.5RORI6E=;-ZW[65
MC2O3C.<7"26KT;ZZ-6W7?JOO/SPT:QO/#M_:7&E21WOB"UU&UO8;B/YQ/>Z?
M,EQ$ML0=HLT>!>21L4L2<'!].^+GQ)T/XK>-?%5_\,)FM-!UQ-.O?%NL2*BW
M&DZ_<6$$7BG0],B52VQ=3AD2&XY41R.P/.:V/BS^P5\?H["+1_"GC#3-4^TW
M4ES]LT-Y8-5OT=RHLXX!Y4EG&5)\W;)S&6SQT\\\._!?QG\(/"UWH/BOPUJ&
MFW2:@#)-]DD9)Y(PQF)FVMY@8G))ED8Y[G%>3G$,?A,-45.A5J2JU$I2IQO&
M,N6RM=IVM=[:'K8+ X:O4ISK3BG3@[+IRW4G=;Z-(\<O/"4,NNV\T<DMI::;
M'&MG V9&F>, 9N"<L[, 7C+=,YYS7J-]J5LD=M;V\R-YJHQ8*(P7=A"T3L?E
M .>A[YR0.:R[Z(VD%QJ%R&AE$FTQSI)%-P,(4W!0B@\ @'CJ>:YZXDCN(ES&
MK*J%5E!&':0%XL@' .[^+(^;!P"*_)LS6(GB(0Q4:L:EJM)1E"=G[11:=TME
M9IO=6ZGW.!5/V<XTI4[<C]Y-)=K=T_E:UO,]9\::S+X"^#WA)W AU;6KSQ)9
MV]VD<ES9V*RW:K!=SO CNID16CC;D>8PY SCYH\$^-O!7AB+4M.DUJSN?$&H
M2R7.IW\=];%[V9<M9V CG,<R10L?,:+EI),DY%?8L^VZ^'WPFTNVCCEN;CPK
M?RW,,L0N D\NLW#))*L@8,4B&<]<#VKY8^,GP8\!>,[NP\,:?X9M;;5Y"9;[
M7-':33M1#!"))A)&0JN"QQ(5X8 ?6,%F.4X>K5P.8X*K4IU95)^VH5G3JQC"
M%-3;C9+EBXW@^;FDGM=(PQ.&QM6$:V%J*G*EJH5')>T:ZP45)2\[]/73?TWX
MQ^([/48889],O7,>Y8;Z;^SXYI9!B)(II,Q.>@E.\?*N,9'.-\8/C#X[^-,/
MAO\ 9*^&_A9[KQAX^U_0K/QE/H-S]N77&U"]BAT+PAI\EMYC-_:FHR0RWTBG
M8EE%)YH6,,P^L_V#/^"+/Q)^+5CXJ\0>!OCSJOA_P;IBPV1T[XI^&%\7:/JN
MHWH>:2TM/+GBNH)8(52:6YC<^1;W%OMCD>8@?N+^P1_P1WMOV6?CVWQR^)>K
M?#;Q=JGAG1+NT\ VO@S0]4TZ.V\2:FWD7?BS6(M75XFO]/TI[O3]&2U^:T>\
M>[$JRP0FOU?AC@?)\;4RO/\  X+&4:&M;"SQDJ4TY-NC+%M\\IR<*2FL)&5-
MQ4I.>C29\%G7$F94H8S+:V+H5)5(P]K[&51SC[M_J]W",;-/]^E+W9:)/I^C
M/[#/[*7AG]C3]FOX>_!'08[675-)TY-5\<ZW;Q[6\1>.=6CCN/$6J.Y9W>W6
MZQ8::K.1#IEG:1*%VD5]=T45^WTX0I0A3IQ484XQA"*V48I))?)?-W;U;/SQ
MMMMO=ZL*.O6BBK$<_JGA;0=8BFBO=-@;S[+^SGF@!MKE;+SA.+>.XMS'+%&)
MAY@5&4!B2.ISR.I?"W1;V=I89IK5);JV:2% H6&PAMS%)961C\OR!-*$G,K"
M1@P=3N#<>G45$J=.5[QCKU22?WI)]#2-6K"W+4DK;*[:^YMK\#YPU7X0ZA%:
MW$MG*9I4>ZDAMH'5T-M$Q^RQKYJQ2-=S(W[PDLJL'"ALJ*\NU/PAKVEND=U8
MS;Y(5GSLD51&ZJ0)&9$"NA8+)M_=QG@R9! ^X*:RJP(958$8(8 @CT((((]J
MQEA:;VNOG=?C_P $[(9C6CI.,9JUGIROONKJ_P MM#X EL+F':[V\RJ2 <+O
MC_B# 2(",C'/S9&,_7Y)_:KUK3O#EQ^S ;YE6[U?]J7P)H.CVYDCCN=0U+4;
M+4%6RT]9&!DG6!9+IU&3Y4+9QD$_LW>^&]#U!M]SIMJTG:6-!#*/I)#L?]>I
M)[G/RM^T)^RM9?%9OAAKWAIO#D7BOX3_ !+L_B3X=3QCISZMHK:C;Z=>:8Q5
M8%$]E?1079-IJ$:RRQ'?_$RNN%7#3A!RIKVDE9J":BY:J]G+W;VUUWM9:G52
MQ]*<HQJ)TD[WG+WHQT;5^5<UF]+V=KIO2YYO= 1W-W&2&Q<SCS%#'S,2.,[B
M!\V1\RXPK9%9S+CA!SU/4Y]S_P#6QS5C4M&^+&@)YOC/X7ZF=MM>W]_JW@;4
M1XGTB"*T9F<&V8#5C-.I\^",0(60%6 D4K7.6?B[PM>7"VPUJVL+UX(;D:9K
M:OHFI1P3\Q>;#J CBBD=@P1/.<N ?X@P'%*3A)<ZE3EI[LE);[VE;E:_PR^1
MZ-.$:L7*E5IU$OY9*_G=7NK>:6QNE5X)4#Y0"><EOJ.?7CIR:CDCW#) '&..
M/7KV_+G'XU;,4A593$YC^]O1!)%*K#Y2DBLT)4<?O%<@[L=:K2\_-GY  OR\
M,&'!!R2.OWB.#GY?:N9-?&I._P -VO.^NA<*:;:;NTFVDF[6\_\ (H,".,<#
MH>O7UQ[U3E7@J"0 .!G '0D__K..V*U!A\JRJ, \C//0@]>V1QZ@_2H7MQQA
M7).3N!Z^@P00/P]JI1:]YKE_[>O\M/O[%>SCJFFFE>VO?U,V>(_V-KZJR MH
M&K@9).&^R2CD<Y(#'KP2?;G^:A/#U^GBOQ/-/#"MLFMZ@;6:"7/GK]LE#><I
MX#(IQMZ?4BOZ9YT']EZYD8,6AZN2K8.52QE8@\=R.G8^@/'\ZD.K6^I7FNS(
ML9,>MZNDR* A0+>3!,]>21U[\\'@UXN:U*<)TH3LK\S4FTEJDGO9WT]&=%"A
MHVKW:7N]='\_+]3BM8AMY(X;5I9(!+?(J3(3O0PONB.1SA7&['0_3(K]:/"%
MCIN@^%/!\-M=6^HZM>:39RW]ZL\-Y=)(FFJ[).T0!@5#(0X889UP^2!7XC_$
M7XG6OAWQAX'\'Z;;'5-9UW56?6%C*>1H.F;62&\OF)/EO<3,BPP#+C <@+T_
M<OP/X81=*\)7*6]G 3HGFWEQ;JL?VDF&$^29$;;(74,I(4,NXD'H*RRN"J5Y
M-*,U"4.:SB[J5^_33KKT5KEU:,H6ERR3L[=+_ATNN[ZGQMI_[8T/^E:SX]^&
M?BWP3X/T[XJI\/\ 0_B7IKVNL64EQ!>R::VIZG8QLEQ:VMS(!N0+(BJQP>!C
MZ0T+Q+X7\?PK?'QEX6\464?B.9+ V@CAF>$7"Q+;7^GWI)^V[D9]L8V&%LGM
MGQGXD?L;ZY=:1XKT3PE\8;G0/ /BK79?BAJ?@[Q)X?@UNWTO7(KU;Q[+1-<A
M<7L5G/. 3&5:2 .6!X "_!OX 2Q^'-(7QE::?8^(]/UVXN; Z<WF:=>6,<TK
MVUX+UB+S[1>%P\P<&6+8H4@X6OILXIX"I2PBH6<H\OMH.*LYJ2M?3?E^Y::;
M&>$G5C*M[5OX7[-W?P];WZW_ #9]>>/?A7\,O%7ABQMM=\!^&-2:]UBTM3=6
MUG#;7R K(946:T"E0X ^9@0O&!7R_P"%_P#@G%\+/CCX+\3>)='\9^(OAKKV
MF^)=1T?3H[:SBUG0Y+?3(Y'BBO8?W<L<BLFWSE)&2"W0U],:9X4F\/Q:'<ZA
M?WTMR=:NUAM[.YDGLSIWD2&*YE28[C>HV00!@* <5]$_!>_TB+X/>+=8TBT;
M3M-COO&.I^5--]H=SI^EW9N[QY&R%:::,R^4I 5CD#T\JKE>6XVJX8G!825X
M3E&:I<LZ;4%\3:76ST??0UAB\7!0C3JU(\U2*NF[6ES2[]HM=M5;J?SG:_;7
M_A?2?#8TQ7U"XTKPU=Z3%<1(<2?V7K6I6,ESY7WH6N7B,S<L<$#.W-<K^SEX
M?U?XO_&+2/ 5CHE_<^,?&6LVNDZ=!+"SQ?9O,#7%S(YP(+6)%EN)Y6(V6\4S
MC[E?1J::GV'08)XB[W'A]-188+L(M8OKN^&T$D[F6;@="7 &#S7[Q_\ !-/]
ME30OA]X;E^.VNZ'9IXQ\9VC67A::2WC-SI'A96,<]S"Y#&.;6ID($L;*7T^&
M,_<NF!_FOAK)GQ1QIF.6TZ/^PT<?7KXW$<J<</@<!BY4?91:5E+&5(^PA&ZO
MS.34E2D??9YF<<DX>PV)<[XNO1A#"1NG)UZM.,IREO>%.,N:5ND;73DC]#?@
MS\*]!^"_PX\,_#WP_%&+;1+&-;V[2-8WU35IE$FI:G,%5?GN[HR.BD?NH!%"
M/EC%>HT45_6]&C2P]*E0H4X4J-&G"E2IPBHPITZ<5"$(Q2248QBDDE^+;?X/
M.<ZDYU*DG*=24ISDW=RE.3E)M]VVW_P$@HHHK0D**** "BBB@ HHHH ****
M"N6\2^!_!WC*VEM/%7AC0]?@F6))%U33;6[<K#)YL(6:2,SQ^5)\Z>7(I5B2
M,9.>IHI-*2LTFGNFDT_DTU^ TVG=-I]TVG]Z:?XGS7J/[+_@<2S7/A#6?%G@
M2XN-1^WSQ:)K$MWI4JM$(WLO[(U<7UG%9%E200VPA".&"$*Y \QU3X)?&318
M(OLM_P"#_'\,<5]/=N8+CPCKDKQ%GL+2TV-J&F2R3H1'++<&!5D!(&UAM^XJ
M*YYX/#S_ .7:@^]-\C^Y:?@=E',,71TC5YEM::4].W,US6_[>9^9^IMK7A\R
MKXI\'>+/"C6L&FRW4UYIKZOHJ2ZG(8888]8T<W$5U+YRF.4(D:0.R^;L5E)F
M@N;:[63[#=VUV89!%.+>XCF:*0<-%-"A$MO-N./)<*RD$,."3^E#HDBE)$61
M&X9'4,K#.<%6!!Y /(ZC->;:]\'_ (<^(I_M=_X7T^*^-ZVHM?Z<C:9>/>O"
MUN]Q+/9-"TTC1M\QE#Y95<C>H-8/ 6;Y*LK/I*[M;71I^5KM;=[:^A3SN3CR
MUZ7-JK2IM)I=7RR6NFRYO^!\/ZG(T.@^*CM430^&=;)4EE8!M-GVOAN,@],,
MP..#VK^-[XS?&ZZ^#8\33Z;JJCQ-K&JZF-%TC]TRW3RW,R'49Q+N\G3[+(9I
M" T]RIC0%#Q_:7^TA\*KWX5_ _XJ>//"?Q"O+&T\)?#'QKJ6H:=XLT^T\0PZ
MO]CTBZNK>%M0D>SO;6XF*"P29))#F99 AD!W?P/1^%=1^)OC[4?$WB&WL;_4
MKN[EG;SA(FGZ=;I,Y\F$RDJ=+@3$@ ^::Z'EMFORKC['?4L7E^$J*5.OB*6(
MK0]G432I4W"ES2<;-1E4O%74=>:U[:?><+4*&:4JV)YFJ>'K1I5(NE.3O*#J
M1;>D5>/17MI=[%?X?7GBK46G\:>)A>:IXLN0-6M;Z:]%E+817ET/,UB^0 HQ
MG ,&F:<1\Z[<HJX:OV8^%G[?#^%-%BT?5/"!N;.:QM8);C43<23VTMLB+,]A
M-:N2$F WR*( ,MC/&:_+J\D>+54\,>$XK7;IRQZC?ZC=PEUN)@!$MY< _P"M
M^T,!!961S%;(F]0#DU]&Z+<VMY_PC$>H^"8=6UF]M&LQ'/J#Z5I&IO 3YK2+
M#&OV1F'WG$F2!GD8KXW+,WQ;E.%'-Z.!K\T>6-:;J\R2=FTI0Y?).^^_0^LQ
M66X64'4E@9UHQ5E*%10Y;ZMN+BV[VTLTU;1=3]8O"?[=7P]UNQUR+[+<VEQ%
MH,SE+[;<6 2XFCC9HXG,5P&C5B<A<C;P"0!7T)\/?'/AOXF:?X?U.RFL([:X
M=K*WM[+48=]Y/;$(\ZY>*>-G=E,D4@RI QFOPNTKX>/XYE^(<'@_PS:^%-8T
M718;>ZL9/$D6I:)%+=7T8B$6H7<D3X;A"4R(4))'RXI=/\&^.='T?2DA\1:I
MH.KZ+<7/F:='=RB. ._E%K6973[2CS)YT-Q$<21A3N YKWZW%V9Y1*A/'RP^
M846]:V&JQA%R4DN22:FU.4?>BF]5INS@AD6"QT)QPSE0K6<?9U*<I633?/SI
MQ32>EFDWWU/Z'OB$J>&-%T/5G?44L9[KQ"8(4C%S=7EU#I4F(K>0Y&P-U(8!
M1EL\XK1^&&LZQI_[&OB759O#DT<$G@SXG7]Q-'<1O<P)=V-Y#%-+&N/F7>,H
M.<<8KY?_ ."<O[,?QN^/FE^)=:^(_P 2O&FC_#CP[9W^D>&+CS5O7OO%&HQ*
MLTEI!J:3P&ULK5S)JGV21"9)[>S2:&7SC'^EDG[+7QU\%_#+Q)\)=!O_  3X
MY\&:SI]_X?L;C=<:!XJL-,UQ!'>WTPOFDTVYGM#)(ZQG4"9$&Y%:151OTC+<
M;BLSP']K4<%5='%863PU*4E3K5$W;GY'%.,7)24&T_:07,M&K_ XNMA<#C*N
M JXJ/-A:JYIQA*47*,9)PNFTI+G]Z+;<7I?=+\T_V8?V?)?C;\1_ VCFWN8=
M'TWPMX5N?%%Q+$1%;Z-INGVLERBG!59[H2)9VZD[A=W<<IRL3@?TM6%A9Z78
MV>F:?;Q6EAI]K;V5E:PJ$AMK2UB2"W@B4<+'%$B1H.RJ!7A/[/?P)TCX(>$X
M--B:&^UZZL-,MM4U06Z13&&PM(HHK'S5>1IDBG\^>27<JS3RLR1QQK&B_0-8
M\$<)PX8P6-G55.>99MCL1CL95C%IPIU*U6IA<)=N5UAH59<\DU&=:I.:5E&W
MD<19W+.,1AE!S6%P.%HX:A"3NI3A"*KU^5)<KK3BK)W<80BF[MA1117VQ\\%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P?Q/\ AOX4^+_P^\7?
M#+QQ92:CX3\:Z)>Z#KEI#<26D\EE>QE&>WN82)(+B%]D]O*-P2:-&974%3_)
M1^U+_P $M/C'^S_XJO(?AYX;UGXA?#-V2?2O&.D:3)>7RVTYE8:5KMAI_GR6
M=[;,A,TBVXL9V\N>%U1O+C_L3HKY+BK@[+.*Z%..*G5PF-P\91PV8X;E]O2A
M*7/*C.$VJ=>A*=ING.SC.\J<X.4N;Z+A_B;,.'JM1X;DK8:NXO$8.LVJ564-
M(S4HISIU(Q;CSQO>+Y9QDE'E_P ]]/"']B:EJ$WC;1K[PW)-IT.D0R_V;-';
ML8)S-#<W4D*,(II2S SN54#<"!CC2M9]=U.9='\/WVAZ[8"<Q6T5Q<16BQE5
MW/.ETSC&50YVD;CQC.:_N@^(_P"S?\#?BS:3VOCSX9^%=:>>V>T^W#3(++4X
M8G<RDP:C8K;W44@D9G602%@S$YY(/YO_ !<_X(M?LL>+;6_OO!-WXG^&VHB
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I*<I3G)RE*3E*4FY2E*3;E*3;;;;;;;;;;;844451(4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #S 08# 2(  A$! Q$!_\0
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MIDPANX/['C=KF:&.1T"WX41ON#] 2/AWXT?LH_$G5/AU^QUX,\%KHGQ T_\
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M?V3^[^OT']5E_,OZ^9]F9C]#^?\ ]>DW1YQ@Y],^N??VKY&C^+OBR5=R3V#
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MDT5O''49)2C3DT^JC=>>J7?0R]C4_D9G?% [?'>K'K^[M_;J0:XI63AF.!D
M_P"<]O\ .17:_%/8WCG5AN.3#;],>@'X>HZ^G6N!4*H^<L5XXX[=.W]/IBO.
MK/\ ?<GVHRU[:.[U]#U<+_#7^'_VTUE,+!2KC@YSCKGMU]NN/IQ5@-'E2) 6
M7&5(*KCUW\@<\8Z]/6LV"6(DJ%P..H_#T_S]>OG_ ,5OB7H?PG^'/C+XB^(K
MN&QT?PEI$^H7<\Q2.-&$<GV78\AV-)+*FTH!NP!C!-$GRIM[)7?HMS2?P_-'
MK)8$X212V0"H60XR./F$9!SUX/2F$J,DDY').&QD=_\ 5],U_&E\5O\ @Y9^
M)7@C4=<&B>"_#-QIEEJ%W:Z7-?0Q27&I012LD,ZXG5]CJ ,L2<CY2%( ^0[O
M_@ZX_:Q+W1T_X0_"MU1\6S7$%YEU+D!I=C<'&"V"0#W8<URK$4ZJO#FM%V;:
MLK[67?8F#2O?\C^^CS<]&R>PVL/U*4UIR@RQP,XSANO_ 'Q[5_ *O_!US^VE
MO;_BS_P6\M<Y+PZ@ !T&2)">OM^G24?\'7'[9CG:?@_\$F] (]2X/J<MT_QK
M2-6"5G??M_P13:;NNW:Q_?F+G/W3N]< _P!4%2+*3R3M'<D'CZ_+7\!G_$5C
M^V7'&[/\&?@E*W5-JZH JCJ&"N"3R.<#'.<8XMV__!U]^UY$$>3X%_!6Y& 6
M7?JBMD]5P7_(=2.^.M>VAYZ>7_!,W))VU^X_OH\[^,,,)Q@B3) R ?N<9QSP
M1R,DXY:65RQ<[AR%(5AMQP#ET"C'3D@9[BOX-[;_ (.R?VIFC*W'[-7P>=R,
MAX]5U) P'4LA9MA_V1T)R!Q6O8_\'8G[1$:J;K]F7X5%';"^7XAU+>#GN6C(
M'7@G YQG%>/GN3Y-Q1E.)R3B#+Z&9Y7C?]YP&)IQJX>I9<L>:$TXR33]Y-:W
M92Q,Z-15J#<:JC:^UK+=6UOI_5]/[K&CA9?G;<N0?F:,#(Z?=;.>^/3KTJ(R
M1PX!,+@[MH^7 Z9W98_ACH?J*_BDTO\ X.K/B5-$CZM^SYX"B<KDV\6O7JC)
M_B$HAX"X.%+<\]ZW8_\ @ZK\2HRB;]GGP9+N_A3Q-?!@0>0,VY&3Q^/TK\JA
M]&_P(C3<7X8\)\S73)L$^M[7=);:?TB_[9S39XZMIMK+3\3^SP)$N=H5P[;\
M?(5#''(^;(; ';'3BIE3'SJX\UAM8N$8!>AX&1N'0$'@8%?QO6__  =2ZCO2
M2?\ 9N\.D9"OL\47 &W.=R_Z,.<DCD'CZ5Z!I'_!TKH^H^8D_P"SS903''E[
M/&2)#G@'<LEOO Z_W>A)SG)QG]&_P*LK^%_"3\O['P5EM_TZ+AG.97]_'5FK
M::RW_P# C^N)T9A\S1E>A&\#*]"-J@!B1T4Y!/UICQ0L54)LCY6155 Q1NH4
MD8!(X)(/K7\I=C_P<W:5=,%D_9[T[!8*1'XVAW,-V"!F,@%AG;GC..@YKL[/
M_@Y)\.7(!;]G6Z Y)$?BRWFX ))#*F.,=\^W2LG]'#P-BKTO#+A.$[IJ2R;!
M75O^X?1[?G8U_MG'=<;5_P#)G_[<?U!E=_+8=C@NS *2WW<@#"X*A-V1N+*"
M#CHY-L?! &?0@\#.<9(Z>GUZ=_YM]$_X.*/AAJ0#ZE\%=4TQ%7+,?$,$QW9
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MYKE7( 48!3?NYP"3QS@U"$(THQ:<6W*3MK>VEM]+]_UMG&5[JUK>9D1:(LC
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M77C;0(H'EGTJ';',4V_8H^0H!R1UZEB>>>2#TJQIGCGPMJ"J(](C*@8R+)2
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M,^F*LM[<Q-$]ZD:*/-?"$CS#@[43*A\#&"*\"B^%GA0R>5+XKOR9%1UB\U)
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MOF;!Y//'%>31?;@0S6]]AG*!S;3[6<'!4$IC)/) SGC(SBM*VL-4G0N+#56
MZC[%=8XQW,6!T SG%3]73UTUUW[_ /#]177=?>O\SU"/4[=X);ACL:*TU&-
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MZ*]]-3IP\HI-N23Y=VU?6WS/DV_^*'@*^\6W5Q++#)=/=OS&LLT\@1R/WD[
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M!/BO4/#6N:+?V]YX9\3Z/J1TV^T>^9P6NK6[!"F-%.9 2">I'!KZTU[]LO\
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M?\$8/^"P.I%8A^QAX_N4B'E02+IVBH?+3  9A=$D8^YD\'=ZUYM%_P $/O\
M@L+%=JS?L:?$A;)YXIKFV2QT?,Z(3\H;[5F-A@#/<8QTK_7_ #&3C]Y(/]UA
MC]5)H$9'_+20_4@_^RUTT\/&,4G?3II^C_K<S/\ (AN/^"-'_!9N3RXK+]BW
MXCZ?;V\QDADMM.T'SGC5SMB=S<'.1RQ((R>>AJY-_P $9O\ @LQ>S//<_LA_
M%&-G5(UA33]!5&7 !#E+COCG!!)Z=!7^NEM;LQQ[DY_08J#)P/WDG4'J.A.
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M[]UQL!VC&!G< ,=Z\\'_  <D?\%?]Q)_:)T,C& %\ >'@.O4YMS3E_X.2/\
M@KZ%(;]HK0V;^%A\/_#X';.\>0,CTQSUSV%*GQ!ER?5Z;1@I/[EJO5A_:-+_
M )\R^2A_F>K6O_!,#_@LA!/'+%^SE\88S;,L-F%GTI'2WP#EGCN!\J./N,>5
MZY%=/!_P3/\ ^"QLL2QW7[/GQK&2YF5-6LPK1E22$"7VQ 1D8P..@Z5\\O\
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M/^"2W_!5+3IYY;3]F+XNI->L9)9H[JSBE>=\EL,NH82,DY5>  3@$$@,N/\
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MS[TZH58C@<  X&/0''\L^_7O4U?W_&2D[K:S2=OY9-/\4?FO;S2?I<****L
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M'&(T&]75'D 5(VPJ@C=@< @BN-U#]MCX?:9,KWWQ*TM#'^X$EQKUA J0OS(
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M#S-0TZ4QY:6.XMMMORLTBG@?C6NEZA$S,;"3>>=R"$'' (W2JQQGDJN,\'/
MKZ"^!O[0G[0OP$U@ZU\(_&_B/PO>*5>XTN._:XT34(8SAX+W2[J:2QG@F3Y)
MHI('20%N@-?D&;\"*MAITJ,L-FN J)MY/Q+0AC,*E)<DH8/'RA+&X5:MPO*K
M"#LK6T6%+$4:F(;E*>&Q-]*M%NCS2CLVDXJ6UM$F^]C]3_A?_P %9M>T:-;'
MQ]IMPLEO*D-U+,&(MY,[?WZ/M^S*S9 RV ?XA@5]Q^$/^"H/PGUY;6SCU&:'
M5+NXM;6TM-/-P;JZN[K:((+:"-G>:9G=8@J AI'VC(YK\O[+]J+]E[]J*S;2
M?VQ_V?;?P7XOU",P6WQV^!\%GH&I1WJC N?$G@]&M].UA%8EY/+:%9"69".!
M67X;^ /PN_9D_:?_ &,/C3\-_CKX$^.OP?\ %/QR\*VHM@K:?XC\/_9-8L6F
ML/&'AK47<6X53S-'-+%M7/2OP?-_HU>%/$F-Q&&QG"68<.9RL/7Q7LL)2CB,
MNQ-H5*B>&QL%*FW4E%\E.<:=2SBG'F:/HZ&>9QEU2E"CF4Y*<Z<)-3DW!2<4
MW+W];)W;5T^VA_31\(/B+XS^)O[1&E_LT:=IVOV/Q!_L/3/%GBRWNY)8HO"7
M@O4[*'5%UK6KN8BVT[=I[[XTN&60NK1J.06^<_VD_P#@IG^S#\&/C!XT^&G@
MSXK7/CO3/"-]-I5UKMJS>1<:Q8L8-2M[>YW%+RUM+N.2%+B(&*1@_ELR\U^P
M7[;VM?L&>#_"OQSNM4_:Z^&O[+?CW]H72M*TCXO_ !(\)Z[I>M?%'4_!VE:<
MX'AWPK!87,]WI,EWI[BWC\@$Q,%41L7./\UW]I75?@1<_&CQG:?LS6?B2V^"
MVEZC+IW@W6/&NIS:AXK\8P6LCQW7BS6)" ;6XUJY$EVMG)M:%)%+*-U>/PE]
M"WPIX@CC%C,KSK"SPG(DZV&C16(=[2G"I)))<RYH0C&4U%N\K1;?T6;<79]@
MJ-.E0S2K*4W?VD*E2ZBE>UE4=EW>_2UC^IO1?^"XGP?\%WL]Y"EQK-O?6D^G
M:M87,K^7>64N5VQ2@%XI!DG>%'&.0!FN4U/_ (+U?!O0?$6@ZSX)\":I!::%
M.]VUI=:K+=MJ$TBLLB3/(X_=(& BR00H"A< 9_D6>9,CS';=PI+$K@\\+R=P
M).<D@GGIW@>2,LR;@$&,,"P+9 .3AL$=O_U<_L&7_1 \(LMPU'#3RK&UZ5"J
MJM.->47!324;IQC=NW2UM7\_EZO%_$5>3J5,QK3G:UW*;NFD]N<_J/L?^"_^
MD:(GB/3+[X:3^)/#GBF__M/4M+.HO821:C%(T]OJ%K<QB4QW"96% P\M559#
MD_+7(0?\'#^KZ%+K<?ACX&6L&F7$*'1["\\37%Q9I?+#+$UUK,<H;[8=TGF(
M8O+"2A9-IV[3_-$9HH\^6@).0"S.0#ZD'@CN1GD \],U6,DA.$C8OP&6/&W!
MZ! "#GI][ !R.E?=Y?\ 1\\)LOE&<.%\'7G%<M\5>I%+JE"24=O/_@<U3B'-
M:E.:GCZD6^KG*,GINGSI[[Z'ZO>,/^"O?[3?B:6_ELM2L=&BO[NZNQ:62MMM
M#<S-(84E.&>.(85,@8P.*^=?$W_!07]J;Q.KQ7/Q&U*UA=SE;::6,E".S*RD
M,#T'3W  KXU6RNQ;KY=H[?-DN$*CD'OM^[G^I'<U)'I\S[ [1(SG 4R#<.,\
MK@G&."?7M7U&7>%/AEE=3VN&X(X;C:3ESO*\+6FW=N]ZE.;T?]7/,CF6,FG[
M3'XJI=N]J]3E;;[<_3UMU['K.K_M#?&K6G:;5/B/XJNT?=OC;5+@9SD#DR^G
M&,<=A@9KS^]\<^,-1"O>^)]?G\QF&'OKF;DC))_>@8SD<9Z\<]<-X;%&*N\M
MQ,K%/W"YCW*3D ,58[<;7VJW(R.H->L?#GX.?%_XF7]IIOPP^%7C?QM<7#E8
MCH?AK5-1@>1L'$EU';-;1)SPSS 8^8X%?8QR[AO+H<V&RG)<!2C!/FK8/+\%
M3BH1>D)1H1=DMKJ]K76AQ5JDJTDH4G5ES:NI*<T[N[?QMWOKKMTV/*4U?5YV
M4R:AJ,I;@*US,Q)R< #DGGL,9Y.>:=#=ZO"_,UYYA^?RS<2F3:/O,4W;L'(Y
M(ZG!ZXK]+-!_X)??M3AVO/BK_P *N^ >C16AOI]1^*_Q"\-^'I1!$0TJ+9)=
M37GG!>!'Y6XG 4$UU\W[*O["NB:BVG>+OV^-)AUY+. WT?@?P#KWBO0+>^/R
M7,2ZL7LA<Q0L#A[19A(/F5#P:\FMQ)D-&T:5.IC5-2O_ &5@)YC1@HM*U2KA
M<.J<$VVKIS2:M*W4='%6:6"HIZ--U4D[]TY_G9GYOZ3XLURQMY&@U&_B8HJD
MB[G6:)APNS;( ,Y.3G.0-O?/]PO_  9_>(-7\0Z/^VQ/K.KW^KRV?B+X=6MM
M)?7$MR;>"33[]I(HS,S%5)"G8,KWSGK_ #:ZQ_P3=/B_P?K?CS]D_P#:#^&O
M[3^E^'-,FUG6?!N@1W7AWXF6VDVX\VXO8?!^KJE]J'DI'*TB6;3R*D9<J 5W
M?T@?\&?%O-:Z=^W1#<6LME<0^+OA[#/:31F*:WFAL=0CDBE0@%948;)$(!1U
M92 0:^@X&Q?#^9Y_*ME<*4Z]%2595<(L'B\+52:=.=*I1I5E>S2DKP:5[MIH
M[<NGC(8E0J85T:3B_P!["HW!VBVERJ5G>VNC>Q_;0BX50.@7 'MQC\@,4^D7
MH/H/Y4M?N*24I6ZZOUNU^A],G=)]PHHHJAA1110 4444 %%%% !1110 4Q^W
MT8_D/7M[]^..:?3'[?1OY5$U?D7_ $\A^8=5_78_C9_X.];2^O/A9^QBNGJQ
M9?B7\0&\R.38P)\+V.1SU7;N!!YY]17\-CZ;KHC\MX[G(()VS,%)'!;"R+ST
MS^/%?W%_\'?UQ-;?"G]B]X)'B+?$[X@J2C%01_PB]D2#C'3\P:_AE:\U%&WK
M=3F-E"G]XQ"@_,3U]L9/4'OBOPOC2-5Y]BO9\J2Y7=IN[Y8Z73T^>Y\EFWM_
MK4O91O%_%JEJM?+I;U_-QT[55/RPW+8SG=(S]>@^:0XQGC''\Z46&J\ 1W2,
M3R4E*-],[CPPZCC]2#4DO+H$;;N?+ E@)&&"?UR>>Y&/8XJE-?WX;Y;B<C':
M1N./KT([=*^94:DN7FDKK76[2>^EV[:GBSCF<IQ<?JR4/A52-YKJ[OFT]7T-
M"XT_5I(9#);7&S.T*LY17&[JY#%R,#@*RXXXZU1.G:LKV\B"YA:T8R6N;F3=
M:N4"&:V9IBT,QVAQ,A$@<;@X.,5FNM1==K33LAP=ID<@\\9PW;\./IQGW-U>
M--&C238<X^^QX/X\ <9R>H&,5W4H8K1)K2\E+E;=N7H]9:J^E[:]CH4<?9/E
M:O9WN^5/OOLGK\K&O<:)K&KW;7VJ7D^JW<C>9/>:U?3ZA=M\@0R/<W=Q+*61
M57 7!X&,\"K#^"TN0574;-RZDJX\N)VD4982E -[$84.1N(')S7*3K<EODDD
M9@0>9&^Z.,X)Q[CCUR/6%7N""(Y',B@%_F;@<D'ZG&<<'(!)!S72OK4K-8AI
MZ[*UG=;VT6GDF[[=2Y/-*JY*F*PW+I9\LKI+SOI_5SM-9\-^'Y+;38+)8["]
M@M9%U1I;GSDGN$W&.:$''E*Y.UD!/"^F*Y&71=(C=5FU6$+M :.)?F5@!N^<
M'UR>G (SZUE7$-]-#/<$L4@ DF#$G?R<9)))QU[8)!/>LSR1(0S1C?+@KG/R
MY& %S@XXSQ^==U"E6C!>UQ51IIW=^KU=G*[\]M%Y"^JXC:KC8<M]/9MI_-M^
MG?6_SZ);?PW;$E[YY@&&512=PSC&>A)Z8XY..N*[OX<>#/%/Q3\267@WX6^#
M[_Q/XBU-V2PL[>./S,(&=WFDD9(H8 B.TUS,ZI!$KR,<(*\;\AAD'U[ 'GGD
M<YSR<8P<]*[CP;XXU_P4=8B\.:]J&@?V[8C2KR_TFXFMM1CM'<&:%98&CE6&
M4$QSJCINB>1<D%@;J8:4X2]C4<ZOV)5I2]C%[)SC%Q;[VNMFKHJ&!C)J4\3*
M<5O[U[WUMN[>I^@47_!/77?#,8N_VA/VG/@/\"[?8)+O1[WQ<GBOQ)%"!YDJ
M0:-X8CO"UW"H,(MW=&9^K \40>$/^"9'PKFU%=:^)'QT_:7U?3K9+PVO@W2]
M/^&?A6]3($L0U36I)]2D P0K10(Q0\*7P*_/JZTPZK+';P:[!J]T[#_2)YV-
MP\R@R!)'N&:1G!!/WCEN?4C"N-%U.%7::PF)21]\D*QRQE^[R>62-YZX/8\8
M[\*RS$S<J>/SNJ^9K_9\!3I8"E&+?NVQ$85:SO&ZD_:IJZOK%-]W+AJ:C&,8
M<J\VW?:][I-OTL?I?9_M]?!#X;P7K?L[?L2_!;P1?Q1%=,\3_%>/4?BQXC>-
MC^ZN?)UEXM,CN%!!,D=HT;'D[NM>.^.O^"BW[7_C2)[*X^+M]X$T61F*^'_A
M=I>E_#O1(PW(1(/#%II]UL12%0/=,=H"L#@Y^'Y99%1$EBP(_,5':,!G!)9X
MSD$A 00%S@8X"C@,+%P"W<9P>0,\X'; ]N*VAD&3T)2DL-'%2E*[GC*D\;4O
MRJ-O:8F=52ZZJ"U>B22-8/D7N-Q33M:RT>NR2.H\4^-O&'C:].I>+/$VN^(K
M]N6N=8U:_P!1ED8\;G-[<3@O[J%^@R:Q[>80[G>"*50K!8Y%'EB0@;74,'VL
MN#@H5 +$#)%4(P60X^]Q@]P<GU_QJTSD;4SSMS^ ('Y9]N?>NJG3A2@J=&$*
M,(JT84H0IQ2W:481A%+OIKW.9Z7:O=V=[N^C7GZGH_PJ^)WB7X5^,].\;>%_
M$7B/PKXDT&1=2\/:QX5U*6VOM.U>&6/[%/+EU22Q\UDAOX)5F@GM998Y8F5R
M1_H0_P#!L]X\\(?&=/VG_CKH%EIVA>*?BA_PKVZ^*?AK28X(K&T^(&B6U]I^
MKZS:06ZI!;0^(L1:DT42+&9Y9B #G/\ G**JD"4G$B$$'H6  )4G^[Z@Y'J*
M_N[_ .#.6QN+?P5^V5-,P$%WXD\ S01="FVQOV#(. HWDD8 ^;Z5ZF2Y?AZ_
M$&"QU)>RQ5.,X5)P7(YTW#WX245",HWBI*_,U*[3CU]C+VW-)NZY;\KU5ULU
M?M=[=]3^VD,><= N1D?3K].GX>M25$AW;3@C*<AA@]><CGGUJ6OUJFY7GS.]
MIM*_;HO1?TSV0HHHK4 HHHH **** "BBB@ HHHH *B!PKDGL3D_C].F1^E2U
M$,!< CJ6Z=<Y]<\],],?@:F32Y4]'*22?SU#2SOY6/Y7_P#@YJ\ _L_?$#X?
M_LK6W[0'Q?UGX0V%CX[\92^'+O2/#$OB4ZQ>_P!@6RW$%S&C(+2.& K("S@[
MBHR3A3_(I#^S=_P3ROG\F/\ ;/\ %T&X_.\_POG52BY/4WPR<XQ].O:OZ9?^
M#OJ8Q_"K]C$8 \WXE?$%<G^]_P (S8]QR!P3Z9/%?PRM<,!(022F1\I/7@#)
MS@KW_#-?S5Q]D>:8GB+%UJ7$.9Y?&7+[.CA(X.=*S2?._;X>I+FOHUS*.S26
MM_$Q\H>VDO84JK44I.4FGHM5HTK6Z[ZGZ:+^S;_P3S65L_MG>+P@8(P3X63G
M<4X&<WI/(Y7:1D9/6IYOV<O^"=2*&_X;(\<2!3N98OA:QP%_B8-?;EYX)( _
MNDC@?FII-O=W,CRK;S2ML+(V3Y:MC@D\+CW.#U'(XKI-'TD+=F.[:YU5;MAY
MUEI(/F?WE%Q=$>445R%,2G=C@^M? U,DS*G*2J<:9TG!+FO#+(VMJ[MX/32^
MK=SSWB(1_P"9?A6N[GI_Z4^NUKOIH?H%'^S5_P $[[^XA@L_VP/'3M*HR#\+
M+C@M@;3Y=]A3USM!/?! R?!?VH/V??V;OAIX>T+6O@O^T;'\7M6N]2ET_4O#
M<WAFYT#4]#MX[8".YN)IF(N8F(V@8 9@0.AKA=#^'WB/4Y4D$;Z7&TC,L=G
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MVIQNK/\ ?75N5IKO=;Z+Y['>"_#\K1GDN'GS7M)8>,)1L]M(==7MT/A[Q/\
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MK[]8U+2;*(A P-X9FP6VL<!,X'4A2 QZXYK^E?\ X(+_ +%T?[$?BO\ :=\
MK>P:BWBBR^'?B6>XMXVB57^SZA"(3NX9AQ@C@$,2<,,?3DGB&V56D%ZH&TL0
M&X^0;@!D9YVX.T] >F1CVC]BO4(+[X\?&Z6"=IA'X,^'L>TMN&]&U($\\\@*
M< X))..E?UQ]"7Z5?BYXN>.>"R#BG&TY997P.+E3PM.DZ<?:TZ:E%RG:VU]7
M?16T/F.,O!G*>#,AJYKA_K4Z]&=)*=9SY>23L[<UDW9Z:;7]3]25 7Y20,(
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MF+8RI!]>.2V, &ORSU'QK<:B2L-R]M;EMH&2@!4$8)! )ZG#=QS[?\X_[0#
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M_;P_:P*L?^%MW65.P'_A$? '"GM_R*G/U.3[U7?]O;]K2,$)\7KM<@?=\(^
M >3SR/"F<>W3OUHHKFH\,\-QK4%'A[(8KVFT<FRI+==%EZ7X$*M56U6HK[VJ
M35_7WM2'_AO7]K0PL3\7KO(+$'_A$O  Y!;'3PIVP/RJQ'^WG^UF4'_%W;KD
M#/\ Q2/@#U_[%2BBO2PO#/#:3:X=R%-.K9K)<JNKXRI>W_"=ULK]Q.M5O_%J
M?^#)]U_>*[_M[_M:AV ^+]X #@ >$O ''_EJ5,W[>'[6&7_XNW<_ZIS_ ,BC
MX Z@'_J5/:BBO/EPWPXY0OP_D?\ OC7_ ")\KVMM_P B_;R*5:JTTZM3I_R\
MG_,O[P2?M[?M:K$H7XO78Y X\(^ ,X(R1G_A%,X) SSSBFQ_MZ_M:&1E/Q=N
MRJJ"H/A'P!P>F1_Q2F0<'!/7%%%+&<+\,Q>,<>',@BUR-..2Y4G?D>MUEZ8W
M6JI:5:BW_P"7D^T/[PV7]O?]K:)T:/XOWB,K1N&7PEX !WB08;(\*9)'8G.*
MZ)?^"D'[:X#*/CIJP"RRHH'A/X?#"H^%'_(I= ./?OFBBOZY^C1E^7X' \3+
M X'!8)2Q.0\RPF$PV%4KTIWYEAZ%%2OUNG<^<SF<I2I\TI2LM.:3E;[VR>R_
MX*/_ +:TL\J2?'35F54!4?\ "*?#X8.0,Y7PD">#W)SWHHHK^J'N_5_FSPS_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $! B8# 2(  A$! Q$!_\0
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M##_PN]#_ /CU 'MM%>,?\-'? ;_HLWPP_P#"ZT+_ .2*/^&CO@-_T6;X8?\
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MO^' ?_!'G_HR?P3_ .%AXS_^:2@#_*!_M.^_Z#NI?^!>L?X4?VG??]!W4O\
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MV8<_\8D^ ..<_;-:/ '3C/IQQ]>*+,#_ #IO[1O_ /H.W/\ X&-2_P!I7O\
MT'-2_P#!N?\ XJO]&#_ATC_P3A_Z-*^&_P#Y6?\ &M#_ (=1_P#!-_\ Z-(^
M%O\ X ZU71]6\OP_X '^<-_;%]_T&]3_ /!S_P#6I?[2O?\ H.:E_P"#<_\
MQ5?Z/'_#J/\ X)S_ /1I7PO_ / 36?\ &K$/_!*G_@G/T_X9)^$O_@'K/;]>
M,\=_H*YP/\X'^V)O^@WJ7_@W'^-5O[=G_P"@KJ?_ (.%K_2%_P"'5'_!.?\
MZ-)^$O\ X)]9I?\ AU?_ ,$Y_P#HTKX7?^ = '^;Q_PDE[_T$]2_\'!JQ_:5
M[_T'-2_\&Y_^*K_1_P#^'5__  3G_P"C2OA=_P" =>8?'C_@F;^P'H/P&^-'
MB/0_V4/A=INL:#\*_'FM:-JUKH^L_P!IV&J:%HF,_K[>YH _G-_X(6_\%&/B
MQ\$/VG_!/[/_ (M\7^(O$WP=^+NK:9X5;PYK&KC5%\*>)F&-$UC1%((*L.""
M#N'!!Q7^AU7^4/\ \$WYO^,YOV7X,8_XO!X7'O\ \AKW[XX]!]:_U>/^6O\
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MOFWZW%HHHKW1#$Z'Z_T%1?\ ++_/]VI4Z'Z_T%1?\LO\_P!V@ K^7S_@[?\
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MQX/^Q=7^.C^U5Y]G^UC^U!<03_:<_M'?';[9:=?^:S>/>OIT[XKX;C/_ '7
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M'& ?5_K+O%VBOEHG\EV^XYGL_1_D=!#>P7<7D7T_VG'/7'^1T'2N@L_"MC>
M&>^N?L]K_P NA_KU]Q_]8UQ\W[KWZ?K^7]*T/[2OH=&N?(Q_];'MS_CVKFQ"
M2O'IJG;MJF]%VZCPSLM';3O;HO-'<3>*]#T*U_L.PGN;J#[9G[):8Y]<'\?\
M]*SX9?#GBJ7R/]*$]KG[9:7F?[2//8^W?G.>?8'AO1[&SBMOW%M<W%UF]O/M
M>?\ ZW^?S&AKUG/Y7]N0?\2VXTL''V0@=OH1]?7ZXKRO]G;Y<+S<[WW^)ONU
M?[OR/7_VGZI?2W7:_+?OZ%?^S/!WAS[/JM[/<G.+T?;/^7'KT_#CH>WK6?\
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M?^/.[N[/^TM3[9Q_PD'Z4OJJ7V5]W_VIC]:D[^\^M]7_ )GG^I?'+X<PR_\
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M **** "O"/VJO^38/VD/^R#?%'_U"Z]WKY__ &KO^36OVF?^R#_$_P#]0HT
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M '$$&;@_U_I_G&:]##8GI^ORZ_/IW.<+R:'S=/,'_+KS_G_('ITXL0^?YO\
MH\__ !]?GVQ_GGK[5S_DWTMU_P ^UN?SX_'Z>_Z58B\^SE\B<W/V?]+_ /S^
M78YHQ-];;ZV]?>L<YV&FV4&I:I;P'_CW_P"7R[M/\^U=!IMY8^&]4N+&>?\
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MZ)M7NK=?E;J?QO?#?XJZ5KTOV#PY!XM\27&3_P @GP?K.I=?I_\ 7QR,5_H
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MF_X+1ZE^TG\&?V];B^^#VJZW<^&/BA\*_#'Q!_LEO[%U/3+#5 3H&N-_Q/\
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M2W$ OK;[/_RY]O\ ]?;O_C6/_P (KY,MO_Q-;FVMN?\ CTS].<\]?S_6L?\
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M%/V/_P!N#]HKQYX7^(T_A7PEXN_X5S9>*/#'AO\ X5E>?\?_ (7UW6O[>/\
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M:;['%I]CD_:,?_7YZ<\=_P#]70?VEYWV?R.__+ICCKS_ "_Q/6O*Q.&Y</\
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M?\-'?':]O,^_QF\>C./RZ?T%?[ A4$$'OG]3G_/]*_Q\_P!LC4O^$I_:A_:
ML;?_ $8ZI^TU\=;+6/7_ )+)X\&[G'3W/'''2OS_ ([^L_5LO^JR:ASOG:[6
M7-IU]V^GXVV]'+/JS?\ M&K=E'O>]E^GZ'BLWCSPY#%Y$$%R+?\ Y<_LG3].
MG0Y&><<U7ATW0]>_TZ&>YMA=?\?GV3/3\_?_ #BNPF\+:5H-J8-*@_Z_/;_/
M''KZ8KG[R;^Q[K3[^#[+;6_VO[%>#_/KG'N,=:_*GB*$GRX6[=[2^)KF>CO\
M[^1[]>@L-:6(]Y-)QMKO9J]O*QH2ZQI7@^P_<'_2#V]_Y^O&/SKCIO$EC,#<
M7T%S;6]U_P ?G;'K_GZ5!##!K_BFXGG@^TZ=:_\ 'G:=/\^N#]>U;]Y^YM;C
MSX+:ZM_?^?;/IS]?3&RH8;#N^(;<I:JSOJ_GWMU^1SW^L*ZT36FMMEZZ[?.Q
M#/X;L8?L\_G_ .CW7_'F,#D]?7\^G-)9ZQH>CQ7%C!!]IN+K_C\N_P .F/?I
M_G%9WVS5=-T&X@G@'V>Z/VW1^A^P?Y]>:@T'3?)B-Q/!^_NL7N?\X_SBNA.U
MGB/^W>7>W2_RMI?U//\ ;QYN5VWMT[V[EB'[#K]U^X@^S7'_ #Z$G_)]^F/T
MK8_L'0[/_3K^?[3]E]>HSC_ZYX)K/O=-@FE%]!_HVH6G^FF[M.ISP<?CUS]*
M)KS^WK_1_P#1\XLS]L[_ &_/^?\ .:/K5E)*32LUH[::]FNATQ6$=E:[TZ=7
M_FS[<_83_;RU?]AG]H[P/\=O#>E:YXCT&RM=1\'?$;PII.LOX9'COX8^-]'7
M0];T4ZW&Z-H.O[E'B;P9XER%D\8Z#X91PR,P/V'>_M1_L;?MX:GJ6F?MP>$-
M4^#WQ,-TMAX"_;W^"7AK0_\ A9J:8FLR?V%H_P"V!\+_  \B^&_C S;E#?%#
MPNWA#QB HVJK%V?\F/W%G]GS!;"WQ_QZ'O\ X>O;\>,<O!-_8^LW&(,6^J?\
M?OMZ_KUZ^U50S3_95A,,W;F][F]ZZYM=7?I?=;Z^1KB,-;WD[>[T\E=;/T6_
MS9]C_M6_L3_&C]DS2_#_ ,0)3X:^+?[/'CP _#C]J/X.WH\;?!#Q6&.!OUD$
MGX>^(L@C_A%_%>?&6<@,2./BBSUC$7G^1]I^RG_3,CKU_P _EFOJ3]E3]L'X
M]_LAW_B9OA-XAT[4OAUXO)L_BA\"?B7H_P#PL?\ 9^^,NFLCQMH_Q/\ A=K^
M/#6NN4DDC_X2I&7QMM=QG:QJE^TKX]_9[^(_CW2_&'[.WP*U+]G+0M<\-:7>
M>/OAM_PER^,_ ]IX\ U[^W&^%JZZJ>(_#WP].=$+>%O%*JHY 4# &N*PV%Y?
MK6%?O<OO)M6YK6>[[M]&_P S##?6;J]N5/7T7:_SL>80V?\ HMO?>?\ N/L?
MVWZ<#IQQ^/TSS6QIWB3XX?'V7X?_  /\ Z7\2/C$/!]IXHL?AO\ #+P]9ZSX
MVU/0M-UW6CKVN_\ "#Z'X?YT!O\ A(R<8Y[^]>;S7F;76-*@@_T?_C]Q@YL.
MG7_/7\J_93_@CY\:;+]F35_VBM1\1?"[]I'Q7\)_B_\ !?3?@U\2?C5^R+H^
MKM\</V?1KNKOK>A>,=&US04=O#R^*GT76G5HRCJ_AWPJ0Y3>C\668;FQ2CBI
M:3=E'F]U-O33;2ZZ?(Z<3B-GAO*Z:^]?G_5C\K+OX#?'^TL/BAJFJ_!OXDZ;
M8?!$:7_PN!=6\!ZSIK?"8:[QH7_";_\ "0?\@ >*^_Z^W@U[-/9#[/."?M7M
M]?Z"OZWOVA/V1]=^$7@O_@J'IOQ8_:)^-O[2NLOX)_X)C^*?"'Q*^(?Q+^)?
MA[QUKGPQ^*GQIU_03X+_ &B?!7A[Q&O_  DFN^%?#NB?\(RA^+*>+F="OC=H
M_!+Y19?VI?V(/V ?'FI_\%1OV>O@[^QZGP7\;?L,Z]^S#KO@#XR^$OBIXS\1
M^./&'_"V/%VA:1XW\&)H?B#Q(WA;0/#K>&-:/ACP3X59@O4@DX4_:1X?CA[-
M3B^;9*2;]Y=KO9,\?$8AOE]W7K=6]>GYG\FGA;1]4\8:]X?\'^'-#U+Q)XX\
M9:QI?AGP?X>TD9U37O%&NZU_86A:*>/3T^F/31\>^%?&7PJ\<>,/AQ\0/#FI
M>$OB!X#\1ZGX8\8>$]6_XENIZ%XGT/\ Y#NC:WZ\#C\B*_KB_:#_ &9/V!OV
M.?C/\#?AWX0_9O\ @7X>_:&_X>0_LF_#+]GWQ5\,?%_[2_B'XE:+\#=&\9_#
M_7_'7C?]HC6O$!?X9+\8O^$C37O"Z+N8'P9X@ \"LV 3T/B3]CC]A2W\>?MC
M?M9_M0^$OA1X^U'XJ?\ !6K]I+X+>.[OXRZ1^TAXDTOP)\,M$\7ZXC:+\+=#
M_9>\-^+%T#XS>*<?\)1X,\4_%1%C.[]T"WR+<N'H1^TTFKN[2OI=V].E]>^H
MDT^Q_&U_;$\&?WX^S\\=S].?\]Z]YT#X)_'[4_!GACX@6'P!^,>M_#_QA>:7
MHOA'QQI'PK\9:CX8\6:IKG&AZ+HFN_\ ".?\3_\ X2OISSG YK[NM?V4_P#@
MG?I_QSL/$4'[>7@'6?AQ;?MD:7X9LOV6_&WPJ^,FG?%S7?@5_P +_P##^@[?
M&WCCQ#X<7PWH/_%NR?$X;Q8@'_"%*<D&OM[_ (*Q_'+_ (*U_"W]NO\ ;*\.
M?#'Q?^V'\-_V9OA]HVE7O@72_A-:>,_#_P"S]\._V>/#^@^ 8_ _C7P=)H7A
MUOAMX%D&OQK'_P +3\,[O&O@OQA&HX"@5S?V'A-;)W2OT^_?S_$;;]?5_P!=
M3\8]8^ '[0_@_0M0\8^,/@!\;/!7AC0;3[;K'B'Q!\'_ (E^&_#.@Z4.O]N:
MYX@\-YT#D9KC]=^%?[0OA?PCI'Q.\1?!;XH^$_AMXGP/#GQ"\0^ _&7AOP-K
MIS_S!-=\0>&_^$8!]C7]+OB+X]?$KXCG_@W<\+?M _M$?%_7/@O^T3X"U6\_
M::T+QO\ %+Q?J'@GX[ZKH7Q=\.Q: /CAH^O:_P#\(WX_7^WCHJ,_BWS76-F
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M\=O_  Y'@VN@YS^QBBOXY_\ B,F_9>_Z,G^.W_AR/!M'_$9-^R]_T9/\=O\
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MV_T/;V_PJAJ6O7WV^WT32H/^)AG_ $STL/\ ]>./IWH_XKBSE\X&VN>_V0<
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M]Q<?)6IPWT,6?(_T?^A_K[?ATJ>&S@ANK?\ \#?\CIG./;WZUT+%/I)_?_\
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M6?KC/'N.O]*_T?[/_@L_^S+#_P PKQ)Z?\?FC?S_ ,^^>AV(?^"V'[,L,O\
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M^,?_ (;;6:;_ ,.W_P!KW_HV;XP_^$'K/^%?Z0/_  ^O_9=_Z 7B3_P+T?\
MPH_X?5_LN_\ 0%\2?^#?1_\ &CV'G^/_   /\W__ (=P?M>_]&U_&+_P@O&/
M_P 32_\ #N7]KS_HV7XQ_P#A!>,:_P!'Z'_@MA^S*/\ 7Z5XDY_ZB^C<?AT/
MKW_ TO\ P^P_9?\ ^@%XN_\ !QHW_P 32^KKR_#_ " _S?\ _AV_^V)YO_)M
MGQ:QZ?\ "!ZS_P#JQC_#.*/^'<'[8G_1LOQB_P#" \8U_I$0_P#!:K]EX?\
M,*\2=O\ E\T;//3\1STHF_X+8?LR_P#0*\2_^!FC;O\ /]/J*Q^KOS_KY ?Y
MJ^L_L'_M->&[K3['Q)\"/BCHMQJO.CVMWX/UG3OM_KSZD_J/K5C_ (=^_M3_
M /1O7Q0_\(_6J_T4/B=_P50_8F^,%KH\'CCP=XDU*XT&\_MK1]6M-8T;3-3L
M-4/ZGZ_EZBK_ ,/5OV._^@%XL_\ !QHW^-;?5UY?U\@/\[G_ (=^_M40Q?\
M)O7Q1)!_Z$_6?KGGU_IV[G_# 7[4'_1 OBU_X1^L_P"%?Z)'_#U#]C2;,']E
M>-N/^HQHWN/3)!_ 4?\ #TK]CN'_ )A7C;_P<:,/Q[_TQGIS71]7CY?A_D!_
MG??\.]_VI_\ HWKXH_\ A(:S63K'[#?[1GANV\_7?@?\0-$@[W=WX/UG\/R_
M^OVK_1@_X>H?L>?] GQO_P"#G1_\*X[Q5_P44_80\;7.CCQ5X5\6^)-/T&\.
MM66D7>LZ,=,_M3V]!QQ[?E3 _P _?_AW!^U[_P!&U_&+_P (+QC_ /$T0_\
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MZ?COZ]IL%Y]GL8/]&M[7_0K/G\\Y^O0],=3TKG]O[#_9>6_-UMS;^=G;?O\
M,UNL3KHFU?MY^7Z7L0?N/^6/^H_'\/Z].?QS1J4T\,6G^1_I.H?;/^)/CIW_
M ,_0X/-8]G#XCLO] GL?M-MCO_\ 6]_7W]Z[C1]-^Q77]JZYG[1:_P#'G:<^
MW;GVY_\ U'GQ$OJVJ?-U[[ZE4$]I7[=>MD_O.?\ "L,$'BWQ!]N_Y#''K_\
MJQ^0Z5U%YY_E7$\'V;T^R?0?B/H1GM]*S]8T&>\NK?7="N/^)P>>/\<=/7@G
M\AC'\GQ5>?:+<FVM@/\ E['/Y?TK@Q-ZZ6*NTU96=U:WEII\A/\ V=/#6O>_
MO;VOY_GJ9\T-]-_;'V'_ $;_ (D^E&]Z\^A]LC)XJQH7D?V7;V__ ).6N/7T
M_P#KX[UL<:/:W-C;_P"D_:O^/R[_ ,/7T^N*X?\ T_1[O]Q/_H]T/\C/;^A[
MYKUL-#ZSA+-6>G2SU6G1'/?ZMUO;7>]_Z_"YV&I?9_L%Q]NG_P"7/OSQ[=/\
M\>U<]%Y_VKPO/KG_ ![]Q=_4>OOZ<59TV$ZE=C^W)_\ B7VMY_QZ=/M^3V[_
M (]\<9[['B3R/$D6)[BVMKBU_P"//Z?G_GITQ6$E+#IX7E;OI>S=K^=O/8.?
MZQKS<MWO>UNM]]?U.X_Y^/W_ *'_  QG\3C/TKA]>\^\NH+&W_Y"%U>?Z'[_
M .)/3'/<U0A'B.&UMX()\<=+O_\ 5U'/K^M=OH.FP:;+<7VJZK;7.L?49L/;
M/T_/\JX/>RZ6SG?=:RM?6UM?GH=_UEXA?5;VY5WMLN__  3E_#>;._UBQG_T
M:?[9_/GG\^/J.M:]YY$\O[C_ (^/?Z?7].V,CBEUC0;'4K^XOM*OK;[1_P O
MG^F?B/\ Z_\ 3BBS\-ZK]E/V[5?[-X]#Q_G./UK=5[?[5M_=V^Y6MU_)&.'O
MAFT]=UWWT\^^NYR]Y9^?%K%]!_R#[6\_TS_I_P"/K[?7J#TQ6AIMG!>16\\'
M_/G].,GN,Y/^'6NX_P")5]@M[&">V%OT]_?I^/3\JK_\(1/Q]AGQIXY_T2\]
M>.O'OP#WZ=ZPQ.)>CU77JNU]D)X;FQ+EK9Z^6NMNFNIY?J7[FZ_TC_/;KC'^
M'KVHU+3?.^SC_/\ ];Z?A@UW']@V.F2V][??Z3J'_+I]K_Y<!S[>U<_./MEU
MJ'VX?Z3P?]+[9_#OG /0_7KWX3,+Z+7IM?Y]7Y'GXK#6?;5^7GY'#Q0_\?'V
MC_EU_P X_ER,].>!6AIL/]I71\G_ $:WM>OM_G]!WKH)88/*_P!/@N?^OL8Z
M?_KST^E9_G6,,IL8(/LMO=9]LCMW/..?_KUZ'UIO[6OK_P $Y_JR[:>G3[BQ
MIL,__+"?_2.@]?SYSC^?7WZ"&\-GB^G/%KU]O\^_IZFN?^Q^3+<0>?\ :;C_
M )^STP2?KSSU/0^]:%G96,,OGZK/]IML#_1/3US^AQTXK@KW>N*]Y7]W2^[5
MNYT+2WU73^?IZE?['/\ V#_:L_\ HWVN\S9V?^>G7GUKL(;R"\M+?R)_Y#N,
M?AC/&<^GO@7FL6&I76/MUM:V_P#SZ=3CCW[#W_H:K'33#%Y\$_\ H_07=H?7
M_)_'MG-<^)B[.T7:VFCVL[=.UCHVWT[]/7\3^Z#_ (-.?^3>OVM/^R\>%_\
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M:A/8SFUT?2S_ *'G_P"MD?\ U_2J&L:/T_Z>O^7S_./R[5_:WH/_  ::>#=
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MD&NPP;'<'*J@:,8&'&<U_')_P7_\1S_M[_\ !9/]A_\ X)G:%J%Z?"WAO6?
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MS]GJ]^)QTF;]D+XLVWPG-T5'C8^+]';QJ-+(PNM'P'_PCH!4="H\8KD< @T
M?V=P=_Q_I5BO$O@-\<?A?^TG\(/ /QT^#/B>V\:_#/XE^'-.\2>$?$-N,KJ&
MFR*<-*N]GBU8,'26-PKJ\(QN1!(WMM !1110 4444 5_^6O^?[U%'_+7_/\
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M& ;E696[;]F6U_:D_P""G>L?M'?M'#]M_P#:!_9;\ ?##]H;XD? /]FWX4?
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M/#\4XXX_$J^)86EC\'*RB1MZ/%%[OH'_  4R\.>)/"7_  3:\4P_"G6H+?\
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M?VC_ /@H_P#L]:[_ ,%LOAM_P4E_9)N/&VG?#X?$CX7^-/'=IXW\-GPWJ?\
M:8T0^ _BL#HA+%CXL\-_*Q8G)&3@DX_H3_X-N/\ @E/\ ?%O[#.O?&7]KK]F
MCPAXW\=?%'XN^*'\'Z/\9/ 1_P"$E\*^ / LD/A_1V30_$ \S0&\2^(]&UOQ
M.R[ C/*@#E3D>;_\'-G_  2P^#7P^_91^#7QQ_9%_9L\.>"/$/@SXVIX+^)&
MC_!'P 1J.M^!?'>@ZX=$UG5](T!(S-%X3\2Z+H95V0,&\0."0NQ$ /[1= \0
M:3XFT32O$6B307>CZYI6EZOI5U;8*W>G:TJRQL!T^=65B1T)&2""*Z&OQO\
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M -?EW_Z/>BO^COZ*%W]'3PC;BI-\&Y6[V>O[I?=Z=-NA^29Y!O-L<U;^//\
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MYGK-%%%?TZ>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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L#W_D!0_[J?RHHHK_ *K/HR_\F$\+?^R3RW_TTC\,SO\ Y&N-_P"OTOU/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #1 4 # 2(  A$! Q$!_\0
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MX/;U[#WKR,RPSQ6%LF_=TZZZOIU._+<0L+BXXM][O3I;_)L\0HKU;_A75O\
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MN7"[IW=[];]]_,LU?A_U4'T_J*H30_Y/X]/Y@X]01WK5C^XOTKZ%[OU?YGS
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M#JMS<VW>TN^?;![9_KG-?>WPM^+6B_$*PPI%KK%L,7EH1T)S@@C)Z=CZ=?4
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M #[=:V/)\5^;;_;I]-N8#_GJ/Z]/H16@(8/M5O??ECC^?J/P/M6A_P ?LO\
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MIOWOX_KQ^&?T/2O'.@*KT4>1[_K_ /6H **L44 %%'G^WZ?_ %ZK^?[?I_\
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MKD:ZZT_X]K?_ '?Z-2P^WR_1 6J***Z3H"BBB@"/_EG_ )_O5R6K2[;T#T4
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MS_3CV.>,Y]C746</E?C_ ('/?L<T ;'D>_Z__6K'K9A_U(^A_E7/>?[?I_\
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M]9PO]+_@A]9\_P ?_MBO#IODG_48/YX]/7^A_KH0V?\ G^?/\C^'M5?^V/\
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:S%%%=> W?JOS1V8;I\O_ &TL4445WG0?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "G 9H# 2(  A$! Q$!_\0
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M3#$G@@D<']#UQZ,?XH>.  #JY)=6 _=1_*>Q.1VX/K[<"O.+6[D:1HYT,3D
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MQ/X%\<^*8_#TW@GP/I'C_P 2:M?XBTJPT/79'BTQ9+AF_P"/NX,99(,;]O)
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M9F^"47BW3Y_B5;>#E\=R^'8I!)<1^%I"=FJ>8A9&@(4G@DXQR0:\=\$_M_\
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MZ[Q$OVAR$C!^49R3@#K]:\W^+GPMTG7/#6H374,,44EM,H8A4"%HV SG')(
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M?\%&?C?XU\6_LG^(?MNIW;RZ[\4--\*:S A,#V6FVYDDGMO*5AL25AM?< Q
M .>!7\O?Q-UNYFU^:'2Y#I^EV#6]E:65N/)-NUM&%+.RX:1Y6!<R<Y)/)KUZ
M$7))2FFY-I6T47_+=/7KU]3BJN+=HW2TLM7T=[OSOW/[L[;_ (*1^$?VYK;0
M_%'P2^(.IZ/K<=J_ASQ'\&?$4KV6H(]YLBM;^.!#Y-P=W)N ,;B-SYZ\1XH_
M9.^('C_48M/U46UEK'E2WDFUXGO%LX \TPMT+A&E=4,:MNR&;/45_)Q^P?\
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M[U?V%3XE^%_B6#X#7MAKOBC2['PAHFJ:WXHBB2;PSX>UC4+ 7$NDVU\A*//
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M$GBM802OJ]=%?K9WNK6LOZN:P@X-ZNTMK[][[6V[Z[B94CD@\\=,9[_CBOW
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M"$YS48)RD^6,9.T4KMN.FYM&@H6E*IS-:2=U=7VBWZ;&>#\I #;AG#$]">G
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MMRX8+$:-J]KW?,NJ=[WEHM3X],A"LV,8'+9&1SSC/)R#VY[]J_<O_@C\\3_
M'_@J&9UW1-^RSJ0D!/!R7!&.G S@\8/N>/SR?_@GQ^W2F2?V4/C.W'./"5YC
M!./0< CT7'T%?L;_ ,$P_P!DO]ISX9?L]_\ !2E/B%\!_B/X-?Q-^S/J6F>'
MTUK0;FUEUC426"V>GQN-UQ/\PQ'&"<CIR:]3+J,H5975N:G.*::;UB[6UOT/
ML>"8/#\0Y=4J1BXQQ%%W;4DU[2FVFDW)I:O;5=#^;:QUO5]%AO[72;NXL[#4
M(S!<Q1'Y)H/F"I(<89<$@?7J>HQ,Y5B0"1@ ],<G/ QDG(Y/ZYKZ/B_9:_:>
MNX(;(? ?XG(J+DN?"NH#/)P0QA &<CN>GM5)_P!DO]IV+>I^ _Q/(#$ CPIJ
M.&Z\\1D<X/..W'-*$)1G4YH<LI-MR2UE9M1N^NEG_P ,?WG4QV'G0PKABW4H
M0HP45)M1HS<(RG"$6KQBG?5*SMH?/I^Z#VSC')P3@<=^@S@G%0@EG\O:"#CG
MOZCD'OG/TQ7T$?V4?VFL$_\ "AOBAQ_U*FH$@@\<&('KQD#'OC./HS]F+_@G
M;^T3\<OBKX<^'5Y\*?'/AM_$$[1#5=:T*XT^PM%1"[37-U=B.&-1TR[C//!P
M >;,\=1RK XG,,5SJAAJ4ZM1TXNI)0BN:34(IRDTD[12;?3L;911IYWF6'R^
MAB\-0E6G&+JXBHJ=.,>O-.224;?D? 5OI[3>8Q98Q&NX$C(;D# ]..>1SSZY
M+((!%*1.F]#R,C' &201[9X.,#T[?LE^TY_P2)_::^ UMJ<R?#CQ+XBM;"94
M2YT&Q75(IT8[4D3['+(QSSP!C!QVKX6T']D?]H[7-3L-,G^"'Q+M8YKA(#<S
M>%+]$4R/M&6:-0BEG7)8X&,G@Y'@95Q+@<\R^KFN"E5E@H1G*3G2J4ZD(TU)
MR:A.,9[1>G+=V[GVN<\)TLBQ^78&KC<OQ%;%1IU:.(P^*IU\+5=1I<M246X4
MU%/7F:=E=GRQ=0HY40QE0>!P>I) P>F,\G'&,\]"/K71OV,OC%JG[.OB#]I$
M>%;F'X::'/\ 89M>N4\J"YN7(399ESFXV,ZAV3Y5/![Y^N_VKO\ @E3^T-^S
MIX>^&^J6/@'Q1XQ_X3WPW::Y)'H6DMJ3Z1<3*)'L+U+-IG@GC# ,DJA@200"
MN3XW=VO_  4!E^#,7P+E\$_&\?"^S::>+P<GAS4X]*,\Q#O)+ L2F;+J"I<'
M!R1Q7+#,\QSW!Y=C.&YTH4'F$8XNIC(5*=26%HU7&LJ<)*,N9N#C%R23TDF:
M5<OR7)<3F5/-*N%QU6>6U'0>&DJN&I59TIVM*G&:<XNUEI:S^7U1_P %#ELY
MO^"4G_!*V&XA:2ZET+XJ+9E?X"/$$._CG)/&,@YQCTK^?(V\NE2/]K@90RMC
M>"ISD@,N< X('0X_'D?T_P#[;G[+7[4GCS_@F?\ \$O=(^'/P)^(_BG6O!^D
M_%%?$NEZ3X=NKN^T.:XUV![6/4;9?WENTZ@O&D@#.@)X%?CYJ/\ P3L_;X\2
MPS75]^RO\8DDMX0 K>$;E&8$_=5<@L0?O#[P)Y:O] ^!)\,9_P"'^%A"O#!<
M;</X:4<!2>&I4\'CZ$Z<I5)XG$R:]I4CJH7;ELO(_P ^>(?:T>(,RY5S82MC
M*[;3?-#][/E2B[.UK7V[GYT2N)'?!X)&#ZC/K@?@2!DD<4Q45<DC([=/QSQ[
M]?\ &ON*?_@FC^WI'\R_LI?&=@Q/3PC=GC&>Q/7US@CO4$?_  3>_;V#$']D
M_P"-) (&/^$/O,'MP1W]>?3)&:_(,52E'&U(YA&^(G4J7E"+G34I2FWK%-.*
M?PM=+!%WBG%^ZE9:V=DKJZN?$*CYP".-PXZ\=<?_ %Z[>XTG2&TFTEM[@RZC
M)GSH,<1Y' !ZYP.W3GN*^IY/^";W[>08A?V3OC0&Q@G_ (0^^YYSR<<G&/7D
M<\@U=L/^"=7[?EI<0S_\,G_&AS$X95;P=>,"4P1D'Y6 [@Y]3UY^OX+S/),D
MQ..P.?Y(LRP6;PAA'CYX.M.>6PE47/B\,E3LZD(.R5]TCGQ,*E2,9TJUITVY
M<BDDINWP2UTOZ6/CW2T.D:C!/<VGF1QON:&96VR+@YRK$9X/'0'TZU+KD1>_
M-ZMB;6WG8RQQ!2B$'&0G &,\9&<9Y.<U]I:O_P $_P#]O[5K@7$O[)OQG5@!
MA5\&W:*  !]T 8Z9(/())SZ+>_\ !/\ _;_U%;..Z_90^-#1VL8CB4>#KQ<*
MN>, DDX!Z]%!(!!R?T?^V. :65YKPMA,RQOU.EFF"S#(L34R>#J3KNI35;V]
M25)U8T:=V_9IV:A;J<?L\7ST\1*G%2=.<*J]H[))-I12=KWZZ'9_\$P-5ANO
M^"AG[%4$>FQ6LL/Q[\!AIE)S(#K$."^=H&T#J01TSUK]3O\ @LK8V&H?\%(O
MVG/^$=L;LZY;^/FDU!H$:0M(EI"RR+A3@C '0=",^GS?_P $Z_V)/VO_  K^
MW%^R'XB\4_LN_%3PMX?\,?&_P3J/B#Q)JOAFZLM/TVPM]6@DGN[^[FVI!;PH
MC,\DC!0H)[<?H;_P4^_9V_;,O?\ @HU^U3XT^''[./Q+\7^&O$/CCS-(U_2_
M#D][INH6GV.)!-:7"J5EA;LZ9!Q7SWB+B^%JO%6'RW/\WPF<Y/FV28#"U<RP
M&5TZ-7!5%0@HTX4G2IKVT)\L*E1:V4FWW^FX2K.A*K+_ '><92FG.7-*Z?-%
MPEJTWNMDC\,]:UN\NHIAJC22ZLTJQS7-Q\UPZ*-@23()!4 #WP!VS7-R,S0Y
MP% R!R>XQ^'?@=.O3FOMGQ!_P3]_;EO5AUJ?]F/XJRW6JR///!%X=G#0R,2Q
M#IMRG7H0 #]:Y.;]@S]NB(.C?LI?%UMK$93PS=OQ@Y)(4@Y'Z],[>/Y/X\X=
MQF"S*>'P_L<1D^&7+EU:G[+VD\(VY49584W*U3V;3FMU)M,^L6+I59SJ5*CG
M5G.\Y2?-*4K_ !7?];'RDJQ(C?*P. QR<@DG@@D]1ST/7&0<U:TFQCO]3MK:
M1WCADD19)NI6-CAF&<#A>_7OTKZTT;]@K]MN\N%2^_98^+T,2A1D^%[Q ?F"
MX),?0 Y/3&.>U?IBG_!$G]I0?"+PMX_M/!.NIK>N1R?;_#+16RZMIB>0LD1G
MM3+YR,Y+(05&",$YK\PQF;X/A?,LGQN+RO%X^E+$TN;"TL%7KTJBA*#<*[I4
MJBA"ILY2:NKGZ!PAPC_K3'$16:Y;@72TC'&8NE0=6\9.T'.4;R]WY;=3\2O$
MGA*PT_41%HMP^I6OEHS21!F8,0-RG:"<@Y'8#'))JSHM[I%G;:E8/HC7E[=0
M^3!&8V>9)@ %9 %+,<\G('0C@<U]5_\ #%?[=G@/Q!K-GIW[+7Q6U5(KB>U6
M]_X1>YN;:98V8"2!P"NP@ J4/S9RI/(KZP^#?_!*;]KCQU\(?B?\=M4^%7B_
MPMXO\$1I-HO@G5]*6VU7Q'*SYD73]/F9)9=BY/[M&R>F3D5^_OC#P[R1Y)QJ
ML/B<KS#-L=#+\?DV&R>6(PF!P&,IJ@ZL85*+O4M4<KN*Y):MJVF&#X8^MX_,
M\KAC\NIQPJJ<]:OBZ24IT7)6I3YDI*3@^1Q=Y)K<_+OX._"7QS\5OB3X=\ ^
M#_#%SKGB;7=5@L[+1(8'>9VDD /F(5)2)5RSLPVJH))K^IK_ (-E?"]]X&_X
M*0_M0^"-7TF'1=9\)_#)M"U>P@8M'#?V&KP17*C.!C>3M8 =#C&:_"#P#\ ?
M^"D'PL^)EE\2O!W[.'QL\/\ B73[AI+?5]*\-W44\(<%)3$3&57*%EW <=>.
MM?T??\&XWPF_:*\/?MW?'[XG_''X0_$#P GC#X:#SO$/C739['^WM<FU1)[H
MK-<!?M%RY)D<+N("G@9Q5X*E4>!XGQ&69U@8\-U<UIU\NRO$8"-/-L5*JY3>
M)C45/]U2A&;3A&:6VET<O%#R'#\-4\%0H>TS6%64*V+A/FI^XW&T;*SC)*ZU
M>]]3^X6)=J<9'  R>.G&!TZG';_&:JJ<I&=QZ!@1@G&<D=QSCL:M5YD7'7F[
MZ-K==_ON?C)^ VN+(VNZUYDH7&K7HW<*Q(F<#'S#((Z$9]>:Y37[*VN-,G4J
MWG;&Q(WS;E&3GO\ +SVX]Q75>(_);7M;+%MPU6] 'W2/WS'J>,#'('X#-<Q>
M2+-F%2"I4J<CD;^.<'G#=P, 9^M<@/5W>Y\]6GARUAU!KAV(9I#YQ4A1@G!(
M)/48 R.OMQ7J-M>>'/#.FW5S-;QL7MI_)<@.[S>4Q1 /FR2<8P./;.11O-)G
M\QT:,!0[ RJ<Y R#P!\OT//XG)\P\4KJ7VBV@@MY)H%(*Q\A0,@9*].?PX &
M.* /SAM/!X^)/A+XJ7'V5_MT_CS6'O)9QODBBC9S;Q ,"40 G8!P#T'<?(UK
MX9U:;2_&/PXEE>&ZN$#Z:TJL4V))^^C;!#!74<,I&TGT)K]<]!\ 3^#O&6OW
MNH1&S\&?$ QM<7!3=!HVO1[P'NXESY<%YY@ G. &5=]?&?QO\%ZMX>^(=GK&
M@V#7=G;3,EQ/"NV.>VE<K)*T^/+\L*2XR<8"]!@E<JOS6U>E[?@!\OZ'^Q_K
M/QG^%VO_  :@DN7\86MW_P );\.Y%C\R&XUZP0R3:%-,1N2#5K<30*^"1(Z;
MN,U\%7O_  ;J_MS?'>XO?'G@GPWX:\+Z=-=.-8LO']S<:'-I<D#E;D"60"&2
MTC"M)YR%05P1[?TG_!/XK? K]G;4O"'Q)^(_B^/5=6CN4DT[P7X4CCU*_+W(
M53<ZU<*3#:6]L)&)1@7.. .#6;^V1^WO\=OVMX_$GPT^ L;_  ^^$*VHTGQ7
M\0(;][&Y%D^/M%KHMM;;);J_F@W0R2[@%9OH#4*R5X6C>-[7WC>WRLVM>R)2
MDKVE9/2UD]$W;7SN>4_\$Y?^"?WA/]DCX)>+_P!G72=9\/\ Q)\>?$M8H?CY
M\0=.MK>Z\(Z5HZDA/ _A*]N$9KV\$Q=[N_A *838<@,/UF\::YX7^#GPNMO!
M=O P\.:;H<>@^'M+#>;+:"VM_*A9#N,C*, LV#@ '::_'SP=XZ^(/P0^'UCX
MCAAFTCPE\/\ 26NA+K4DNFZ9>:?818N=;US4+@JA:YE!D:1R[RR$! <\_'/P
MS_X*O^#/VC_B_I_A[Q)9-JC:%XQL[_2]2\-ZHTVE7%NDYM[C3[Z*1/\ CSN@
MV$9P$<@'/S"IE=W:2ENVTVTGU3^_9^A1P_[5/A?Q-XB\7>(O%?V'4W\-:S;R
M>'+J]F1SIS65R#%-:-)G8'D)P V I ;UK^:#X@?L_P#B#PW^U!I'A%F_L^R;
MQ!I>I->7LD<,&E:;'<QW+32REMA41H/*V E\A1ST_P!"3PS8^$?BY=>+_#T/
MA./3O#5C,=0OM&\0:%.MDMOJJO*)[*[FCCMKMX@?,BF@9@% /O7XG_\ !0/]
MCKX&7?Q*^'_C+18;G7I+.\_L?4G\,W<-@FF6ZR"6*XU&*1&.I21292* , IP
M<D9%13JN$I1<;N46KKM9K;HU>W],N+;2BK::I_UOY'W]^RW^T#XZ^!?PA\(6
M6O'0K2Q^(.L+JW@RWU",)K&I62+';R3) A5X[*XA6.1'E(#L<H,\U^_'P_\
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MD8<G_A+=4YYY!_?#/H3R>HZ57'[5G[3+,%C^/?Q8"F3Y7'B_5"&SP<@R?=W
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M%2;!ZG]/\*^&T=]G9M/K9K='Y+KK?>[_ #/Y^/$TJC7-:)R6_M>_W #@+YS
M=>OUP#QTYP./>]"L^TD'" $+D<9))_$\#.?RKJ/$Q)UW6P1R^KWX'. JB9B
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M&^,+O]H/X0:9\7=6U"XTGQ'HTVJ>%O%'@YV#P0:AIC>2MU;P,<P17>?M43%
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M, J3U/H,C(YK$M_AC=>)]+U^RUV[,*:UIFIZ:T:C!#7EK+!%(QR" LCJ3@8
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M[2JVZ?\ !*W]CI9CN!^+GQ7(/4[C!HO!].I!'4<%@>:_&6;?!-YL:E #D'!
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MX9)%:9B&7Y",$'(88&.<'K5&+PKXJ*LK^'-7!  0'3[C#!>=APA'(^4'OGD
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M7XO"%FJQWWB:>\A#1WD^F76I68@LP"TEK,EH\,DY9?+9U*AA7I&A?M=W.M^
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MI,\@$'/&T 8Z8X[#/0YJ3:OH/\__ *_\X%%%)4*2^Q%^J7^0#?*C(QL7'3&
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MW?=_>P,2$ $<+T_S_G^5)Y*9!QR.F>1TQTX[<444OJ]*]^17[V7^0AQC4G)
M_ 8R><Y__71Y:8QM ^G;Z4441HT_>?*KW:O97MVVV 3RD'103ZD9/IZCM_DF
MF^1'G.!GKG'\7K_];]:**'0I)-J*O;LO\@) BJ,!0!]*=116JC&*44DDMDDD
&ONM8#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %& BP# 2(  A$! Q$!_\0
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MQW:72_\ ":CPM\-+_5] ^(GCGPXK>"+KQ[KHN==T23PYH">(VD>>XE%N2X<
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M1S&70_#/]@,LS>(I&2)8CDR(R%5_DU_:[L/#_P 0/AA_P<B>%?@QX-O]3O\
M5OCG^Q+\7+/0/"7PZU@MKNF>!7^$*_'/QGHB#PXQ\??\(KXCT#QVWC@>%R)
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M>M4EM=.'Q&\"ZC_P@_B(!5;P-\0-!BCU[X5^-M(9%&6\*_$#1?#OB9!C.R+
M(4*!_-!X/T7]I;XV_L ?"7_@IC\6OA9-XV\8_%;_ (*-?LP_M1_M??#3X>>'
M1XUU3Q7^QS^R<O\ PHS0H]&T)>?'F@>&-?\ !0_:AB\*C[ZZZQ)5$W, ?U'Z
M5^VK^R;KW@O2?B1I/[1_P5OO &N>/]*^$6D^+K?XE>#6\+ZA\4-<<_V-\.1J
MPNGB3Q].#F/PNSK<IN/F1DYQ<7]L+]EE;'Q[J5S^T-\%+2Q^%'BVP\ _$JZN
MOBGX.T]?A_X]8)_Q1?C5O[=6/0?$N7)3PW<9EF ?Y'#2>7_+/^W5X1?XN^(?
M^"B7[9'[-/@?QIXD_9?U:;_@EGXF\8:MX1^&WC18OBS\3_V</VGE\;_'#XG^
M"O!K>'#XD\='X5_!AM#\->,_$OACPHS?ZP*\P\%S2#YC_;O^(?@'X]?#G_@L
M7XXB^"_Q;@\ _M ?M4_\$L_%WP4O?B)^S?\ $SPV?B9X%\$Q_"7P]\5?&O@@
MZY\.8 SGP[HGC=CC'C!_!@^:)HLPL ?VQ^!_V@_@C\3OAYJ'Q4^'?Q9^&_CS
MX<:)-XFM]>\?^#O'6@>(_ VC/X%D8^-&U;QCHUW-X=MD\,O%/_PDN^Z$=N4=
M97Q$!7 6?[9O[*NL> ?$'Q-T?]HKX-7?P\\,:MI^B>(O&5K\3?"":9H_B#77
MB70M'U;;<!HO$/B0NC>$-!,<DWBS<$MX96EB5_G?]K;X??LY6/\ P38_:+\,
M>'?A7JEU^SGXS^!'BS4=8\!?LM^#=*\-^,]<\*>--)#:YJWPPT+P]X>$2^)6
MBF_X22-F\)DR2)YQB(B:./\ G=U7XQ^,?!'@.YN/B5\+_#G[1VC^$/V_OV-]
M&\'?\%2] _9S^+PC270/@UXB?P7^T#\4OV>OA[%$_P 0?VB/V5M T;1/@6?^
M$5!^#?\ PF6O>%%\=Q&?PI)X-D /ZNI_VOOV7;3POX2\?:C^T3\#],\"^.[/
M6+SP)XNU7XO^"M.\-^+QH2SMK\>@:U+X@%IK9\)#2]3D\821M*WA5XVBO OD
MS,N1X1_;C_8[^('B'X>^$O G[5/[/GC3Q9\6-*U76?A;X:\+_%OP1J7B/X@Z
M9HXF35+_ ,&Z/#K\TFNQ02Z9JQDGMQ+'"L+%Y&07!/\ (1\'KSX0ZUX<_P""
M>/PD^.?@GQKXE\8_"_\ X+;?M8>*/B*_[0G[.'C+P[XE;P+XZUGX\>.M \::
MYH'B'X<Q>&-#\.^*O$7C?X5^*/&T?A&5/!W@WQCKWAH$Q@&2I?AM=?LP>"K?
MX6>)/!O@#PWX;\3Z9_P<L^)_&6CZQI/P7US3O$VG?L[ZWKGCO9K2:M_PC1\1
M:#\&QX;US169]R^#EV1H%96.P _KPT_]M[]CS7_'^@_"'PW^U/\ L[:Y\5?%
M-YJEAX>^'>C_ !I^&NJ>.]>U/1L_VWH^DZ#HWB8W)\01DX\I,R!V.Z/:K!?F
M/]CW]MKQIXQTK]NK6/VN]9^"'PPTS]D7]K[QQ^S_ /\ "6^'=6UCPYX&_P"$
M'T'P5\*/$VBZYXBU[Q[K>(]?N/\ A-F69W:&,.L,40224J_\QWP;^%OP.^,'
MPN_:C_9A^#'PNT1OV[+;_@O!\4/'?PKU[PM\'=7L=3^%7@7X6?M8^'];USXF
MCXJZ#X:?PUX=^'O@SX;:#XY\,(W_  EX ,H\$HRMXF0KZ3\3O%VF^/M2_:(^
M(>F7WQKUG]G[X8_\%Z(?V@?VC;WX+Z!\1]*^)UE\#-8_9G\/_"/P1^T%X.,/
MAAO$FN_#[X5?&G0'\2NGA*'Q> -%$L<13RP0#^S'X8_%+X;?&GP;IWQ#^$GC
M[P?\2O NN(QTKQ9X'\1:5XD\-WQ5L:B+?6M#:6!I$(R^Z16#^5(50.H'I]?D
MI_P2I\%? KPI\/\ XX>(OV9O"WQ[@^$WQ:^.^K_$B#XM_M :GX[_ .$C^//C
MG7M"T-O'?Q-T#P1\0?#OA/Q)X6\.OXAA'AM9)O"'A6/Q;-H>O^+LS-*LQ_6N
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /6K\JO!_P"WYXI^*-OX3L/#_P "_$WAT?M&Z0+W]EGQO=>.-#T_3_'>F_\
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M_GM7/PS?NOP_3G\<?J>E8:=G]_\ P"?[2;VBW\G_ )']YOC;_@O?_P $[O"
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M_; XKIR^TL+*36KUU6NMV?,9BL/]:TS)KFOHKVOY67JO,^V-=^,'C_Q)*?\
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M^W <XW=!6=H/P:^!'AN(PZ7\%O"-R;NS_P!,N_%>K^,O&OV_KG:NO^)-H'H
M,#&!QT^NCB8_58WBKZ=K[*[_ $/)>&PJ?Q.Z=]WW?6^O]?/C]2_:6^#NC?\
M']XXTTW'3_1+S_ZQ'T_KGGS^;]K3X<ZE+Y'AS2O%OBVX)_YE[PWK.I'\<=./
M\]J^B=-TWPMX<S#X=^&?PF\.&VR2=*^''@TDDGG)_P"$;.3Z'G)J_/XP\5>5
MY$&N:E;V_P#SZ6EY_9GY_P#"/9_+FL<1]4T_FTV[_EO_ %<W7U16LWHU;UZ?
M,^:/^%S_ !3UC[1!X<_9S^+5R>GVO5M'_P"$;TOZ_P#%0>W'4^_I6->:]^U#
M>?\ -.?"/A+_ +&'QYHWX]/3C_Z_%?1%Y-/>?O[[[3<W%U_R]W??WY_SZ\5G
M30^3%Y_;VY_7G(X]?3UP.=XBRLW;3J[:?-G=]8C9;;>7ZL\(.@_M)WL7^G?$
MWX6^&[?J?[)L]9\28Y'(_P"*;_+V[=*K_P#"G_'.L1?\3SX_>)+DC_H7O#7]
MF_\ NR?6OH"S_??9X)_]&_P^G\O7\*)IO*_S_/VSCMUKSY8G?7O^O];?(/K"
M\OP_S/G>']F/P=>?:)]<\5?$CQ)_U]^)/[-]<>O;CT)/TKL--_9I^"UG+Y__
M  BOVD=_[6UC6=2^O^/3W..E>P0S>=%Y^#]H_P ?PSCIGKSUS6A#Y\,HY]>O
M?(YX]^AZYKS_ .T^EOZ^X?UCZSI:W+\MO/3<Y[0?A7\,M'BMOL/@#P3;?]RW
MHVI?UXSV]>OO7J-GIMC9GR+&"VM;?C_CTL_[-^OZ?ECUQ7/P2_\ +#'T!_$_
M_6Y]ZZ>SF'E=OY?3C_)/U!KS\3B<7TV>^O1^GJ=!L_N)O_ /Z]/\?Q_3@ALX
M/]? ?M7\O<#]/4YZ]J(9O^F'KG]./ZYSZ"K$/[KWZ_K^7]*X>:7\TOO?^9Z!
ML6<,$,IY/VCGCW_IQ].G7@5T%G^YEQ_(#&/S_'\?K6/9_OHL?R!SG\_Q_#ZU
ML0?N/]?SG'_'I[9Z_ICTQQGNH_%'_$OS0'T]^SCKUCX6^+O@'6Q]I/\ 9?B[
MPS>?:^O/]LXP><<G_/I_HMZ=<PW=C:WL'$%W:QW0/)^\%Z^F%)'U'?O_ )JW
M@^\\C5-.G'_+K>=NN?\ /^37^C;\)-2&N?"GX8>(&!/]J^ /"=WC/(.K:-HT
MH'X J,<].O(QW9+:.:X^]E>UMNT=MOP.Y_[I%===/^ >IT445]24%%>(^+/B
M[X>\-?$KP/\ "VWCGUOQ=XRTW6?$\FDV5QIBGPKX#T B'6OB5K9E;S$\/IX@
MUC0/##O&5S<:VKK@*ZOR?B#]I+X:>'?$'P[T^ZUVPO/"?Q0N_$VA>%?B-I>L
MZ5JG@,^.] TB;Q!)X*UC6=(DD30]=NO#NC^(/$L32,(Q#H'B-"=UMM4 ^FJ*
M^/OV=OVN/!7[2/PKC^.GAFV@\)?!G49DNO"/C_Q%XU^'.H:5XOT4*3_;*-X9
M\4>)V\/AM\22^'?%I\,>*H7'SVR9<)O_ !"_:O\ @WX*^&'Q1^)?A_Q/H/Q6
M7X6_#CQK\4]8\)_#;Q9X0\1>*-2\.>!;?6I]=ET72AX@42_\@/5[?SA(L1GB
M> R--B$ 'U%17EEK\4?A^=$\,:[JGB?0/#W_  E/A_2_$VE6?B#6-(TR_.GZ
MVD,D4N)9%#!3JL<>8]R^8S*<9F(\KU[]J7X:^&_CMX:^!6NZC9:3J7BCP'XD
M\8:7XTU37_!NG^!SJOASQOX%\#R^"%-QX@'B"7Q[+XA\=:%$GAQ;9':/<1(9
M601 'U/17S+\<?VDOA_\$?AC\:/B#=7Z^-M0^!7PXUGXD^.?AQX)U?PIJ'Q.
MLO#7A[1)-9>4Z'K6OVC6;/&C/%-XB:WCD:1GB=RT9EZ+7OC5X/TGPIXWUO3M
M0T_Q5XH^'W@2;Q_XB^&?A_6O#Z^-3IJZ,^NVPD\/R:\LN@KX@_Y=9/$;Q)(&
M(=I,[B >\45\/Z9^W'\*-?\  /[-?Q%\*6VJ>+-$_:/\<?#/P+91>&-1\*:O
MJ/PW\0_%7P;-XX\/:3\2U3Q S:-<" +%<6UN)IHW>%1&$GMVN/IA?BA\-I;/
MQ3J)^(O@PV7@BY6R\87B^*]#6P\'7X4JT7B287+)H+;LL!X@:(*ZAE7;\S '
MI%%?)WQ8_:H^'/PD7X-M)<1^+[?XW?$7X=^ O""^%?$'A#4;]A\6-<CT'0/&
M1BFU^WFU?P$-;U;0DE\1^$X?%/D_:#OBD.TCZQH **\.T[XZ_"#5?B:/A#I_
MQ&\(W_Q1-OXFO&\$6U]N\1FP\$3^'5\0,(S*P)\+GQKX>7Q,I\R2%O$,*%5)
M>&H]7_:!^#OAOPMXE\>ZW\2/!&A>#_"GC)?AYXD\1:MJ\.GZ?HGCF76(-!'A
M#5B680ZZ/$6LZ-;M$RJ[G6%955<22@'NM%?/FL?M#_!CP_X\O_ACK?Q*\):=
MX[TZR6^U+PM-J9?6;93HTGB(Q%5#QG7%\.Z9+XI'A,2CQ6/!B_\ "7I;BR97
MJ3P=^T7\$/B!)\/(_!'Q*\(^*#\6?#.I^,_AH-!UB/4/^$U\*:*8QK7B[P^(
M"Q?P]$^JQ*_B)'6&5I"!+*5 H ]_HKPK5_V@/@[I'C/Q!\.[WQ_X;MO&_AL^
M 1XD\+-?J=5T.+XJ:V?#W@&35M)178+XK\1#^P[=LEVE=26B#%ATWP_^)OP_
M^*NCS^(/ /BO1/%VB6'B#Q'X9O=3TFX2XL8_$G@C7)M!\0:09&"D/X?UZ%X'
M()"R ;"Y^9@#T^BO/;OQYX1M/$^D^#I]<TU?$WB&U\47^CZ.!&U]J"^")-$/
MB$J "I;PZ-?T4RY))$P.=RC/=>=#_P ]O_'C_A0!8HKROQ7\3_A]X#N6T_Q1
MXP\.:'<Q^&_$WC)K;5[Q-/-GX6\#[9?$6N. J;=$\-*5-PQ3JVY&)!:O*6_:
MX_9VL=-\-ZUJWQB\&:5HOC34-:M_#%YJES?Z9%K T+6] \/:]JZOKD5O,?#N
M@>)->T;0Y?%2AO"4<_B+0E^V+$]N& /JJBJWFCR_WPQV./7],'_/2O,Y?BS\
M.+3XFZ?\()_%^B6GQ/U7PWJ?C6Q\"O>@>(+[PQH]R-*DU[R1D#1P^/WC@?O-
MK DAE(!ZK17">$O&WA7QD=?'A37=.US_ (1CQ+JG@SQ(EG<AY-#\3Z$\2:WH
MVKJK KK=N\BF5=OR@J2X^;S.[H 8P^7GDCN?<UP5X/)FN)_])_T4<_3IR._Z
M_K@^@5FW=N)HIH3CRIUQGK@D#=^?O_B:&E)6?GND]U;KV//Q.'^L)]+)O33H
M[7/\['XD?$+2?B%XM\<:KH6E>)--\/\ _">:I>Z-J_B&ST;3?M^E:[K6O]_^
M$D]>O)R.#DUY/>00?Z1^OY]/Z<9YKUCXJ> ]5\'Z7X@U6PL=;_X0[2_'FJ>&
M-'\0W=G_ &9I>O?V%K6O^F>>_P#Q2><=!7C\UY_G^7'\Q^/O7H8?#KZJ]4KO
M:]N_H?+RA[UG%-WMJEWMU6QR^I_ZK_2)^H^G3'/<8_+Z>G'^5-Z?H/\ "NXF
MLIIOM!/'VK_.._J?7(/USGS0P9_U'''U_P ]OZ=Z/]V\_P ;_P!?A<Z/JW6W
MX?\  ./GA@\WK=?Z*0/PZ]/ZC_ZU9\TW[W\?UX_#/Z'I7430P0_N1_I.?8?_
M *_QQU]*Q[R'M]/_ -9/\ACZ]Z\_$8G5?UV73Y?@!CS>1-CZ>F,YSZXX^G3T
MZ58_=?YVUG^=Y,W[^ ]?7J3S_3)[]3GIDAF\Z7SA/VSP/\@]OPSZ\<V)U3>F
MW3T8%BK$/GPY^OKG&,>F>?KU]>M5X?W_ ._Q_+C^7<_T(S17D8GK\_\ VX]C
M#8=;_P!=^OS7W^AT$/[WVZ_I^?\ 6M"SF_>_\NWOST/T '/3\_>N?AF_=?\
M/S_+WQDGOGCOFM"&;][^/Z\_AG]!TKQSH/0(+R?_ $:#S^PR?\_A^-=!9_\
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M8WU<8I)6U]U=-MNR9Y68\/8?&8OZW*4^B:3E9N[7>V_0\ T_1/$$GD%M,UE
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M1_D_EFO-#^Z_Z>./_K9]#W_3/K6AF_>_O_Z=/;K_ (^GK7D8G#[_ ->>R^2
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M6_ O['FO?L]Z#XXCT3P3K6O^'?%WA7Q%\8_^$DUY?$_C"+Q?_P (C%$Z^(/
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M+>(M9T;XZ+"%\'Q/XU\2?$WP28Y%\&^"D/Z]_P#"[O@Q_P!%7^&7_A<^$/\
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M6B*:#4I?^)7-]I/:T%YCUZY]._;Z5Z!_P3K_ &8_ _QLT'Q1XW^(U]J6I_\
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MN/!VM_:/>S_+N#_2M@_ 'XJ3VO\ R*MSW_X^[PGOU/0]<_YY'W!J7Q(L8?\
M7ZYIMMR?^7P]>OY]>OT-<A#\;-"\WR/[<TS_ (_#_H?]L:-GUZ=,8_SWKS<Q
MX=^K)M[;RZ_?O]SZGHT,WE;X6O\ %%K[[JQ\C3? WX@0_P"OL+:VSQ_Q^>@S
M^?X]SZ8KZAT'_@F;^V7XDT'1_%5CX \-VWA_7[/2[W1[O5O'FC:;]O\ [=&/
M7MWSBM>\\;&\Y@(Q=?Y_PXY_7C^K_P"$OQVT[0OV%/V2==\.^$-5\?>,_B=H
M'A3X=^#?"'A*T&I>(]0?0V.A^(-<89S_ &!X5\-Z%K'B?QFQ!"!)<%?,Y_,^
M*\/+"X6^#;4K7Z[JUETW9]9P]+"XG$IXN-TY)::*SO=N^EEY;W/Y,/$G_!-/
M]LSP3_9_V[X<Z)J5QJG^FV=IX>\2?VEG_P ML_U_"NP\'_\ !+7]N?Q5%H\]
MC\.M-TVPNK/[;9W>K>)/^)7G^N.?_P!=?TZ?\%"_VU?#'["?PM^'?QI^(>E_
M$)K#4O%NH> &M$M5+C4]=\'RZXI=1XD\),%$F@,(V+-EQ,-JLIKX)_X?B_"G
MP?X#^'/BN7PYJ7B/2?'^LDZ1I:W@TW5-!;8OCE6UPL".!K2D8&/E!.<D5^;5
M\XS?")?6U-1Y59I2=D[=ET6Q^NY)P/B>(?\ D39?3JR;:4?:0_>-:)1YI6?-
M*RWM[S/A'P3_ ,$3_P!M'Q');F^@\)>$A]L_YBUGK(P!ZDXQ@#)XR/Y_0^A?
M\$%?CYJ45N-=^*VAZ9<6H_X]+3P(,\=?^)Y_PL@^W&.H]\5^B_[.W_!83X2?
M'H&;2OA9KEK<Z9JVFV'V2[O?!XX.M?V &!1E((_MO(((<=0P.[/[I:7J,&JZ
M99:D!Q-;K<'CCE5)XY QN^N/?%?3Y+0PV>Q3>92TM)QBVGHME=Q[-/T/)XLX
M>X@X.E#!Y_PY'*'435*;3?M$O>YDTW?1J6G?Y'\NFA?\&^7Q$D/_ !-OVC-&
MTZW]$\ ES^(7Q&<>V1C)]J]K\._\&_>AV9AN?$'[3OB2ZNA_Q^+I?PYT;9?G
MT:36?$-P5XSD[&^A[?T;;5ZX'K[8^G3I_C2;QZ']/\:^GH9!E:>LY2L[ZSNK
MIK^:3['PSQ$K:..O:WRU>O\ 6Q^<7[0_Q=^!?[ /[,OPCTWXL>.+_3?!/A^^
M\+_#'2_$-QI9U74K_5-%T+69$+@A5\QX=&U5\%6V*P"LR?,WQ]I__!>O_@GI
MX6TK[!9>./'WB6>V/(M? >LZ?D#T!XZ_49]<G/T#_P %;/V.O"7[:_P#\$_#
M+QA\1?%GPVL-"^+FD^,+/5?"5IHNHZG?:A'X1\2:!%I 37AY8$O]MR,"H0]F
M!  3\?\ 0O\ @VG^!]YH6GZY!^UK\8\75G_QZ7?@_P &C^7?OQ^>:W>(P>#Q
M7+:]E9+Y;7_3S.+$+$M>ZTHM[Z:-]7;UO\CZS\0?\%^?V(;KQ+H'BBPT7XR:
MEJ&A66IV5G:C1])T[3+T:ZB(1K(>5_+!VY4*556.2K,6+?&W[:/_  5O_8;_
M &U?!_AKX=_$GX0?M!W'A?PEXM'C*TM/"WC?1O!;WVJKHVN:%&NLO'X>\5 1
M1KKDN(V1L/(7$@PR/-J7_!NO\'=-B%O_ ,-->/[JXQ_R]^&^_3_H9,>_;@Y[
M5^4'_!4__@F-8_L.?"3P#\0/ 'Q;N?&UQXP\7ZGX9O=)N]'UGPW]A_XDPUS^
MVO\ D9/%WKG/MT[C"AQ)A7BWA/[.WO[R>[=TFVOOW#^S,5*TGF"M:^L>C6VW
M3;5'PM\0]8\*ZEXR\43^!K'4M,\#W6KZI_PC>DZM>?VGJ=AX8Q_Q(O[=Z>_;
MU&>.>_U+]J'X[:O\(=8^!6N?%KQKXD^%&NZOX8UB\\*>(?$>LZEIH'@?1@=$
MT0'Q!@^'O#KE5W>%0<$KSG K\J+R]\?_ /+?Q5J78?Y_P^OM6]\+="\5>.OB
MG\./!$WBK4C;^._'?A?P9]KNR ;#^W=:T#0<?Y'^%>A+%[N]MW:^WEOTV/(_
MLURQ6DN:[<+Q=^:5[<JMHY/^57?2Q^N,7[<?[247B&W\0P>/K6VU^V\=?!SQ
M\;K_ (0_P;_R,W[.'@W_ (07X4:S]/"GAWG!/_%9C@8'%8'Q._:B^-/Q@^&'
MACX2^/[[PEKGACP>3:>';O\ X5OX-_X3G0M,.M:]KW]C?\)Q_P (V?$X\.GQ
M'K6MC_A%AC(&,5H_$']AOP/X)\)?8;'Q5KESXYTO2/CM>W7B#5KS_B6:@/ N
MM9T+6O[#QG.?[<V\^OJ!7Z7>%/!/@?X;^"_!_@^#0_#>IW_A?P?X8T?5_$/_
M  C6C?VGKVIZ)HV[7=:USKP ?R'IBO?R6A'-96<HZ:;KK;=7^\X<TA4RB'M9
MTZD(._+.<)1B_24HQB]NDF?)'QQ_X*??M)>.O&EKJ?PY_LWX7>%]+725TCP]
MI7@_P;J>IZAJN@_!D?"@:UXW\<'PWGQ^/^$>UO6CX(7Q4<>"_P"W@.:^>/!'
M[8'[5'@GX.V_P1\':Y]F\(VVD^*/#7AO5SX"T;4_B9X2\,^.M:_MWQUX,\#^
M-SX:/B;P_P"'O%GB+C_A%@/2OT?UC7O#D,O[C2M-MOI9Z-^GIC/I[^M<?J7B
MJQAE_<?9QQQ]D[]_?_./P^Q7"5X\Z^%;R2]U;;RO9?>?/2XKDKJS6EX[KW>^
MVVJUVU6NJO\ ,^I?\%"?V]==\1>'_$4]]HES/X7UCQ+XG^R6GP'\&Z;IOBW5
M/&W@O_A _'&M>-]%/AO/Q _X2KPY_P CM_PEGTR5XKE]>_; _;@\:Z#X_P!#
M\8P:)XMT?XBV7A>QUBT\0_!+P;J6F:%JFA>#3X%T+6O! 'AO'@#Q%_PKLGPS
M_P )3X4!R<YZU] :EXJ_>_Z\?0]OY<?U->?ZEXVG\K]P<?T__7_]?Z$N'+)I
MNUD[WTMH=&'X@QCW@_>_NO9N_;^OF<;X)_:/_:5A_:B^&O[4WQ%\$Z;X^\4>
M%=(_X0OQ%:VOAO1?!)^)/@/_ (0W7_ NNZ+KFN>'_#8/_"1>*_#FN8'BG/N*
M\QA^+7[5VCWGA<Z5JO\ 9FG> _@7XI_9H\'6=WI'@[^T_#_P*\>'7SKW@PG_
M +CFN?\ %4'_ (K,8Z<XKL+SQY?6=SYX^T_E_A_//?US7/WGC#[;F?\ Y>/^
M7S&.QZ'\_P">>G/S&)RW#8>32;;YFM'?6[5M&];_ #\CO_M#%W5XM:J_-=:/
M;=+I>W?I<^C_ (;?$W_@I)\=_%%_XP\#V/PE\6ZSX5^'&J?";QUJWB'X<_!S
M33X\\!^.M%T'0?\ BZ9_X1LGQ_XA'ASP3H>/%'BSY1_8&-N, >(:#_P3!_:]
MO+7^W;&#X;Z;_9?^G&[_ .$\UG4A8?AX?\-=.G ]^W3]T/\ @@#XR\+:AXU_
M:C\/>*H-&:PTSX=>%_&1N=4L=';['I>C:SKT6MZRX".RH&='=P/D"%V.T-7Z
MC_!7XOWGQR\ ^-_&^EZ%\8/"?AG6V\5+X:MK7P?K&FZ9KOAG0U.A:)K2$^&M
MW_"/;1R%'*CO@X_'N*\[S3+,U^J83X=^^VOY:'Z1DF&RW%8.^*34M+-\RWM?
M5+H]K[Z7L?SP>"?V9_\ @K'XDM? &A3_ !4MO&UM\'/$FH_$'P+_ ,)O_P )
MI\2-3T+QWXWT4Z$/&1'B#PY_Q4'B#PGN(\%#Y?\ A"\\=<U]C? #]BG_ (*2
M^!-6^'%CXRU?PUXWT?X2^'?'1^'/V3P'K&;#QYKO@WQYX&\"^,O''CG_ )&C
MQ]_PJH^-];_XI;WXX( _>'PYJ.JQ>)_"\\.J?VG;ZIH^EV5W_IAU+!_MG0-<
M)7'B3Q:00I(R"" >V:^F+NR,7V"<V7VF<V9_TL:1HVI<<=]?\1@@9YZMUZX(
M%?/X;B+-L3BE&5X[)\R:2UM=7MMO^AZV)R[!X7"WC&,MW%Z/;5+2[73U3Z,_
MC_TC_@W9_:2FFL(-=^(%JOVJS^VF[\/^$=& !8_\@77/^$@\2\#.,<]._>O;
M?#O_  ;3>/-0%N=<^/S:,5!^5?#6C9]L$_\ "6J.<<DKZ$]Z_KK\.>3_ &9;
MD0?9N.A]?P(QQGZ>]=!YQ]_R%?40Y='B\RWL^5-+>SY?T_$\9X^5K1R^"TLG
M9MK2R>MEO9];G\M?AW_@V'\!0H3XI_:L^(-Q"!E;+0? G@T*W/.7UI9P/?Y2
M>.!TQ^T?[!7_  3Y^&7_  3\\"^+_ _PU\7>._&4'CWQ%8>)O$NJ>.KO0'OA
MJEOHZ:0HTM_#GASPS#%&ZKG+QM( P*&.08?[Z\_V_3_Z]2><H(&.>/?IUR2?
MKGZ \5]#@YY3>+4TY*UGS*]]-M>_;OKNS@Q$L37U=D_1+\NR+E%,3H?K_04^
MOI4X\J::Y6E9W35K=[M/[S$****H HHK,O=1L=.C$]]<06T"C!N+E@!GKSP#
MV]1].*F4HQC*4I1C&*<G*32BDNK;:27FVEYC2;=HIR?9)M_<DV:=%<;_ ,)W
MX2_Z&SPQ_P"%#I/O_P!-?I^OKP?\)WX1_P"AL\,_^%#I/_QSZ?Y/'#_:>#_Z
M"L-_X/H?_+RO9U?^?57_ ,%5/_D#LJ*R[2\MM1M8KFRN(+BVN%)MKJU/RX()
MR/0$@\#'?(SS6I_GUKNC*,HJ491E&2NI1DI1:\I1;3^39+33LTT^S33^:=FO
MN"BBBJ$%%%% !6=>1?Z-/[C/IZ=?SQZ]NV:T:J7>?LT_.?E.>.O"X^F* 5].
M6][JR_16^[3N?,W[&<?_ !BE^SP,?\T@\"= 1_S!(N@'^]].,XZY^E_(/]Y_
MR-?EG^RA^TU>V/[._P &_"UE\"_BYK.H>'/A7X!L+TZ1K'P:90/[%4?VT(I?
MC8^OG0 44B22%V &P BOHVS_ &JM;O8_M%C^S=\<-2MO^?JUU#X"D'\#\;B3
MCCTX!Z=:X/K>"[J]W>RN_=WV?36_;R.IX',;7>7UE&\5=QGHYZP3;25Y7O%/
M62U29]?^0<GYVX)'\_?V-'D'^\_^?_U'\J^0[?\ :LU2ZM?M]O\ LZ?&VZM_
M^?JUOO@(>H&/O?&TGCU''Y\S3?M2Z[#_ *[]FGX\?A=_!?IQ_P!5IZ]>>V3T
MH^N8'EWC:UK\R].Y3RG,UO1Q";;5G3JIWC9RBER)MQ37,DFXZ-I)IFGK\6/V
MTOA?G_HV3X[CG_LI_P  Q['H3S^..E?5Q0'V^G%?GSX,^)^K?$']LSP7_:OP
MM^('PX&E?LQ_&4*WC<^#&.M!OB=\ QOT=O _BOQ8&6/)9CYBY4;4&< _H.6
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M W[7?P<L_#OC_P (?&S2M<^*V@>.O$?B4:MI5IK.M>#--7P/K>KZ]KATE?\
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MO=^]22M=MMMNRLW?R/T;^T#U'Z?XTGVM1SG\<'O^/N/SKYP_X61;_P#/P/\
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M')-.#E>LTTVC]P_B_#JL'Q,\0:5??$#Q+K6H?\*L^,>LWMY_Q)M-(_XG>O\
M_$EQU_X1WQ9^=>CZ]XJ\?^&]9N)[[5?^$_T:U_X_/]#_ +-\3:>.O'_,L>(
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MMU]_S/!]'\506>M6_P!NG_XE]U::K9:P?^?#2]=QQ]?R]\]\^:6?P?XHT_\
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M7O\ Y6=!/OQD#TSGI7]W0\29ER._ ]>GY?YZU^(<=X;ZUC5+^5KWM+Z6TO\
M+N?8\.^[A7';7;;\#V#3O&T$VC:/]GGMK6?[9XIQ:?\ $F_XE_\ Q.M?[_\
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MI^-?&A\3>4TC2C0!%X:D2.6,JV7$3/')\I?'[X!:7^U_\2_A+X._:=\7:/\
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M5/V>_!%O -&U2R:Z'QY^&F1G.W(_X23(SSU'TR.GN%[_ ,&^'_!6N6&X\KX
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MMSR/A[*]?=]/>?\ D=JSO-'_ ,QK<4]N56MVV[:>A_.K#^P)^UKIVJZO;_\
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M>A?LY:Y$%VC8/#/Q5\<)XQ<817\ ?#,98(RGIOAW^U(WB3]JS2_A)#JI\5>
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M_:?_ ."COQ'^#7@G]J;]G#1OBKIWAGXU? #XX:/HW_"Z/&KZ.U]%^SSK>B_
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MQS4L1G>,Q&-Q#C=)XC%5ZV(K2L[M<U6M4DKMNS2;T'CH,^@I:**Z3A"BBB@
MI#T.?0TM!&01ZC% 'QC^T!^S7:_$RZB\=^!;G2O"7QIT72)M'LM>U+2#?^"_
M'WA[<S_\*S^-FB%D3QU\.[K_ )9O)(OBOP;=L?%W@N:WNV,4_P !?#K7]8\+
M?##]H73/C1XH\=^+/BO\.[_Q7\0-9^&>I^"?!^O>-OA3X<CT^2X\&Q_"K1/#
M.X?%WX?F='E^#GBE0&O&0PW2>$?'"/X,@_<5T!4#=@Y)YY/IVSTQ^?Y5\O?&
MG]G_ ,._%FPT?Q#I^M:MX%^*_@E]1U3X=?%CPU8R2>(/"NI7*I)J>CZKI 0Q
M^*/A]XE4)#XU^&7B"<V?BJW16 L/%T%EXHM/&S?*O[1CI)<SC)*+5DVD[:;.
MS2=O7;<^DX?XGQ>2U*="4FLNA6I5>:[;@X2BVXR5W'FA>,N75Q]UN4;P?YZ_
M#?X,_%*^^'W[/OCOP/\ %I$^*%\/ UU\9_BQ\4O@SH__  M7XQ_!]7FUH_#3
M7!&L7_"!>(7_ +;4;9(6^SR1MY027S6/F/C?]C7P#^V_\6O'UKIFI^-/$GPU
MNM;\-:?\1OB;JGBW5;[P/\.-7\#-)HOB'X:_LLZ$A$$?Q"\5I')X>^-_BK(\
M&^#EX\OQ?\0AY7A#U_X/?LG_ !MU#7OB?X2\?GQE\+/ 'B[QSJOC#XV>(+/X
MP:MXRO?C!J&LH&D\(?L],7_X2CX0?!?Q+'&1XU7Q0J>-(TD;P-X&"PB3QY#^
MK7A/PGX>\%>&M,\,>$=#TOPWX<\-:9%H_AK1='M$LM+TK2PJQQV&F0HJ^1%&
ML(7"@?,%Y7D#AX<RG&95B7C55<,Q3LI\TH\L).4;1E&2:O%N[3=[ZMVN?0<8
M\:0Q]/&9?A9T\SR[-()S3RN$8\J5/%_491E>/+1E%+ RY8.$(M)4T_9F5\+/
MA3X$^#'@7P[\.OAOX6LO!_@KPOI"Z5I&@:0LD,5HL<<&2ZLSMJVL2,K&76YG
M,SD,'<X?/K6!Z#\A2*3M&3S@9_+O3B >#7U#;;;;O)MMOS;;;^]O7S\S\YC;
ME24>567NVLDK*T;;:*RMY>04F!Z#\A2T4K%%?R(/^>4/Y#_XFF"T@B_U-O"#
M[C_ZQ_G5NB@"OY,/_/'_ ,=/^-)Y,,0^6$'MD#/K_+'3BK-% GL_1_D-7'('
M8G^9Q7SK\6_VFO@O\%-7TSP[\2/%W_".:KKFER:OI5O_ &/J^I->6$4C12-&
M-%MYRS)(CH!N5>,AB"2?HH<=!U)S^!.*_"7_ (*L3^5\7?A@0,?\6ZU@<_\
M8?? Y/8?X"N;$XGZM&Z3Z=-GT\K7V'05WKW_ %7XGZ$_\/!OV4/^BFO_ .$E
MXU]O^I<_SD^G"_\ #P;]E#_HIK_^$EXT_P#F<_SD^V/YL9\>;^XQG Z>F/\
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M=70LK*V0=6>5V5%4D9._AB>3E@I _P K?+MZ>6WD:=%</_PL?X>?]#WX-_\
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M?[O+T7Y ?ES-_P!-_P <_KC'^>GM1_T\?K^G_P!;K[^]6)C!_P ?'^D_F/\
M/UZ#./6J]>2=-WW?WLL?ZW[-COG\?\_C^-6/(]_U_P#K57AA_P"WGUQW],_T
MX'UP:V(8?_U_U_Q/X"@.9]W]["RQYH\_^O3OG\.G?/M700P])_UM/SSR?\^G
M2L>&'R<^=_HWK^'?L>/3M6A#-ZSG_2L'G_/U_(5SF_UGS_'_ ()U%G^YQ/\
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M#XC\6/+KTG_"U2CM).JQG1<+_KY#7],M !111D'H0: "BBB@ HHHH$]GZ/\
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M_MOP-XH\#>)/"S3(BZ%\3U!<J)*^NO!_PX_;DO/V[M=^*-_\<OA;JO[/FN?
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MD>;ZQ_:L/BWR!_HVG_8_]#_TL?\ UO\ /3K6C9V<'FW$'GZE<_Z9C_C\'?\
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M< G&/R_KZ8_K7L'@H_\ &*_C[WOM5'Z:(?Z5\<>//&$'@GP;J&J^?G4/L?\
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M+7Z<G]3^?/MCFN(LYN_U_P#KC'\SG^E=39S'S>_\_IQ_D#Z$UK4UIS_P2_\
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M)2NY6<M6OB?7;7IJ]+#S#'SS+,L;F6(:4\P<7*,6^6+C%1]V]M/=ZZ]V]W*
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MZ^&WA?KZ?\3_ .G^1@>_]7&I3#RN/Z__ %L_Y]#7\K__  6PS_POCP_/D?\
M(A^%\_A_;_'3G/3H#U[XKG_YC/O_ %.@_GG\-GR?$>GC_I\_QXY/]?;/>O[F
M?^"+5Y]L_8W\^#/V?_A9/BC_ -,N@=O\]<YK^&;0?^0_I_[C_E\Q_@?Y<_3B
MO[8/^"#]Y]L_8MN(!UM?BIXHX_\ !![GU_\ U"C$]?G^IZ.*_P!T?H?MAYW[
MK_..GTST[?KFL^J\TW3\^?Z?R SZDFJ$TW[K]Q_7.??K_AGGWKQ\2[7?:[^Z
MY>!A[2I1A_/4IPO_ (ITXWV>W-<QK+Q)H=G:W$%_JNFVWM>7F?\ /?ZGBNAT
MWQ5X<O/W$&N:)<W'VS[%]D^V<9SG/;'UZ_SK^37Q5^TMJNL?$;XH:5JOBKQ)
M;:AI>L"RL]6N[T:EC_#)_P G(KQ?P'^T)JMGXH_XE7C'Q;;7%U>:K8WGV6\Q
M]OTO\^3QG_))^/Q'$.*PN+4;)I-;*ZM>W;1_YG]3Y7]'A8[ 0Q_]IKFG3A44
M.97]^G&:5K].9+;[S^XBS_U1^@_F*V8._P"/]*_+?_@G!^T)XQ^,VE^*/#FN
MSW-SI_@VSTO['=W?_$RU._\ [=_Q_KWQ@?JA9>?^''7U_P ]?QK[?"XEXO"+
M%]TO=VW_ *['\V<6<.XGA;B+,\IQ34E%M)JST3=MKVO:^AL6</E?C_@<]^QS
M6Q!W_'^E9\'?\?Z58@[_ (_TKI/GS8@[_C_2M"&'_P#7_7_$_@*SX._X_P!*
MV(?WOMU_3\_ZUY^)ZV\_U"U].^GWZ'T7JVFWVH_L2_%JQTJ&;4=0NY-6%E:6
MOWG/]JZ(0J=>< L>ORJ3C K\A+O]E'XF^,);>_OK'3=#M^_]KZQSV]R,Y'-?
MMMX*O8=-_9;\?7T\HMUM;W526)'RC;H/;KG.!CG )/-?$-Y\0K&&6X_?YZ]<
M]/\ (/\ /BOS_C7AS"9]B<LEBU\,7JMU%=';H^U[>1]MPUQ%BLAPV9X;"[SY
M7S/5II):=^^ESYG\-_LHZYX4^SSSZYX2ML\_;/\ B<ZEC\!_7J.W>O+_ -HK
M4M#^&_A?6/$?BKXC:;X2\'^%[/[=XDU:[LC_ &98GC&M =STZ=^XKZXUCX@V
M/V"Y_P!._P .A_7\>1@U^='[2VD>!_C-X2\8?"OQ]]IU+P?XRT?^Q=8M+2\_
MLW5!I8.?^0YVZ<'COD]:^?PW!/#\='\.S5GJKZK\ST<1QYG[LUF&UFO=VVTV
M?DOD?+VC_P#!0[]A&&_N(/%?[5'AO1-/M;/_ (^])\'^,O&QO^O_ $+_ +Y[
M^W'48_C#_@I/_P $V;.[^T:7^TUX_P#$EO\ \OGV/X#ZS_\ -)G'K_G'S_\
M#S_@C/\ L,>)/%&CZ5//\8_[/NKS//Q(_P#P;]O\X&?:?%7_  0W_81TV7_0
M=4^,?/\ S]^/?[2Y_P#":Z]OQ_&O9_U4X,PN%7-ETI.Z=]6]]>_G8X/^(B<5
MO%6CF6FRTVTTTMT]#GO^'NG_  3\T"PN(+'5?C_K>H9_T.[TGX5^#=-_+_A(
M/B1_3M]*_##XP?\ !2;]JCXG>,KC7-)^(USX)T?2[W5/^$:TGPGH^C:;IO\
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MN3=[WOK>_JSX7-L/]6Q,H7ZW7H[_ .0M%?-_C?X]>'_"_P 7O!_P;L7TR_\
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MJ>!FL'&5G[LMGT?^0?6O[WX__;'E^I7GM],_U_0\>P]J_E__ ."TD/VSXO\
MA^<_]$WTOU]-?/\ AC_]5?T\>*O"OB.$X@GMO7U^@Z=/7U[U_,O_ ,%A]'OH
M?B!X7^W?\?%UX#XQ_P!AK7_Z?3^=>=AX_P"V:K3FZ_\ !^9WIII-=3^=_P *
MP^=XM\/P'FX_MC2\'G_/)Z=>.OI7]G'_  09F_XQ+^(%CS_Q*_C9XILL]\=?
M;_ZW;FOXW_A[IL\WCSP__P!.NL?;<^GO_GM]*_L0_P""#^FZK-^SQ\<(/^?7
MX\:I]C^O]B]/\^G-=&)Z_/\ 4Z7+366GF]/Q9^W$TW3\^?Z?R SZDFLC[9;^
MA_/_ .O2:QIFN0Q7'_'M[?X].#Z>GZ#S>\U+7891^XMOITXR3WZ'KVZG->!B
MHOWM'UZ/^\>KES_?X>UG^^HO==*M+UT/XK_&TL\/Q]^-'_/O_P ))_[FM?\
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M3OG6B1XD&/SYYSFON+]MCX\:5X@\>:'XH&JW-S<Z'^SZWC_5[2V_XF6J:?\
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M.>X[?CGZU!_P@7CW_H1_%O\ X36LUZ7-'^9?>O\ ,X/JWE^'_ //A9^3%_\
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M_#7[,W[8MSI%U9F\T?5O#OP@^,NIZ7?8) UG1-<'ALC/'\!9<$>G'ZG>#O\
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M6I;233TTZI'Y_G6N*=I*5DES)WN]KWUWM?YA1117U!YX4444 %%%% !1110
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #; CH# 2(  A$! Q$!_\0
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MC/5/!GPN\._$7X7:[X:U+4-2T71M"UV76=<4F0:%X<6/7]'\KQ'(&BWE1E5
M9?TLB=/[V<'/4<'@#KSGMR.@Z]:_G"U3QM^T3^SU\4/^"/\ \$;G]H#Q)X_T
MKXQ:OXSO/B7J>N>'O"&EZKK_ (:'@K1?$>A>$BEMEH]#\-^9_P (^)(@;J1)
M8G9O,VI'J_ S7?VS_P#@H+\3_P!J/XF^!OVP?$O[-?@[X$_'C5?@Q\(?AEX4
M\'>#_$GAJ_'@$HNN:Y\4AKZ'Q#KX\52R1%8=T"11[C"NV((.#,.%:<*=7'X3
M'1>7THUI-^_*W)FE;+()1Y%4<I.ESM.*2C=W=XM\V*R6*4L3"2<%S14M97]Z
M4%9;Z\KOIIINC^BDL%VA\9W$_0YZ]ST)Z]*\^\8?$'P1X";14\7>+/#7A1O%
M.KV?AOPZ/$?B+2=%;7?$,I<PZ/H2ZQ+$VMZY($_=VT(:65558P)$D(_ ?]O?
MXS:_H_Q9^,^D>%O^"B'QO\+>.?AQX$C\3>&O@#^S5\#V\::=X"U#1O!T6N3G
MXTZ[X>\*^-6"^*]=195B\6&*/PGX21%)0.UP/A;]IKQS\</VN_V9/^"2?[0/
MB_XSZAX;\4?$+XY^$OA]>:7I'AS13IMA\4-%\;>)-!_X7]HBA./$4:Z K#PM
MO/@L^;]U,;FWRC@7$8V>"EBL?[/+\QG5ASSI3BURY?5QRY>=0<HM4[.5E&^B
M<FXMU@N'I8F6"E*:49\W*K.Z]R4EK>UW;732W=V/Z>?B!^US\)/AG\??@_\
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MI^,4\)>+8?$OB+QID^>,P+X+W,!&5.P?7'C'Q]XS^+'_  4*_P""-7Q"\?\
MA?4/!GC;QE\"/BQK7BKPCK,#:=JGA_Q/)X!UQ]?CET<DM&!-)(4!R(X3$ .
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MX:_X2#Q.9-\$8RL*M^Z15 0>L?MF?$[]JO\ X)V?LHOI/_#2_B3X^>-OB_\
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MU"]^([>)-";0I]=UW6@8_*UZ1]TLK1*OF3R33.%EDD<_HX&^7CD@ 8Z>WO\
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M4>:VJ:NG%',\5AHJA1=H7Y[VO;6[U:>_6UK[;'XU^"?^"7WC"U^,G[-_QO\
MB[^UG\1?C'XM_9JO-3M?"&F:EX!\'>%?#4OAVZT,Z"VD2:)H$2+]JV['/B=G
M>X8;2RJ-K'V#X/?\$]]'^#?AG]MGPI;_ !$UW78OVS_&7Q,\8:O/=Z+I.G+X
M#/CW1M:T7^RM&"!O[<"+K!=6F5/F 0,F\%OTW!R,!<KCKG&?T[X]?K3F7/MZ
M\=?\_P!:VQ&>YSBE&.)QB<4H12C"*BE"HZ\$HQ2BK59.HO=3YFY.[;;NOG.+
MK_:NU:R2LM))[:+1WZ=C\8-<_P""17@S4?V7_P!F[X Z3\9/'OA3XA?LK:OJ
M'B+X,_M%:#I>AZ?XWT'5M:UF36]6ECT4RM#FY1XHS!A2PT6)V9678W4ZY_P3
M F^*'P!\6?"#]H3]ISXS?&KQOXH\;>'/B;I'QCU)=!\,^(OAUXZ\&Z5;:1H5
MYX&T7P[&/#GA]H$%PYBC!2X>9RQ+A"/UQPO^1_\ 6]S]<'^]P87\?PZ_7&.Y
MY]CZ\5#/LXA*$EC6I0G*<9*"]I%RGSRY9V<XJ4KRE&,E%N3;6H_[:S---3UO
MN[7L[75]6D[:I.UNG0_.7]G_ /9/_:,^&OC,^)OC#^VM\2?V@-(M?">H>&M)
M\%:M\//!/@;PV[:D1Y>O:\?#@W^(-?AVD1RR,GEKC ",%;LOV%/V--,_8A^#
MVI?![3/&^K>/]/U+XD>-_B$==UG2]*TB]!\9W,<_]E>3HH2(^0\:NEP%+%=R
MJWW0?NDC."#\O/;H!Z_3GW)_5&PPP>HQSZ@9_$9_'\.M<%?-\QQ,<93;C%3E
M!VC&,4Y03Y9<L5&-X\S:TZO86(S#$XE>])*_Q))*]M.GKVOUU/@S]H#]BK1O
MC_\ M%_LM?M#:EXXUSPUJW[,/B/Q1KFD^$[+1]+U+3O%SZY;)#*FK:NV)=$V
MQQHZ>2"SEBH42!BS_ 7['&F^ OVO?CM^UQ!XRUJ_U;XW_#[PA\/KOP3<:5I,
M>EZ$G@8LL>LC6%_?.7*A?)< $$@&1HRM?>+?=!''7H"3C]<_C^6*!R,D9Y'4
M'CDY]Q_]?H<U4<RQZPT:'USX::I)<JLJ?M56]G;;E]HN>W?4PCF&)BO8)RY5
M;6RV4E);+^9+S/Q63_@CWX+;]DVV_9A7XT^-;6_\/?'N^_:)\$?%6W\.Z*FJ
M^%/'1UV3Q#;8T!E7P]K>AQR2RIY,R1AS-@.KH5KOOA)_P37\2>!OVE+;]JSX
ME?M+_$/XU?%-_A3XB^%>K7&M>#O!OA71[_2=?NHKG26T70_#B(OA]O#C&4LH
M+>>SL\I;S)=GZV_+_=//.!GCI]!W.,>WK2?+_=/YGV_Q_EZ\=L^(\ZFG;'/W
MI2E.\5[W-*G*HKK7EG*C!R5^5N*;3.S^VLR2:]I92OS62N]MW9/7E6EW:U]S
M\[?V1OV'-)_9._9?\0?LSZ7XZU[QG8^(;WXDWR^*]6T?2=-U%?\ A9DT[%CH
M\4@CV^&UGVA) H=%.Y7QLC^6-._X(W^$M"^!O[-/PV\,_&GQ?X;^*/[+?CJ_
M\>_#?X^:9X:T$>)5;7-=GUW7/".JZ.3Y<F@W1EBB\IY5VK'&2$D=HV_;EB"<
MYSGICC _$'/>G$K@CTZ@YXR<'GGUYQFHAQ%G:KX_$?VA)/,IJI545RJI-0<'
M[2*TFI)RYHM.+O9QT5LO[2Q<7)J4DZG\3WG:735-ZVMUOJO)'X]:S_P3*^(/
MA7XK?%GXF?LR_MB?$;]F*Q^.NL-XO^)O@+1/ /@?QUX8O?'DNU-9\8Z"?$ZA
MO#TURFT%(P^X+M9B"H?UCQK^P-#\1?B)^Q;\3/%7QE\:ZSXB_8[O-:U&TU/6
M]&T?4M3^+.IZUH^@+-J_C/5D7S-"8MHV[,,1+R.0/WC)YGZ7X'I_7U]?J?S-
M+@>@_P Y_P 3^9J'GV8M\TL9>?)*G*?+'GE"5/V4HRG93E%TOW?+*37+I:R)
M>98MW]^5W=.[W3336_8@@XA ]C_*IZ0'/8C@=??/Z>]+7G7OKWU^_4XV[MON
MV_O"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111D>H_S
M_P#K'YT &!Z#_/\ ^H?E11D>H_S_ /K'YT9'J/\ /_ZQ^= !1110 4444 %%
M%%*R[+[D 8'H/\__ *A^5&!Z#_/_ .H?E12-T/T/\J8$6/N^_P"O)_\ K5R/
MB/5;S3(8/L_V<?:20?M1; XSPJ^Q^N?6NM_N]NIS^)SW[ 9Q[^IKYA_:'\63
M>%[/PY)#-CS[S4/7G*[L^^"V,8QP?4U\YQ3GF%X?RNKFF*4G3I_R[V=V_G;:
M_6QZ_#V6O-<WR_ +656;7+O=VE9-+?9(]$_X3+6_^>.G]N^3VQ[]Q3?^$PUK
MTTWG_IU/M_M>_P#GC/Q'_P +9OO?_/XU7_X6S?>_^?QK\9_XCIPE>U\\OMH]
M.;;W==N;;RL?L_\ Q"C&;_V:GUZ_Y]3[B/C/6>\.GC_M@R_^S"G?\)GJ9Z'3
M3_V[O_\ %U^4_P"T5^U_J?P4^'7_  D.AZ'_ ,);XWU[6-*\'?#GP0+W!\6>
M*M</R:-QSDX;G/8X.*SO@9^VI+\3?V>M)^.?C"#3_!,"Z)XFUSQC:?;1J6F:
M O@II%USYB0204;(R2!TYKZ/"^(N58S"+%)9^E=;JT;-JS:VMJK^0?\ $(L;
M]7^L_P!G))R5.+N^;F;>B6O2[7>S['ZU-XTUMA@C3<?5N_/<\Y]\T@\9ZT.B
MZ;_WT_\ C7\^WAG_ (*3_&[QUXM\,7_A;X3>$M/^&'BB\ T;_A.?'@\-_$S7
M/"V"?^$Q&B ?\(UH"%MQVR._L<?=_2R'XM3S26Y@F'V:Z_X\[O&>V,'UXX%8
M9MXFY5E[IPKN<W.48JRO;G<4KV;U2EKV=^A-3PFQ5!JA*E&,W9VNI25[.UUM
M?]?4^W!XUUELC;IQP>Y<?S/]?6F?\)CK [V /_7"0?\ M2OQ2\,?M\^./$G[
M4Q^!)^$NI>$O!%KX$\4>-&\;>*KXCQ+KVF:'K(\/_P!M:+H?!T/P]_;^P9DW
M$X#*J# &-\<?V^OB;X>^(WB+X6_ _P '^$_&FK_#O2-,OO'FJ^-O$.L:5IEC
MJ>O*=<T+P9HHT$,6\0MX=)D!8YQM!&5.[UH<;X26(6'4FHRC&2_[>BI=^S7]
M;[+P<QU?$*V6VERW7OZ<J6CM>RN[*U[MO2[V_<G_ (3/6_[UC_WXD_\ BZ</
M&NM') TT#G'+_P"?:OPUUG_@I-<7'P4^"_CWP;X..L_$CX[#4K7PAX*U;6%T
M[2]#;0V;_A.=9UO7",#P[X3"Y?\ B^92&Y)%;X7?\%'=<?P+^T'K'QO\-:=X
M4U_]GBVTO5_$8\)7G]HZ5XITGQQ&\G@9M#_M\9 \5A HR0"S*H(R,U_KCA7+
ME5[WV2?-:[>FF^\EYV;U9U/P;S6.%>*>6Q4%-4XW;NY.:AI&]W:4E%NSUN]8
MIM?N@/&6M#H;$?\ ;"7_ ..4\^-=:[C3!^)']:_ OX4_\%"_C/KWQF^&_@#X
MJ_#/PWX2\/?&,>)[/PA=>'_$>K:GXE\*^)O#^AG7CH/CG>NQ?$!\.*&8(8^<
M'*J*_17_ (6O>^A/.>3_ /7Y_'U->)G'B=D^2.,<6\\<IM1T4;7=DEWY;O\
M\![/0Y:_@_C,+>6)II6BIZ/F5FF]HK2S5M=VC]&]#OYM2TZ"\G\D3G(R#@Y(
M_3IVQD^U=#W?G'7^8_R:\6^"FNRZ_P"![+5)QR;J])/.2/,<=/3G(X]3ZFO:
M P&".ZC]#@_RQ_\ 7K]6R3,<-FV4Y?CL*VX581DE)6DG))N_?1IM][H_"LTP
MJP>:YE@[)*G5E!)=%%\KMM;TWN34445[1Q!1@>@_S_\ J'Y444 %%%% !111
M0 4A /4 _49I:* "BBB@ HHHH **** $P,8P,>F./RHP,8P,>F./RI:* "C
M]!_G_P#4/RHHH **** "BBBE9=E]R ****8!1110 4444 %%%% !1110 444
M4 %%%% !1103@$^@S2;44V]DFWZ)-O\ ! 0#']W/XGW_ ,/T/X+Q_=_4^_\
MG\#^'QMKO[:OPE\-Z[K'AS5K'Q8=1T+6-4T2^N[72=(;3%U/1&'FJLG_  D8
M8J" 5R 3@9V 95\/[;?PDFQY-EXO./\ J%:/VY[>(AZ=.Y[>OC/B')HN47CJ
M2<6XM.2333MK?S3WW-_J&,>JA.V^D96MOO=GV/M]F[^GO_A^OTR;?9OT]_\
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MGV)\1\XXZ@@8(KJ_M#"+3F3[>:[ZG-[6+TO=VV3O\K;Z>A^BM%?G'-_P4N^
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M+^O9>+W!T:<OW^'YHP?Q5:5N91>_[S:ZUMTN?B%X]^-_COQY^U&_Q \%^'?
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M::=]3^,^*:T<5Q%G&+C91J8FK.-MFI3;5K63O9;7+5%%%?5GA!1110 4444
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M/"]&\<?&R]^&^K^(=6^$.BZ7\3;,:B=)^&UK\3-,U"PU%TVK"K^.3X:5=(!
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M;_@6Z*3(]1^8HR/4?F*Z[/L_N?\ D<]GV?W/_(6BF>8G]X5Q,/C'PY-XLO\
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MM#5-=\:>(/[=QUQZ?C[U_,/^U%X5\#^&_CG\0-#^&7^C>#M*UC[%HUI:7?\
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M/W'_ (F+QO-?_4#A=:W3>'H-KKK^YW77SN?6?\1 BW_R)Z#UWY5K_P"4EO\
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M/_!-O]JKX)?LKZCXJE^*"ZTVHZ]\./ .BZ.-)TA?$(P7UW6]<SDA54O(BY)
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MY]>*KV=Y_H%Q/G_E\_T/_P"OD_3^GK7L$_P!OIHKC0_^$D/VC5;S_C[-GG[
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M.._KQ_C7S?>?$[Q'#+;P6.J_:;?/_'U=V77KG!^N!QR..XY>(K]E]R_R7SU
M^D/&T-C#8:/XJXTW4/"]G_Q.+NTO/^0]JO;6NO\ Q3_'&>1D>M?(_C;QAH?B
M36=8@GOKFVM]4L]+^VBTYZ]L?ETZ'W-'C#Q)I6O2Z?8ZYJOC;6O"_P!L_P")
MQ::39Z-_:=_I?'_(#_\ UFN0LOAC!_H^N:5X<\6W6C=;RSU;C4^GX]_\COY\
ML0[/?9]_\SH.W\!^*? _@+1O$&E6-C_:5SXHS9:Q=W=G_P ?^E9_Y O;_/2N
M7\4_%2^TW5+>Q\*_9M-M[JS%[]DM,Z;^GKG\>*X>S\-P7NJ:A!_97BVYP?\
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M5>'_  ,OQ.\:*?\ A,6'@GQ_\-40KXU\5)"K>28M)MK2U]O*X'[B^8/3_/\
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MEL7#&,[D[\!5S/*\+F.%PT(N.:Q>\$U%6:E9RB^1M7V:NM-=4.[\U;??NS]
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MDM?<W\KZW>GDNOR.@^H++_@C=I6D>)[738/VDO'C_ 37/B;^RQ\:OBK\$X?
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MU/+>.D\::$/ REHPP&/$AT<$,J[26PN25/T?7ZMPPFLMA>]N;1N^WS/(Q?\
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M0GQ(NCB?1_C)X5\)I\._#D$NLEO!_A3PM)XH:+^V6\V:/:8Y?V(HHH ****
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M_@GM_P (!JFJZWJ7C#2_BIX#\::/_H?_ !+/[+_MK7]!_P"0YP#_ ,ASOQC
MYQ7XJ_L=_P#!&G_@H#^U9^SEX'^/'P1_9]T+QI\-O'?_  DX\-^+;WQEX-TO
M4]0_L/6]>\/ZY_Q(_$..OB71-;4#.2S #)(%?4Y;F'UO"_64M=K;^O?;1'BX
MIM8EZV6O5I=?-?H?F3^Q;-!_PV'^RO[_ +0GPO\ _4UT#UY_S]"/]L^'_50?
M3^HK_-,_9N_X(&?\%4O G[1OP-\;^(OV8M!T[PQX/^*G@/Q/XBU4?$OP639:
M7H>L%]<VC.6R@+C'506Z5_I:P_ZD?0_RKOWU.)[OU?YD]%%%= @HHHH ****
M "BOY4?VW_VV?VQO!OQ/_P""AG[0?PQ_:%USP%\/_P#@FM\??V)?A/X:_9IT
MOPGX.UCP3\>/"_QP3X2:W\4C\4YO$GAL^*9/$/BC_A:G_",>"6\*>,/!TG@[
M^PV=G+R.]?:'_!9W]H[X^?!&W_9(T'X+>,?C1I>G_%OXC_$6T^*'P\_93\,^
M#/'/[9WCGPQX>^&6L^(M 'P1\%?$'PWXL\+W.A>#_%L6B77QDN)(4DB\'2R-
M$5W-0!^[U%?C1_P3Z_;RM/C!^S%^RG\-_B-^TCX \??MP?&+X _\)LVJ^'_A
M_P",=5\%:UKZC7 =1UMM"\/^$?"R>(/"<NB2^'/'7AD>+/"+GQ7H?B>WB5&C
M@=;7_!(CXP_M#?%+P]^W+X<_:4^+ES\<O%_P$_X*!?'/]G_1O')\"Z)\/-/F
M\,^!M ^'FS2]'\'Z&9SI&BQ:[J^L^7).\S2*I8NRJ6 !^QM%?S[?%7XA_M@^
M$_\ @L!^SG\)/@E^UGXS^-7A/QN?B?X]_:S_ &9+[P%\-X_A?^S9^S$GAX?\
M*JUQO$.@^&!XGT+Q_P"*?B&5C\%S^*/%S^,?&3!XMH\$1/&OHG[?O_!5+XD?
ML?\ Q@^*_P *_AW^RPOQQLO@)^R-8_MK?%KQQ<_&O2/AK8:)\(8_''B#P;KN
MC:)I&L^'/%#:_P#$"4^&I)O"4#8CN#F.3*EDE /W%HK^6S]JG_@KK^TM-^SS
M^U!IND?"6?\ 9-^-OP<U/_@G9\3O FLQ>//!WQJEU[X$_M?_ +1&A>!H5UN)
M_"X\-Z#X^30-'\0^'/&'A?S/%\4*Z^C6OC,Q2!D_J)MN5'^Z/Y+0!)_!_P "
M_I7SEX#\5^!M;^)'QTT#P]X=.B^)_"7C'POHWQ#U1[#2].7Q7J>L^!M"\0:#
MK!F12=:*^'M7T/PZ)9,N&!4 .4"_1O\ !_P+^E?._@";X7-\0_CH/ ,<P\;0
M>+_# ^+?VG^U,-XE_P"$)T,Z#M#[@P_X1D:,?E'*[CM*UXG$-Y91CHKFW^S=
MNVFR5WIN[=F"DEB87:6^]N_F=3XZ\">&_B=X(\2^ /&=KJESX;\8:1J6AZPF
MC^(-<\-:J=+>) _]F:[X>NM \1Z+,0B!)_#DT<@9<F9U=S)\Q?##]A']F#X4
M?#3XW?"WPMX#URYT']I--0B^/NO^+O'WQ*\;?$;XK2:]X4;P!,/&OQ4\3>)/
M$WC#Q!Y'AHMH$3MXI$/ABW53 8O,$AYSX3_LQ?M)> OB_8^,_&?[>7Q1^,?P
MYEO/$_B;5_@MXM^&_P ,],T_5/&VNOJJ:-)H?C715C\3Z%\-/!_AV>)?"OPM
M F3_ (2_01XRE\:L[FWK^57XE_M1?M!^$_VF/VQ/B/\ !_XN_$?Q)XFN)/\
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M_:SUKXJI^V/^TC\3D_;S\;_M1?M-_";QO\ +?]K;XQ?"GQ'X3\"Z+XRU_0O
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M6A>-M8TSQY\:_!WAI_#GBE=(TCPQX*_X6IXP\&^#AXS;Q'*WC;Q7N3P?6_\
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MWB']H?PE\6/B'\3-+^,'Q$M-"_:,^+VG_#3QUXIT,2G0T\9_"Y/$7_"+^(=
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MWKH.D:WHB,T6NQ^&5;,0N)D)/'E(ZN:^IB54';P>/4_SXZ&@%6 W8S^(_/\
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MDR$"MN)KZ8R,9SP?\]*8=GH3^?\ 4BE]6IVM1C!7T?NQ?Z>HU16VOE9O_/\
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MN/E\&RI'$ZM'_3/10!_.EX-_X)4_&3POXK^ _C)7^#,&O?#_ /X+&_M$?\%
MO'&L::^OQ:QKWP>^+.C_ !=T71-#.LMX6$NJ_$94\;^'5/AL!O")71I(W\9H
M8UW_ *C?L7?!'Q/\!M+_ &@+7Q/X8\'>&KOXL_M:_'?XYV:^#?%GC?Q?'KND
M_%/Q/'JNCZWK?_"20;- \3S$[?%'A7PL#X+\,A U@WE/-/7W/10 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $/ G # 2(  A$! Q$!_\0
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MY5]S_P @(?)3T7_OD4ODI_=7_OD>_M]/U]>):*/JV&_E7W/_ " B\E/[J_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,0XU<#B91ORQE"E*4;7LI:Q5D]';7??O_:\TD+2*!(@*B0,,@<A06(]E!!)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4&BV5WK5C/\ VM9:_<Z3JDNAQ>+-2\':C//9ZOX[U#4?%&J7EQ&R:0W<Q?\
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M?YY_^M^?M1Y@]#_D_P"'Z\>]'M:?_/R'_@2#7M+_ ,!?^0^BHO,X)QC R<D
M<=>?8Y'ZXH24,,X'X,#GZ8SU[#-'M(W5KR3?Q1BY17E*2TB^NMM 5W?1JV]T
MT2T4P2 D#&"3CK_G\:?5J2;:7V;7TTU5]'L_D 4444P"BBB@ HHHH **** "
MDP,YQS_D4,=HSUII?! P<D9_'CC]1^M-)O;U$Y*-KNUW9>KZ#Z*J^<54?)D[
M@I .",]^?4]/_P!5!N<;<+NRY0D'[N,=1SR2>/S.*%&3=DGU]-//;H3*<8*;
MDVE3Y.9V;MSNT=EK=OIMUL6J3G)Y./3&/U[_ (50:]*LRF)MJH7#\@$JQ609
M950"/*$'>Q<%L %#GP;Q!^U?^SQX8T[QWJFL?%[P$;7X96Z77C^'2O$%IKVJ
M^$+22YCLEN=?T30_[0UBPA-Y+%;;WL3B1L,%((K&=:E3JQI3J1C4FKQBVE==
M[MI:===.QW8;+\PQKFL%@<9C.1TXU'A<+7Q"I.LW&DJDJ-*I"#JS3A2524'4
MG:$5*3L?1-%8=GKUCJ.F6FKV$\-S87UI!?VMP)#'%-9W44=Q!/F9$:-7MY5F
M5)%2381N1"<5A^*?'FB>"/#6M^+O%US#H>@^&M+O=:UV^N)&E33]+L(C/=7L
MD5K'<74D,<2NQ\JW>0E&"QMUJI3A"-6<JE-*BN:I^\A>*LW=KFNU9-JRMH^S
MME3PV)JU(4J6&KU*]2O3PL,/"C4EB)XBI45*%*-%1=24G5:IM*+M.48MIR5^
MXI,A<#IZ=3_GK7&>$O'OAOQUX:\.^,?".H0ZYX7\6:7I^M^'M:M6=+;5-(U2
MUCO;&^MTN(H9_+N+:6-HT>%)0S;)4A8&MY=41BRB/#J67RV.)%959L% &)&U
M2,Q>9@D9 &<.,X2BYQG!P48R<E.-E&23C)OFV::L]M416I5L/4E2KT*]*I"I
M4I5*=2C4A.E4I3E3J0JP<%*FX5(RA-2BN646FDTT:H(!VCMVY^O6EK%75E*J
MWE,VYBB%"S*2"BC<3$KJ"S,3(4:)8@)3( ZUX+%^US^S]/XN@\#0_$C0)/$]
MU\29?@_;Z0)+H7DOQ+M]'?Q!<>$@AM?+&H0Z(CZD[><8!"-OF;B,Q.M2IVYJ
MD+R:22G%MN325DFV[MK[SIP&79AFGUIY;@,9CHX*G[;%SPN%Q%:GAJ"4VZ]:
M<*+A3HKV=2]635-.$DY)Q:/I2BF!L@,1@$9!R.1U _+WQGZTSS'W !,C."2P
M!_+^F/R[:<RV^>S.&4E&U[ZNVB;L_.U[$U%%%,H**** "O(?C#X@L-&T;2;&
MZ,GVKQ'JRZ/I@ACWR->+:7.H,(WW*8&-M938E!;'W2,$FO7J^=/V@8)I7^%\
MB+*(;?QS))<318S )/#FM6\+%BK; \\T<0; Y<#O3C%R:BE=O9?*_P"@FTE=
M[+^NFI[G'88:(BYO"T!D ,MSO8+/&RL'8PY9HAEH<DA'.[<RG%0C1]L:0B_O
MV*636)+7)+F-I1(+DD! ;H %5EVD 8&!@DLTK6[75;2>YMI"\%M<7=C/.XV;
M9[([)G?.,JGJ,YP2*Q9-663Q+I4EO<"6QGTF5A)$X>VF:5IFC<RY W(EM))M
MP201TQDEFKIJS5[KTW_(F=2%-*4W9.UFT^NG;S-6Z\-:?J;Q'43)J,5K>6=[
M!!?,)TANK$%8IXQMCVO(K.)@PE24B-CRE6AIDZ/DZC?.J).%!G51)]ID9CYH
M2 8^SY6.V*'*1CG+ &K,>HP;(BTL*F7RHX_,FC3?(XRB DDF21/WD<8!9AD#
M/6J>EZ]9:S#=7%F)=EI>W6GS+,AB=9K20)(S*02L;-DJYX,?[SU 4/>C*I%-
MP@^64K.R;=DFO-II:,=^90E'5<\;/UO;<\4^--BT=[\'D6YN )?B?IED[?:)
M$E1?^$4\6$W"21@>;<!MA1IU*_NU8\@ 1_!"Q^TVOQ/4WEY#)+\5?$KO);2^
M24-O):;1"/F51-'&@N,K\\AE;D-DW_C5*'U#X.L2 @^*FG2AT^<,1X7\4  ?
M=!4J699,X.TC W"F_ MU2+XF*"&(^*?B@$9PP>5;.0#:?X0'/S]#M./0>=>#
MS&E:]W1J6TDKOE6]]._3\#Z]2J+A2:E*T;TDK\MDO[8EI>VEK)O7MUW]N?36
MDQNO]0*BY%SM\^,*XV[3:R*L #V;#):%LDDG+$8 Q].\/Z=H26]EITCV,27F
MHWR6=H(K:&>74I9)KC=#'$!)Y,DC.I ^51N8$BM*TURSOKF^M+9U>?39TM;Q
M6;:L5TZB18-Q&&=HOW@VDX!&1UK@O%DXC\9^%+YYG2'3+;4'EB1W$4QU*WN[
M6$R;6"GR9K5F7<#N+@+M*$GTY0E"2C-6DTFDUK9I-/2^C337D_,^/FU;1IV>
MR:EZ_"VSN8=,,.3]OU60O;26A>2\23RU,CSFX1O*R)\G9%(<E8PBLORTXZ0L
M@F87U\'N$LP7\\-(BVV& 4A0H,IYE8#YRS'O7*:9=W-EX,N8HW>2]LX;^!))
MICOENV=IDW2/DH7,X$:L7(7;@D  :=AXIT^*Q@-[/MN8+73OMH )$;WC?9X3
MD#!#S1NHP>-I)ZU#:6KT.?VE*Z4II/[*UWV[$6MRW&F7&D0QW5Y-_;'B.-;E
MFNF1K6W>WD5H[79'@6ZR>7MA<X!;!:M-O#&F-=0:H8(SK%MI[Z=!J<B137L=
MO(X9B+AX3)YK '+CNQX( K&\6[C<:=-D+';B>ZWL1\B17VAN]P@/WO*@,X*\
M$[B 033V\=V(\AHK2YFMY](N-5CGXCR+>41BUV$%O/D19Y0<[0D!&"6XF=2%
M-.4I62W=GI]R9V4*&(K2M"FYIKW;-7;OKNU;YZ:G3MI_R.HN)P#';QC=-*6
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MOB3P/K6G3:UIGB?2+P7>DWFC6YG$]_#<)'DQPFWD24.J%95>/.Y>?COX:_\
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M?1YTOH5@8N\?>>#_  5X\C_:J\+W=]X3\1O+_P /,M2UO4[Q/#^JII?]DR?
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M8[<C)7D@$XIVL_\ (,U'_KUE_P#13U\KQ4K<,Y_YY3F3_P#+2H32_P!XPO\
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M_'UY>:7>O;W/]LP71CV(OZ:1?\%";68\? ISE-@ ^(MT!'N8._D_\4D?(+[
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M3+;V6EK'>W$[H'$,<4BAGVL0,@,0&.0I.X#<%KJJ\C^/*E_@]\0T52Y;PU?
MHJ[G93Y>[8 "=X&2F ?F .#C!-?LRY'TDE?E?>W6W835TUIJFM5=:KJNIX?X
MG^)>B_#'PMX4U.\\)7WC6^\07NNZ@O\ 95CI4)%I_:%I;1F^N[N-&9I'U6Q0
M7(+SO&L@E)BBP/+=;_:B\$-H4NFP?#V\O]?NYX=*O_#FKMH/AXFPOKSPU#J>
MNM?06Y@;1?#?]NM!-J$:I;:A=:?/$ [B-E^N_AD=-UKP'H6$AG6S9;*3SK>&
M;RWA*"14$BL1'NV,I?(ZLVYE0K8FTK2;CQ'HDT%EITMA-:3V]PD>FV++);7J
M7IMX)I8X5+6L4EHSI;,QMS*1*\;RHDB<=:ECZCM1QC2?Q<UHM]6XO>[2>G32
MVI]3EN:\*8#"X:AFW#F.Q^(IU)25:CF]3#8?5.RJ4(Q:<5=<KBTTU9W3=OC#
M_AJ+P[;7LWA[PIX!M;C3]!FU/1KW7+\:?<B.Y\.(DEP-/TR&UBU#Q'>:T@N[
M=-/L;V&XTR;3HI$S;W3*>QL?VE?#&IZA9V5O\.]16W_M*&;5)H+/P]=:=IFC
M7=]!I5C=7[*B0O?6U_=VL=YH]JO]H64DX2Z9F0D_9C:+H-H(Y#8:9:F.Y)AD
M-M;>6E[?%L3Q(59$GFN+ALSLI=]S(S%&P*.@VOAJX34;;2].TV%-/U6ZMM26
M*PMX!+J48AGN;LQQ11Q^;=3R+/)-Y>9)8P_WE!K&EA\Q3<Y8IUH1D^:,KJ-K
M[)W=[:)-ZNU]W8]'%9]P1.@X8;@_$T*KIJ$*]7.*]>'M)1:<YTY4N63;?-%7
M44_=6D;R\4^+>B:?#>_!V-+*PCG7XJ6"7$D>G62AKE_#'B>07!A6,H#M"-$C
M+L4,6" G=4_P0\/6LEI\3H[=+&W4_$SQ+ FW2M/DCCEM6L\74<$D#1AY'#RM
M"P,7FRR2#!8!=OXSJ(]1^$*$L57XK:?+)+(6.$_X1;Q3))(68G]VH.P+DA<8
M "C 7X&2QK#\1HM\9E_X6;XHN HD#E[9I;91.@!'RD,% ).''<,!5./+C*4I
MKWY4YV46V[<M[MK7UT.5U*CX2<4G3I0]G:G&-Z<8O-Y:)Z*/+O:_VOF>@6WP
M\T&PU'6-4L[.Q@O-;N;2XOQ+:1W-LX@CV2B&VN%:&W%S@-(8E4*^=A7 SI)X
M2L(W@D9+!XH;NZNG@72-/2.YBF1XX[=A'%N9;2(CRB 6=U7>2.F_'J%G/=7-
ME!<))=6(C%Y C#=;+<J7@:4$G[Z@LN"<KSCI7!>-)KBV\0^!Y+>ZGACM]1N[
MF^6.0JES!)_9ND+'<)P&B\W4XW"_+\Z;@<@Y]!W4E%IIM)W:=K/S\UJO+4^/
M<DM;[=MS?B\+V80Y_L]PUO(B@Z'IR()7D9H+O8L"AY8;<QP^2V;=]GF-%O9B
M6/X3L]KQQIIR*?LK1C^Q]/DCAGB)^U7"Q/%Y;O?1,T,J2 QP*VZW5' -4]!U
M._7PU//<S--/:1WTBS3?-(Y8)=VL;G@%$2Y2(!0I$2(NX,"QU-*UJ"?2[2?4
MKFWAOEL(+S4XPYC6W,A9'<H78K'YZ.B;V).,$DC):75K3YV^]'/.M%^[&5I;
MZ^ZFMFDWHWY=CCO%?A7PZ1HLNIV%O.L/B6V?3HHK:***S%UY9FAD,05[A)I;
M?>[3EBI9D3:@ KK6\):8)HI/L]BQACG4 Z5IV"\JA8FR+8;8[<;V6$92265Y
M9"TF&%+Q8I==)^>,Q1W,VHN7?;&#90B2(EB"=A#DN,Y_ND<UH2^*-+CN+6WC
MG#_:;:]N8YD4M$L6FX%QN;C+$@[.1NQD9R#4RDHIMZ)=.M^U]+^GJ=&'A6JR
MGRP<K).\5=66[=ME;[]B$>$=+!B=8;2.6"T6WAGCTW3TN(YL*LMR)?(+O]H4
M%)[:4R6SHS*8\'-2/X1L"TC1VVFQ&5X_,(TNR9GAS!]KMWS"$9;]862678)8
M%F86[+L2KT>OZ7+:"]-Y:Q6XM([Z5I92K16<R@QS.H!**20I)[\9SFM(W$86
M.0O$(I?)$,A8*LS3'*",EB6+*05 R3]!1%\R4K-)[.2M?\QU>:E+EG"2DMTH
MN_;6Z7;[[G.3>#].EP%M;"&,RSF98M,L5::VN(WCDL]_E9A788E%Q&OVD"!,
MN2SDYFD?#C1M#TZWTS3X;1(+=;W#RV%I<3/+=S--',SS0O\ -:,0J #]\JXF
M8@L#U5UK%G9WFFV$\XBN]6DFBL8I"096@M9;R3C<#@10NN?[^%ZD9HP>(K&[
MN=-M[-ENX]36_>"[M@9K>,Z8ZQW<<S!UVNTA*1>X.=W)IDJ2?1I]%+1OTUU(
M!X1L?*:-K?3"YA6%)ETFRB:,X)F=42$1M]HD/FNKJRJV0O' BO/"VG);7TK6
M>EE! \BQII5C'Y8AMY T<;K '439.]@P=>-A%;=[J^G6/GFZN[6W%O D\OF2
M'<B.Y3>4&"0< +P"6/IUGO61]/O&C97!L;ALJ#A@]NY5E);&TC_>ZXR#0[JS
MLVGU2NO2_<K5;IKM=6OZ=REH7.AZ*"!C^R=.9< +L46L(6,8_A Z9ZTNL_\
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M_P BLL"!PP,G#!E4/\JLJJG'&<,H*L"Q!#-QGFK.3NY8#D<#./\ ZWOG\J>
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M".5P$NHXI;*X+1/;W,L3*32_:)$]QX-\.I$TDC0_$#P3<(?+#@B/5TDFNV?
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M$1(GE2QE0B&.5-S QX!"<X P)P^"QL9^UGB*F(I1:YHV4E*6R:W45?6R_P"
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MVDZOXRU"_L-7M+ZV)@D@U2"87:;2P8R$C"FOZ(MBR%=PS@$Y]#N//USQZBI
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M1Z:%U*LJB@I62@FHI=%<]E)&0<DG+*=IX)4 G/;KDCT)Q65K/_(,U+VM9?\
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M3RDOF>7HOAUS@]"UYJP!!'?A@#]2*>?^":'AP]?BSXF/IG1M)./_ !ROH_\
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M:ZQIUY\8= -SIM["+B"XC6QO!GR0KAFC#Y4E<C+=C7[-5^+W_!:SPIXI\9?
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M^[E)N*Y;)Z*R_0]%MKVW6U2:=EL( -WFW,@BC10"2\DDN$2-0"[R.=BH"S'
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M^)/P;UGP?H-U^V5X6U3Q9^T[8^-[W]AN'Q?X!\):;X/\2>!O'>E>&!::U/\
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M&G@S43JVAW.J6=JMEJ]H+H);":6T>YA\^,V\3?,.1ET7\P]#MK"?XN:O\.=
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M,/G%?!8#(:6)H818FIB(0H?6*V/H.HU[%3C/V<>;GLHIIV_L;PJ^AYQ)XG<
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M(X&<8R:_DD^'/[5?Q1_9U_9Q\)>#YO''B#X?:=J?_!-G0M7^".G1:#J)DO\
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MLS\1_!W_  6#TO3)-#UF;5K_ /:-\+7WP@^",FFVWPV^%\GPP\9:Y\6/BO\
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MQGA>\\%WZ7\6GC4(+"&:V-AJ>HN)%7[5^%W[(W[/'P4U31-;^&GPMT?PU?\
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MZW\$$\06K7<6I:#X0N4NG?4-6N<Z/KFFV4&FWZRZ9&E>7?LJ?#CX@?!?Q/\
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M-N,8I[*RT444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 -;G
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M?L>+Z_\ %K/BISGM_P CL.#W_.L_[#H=>)^%5_W4L=_\Y-Q>TCS.7LZVKO\
M"N][?'^9^@N]?7]#_A36=0K$D  'D].G7Z#O7P!_PC/_  4R_P"BK?L??^&N
M^*?M_P!3M[_S]#@'AG_@I@3A_BK^Q\RYY'_"K_BHI(';=_PFK8Y[[3G/0@&I
M>1T+/_C)N%VK/2.88YR](K^QDFWLE=7;W&ZMD[4JU[72<8I/M?W]B#X=\_\
M!2']I!L';_PSQ\$ &(^4G^W/%G0]#U[9//2OT%4@8SW) ^ORU\+?L\? 3X\^
M$OCI\6?CQ\>_&_PR\4>(?B'X+\#>!]*TKX7>%O$WAW2-$TSP;<ZK=M<7LGB;
M6-3N+VZOIM3)7R5B2-4"D%0&K[F4#?QD9.2""0>A&T]O3Z<G/-7Q9B<'6S+
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M\/-9^"WP@^,WQR^'/C?2OA_+XPUOXX?#7X??!3X&:7\8KOXY^-=-;2X_"?\
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M[W<?[A_7_"C<?[A_7_"N"_X6)X:_Y^YO_ 6[]_\ IA[G\S1_PL3PU_S]S?\
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M?\*-Q_N']?\ "N"_X6)X:_Y^YO\ P%N_?_IA[G\S1_PL3PU_S]S?^ MW[_\
M3#W/YFC_ (BGX>?]%=D__@ZI_P#* ^H8[_H%J?A_F=[N/]P_K_A1N/\ </Z_
MX5P7_"Q/#7_/W-_X"W?O_P!,/<_F:/\ A8GAK_G[F_\  6[]_P#IA[G\S1_Q
M%/P\_P"BNR?_ ,'5/_E ?4,=_P! M3\/\SO=Q_N']?\ "C<?[A_7_"N"_P"%
MB>&O^?N;_P !;OW_ .F'N?S-'_"Q/#7_ #]S?^ MW[_],/<_F:/^(I^'G_17
M9/\ ^#JG_P H#ZACO^@6I^'^9WNX_P!P_K_A2$DX^0Y&<'GC(P2..N.*X/\
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M6ZQW_P"F&>Y[]S6C\5?#YV_XR[*-%96K5-M/^H?T$\!C96OA*CU[1>O?5GP
M?^"2_P"RC%X8\!^$K"U^*UA:?"/Q7J_BCX,:S;_%?Q!)XA^#-OK^F7&D:WX.
M^&FJW\5[)H'@/4=-NI;&Y\+RV]];RQ16;)+$UM$R>PZ!_P $_OV;_"OQ@TSX
M[Z'X3UB/XFZ5X_NOB?9Z[=>)]5NK9?&]]\'['X'W6M7&F/(+.X$W@'2['3I;
M542%[UI]3"I.Q)^GO^%B>&O^?R8_6UNO?T@'J:/^%B>&?^?N7_P%N_\ XQ[F
MI7BGX>)N2XNRA.2:;]M4V=K_ /,/Z!]0QTDHO"U;1:DE=:-7MI>QX)9?L4_
M73O"_P"TIX3L_!\D&F_M=>)/%'BKX[2KJ,HU7Q'?^,_#.C^$->M;/6(HX[_2
MM/;0M&L[>TM[2X9;.XCEO;54N;F5CY+XI_X)?_LE^+?&?@KQEJG@OQ,)?!W@
M_P"#W@R^T"R\>^(]/\(_$71?V?KRTU#X+6WQ3\.0S?9?'5Q\.[^SCO=!O]3,
M,R/B.]%[&$CC^U?^%B>&?^?N8?2UNO\ XQ1_PL3PU_S]S'_MUNO?_IA[FI7B
MAX=Q5O\ 6W*-[J]:IH_+_9^X_J..YF_JE2[5F[K:][;['P==?\$H/V1WO[#5
M=+T3Q_X8U?0?B3\4?B=X4U?PYX_U.UOO"FH?&S4-.U?XK^&?#_VNUO+?3O _
MC36=-@UG4_#;174,>J/-J.G3V-Y,SK)XB_X)1_L?>*?%OCOQ5K?@OQ5?1?$"
M?X@ZMJ_@P>/?$$'P\L?%_P 5?!P\ _$'XAZ!X21Q8Z/X_P#%7A2,Z?JOB*%7
M<W%W>7MO;PW$\LK?=W_"Q/#7_/W-_P" MW[_ /3#W/YFC_A8GAK_ )^YO_ 6
M[]_^F'N?S-4_%+P]?+?B[*/==X_OJF[5O^@<%@<=%MK"U+M6>J^6S/D%_P#@
MFQ^RO/<)>S^#-<-VGB_X1^.!(/%NKAUU[X(_"C4/@M\/'W!@C6>C_#_5;_3+
MBQVBVU.]N&U.Y7[6D3KSW@__ ()<_LP_#>]6\^&,?Q1^&_G_  PT'X4ZU;>"
M_B?XCT?3O%&A>$]&OO#GA#6?%6GCSK;7_%_A/0]1N+#0=>O8#Y,$5I!>V]ZD
M"Y^W_P#A8GAK_G[F_P# 6[]_^F'N?S-'_"Q/#7_/W-_X"W?O_P!,/<_F:(^*
M7AZI2DN+<HYFDG^^J;+;3ZOH$L#C963PM3[_ /@GF_[./[-/PO\ V5/A5X>^
M"WP9T.?0/ /AF[\1:E86M[>RZA?SZMXK\0W_ (I\1:EJ%ZX1I[C6/$6JZAJ\
MT=M%:6%K)*+2SL;>T6.)/H7<?[A_7_"N"_X6)X:_Y^YO_ 6[]_\ IA[G\S1_
MPL3PU_S]S?\ @+=^_P#TP]S^9IOQ4\/7OQ=E"?\ U^J?_,XO[/QRVPE3\/\
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)2^C6NCVMT/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %' <L# 2(  A$! Q$!_\0
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MOI.FVHVVUKIWA#1=.TZS!!&/+3Q%'$O7DJ@#<@C.,_BI#_KA]3_.M&#O^/\
M2CZUBOYE]Z_S,/JWE^'_  #]B+C]MG]F?4]4AUN[\#>*M0UF"V$-MK$W@?PG
M>:A9:>NJQZJL:ZF/$DB1Q+K44?B,*LFQ7!N1#YX#UU__  \'^!__ $"?B3_X
M3FD>_P#U,7T_7TY_%&'_ %(^A_E5^#O^/]*/K&*[K[U_F'U;R_#_ .U/V?\
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M?I_]>K$,W_ZOZ?XC\10=&'V^7Z(V//\ ;]/_ *]%9_G^WZ?_ %ZL>?[?I_\
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MY_\ K=AP7EGXCA_U'AS6[GT^R'CI_4>_]:[GPK#]L\)>%[^<W-S<76C:4/\
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M..M>@?8_;_QZC['[?^/4KK_H6W\[?C^H?5WY_C_D</\ \+"_:%A_YISX)_\
M"DSSSZX_'//>D_X6/^T)_P!$X\%?^%+K'^%=S]C]O_'JL0Z;![]S_0]_R]/>
MMKK[67)>M@^KOS_'_(X__A9W[0L/3X<^">Q'_$XUGKS_ )YJO_PM3]HK_HF/
M@G_P<:S7H/\ 9UOZ&C^SK?T-:WPG_0N7WO\ S-SAH?BI^T-#S_P@_@ ]2?\
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MN<#\0/&'_(Y>,O\ L9/$_P#Z>ZQX._X_TK1\;_\ (X^,/^QE\4?^GJL:#O\
MC_2N<:W7JOS-B&;_ /5_3_$?B*T*SX._X_TK0I/9^C_(VQ&WR_1A7M'P._Y*
M/IW_ %YZK_(5XO7L/P-F\GXE^'P>MU_:@_\ *+_^O^?O58??Y_JCG>S]'^1]
MK^)(;V?1M8@L8+FYN/['U3[':6G_ $%!HO3 [8__ %\5\7_!_P '_%OP?JGB
MC_A*Y_'_ -GNO#?V*SN])N]&U+3+_5-"'3^P\_\ 0N#0_P#A"/7'B?FONB?M
M^']:^5_BUX#^,6L:]J&J^ /&-S;:?JEYX7LO^$>_MC^S?[!SQKNM>G_<K9Z#
MUZ_;9-7CIAG&/?FFE;YM].^NUSP,[RZ<E@,5%SO*,DU!OFU32T3WUT;6]CP>
M;P3\:=,^$OQQ\*P?\)_;>,-5LQ>^ KN[O!J7_$KZZ%C7/#W/_"Q/7PMUP<'T
MKH/V/_!_Q;\'^%_&%A\6Y];NM0_X20_V/_PD.L:SJ6I_V7_8N<_X9_\ U]1J
M7P2^+?\ 96GZ'!\6[DZ/:V>J:+>?\ADF_P!+_L7^P-"SZ>_].*]X\$Z/?>&_
M"7A_PW?3VVI7&E:/]AO+OM?].O\ GZYKV,?F\5EF8X11R'F6TE%<_;1J-[^C
M^(\#*,HQDLTP&+E+/^3*W)N,I/DES.3U3:4HV:WOH;$_;\/ZUGU?F_UQ^H_G
M61/V_#^M?#K9;;+;;;IY=O*Q^CO$*[]7O:^[WUW[^=RO/V_#^M5Y^WX?UI9O
M]2?H/Y56IA]9\_Q_X(57JQ/V_#^M5Y^WX?UH.<KT57G[?A_6J] 'SO>?M.>
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MZ^?^9WX?;Y?HC0JQ6?5BL2GN_5_F6**K^?[?I_\ 7H\_V_3_ .O0(^@/ ?\
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M?1_A?_PC?BSQ#XPT;^T_"7CWQUXT_MWQUHNAZ'_Q5WB?_A'?^97/BGM_;_\
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M^O17X7_\$V?VM/CO\<?CGXP\'?$;XQ:)XW\/W7@[5/B#>>'M6\-_V9XGL/%
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MS2_^$:S>#4M,L-+_ +%T#_D!\_CVZ_4#ZI\CW_7_ .M7YW_MI:#8Z/KWP_\
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MAL9IK>>:"VN;BUO?MMG]KLQ_H&J?7CWK\+Q_P6J^&7ANUMY_'&AZ)IMO:_\
M'X;/Q)_Q,P>__$DY_'VR.M>D?$+_ (*]? CPKX2\+:Y8SVVMZQXQO/L6C^'K
MR]_X1OW[_P".3VKT#SKKNOO1^L$WAOP=/_:'G^%?#?\ Q-?]-UC_ (IO1O\
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M5_F!_1!\ 9O^+T_!_M_Q<CPOUR?^8UQCT]NWKZG^E"OX]_V(?VHO"OC;X_?
M_P .:K]I\-^(+KXD>&+*SM+O_D&:@?[;QC' _7TXK^PBN[#[?+]$<V*W?I+\
MPHHHKI,#^:3_ (+?_%*P\ _&3X(V%[;ZC<+J?PL\3WJBSSD*/&"#!Z<C''^S
MMK\2_P#AH_PW_P ^.M_^ 8K]1?\ @X;_ .2^_L\^WP?\4?\ J9*:_GQG[?A_
M6OE\6_\ :M^MGJ=^%V7J_P T?8__  TKX5_Y]];_ / (U9A_:6\*_P#42_\
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M?_UU^C'[8&@V.C^#?V=YX)_M/]J7GVWZ_P#$DT#N?Y?3H.O[W^&_^".?P/\
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MC--BN+>Q@\ 6W3'_ !39U+TR/^1D_7/>OMCX>_\ !6[]L2SL/L-C??#;J/\
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M3X)Y^WY_E[_E6?J?_!4K]NV\^T6.JWWA.YM_^/*\M+OX)Z-W_P#U>OXD4_\
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M$_;\/ZUCS?NO?I^OY?TIG=]7TO;2U]O*_8)IKCIV]>_7_'WQZ9).#S_;]/\
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M (1K'3\>/6J^LX:VRN!7_P""7>F_VO\  :XOO/N?]%\8:I9?Y].WO^-?T0?
MW6;[1[#1X//^TVW_ #Z=^.!_3'0CTQ7XO_&?QM\,O^":F@^!O@[X/^%>IW7_
M  E&C:IXG'V3Q)_Q_P"J#6?[ &LZX6.?^$B ]!C@ <5XOH__  5H^-,$5O\
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M]#YX\SS_ -1K7^<\=!]<\GT%<?/V_#^M>:=!GS]OP_K6?_RR_P _W:T)H?\
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MZ[_0?IQ7^HA\2/#=CK'AS4-<M[&Y_M"U\-ZI]C%YX;_M+2_^)[_8'_(<]_\
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M_MS/2N7O/VHO'%YJEQ??V5IMM;W7B32_$]YI-G>ZS_9E_JG]M?V]_P 3SO\
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ML'BO]CS]F?QC96-OK>H77[-^E_;+O5M'UG4?[  ^&.@>O.<_]#9U'M7\W_\
MP6&LYX?!'PGU6>QU+3?[+\>?V+]KN\_V9?\ _%%_\P/0^_\ R ^GKGOG&S^S
M[_P6VO/A[^RKX/\ @[XH^"VJ:Y/\.?#0^'Q\1^"OB./#.FZ[X9.B#0M$&N:%
M_P (ZP_X2$>'MRJV<N K;4)*C\I_VT/VT?''[2.F>!M";PWIOA+P-X8M-3&D
M>';.^UCQ%J>H:IH9'A\ZUKFO,"NO\'[S @=2"!QTI7:7<\>OEV*^JI]-'\M'
MMTTU/[]_A5XD^'/CSX<^%Y_&/A7X;>)+@?!+X-WME=^(/#6C?\)-?_V[HO\
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MI7B7POX+O-6^QZ+_ *?_ &[HO]O?VT/S_P"$7_/WKTCX#Z#8Z]\*OBQ!??\
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M_L#[Y_H*_,>S^$NA0RX\CK[?X>G^-?K1^R7#?6?@BXTGSS<Z/:WG_$GM+O\
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MD_X.))O)_:"_9W..OP@\3G/_ '.*_P"&.^>E?SY>=^Z_SCI],].WZYK]_?\
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M/=8T8>.?AH?[%T#03_Q(_$'_ !3'Q P=#T/]#WQ6A\5/^"I7@>'QOX@G\'>
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MR?7O\-^GZ9[]Z_4B#O\ C_2CR/?]?_K5T?5,'V7]?(P/R'O?^"2/CB\E\_\
MX:3^"?3_ *%SXR=O^Z;=L<<=/RKH-!_X).>.-'_U_P"TG\$^O_+IX;^,A_\
M=;_7'X5^M%6*P^K87^G_ , Z#\I]2_X)1^,=2_YN,^#G?/\ Q3?QD&/K_P 4
MWT^GXBN'O/\ @CSX_O)C/_PTG\$SZ'_A&_C)^'3X;]?;OC(XXK]H+/M_P*K'
MG^WZ?_7K;ZLNWX?\ #\9[/\ X(_^.(?^;D_@G_X3?QD_^=OU/J><#BNPL_\
M@DOXQAQ_QD9\$_3_ )%OXR?_ #-\_3UX]Z_7B#O^/]*L4?5O+\/^ <Y^2'_#
MISQ?_P!'&?!S_P )SXE__,Y20_\ !)WQQ_T<+\'!_P!RW\9,=>?^9;[GWX]<
MFOUXK0@[_C_2NCZMY?A_P /R'A_X).^.!_S7[X.=_P#F6_C)SGC_ *%O/\CV
M.!P:_P#PZ0\<3=/VA?@X2>__  C?Q+]SG_D6NW/?CTZY_9"#O^/]*L5A]7?G
M^/\ D!^+_P#PZ%\>_P#1PWP3_P#!/\2O_F;H_P"'17Q _P"CAO@W_P"$U\2_
M_F:K]H**W^K+M^'_   /QGA_X)%>/^/^,A?@YG_L6_B7]3_S+?88_IDUKV7_
M  2=\?V?_-?O@YZ?\BW\2_\ YF_?GI_A^Q-%5]6PO]/_ ( 'Y'?\.M_'_P#T
M7_X.?^$W\3?_ )G*=_PZ]\<?]%^^$G_A-_$O_P"9NOUO\CW_ %_^M5?R/?\
M7_ZU+^SL'_,ON ^)/V0_^"</CCPC^U#\ O&@^,_PPU[_ (0KXH^&?%5WHMEI
M'Q'TO5=1TO0%.O[=!,GAV.(,Q&!YDD: G+.J@FO[&F!(('6OPP_9IA\GX^_"
M\X'_ "&-4 _\$NO^Y_SQGK7[FJ>%XZYY].?Z_P!*[:%!06^FRMV_KL<V*^)^
MDOS'T445U&!_//\ \%D/V/M)_:)^)GP7\5ZI\<-%^%HT+P)XG\,VEAJW@/Q?
MXV&KG^UTUT:F!X; "B( +M.2&!&XC!K\;S_P3'\*P_\ -XG@D?3X)?$O_P"M
MZ_KQS7]#W_!3V0+XH^$ ]='\4$^G_(9\/@9/;IG\<'I7YDPP_P#Z_P"O^)_
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M "KG O\ D>_Z_P#UJ/(]_P!?_K57@[_C_2K% !_JO\YSG\O3VZ?F44?\M?\
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M<X&Q17/_ -KV7_/?^=$.O6,UU]A@/^D?8Q>GW&/\X_Q P ?2'[-/_)=OAO\
M]AC5/_3-K]?N17X7_LQS&;X^?"X?]1C5![C_ (DNOG\>A]S_ #_="N_#[?+]
M$<V*W?I+\V%%%%=)@?C-_P %29C#XH^#_OH_B@]?76O#_P".?_K=\5^5'VSW
M_P#':_43_@JQ-Y'B[X-_]B_XI]A_R&/#WOWQSZU^2?VSW_\ ':\7$_[U\_\
M,[\/M\OT1U'VSW_\=H^V>_\ X[7+_;/?_P =H^V>_P#X[6)3W?J_S.XT>SU7
MQ)%<3Z%;W.I?9;S[%>?9/^8?JOX\ 8]/?(SUV?\ A%?&/_0#U/\ S_P&M_X
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MC_S\6E>?>1[_ *__ %J*/JW6WX?\ #T#^TK#_GX_\G?_ *]']IV__/>U_P#
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MQF\*P^//'$'_  D>F_Z+XP\4?^GK7^OZYXQ[UR'_  NKP-_T,>F?D?\ &O/
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MK@=.<\<G^0_^O1B,3BE;Y7]%_7](Z:&3\/8G!RQ:ERNSY4Y6[V6ZZ6V_X?\
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M3IO3]?3O_P#6](@\;>%=8M?MVAZYIFI6]U_R]VEYC Z9/X\4 ?&_B3_@G9\
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M?J7[[7K>>"W^TW']L9-I:<^W8'_]1^IK_0@_8Y\'_"3QMI?Q8@^,/PY^&_Q
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M/^#=8U2QL]*N_P#B8G0=+_Y /?G_ #SQ7#_$GPWJO_";^1_96I7/_%'>%_\
MCTLQ_P! 7_'C%>AAL.EN[>5[>??UV??4YWF7UEM7]Y:7ZNU]/P/V(^&/_!9[
MX[ZQJGB#PWI5C<'2-+\(:I>FZ\0ZO_:6J#5 .">.A/'7&0<XXS^>^@_MX?&*
M]M=0G\5SVWB3Q!WU:[_XEGV__L.<G'Z_6J_[(OP3\5'Q)XPU7Q5I6I>&]'U3
MP'JGABSU;Q#9_P!F_P#$UUWUZX_QYZ\CG]._85_:,AB\0?V%X._X3:WT&\'^
ME^'\?\3#2^G]M:&>A_3GZ5U?[)K9Z][]?^''A\0]5)/SO?TZ_/;S\CN- _;V
M^,7]O:?!H?\ 9OANX_MC2_\ B;6EYK(U,?X@C\ .V*_J0_9+_:B\<>)(K?0_
MB-/_ &W]E_YF'_F)_7ZC\,^_&/Y3_AC^P3^U#J?C+P_/JWPKU+PGH]UXDTN]
MO-6\67FC:;C2O<>F?4_S-?U$? [PK<:;?SSP06WV<]?LGXXZX'7KUZ].AH2<
MOA3E_A3E^29LY16\HK_$TOS:/VX\*S0:E86\\&;G[5Q[=_Z_TYKH)H?\G\>G
M\P<>H([UY_\ !FSG_P"$<M_3_ '_ #^!]>?:)M,\[T'\^?\ )X^@Z#%7&E5E
MM2JOTI5'^4&+GA_/'_P*/^9Q_P!C]O\ QZC['[?^/5U']FS^=_J/U[;LY_SV
MYJM]CG_YXW/Y+_C0L#6EM1JO_N%4_P#E8<\/YX_^!1_S.0U*\TK1[7[=JNJZ
M=HFG\_Z7JUY_9NF>O?T^O_U\\>+_  =BXG_X2KPW]GM?^/O_ (G&CYL/SZ<5
MQ_QRTW^TO"VC:5?>%?$GBW3[KQ?I?]L6GA[_ (ENIZ#I?_0:Z _CUZ>G'R/=
M_##0_P"WOL5Q\%O']S_PF0U36O$G^F_V:;#5/[:_Y O_ "+?7C0_%!QR>_ H
M^H5O^?%;_P $U?\ Y6"J4G_R\I_^!P_^3/MB;XD?#*'[3Y_CCPE;?91I?_,R
MZ*?^0[G^PO\ /OTJQ_PGO@#[5;V/_"8^&S<77-G:?VQ^G?IZ^GM7Q?\ "KX,
M^#_B%%\0)_$?PR\6^";BU\2:7HO^EZQK/]IZ]I>A8_L+6^/#??\ /IWKZ@A^
M&_@?3;;3['[!<VUOH'^A:1]KUC'V#3.<:*<YKH^H5^E"M?I^YJ;]/^7?<V]I
M@+?Q*=[?SPWMVYNYZ1#>6.IQ^?87%M<V^!9?:[2\_J.WTS^)Z_S[_'B;[9\<
M_BC??\_7CS5,^O'^1T'U]_W0T>;P!X)T:WTJQU7PWHFGVN?^/OQ+HW_ZNG'/
ML/05^!_Q"O8-2^(/CF^@GMKJWNO&'BB]L[O_ +C73/IW->=BL%C:=GC:<Z<7
MMS0E"]MFN:,;Z6VN8QG3G?DG"=M^2<96]>64K?AJ?H/_ ,$M_B3XQ@_;?_9Q
M\+?VY<W6@:IXOU:RO+.[8ZAG_BBO$ QNSQGN>U?W,U_!M_P2]_Y/^_9A_P"Q
MYU3_ -0O7Z_O)K3#[?+]$88KXGZ2_-A111728'\JW_!QI_R/G[*'_8N?%'_T
M]> J_FPFA@\[Z^O;\N?Y&OZ5O^#C*(-XU_96/KX;^*/OP-;\ ]1C';\?;O\
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MQ/\ ^2E_$G_L?/'W_IYUVN'FF_=?A^G'XX_4=*[#XD3>=\2_B1[^//'GX?\
M$ZU\].GY?7K7#S3=/SY_I_(#/J2:YSZ SYINGY\_T_D!GU)-5_/]OT_^O5B?
MM^']:S_/]OT_^O2>S]'^1Y^)CO9=]EZ_\ //]OT_^O5>K'G^WZ?_ %ZK_P#+
M7_/]ZKPEN>"Z<\5K_BBC@6Z]5^9^\'[ <%]XDE^*.AV,%S<ZA=_"OX#ZU9VE
MI9Z-J7V\?VUT_P"*@Y]OUKYG_;>T&?3=&^('VZ^^S6WVWXH?8Q:>&_\ A&],
ML-+_ +&']A?\3WD>_I^==A^Q#\8/AS\,=0U&^\?^/_!/@G_A,OA5X#\,>&[O
MQ7XD_P"$;TR_\4:%K7.B_P!N?\P#Q%_PCGU'2O!_^"F7[47P/TW1]0%]\3?@
MG_9^?'GVNUTGQY_PLCQ-KVJ:[_R O[#T/0/$GBX+R!UQQGDBOL\WH1P]?*^5
MIIQBY*+32O%?$DVNKWV[;'SF2QG]2S2\9?\ ([SCENI+W6G9*Z2Y7TMH^ES\
M=_\ @C/_ ,3+]M+P?8_8;G4KB[T?QY9?9+2\.F\_V+Q_Q/.O^<X[U_4O^T5X
M;US7M4\'^%+Z^\;:EI_BCQAX]LM9^U^)/^/#2SHG3G_D8.W0X\%YK^4C_@A[
MKUC-_P % /A?!?3W%MI^IVGCVRO/L=F-2U/^S-<\%^(!_P @0=1[CK^5?UH?
M$F\_M[XC?"Z?0[[P3<^%_P#A,?'ALR=&UG_A)O[4Z:]_8?OC^W/QZXKAQ.&C
MOI?Y>O3_ #+RB$OJTURRWET?>2['XO\ _!.7]DOX+?&SX\?\%,-#^)OVGPW_
M ,*N^)'A>R\'^++2S_M+^P=+_MKQ[_S _P#N!Z%U^I]OU0\;?\$_? 'PVUG3
M[ZQ^('@G1-/NM'TNQ^R6GAO6?[3U[5/[%_Y#7_(R?X\5^?W_  3!F_M+]J#_
M (*X06-]J7V?_A:FEX_X1Z\.I:G??\3KQ]_S SG_ (2#U^@^E?L#\9M8U76-
M9\+V.N3ZE<SW7CS^Q='(\-_\@'_B2_V#S_Q3?_%/#CKU'Z5PZK35>1Z&7X:T
MKOHV]?5Z(_)_XPZ#\*[NZ^ \'AR ^+=/\9?M4? ?X?:Q=W=G_9NF7_A?QUK7
M]@Z[[<<X[5^H/C;_ ()U_#G3;#Q1_P *7\<>&[G6/^)7]CTGQO\ \REI>>.?
M#_H?^AL_/N/S_P#CQIL_@.U_8_\  %]/;:CK&E_MX?LO"\U;_G_U3_A-/\\X
M_2OU6\5:]X_T&Z\8?\(KKFB7/BC5/^%7Z+>6GB'1_P#CPTO^V?\ B>Z*==ZD
M?\(YH?;/'MR%0P_Q2;[O\WU?RT_R1VXGE6*25NFUNWD?$'Q"T?0_@SX<%CXY
M\8^$KGQ!=6?V+1_^$3_XF6I\]?P_F>W6OY!]-_:*^/UGXR\00:5\8_B1IEO_
M &QJGV.TM/$FL_\ 0:SSDGJ1GTZ=:_K(\;:/!J-KK'CCR/"5SH_A?QY\4++^
MR=)LQ_R%-=_L#^PL_P#"0>__ .K)K^+[1]>TK_A*/$,]]?:;;?:M8U3G[9W_
M +:P/J3ZC//Z?I'AW0P#QT5F'(X\ZUJ./+9RZ\VEK;^5SY'BOZXL)+V?/>SL
MZ=^?9VMR:W[7ZI'Z=?#?]I;]J_4K6WL=*^.WQCN;FZY%I:>,-9SST]?_ -?U
MS7L__"U/VW[O2_[6_P"%M_'7^SK6[_L7[7_PLG6?^0F!_P!C(1[_ .>?B?X/
M_$+2O!]_;Z[8^)/#=MJ%K_S]WFC=>3^I]OR%?1$W[3FM_9=0L8/'/@FVT_5+
MS2[V\M+/^QO[,_XD.>WL,<XQ]37]C9=@.$U@X_5WPO?EBY>T>'YME>_,[WU=
M_,_G;%5\\6,?_"AQ,E>7PQJ\JU>UEMT]+'I$WC#]N#[5]A_X6;\?KFX%G_;7
M^B>/-9_Y!?X^).,\=#UZ40ZE^W=>1>'[Z#QQ\?KG3_%'_(N7=Y\2-9QKN?\
MN9 ?ZGFO+_\ AI;5!K/_  D?_"8^ +G4/L?]BWEW=V>C<:5_T!>O(]ZT(?VQ
MO&-G:^%[&#XC>"?[/\+V?V+PW:?\2;_0!^G'\A71+ <.;X:7"FFK][#:]]+]
M=?ZV7U[-/^@WB?[JW_R)L7NO?MI"*XGG\?\ QL^SZ7K']BWET/B1K.?[4_\
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MK6?[4_MHZ]_T,G_(N^OA;O\ E7H%Y^V9\1M2\1_\)'?:'X;N=0&C_P!BV?\
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MJQ5BJ]!SRPM[Z;WZ=_D?"_[5UY?:EJFC6'D?\2?2[S2^Q_#IQ[]LY]N/S/\
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M#_P(^)O@?Q_HFGZ#X/\ %'@OPW\3?A/_ &-J7_$KU[13_87]N>!_$'_"(_\
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MHHK+V,//[SF<W=[;OH=QIG_!"C_@I3%_KOV?]&.?^JO?!T]1[?$CT'X5H?\
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MKQQC)[?ICIZ=/SHHK?!0C34E%6_'L3CIRJ23E_(]M-F[?DA:***[SD/Y;?\
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M_P SPV;X _%2*6WA'@ZYZ=?[8\'>X_Z&3G_/3%><Z]^SE\7;VZQ_P@MT,?\
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2-"+O?M^OF6ZL[O7J^K[^I__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "@ G0# 2(  A$! Q$!_\0
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M1G;:I.%. 3Q7S;\&OVJO ?QY\2WVB_#[PC\9)- M=,N=4LOB7XE^%'BOP?\
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M_P *6BO*/6&G(*\DY.#G']UCV [BG4UNJ?[Q_P#0&IU !1110 4444 %%%%
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M;J9@L[?6]1E,/G6Z71>./]%/^":]Q^UK^S1_P;M:[XM\%> O%L'QR\%_!_\
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M:EJD-@ES;W4RVPD3IM#_ &>_@1X9TCX;:!X<^#?PQT'0_@YJ$VK_  GT?1O
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M-CJ6HZEI&GW/P]U>.]U/1P6U.QMLPM-<V0 ),\:*2N 3C.*^HJ^;/VP]6O\
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MC^TB^E'@L#C8YSFO@VLUH.5'&UZ?!-5</<+5::H3JTLZS/#<4U/K^>SH5^?
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MK-'USJ_AGPWX@FTRYU[P_H>MW&B7@U'1I]7TFPU*;2-04 +?:9+>V\SV%XH
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M,ERTJK(92X!'4111011P01QPPPQI%##$BQQ111J$CCCC0!(XXT 5$4!54!5
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M YUA?K&,AB(0A7PN)GALOQ4(N$(XNCA*L<7BU3KJU:C2Q67J=*49TJ\;I/\
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MJ^XNK7]F[XT7-C=265Y!X!UR6VO(@#):SQP;H[A >"T+ 2 '@[<'@U\*Z?\
M\%-M"U".30_%%H/@UXLGB<64_CKP_?WWAXW 7*;KZPU&%7B=MJD2/;LJDD/D
M<^-?%[]I;]KCQ7X=C^%^O^&_@[K?A/XWP-X)TWQ7X-77VEL4UQ-KWI@FU._4
MQP:?YE]]L\N2UB5<R%0 3_>_%G[13Z,W$'"G&/#?]I\<91FF=<)<5Y9E='B3
M@#,\KP6:5<=POQ#AHSP.8U,TS#*,?AJ7UCGQ;H9A5G2P\:LJF%FK4ZO\Y\%?
M1L\3\LXQX;QF?X'(>'Z.5Y_D^<5*?$&>87!4\URK)\QP6<9IB,CQ+P6/R;/H
MX;*\LS"O5PV"SB5><*3I/#-UX1G\-KJVK?"O]M#QUX:U/Q)_:<_C?PGX>ET[
M6KZU2T-U'=V%M-9/-;6ZS1-)'&TR*V=K@!F8-EA]X:BL=Y9Z-I\FLW-IJJ/Y
ML5S8I&+>XN$5E43%U<-&%+&-6(!8C>3R*^*OVE/A/HW[0_C2U\;?LY_%[X9^
M,?BO\)].M?!_CGP-X=\>>&=4U^SDT=WMM.^VVVG:E=7.EZM#)#<6<]AJL=KY
MCQ-&L@ECE0>2Z'^V'J?P3N4\)?M4:?\ \(%_9;P!]<UZ2+1[>VBN&$5D;B>\
MDAMXUO9,&"=9Y8KGGR';D5_@9C>%<;Q[E/"^:<-I8GC#*^&\LP'$G"'U&67\
M5+$Y=A*V#P>/PF0XW+<'B\=EV.RVI@,5A_J67UL-B:.*A4PM22G _O['9-@_
M%+A3A7B[A'-\ES'B+(>$\'EW&/#U*OEF SJAB.':&,RJ.:4<#BOJM'$97+!0
MPU2:P\?J4?:3C&O0JPG0H_IM<Z/HMQ#'<W]I!=SVR*&>2UB:69\(6VE8R;=#
M(0[Q6OEPON82+@D5MO+:PVUM':6]M"F5W+"B1B,A>758E"*R 'J5 ''4YKP/
MPM\?/ OB2:=]+U_1I-$:UCDMKQKZ%UFWQF1AP=[&1)$;(!!&W# 9-<IX[_:F
M\!>%(K73]%G&MZI?3I;2V=ILG2*.1DC>>0 G<%W?/NPHP02>:_+H<'<68W&T
M\LCD^;UL33DY_5ZE/$0I8:$Z<YR]NJL:='"^R49N2FUR22IOETC+\OH\!<:8
M_,*>54\ASFOB8-550G2Q,*&%I5*52K)XB56-/#X2,(QJ3ESS2C+E@VN:'/VW
M[1GQ2T_P/\.M0C?4HVU74K"6*VC49:Y:Y1H854+RTP#95#E2R[\9R*M_\$:I
M;X^*OBO',DQMR/#[S3.K")=3-AKTDML'QL:=()@TJJ254KNX(-?)/QMTWX:Z
ME<2Z]XF\8ZNJVBN+6SCU*U6SLFR7D>W@:UD<2'+B)B7$61M  X[W]E?]JCXG
M:1K=MIGP1\.?"SP9\+_"&G:AJWB77_$MC=F*:PF!T^XU_7M0?5;2\U+5))G,
MD(MIX]\Q1)BMN!%7]8?1XQN2>&F=>'/%.88?&PR+A_Q0X)XUXXX@Q>$J86EE
MF5<-YRLRJ4<JP2IU<9GN95(NE@\ORS+XQJXG%XIM3C35&G5_1^(?#_&9A]'3
MC/A/AG J>8<20H8O.L]XCJ+AO)\!4PF*PF)P6%PE2MA,=B<RQ,YTZ6 P6%P6
M$J2JXS'>T;5+ZO1K_P!0=%?AMJ/_  6&T^SU1K/0_ 6J>.=$TZ7[+JOB_0]'
MEM-,EFB!2XN=,M+K56N+BT$B,T;%@70C:2/FI_B/_@IA\1O&^DPZM^SCKGP<
M\1:T\L5O=?#GQQHWB'2/%=D#&[S78>+7XX;B" HL<RI&Q5I4(;;NQ_N7']H=
M]':,L*\<O$[*<+BN51S'-/#3.,/E^&<TY4UF>(P^<YC/)_:0]^,LWPF7P47%
M5:E&<E _@%?0]\>:<L++,>%<-DF#Q?+RYIG&:4<-EF$E.+G2AF^)PV%S2ID4
MJU-*I3>>8+*Z:C*"K5</.:IK]QJ*_F-\1_\ !9+]JGP?J%WH'C#X<?#7PWKF
MFS>1J"_V#X@U*VCR"T<P,/BF,B.:,":/YW8Q,"57%>R_LS_\%;_BG\:OCI\+
M?A9JFB> );#QQXHT[0M2N-$T36K:YM;:\D*O<P3W7B"[CBD4%<++;R*""/FS
MQ^A9/],/P5S_ !^49=E6,XJQ=;/,?E^79=6I\*8R>!JULTQ>$P>#JRQU/,JN
M&AA:E7&T)/$.<HQI.53DDH\K^AS;Z#?CYD^0YGQ)B<#P96RG*,HQ^>8RO@.-
MLKQK_LS+LNQ.:U\105+ PAB%/!86K5PZI57[=\D(24IJW]!M%%%?U(?Q^%%%
M% !1110!\/>-HT_MW46N]>AA'V[4"D"EY-J_VK?85DW@9'S C'88(Z#\2/\
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MDBA18_G:+>Q=@,LQ9AN8C<>#R*]6M[F.!%$95CO"R!_ODE<*.I))[)C/  8
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M1E0_TW5GZL,Z5J8Z9T^]&<XZVTHZ]OKVK^_,X_9]^'<L@SC#8CQ0\7<50?\
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MT\3&M2E-RI5Z=2%2$I.4*E-OF_.Z/QGX_P#@L/$&@_$WPGHWQM^&_B;4EO\
M7H?%-K$?$UK=);QVGVJSUH1BYMKC[''&D>[,>Y5.8V+[ON?]B?X/_LKGXH_"
M_P".GPZTO7+1=1\6Z;I^CZ5J]])*F@>*KF_2 6+6J@9N8G\SRY)998O)VS+]
M]17F?QUT :EX>NI;NV68>5,TLD<0=2J#Y>1A4887.0QZMG@4S_@G)J]A<ZKH
M?@Q+N(:EH'Q^^'NOVVG",_:);*>]>UO[J+ *K%;F*'[0<JR;E<C:P-?T9X38
MRMGO%WA?Q!E>(S+A_,*GC'X48#BBEP[CL3@\HSK+,7QMPS@ZE7,,HI2GE]/$
M4GAL#1GC<)A<ME/#3G2Q*G3FFOK>/L1+B/P8XQXHR?$9GPWFL\)B<NXMI<-8
M_$X3)\ZRK&Y'G& K5\?D\/;Y?A\13^JY?1GC\!ALIG/!U*E#%^THSBX_U*44
M45_U,'^%H4444 %%%% 'P7XUT/3KGQ+JLMKJ$EC=O?:DTKV.I9(D.JWV1):R
MDA6W??53@'. .!7\T?\ P7<\6^,;?7OV:/!TVAZQK-MX9TSXX?$+2(KBZTQU
M\230:'HN@VPT^.SN)IXI))Y/L82\ACD9Y0%5QG'](?C6+P%=>*]9%T(+*^74
MM46=G:ZLG>;^U;[S'\P-Y;Y.2648.>.M?RT_\%K-1\;CXY^'(/!>F:9K'B?P
M3^S/XMU'P-IFF:U>:P;O4?$/CA)],>[%U;Q1VNI7,>CNJ6J^=#*T*H6(!#?=
MX"*<J5HP=J<)7C.4G%JG%WC33]^22LU:RWZH^$QCM*I=M)U9IW2BFG4<4I3^
MS&\KWOT>J2=OYA_ 7Q,U_P ;:4+C5?AQ%X9^(6H^,;N,W2:;:0^&);))S<QQ
MZEX>CT0ZK9W$-BOV&;47UEA>7[ES9; T;>RS_$;Q[JGQCUWP[XH\ VOA[PUH
M&@:*OA>X_L"VG?6=;"6TLAO+ZY>-Y=&O()KB"WM[&&XO-+F6,?9Y%1F/EGPK
MU?XT^*;;PKI7BGPC\1=,^*,GB*^N?$'C*6;5;--4M!++/;Q7'AFZ\+6NF0S-
M*\&G1O9ZG"(K>%YI#*SR%?78-2_://QQ\<V?Q'TC7+;PY;"RM_ -EH"QP^&;
M4VZ0&[UF.Z.F7,>K0ZLC7"SV]]J-LME*PD(8*L1^@C27U;*W[*BY5O:3J2CC
M9*I6485)J.81;5/ 2C=.E3H1C*J[4)<TW)GV&+P>%A#((O <-N4LKS#$5>7B
MW%3K8B$:=X_VC%XATLH<&_:8/!X94YU[SP\U*=1V\9'C7Q_?>*?'FL:GH6@6
MVJ:-K<UGX4\&/X?FMIM5T>."6-Y9=5*RWC:G)="VFBNETV6T-B91]J@D5$;Q
MW3_&'Q'31];\1:MIGAF]\:7^LS0V/@V#3G@MM.T%HF222ZO\2WD=_:W:@$-I
MZ07<3ES>HX"U[!H.J_&6X\4?$"Z\9WGB-?$1UF23PGHK:58Q:!IOA^"6=([2
M6-+,17:7T)MY(=475RL4B2+]G=YOW7BVEW'Q+@TW6;W6?%4VI>,[J_NC>:5<
M:"J:;I$6UA#:1&**WVQPOM ?[1=B:-?W+$Y)\Z<%*G3;BTWA:U5R>+AS.:K.
M*JSI\WNXE+]W3P*CK22KRAS7;RHX:E/#5)1P62J5/(*.(=1\0U%4G4>)C%8C
MZNZJ3QJBW".3044Z:>+<=I/FH=0\>:5H<5U?)X4U_6=?O[R2Z@A46]GHNBM%
M&+7S-HO+E;A9VG1X;A+:+RDCQ<&8LJ\I(OC32- NK/6$\/W^H7H7[+=6;PRV
M"PWDS"*2[MHLF"&RA>)5#RJ\D@=AM56%;$6G>-=-MW)\>Z=K%YJ4LPOY+O2-
MT6ER%U"NR6D=N8[=2S.(IED=2F,L"36/?6FM:!9R:>?$MEX@GN+<23:ND5NU
MO:M<OL=GM+6)4"VL9W*)=S.6+,N $KAK4Y1<FJ<XJ/L8O_:J=;E=2$;WDI/V
MDJS;;DKQPTI.-TH6.[$X*%.K6C' 9;!0Q>30DJ&?_686K0H\U-5G6:E'$RDW
M6Q*;662DX-Q5+F7$Z+X<\:64UOJ=KJ]IJ.AQ:G-8W^GRVUC8^2(B/-O;?R90
MQB(8-%(82TF GS-G']27_!$&=+GX3_%_3\[CIGQ5L)L,>534_#,$N2#W)MLG
MH#GT&!_+0?".O:/>)K6E^*8[V%-2:TN=)GET^X>\L2^1J8-OY+V<$N=T<;QK
M(H&4!+;3_23_ ,$,O%-O8:7^T3I5V7D*^(_ 6LK&,EL2Z+J-E(23_"9$ R<D
MX .2,5Y&:4W##SC*G*DXNE+EE65:ZYVN:,TY)1>MH-WBU>UIJ_1F>%J8+.:5
M!X6CA93P2_=4,PCF497^LI5%7C5JJ*G[+W://[JIJHER8F#E_>I^P%%Y/PHU
M]>A/BPD@# '_ !(])Z<_Y/Y5]UU\!_\ !/#49=3^$GB2XDC\I?\ A,62),8(
MC&A:1@GU).3G^F*^_*^<E9R=MNFENBZ&-FM'NMPHHHJ0/C+]KS]@7]F;]N!?
MA9=?'OP=J6I^)?@CXSMOB!\)O'/A;Q)K/@[QMX$\4VKP2I?:)XAT*YMKH023
MVEG<7.G78NM/N9K.VDFMG,?/Q5_P4N_9V_:)U']AKX_Z!9?'2;XN>%-(\&CQ
M+)X8\=?#+0[GXA7,'A;4;362FC>-O!=WX8M7OK>&T,PN-6\(:I<S1P2B6Y,D
MAE'[15B>)=(77_#NN:&WEXU?2=0T[]\N^+-Y:RP+YJ$$/'N<;U((9<@@@XKU
M<ES:ODN;Y3FU&*JU,IS+ YC2I3;4)RP>+H8KV?,DY4XU?92A*4-4JCDDVK/R
M\ZRJCG649ME-:4J5/-LMQV75:M-)SA'&X2OA?:*+:C.5+VT:D8STDZ:BY).Z
M_P KFYU"6-K>\LYY;>YM98KJUN8V9);>YMY%F@EC=<,DD,J(Z,#N611R",C^
MN+]C']H"T_:1_9]\(^-9IXG\5Z3;KX4\=VJNK2V_B;1X8XI+MT'S+#K-MY&J
M6[$ ,+B:-21$:_([_@J=^P/JGP'\7Z_\6OA_H9M_ UWK$EI\0/#5@GFQ^!/$
MUPPD&HP1Q[C'X;UWS8[F$@+'87%PB_+;W$++\]_\$S?VE3\#_CO!X/\ $-^;
M?X>_%U[/PWJOFR 6NE^)O-V>&M:;>P2-6N9#I=W+@?Z/=QN[!(./[C\1<!E7
MC'X54>*>&?\ :,RR.-;-,/AO=EC:#I48O/<CQ$87DL1&A#ZS027)7GA*->AS
M0Q4;?P5X<YCG'@SXN8GA'BF^'ROB!T<MK8M\T<%B'5KR_P!7L]PTYVC]7G6G
M]3Q#;Y\/'&5\/B.2>$:?]05V@!8#@GH?3KSU'&><\'!Y[UR]TI!;/?(SC'/O
MDCZX]#[XKLKN(JS$@$<^_)SGU]>/7Z5R=X#A@.@/S'KG!X.>_IFOX:BN;EM9
MJR;?9M:W^[;8_O5)NR6_W^JTUW7WFIX$UW^Q/$=L7<K:7^+&ZY("^8W[F7T_
M=R[>2.%<\BOFW_@K#IVM?#'X:?#_ /X*'^ ?"U]XP\4_LE6WB#1?C'X1T::*
MVU?Q_P#LU>.5AM_&>D1RR_NFNO!OB&#0/'FDR3@QVJV>L.S".216]:N,JV5W
M @\'N"".>#Q@\C..?3&:^ROA1K^G>*_#[:3KEK9:K8:I9RZ+K>FZE;0WUA>D
M1^5);WME=)+!<VU];G;+#/&\4JLR,K X/=@L5B,OQ-#&82JZ.(PE6%?#U59N
M-2G*\;Q>DD[M2B_=G"4H25FS+&8.CB\+7PF*IJKAL31G1JTW]NG47+*%UK&5
MK.,UK&<8RCK%,_AG\*?&G_@L=_P4TU"XL?V&_P!E^?X!?"?6+J6-OB[JE@ND
M+'I]_(97N;CXJ^-+2T@\MO,>X:/P7I,A$A=(KF5B-WZ/_LR_\&J_A/4M<M?B
M=_P44_:5\:_M >-[FX74-3\$^ ]5U73/#CS.WG3V>K^/-<:?Q3JD+NS)-'HE
MKH$. 1#.Z&OZ_+6RM;"SMM-T^UM-/TVRB6"RTZPMH;*PLX4 5(;6SM8XK:WC
M10%5(8T4 # IYBR<8Y[ 'D^X'X>W?O77FF=YQGE7VN;YEC,?)/FC3KUI?5Z?
M2U+#4W3P\$MDU1<K)7F]S@RO*,IR6DJ.4Y;A,!'E2E.C1C[:HNKJ8B:G7J7>
MKYJEKZ\JTM\4>"?V._@?^R?\$/&?@K]B_P"$WP\^ .OR>%M2M]!\3^%_"EA>
M>(H]8:T:*#5M4UN^2XUG6KQ,>8SWU_*CR8EDC?85;XA_X)N_M1_%_P 1_'#X
MB?LR_%[XF:M\9=8T30=<\6Q^(]:\-:AH>M>$;G1-9LM.FTR]GOHXWU#1M:M]
M1AN--E/F+;7MK>VT$TL07'[&:_XO\,^%X'FUG5+:WV*Q\@NDDS8&<>6#P3T
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MM)U+Q1IBW'B/0YK.>'[-,]SY93Q-I*31LR2[SK$4*DNTHR0/X5-/UH2,J),
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M])M]!\ ^'O"\?AJVT&.>V47]YJ&J/]IUC6O$[3P:U/J=V\T$L)B0M[1\*?\
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M/[XVC))/[4OB$G.?^B:?#;'';WQ_^O\ JTK^6+_@TKTJ?2?V _C)%<;1+/\
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M_"Y?VR]%\/?$"S\(77P_C^+GP]T3X+?$6P\%?%;4/!JQP1:)/XTL(8=3-O\
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M))BDLGM_M'F@HJMN!/US_P %BM&^ .C_ ++.M?$#]H#PYJMY\.)/$7A+P/\
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M +T;/*GD_B!VSP/4>]?6OBU1<R3,!GDG Z<]#@].IP<=2">>:\4U'2&:7+*
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MS'P*MOB"]G-^SL/"%R/$DOPB@^)X^%LWB%?B>VKF\'Q+9@WBU-&&A#PY@_V
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M.!R_&2R.EE^%G3S'ARMQ%EN.ABL1AO[2P$<%5P9]\4445]2?@H4444 %%%%
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M #/^-&![_F?\: $;JG^\?_0&IU)@?_K)./IGIUI: "BBB@ HHHH **** /\
M)U_X*]O91?\ !5#]M@LN9Q\>_%!<')8AC:D@+C(QTR,\GCKSXUX8M;35M'AM
M+E%2WDMW&PJ""' !!#9!) # ]5Q@D5_;1^U9_P &Q'PA_:H_:6^,G[2>M?M5
M?$/PGK'QA\=ZIXYO?#6F_#GPYJ5CHD^IM&S:=::C<>([6XNX83&-EQ+;0R,
MNY,AB^#H/_!K5\'-#M(+8?M8?$2[:  &:3X:^'(F?'&2J>)V"Y7@@'&?FQVK
MR,7A<15DG"-[2;UG%=[-)M;?>K^IT.<.6U]>6/V7:Z5O+;?S?4_@W^)OP7CT
MF=M9T)/]&G8D(@PBN028G P?G()3C"]0017C-DEY97<-[8SW&FZMIL@E@DAD
M,-S!+&W#1L.2K$'@Y2520Q!Y/^B;=?\ !L/\'+NW-M+^U%X],;+M93\-_#S
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MU#2=/@LK+PY9W/B72[6&[N=*M%\7W>NWVG:7-);Z=>VLCM.:?PJ^ ?B'Q?\
MMV?%+]K[QW\*;GX61^'?A[!\#_AU::GXET?7=0^(4]OKEW-KWQBN-.T*\O\
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4K,,XEA\/[ HHHKT3XT**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #G B8# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(O\ 53"YI@<;BWFBH4L1*-3">SY*4(5JU&$IU>=J";;;5DFVC^NO]JW]K/\
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MV2BN?=:I:OSU1ZWJO_!6C]BO3/%/@'PM_P + UN^B\>:CX(T4^,M,\*:K=>
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CP-Y&!R1V']T_\
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MV?Q*U?P+JXO/''P^&F6'BC1+'71NTOQ!X<+Z2VE!M(TP(=.32[#]!]2_8!^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7AWQ9\0LT\2LWCD.#QE#/\?"O&G'"8J52^#P]X^Q4HR2<N22FU?GBFDWO Y
M/J,T4#&!CICCZ45^E'\5!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF 4444 %%%% !1110 4444 %%%% !1110 449!Z$&B@ HHHH **** "BBB@
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M;1=F^6USK(]<\,,57_A-/B OF"#YGOP!%G[-@D?9RW/VJYW95B1I=WCKI_\
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M&@:]I&M_8_(^U#2-2M-3%I]JW"W-TUE=R*F]K>X(5FRZJQ (5B>AKK$%%%%
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M#<=8X:H[SDM'[]17ZI::_EV.X?S#+,PK?6J[M=J-O@<5MRV6NEKZV5S^G_\
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MP]:%[S1-<\86>E6]U<0RZIJ'A>ZU72KS_CRL[.ZM-6T7_B7_ &'[=]KT_/\
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M86_Q@^-%MIME\9/B2=&M] U7Q1>Z5#86?C+6!I M+LV6H8O#98W9;(U0EAT
MKYOB_C/#\)X'!XZ6!K9IA\3)Q7U+WFFK-22Y9I)W\MG<_IOZ-/T<,?\ 2.XE
MSWAO!\:<.\%ULCP$<<\PXDJQH8/&*>(E0]G3E/$X9*<;<S]Z3M;0_P!$[XJ_
MM-_!7X,>+OAKX)^)7CC2/"6J_%K4]5T/P=<:M<V]KI,NJZ-IZZ@;35-6E=4T
MMKQ7":=<W)VS:B5@WAB5/T'&ZRA722.2*11MV'<K^I#@]L]CT]CS_E5^//BA
M\4O'4>F7/Q4\=_$?Q)_8]^;K0=1\<7>NV\^FZC=VMU9W7]EZK?6>G?8[W4+
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M(([&/X??!KP%X?GL+86\=Y:>'M/6ZE+0"UGN9FV;FO;Z,,LMYMWN<Y*?=/\
M6?%'TRO!S+</2P?!_ =?'RP[DX/#Y9E_#>"E=-J[G'$XN7,[<S?O1MKSM\R_
MJK)N .*9U*M3,<RE0NDE]9Q>(QMK*EK%7IQT_>6O>.JNK:/^ CP#^RE^T_\
M%>[TX? _]AWQG;R:K 4TGQ3XQMM*\*6]C/>6IL_LUK:G^T1>C /WM3_XE/\
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MPWJ<5Q'=:0FA:796,WVNUO-'S]ELK'K]AN_[/_M#/IC->S_\$M? O[/OPV\
M?''P%^S]X='AS3- ^..O0^+M*M[JTGT73/$)TVSM;C1-'M;34M1_LZRTN2SN
M6^PZA%I^L*;O.IHSLNWQ#QWXHMO!?@OQ5XMN;S3+&'P]H6L:G]HU>Z\G2_M%
MG:WGV3[7=_;M-&?MPM..,].]>$_\&W'Q(?XN_LQ_M"?$9Y99#XK_ &F?'U^(
MI[7[#]DVW=U9G3/LV3DZ=]E&G;LZEG[)G^UM2QN7\/SK/<;GN,>.QKBZD]7-
MM2G+5OXY-SEY7E)]^I[^'P]+#1<*"2C'3W=H^5E:S^2\C^CFBBBO+-PHHHH
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M=8\&:EXET?PWX2\86&L?\)1X+T_PY<SZK>8U36/LG]DZM>G4M/LO[1Z_V?\
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MN[<2/SR^,'VGPWX=US_A0H\.R^,#%<VOA/5_B-%JL^DR:A:,;.ZN-6^QV?\
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MWCV\UAX<^(/@^PNY(HLSP_9+K6+.TZ'_ (\?L-G>:?Z_\>'H:_EZ^$'B /\
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M6/AS#>[;+3+6T^RW=Y>ZUJ7VY?\ 0[;_ $ Z9I8P#_S%Q_:M?2EC_P &K_\
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ML?N7^0KON_O?^8;5_NK^0_PI0 .@ ^@Q113LNRWO\^_KY[BN^[^]BT444 &
M.@ HHHH **** "DP/0?E_GT'Y444 &!Z#\A1@>@_(444 +1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  _ #\# 2(  A$! Q$!_\0
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MTN;1-1O!N6UN=?\ "L&A:YHAF:%+R>RUN&V!>R*5\>?LQ?M:Z!XXT[PY?_\
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E(5M888;>VMXX8(56N.I54E:-W?5MKY]>[W.BG3Y=]_E;^D?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !O F0# 2(  A$! Q$!_\0
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M^9_]D[_@J+_P4/\ ^'Q<_P#P2M_;N\)?LB>$9H/@7JGQA\.>._@KH_Q=M_\
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MS2]/UG39_),^GZK9V^H6$Y@F2>)IK6[CFMY&AGCCFB9T9HY8T=<,@-::J%
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M7Q*32=7\,08!D@EO]/N-2^&^I6^X>9'/\/->A38GF/-^K7_!<[]D[5?VTO\
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M^E?$?5(I==^),NMR>&]1U?1)KS4_'6I^(-46;3]4OH9+6\MSY^_Y$ /Y^O\
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M-?%WC?XG6_B+X8ZZGASXB7^B?LS?M-^,? _@K6#HVE>(;BW\1?$WP;\(=?\
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M_4_X7_\ #S+_ .=)^IM%?EE]D_X+(_\ 05_8,_\  ?XP_P#R+1]D_P""R/\
MT%?V#/\ P'^,/_R+1_KM+_HB_$+_ ,1:'_T1A_J]_P!3_A?_ ,/,O_G2?J;1
M7Y9?9/\ @LC_ -!7]@S_ ,!_C#_\BT?9/^"R/_05_8,_\!_C#_\ (M'^NTO^
MB+\0O_$6A_\ 1&'^KW_4_P"%_P#P\R_^=)^IM%?EE]D_X+(_]!7]@S_P'^,/
M_P BT?9/^"R/_05_8,_\!_C#_P#(M'^NTO\ HB_$+_Q%H?\ T1A_J]_U/^%_
M_#S+_P"=)^IM%?EE]D_X+(_]!7]@S_P'^,/_ ,BT?9/^"R/_ $%?V#/_  '^
M,/\ \BT?Z[2_Z(OQ"_\ $6A_]$8?ZO?]3_A?_P /,O\ YTGZFT5^67V3_@LC
M_P!!7]@S_P !_C#_ /(M'V3_ (+(_P#05_8,_P# ?XP__(M'^NTO^B+\0O\
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21110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  < @H# 2(  A$! Q$!_\0
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M_F7KZ^HH_L# ?\_,U_\ #YG?_P ] ^M5_P#J'_\ "' __,Q\@_\ "D/VD_\
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MQ_8& _Y^9K_X?,[_ /GH'UJO_P!0_P#X0X'_ .9C@?\ A2'[2?\ T>AXX_\
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M[K'A739M7UZVM-*\1Z+I6H1P6.G0/<+J5U;V^F7FZ&&QO+FYN;:&8_L# ?\
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M_GYFO_A\SO\ ^>@?6J__ %#_ /A#@?\ YF/&?^%(?M)_]'H>./\ PRGP,_\
MF7H_X4A^TG_T>AXX_P##*? S_P"9>O0[_P#:9^"FEZAXAT[4/'-A:R>%IKFT
MUB[DLM;_ +(BU&SUNV\,W&C6FOC2SH.K^((_$=W!X?\ ^$=T?4M0UR37)$TJ
M*PDO]]NEN3]HGX3P1V5Q/XBN8[:[A:XN+@>&_%TD?A^"/4+S2I9?&;1Z R^
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M?#<:5J,-MZY1_8& _P"?F:_^'S.__GH'UJO_ -0__A#@?_F8^0?^%(?M)_\
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M#I7Y:F8N^_/F^;S^[FS&5@^MU^]#Y8+!+\L,@HHHKUSG"BBB@ HHHH ****
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MX.T/X=^)KY8+_P"'>OZOHKZU'K'B'38;S0_$FA:;;307D&JVB7[^%>(=!9O
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MI=:QHEG>V.G6?B2^E^%>KQ-<>&OAW\2?#_A+0=+86_\ PD'C#Q%)9^'=)O\
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B.JWD&D;+SZ_HHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>25
<FILENAME>advb-20250630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Oct 08 20:28:35 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:advb="http://www.advanbiomed.com/20250630" targetNamespace="http://www.advanbiomed.com/20250630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="advb-20250630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="advb-20250630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="advb-20250630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="advb-20250630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ConsolidatedBalanceSheet" id="advb_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals" id="advb_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ConsolidatedIncomeStatement" id="advb_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ShareholdersEquityType2or3" id="advb_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Consolidated Statements of Changes in Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ConsolidatedCashFlow" id="advb_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ConsolidatedCashFlowAlt0" id="advb_r_ConsolidatedCashFlowAlt0">
        <link:definition>995305 - Statement - Consolidated Statements of Cash Flows Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/OrganizationandPrincipalActivities" id="advb_r_OrganizationandPrincipalActivities">
        <link:definition>995306 - Disclosure - Organization and Principal Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/LiquidityandGoingConcern" id="advb_r_LiquidityandGoingConcern">
        <link:definition>995307 - Disclosure - Liquidity and Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPolicies" id="advb_r_SummaryofSignificantAccountingPolicies">
        <link:definition>995308 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNet" id="advb_r_PrepaidExpensesandOtherCurrentAssetsNet">
        <link:definition>995309 - Disclosure - Prepaid Expenses and Other Current Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/EquipmentNet" id="advb_r_EquipmentNet">
        <link:definition>995310 - Disclosure - Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/IntangibleAssetsNet" id="advb_r_IntangibleAssetsNet">
        <link:definition>995311 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrent" id="advb_r_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrent">
        <link:definition>995312 - Disclosure - Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties &#8211; Related Corporarions, Non-Current</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/OtherExpenseNet" id="advb_r_OtherExpenseNet">
        <link:definition>995313 - Disclosure - Other Expense, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/Equity" id="advb_r_Equity">
        <link:definition>995314 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/IncomeTaxes" id="advb_r_IncomeTaxes">
        <link:definition>995315 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/StockOption" id="advb_r_StockOption">
        <link:definition>995316 - Disclosure - Stock Option</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/RelatedPartyTransactions" id="advb_r_RelatedPartyTransactions">
        <link:definition>995317 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/SegmentInformation" id="advb_r_SegmentInformation">
        <link:definition>995318 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ConcentrationsandRisks" id="advb_r_ConcentrationsandRisks">
        <link:definition>995319 - Disclosure - Concentrations and Risks</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/CommitmentsandContingencies" id="advb_r_CommitmentsandContingencies">
        <link:definition>995320 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/SubsequentEvents" id="advb_r_SubsequentEvents">
        <link:definition>995321 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/AccountingPoliciesByPolicy" id="advb_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesTables" id="advb_r_OrganizationandPrincipalActivitiesTables">
        <link:definition>996001 - Disclosure - Organization and Principal Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesTables" id="advb_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNetTables" id="advb_r_PrepaidExpensesandOtherCurrentAssetsNetTables">
        <link:definition>996003 - Disclosure - Prepaid Expenses and Other Current Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/EquipmentNetTables" id="advb_r_EquipmentNetTables">
        <link:definition>996004 - Disclosure - Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/IntangibleAssetsNetTables" id="advb_r_IntangibleAssetsNetTables">
        <link:definition>996005 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentTables" id="advb_r_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentTables">
        <link:definition>996006 - Disclosure - Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties &#8211; Related Corporarions, Non-Current (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/OtherExpenseNetTables" id="advb_r_OtherExpenseNetTables">
        <link:definition>996007 - Disclosure - Other Expense, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/IncomeTaxesTables" id="advb_r_IncomeTaxesTables">
        <link:definition>996008 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/RelatedPartyTransactionsTables" id="advb_r_RelatedPartyTransactionsTables">
        <link:definition>996009 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/SegmentInformationTables" id="advb_r_SegmentInformationTables">
        <link:definition>996010 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/CommitmentsandContingenciesTables" id="advb_r_CommitmentsandContingenciesTables">
        <link:definition>996011 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails" id="advb_r_OrganizationandPrincipalActivitiesDetails">
        <link:definition>996012 - Disclosure - Organization and Principal Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable" id="advb_r_ScheduleofSubsidiariesTable">
        <link:definition>996013 - Disclosure - Organization and Principal Activities - Schedule of Subsidiaries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails" id="advb_r_LiquidityandGoingConcernDetails">
        <link:definition>996014 - Disclosure - Liquidity and Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][ncGlnwkCHXDRkMtw6q7IPBJ/UidFBloH3iGpjEoNL4frta4fsJDBmlGUhppU9Y4HfvBovodvyiOURG/KtSCuG2+QOgp0EBO5oQKtOJkgi9lsMGa0yqc20JHxh6yZQwHwIPvkQiIiYmaoFQfAsPqqNPa5qkKaGHbRONvsHbBV/SYOI3JLMOoL5CXVHAkakY5B+tG9eD/i+YPM6UvE3TI5N9R6/ZzPURyGdlhLYrK6ctU3/smg3oY4LfGHlDotex6lRBOTYTbNgYH7Ywikbe4v7/lrTU6bTVFwDyCJA2xrLQ2FKEJXJAjOLgIcQhvWwvFKhCdVZzA08SycxBQQxEA/iG2ZPyTMZzx11A==] CSR-->
      <link:roleType roleURI="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails" id="advb_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996015 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable" id="advb_r_ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable">
        <link:definition>996016 - Disclosure - Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates used in Preparing Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable" id="advb_r_ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable">
        <link:definition>996017 - Disclosure - Summary of Significant Accounting Policies - Schedule of Intangible Assets are stated at Cost less Accumulated Amortization and Impairment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable" id="advb_r_ScheduleofEstimatedUsefulLivesTable">
        <link:definition>996018 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable" id="advb_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable">
        <link:definition>996019 - Disclosure - Prepaid Expenses and Other Current Assets, Net - Schedule of Prepaid Expenses and Other Current Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/EquipmentNetDetails" id="advb_r_EquipmentNetDetails">
        <link:definition>996020 - Disclosure - Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable" id="advb_r_ScheduleofEquipmentNetTable">
        <link:definition>996021 - Disclosure - Equipment, Net - Schedule of Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable" id="advb_r_ScheduleofCompanysFiniteLivedIntangibleAssetsTable">
        <link:definition>996022 - Disclosure - Intangible Assets, Net - Schedule of Company&#8217;s Finite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentDetails" id="advb_r_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentDetails">
        <link:definition>996023 - Disclosure - Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties &#8211; Related Corporarions, Non-Current (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable" id="advb_r_ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable">
        <link:definition>996024 - Disclosure - Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties &#8211; Related Corporarions, Non-Current - Schedule of Account Payable, Accrued Expenses and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable" id="advb_r_ScheduleofOtherExpenseNetTable">
        <link:definition>996025 - Disclosure - Other Expense, Net - Schedule of Other Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/EquityDetails" id="advb_r_EquityDetails">
        <link:definition>996026 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/IncomeTaxesDetails" id="advb_r_IncomeTaxesDetails">
        <link:definition>996027 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable" id="advb_r_ScheduleofReconcilestheOperatingProfitTable">
        <link:definition>996028 - Disclosure - Income Taxes - Schedule of Reconciles the Operating Profit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable" id="advb_r_ScheduleofComponentofDeferredTaxAssetsTable">
        <link:definition>996029 - Disclosure - Income Taxes - Schedule of Component of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/StockOptionDetails" id="advb_r_StockOptionDetails">
        <link:definition>996030 - Disclosure - Stock Option (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails" id="advb_r_RelatedPartyTransactionsDetails">
        <link:definition>996031 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable" id="advb_r_ScheduleofRelatedPartiesTransactionsTable">
        <link:definition>996032 - Disclosure - Related Party Transactions - Schedule of Related Parties Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/SegmentInformationDetails" id="advb_r_SegmentInformationDetails">
        <link:definition>996033 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable" id="advb_r_ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable">
        <link:definition>996034 - Disclosure - Segment Information - Schedule of Significant Expense Categories in Single Operating Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ConcentrationsandRisksDetails" id="advb_r_ConcentrationsandRisksDetails">
        <link:definition>996035 - Disclosure - Concentrations and Risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable" id="advb_r_ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable">
        <link:definition>996036 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease ROU Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable" id="advb_r_ScheduleofFutureMinimumLeasePaymentsTable">
        <link:definition>996037 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.advanbiomed.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd"/>
  <xs:element name="ScheduleOfSubsidiariesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ScheduleOfSubsidiariesAbstract"/>
  <xs:element name="ScheduleOfCurrencyExchangeRatesUsedInPreparingFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ScheduleOfCurrencyExchangeRatesUsedInPreparingFinancialStatementsAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAreStatedAtCostLessAccumulatedAmortizationAndImpairmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ScheduleOfIntangibleAssetsAreStatedAtCostLessAccumulatedAmortizationAndImpairmentAbstract"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ScheduleOfEstimatedUsefulLivesAbstract"/>
  <xs:element name="ScheduleOfEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ScheduleOfEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfCompanySFiniteLivedIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ScheduleOfCompanySFiniteLivedIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfAccountPayableAccruedExpensesAndOtherLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ScheduleOfAccountPayableAccruedExpensesAndOtherLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfRelatedPartiesTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ScheduleOfRelatedPartiesTransactionsAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_UnlabeledAbstract0"/>
  <xs:element name="AmountDueToRelatedPartiesMajorStockholdersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_AmountDueToRelatedPartiesMajorStockholdersAbstract"/>
  <xs:element name="NameOfRelatedPartyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_NameOfRelatedPartyAbstract"/>
  <xs:element name="AmountDueToRelatedPartiesRelatedCorporationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_AmountDueToRelatedPartiesRelatedCorporationsAbstract"/>
  <xs:element name="CurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_CurrentAbstract"/>
  <xs:element name="NameOfRelatedPartyAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_NameOfRelatedPartyAbstract0"/>
  <xs:element name="NonCurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_NonCurrentAbstract"/>
  <xs:element name="NameOfRelatedPartyAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_NameOfRelatedPartyAbstract1"/>
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders"/>
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations"/>
  <xs:element name="StockSplitPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_StockSplitPolicyTextBlock"/>
  <xs:element name="RelatedPartiesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_RelatedPartiesPolicyTextBlock"/>
  <xs:element name="DeferredInitialPublicOfferingIPOCostsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="advb_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="advb_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable"/>
  <xs:element name="PrepaidExpensesAndOtherCurrentAssetGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="advb_PrepaidExpensesAndOtherCurrentAssetGross"/>
  <xs:element name="IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="advb_IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable"/>
  <xs:element name="AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="advb_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable"/>
  <xs:element name="OtherNonoperatingIncomeExpenseGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="advb_OtherNonoperatingIncomeExpenseGross"/>
  <xs:element name="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate"/>
  <xs:element name="EffectOfTaxLossesCarryForwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="advb_EffectOfTaxLossesCarryForwards"/>
  <xs:element name="OrganizationandPrincipalActivitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="advb_OrganizationandPrincipalActivitiesDetailsTable"/>
  <xs:element name="NetProceedsFromInitialPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="advb_NetProceedsFromInitialPublicOffering"/>
  <xs:element name="BusinessCombinationConsiderationNetAssetFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="advb_BusinessCombinationConsiderationNetAssetFairValue"/>
  <xs:element name="LiquidityandGoingConcernDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="advb_LiquidityandGoingConcernDetailsTable"/>
  <xs:element name="workingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="advb_workingCapital"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="advb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="ForwardShareSplitIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="advb_ForwardShareSplitIssued"/>
  <xs:element name="ForwardShareSplitOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="advb_ForwardShareSplitOutstanding"/>
  <xs:element name="DeferredInitialPublicOfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="advb_DeferredInitialPublicOfferingCost"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="advb_EquityDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="advb_IncomeTaxesDetailsTable"/>
  <xs:element name="NetOperatingLossCarryForwardOffset" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_NetOperatingLossCarryForwardOffset"/>
  <xs:element name="StockOptionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="advb_StockOptionDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="advb_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="WorkingCapitalLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="advb_WorkingCapitalLoan"/>
  <xs:element name="NumberOfDaysForOperationalExpenses" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_NumberOfDaysForOperationalExpenses"/>
  <xs:element name="AdvanceOnVenturesLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_AdvanceOnVenturesLimitedMember"/>
  <xs:element name="AdvancedBiomedHKLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_AdvancedBiomedHKLimitedMember"/>
  <xs:element name="AdvancedBiomedIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_AdvancedBiomedIncMember"/>
  <xs:element name="AdvancedBiomedIncTaiwanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_AdvancedBiomedIncTaiwanMember"/>
  <xs:element name="BeijingYitanJiaruiTechnologyCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_BeijingYitanJiaruiTechnologyCoLtdMember"/>
  <xs:element name="ChenYiLeeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ChenYiLeeMember"/>
  <xs:element name="CurrencyExchangeAverageRateMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_CurrencyExchangeAverageRateMember"/>
  <xs:element name="DrHungToPauMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_DrHungToPauMember"/>
  <xs:element name="DrYiLuMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_DrYiLuMember"/>
  <xs:element name="FiscalYearEndCurrencyRateMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_FiscalYearEndCurrencyRateMember"/>
  <xs:element name="HanyuAssetsCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_HanyuAssetsCoLtdMember"/>
  <xs:element name="HungToPauPhDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_HungToPauPhDMember"/>
  <xs:element name="JianWangMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_JianWangMember"/>
  <xs:element name="LabEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_LabEquipmentMember"/>
  <xs:element name="MajorStockholdersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_MajorStockholdersMember"/>
  <xs:element name="NanzhenShenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_NanzhenShenMember"/>
  <xs:element name="NewlinkTechnologyIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_NewlinkTechnologyIncMember"/>
  <xs:element name="QiangChenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_QiangChenMember"/>
  <xs:element name="RelatedCorporationsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_RelatedCorporationsMember"/>
  <xs:element name="SglcellLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_SglcellLtdMember"/>
  <xs:element name="ShandongSglcellMedicalDevicesCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ShandongSglcellMedicalDevicesCoLtdMember"/>
  <xs:element name="ShanghaiJunfuElectronicTechnologyCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ShanghaiJunfuElectronicTechnologyCoLtdMember"/>
  <xs:element name="ShanghaiSglcellBiotechCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ShanghaiSglcellBiotechCoLtdMember"/>
  <xs:element name="ShareExchangeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_ShareExchangeMember"/>
  <xs:element name="StevenIFangChengPhDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_StevenIFangChengPhDMember"/>
  <xs:element name="TwoThousandTwentyThreePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_TwoThousandTwentyThreePlanMember"/>
  <xs:element name="WellFancyDevelopmentLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_WellFancyDevelopmentLtdMember"/>
  <xs:element name="XiaoyuanLuoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_XiaoyuanLuoMember"/>
  <xs:element name="YiLuPhDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_YiLuPhDMember"/>
  <xs:element name="YiminJinMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_YiminJinMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="advb_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>26
<FILENAME>advb-20250630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Oct 08 20:28:35 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConsolidatedBalanceSheet" roleURI="http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConsolidatedIncomeStatement" roleURI="http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConsolidatedCashFlow" roleURI="http://www.advanbiomed.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable" roleURI="http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofEquipmentNetTable" roleURI="http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofCompanysFiniteLivedIntangibleAssetsTable" roleURI="http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable" roleURI="http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofOtherExpenseNetTable" roleURI="http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofReconcilestheOperatingProfitTable" roleURI="http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofComponentofDeferredTaxAssetsTable" roleURI="http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable" roleURI="http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable" roleURI="http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofFutureMinimumLeasePaymentsTable" roleURI="http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable"/>
  <calculationLink xlink:role="http://www.advanbiomed.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DeferredCosts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.advanbiomed.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.advanbiomed.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
<!-- [WMV6][fCLk6G22MOoG/fuLGHo1ixpk58rpTAgMQrx6voCRBoRnrkEJnDXJ26UZz0KwGuFtqP1wJPb/jtPjJT16j653/SHHl8D3ugAkpT7p0tOx2AVqPXEsu54QOBb7USar2ccTJgolHDizImJk8fZun2amZiiUC92G0fsHR/6MvrAs0PSDc6fKY9P89raXqD4dHCG+abIlCVYhHwSKRow9tbYJ/en505XYVj8QGqwrdHkjx2bSYTtrdu/ikZJwN1tU3eKhThOqJzt7Rc5FaW9HofVI4SzhKq0BjhWy+21CBWVZ8+oc0RoiMgQdCZjXlAmfFm5/vPmT9ukQfNj9hAewuXfQ4WfcGH1loAvozQ==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="advb_PrepaidExpensesAndOtherCurrentAssetGross" xlink:href="advb-20250630.xsd#advb_PrepaidExpensesAndOtherCurrentAssetGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="advb_PrepaidExpensesAndOtherCurrentAssetGross" xlink:to="us-gaap_PrepaidTaxes" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="advb_PrepaidExpensesAndOtherCurrentAssetGross" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="advb_PrepaidExpensesAndOtherCurrentAssetGross" xlink:to="us-gaap_DepositsAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="advb_PrepaidExpensesAndOtherCurrentAssetGross" xlink:to="us-gaap_PrepaidExpenseCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="advb_PrepaidExpensesAndOtherCurrentAssetGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="advb_OtherNonoperatingIncomeExpenseGross" xlink:href="advb-20250630.xsd#advb_OtherNonoperatingIncomeExpenseGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="advb_OtherNonoperatingIncomeExpenseGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="advb_EffectOfTaxLossesCarryForwards" xlink:href="advb-20250630.xsd#advb_EffectOfTaxLossesCarryForwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="advb_EffectOfTaxLossesCarryForwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>27
<FILENAME>advb-20250630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Oct 08 20:28:35 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConsolidatedBalanceSheet" roleURI="http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConsolidatedIncomeStatement" roleURI="http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ShareholdersEquityType2or3" roleURI="http://www.advanbiomed.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConsolidatedCashFlow" roleURI="http://www.advanbiomed.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_OrganizationandPrincipalActivities" roleURI="http://www.advanbiomed.com/role/OrganizationandPrincipalActivities"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_LiquidityandGoingConcern" roleURI="http://www.advanbiomed.com/role/LiquidityandGoingConcern"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_PrepaidExpensesandOtherCurrentAssetsNet" roleURI="http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_EquipmentNet" roleURI="http://www.advanbiomed.com/role/EquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_IntangibleAssetsNet" roleURI="http://www.advanbiomed.com/role/IntangibleAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrent" roleURI="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrent"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_OtherExpenseNet" roleURI="http://www.advanbiomed.com/role/OtherExpenseNet"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_Equity" roleURI="http://www.advanbiomed.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_IncomeTaxes" roleURI="http://www.advanbiomed.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_StockOption" roleURI="http://www.advanbiomed.com/role/StockOption"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_RelatedPartyTransactions" roleURI="http://www.advanbiomed.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SegmentInformation" roleURI="http://www.advanbiomed.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConcentrationsandRisks" roleURI="http://www.advanbiomed.com/role/ConcentrationsandRisks"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_CommitmentsandContingencies" roleURI="http://www.advanbiomed.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SubsequentEvents" roleURI="http://www.advanbiomed.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_AccountingPoliciesByPolicy" roleURI="http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_OrganizationandPrincipalActivitiesTables" roleURI="http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_PrepaidExpensesandOtherCurrentAssetsNetTables" roleURI="http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_EquipmentNetTables" roleURI="http://www.advanbiomed.com/role/EquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_IntangibleAssetsNetTables" roleURI="http://www.advanbiomed.com/role/IntangibleAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentTables" roleURI="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_OtherExpenseNetTables" roleURI="http://www.advanbiomed.com/role/OtherExpenseNetTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_IncomeTaxesTables" roleURI="http://www.advanbiomed.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_RelatedPartyTransactionsTables" roleURI="http://www.advanbiomed.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SegmentInformationTables" roleURI="http://www.advanbiomed.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_CommitmentsandContingenciesTables" roleURI="http://www.advanbiomed.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofSubsidiariesTable" roleURI="http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable" roleURI="http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable" roleURI="http://www.advanbiomed.com/role/ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofEstimatedUsefulLivesTable" roleURI="http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable" roleURI="http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofEquipmentNetTable" roleURI="http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofCompanysFiniteLivedIntangibleAssetsTable" roleURI="http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable" roleURI="http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofOtherExpenseNetTable" roleURI="http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofReconcilestheOperatingProfitTable" roleURI="http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofComponentofDeferredTaxAssetsTable" roleURI="http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofRelatedPartiesTransactionsTable" roleURI="http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable" roleURI="http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable" roleURI="http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofFutureMinimumLeasePaymentsTable" roleURI="http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_OrganizationandPrincipalActivitiesDetails" roleURI="http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_LiquidityandGoingConcernDetails" roleURI="http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_EquipmentNetDetails" roleURI="http://www.advanbiomed.com/role/EquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentDetails" roleURI="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_EquityDetails" roleURI="http://www.advanbiomed.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_IncomeTaxesDetails" roleURI="http://www.advanbiomed.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_StockOptionDetails" roleURI="http://www.advanbiomed.com/role/StockOptionDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_RelatedPartyTransactionsDetails" roleURI="http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SegmentInformationDetails" roleURI="http://www.advanbiomed.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConcentrationsandRisksDetails" roleURI="http://www.advanbiomed.com/role/ConcentrationsandRisksDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateJointVentureMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_CorporateJointVentureMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCosts" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="23" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorityShareholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MajorityShareholderMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_MajorityShareholderMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateJointVentureMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_CorporateJointVentureMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" xlink:href="advb-20250630.xsd#advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" xlink:href="advb-20250630.xsd#advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_MajorStockholdersMember" xlink:href="advb-20250630.xsd#advb_MajorStockholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_MajorStockholdersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateJointVentureMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_CorporateJointVentureMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPaidNet" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxesPaid" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/OrganizationandPrincipalActivities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/LiquidityandGoingConcern" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/EquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/IntangibleAssetsNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrent" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/OtherExpenseNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/StockOption" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ConcentrationsandRisks" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_StockSplitPolicyTextBlock" xlink:href="advb-20250630.xsd#advb_StockSplitPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="advb_StockSplitPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_RelatedPartiesPolicyTextBlock" xlink:href="advb-20250630.xsd#advb_RelatedPartiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="advb_RelatedPartiesPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock" xlink:href="advb-20250630.xsd#advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock" xlink:href="advb-20250630.xsd#advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/EquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/IntangibleAssetsNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/OtherExpenseNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/SegmentInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_AdvancedBiomedIncMember" xlink:href="advb-20250630.xsd#advb_AdvancedBiomedIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="advb_AdvancedBiomedIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_AdvancedBiomedIncTaiwanMember" xlink:href="advb-20250630.xsd#advb_AdvancedBiomedIncTaiwanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="advb_AdvancedBiomedIncTaiwanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_AdvancedBiomedHKLimitedMember" xlink:href="advb-20250630.xsd#advb_AdvancedBiomedHKLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="advb_AdvancedBiomedHKLimitedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_ShanghaiSglcellBiotechCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiSglcellBiotechCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="advb_ShanghaiSglcellBiotechCoLtdMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OpenForwardForeignCurrencyContractLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OpenForwardForeignCurrencyContractLineItems"/>
    <loc xlink:type="locator" xlink:label="advb_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable" xlink:href="advb-20250630.xsd#advb_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OpenForwardForeignCurrencyContractLineItems" xlink:to="advb_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntercompanyForeignCurrencyBalanceNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntercompanyForeignCurrencyBalanceNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable" xlink:to="srt_CurrencyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_FiscalYearEndCurrencyRateMember" xlink:href="advb-20250630.xsd#advb_FiscalYearEndCurrencyRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain" xlink:to="advb_FiscalYearEndCurrencyRateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_CurrencyExchangeAverageRateMember" xlink:href="advb-20250630.xsd#advb_CurrencyExchangeAverageRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain" xlink:to="advb_CurrencyExchangeAverageRateMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_TWD" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_TWD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_TWD" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_CNY"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CNY" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_HKD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_HKD" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OpenForwardForeignCurrencyContractLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="advb_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:href="advb-20250630.xsd#advb_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="advb_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidTaxes" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_PrepaidExpensesAndOtherCurrentAssetGross" xlink:href="advb-20250630.xsd#advb_PrepaidExpensesAndOtherCurrentAssetGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="advb_PrepaidExpensesAndOtherCurrentAssetGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable" xlink:type="extended">
<!-- [WMV6][q2EVDcRQZBVyDDh/M4GHIEkp+M6XBLPnW6fKGKHvWPrmq/4wFwClGErB7gZONVQYiekTq0ZdA+5dKlC7L6A381+aTb6sR47MMkinJmYzCNhED5ZPSIBUWYhmgOpACF1LvEZmM4d9GLPQks9mgRVFITHoEyZs4XL+urzw+yj3cjiqzYmWm9UHucIudn9lZr7+WwiFUpre+gylJ9uclSXliWeo+q8c4mmW3e7jb64jYWytKpEyoGfij985e1qclVuoOh9OkTfzjgKep+/3W49DNroc0VgQlOmxBV6vWy0q+7dZozGWcGdJisLNIVH8bUFsUhMJyXpJcqXrhNNgdpb7wkksvVtJXGTi] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_LabEquipmentMember" xlink:href="advb-20250630.xsd#advb_LabEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="advb_LabEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="advb_IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable" xlink:href="advb-20250630.xsd#advb_IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="advb_IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableLineItems"/>
    <loc xlink:type="locator" xlink:label="advb_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable" xlink:href="advb-20250630.xsd#advb_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="advb_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorityShareholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MajorityShareholderMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_MajorityShareholderMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateJointVentureMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_CorporateJointVentureMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentOfOtherExpenseNonoperatingLineItems"/>
    <loc xlink:type="locator" xlink:label="advb_OtherNonoperatingIncomeExpenseGross" xlink:href="advb-20250630.xsd#advb_OtherNonoperatingIncomeExpenseGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:to="advb_OtherNonoperatingIncomeExpenseGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="stpr_NV" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NV"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_NV" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_TW" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_TW"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_TW" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate" xlink:href="advb-20250630.xsd#advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_EffectOfTaxLossesCarryForwards" xlink:href="advb-20250630.xsd#advb_EffectOfTaxLossesCarryForwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="advb_EffectOfTaxLossesCarryForwards" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_YiLuPhDMember" xlink:href="advb-20250630.xsd#advb_YiLuPhDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_YiLuPhDMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_HungToPauPhDMember" xlink:href="advb-20250630.xsd#advb_HungToPauPhDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_HungToPauPhDMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_StevenIFangChengPhDMember" xlink:href="advb-20250630.xsd#advb_StevenIFangChengPhDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_StevenIFangChengPhDMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_ChenYiLeeMember" xlink:href="advb-20250630.xsd#advb_ChenYiLeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_ChenYiLeeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_AdvanceOnVenturesLimitedMember" xlink:href="advb-20250630.xsd#advb_AdvanceOnVenturesLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_AdvanceOnVenturesLimitedMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_WellFancyDevelopmentLtdMember" xlink:href="advb-20250630.xsd#advb_WellFancyDevelopmentLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_WellFancyDevelopmentLtdMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_ShanghaiJunfuElectronicTechnologyCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiJunfuElectronicTechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_ShanghaiJunfuElectronicTechnologyCoLtdMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_MajorStockholdersMember" xlink:href="advb-20250630.xsd#advb_MajorStockholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_MajorStockholdersMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_RelatedCorporationsMember" xlink:href="advb-20250630.xsd#advb_RelatedCorporationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_RelatedCorporationsMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <loc xlink:type="locator" xlink:label="advb_OrganizationandPrincipalActivitiesDetailsTable" xlink:href="advb-20250630.xsd#advb_OrganizationandPrincipalActivitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="advb_OrganizationandPrincipalActivitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="srt_OwnershipAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_TransactionTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_ShanghaiSglcellBiotechCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiSglcellBiotechCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="advb_ShanghaiSglcellBiotechCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_ChenYiLeeMember" xlink:href="advb-20250630.xsd#advb_ChenYiLeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="advb_ChenYiLeeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_DrYiLuMember" xlink:href="advb-20250630.xsd#advb_DrYiLuMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="advb_DrYiLuMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_ShareExchangeMember" xlink:href="advb-20250630.xsd#advb_ShareExchangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="advb_ShareExchangeMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_ShanghaiSglcellBiotechCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_BeijingYitanJiaruiTechnologyCoLtdMember" xlink:href="advb-20250630.xsd#advb_BeijingYitanJiaruiTechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_BeijingYitanJiaruiTechnologyCoLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_ShandongSglcellMedicalDevicesCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShandongSglcellMedicalDevicesCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_ShandongSglcellMedicalDevicesCoLtdMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_DrHungToPauMember" xlink:href="advb-20250630.xsd#advb_DrHungToPauMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_DrHungToPauMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_SglcellLtdMember" xlink:href="advb-20250630.xsd#advb_SglcellLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_SglcellLtdMember" order="5" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_DrYiLuMember" order="6" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_ChenYiLeeMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_AdvancedBiomedHKLimitedMember" xlink:href="advb-20250630.xsd#advb_AdvancedBiomedHKLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_AdvancedBiomedHKLimitedMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_AdvanceOnVenturesLimitedMember" xlink:href="advb-20250630.xsd#advb_AdvanceOnVenturesLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_AdvanceOnVenturesLimitedMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_YiminJinMember" xlink:href="advb-20250630.xsd#advb_YiminJinMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_YiminJinMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_XiaoyuanLuoMember" xlink:href="advb-20250630.xsd#advb_XiaoyuanLuoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_XiaoyuanLuoMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_NanzhenShenMember" xlink:href="advb-20250630.xsd#advb_NanzhenShenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_NanzhenShenMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_JianWangMember" xlink:href="advb-20250630.xsd#advb_JianWangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_JianWangMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_QiangChenMember" xlink:href="advb-20250630.xsd#advb_QiangChenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_QiangChenMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_HanyuAssetsCoLtdMember" xlink:href="advb-20250630.xsd#advb_HanyuAssetsCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_HanyuAssetsCoLtdMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_NewlinkTechnologyIncMember" xlink:href="advb-20250630.xsd#advb_NewlinkTechnologyIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="advb_NewlinkTechnologyIncMember" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_NetProceedsFromInitialPublicOffering" xlink:href="advb-20250630.xsd#advb_NetProceedsFromInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="advb_NetProceedsFromInitialPublicOffering" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_BusinessCombinationConsiderationNetAssetFairValue" xlink:href="advb-20250630.xsd#advb_BusinessCombinationConsiderationNetAssetFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="advb_BusinessCombinationConsiderationNetAssetFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <loc xlink:type="locator" xlink:label="advb_LiquidityandGoingConcernDetailsTable" xlink:href="advb-20250630.xsd#advb_LiquidityandGoingConcernDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="advb_LiquidityandGoingConcernDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_LiquidityandGoingConcernDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_LiquidityandGoingConcernDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_workingCapital" xlink:href="advb-20250630.xsd#advb_workingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="advb_workingCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <loc xlink:type="locator" xlink:label="advb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="advb-20250630.xsd#advb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="advb_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_ShanghaiSglcellBiotechCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiSglcellBiotechCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_ShanghaiSglcellBiotechCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_ForwardShareSplitIssued" xlink:href="advb-20250630.xsd#advb_ForwardShareSplitIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="advb_ForwardShareSplitIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_ForwardShareSplitOutstanding" xlink:href="advb-20250630.xsd#advb_ForwardShareSplitOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="advb_ForwardShareSplitOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_DeferredInitialPublicOfferingCost" xlink:href="advb-20250630.xsd#advb_DeferredInitialPublicOfferingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="advb_DeferredInitialPublicOfferingCost" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/EquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtTerm" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="advb_EquityDetailsTable" xlink:href="advb-20250630.xsd#advb_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="advb_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_EquityDetailsTable" xlink:to="srt_RangeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="advb_IncomeTaxesDetailsTable" xlink:href="advb-20250630.xsd#advb_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="advb_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="stpr_NV" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NV"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_NV" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_CN" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_TW" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_TW"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_TW" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_HK"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_HK" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_US" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_NetOperatingLossCarryForwardOffset" xlink:href="advb-20250630.xsd#advb_NetOperatingLossCarryForwardOffset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="advb_NetOperatingLossCarryForwardOffset" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/StockOptionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="advb_StockOptionDetailsTable" xlink:href="advb-20250630.xsd#advb_StockOptionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="advb_StockOptionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_StockOptionDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_StockOptionDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_TwoThousandTwentyThreePlanMember" xlink:href="advb-20250630.xsd#advb_TwoThousandTwentyThreePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="advb_TwoThousandTwentyThreePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="advb_RelatedPartyTransactionsDetailsTable" xlink:href="advb-20250630.xsd#advb_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="advb_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="advb_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_AdvancedBiomedIncTaiwanMember" xlink:href="advb-20250630.xsd#advb_AdvancedBiomedIncTaiwanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="advb_AdvancedBiomedIncTaiwanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_ShanghaiSglcellBiotechCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiSglcellBiotechCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="advb_ShanghaiSglcellBiotechCoLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_ShanghaiJunfuElectronicTechnologyCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiJunfuElectronicTechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="advb_ShanghaiJunfuElectronicTechnologyCoLtdMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_YiLuPhDMember" xlink:href="advb-20250630.xsd#advb_YiLuPhDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_YiLuPhDMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_HungToPauPhDMember" xlink:href="advb-20250630.xsd#advb_HungToPauPhDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_HungToPauPhDMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_WellFancyDevelopmentLtdMember" xlink:href="advb-20250630.xsd#advb_WellFancyDevelopmentLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="advb_WellFancyDevelopmentLtdMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredDebtMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_UnsecuredDebtMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_UnsecuredDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="advb_WorkingCapitalLoan" xlink:href="advb-20250630.xsd#advb_WorkingCapitalLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="advb_WorkingCapitalLoan" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.advanbiomed.com/role/ConcentrationsandRisksDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract"/>
    <loc xlink:type="locator" xlink:label="advb_NumberOfDaysForOperationalExpenses" xlink:href="advb-20250630.xsd#advb_NumberOfDaysForOperationalExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="advb_NumberOfDaysForOperationalExpenses" order="0" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>28
<FILENAME>advb-20250630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Oct 08 20:28:35 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Loss before tax (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net cash outflows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Net increase (decrease) in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash at beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash at year end</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Principal Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Liquidity and Going Concern [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis_lbl" xml:lang="en-US">Intra-Entity Foreign Currency Balance by Description [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_PrepaidExpensesAndOtherCurrentAssetGross" xlink:href="advb-20250630.xsd#advb_PrepaidExpensesAndOtherCurrentAssetGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="advb_PrepaidExpensesAndOtherCurrentAssetGross_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_PrepaidExpensesAndOtherCurrentAssetGross" xlink:to="advb_PrepaidExpensesAndOtherCurrentAssetGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid expenses and other current assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Intangible Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-lived intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties &#8211; Related Corporarions, Non-Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total Accounts payable, accruals, and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts payable, accruals, and other current liabilities (including amount due to related parties &#8211; major stockholders as of June 30, 2025 and 2024, with $172,767 and $113,812 due to related parties &#8211; related corporations, and $916,036 and $674,262 due to related corporations, respectively (1))</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other Expense, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentOfOtherExpenseNonoperatingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems_lbl" xml:lang="en-US">Schedule of Other Expense, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:to="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLossAbstract_lbl" xml:lang="en-US">Schedule of Reconciles the Operating Profit [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_OperatingIncomeLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision for taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Schedule of Component of Deferred Tax Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock Option [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl" xml:lang="en-US">Schedule of Significant Expense Categories in Single Operating Segment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_lbl" xml:lang="en-US">Concentrations and Risks [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Schedule of Operating Lease ROU Assets and Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Present value of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Future Minimum Lease Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future lease payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating lease ROU asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred initial public offering (&#8220;IPO&#8221;) costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Due to related parties (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Amount due to related Amount due to related parties &#8211; related corporations, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease payable - current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating lease liabilities, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Amount due to related parties &#8211; related corporations, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Amount due to related Amount due to related parties &#8211; related corporations, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease payable &#8211; non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Non-current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating lease liabilities, non-current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock $0.001 par value per share; as of June 30, 2025 and 2024; 400,000,000 and 400,000,000 shares authorized; 21,640,000 and 20,000,000 shares issued and outstanding, respectively*</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common stock retain a par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation gain, net of taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Weighted average number of shares of common stock in computing net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" xlink:href="advb-20250630.xsd#advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders_lbl" xml:lang="en-US">Waiver of amount due to related parties &#8211; major stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" xlink:to="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" xlink:href="advb-20250630.xsd#advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations_lbl" xml:lang="en-US">Waiver of amount due to related parties &#8211; related corporations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" xlink:to="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_UnlabeledAbstract" xlink:href="advb-20250630.xsd#advb_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_UnlabeledAbstract" xlink:to="advb_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of stocks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of stocks (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Common stock, shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Shares of common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustment:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_UnlabeledAbstract0" xlink:href="advb-20250630.xsd#advb_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_UnlabeledAbstract0" xlink:to="advb_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accounts payable, accruals and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease obligations, net cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds from issuance of stock in IPO/(prepayments for IPO costs)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Foreign currency effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplementary Cash Flow Information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_lbl" xml:lang="en-US">Cash received for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayments to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Settle debt of total amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl1" xml:lang="en-US">Repayment to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorityShareholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MajorityShareholderMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorityShareholderMember_lbl" xml:lang="en-US">Major stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorityShareholderMember" xlink:to="us-gaap_MajorityShareholderMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MajorityShareholderMember_lbl0" xml:lang="en-US">Major Stockholders [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorityShareholderMember" xlink:to="us-gaap_MajorityShareholderMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateJointVentureMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateJointVentureMember_lbl" xml:lang="en-US">Related corporations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateJointVentureMember" xlink:to="us-gaap_CorporateJointVentureMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CorporateJointVentureMember_lbl0" xml:lang="en-US">Related Corporations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateJointVentureMember" xlink:to="us-gaap_CorporateJointVentureMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CorporateJointVentureMember_lbl1" xml:lang="en-US">Related Corporations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateJointVentureMember" xlink:to="us-gaap_CorporateJointVentureMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_MajorStockholdersMember" xlink:href="advb-20250630.xsd#advb_MajorStockholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_MajorStockholdersMember_lbl" xml:lang="en-US">Major Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_MajorStockholdersMember" xlink:to="advb_MajorStockholdersMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="advb_MajorStockholdersMember_lbl0" xml:lang="en-US">Major Stockholders [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_MajorStockholdersMember" xlink:to="advb_MajorStockholdersMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND PRINCIPAL ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl" xml:lang="en-US">Schedule of Subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate_lbl" xml:lang="en-US">Date of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl" xml:lang="en-US">Percentage of effective ownership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl" xml:lang="en-US">Place of incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl" xml:lang="en-US">Principal Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">LIQUIDITY AND GOING CONCERN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl" xml:lang="en-US">Schedule of Currency Exchange Rates used in Preparing Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xml:lang="en-US">Currency exchange rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets are stated at Cost less Accumulated Amortization and Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Straight-line basis over the estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <loc xlink:type="locator" xlink:label="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock" xlink:href="advb-20250630.xsd#advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock" xlink:to="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidTaxes_lbl" xml:lang="en-US">Tax refundable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Finite-Lived Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-lived intangible assets, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-lived intangible assets (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE, ACCRUALS AND OTHER CURRENT LIABILITIES AND AMOUNT DUE TO RELATED PARTIES &#8211; RELATED CORPORARIONS, NON-CURRENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Account Payable, Accrued Expenses and Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Payroll payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Amount due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Amount due to related parties &#8211; major stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Amount due to related parties &#8211; related corporations, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xml:lang="en-US">OTHER EXPENSE, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock_lbl" xml:lang="en-US">Schedule of Other Expense, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_OtherNonoperatingIncomeExpenseGross" xlink:href="advb-20250630.xsd#advb_OtherNonoperatingIncomeExpenseGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_OtherNonoperatingIncomeExpenseGross_lbl" xml:lang="en-US">Other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_OtherNonoperatingIncomeExpenseGross" xlink:to="advb_OtherNonoperatingIncomeExpenseGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_lbl" xml:lang="en-US">Foreign exchange loss, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciles the Operating Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax at federal statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Statutory tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate" xlink:href="advb-20250630.xsd#advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax expense calculated at the statutory tax rate (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate" xlink:to="advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_EffectOfTaxLossesCarryForwards" xlink:href="advb-20250630.xsd#advb_EffectOfTaxLossesCarryForwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_EffectOfTaxLossesCarryForwards_lbl" xml:lang="en-US">Effect of tax losses carry forwards (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_EffectOfTaxLossesCarryForwards" xlink:to="advb_EffectOfTaxLossesCarryForwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Effect of subsidiaries foreign income (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Changes in valuation allowances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Different foreign subsidiary tax rate impact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">Taxable income rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Component of Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK OPTION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Parties Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xml:lang="en-US">Relationship to Us</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_AmountDueToRelatedPartiesMajorStockholdersAbstract" xlink:href="advb-20250630.xsd#advb_AmountDueToRelatedPartiesMajorStockholdersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_AmountDueToRelatedPartiesMajorStockholdersAbstract_lbl" xml:lang="en-US">Amount due to related parties &#8211; major stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AmountDueToRelatedPartiesMajorStockholdersAbstract" xlink:to="advb_AmountDueToRelatedPartiesMajorStockholdersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_NameOfRelatedPartyAbstract" xlink:href="advb-20250630.xsd#advb_NameOfRelatedPartyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_NameOfRelatedPartyAbstract_lbl" xml:lang="en-US">Name of related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NameOfRelatedPartyAbstract" xlink:to="advb_NameOfRelatedPartyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_AmountDueToRelatedPartiesRelatedCorporationsAbstract" xlink:href="advb-20250630.xsd#advb_AmountDueToRelatedPartiesRelatedCorporationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_AmountDueToRelatedPartiesRelatedCorporationsAbstract_lbl" xml:lang="en-US">Amount due to related parties &#8211; related corporations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AmountDueToRelatedPartiesRelatedCorporationsAbstract" xlink:to="advb_AmountDueToRelatedPartiesRelatedCorporationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_CurrentAbstract" xlink:href="advb-20250630.xsd#advb_CurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_CurrentAbstract_lbl" xml:lang="en-US">Current:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_CurrentAbstract" xlink:to="advb_CurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_NameOfRelatedPartyAbstract0" xlink:href="advb-20250630.xsd#advb_NameOfRelatedPartyAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_NameOfRelatedPartyAbstract0_lbl" xml:lang="en-US">Name of related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NameOfRelatedPartyAbstract0" xlink:to="advb_NameOfRelatedPartyAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_NonCurrentAbstract" xlink:href="advb-20250630.xsd#advb_NonCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_NonCurrentAbstract_lbl" xml:lang="en-US">Non-Current:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NonCurrentAbstract" xlink:to="advb_NonCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_NameOfRelatedPartyAbstract1" xlink:href="advb-20250630.xsd#advb_NameOfRelatedPartyAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_NameOfRelatedPartyAbstract1_lbl" xml:lang="en-US">Name of related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NameOfRelatedPartyAbstract1" xlink:to="advb_NameOfRelatedPartyAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Significant Expense Categories in Single Operating Segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CONCENTRATIONS AND RISKS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Lease ROU Assets and Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesOperatingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2030</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_lbl" xml:lang="en-US">Less: allowance for credit losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:to="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_AdvancedBiomedIncMember" xlink:href="advb-20250630.xsd#advb_AdvancedBiomedIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_AdvancedBiomedIncMember_lbl" xml:lang="en-US">Advanced Biomed Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdvancedBiomedIncMember" xlink:to="advb_AdvancedBiomedIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_AdvancedBiomedIncTaiwanMember" xlink:href="advb-20250630.xsd#advb_AdvancedBiomedIncTaiwanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_AdvancedBiomedIncTaiwanMember_lbl" xml:lang="en-US">Advanced Biomed Inc. (Taiwan) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdvancedBiomedIncTaiwanMember" xlink:to="advb_AdvancedBiomedIncTaiwanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_AdvancedBiomedHKLimitedMember" xlink:href="advb-20250630.xsd#advb_AdvancedBiomedHKLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_AdvancedBiomedHKLimitedMember_lbl" xml:lang="en-US">Advanced Biomed HK Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdvancedBiomedHKLimitedMember" xlink:to="advb_AdvancedBiomedHKLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_ShanghaiSglcellBiotechCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiSglcellBiotechCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_ShanghaiSglcellBiotechCoLtdMember_lbl" xml:lang="en-US">Shanghai Sglcell Biotech Co., Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ShanghaiSglcellBiotechCoLtdMember" xlink:to="advb_ShanghaiSglcellBiotechCoLtdMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="advb_ShanghaiSglcellBiotechCoLtdMember_lbl0" xml:lang="en-US">Shanghai Sglcell Biotech Co Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ShanghaiSglcellBiotechCoLtdMember" xlink:to="advb_ShanghaiSglcellBiotechCoLtdMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="currency_TWD" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_TWD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_TWD_lbl" xml:lang="en-US">US$ to NT$ [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_TWD" xlink:to="currency_TWD_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_FiscalYearEndCurrencyRateMember" xlink:href="advb-20250630.xsd#advb_FiscalYearEndCurrencyRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_FiscalYearEndCurrencyRateMember_lbl" xml:lang="en-US">Fiscal Year End [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_FiscalYearEndCurrencyRateMember" xlink:to="advb_FiscalYearEndCurrencyRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_CurrencyExchangeAverageRateMember" xlink:href="advb-20250630.xsd#advb_CurrencyExchangeAverageRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_CurrencyExchangeAverageRateMember_lbl" xml:lang="en-US">Average Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_CurrencyExchangeAverageRateMember" xlink:to="advb_CurrencyExchangeAverageRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_CNY"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_CNY_lbl" xml:lang="en-US">US$ to CNY [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CNY" xlink:to="currency_CNY_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_HKD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_HKD_lbl" xml:lang="en-US">US$ to HKD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_HKD" xlink:to="currency_HKD_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Lab Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_LabEquipmentMember" xlink:href="advb-20250630.xsd#advb_LabEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_LabEquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_LabEquipmentMember" xlink:to="advb_LabEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="stpr_NV" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NV"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="stpr_NV_lbl" xml:lang="en-US">State of Nevada [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NV" xlink:to="stpr_NV_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="stpr_NV_lbl0" xml:lang="en-US">NEVADA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NV" xlink:to="stpr_NV_lbl0"/>
    <loc xlink:type="locator" xlink:label="country_TW" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_TW"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_TW_lbl" xml:lang="en-US">Taiwan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_TW" xlink:to="country_TW_lbl"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CN_lbl" xml:lang="en-US">China [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_HK"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_HK_lbl" xml:lang="en-US">Hong Kong [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="country_HK_lbl0" xml:lang="en-US">HONG KONG</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl0"/>
    <loc xlink:type="locator" xlink:label="advb_YiLuPhDMember" xlink:href="advb-20250630.xsd#advb_YiLuPhDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_YiLuPhDMember_lbl" xml:lang="en-US">Yi Lu, Ph.D.[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_YiLuPhDMember" xlink:to="advb_YiLuPhDMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="advb_YiLuPhDMember_lbl0" xml:lang="en-US">Yi Lu, Ph.D. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_YiLuPhDMember" xlink:to="advb_YiLuPhDMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="advb_HungToPauPhDMember" xlink:href="advb-20250630.xsd#advb_HungToPauPhDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_HungToPauPhDMember_lbl" xml:lang="en-US">Hung To Pau, Ph.D. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_HungToPauPhDMember" xlink:to="advb_HungToPauPhDMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_StevenIFangChengPhDMember" xlink:href="advb-20250630.xsd#advb_StevenIFangChengPhDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_StevenIFangChengPhDMember_lbl" xml:lang="en-US">Steven I-Fang Cheng, Ph.D. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_StevenIFangChengPhDMember" xlink:to="advb_StevenIFangChengPhDMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_ChenYiLeeMember" xlink:href="advb-20250630.xsd#advb_ChenYiLeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_ChenYiLeeMember_lbl" xml:lang="en-US">Chen-Yi Lee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ChenYiLeeMember" xlink:to="advb_ChenYiLeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_AdvanceOnVenturesLimitedMember" xlink:href="advb-20250630.xsd#advb_AdvanceOnVenturesLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_AdvanceOnVenturesLimitedMember_lbl" xml:lang="en-US">Advance On Ventures Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdvanceOnVenturesLimitedMember" xlink:to="advb_AdvanceOnVenturesLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_WellFancyDevelopmentLtdMember" xlink:href="advb-20250630.xsd#advb_WellFancyDevelopmentLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_WellFancyDevelopmentLtdMember_lbl" xml:lang="en-US">Well Fancy Development Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_WellFancyDevelopmentLtdMember" xlink:to="advb_WellFancyDevelopmentLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_ShanghaiJunfuElectronicTechnologyCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiJunfuElectronicTechnologyCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_ShanghaiJunfuElectronicTechnologyCoLtdMember_lbl" xml:lang="en-US">Shanghai Junfu Electronic Technology Co., Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ShanghaiJunfuElectronicTechnologyCoLtdMember" xlink:to="advb_ShanghaiJunfuElectronicTechnologyCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_RelatedCorporationsMember" xlink:href="advb-20250630.xsd#advb_RelatedCorporationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_RelatedCorporationsMember_lbl" xml:lang="en-US">Related Corporations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_RelatedCorporationsMember" xlink:to="advb_RelatedCorporationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Combination [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US">Transaction Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Common stock price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Share issued price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="advb_NetProceedsFromInitialPublicOffering" xlink:href="advb-20250630.xsd#advb_NetProceedsFromInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_NetProceedsFromInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds from IPO (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NetProceedsFromInitialPublicOffering" xlink:to="advb_NetProceedsFromInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl" xml:lang="en-US">Percentage of equity interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Aggregate consideration amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_BusinessCombinationConsiderationNetAssetFairValue" xlink:href="advb-20250630.xsd#advb_BusinessCombinationConsiderationNetAssetFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_BusinessCombinationConsiderationNetAssetFairValue_lbl" xml:lang="en-US">Net asset value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_BusinessCombinationConsiderationNetAssetFairValue" xlink:to="advb_BusinessCombinationConsiderationNetAssetFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Date of incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US">Issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_workingCapital" xlink:href="advb-20250630.xsd#advb_workingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_workingCapital_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_workingCapital" xlink:to="advb_workingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Purchase from common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_ForwardShareSplitIssued" xlink:href="advb-20250630.xsd#advb_ForwardShareSplitIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_ForwardShareSplitIssued_lbl" xml:lang="en-US">Forward share split issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ForwardShareSplitIssued" xlink:to="advb_ForwardShareSplitIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_ForwardShareSplitOutstanding" xlink:href="advb-20250630.xsd#advb_ForwardShareSplitOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_ForwardShareSplitOutstanding_lbl" xml:lang="en-US">Forward share split outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ForwardShareSplitOutstanding" xlink:to="advb_ForwardShareSplitOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Percentage split ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl" xml:lang="en-US">Adjusted share split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl0" xml:lang="en-US">Share split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_lbl" xml:lang="en-US">Capitalized deferred costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareNet" xlink:to="us-gaap_CapitalizedComputerSoftwareNet_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_DeferredInitialPublicOfferingCost" xlink:href="advb-20250630.xsd#advb_DeferredInitialPublicOfferingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_DeferredInitialPublicOfferingCost_lbl" xml:lang="en-US">Deferred initial public offering cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_DeferredInitialPublicOfferingCost" xlink:to="advb_DeferredInitialPublicOfferingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xml:lang="en-US">Tax position, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTerm_lbl" xml:lang="en-US">Remaining loan term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Subject to state income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_NetOperatingLossCarryForwardOffset" xlink:href="advb-20250630.xsd#advb_NetOperatingLossCarryForwardOffset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_NetOperatingLossCarryForwardOffset_lbl" xml:lang="en-US">Net operating loss carry forward offset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NetOperatingLossCarryForwardOffset" xlink:to="advb_NetOperatingLossCarryForwardOffset_lbl"/>
<!-- [WMV6][EroXWN3dzULnFXnUBhcKjx0Zz/FZURIQSQuynOf3lsJ/wTvzM9MWs+R+YWMOJk52d2a8jGwOzjHj5LX1jDV4F4tyioTWmhplI1xKhur84qOqkueCdKAclwIxQfAAy7w0oRnmu8haxlOCPMZT3qH4tBEi2GJS3l8EM71bueBtGNhhsuoiCA4255+4hbjWJV8dI+94S1niqRdf0DODxYZimNfQXxGEOwny9hpWhE8QvGk45A9iM9Vc1B8eHJ4CRUJvgSBsh088jWXQLHygflXPn7lA5og7Tvu+3EJWXtxABpCeXRhoN2mter26ebCF1eM8uJT6loNsFefaKr786dLlxM/VT7OXnEcT] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Term of option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Common stock under the plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock options to purchase any shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnsecuredDebt_lbl" xml:lang="en-US">Interest-free loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_WorkingCapitalLoan" xlink:href="advb-20250630.xsd#advb_WorkingCapitalLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_WorkingCapitalLoan_lbl" xml:lang="en-US">Working capital loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_WorkingCapitalLoan" xlink:to="advb_WorkingCapitalLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Payment to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_NumberOfDaysForOperationalExpenses" xlink:href="advb-20250630.xsd#advb_NumberOfDaysForOperationalExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_NumberOfDaysForOperationalExpenses_lbl" xml:lang="en-US">Period of operational expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NumberOfDaysForOperationalExpenses" xlink:to="advb_NumberOfDaysForOperationalExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_StockSplitPolicyTextBlock" xlink:href="advb-20250630.xsd#advb_StockSplitPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_StockSplitPolicyTextBlock_lbl" xml:lang="en-US">Stock split and reverse share split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_StockSplitPolicyTextBlock" xlink:to="advb_StockSplitPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Risks and uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign currency translation and transaction and convenience translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_RelatedPartiesPolicyTextBlock" xlink:href="advb-20250630.xsd#advb_RelatedPartiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_RelatedPartiesPolicyTextBlock_lbl" xml:lang="en-US">Related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_RelatedPartiesPolicyTextBlock" xlink:to="advb_RelatedPartiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock" xlink:href="advb-20250630.xsd#advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred Initial Public Offering (&#8220;IPO&#8221;) costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock" xlink:to="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent accounting pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">Initial Public Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="advb_BeijingYitanJiaruiTechnologyCoLtdMember" xlink:href="advb-20250630.xsd#advb_BeijingYitanJiaruiTechnologyCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_BeijingYitanJiaruiTechnologyCoLtdMember_lbl" xml:lang="en-US">Beijing Yitan Jiarui Technology Co., Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_BeijingYitanJiaruiTechnologyCoLtdMember" xlink:to="advb_BeijingYitanJiaruiTechnologyCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xml:lang="en-US">Business Combination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_ShandongSglcellMedicalDevicesCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShandongSglcellMedicalDevicesCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_ShandongSglcellMedicalDevicesCoLtdMember_lbl" xml:lang="en-US">Shandong Sglcell Medical Devices Co Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ShandongSglcellMedicalDevicesCoLtdMember" xlink:to="advb_ShandongSglcellMedicalDevicesCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_DrHungToPauMember" xlink:href="advb-20250630.xsd#advb_DrHungToPauMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_DrHungToPauMember_lbl" xml:lang="en-US">Dr. Hung To Pau [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_DrHungToPauMember" xlink:to="advb_DrHungToPauMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_SglcellLtdMember" xlink:href="advb-20250630.xsd#advb_SglcellLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_SglcellLtdMember_lbl" xml:lang="en-US">Sglcell Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_SglcellLtdMember" xlink:to="advb_SglcellLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_DrYiLuMember" xlink:href="advb-20250630.xsd#advb_DrYiLuMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_DrYiLuMember_lbl" xml:lang="en-US">Dr. Yi Lu [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_DrYiLuMember" xlink:to="advb_DrYiLuMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_ShareExchangeMember" xlink:href="advb-20250630.xsd#advb_ShareExchangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_ShareExchangeMember_lbl" xml:lang="en-US">Share Exchange [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ShareExchangeMember" xlink:to="advb_ShareExchangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_YiminJinMember" xlink:href="advb-20250630.xsd#advb_YiminJinMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_YiminJinMember_lbl" xml:lang="en-US">Yimin Jin [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_YiminJinMember" xlink:to="advb_YiminJinMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_XiaoyuanLuoMember" xlink:href="advb-20250630.xsd#advb_XiaoyuanLuoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_XiaoyuanLuoMember_lbl" xml:lang="en-US">Xiaoyuan Luo [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_XiaoyuanLuoMember" xlink:to="advb_XiaoyuanLuoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_NanzhenShenMember" xlink:href="advb-20250630.xsd#advb_NanzhenShenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_NanzhenShenMember_lbl" xml:lang="en-US">Nanzhen Shen [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NanzhenShenMember" xlink:to="advb_NanzhenShenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_JianWangMember" xlink:href="advb-20250630.xsd#advb_JianWangMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_JianWangMember_lbl" xml:lang="en-US">Jian Wang [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_JianWangMember" xlink:to="advb_JianWangMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_QiangChenMember" xlink:href="advb-20250630.xsd#advb_QiangChenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_QiangChenMember_lbl" xml:lang="en-US">Qiang Chen [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_QiangChenMember" xlink:to="advb_QiangChenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_HanyuAssetsCoLtdMember" xlink:href="advb-20250630.xsd#advb_HanyuAssetsCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_HanyuAssetsCoLtdMember_lbl" xml:lang="en-US">Hanyu Assets Co. Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_HanyuAssetsCoLtdMember" xlink:to="advb_HanyuAssetsCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_NewlinkTechnologyIncMember" xlink:href="advb-20250630.xsd#advb_NewlinkTechnologyIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_NewlinkTechnologyIncMember_lbl" xml:lang="en-US">Newlink Technology Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NewlinkTechnologyIncMember" xlink:to="advb_NewlinkTechnologyIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">US [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_TwoThousandTwentyThreePlanMember" xlink:href="advb-20250630.xsd#advb_TwoThousandTwentyThreePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="advb_TwoThousandTwentyThreePlanMember_lbl" xml:lang="en-US">2023 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_TwoThousandTwentyThreePlanMember" xlink:to="advb_TwoThousandTwentyThreePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredDebtMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnsecuredDebtMember_lbl" xml:lang="en-US">Unsecured Debt [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtMember" xlink:to="us-gaap_UnsecuredDebtMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl" xml:lang="en-US">Subsidiary of LLC or LP [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl" xml:lang="en-US">Schedule of Subsidiaries [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntercompanyForeignCurrencyBalanceNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain_lbl" xml:lang="en-US">Intra-Entity Foreign Currency Balance, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable" xlink:href="advb-20250630.xsd#advb_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates used in Preparing Financial Statements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable" xlink:to="advb_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenForwardForeignCurrencyContractLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OpenForwardForeignCurrencyContractLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OpenForwardForeignCurrencyContractLineItems_lbl" xml:lang="en-US">Schedule of Currency Exchange Rates used in Preparing Financial Statements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenForwardForeignCurrencyContractLineItems" xlink:to="us-gaap_OpenForwardForeignCurrencyContractLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US">Schedule of Intangible Assets are stated at Cost less Accumulated Amortization and Impairment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:href="advb-20250630.xsd#advb_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:to="advb_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0" xml:lang="en-US">Schedule of Equipment, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="advb_IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable" xlink:href="advb-20250630.xsd#advb_IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable_lbl" xml:lang="en-US">Intangible Assets, Net - Schedule of Company&#8217;s Finite-Lived Intangible Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable" xlink:to="advb_IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Schedule of Company&#8217;s Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable" xlink:href="advb-20250630.xsd#advb_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable_lbl" xml:lang="en-US">Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties &#8211; Related Corporarions, Non-Current - Schedule of Account Payable, Accrued Expenses and Other Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable" xlink:to="advb_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableLineItems_lbl" xml:lang="en-US">Schedule of Account Payable, Accrued Expenses and Other Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_DividendsPayableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Combination [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionDomain_lbl" xml:lang="en-US">Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_OrganizationandPrincipalActivitiesDetailsTable" xlink:href="advb-20250630.xsd#advb_OrganizationandPrincipalActivitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_OrganizationandPrincipalActivitiesDetailsTable_lbl" xml:lang="en-US">Organization and Principal Activities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_OrganizationandPrincipalActivitiesDetailsTable" xlink:to="advb_OrganizationandPrincipalActivitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Organization and Principal Activities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_LiquidityandGoingConcernDetailsTable" xlink:href="advb-20250630.xsd#advb_LiquidityandGoingConcernDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_LiquidityandGoingConcernDetailsTable_lbl" xml:lang="en-US">Liquidity and Going Concern (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_LiquidityandGoingConcernDetailsTable" xlink:to="advb_LiquidityandGoingConcernDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US">Liquidity and Going Concern [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="advb-20250630.xsd#advb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="advb_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_EquityDetailsTable" xlink:href="advb-20250630.xsd#advb_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_EquityDetailsTable" xlink:to="advb_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Jurisdiction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_IncomeTaxesDetailsTable" xlink:href="advb-20250630.xsd#advb_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_IncomeTaxesDetailsTable" xlink:to="advb_IncomeTaxesDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl0" xml:lang="en-US">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_StockOptionDetailsTable" xlink:href="advb-20250630.xsd#advb_StockOptionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_StockOptionDetailsTable_lbl" xml:lang="en-US">Stock Option (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_StockOptionDetailsTable" xlink:to="advb_StockOptionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Stock Option [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_RelatedPartyTransactionsDetailsTable" xlink:href="advb-20250630.xsd#advb_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_RelatedPartyTransactionsDetailsTable" xlink:to="advb_RelatedPartyTransactionsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl0" xml:lang="en-US">Related Party Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders_lbl0" xml:lang="en-US">Amount of increase to additional paid-in capital (APIC) for waiver of amount due to related parties &#8211; major stockholders.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" xlink:to="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations_lbl0" xml:lang="en-US">Amount of increase (decrease) in additional paid-in capital (APIC) waiver of the amount due to related parties &#8211; related corporations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" xlink:to="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_BusinessCombinationConsiderationNetAssetFairValue_lbl0" xml:lang="en-US">The amount of business combination consideration net assets fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_BusinessCombinationConsiderationNetAssetFairValue" xlink:to="advb_BusinessCombinationConsiderationNetAssetFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_DeferredInitialPublicOfferingCost_lbl0" xml:lang="en-US">Deferred initial public offering cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_DeferredInitialPublicOfferingCost" xlink:to="advb_DeferredInitialPublicOfferingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock_lbl0" xml:lang="en-US">The disclosure of accounting policies for deferred initial public offering (&#8220;IPO&#8221;) costs .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock" xlink:to="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_EffectOfTaxLossesCarryForwards_lbl0" xml:lang="en-US">Effect of tax losses carry forwards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_EffectOfTaxLossesCarryForwards" xlink:to="advb_EffectOfTaxLossesCarryForwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_ForwardShareSplitIssued_lbl0" xml:lang="en-US">Forward share split issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ForwardShareSplitIssued" xlink:to="advb_ForwardShareSplitIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_ForwardShareSplitOutstanding_lbl0" xml:lang="en-US">Forward share split outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ForwardShareSplitOutstanding" xlink:to="advb_ForwardShareSplitOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate" xlink:to="advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_NetOperatingLossCarryForwardOffset_lbl0" xml:lang="en-US">Represents the percentage of net operating loss carry forward offset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NetOperatingLossCarryForwardOffset" xlink:to="advb_NetOperatingLossCarryForwardOffset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_NetProceedsFromInitialPublicOffering_lbl0" xml:lang="en-US">The amount of net proceeds from initial public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NetProceedsFromInitialPublicOffering" xlink:to="advb_NetProceedsFromInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_NumberOfDaysForOperationalExpenses_lbl0" xml:lang="en-US">Represent number of days operational expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NumberOfDaysForOperationalExpenses" xlink:to="advb_NumberOfDaysForOperationalExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_OtherNonoperatingIncomeExpenseGross_lbl0" xml:lang="en-US">Amount of income (expense) related to nonoperating activities, classified as gross.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_OtherNonoperatingIncomeExpenseGross" xlink:to="advb_OtherNonoperatingIncomeExpenseGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_PrepaidExpensesAndOtherCurrentAssetGross_lbl0" xml:lang="en-US">Represents the amount of prepaid expenses and other current asset, gross.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_PrepaidExpensesAndOtherCurrentAssetGross" xlink:to="advb_PrepaidExpensesAndOtherCurrentAssetGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_RelatedPartiesPolicyTextBlock_lbl0" xml:lang="en-US">Related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_RelatedPartiesPolicyTextBlock" xlink:to="advb_RelatedPartiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock_lbl0" xml:lang="en-US">Schedule of estimated useful lives of equipment, net at cost less accumulated depreciation and impairment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock" xlink:to="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_StockSplitPolicyTextBlock_lbl0" xml:lang="en-US">Stock Split and Reverse Share Split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_StockSplitPolicyTextBlock" xlink:to="advb_StockSplitPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_WorkingCapitalLoan_lbl0" xml:lang="en-US">The amount of working capital loan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_WorkingCapitalLoan" xlink:to="advb_WorkingCapitalLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="advb_workingCapital_lbl0" xml:lang="en-US">Amount of total working capital as defined by regulatory framework.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_workingCapital" xlink:to="advb_workingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_LabEquipmentMember_lbl0" xml:lang="en-US">Lab Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_LabEquipmentMember" xlink:to="advb_LabEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="advb_ScheduleOfEquipmentNetAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ScheduleOfEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ScheduleOfEquipmentNetAbstract" xlink:to="advb_ScheduleOfEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidTaxes_lbl0" xml:lang="en-US">Prepaid Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl0" xml:lang="en-US">Computer Software, Intangible Asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Business Purpose</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_CurrencyExchangeAverageRateMember_lbl0" xml:lang="en-US">Currency Exchange Average Rate Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_CurrencyExchangeAverageRateMember" xlink:to="advb_CurrencyExchangeAverageRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_lbl0" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_AmountDueToRelatedPartiesRelatedCorporationsAbstract_lbl0" xml:lang="en-US">Amount Due To Related Parties Related Corporations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AmountDueToRelatedPartiesRelatedCorporationsAbstract" xlink:to="advb_AmountDueToRelatedPartiesRelatedCorporationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl1" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_RelatedPartiesPolicyTextBlock_lbl1" xml:lang="en-US">Related Parties Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_RelatedPartiesPolicyTextBlock" xlink:to="advb_RelatedPartiesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_HKD_lbl0" xml:lang="en-US">Hong Kong, Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_HKD" xlink:to="currency_HKD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_HK_lbl1" xml:lang="en-US">HONG KONG</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="advb_ScheduleOfEstimatedUsefulLivesAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfEstimatedUsefulLivesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ScheduleOfEstimatedUsefulLivesAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Useful Lives Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ScheduleOfEstimatedUsefulLivesAbstract" xlink:to="advb_ScheduleOfEstimatedUsefulLivesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="advb_ScheduleOfSubsidiariesAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfSubsidiariesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ScheduleOfSubsidiariesAbstract_lbl" xml:lang="en-US">Schedule Of Subsidiaries Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ScheduleOfSubsidiariesAbstract" xlink:to="advb_ScheduleOfSubsidiariesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl0" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_AdvanceOnVenturesLimitedMember_lbl0" xml:lang="en-US">Advance On Ventures Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdvanceOnVenturesLimitedMember" xlink:to="advb_AdvanceOnVenturesLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_PrepaidExpensesAndOtherCurrentAssetGross_lbl1" xml:lang="en-US">Prepaid Expenses And Other Current Asset Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_PrepaidExpensesAndOtherCurrentAssetGross" xlink:to="advb_PrepaidExpensesAndOtherCurrentAssetGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_RelatedCorporationsMember_lbl0" xml:lang="en-US">Related Corporations Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_RelatedCorporationsMember" xlink:to="advb_RelatedCorporationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ChenYiLeeMember_lbl0" xml:lang="en-US">Chen Yi Lee Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ChenYiLeeMember" xlink:to="advb_ChenYiLeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_NV_lbl1" xml:lang="en-US">NEVADA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NV" xlink:to="stpr_NV_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_WellFancyDevelopmentLtdMember_lbl0" xml:lang="en-US">Well Fancy Development Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_WellFancyDevelopmentLtdMember" xlink:to="advb_WellFancyDevelopmentLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_YiLuPhDMember_lbl1" xml:lang="en-US">Yi Lu Ph DMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_YiLuPhDMember" xlink:to="advb_YiLuPhDMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl0" xml:lang="en-US">Income Tax Examination, Likelihood of Unfavorable Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTerm_lbl0" xml:lang="en-US">Long-Term Debt, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_WorkingCapitalLoan_lbl1" xml:lang="en-US">Working Capital Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_WorkingCapitalLoan" xlink:to="advb_WorkingCapitalLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ShandongSglcellMedicalDevicesCoLtdMember_lbl0" xml:lang="en-US">Shandong Sglcell Medical Devices Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ShandongSglcellMedicalDevicesCoLtdMember" xlink:to="advb_ShandongSglcellMedicalDevicesCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_MajorStockholdersMember_lbl1" xml:lang="en-US">Major Stockholders Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_MajorStockholdersMember" xlink:to="advb_MajorStockholdersMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="advb_ScheduleOfCurrencyExchangeRatesUsedInPreparingFinancialStatementsAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfCurrencyExchangeRatesUsedInPreparingFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ScheduleOfCurrencyExchangeRatesUsedInPreparingFinancialStatementsAbstract_lbl" xml:lang="en-US">Schedule Of Currency Exchange Rates Used In Preparing Financial Statements Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ScheduleOfCurrencyExchangeRatesUsedInPreparingFinancialStatementsAbstract" xlink:to="advb_ScheduleOfCurrencyExchangeRatesUsedInPreparingFinancialStatementsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_NonCurrentAbstract_lbl0" xml:lang="en-US">Non Current Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NonCurrentAbstract" xlink:to="advb_NonCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ShareExchangeMember_lbl0" xml:lang="en-US">Share Exchange Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ShareExchangeMember" xlink:to="advb_ShareExchangeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_JianWangMember_lbl0" xml:lang="en-US">Jian Wang Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_JianWangMember" xlink:to="advb_JianWangMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl0" xml:lang="en-US">CHINA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ForwardShareSplitIssued_lbl1" xml:lang="en-US">Forward Share Split Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ForwardShareSplitIssued" xlink:to="advb_ForwardShareSplitIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_NumberOfDaysForOperationalExpenses_lbl1" xml:lang="en-US">Number Of Days For Operational Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NumberOfDaysForOperationalExpenses" xlink:to="advb_NumberOfDaysForOperationalExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_CNY_lbl0" xml:lang="en-US">China, Yuan Renminbi</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CNY" xlink:to="currency_CNY_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_lbl0" xml:lang="en-US">Other Significant Noncash Transaction, Value of Consideration Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Estimated Useful Lives Of Equipment Net At Cost Less Accumulated Depreciation And Impairment Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock" xlink:to="advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0" xml:lang="en-US">Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_NetOperatingLossCarryForwardOffset_lbl1" xml:lang="en-US">Net Operating Loss Carry Forward Offset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NetOperatingLossCarryForwardOffset" xlink:to="advb_NetOperatingLossCarryForwardOffset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_NewlinkTechnologyIncMember_lbl0" xml:lang="en-US">Newlink Technology Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NewlinkTechnologyIncMember" xlink:to="advb_NewlinkTechnologyIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_HanyuAssetsCoLtdMember_lbl0" xml:lang="en-US">Hanyu Assets Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_HanyuAssetsCoLtdMember" xlink:to="advb_HanyuAssetsCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_TW_lbl0" xml:lang="en-US">TAIWAN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_TW" xlink:to="country_TW_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl2" xml:lang="en-US">Repayments of Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl2" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl0" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interest, Share Issued, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ShanghaiJunfuElectronicTechnologyCoLtdMember_lbl0" xml:lang="en-US">Shanghai Junfu Electronic Technology Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ShanghaiJunfuElectronicTechnologyCoLtdMember" xlink:to="advb_ShanghaiJunfuElectronicTechnologyCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_lbl0" xml:lang="en-US">Allowance for Credit Loss, Receivable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:to="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl0" xml:lang="en-US">Leases, Operating [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_YiminJinMember_lbl0" xml:lang="en-US">Yimin Jin Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_YiminJinMember" xlink:to="advb_YiminJinMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_SglcellLtdMember_lbl0" xml:lang="en-US">Sglcell Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_SglcellLtdMember" xlink:to="advb_SglcellLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl0" xml:lang="en-US">Other Nonoperating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl1" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl0" xml:lang="en-US">Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_DeferredInitialPublicOfferingCost_lbl1" xml:lang="en-US">Deferred Initial Public Offering Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_DeferredInitialPublicOfferingCost" xlink:to="advb_DeferredInitialPublicOfferingCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorityShareholderMember_lbl1" xml:lang="en-US">Majority Shareholder [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorityShareholderMember" xlink:to="us-gaap_MajorityShareholderMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateJointVentureMember_lbl2" xml:lang="en-US">Corporate Joint Venture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateJointVentureMember" xlink:to="us-gaap_CorporateJointVentureMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_NameOfRelatedPartyAbstract_lbl0" xml:lang="en-US">Name Of Related Party Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NameOfRelatedPartyAbstract" xlink:to="advb_NameOfRelatedPartyAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_BusinessCombinationConsiderationNetAssetFairValue_lbl1" xml:lang="en-US">Business Combination Consideration Net Asset Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_BusinessCombinationConsiderationNetAssetFairValue" xlink:to="advb_BusinessCombinationConsiderationNetAssetFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0" xml:lang="en-US">Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_AdvancedBiomedIncMember_lbl0" xml:lang="en-US">Advanced Biomed Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdvancedBiomedIncMember" xlink:to="advb_AdvancedBiomedIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_StockSplitPolicyTextBlock_lbl1" xml:lang="en-US">Stock Split Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_StockSplitPolicyTextBlock" xlink:to="advb_StockSplitPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl1" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_CurrentAbstract_lbl0" xml:lang="en-US">Current Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_CurrentAbstract" xlink:to="advb_CurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_TwoThousandTwentyThreePlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Three Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_TwoThousandTwentyThreePlanMember" xlink:to="advb_TwoThousandTwentyThreePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_NetProceedsFromInitialPublicOffering_lbl1" xml:lang="en-US">Net Proceeds From Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NetProceedsFromInitialPublicOffering" xlink:to="advb_NetProceedsFromInitialPublicOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl2" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_UnlabeledAbstract0" xlink:to="advb_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl0" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock_lbl1" xml:lang="en-US">Deferred Initial Public Offering IPOCosts Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock" xlink:to="advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0" xml:lang="en-US">Other Nonoperating Income and Expense [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl2" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_AdvancedBiomedHKLimitedMember_lbl0" xml:lang="en-US">Advanced Biomed HKLimited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdvancedBiomedHKLimitedMember" xlink:to="advb_AdvancedBiomedHKLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl0" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl0" xml:lang="en-US">Accrued Payroll Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_NameOfRelatedPartyAbstract1_lbl0" xml:lang="en-US">Name Of Related Party Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NameOfRelatedPartyAbstract1" xlink:to="advb_NameOfRelatedPartyAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ShanghaiSglcellBiotechCoLtdMember_lbl1" xml:lang="en-US">Shanghai Sglcell Biotech Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ShanghaiSglcellBiotechCoLtdMember" xlink:to="advb_ShanghaiSglcellBiotechCoLtdMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl1" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US">Income Tax Reconciliation Income Tax Expense Benefit At Calculated Federal Statutory Income Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate" xlink:to="advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders_lbl1" xml:lang="en-US">Adjustments To Additional Paid In Capital Waiver Of Amount Due To Related Parties Major Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" xlink:to="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_AdvancedBiomedIncTaiwanMember_lbl0" xml:lang="en-US">Advanced Biomed Inc Taiwan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdvancedBiomedIncTaiwanMember" xlink:to="advb_AdvancedBiomedIncTaiwanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_NameOfRelatedPartyAbstract0_lbl0" xml:lang="en-US">Name Of Related Party Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NameOfRelatedPartyAbstract0" xlink:to="advb_NameOfRelatedPartyAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_StevenIFangChengPhDMember_lbl0" xml:lang="en-US">Steven IFang Cheng Ph DMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_StevenIFangChengPhDMember" xlink:to="advb_StevenIFangChengPhDMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ForwardShareSplitOutstanding_lbl1" xml:lang="en-US">Forward Share Split Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ForwardShareSplitOutstanding" xlink:to="advb_ForwardShareSplitOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebt_lbl0" xml:lang="en-US">Unsecured Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl2" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_UnlabeledAbstract" xlink:to="advb_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_HungToPauPhDMember_lbl0" xml:lang="en-US">Hung To Pau Ph DMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_HungToPauPhDMember" xlink:to="advb_HungToPauPhDMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_BeijingYitanJiaruiTechnologyCoLtdMember_lbl0" xml:lang="en-US">Beijing Yitan Jiarui Technology Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_BeijingYitanJiaruiTechnologyCoLtdMember" xlink:to="advb_BeijingYitanJiaruiTechnologyCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_XiaoyuanLuoMember_lbl0" xml:lang="en-US">Xiaoyuan Luo Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_XiaoyuanLuoMember" xlink:to="advb_XiaoyuanLuoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_DrHungToPauMember_lbl0" xml:lang="en-US">Dr Hung To Pau Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_DrHungToPauMember" xlink:to="advb_DrHungToPauMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl1" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="advb_ScheduleOfRelatedPartiesTransactionsAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfRelatedPartiesTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ScheduleOfRelatedPartiesTransactionsAbstract_lbl" xml:lang="en-US">Schedule Of Related Parties Transactions Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ScheduleOfRelatedPartiesTransactionsAbstract" xlink:to="advb_ScheduleOfRelatedPartiesTransactionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock_lbl0" xml:lang="en-US">Schedule of Other Nonoperating Expense, by Component [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_OtherNonoperatingIncomeExpenseGross_lbl1" xml:lang="en-US">Other Nonoperating Income Expense Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_OtherNonoperatingIncomeExpenseGross" xlink:to="advb_OtherNonoperatingIncomeExpenseGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl0" xml:lang="en-US">Business Combination, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0" xml:lang="en-US">Business Combination, Series of Individually Immaterial Business Combinations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_EffectOfTaxLossesCarryForwards_lbl1" xml:lang="en-US">Effect Of Tax Losses Carry Forwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_EffectOfTaxLossesCarryForwards" xlink:to="advb_EffectOfTaxLossesCarryForwards_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations_lbl1" xml:lang="en-US">Adjustments To Additional Paid In Capital Waiver Of Amount Due To Related Parties Related Corporations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" xlink:to="advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_FiscalYearEndCurrencyRateMember_lbl0" xml:lang="en-US">Fiscal Year End Currency Rate Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_FiscalYearEndCurrencyRateMember" xlink:to="advb_FiscalYearEndCurrencyRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_NanzhenShenMember_lbl0" xml:lang="en-US">Nanzhen Shen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_NanzhenShenMember" xlink:to="advb_NanzhenShenMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_AmountDueToRelatedPartiesMajorStockholdersAbstract_lbl0" xml:lang="en-US">Amount Due To Related Parties Major Stockholders Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_AmountDueToRelatedPartiesMajorStockholdersAbstract" xlink:to="advb_AmountDueToRelatedPartiesMajorStockholdersAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="advb_ScheduleOfAccountPayableAccruedExpensesAndOtherLiabilitiesAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfAccountPayableAccruedExpensesAndOtherLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ScheduleOfAccountPayableAccruedExpensesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Account Payable Accrued Expenses And Other Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ScheduleOfAccountPayableAccruedExpensesAndOtherLiabilitiesAbstract" xlink:to="advb_ScheduleOfAccountPayableAccruedExpensesAndOtherLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="advb_ScheduleOfIntangibleAssetsAreStatedAtCostLessAccumulatedAmortizationAndImpairmentAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfIntangibleAssetsAreStatedAtCostLessAccumulatedAmortizationAndImpairmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ScheduleOfIntangibleAssetsAreStatedAtCostLessAccumulatedAmortizationAndImpairmentAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets Are Stated At Cost Less Accumulated Amortization And Impairment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ScheduleOfIntangibleAssetsAreStatedAtCostLessAccumulatedAmortizationAndImpairmentAbstract" xlink:to="advb_ScheduleOfIntangibleAssetsAreStatedAtCostLessAccumulatedAmortizationAndImpairmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_TWD_lbl0" xml:lang="en-US">Taiwan, New Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_TWD" xlink:to="currency_TWD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareNet_lbl0" xml:lang="en-US">Capitalized Computer Software, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareNet" xlink:to="us-gaap_CapitalizedComputerSoftwareNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebtMember_lbl0" xml:lang="en-US">Unsecured Debt [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtMember" xlink:to="us-gaap_UnsecuredDebtMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_QiangChenMember_lbl0" xml:lang="en-US">Qiang Chen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_QiangChenMember" xlink:to="advb_QiangChenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl0" xml:lang="en-US">Deferred Costs, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_DrYiLuMember_lbl0" xml:lang="en-US">Dr Yi Lu Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_DrYiLuMember" xlink:to="advb_DrYiLuMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="advb_ScheduleOfCompanySFiniteLivedIntangibleAssetsAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfCompanySFiniteLivedIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_ScheduleOfCompanySFiniteLivedIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Company SFinite Lived Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_ScheduleOfCompanySFiniteLivedIntangibleAssetsAbstract" xlink:to="advb_ScheduleOfCompanySFiniteLivedIntangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Description of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="advb_workingCapital_lbl1" xml:lang="en-US">working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="advb_workingCapital" xlink:to="advb_workingCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl1" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl0" xml:lang="en-US">Deposits Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>29
<FILENAME>advb-20250630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Oct 08 20:28:35 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConsolidatedBalanceSheet" roleURI="http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConsolidatedIncomeStatement" roleURI="http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ShareholdersEquityType2or3" roleURI="http://www.advanbiomed.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConsolidatedCashFlow" roleURI="http://www.advanbiomed.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_OrganizationandPrincipalActivities" roleURI="http://www.advanbiomed.com/role/OrganizationandPrincipalActivities"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_LiquidityandGoingConcern" roleURI="http://www.advanbiomed.com/role/LiquidityandGoingConcern"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_PrepaidExpensesandOtherCurrentAssetsNet" roleURI="http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_EquipmentNet" roleURI="http://www.advanbiomed.com/role/EquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_IntangibleAssetsNet" roleURI="http://www.advanbiomed.com/role/IntangibleAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrent" roleURI="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrent"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_OtherExpenseNet" roleURI="http://www.advanbiomed.com/role/OtherExpenseNet"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_Equity" roleURI="http://www.advanbiomed.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_IncomeTaxes" roleURI="http://www.advanbiomed.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_StockOption" roleURI="http://www.advanbiomed.com/role/StockOption"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_RelatedPartyTransactions" roleURI="http://www.advanbiomed.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SegmentInformation" roleURI="http://www.advanbiomed.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConcentrationsandRisks" roleURI="http://www.advanbiomed.com/role/ConcentrationsandRisks"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_CommitmentsandContingencies" roleURI="http://www.advanbiomed.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SubsequentEvents" roleURI="http://www.advanbiomed.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_AccountingPoliciesByPolicy" roleURI="http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_OrganizationandPrincipalActivitiesTables" roleURI="http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_PrepaidExpensesandOtherCurrentAssetsNetTables" roleURI="http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_EquipmentNetTables" roleURI="http://www.advanbiomed.com/role/EquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_IntangibleAssetsNetTables" roleURI="http://www.advanbiomed.com/role/IntangibleAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentTables" roleURI="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_OtherExpenseNetTables" roleURI="http://www.advanbiomed.com/role/OtherExpenseNetTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_IncomeTaxesTables" roleURI="http://www.advanbiomed.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_RelatedPartyTransactionsTables" roleURI="http://www.advanbiomed.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SegmentInformationTables" roleURI="http://www.advanbiomed.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_CommitmentsandContingenciesTables" roleURI="http://www.advanbiomed.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofSubsidiariesTable" roleURI="http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable" roleURI="http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable" roleURI="http://www.advanbiomed.com/role/ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofEstimatedUsefulLivesTable" roleURI="http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable" roleURI="http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofEquipmentNetTable" roleURI="http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofCompanysFiniteLivedIntangibleAssetsTable" roleURI="http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable" roleURI="http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofOtherExpenseNetTable" roleURI="http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofReconcilestheOperatingProfitTable" roleURI="http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofComponentofDeferredTaxAssetsTable" roleURI="http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofRelatedPartiesTransactionsTable" roleURI="http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable" roleURI="http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable" roleURI="http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ScheduleofFutureMinimumLeasePaymentsTable" roleURI="http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_OrganizationandPrincipalActivitiesDetails" roleURI="http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_LiquidityandGoingConcernDetails" roleURI="http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_EquipmentNetDetails" roleURI="http://www.advanbiomed.com/role/EquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentDetails" roleURI="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_EquityDetails" roleURI="http://www.advanbiomed.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_IncomeTaxesDetails" roleURI="http://www.advanbiomed.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_StockOptionDetails" roleURI="http://www.advanbiomed.com/role/StockOptionDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_RelatedPartyTransactionsDetails" roleURI="http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_SegmentInformationDetails" roleURI="http://www.advanbiomed.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="advb-20250630.xsd#advb_r_ConcentrationsandRisksDetails" roleURI="http://www.advanbiomed.com/role/ConcentrationsandRisksDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateJointVentureMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_CorporateJointVentureMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorityShareholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MajorityShareholderMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_MajorityShareholderMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateJointVentureMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_CorporateJointVentureMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" xlink:href="advb-20250630.xsd#advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" xlink:href="advb-20250630.xsd#advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MajorStockholdersMember" xlink:href="advb-20250630.xsd#advb_MajorStockholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MajorStockholdersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateJointVentureMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_CorporateJointVentureMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/OrganizationandPrincipalActivities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/LiquidityandGoingConcern" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/EquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/IntangibleAssetsNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrent" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/OtherExpenseNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/StockOption" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ConcentrationsandRisks" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockSplitPolicyTextBlock" xlink:href="advb-20250630.xsd#advb_StockSplitPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="StockSplitPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesPolicyTextBlock" xlink:href="advb-20250630.xsd#advb_RelatedPartiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RelatedPartiesPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredInitialPublicOfferingIPOCostsPolicyTextBlock" xlink:href="advb-20250630.xsd#advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DeferredInitialPublicOfferingIPOCostsPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock" xlink:href="advb-20250630.xsd#advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/EquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/IntangibleAssetsNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/OtherExpenseNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/SegmentInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSubsidiariesAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfSubsidiariesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSubsidiariesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AdvancedBiomedIncMember" xlink:href="advb-20250630.xsd#advb_AdvancedBiomedIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AdvancedBiomedIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvancedBiomedIncTaiwanMember" xlink:href="advb-20250630.xsd#advb_AdvancedBiomedIncTaiwanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AdvancedBiomedIncTaiwanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvancedBiomedHKLimitedMember" xlink:href="advb-20250630.xsd#advb_AdvancedBiomedHKLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AdvancedBiomedHKLimitedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShanghaiSglcellBiotechCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiSglcellBiotechCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ShanghaiSglcellBiotechCoLtdMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCurrencyExchangeRatesUsedInPreparingFinancialStatementsAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfCurrencyExchangeRatesUsedInPreparingFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable" xlink:href="advb-20250630.xsd#advb_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenForwardForeignCurrencyContractLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OpenForwardForeignCurrencyContractLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCurrencyExchangeRatesUsedInPreparingFinancialStatementsAbstract" xlink:to="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FiscalYearEndCurrencyRateMember" xlink:href="advb-20250630.xsd#advb_FiscalYearEndCurrencyRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:to="FiscalYearEndCurrencyRateMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrencyExchangeAverageRateMember" xlink:href="advb-20250630.xsd#advb_CurrencyExchangeAverageRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis" xlink:to="CurrencyExchangeAverageRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable" xlink:to="srt_CurrencyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="currency_TWD" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_TWD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_TWD" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_CNY"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_CNY" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_HKD" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_HKD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_HKD" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable" xlink:to="us-gaap_OpenForwardForeignCurrencyContractLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OpenForwardForeignCurrencyContractLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAreStatedAtCostLessAccumulatedAmortizationAndImpairmentAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfIntangibleAssetsAreStatedAtCostLessAccumulatedAmortizationAndImpairmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAreStatedAtCostLessAccumulatedAmortizationAndImpairmentAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfEstimatedUsefulLivesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:href="advb-20250630.xsd#advb_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsefulLivesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidTaxes" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
<!-- [WMV6][rW0wAo72K2Z2GYj4qk42BpMrkTX4cYpinHQYLS9J8TWhQLdX6HAF3SwWy/5vdjdWDIlZSjvY12yLkuv8WEFoJ/rDmTqGGl3crFnztf/Mhcz2zJnC+RyUaaLgdVgjYC4a921IjqJFk16gJGTfWWuwrj4rFdpVyDVCkbfoRSvR00mU8yQwHu30NlwJlQ9Dqz2/3jSxwpKsrKKBwNNmsBgy34iGn9+DP5XdfeNwD7xX2vrDSzfMV4cPLgSfrcLNlCGEJwCu736XZYqEGGufrxOY98RI7oQpn/wsTMRrZ2FB3xC8FP8GWwhXtfNzOgMuGqLU9H2f1IfRay8B8L4dY4pQ1wW4c7KeJqVAkw==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetGross" xlink:href="advb-20250630.xsd#advb_PrepaidExpensesAndOtherCurrentAssetGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="PrepaidExpensesAndOtherCurrentAssetGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEquipmentNetAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LabEquipmentMember" xlink:href="advb-20250630.xsd#advb_LabEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LabEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySFiniteLivedIntangibleAssetsAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfCompanySFiniteLivedIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable" xlink:href="advb-20250630.xsd#advb_IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySFiniteLivedIntangibleAssetsAbstract" xlink:to="IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountPayableAccruedExpensesAndOtherLiabilitiesAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfAccountPayableAccruedExpensesAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable" xlink:href="advb-20250630.xsd#advb_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountPayableAccruedExpensesAndOtherLiabilitiesAbstract" xlink:to="AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorityShareholderMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MajorityShareholderMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_MajorityShareholderMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateJointVentureMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_CorporateJointVentureMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable" xlink:to="us-gaap_DividendsPayableLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentOfOtherExpenseNonoperatingLineItems"/>
    <loc xlink:type="locator" xlink:label="OtherNonoperatingIncomeExpenseGross" xlink:href="advb-20250630.xsd#advb_OtherNonoperatingIncomeExpenseGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:to="OtherNonoperatingIncomeExpenseGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentOfOtherExpenseNonoperatingLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLossAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLossAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="stpr_NV" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NV"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="stpr_NV" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_TW" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_TW"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_TW" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_HK" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate" xlink:href="advb-20250630.xsd#advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfTaxLossesCarryForwards" xlink:href="advb-20250630.xsd#advb_EffectOfTaxLossesCarryForwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="EffectOfTaxLossesCarryForwards" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartiesTransactionsAbstract" xlink:href="advb-20250630.xsd#advb_ScheduleOfRelatedPartiesTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartiesTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="YiLuPhDMember" xlink:href="advb-20250630.xsd#advb_YiLuPhDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="YiLuPhDMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HungToPauPhDMember" xlink:href="advb-20250630.xsd#advb_HungToPauPhDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="HungToPauPhDMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StevenIFangChengPhDMember" xlink:href="advb-20250630.xsd#advb_StevenIFangChengPhDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="StevenIFangChengPhDMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChenYiLeeMember" xlink:href="advb-20250630.xsd#advb_ChenYiLeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChenYiLeeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvanceOnVenturesLimitedMember" xlink:href="advb-20250630.xsd#advb_AdvanceOnVenturesLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AdvanceOnVenturesLimitedMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WellFancyDevelopmentLtdMember" xlink:href="advb-20250630.xsd#advb_WellFancyDevelopmentLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="WellFancyDevelopmentLtdMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShanghaiJunfuElectronicTechnologyCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiJunfuElectronicTechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ShanghaiJunfuElectronicTechnologyCoLtdMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MajorStockholdersMember" xlink:href="advb-20250630.xsd#advb_MajorStockholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MajorStockholdersMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RelatedCorporationsMember" xlink:href="advb-20250630.xsd#advb_RelatedCorporationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedCorporationsMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NameOfRelatedPartyAbstract" xlink:href="advb-20250630.xsd#advb_NameOfRelatedPartyAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="NameOfRelatedPartyAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfRelatedPartyAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NameOfRelatedPartyAbstract0" xlink:href="advb-20250630.xsd#advb_NameOfRelatedPartyAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="NameOfRelatedPartyAbstract0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfRelatedPartyAbstract0" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NameOfRelatedPartyAbstract1" xlink:href="advb-20250630.xsd#advb_NameOfRelatedPartyAbstract1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="NameOfRelatedPartyAbstract1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfRelatedPartyAbstract1" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandPrincipalActivitiesDetailsTable" xlink:href="advb-20250630.xsd#advb_OrganizationandPrincipalActivitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationandPrincipalActivitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="srt_OwnershipAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ShanghaiSglcellBiotechCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiSglcellBiotechCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ShanghaiSglcellBiotechCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChenYiLeeMember" xlink:href="advb-20250630.xsd#advb_ChenYiLeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ChenYiLeeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_TransactionTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeMember" xlink:href="advb-20250630.xsd#advb_ShareExchangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="ShareExchangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ShanghaiSglcellBiotechCoLtdMember_0" xlink:href="advb-20250630.xsd#advb_ShanghaiSglcellBiotechCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="ShanghaiSglcellBiotechCoLtdMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeijingYitanJiaruiTechnologyCoLtdMember" xlink:href="advb-20250630.xsd#advb_BeijingYitanJiaruiTechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="BeijingYitanJiaruiTechnologyCoLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShandongSglcellMedicalDevicesCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShandongSglcellMedicalDevicesCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="ShandongSglcellMedicalDevicesCoLtdMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DrHungToPauMember" xlink:href="advb-20250630.xsd#advb_DrHungToPauMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="DrHungToPauMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SglcellLtdMember" xlink:href="advb-20250630.xsd#advb_SglcellLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="SglcellLtdMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DrYiLuMember" xlink:href="advb-20250630.xsd#advb_DrYiLuMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="DrYiLuMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChenYiLeeMember_0" xlink:href="advb-20250630.xsd#advb_ChenYiLeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="ChenYiLeeMember_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvancedBiomedHKLimitedMember" xlink:href="advb-20250630.xsd#advb_AdvancedBiomedHKLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="AdvancedBiomedHKLimitedMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvanceOnVenturesLimitedMember" xlink:href="advb-20250630.xsd#advb_AdvanceOnVenturesLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="AdvanceOnVenturesLimitedMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YiminJinMember" xlink:href="advb-20250630.xsd#advb_YiminJinMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="YiminJinMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="XiaoyuanLuoMember" xlink:href="advb-20250630.xsd#advb_XiaoyuanLuoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="XiaoyuanLuoMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NanzhenShenMember" xlink:href="advb-20250630.xsd#advb_NanzhenShenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="NanzhenShenMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JianWangMember" xlink:href="advb-20250630.xsd#advb_JianWangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="JianWangMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="QiangChenMember" xlink:href="advb-20250630.xsd#advb_QiangChenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="QiangChenMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HanyuAssetsCoLtdMember" xlink:href="advb-20250630.xsd#advb_HanyuAssetsCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="HanyuAssetsCoLtdMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewlinkTechnologyIncMember" xlink:href="advb-20250630.xsd#advb_NewlinkTechnologyIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="NewlinkTechnologyIncMember" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrYiLuMember_0" xlink:href="advb-20250630.xsd#advb_DrYiLuMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DrYiLuMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandPrincipalActivitiesDetailsTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceedsFromInitialPublicOffering" xlink:href="advb-20250630.xsd#advb_NetProceedsFromInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="NetProceedsFromInitialPublicOffering" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationConsiderationNetAssetFairValue" xlink:href="advb-20250630.xsd#advb_BusinessCombinationConsiderationNetAssetFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="BusinessCombinationConsiderationNetAssetFairValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="LiquidityandGoingConcernDetailsTable" xlink:href="advb-20250630.xsd#advb_LiquidityandGoingConcernDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="LiquidityandGoingConcernDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityandGoingConcernDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityandGoingConcernDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityandGoingConcernDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="workingCapital" xlink:href="advb-20250630.xsd#advb_workingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="workingCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="advb-20250630.xsd#advb_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ShanghaiSglcellBiotechCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiSglcellBiotechCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ShanghaiSglcellBiotechCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ForwardShareSplitIssued" xlink:href="advb-20250630.xsd#advb_ForwardShareSplitIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="ForwardShareSplitIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForwardShareSplitOutstanding" xlink:href="advb-20250630.xsd#advb_ForwardShareSplitOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="ForwardShareSplitOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredInitialPublicOfferingCost" xlink:href="advb-20250630.xsd#advb_DeferredInitialPublicOfferingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="DeferredInitialPublicOfferingCost" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/EquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="advb-20250630.xsd#advb_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="advb-20250630.xsd#advb_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="stpr_NV" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NV"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="stpr_NV" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="country_CN" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_TW" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_TW"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="country_TW" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_HK" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_HK"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="country_HK" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="country_US" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetOperatingLossCarryForwardOffset" xlink:href="advb-20250630.xsd#advb_NetOperatingLossCarryForwardOffset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="NetOperatingLossCarryForwardOffset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/StockOptionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockOptionDetailsTable" xlink:href="advb-20250630.xsd#advb_StockOptionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="StockOptionDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyThreePlanMember" xlink:href="advb-20250630.xsd#advb_TwoThousandTwentyThreePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyThreePlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionDetailsTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="advb-20250630.xsd#advb_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredDebtMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_UnsecuredDebtMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="YiLuPhDMember" xlink:href="advb-20250630.xsd#advb_YiLuPhDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="YiLuPhDMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="HungToPauPhDMember" xlink:href="advb-20250630.xsd#advb_HungToPauPhDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="HungToPauPhDMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WellFancyDevelopmentLtdMember" xlink:href="advb-20250630.xsd#advb_WellFancyDevelopmentLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="WellFancyDevelopmentLtdMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AdvancedBiomedIncTaiwanMember" xlink:href="advb-20250630.xsd#advb_AdvancedBiomedIncTaiwanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AdvancedBiomedIncTaiwanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShanghaiSglcellBiotechCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiSglcellBiotechCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ShanghaiSglcellBiotechCoLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShanghaiJunfuElectronicTechnologyCoLtdMember" xlink:href="advb-20250630.xsd#advb_ShanghaiJunfuElectronicTechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ShanghaiJunfuElectronicTechnologyCoLtdMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_UnsecuredDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapitalLoan" xlink:href="advb-20250630.xsd#advb_WorkingCapitalLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="WorkingCapitalLoan" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.advanbiomed.com/role/ConcentrationsandRisksDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfDaysForOperationalExpenses" xlink:href="advb-20250630.xsd#advb_NumberOfDaysForOperationalExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="NumberOfDaysForOperationalExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Oct. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Advanced Biomed Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001941029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-2177170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="nump">$ 4,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation, Date of Incorporation</a></td>
<td class="text">Jul. 16,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">No. 689-85 Xiaodong Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Yongkang District<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tainan City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">TW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">00000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+ 886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6-3121716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADVB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,640,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">WWC, P.C.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Financial Statements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Advanced Biomed Inc. and its subsidiaries (collectively the &#8220;Company&#8221;) as of June 30, 2025 and 2024, and
the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash flows in each
of the years for the two-year period ended June 30, 2025, and the related notes (collectively referred to as the consolidated financial
statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of
the Company as of June 30, 2025, and 2024, and the results of its operations and its cash flows in each of the years for the two-year
period ended June 30, 2025, in conformity with accounting principles generally accepted in the United States of America.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,903,915<span></span>
</td>
<td class="nump">$ 2,607,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,128,656<span></span>
</td>
<td class="nump">443,137<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,032,571<span></span>
</td>
<td class="nump">3,051,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">331,346<span></span>
</td>
<td class="nump">524,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">65,399<span></span>
</td>
<td class="nump">126,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">118,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred initial public offering (&#8220;IPO&#8221;) costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">638,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,027<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">479,772<span></span>
</td>
<td class="nump">1,409,137<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,512,343<span></span>
</td>
<td class="nump">4,460,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accruals, and other current liabilities (including amount due to related parties &#8211; major stockholders as of June 30, 2025 and 2024, with $172,767 and $113,812 due to related parties &#8211; related corporations, and $916,036 and $674,262 due to related corporations, respectively (1))</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,853,317<span></span>
</td>
<td class="nump">2,670,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease payable - current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,811<span></span>
</td>
<td class="nump">62,211<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,889,128<span></span>
</td>
<td class="nump">2,732,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease payable &#8211; non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,879<span></span>
</td>
<td class="nump">64,529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">145,651<span></span>
</td>
<td class="nump">64,529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,034,779<span></span>
</td>
<td class="nump">2,796,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock $0.001 par value per share; as of June 30, 2025 and 2024; 400,000,000 and 400,000,000 shares authorized; 21,640,000 and 20,000,000 shares issued and outstanding, respectively*</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">21,640<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,347,278<span></span>
</td>
<td class="nump">16,493,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19,233,044)<span></span>
</td>
<td class="num">(15,974,075)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,341,690<span></span>
</td>
<td class="nump">1,123,344<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,477,564<span></span>
</td>
<td class="nump">1,663,258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,512,343<span></span>
</td>
<td class="nump">4,460,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Related corporations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Amount due to related parties &#8211; related corporations, non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 139,772<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">21,640,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">21,640,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Major stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 172,767<span></span>
</td>
<td class="nump">$ 113,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Related corporations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Due to related parties (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 916,036<span></span>
</td>
<td class="nump">$ 674,262<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">See Note 12 for disclosure of related parties amounts.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (909,771)<span></span>
</td>
<td class="num">$ (880,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,111,265)<span></span>
</td>
<td class="num">(1,661,379)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,021,036)<span></span>
</td>
<td class="num">(2,541,572)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,915<span></span>
</td>
<td class="nump">53,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(262,848)<span></span>
</td>
<td class="num">(294,201)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(237,933)<span></span>
</td>
<td class="num">(240,706)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,258,969)<span></span>
</td>
<td class="num">(2,782,278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,258,969)<span></span>
</td>
<td class="num">(2,782,278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation gain, net of taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">218,346<span></span>
</td>
<td class="nump">319,324<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (3,040,623)<span></span>
</td>
<td class="num">$ (2,462,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of shares of common stock in computing net loss per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,525,699<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,525,699<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th" colspan="2"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Accumulated other comprehensive income</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">$ 13,673,365<span></span>
</td>
<td class="nump">$ 804,020<span></span>
</td>
<td class="num">$ (13,191,797)<span></span>
</td>
<td class="nump">$ 1,305,588<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders', window );">Waiver of amount due to related parties &#8211; major stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">1,233,764<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,233,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations', window );">Waiver of amount due to related parties &#8211; related corporations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">1,586,860<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,586,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,782,278)<span></span>
</td>
<td class="num">(2,782,278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="nump">319,324<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">319,324<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">16,493,989<span></span>
</td>
<td class="nump">1,123,344<span></span>
</td>
<td class="num">(15,974,075)<span></span>
</td>
<td class="nump">1,663,258<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,258,969)<span></span>
</td>
<td class="num">(3,258,969)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stocks</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,640<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">4,853,289<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,854,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stocks (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,640,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="nump">218,346<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">218,346<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21,640<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">$ 21,347,278<span></span>
</td>
<td class="nump">$ 1,341,690<span></span>
</td>
<td class="num">$ (19,233,044)<span></span>
</td>
<td class="nump">$ 3,477,564<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">21,640,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for waiver of amount due to related parties &#8211; major stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid-in capital (APIC) waiver of the amount due to related parties &#8211; related corporations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,258,969)<span></span>
</td>
<td class="num">$ (2,782,278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">343,830<span></span>
</td>
<td class="nump">399,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,685,519)<span></span>
</td>
<td class="num">(279,425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable, accruals and other current liabilities</a></td>
<td class="num">(117,661)<span></span>
</td>
<td class="nump">479,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease obligations, net cash</a></td>
<td class="num">(23,709)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(83,027)<span></span>
</td>
<td class="nump">56,127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(5,825,055)<span></span>
</td>
<td class="num">(2,126,340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(31,650)<span></span>
</td>
<td class="num">(74,110)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="num">(31,650)<span></span>
</td>
<td class="num">(74,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance of stock in IPO/(prepayments for IPO costs)</a></td>
<td class="nump">5,493,800<span></span>
</td>
<td class="num">(85,400)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">5,934,301<span></span>
</td>
<td class="nump">1,866,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Foreign currency effect</a></td>
<td class="nump">218,346<span></span>
</td>
<td class="nump">319,324<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash</a></td>
<td class="nump">295,942<span></span>
</td>
<td class="num">(14,306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of the year</a></td>
<td class="nump">2,607,973<span></span>
</td>
<td class="nump">2,622,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at year end</a></td>
<td class="nump">2,903,915<span></span>
</td>
<td class="nump">2,607,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="nump">295,942<span></span>
</td>
<td class="num">(14,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Cash received for interest</a></td>
<td class="nump">24,915<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_MajorStockholdersMember', window );">Major Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related parties</a></td>
<td class="nump">296,507<span></span>
</td>
<td class="nump">294,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments to related parties</a></td>
<td class="num">(237,552)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Related Corporations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related parties</a></td>
<td class="nump">981,546<span></span>
</td>
<td class="nump">1,657,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments to related parties</a></td>
<td class="num">$ (600,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration received in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_MajorStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_MajorStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Principal Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Principal Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND PRINCIPAL ACTIVITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. ORGANIZATION AND PRINCIPAL ACTIVITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2021, Advanced Biomed Inc. (the &#8220;Company&#8221;)
was incorporated in the State of Nevada, as an investment holding company. The Company&#8217;s principal executive offices are located
in Tainan City, Taiwan. The Company has no substantive operations and assets. It is holding Company that holds all of the issued and outstanding
shares of Advanced Biomed HK Limited and Advanced Biomed Inc. (Taiwan).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2025, the Company announced the closing of its initial
public offering (the "Offering") of 1,640,000 shares of common stock (the &#8220;Shares&#8221;), at a public offering price
of US$4.00 per share for total gross proceeds of US$6.56 million. The Company raised total net proceeds of approximately US$5.49 million,
which was reflected in the statement of cash flows, after deducting underwriting discounts and commissions and outstanding offering expenses
upon the completion of listing. The common stock of the Company began trading on the Nasdaq Capital Market under the ticker symbol &#8220;ADVB&#8221;
from March 6, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt"><i>(1)</i></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Establishment of Advanced Biomed HK Limited </i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2021, the Company incorporated a
wholly owned subsidiary, Advanced Biomed HK Limited, in Hong Kong to facilitate market development and commercialization of the Company&#8217;s
oncology products for sale and distribution in the People&#8217;s Republic of China (the &#8220;PRC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt"><i>(2)</i></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Acquisition of Shanghai Sglcell Biotech Co., Ltd. and its subsidiaries</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2022, Advanced Biomed HK Limited
acquired 100% equity interest of Shanghai Sglcell Biotech Co., Ltd. Shanghai Sglcell Biotech Co., Ltd. was established in the PRC on April
12, 2019. It is engaged in the establishment and operation of medical clinics in the PRC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shanghai Sglcell Biotech Co., Ltd. owns 100% equity
interest of two subsidiaries namely 1.) Shandong Sglcell Medical Devices Co., Ltd. and 2.) Nanjing Yitian Biotech Co., Ltd. Shandong Sglcell
Medical Devices Co., Ltd. was incorporated in the PRC on July 8, 2021 to carry out the establishment of medical clinics, and the supply
of medical products and services to clinics in the PRC. Nanjing Yitian Biotech Co., Ltd. was established in the PRC on January 6, 2017.
Nanjing Yitian Biotech Co., Ltd. wholly owns a subsidiary, Beijing Yitan Jiarui Technology Co. Ltd., which was established in the PRC
on October 20, 2017. Both were established to carry out marketing and clinical services in the PRC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 8, 2023, Shanghai Sglcell Biotech Co.,
Ltd. transferred its wholly owned subsidiary, Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co.,
Ltd., to independent third-party individuals at aggregate consideration of CNY500,000 (approximately US$71,942) without any other obligations
arising from the transfer. Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co., Ltd. have not commenced
business activity since it was acquired on January 1, 2022 and the Company believed the transfer will improve in operational efficiency.
The consideration is determined by the Company according to the net assets appraisal report issued by an independent third-party appraisal
company on May 31, 2023, as of the date of May 31, 2023, the net assets value of Nanjing Yitian Biotech Co., Ltd. and its subsidiary,
Beijing Yitan Jiarui Technology Co., Ltd., was CNY498,587 (approximately US$71,739).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 9, 2023, Shandong Sglcell Biotech Co.,
Ltd., the wholly owned subsidiary of Shanghai Sglcell Biotech Co., Ltd., was transferred to independent third-party individuals at zero
consideration without any other obligations arising from the transfer. Shandong Sglcell Biotech Co., Ltd. has been inactive since it was
incorporated on July 8, 2022 and the Company believed the transfer will improve in operational efficiency. The consideration is determined
by the Company according to the net assets appraisal report issued by an independent third-party appraisal company on May 31, 2023, as
of the date of May 31, 2023, the net assets value of Shandong Sglcell Medical Devices Co., Ltd., was zero.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-size: 10pt"><i>(3)</i></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><i>Subsidiary established under Advanced Biomed HK Limited</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advanced Biomed HK Limited incorporated a wholly
owned subsidiary, Sglcell (Huangshan) Biotech Co., Ltd., in the PRC on March 4, 2022; it was established for the expected future manufacturing
of medical devices in the PRC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 15, 2023, Sglcell (Huangshan) Biotech
Co., Ltd., the wholly owned subsidiary of Advanced Biomed HK Limited, was transferred to an independent third-party corporation at zero
consideration without any other obligations arising from the transfers. Sglcell (Huangshan) Biotech Co., Ltd. has been dormant since its
incorporation date from March 4, 2022 and the Company believed the transfer will improve in operational efficiency. The consideration
is determined by the Company according to the net assets appraisal report issued by an independent third-party appraisal company on May
31, 2023, as of the date of May 31, 2023, the net assets value of Shandong Sglcell Medical Devices Co., Ltd., was zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i>&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-size: 10pt"><i>(4)</i></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><i>Reorganization of Advanced Biomed Inc. (Taiwan) </i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advanced Biomed Inc. (Taiwan) was established
in Taiwan on September 1, 2014. It is primarily focused on mainly operates as a research and development of new center for technologies
in the field of oncology to help efficiently and cost-effectively identify and diagnose cancer cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On date of incorporation, July 16, 2021, the Company
issued 8,000,000 shares to Dr. Hung To Pau. On March 15, 2022, Dr. Hung To Pau transferred all of his 8,000,000 shares to Sglcell Ltd,
an exempted company incorporated under the law of Cayman Islands, the sole stockholder of which is Dr. Hung To Pau for a total consideration
of $8,000. The Company was dormant and has no substantive assets. On June 8, 2022, Sglcell Ltd transferred all of its 8,000,000 shares
to Dr. Yi Lu for a total consideration of $8,000. In July 2022, the Company consummated a reorganization of Advanced Biomed Inc. (Taiwan)
under share exchange arrangement of its then existing stockholders, who collectively owned all the equity interests of Advanced Biomed
Inc. (Taiwan) prior to the reorganization, transferred their respective shares in Advanced Biomed Inc. (Taiwan) to the Company. Prior
to the re-organization, Advanced Biomed Inc. (Taiwan) was directly owned and controlled by Dr. Yi Lu and Chen-Yi Lee with 99.93% and 0.07%
beneficial ownership interest, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">The Share Exchange</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to a share exchange agreement (the &#8220;Agreement&#8221;)
dated July 11, 2022, Dr. Yi Lu and Chen-Yi Lee transferred their respective shares in Advanced Biomed Inc. (Taiwan) at the time of the
Agreement, representing in aggregate 100% of the issued share capital of Advanced Biomed Inc. (Taiwan), to the Company. The consideration
for the share transfers was satisfied by the allotment and issuance of an aggregate of 385,257 fully paid up shares of common stock to
Dr. Yi Lu and Chen-Yi Lee. Following the completion of the share exchange and related issuances by and among the Company, Dr. Yi Lu and
Chen-Yi Lee, Advanced Biomed Inc. (Taiwan) ultimately became a wholly-owned subsidiary of the Company, and Dr. Yi Lu and Chen-Yi Lee became
the beneficial owners of the Company with percentage ownerships of 99.99% and 0.01% as of August 12, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequently, on October 24, 2022, the Company
issued 365,368 shares to Chen-Yi Lee, and on October 24, 2022, the Company also issued 2,730,000 shares to Advance On Ventures Limited,
a company incorporated under the law of British Virgin Islands (the &#8220;Ventures Limited&#8221;), the beneficial owners of which are
employees of Advanced Biomed Taiwan. The Company issued 4,405,625 shares, 2,193,750 shares, 2,060,000 shares, 1,511,250 shares, 1,243,750
shares, 1,230,000 shares respectively to Dr. Hung To Pau, Yimin Jin, Xiaoyuan Luo, Nanzhen Shen, Jian Wang and Qiang Chen pursuant to
the Debt-For-Equity Exchange Agreement the Company entered into with the abovementioned stockholders on June 30, 2022 to settle debt of
a total amount of NTD 174,020,033 and RMB22,200,000 (approximately $9.04 million). On October 25, 2022, the Company issued 625,000 shares
to Hanyu Assets Co. Ltd. pursuant to the Investment Agreement the Company entered into with Hanyu Assets Co. Ltd. on June 6, 2022, and
the Company issued 250,000 shares to Newlink Technology Inc. pursuant to the Investment Agreement the Company entered into with Newlink
Technology Inc. on June 6, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of the reorganization, Dr. Yi
Lu&#8217;s percentage of ownerships of the Company became 33.54% as of October 25, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 7, 2022, the Company obtained the
approval of the Investment Commission of the Ministry of Economic Affairs (&#8220;Taiwan Investment Commission&#8221;) for the reorganization,
and the issuance number of which is &#8220;<span style="font-family: Times New Roman, Times, Serif">&#32147;&#23529;&#19968;&#23383;&#31532;</span>11100116890<span style="font-family: Times New Roman, Times, Serif">&#34399;</span>&#8221;.
Additionally, the Bureau of Economic Development of Tainan City Government has also approved the reorganization in accordance with the
Taiwan Company Act on December 26, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to this reorganization, the Company
determined that Advanced Biomed Inc. (Taiwan) is the predecessor entity as the Company is an investment holding company with no business
activities carried out and all of the business of Advanced Biomed Inc. (Taiwan) acquired formed substantially all of the business of
the Company under Rule 405 of Regulation C. To reflect the real economic substance of the Company&#8217;s business under the reorganization,
the accompanying consolidated financial statements were prepared assuming that the share exchange transaction, as disclosed above has
been completed, and the Company exercises control of Advanced Biomed Inc. (Taiwan). The transaction detailed above has been accounted
for as reverse takeover and recapitalization of the Company; whereby the Company (the legal acquirer) is considered the accounting acquiree,
and Advanced Biomed Inc. (Taiwan)(the legal acquiree) is considered as the accounting acquirer. This transaction is deemed to be a continuation
of the business of Advanced Biomed Inc. (Taiwan); therefore, no goodwill has been recorded for this transaction, and the Company&#8217;s
historical financial information prior to the date of the recapitalization transaction is that of Advanced Biomed Inc. (Taiwan) and historical
changes in stockholders&#8217; deficit and its results of operations have been presented from the beginning of the first period presented.
The above-mentioned equity is before the stock split on May 16, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and its subsidiaries are in the table
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="15" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Percentage of effective ownership</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date of <br/> Incorporation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold; vertical-align: top">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold; vertical-align: top">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Place of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>incorporation</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Principal <br/> Activities</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left">Advanced Biomed Inc.</td><td>&#160;</td> <td style="vertical-align: top; text-align: center">July 16, 2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="vertical-align: top; text-align: right">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="vertical-align: top; text-align: right">&#160;</td><td>&#160;</td> <td style="vertical-align: top; text-align: center">Nevada</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">Investment holding</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; width: 25%; text-align: left">Advanced Biomed Inc. (Taiwan)</td><td style="width: 1%">&#160;</td> <td style="vertical-align: top; width: 14%; text-align: center">September 1, 2014</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="vertical-align: top; width: 9%; text-align: right">100</td><td style="vertical-align: top; width: 1%; text-align: right">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="vertical-align: top; width: 9%; text-align: right">100</td><td style="vertical-align: top; width: 1%; text-align: right">%</td><td style="width: 1%">&#160;</td> <td style="vertical-align: top; width: 14%; text-align: center">Taiwan</td><td style="width: 1%">&#160;</td> <td style="vertical-align: top; width: 20%; text-align: left">Research and development of various advanced and innovative microfluidic biochip technologies, and provide the leading application of such technologies in precision oncology detection, diagnosis and treatment</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left">Advanced Biomed HK Limited</td><td>&#160;</td> <td style="vertical-align: top; text-align: center">August 10, 2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">100</td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">100</td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td> <td style="vertical-align: top; text-align: center">Hong Kong</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">Market development</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left">Shanghai Sglcell Biotech Co., Ltd.</td><td>&#160;</td> <td style="vertical-align: top; text-align: center">April 12, 2019</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">100</td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">100</td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td> <td style="vertical-align: top; text-align: center">People&#8217;s Republic of China</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">Clinical-related business</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
are presented assuming that the Company was in existence at the beginning of the first period presented.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Liquidity and Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY AND GOING CONCERN</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. LIQUIDITY AND GOING CONCERN</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in conformity with U.S. GAAP which contemplates continuation of the Company on a going concern basis. The going concern
basis assumes that assets are realized, and liabilities are settled in the ordinary course of business at amounts disclosed in the consolidated
financial statements. The Company&#8217;s ability to continue as a going concern depends upon its ability to develop, register and obtain
regulatory approval for commercial sell of its products to generate positive operating cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To sustain its ability to support the Company&#8217;s
operating activities, the Company may have to consider supplementing its available sources of funds through the following sources:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">raise additional capital; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash generated from upcoming operations; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial support from the Company&#8217;s related party and stockholders as well as third parties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company certain related parties have waived
off the amount due to them as of June 30, 2024, which amounted to $2,820,624 in order to improve the Company&#8217;s working capital.
The Company completed its initial public offering. In the initial public offering, the Company issued 1,640,000 shares of common stock
at a price of US$4.00 per share. The Company received gross proceeds in the amount of US$6.56 million before deducting any underwriting
discounts or expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 6, 2025, the Company entered into a purchase
agreement (the &#8220;ELOC Agreement&#8221;) with HELENA GLOBAL INVESTMENT OPPORTUNITIES I LTD. (the &#8220;Investor&#8221; or &#8220;Selling
Stockholder&#8221;), pursuant to which the Company have the right to issue and sell to the Investor, from time to time as provided therein,
and the Investor is obligated to purchase from us, up to Twenty-Five Million United States Dollars ($25,000,000) of the Company&#8217;s
Common Stock, subject to terms and conditions set forth in the ELOC Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, for the financial year ended June 30,
2025, the Company reported net loss of $3,258,969. In addition, the Company had net cash outflows of $5,825,055 from operating activities
for the financial year ended June 30, 2025. These conditions give rise to substantial doubt as to whether the Company will be able to
continue as a going concern. The consolidated financial statements for the financial years ended June 30, 2025 and 2024 have been prepared
on a going concern basis and do not include any adjustments to reflect the possible future effects on the recoverability and classifications
of assets or the amounts and classifications of liabilities that may result from the inability of the Company to continue as a going concern.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(a) Basis of presentation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;)
and pursuant to the regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(b) Consolidation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the financial statements of the Company and its subsidiaries. All inter-company transactions, if any, and balances due to, due from, long-term
investment subsidiary, and registered paid in capital have been eliminated upon consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business combinations are accounted for using
the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective
fair values as of the acquisition date in the Company&#8217;s consolidated financial statements. Any excess fair value of consideration
transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection
with the business combination are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent
reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in the consolidated statements
of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When the Company determines that assets acquired
do not meet the definition of a business under the acquisition method of accounting, acquired assets is expensed, no goodwill is recorded,
and any contingent consideration is recognized only when it becomes payable or is paid.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(c) Use of estimates</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to useful lives for equipment
and intangible assets, assumptions used in assessing right of use assets, impairment of long-lived assets and uncertain tax position.
Actual results could vary from the estimates and assumptions that were used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(d) Stock split and reverse share
split</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2023, the Company effected a forward
share split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, the Company
now have 100,000,000 common stock issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the
above transactions on a retroactive basis similar to share split or dividend pursuant to ASC 260. All references made to share or per
share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect
the 4 for 1 share split. The shares of common stock retain a par value of $0.001 per share. Accordingly, an amount equal to the par value
of the increased shares resulting from the share split was reclassified from &#8220;Additional paid-in capital&#8221; to &#8220;Common
stock&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 15, 2024, the Company effected the
reverse share split of all issued and outstanding shares of 100,000,000 shares at a ratio of 5:1. As a result of the reverse share split,
the Company now have 20,000,000 common stock issued and outstanding as of the date hereof. Unless indicated or the context otherwise requires,
all number of common stock in this report has been retrospectively adjusted for the reverse share split, as if such reverse share split
occurred on the first day of the years presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(e) Risks and uncertainties</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The main operations of the Company are located
in Taiwan and mainland China. Accordingly, the Company&#8217;s business, financial condition, and results of operations may be influenced
by political, economic, and legal environments in Taiwan and mainland China, as well as by the general state of the economy in these two
countries. The Company&#8217;s results may be adversely affected by changes in the political, regulatory and social conditions in these
two countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&#8217;s operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(f) Foreign currency translation and transaction
and convenience translation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
are presented in the US Dollar (&#8220;US$&#8221;), which is the reporting currency of the Company. The functional currency of the Company
is the US$. Advanced Biomed Inc. (Taiwan) uses New Taiwan dollar (&#8220;NT$&#8221;) as its functional currency. Advanced Biomed HK Limited
uses Hong Kong dollars (&#8220;HKD&#8221;) and Shanghai Sglcell Biotech Co., Ltd. uses Chinese Yuan (&#8220;CNY&#8221;) as their functional
currencies, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities denominated in currencies
other than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the balance sheet
date. Translation gains and losses are recognized in the consolidated statements of income and comprehensive income as other comprehensive
income or loss. Transactions in currencies other than the reporting currency are measured and recorded in the reporting currency at the
exchange rate prevailing on the transaction date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated
statements of income and comprehensive income as other income (other expense).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value of foreign currencies including, the
NT$, CNY and HKD, may fluctuate against the US Dollar. Any significant variations of the aforementioned currencies relative to the US
Dollar may materially affect the Company&#8217;s financial condition in terms of reporting in US Dollar. The following table outlines
the currency exchange rates that were used in preparing the accompanying consolidated financial statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">US$ to NT$ fiscal year end</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29.18</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">32.45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">US$ to NT$ average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.83</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">US$ to CNY fiscal year end</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">US$ to CNY average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.23</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">US$ to HKD fiscal year end</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.81</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">US$ to HKD average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.82</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(g) Fair value measurement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance defines fair value as the
price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded
at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions
that market participants would use when pricing the asset or liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance establishes a fair value hierarchy
that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
A financial instrument&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant
to the fair value measurement. Accounting guidance establishes three levels of inputs that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 1 applies to assets or liabilities for which there are quoted prices, in active markets for identical assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical asset or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3 applies to asset or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash, other current assets, leases payable, accounts
payables, accruals and other current liabilities are financial assets and liabilities. Cash, other current assets, accounts payable, accruals
and other current liabilities are subject to fair value measurement; however, because of their being short term in nature management believes
their carrying values approximate their fair value. Financial instruments are fair value financial assets that are marked to fair value
and are accounted for under as Level 3 under the above hierarchy. The Company accounts for lease payables at amortized cost and has elected
NOT to account for them under the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(h) Related parties</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We adopted ASC 850, Related Party Disclosures,
for the identification of related parties and disclosure of related party transactions for the years ended June 30, 2025 and 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(i) Cash </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash consists of cash on hand, the Company&#8217;s
demand deposit placed with financial institutions, which have original maturities of less than three months and unrestricted as to withdrawal
and use. Deposits are held at highly liquid and well capitalized financial institutions. Risk of loss is not expected by management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(j) Intangible assets, net</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s intangible assets are stated
at cost less accumulated amortization and impairment, if any, and amortized on a straight-line basis over the estimated useful lives of
the assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Category</b></span></td> <td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: justify">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Estimated <br/>
useful lives</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Software</span></td> <td style="white-space: nowrap; text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">3 years</span></td></tr> <tr style="vertical-align: top; "> <td style="width: 88%"><span style="font-size: 10pt">Patents</span></td> <td style="white-space: nowrap; width: 1%; text-align: justify">&#160;</td> <td style="text-align: center; width: 11%"><span style="font-size: 10pt">6 years</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Software represents purchased software and is
amortized straight-line over the Company&#8217;s estimates to generate economic benefits from such software, generally three years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents represent the estimated fair value assigned to finite-lived
intangible assets acquired in a transaction that is accounted for as an acquisition of assets rather than a business combination are initially
recognized in accordance with other application GAAP. Any consideration transferred in excess of the fair value of the assets acquired
is allocated to each asset acquired on a relative fair value basis. Amortization is computed using the straight-line method over the estimated
useful lives of the respective finite-lived intangible assets, generally six years. Intangible assets are reviewed for impairment at least
annually or more frequently if indicators of potential impairment exist. The Company reviews finite-lived intangible assets for impairment
at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be
recoverable. If the carrying value of a finite-lived intangible asset exceeds its fair value, then it is written down to its adjusted
fair value. The Company had previously recognized an impairment loss on certain intangible assets in prior years. The remaining intangible
assets were assessed for impairment as of the balance sheet date, and management concluded that no further impairment was required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(k) Equipment, net</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment, net are stated at cost less accumulated
depreciation and impairment, if any, and depreciated on a straight-line basis over the estimated useful lives of the assets. Cost represents
the purchase price of the asset and other costs incurred to bring the asset into its intended use. Estimated useful lives are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 88%"><span style="font-size: 10pt"><b>Category</b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; width: 11%"><span style="font-size: 10pt"><b>Estimated <br/>
useful lives</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Lab equipment</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 to 5 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">Computer equipment</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 to 5 years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Furniture and fixtures</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 to 5 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 years</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenditure for repair and maintenance costs,
which do not materially extend the useful lives of the assets, are charged to expenses as incurred, whereas the expenditure for major
renewals and betterment that substantially extends the useful lives of property and equipment are capitalized as additions to the related
assets. Retirements, sales and disposals of assets are recorded by removing the costs, accumulated depreciation and impairment with any
resulting gain or loss recognized in the consolidated statements of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>(l) Deferred Initial Public Offering (&#8220;IPO&#8221;) costs&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company complies with the requirement of the
ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses of Offering&#8221;. Initial public
offering expense directly attributable to offering of securities are deferred and would be charged against the gross proceeds of the offering,
as a reduction in share capital. These deferred expenses mainly consist of underwriting, legal and other expenses incurred through the
balance sheet date that are directly related to the intended IPO. As of June 30, 2024, the Company capitalized US$638,871 of deferred
initial public offering costs. As of June 30, 2025, the Company had completed its Initial Public Offering, and the accumulated deferred
IPO cost was <span style="-sec-ix-hidden: hidden-fact-38">Nil</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(m) Impairment of long-lived assets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews its long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When
these events occur, the Company measures impairment by comparing the carrying value of the long-lived assets to the estimated undiscounted
future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted
cash flow is less than the carrying amount of the assets, the Company would recognize an impairment loss, which is the excess of carrying
amount over the fair value of the assets, using the expected future discounted cash flows. As of June 30, 2025 and 2024, the Company had
<span style="-sec-ix-hidden: hidden-fact-39"><span style="-sec-ix-hidden: hidden-fact-40">no</span></span> remaining carrying amount of finite-lived intangible related to purchased patents from the acquisition of Shanghai Sglcell Biotech
Co., Ltd. as the assets were fully impaired in 2022.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(n) Commitments and contingencies</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the Company
is subject to commitments and contingencies, including operating lease commitments, legal proceedings and claims arising out of its business
that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes a liability for such
contingency if it determines it is probable that a loss will occur, and a reasonable estimate of the loss can be made. The Company may
consider many factors in making these assessments on liability for contingencies, including historical and the specific facts and circumstances
of each matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(o) Research and development expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses include costs
directly attributable to the conduct of research and development programs, including licensing fees, cost of salaries, payroll taxes and
other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing
costs and professional services. All costs associated with research and developments are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has already started the registration
process and plans to start clinical research in November 2025, which are expected to end in May 2026, and we expect to obtain the required
registration certificate by October 2027. As of June 30, 2025, the Company has not commenced sales of the products nor have any revenue-generating
products and do not expect sales of revenue-generating product candidates until the Company has completed clinical development, submitted
regulatory filings, and received applicable regulatory approvals for candidate products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hence, the Company incurred its research and development
cost during the years ended June 30, 2025 and 2024, which is in compliance under ASC 730-10-25.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(p) General and administrative expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses mainly consist
of staff cost, depreciation, office supplies and upkeep expenses, travelling and entertainment, legal and professional fees, property
and related expenses, other miscellaneous administrative expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(q) Operating leases</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Prior to the adoption of ASC 842 on January
1, 2019:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases, mainly leases of factory buildings, offices
and employee dormitories, where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for
as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The
Company had no finance leases for any of the periods stated herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Upon and hereafter the adoption of ASC 842
on January 1, 2019:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines if an arrangement is a
lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, operating lease liability,
and operating lease liability, non-current in the Company&#8217;s consolidated balance sheets. ROU assets represent the Company&#8217;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments
arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease
payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is
reasonably certain that it will exercise that option, if any. As the Company&#8217;s leases do not provide an implicit rate, the Company
used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.
The Company has elected to adopt the following lease policies in conjunction with the adoption of ASU 2016-02: (i) for leases that have
lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Company elected not
to apply ASC 842 recognition requirements; and (ii) the Company elected to apply the package of practical expedients for existing arrangements
entered into prior to January 1, 2019 to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification
applied to existing leases, and (c) initial direct costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<i>(r) Income Taxes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company
is able to realize their benefits, or future deductibility is uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 740, a tax position is recognized as
a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not
that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical
merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount
of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50
percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition
threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that
no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the
threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense
in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the years ended June 30, 2025
and 2024. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures
and transition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Valuation of Deferred Tax Assets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is recorded to reduce the
Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results
in the period such determination was made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(s) Loss per share</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per share is computed by dividing net loss
attributable to common stockholders&#160;by the weighted average number of common stock outstanding during the year. Diluted earnings
per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted
into common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(t) Segment Reporting</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 280, &#8220;Segment Reporting&#8221;,
establishes standards for reporting information about operating segments on a basis consistent with the Company&#8217;s internal organizational
structure as well as information about geographical areas, business segments and major customers in financial statements for details on
the Company&#8217;s business segments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the management approach to determine
reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#8217;s chief
operating decision maker (&#8220;CODM&#8221;) for making decisions, allocating resources and assessing performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s CODM has been identified as
the CEO, who reviews results when making decisions about allocating resources and assessing the performance of the Company. For the years
ended June 30, 2025 and 2024, the CODM reviewed the consolidated results when making decisions about allocating resources and assessing
performance of the Company as a whole, and the Company has only one reportable segment.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(u) Recent accounting pronouncements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2023, the FASB issued ASU 2023-06,
&#8220;Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative.&#8221;
This amendment incorporates certain U.S. Securities and Exchange Commission (SEC) disclosure requirements into the FASB Accounting Standards
Codification. The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification
Topics, allow users to more easily compare entities subject to the SEC&#8217;s existing disclosures with those entities that were not
previously subject to the requirements, and align the requirements in the Codification with the SEC&#8217;s regulations. For entities
subject to the SEC&#8217;s existing disclosure requirements and for entities required to file or furnish financial statements with or
to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer,
the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. For all other
entities, the amendments will be effective two years later. However, if by June 30, 2027, the SEC has not removed the related disclosure
from its regulations, the amendments will be removed from the Codification and not become effective for any entity. The Company does not
expect the adoption of ASU 2023-06 to have a material impact on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740)&#160;&#8212;&#160;Improvements to income Tax Disclosures. The amendment in this update are effective for annual
periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods
beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available
for issuance. The Company has adopted ASU 2023-09 on July 1, 2024 and the adoption
of the standard did not have a material impact to the overall financial presentation. See Note 10 for further information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2024, the FASB issued ASU 2024-01, Compensation
&#8212; Stock Compensation (Topic 718)&#160;&#8212;&#160;Scope Application of Profits Interest and Similar Award. For public business
entities, the amendments in this Update are effective for annual periods beginning after December 15, 2024, and interim periods within
those annual periods. For all other entities, the amendments are effective for annual periods beginning after December 15, 2025, and interim
periods within those annual periods. Early adoption is permitted for both interim and annual financial statements that have not yet been
issued or made available for issuance. If an entity adopts the amendments in an interim period, it should adopt them as of the beginning
of the annual period that includes that interim period. The Company believes the future adoption of this ASU is not expected
to have a material impact on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March&#160;2024, the FASB issued ASU&#160;2024-02,
&#8220;Codification Improvements&#160;&#8212;&#160;Amendments to Remove References to the Concepts Statements&#8221;. This update contains
amendments to the Codification that remove references to various FASB Concepts Statements. These issues to remove references to various
Concepts Statements and the amendments apply to all reporting entities within the scope of the affected accounting guidance. The amendments
in this Update are effective for public business entities for fiscal&#160;years beginning after December&#160;15, 2024. Early application
of the amendments in this Update is permitted for any fiscal year or interim period for which financial statements have not yet been issued
(or made available for issuance). The Company is currently evaluating the impact of adoption on the Company&#8217;s
related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November&#160;2024, the FASB issued ASU&#160;2024-03,
Income Statement&#160;&#8212;&#160;Reporting Comprehensive Income&#160;&#8212;&#160;Expense Disaggregation Disclosures (Subtopic&#160;220-40):
Disaggregation of Income Statement Expenses and in January&#160;2025, the FASB issued ASU&#160;2025-01, Income Statement&#160;&#8212;&#160;Reporting
Comprehensive Income&#160;&#8212;&#160;Expense Disaggregation Disclosures (Subtopic&#160;220-40): Clarifying the Effective Date (&#8220;ASU&#160;2025-01&#8221;).
The ASU requires a public business entity to provide disaggregated disclosures of certain categories of expenses on an annual and interim
basis including purchases of inventory, employee compensation, depreciation, and intangible asset amortization for each income statement
line item that contains those expenses. ASU&#160;2024-03, as clarified by ASU&#160;2025-01 is effective for annual reporting periods beginning
after December&#160;15, 2026, and interim periods beginning after December&#160;15, 2027, with prospective or retrospective application
permitted. The Company is currently evaluating the impact of adoption on the Company&#8217;s related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as mentioned above, the Company does not
believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&#8217;s
consolidated balance sheets, statements of operations and comprehensive loss and statements of cash flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>4. PREPAID EXPENSES AND OTHER CURRENT ASSETS,
NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Tax refundable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">221,889</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">161,142</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,548</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,035</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,782</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Prepayment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,894,437</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237,960</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,128,656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">443,137</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: allowance for credit losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total prepaid expenses and other current assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,128,656</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">443,137</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in">*</td><td style="text-align: justify">The amount due from a related corporation, which the Company&#8217;s major stockholders
have controlling equity interest in, as of June 30, 2025 are non-trade, unsecured, interest-free and repayable on demand.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>5. EQUIPMENT, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment, net, consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,619,480</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,486,392</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,917</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,745</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,332</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">204,430</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">201,516</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,894,332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,754,985</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,562,986</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,230,457</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Equipment, net</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">331,346</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">524,528</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expenses were approximately US$224,832
and US$268,279 for the years ended June 30, 2025 and 2024, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>6. INTANGIBLE ASSETS, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the carrying amount
of the Company&#8217;s finite-lived intangible assets:</p>

<p style="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Acquired technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">372,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">391,016</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(372,197</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(272,018</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">118,998</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2025 and 2024, the Company had
no remaining carrying amount of finite-lived intangible related to purchased patents from the acquisition of Shanghai Sglcell Biotech
Co., Ltd. as the assets were fully impaired in 2022.&#160;<b>&#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties &#8211; Related Corporarions, Non-Current<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties &#8211; Related Corporarions, Non-Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE, ACCRUALS AND OTHER CURRENT LIABILITIES AND AMOUNT DUE TO RELATED PARTIES &#8211; RELATED CORPORARIONS, NON-CURRENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>7. ACCOUNTS PAYABLE, ACCRUALS AND OTHER CURRENT
LIABILITIES AND AMOUNT DUE TO RELATED PARTIES <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;
RELATED CORPORARIONS, NON-CURRENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Payable, accrued expenses and other liabilities
consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Accounts payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">632,697</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">620,476</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Payroll payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,216</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,113</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Amount due to related parties &#8211; major stockholders *</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172,767</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113,812</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Amount due to related parties &#8211; related corporations**</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">916,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">674,262</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other payable#</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,102,601</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,184,586</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">&#160;Total Accounts payable, accruals, and other current liabilities</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,853,317</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,670,249</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Amount due to related parties &#8211; related corporations, non-current***</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">139,772</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in; text-align: right"></td><td style="width: 0.25in">*</td><td style="text-align: justify">The amount due to the Company&#8217;s major stockholders as of June 30, 2025 and 2024 is
non-trade, unsecured, interest-free and repayable on demand.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in; text-align: right"></td><td style="width: 0.25in">**</td><td style="text-align: justify">The amount due to related corporations, which the Company&#8217;s major stockholders have
controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and repayable on demand.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 0pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td> <td style="padding-bottom: 0pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount due to related corporations, which the Company&#8217;s major stockholders have controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and the remaining loan term are over one year. The Company believes the carrying value approximates fair value.</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in; text-align: right"></td><td style="width: 0.25in">#</td><td style="text-align: justify">The amount consists of payables owed to third party creditors, which are unsecured, interest-free
and repayable on demand, and other payables due to operational use.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other Expense, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">OTHER EXPENSE, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8.
OTHER EXPENSE, NET</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expense), net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(29,040</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">486</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Foreign exchange loss, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(233,808</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(294,687</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Other expense, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(262,848</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(294,201</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>9. EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the sake of undertaking a public offering
of the Company&#8217;s common stock, the Company has performed a series of re-organizing transactions resulting in 20,000,000 of common
stock and 20,000,000 of common stock outstanding as of December 31, 2024 and June 30, 2024 giving the retroactive effects to the 4 for
1 share split effected on May 16, 2023 and 5 for 1 reverse share split effected on October 15, 2024. The Company has accounted for these
shares had they been issued and outstanding at the beginning of the first period presented. The Company only has one single class of common
stock that is accounted for as permanent equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2023, the Company effected a forward
share split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, the Company
now have 100,000,000 common stock issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the
above transactions on a retroactive basis similar to share split or dividend pursuant to ASC 260. All references made to share or per
share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect
the 4 for 1 share split. The shares of common stock retain a par value of $0.001&#160;per share. Accordingly, an amount equal to the par
value of the increased shares resulting from the stock split was reclassified from &#8220;Additional paid-in capital&#8221; to &#8220;Common
stock&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 15, 2024, the Company effected the
reverse share split of all issued and outstanding shares of 100,000,000 shares at a ratio of 5:1. As a result of the reverse share split,
the Company now have 20,000,000 common stock issued and outstanding as of the date hereof. Unless indicated or the context otherwise requires,
all number of common stock&#160;in this report has been retrospectively adjusted for the reverse share split, as if such reverse share
split occurred on the first day of the years presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2025, the Company completed its initial
public offering. In the initial public offering, the Company issued 1,640,000 shares of common stock at a price of US$4.00 per share.
The Company received gross proceeds in the amount of US$6.56 million before deducting any underwriting discounts or expenses. The Shares
began trading on the Nasdaq Capital Market on March 6, 2025 under the ticker symbol &#8220;ADVB.&#8221;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is not an operating company but a
holding company incorporated in the State of Nevada and is considered U.S. tax resident under U.S. tax laws; accordingly, it is subject
to U.S. tax laws at a statutory tax rate of 21%. The Company is subject to the State of Nevada tax laws at a tax rate of&#160;0%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s net deferred income tax assets
as of June 30, 2025and 2024 consist of net operating loss carry forwards. The net operating loss carry forwards for U.S. federal tax and
Taiwan, China, Hong Kong tax purposes are available for carry forward indefinitely for use in offsetting taxable income. The U.S. federal
net operating loss carry forward offset is limited to up to 80% of the taxable income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2025 and 2024, the Company had
total net operating loss carry forwards of approximately $13,167,716 and $8,767,393, respectively, which consists of China net operating
loss carry forwards of $4,896,250&#160;and $3,817,009, respectively, Taiwan net operating losses of $5,824,336&#160;and $4,200,888, respectively,
Hong Kong net operating loss carry forwards of $94,686 and $5,014, respectively, and US net operating loss carry forwards of $2,352,444
and $744,480, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Taiwan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company&#8217;s operating
subsidiary, Advanced Biomed Inc. (Taiwan) is considered Taiwan tax resident enterprises under Taiwan tax laws; accordingly, it is subject
to enterprise income tax on its taxable income as determined under Taiwan tax laws at a statutory tax rate of 20%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>China</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company&#8217;s operating
subsidiary, Shanghai Sglcell Biotech Co., Ltd. is considered PRC resident enterprises under Enterprise Income Tax Law of the PRC; accordingly,
it is subject to enterprise income tax on their taxable income as determined under Enterprise Income Tax Law of the PRC at a statutory
tax rate of 25%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Hong Kong</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Under the current Hong&#160;Kong
Inland Revenue Ordinance, a two-tier&#160;corporate income tax system was implemented in Hong&#160;Kong, which is 8.25% for the first
HK$2.0&#160;million taxable income, and 16.5% for the subsequent taxable income generated from operations in Hong&#160;Kong. The Company&#8217;s
subsidiary, Advanced Biomed HK Limited is considered Hong Kong tax resident under Hong Kong Tax Law; accordingly, it is subject to corporate
income tax on its taxable income at 8.25% with <span style="-sec-ix-hidden: hidden-fact-64">nil</span> and <span style="-sec-ix-hidden: hidden-fact-65">nil</span> for the years ended June 30, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The income tax provision consists of the following
component:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">The following table reconciles the operating
profit to the Company&#8217;s effective tax rate:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Loss before tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(3,258,969</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,782,278</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Statutory income tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax expense calculated at the statutory tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effect of tax losses carry forwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,890,755</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,019,708</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of subsidiaries foreign income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,890,755</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,019,708</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Effective tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The component of deferred tax assets are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating losses carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,890,755</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,019,708</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,890,755</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,019,708</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In assessing
the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred
tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income
during the periods in which those temporary differences become deductible. Management considers the cumulative earnings and projected
future taxable income in making this assessment. Recovery of substantially all of the Company&#8217;s deferred tax assets is dependent
upon the generation of future income, exclusive of reversing taxable temporary differences.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the differences between the
federal income tax rate and the effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>State of Nevada</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Tax at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Provision for taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Taiwan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Tax at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Different foreign subsidiary tax rate impact</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Provision for taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>China</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Tax at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Different foreign subsidiary tax rate impact</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Provision for taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Hong Kong</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Tax at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Different foreign subsidiary tax rate impact</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12.75</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12.75</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.25</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.25</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Provision for taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Option [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK OPTION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. STOCK OPTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective from March 30, 2023, the Stock Incentive
Plan (the &#8220;2023 Plan&#8221;) was approved by the Company's Board of Directors. Under the 2023 Plan, the Board of Directors may grant
options or purchase rights to purchase common stock to officers, employees, and other persons who provide services to the Company or any
related company. The participants to whom awards are granted, the type of awards granted, the number of shares covered for each award,
and the purchase or exercise price, conditions and other terms of each award are determined by the Board of Directors, except that the
term of the options shall not exceed 10 years. A total of 15 million shares of our common stock are subject to the 2023 Plan and maybe
either a qualified or non-qualified stock option. The shares issued for the 2023 Plan may be either treasury or authorized and unissued
shares. As of the date of this report, the Company has granted <span style="-sec-ix-hidden: hidden-fact-66">no</span> stock options to purchase any shares of the common stock under the 2023
Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>12. RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These related parties of the Company with whom
transactions are reported in these financial statements are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 35%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Related Party</b></span></td> <td style="width: 1%">&#160;</td> <td style="width: 64%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship to Us</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi Lu, Ph.D.</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board and Chief Executive Officer of the Company</span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau, Ph.D.</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder of the Company</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven I-Fang Cheng, Ph.D.</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Chief Technology Officer of the Company</span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chen-Yi Lee</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chen-Yi Lee is the sole director and the controlling person of Advance On Ventures Limited, which owns 10.92% equity interest in the Company and has sole voting and dispositive power over shares beneficially owned by Advance On Ventures Limited. Chen-Yi Lee is also the Stockholder of the Company</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance On Ventures Limited</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder of the Company</span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Fancy Development Ltd</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau is the director and stockholder of the entity</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd.</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau is the legal person and stockholder of the entity</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of business, during the&#160;fiscal
years ended June&#160;30, 2025 and 2024, the Company was involved in certain transactions, either at cost or current market prices, and
on the normal commercial terms with related parties. The following table provides the transactions with these parties for the&#160;years
as presented (for the portion of such period that they were considered related):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Amount due to related parties &#8211; major stockholders</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"><span style="text-decoration:underline">Name of related party</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi Lu, Ph.D. <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">122,626</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">110,268</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chen-Yi Lee <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,544</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau, Ph.D. <sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,705</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">172,767</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">113,812</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Amount due to related parties &#8211; related corporations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Name of related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Fancy Development Ltd <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">211,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd. <sup>(5)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">704,953</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">674,262</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">916,036</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">674,262</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Non-Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Name of related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Fancy Development Ltd <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd. <sup>(5)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">69,797</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">139,772</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Advanced Biomed Inc.(Taiwan) entered into an unsecured, interest-free loan to Yi Lu amounting to NTD 3,578,212 (approximately US$122,626) for general working capital in January 2023. As of June 30, 2025 and 2024, the loan balance due to Yi Lu amounted to US$122,626 and US$110,268, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Payments of expenses on behalf of Advanced Biomed Inc. (Taiwan).</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Advanced Biomed Inc.(HK) entered into one unsecured, interest-free loan to Hung To Pau, Ph.D. amounting to US$200,000 for general working capital in July 2024 and the amount was full settled in 2025. And Shanghai Sglcell Biotech Co., Ltd entered into three unsecured, interest-free loans to Hung To Pau, Ph.D. amounting to RMB122,566 (approximately US$17,110), RMB121,681 (approximately US$16,986) and RMB76,000 (approximately US$10,609) for general working capital in October 2024, November 2024 and December 2024. As of June 30, 2025, the loan balance due to Hung To Pau, Ph.D. totally amounted to RMB320,247 (approximately US$44,705) for general working capital.</span></td></tr>
</table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">4.</span></td> <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Advanced Biomed Inc.(Taiwan) entered into seven unsecured, interest-free
loans to Well Fancy Development Ltd amounting to NTD 5,740,600 (approximately US$196,731), NTD 1,911,944 (approximately US$65,522), NTD
1,906,840 (approximately US$65,347), NTD 3,121,500 (approximately US$106,974), NTD 1,798,060 (approximately US$61,620), NTD 1,291,552
(approximately US$44,262) and NTD 455,992 (approximately US$15,627) for general working capital in July 2024, October 2024, November 2024,
December 2024, January 2025, February 2025 and March 2025. In March 2025, Advanced Biomed Inc.(HK) paid US$550,000 to Well Fancy Development
Ltd for Advanced Biomed Inc.(Taiwan)&#8217;s debt. And Advanced Biomed Inc. entered into two unsecured, interest-free loan to Well Fancy
Development Ltd amounting to US$119,975 and US$205,000 for general working capital in November 2024 and March 2025. In March 2025, Advanced
Biomed Inc. paid US$50,000 to Well Fancy Development Ltd for repayment. As of June 30, 2025, the loan balance due to Well Fancy Development
Ltd totally amounted to NTD 177,488(approximately US$6,083) and US$274,975 for general working capital.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Sglcell Biotech Co., Ltd entered into nine unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. amounting to RMB500,000 (approximately US$69,797) in April 2023, May 2023, June 2023 and September 2023, respectively, and RMB700,000 (approximately US$97,716), RMB1,000,000 (approximately US$139,595), RMB500,000 (approximately US$69,797), RMB700,000 (approximately US$97,716) and RMB650,000 (approximately US$90,738) in January 2024, March 2024, March 2024, June 2024 and October 2024, respectively, for general working capital. As of June 30, 2025 and 2024 the loan balance due to Shanghai Junfu Electronic Technology Co., Ltd totally amounted to RMB5,550,000 (approximately US$774,750) and RMB4,900,000 (approximately to US$674,262), respectively.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>13. SEGMENT INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates and manages its business
as a single reportable segment, which is consistent with how the Chief Operating Decision Maker (&#8220;CODM&#8221;), the Chief Executive
Officer, makes operating decisions and allocates resources. The CODM assesses performance and results of operations at the Company level.
The Company&#8217;s operations are centralized and integrated, with financial results reviewed and managed on a consolidated basis. Accordingly,
management has determined that the Company has one reportable segment under ASC Topic 280, Segment Reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Measure of Segment Profit or Loss</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CODM assesses performance for the segment
and decides how to allocate resources by regularly reviewing the consolidated net income from the statement of operations, after taking
into account the Company&#8217;s strategic priorities, its cash balance, and its expected use of cash. The following table presents the
significant expense categories in the Company&#8217;s single operating segment:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/> year ended <br/> June&#160;30, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/> year ended <br/> June&#160;30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(909,771</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(880,193</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,111,265</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,661,379</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(237,933</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(240,706</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net Loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(3,258,969</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(2,782,278</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations and Risks<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract', window );"><strong>Concentrations and Risks [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS AND RISKS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>14. CONCENTRATIONS AND RISKS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Credit Risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Credit risk is the potential financial loss to
the Company resulting from the failure of a customer or a counterparty to settle its financial and contractual obligations to the Company,
as and when they fall due. As the Company does not hold any collateral, the maximum exposure to credit risk is the carrying amounts of
other receivables (exclude prepayments) and cash and bank deposits presented on the consolidated balance sheets. The Company has no other
financial assets which carry significant exposure to credit risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidity Risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity risk is the risk that the Company will
encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another
financial asset. The Company&#8217;s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient
liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking
damage to the Company&#8217;s reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Typically, the Company ensures that it has sufficient
cash on demand to meet expected operational expenses for a period of 60 days, including the servicing of financial obligations; this excludes
the potential impact of extreme circumstances that cannot reasonably be predicted, such as natural disasters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Foreign currency risk</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign currency risk is the risk that the fair
value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The company&#8217;s exposure to
the risk of changes in foreign exchange rates relates primarily to the Company&#8217;s operating activities (when expense is denominated
in a foreign currency) and the Company&#8217;s net investments in foreign subsidiaries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Impact of Inflation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inflation in Taiwan and PRC has not materially
affected the Company&#8217;s profitability and operating results. However, the Company can provide no assurance that we will be unaffected
by higher inflation rates in Taiwan and PRC or globally in the future.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-3A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>15. COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Contingencies</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the ordinary course of business, the Company
may be subject to legal proceedings regarding contractual and employment relationships and a variety of other matters. The Company records
contingent liabilities resulting from such claims, when a loss is assessed to be probable, and the amount of the loss is reasonably estimable.
In the opinion of management, there were no pending or threatened claims and litigation as of June 30, 2025 and up through October 8,
2025, the issuance date of these consolidated financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Lease commitment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines if a contract contains
a lease at inception. US GAAP requires that the Company&#8217;s leases be evaluated and classified as operating or finance leases for
financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation
includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods
when the exercise of the renewal option is reasonably certain and failure to exercise such option which results in an economic penalty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right-of-use assets relate to leases of office
premises and a dormitory for employees in the PRC and the laboratory in Taiwan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recognized operating lease ROU assets and
lease liabilities as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease ROU asset</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">65,399</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">126,740</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current portion</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">35,811</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">62,211</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,879</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,529</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">41,690</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">126,740</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2025, future minimum lease payments
under the non-cancellable operating leases are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Future payment</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">36,532</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,929</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total future lease payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,461</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(771</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Present value of operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">41,690</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease liabilities, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,811</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease liabilities, non-current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,879</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes other supplemental information
about the Company&#8217;s operating lease as of June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Weighted average discount rate</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.40</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average remaining lease term (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.15</td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>16. SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has assessed all events from June
30, 2025 through October 8, 2025, which is the date that these consolidated financial statements are available to be issued, unless as
disclosed below, there are not any material subsequent events that require disclosure in these consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (3,258,969)<span></span>
</td>
<td class="num">$ (2,782,278)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize the importance
of identifying, assessing, and managing material risks from cybersecurity threats, as defined in Item 106(a) of Regulation S-K. Our risk
management program is designed to detect, evaluate, and mitigate cybersecurity risks, and is informed by applicable laws, regulations,
and industry best practices.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Chief Executive Officer
oversees our cybersecurity program and leads our incident response efforts. The incident response team is cross-functional, drawing members
from cybersecurity, IT support, mining operations, software engineering, compliance, legal, contractors, and partners.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When a potential incident
is detected, the cybersecurity team validates it before escalating to the incident response team for triage. Significant incidents are
escalated to executive management. Response actions such as allocating resources, setting priorities, creating action plans, and notifying
external parties are directed by the Chief Executive Officer in coordination with the cross-functional working group. We also consult
outside counsel on materiality assessments and disclosure decisions, with executive management making the final determinations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2025, we did not identify
any cybersecurity threats that materially affected, or are reasonably likely to materially affect, our strategy, operations, or financial
condition. However, no program can eliminate all risks, and we cannot guarantee that undetected incidents have not occurred. See Part
I, Item 1A. &#8220;Risk Factors&#8221; of this Annual Report for further details.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">The incident response team is cross-functional, drawing members
from cybersecurity, IT support, mining operations, software engineering, compliance, legal, contractors, and partners.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">In 2025, we did not identify
any cybersecurity threats that materially affected, or are reasonably likely to materially affect, our strategy, operations, or financial
condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Chief Executive Officer
oversees our cybersecurity program and leads our incident response efforts. The incident response team is cross-functional, drawing members
from cybersecurity, IT support, mining operations, software engineering, compliance, legal, contractors, and partners.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(a) Basis of presentation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;)
and pursuant to the regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(b) Consolidation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the financial statements of the Company and its subsidiaries. All inter-company transactions, if any, and balances due to, due from, long-term
investment subsidiary, and registered paid in capital have been eliminated upon consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Business combinations are accounted for using
the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective
fair values as of the acquisition date in the Company&#8217;s consolidated financial statements. Any excess fair value of consideration
transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection
with the business combination are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent
reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in the consolidated statements
of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When the Company determines that assets acquired
do not meet the definition of a business under the acquisition method of accounting, acquired assets is expensed, no goodwill is recorded,
and any contingent consideration is recognized only when it becomes payable or is paid.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(c) Use of estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to useful lives for equipment
and intangible assets, assumptions used in assessing right of use assets, impairment of long-lived assets and uncertain tax position.
Actual results could vary from the estimates and assumptions that were used.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_StockSplitPolicyTextBlock', window );">Stock split and reverse share split</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(d) Stock split and reverse share
split</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2023, the Company effected a forward
share split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, the Company
now have 100,000,000 common stock issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the
above transactions on a retroactive basis similar to share split or dividend pursuant to ASC 260. All references made to share or per
share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect
the 4 for 1 share split. The shares of common stock retain a par value of $0.001 per share. Accordingly, an amount equal to the par value
of the increased shares resulting from the share split was reclassified from &#8220;Additional paid-in capital&#8221; to &#8220;Common
stock&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 15, 2024, the Company effected the
reverse share split of all issued and outstanding shares of 100,000,000 shares at a ratio of 5:1. As a result of the reverse share split,
the Company now have 20,000,000 common stock issued and outstanding as of the date hereof. Unless indicated or the context otherwise requires,
all number of common stock in this report has been retrospectively adjusted for the reverse share split, as if such reverse share split
occurred on the first day of the years presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(e) Risks and uncertainties</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The main operations of the Company are located
in Taiwan and mainland China. Accordingly, the Company&#8217;s business, financial condition, and results of operations may be influenced
by political, economic, and legal environments in Taiwan and mainland China, as well as by the general state of the economy in these two
countries. The Company&#8217;s results may be adversely affected by changes in the political, regulatory and social conditions in these
two countries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&#8217;s operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation and transaction and convenience translation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(f) Foreign currency translation and transaction
and convenience translation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
are presented in the US Dollar (&#8220;US$&#8221;), which is the reporting currency of the Company. The functional currency of the Company
is the US$. Advanced Biomed Inc. (Taiwan) uses New Taiwan dollar (&#8220;NT$&#8221;) as its functional currency. Advanced Biomed HK Limited
uses Hong Kong dollars (&#8220;HKD&#8221;) and Shanghai Sglcell Biotech Co., Ltd. uses Chinese Yuan (&#8220;CNY&#8221;) as their functional
currencies, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assets and liabilities denominated in currencies
other than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the balance sheet
date. Translation gains and losses are recognized in the consolidated statements of income and comprehensive income as other comprehensive
income or loss. Transactions in currencies other than the reporting currency are measured and recorded in the reporting currency at the
exchange rate prevailing on the transaction date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated
statements of income and comprehensive income as other income (other expense).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value of foreign currencies including, the
NT$, CNY and HKD, may fluctuate against the US Dollar. Any significant variations of the aforementioned currencies relative to the US
Dollar may materially affect the Company&#8217;s financial condition in terms of reporting in US Dollar. The following table outlines
the currency exchange rates that were used in preparing the accompanying consolidated financial statements:</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">US$ to NT$ fiscal year end</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29.18</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">32.45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">US$ to NT$ average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.83</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">US$ to CNY fiscal year end</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">US$ to CNY average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.23</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">US$ to HKD fiscal year end</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.81</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">US$ to HKD average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.82</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(g) Fair value measurement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance defines fair value as the
price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded
at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions
that market participants would use when pricing the asset or liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting guidance establishes a fair value hierarchy
that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
A financial instrument&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant
to the fair value measurement. Accounting guidance establishes three levels of inputs that may be used to measure fair value:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 1 applies to assets or liabilities for which there are quoted prices, in active markets for identical assets or liabilities.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical asset or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3 applies to asset or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash, other current assets, leases payable, accounts
payables, accruals and other current liabilities are financial assets and liabilities. Cash, other current assets, accounts payable, accruals
and other current liabilities are subject to fair value measurement; however, because of their being short term in nature management believes
their carrying values approximate their fair value. Financial instruments are fair value financial assets that are marked to fair value
and are accounted for under as Level 3 under the above hierarchy. The Company accounts for lease payables at amortized cost and has elected
NOT to account for them under the fair value hierarchy.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_RelatedPartiesPolicyTextBlock', window );">Related parties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(h) Related parties</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We adopted ASC 850, Related Party Disclosures,
for the identification of related parties and disclosure of related party transactions for the years ended June 30, 2025 and 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(i) Cash </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash consists of cash on hand, the Company&#8217;s
demand deposit placed with financial institutions, which have original maturities of less than three months and unrestricted as to withdrawal
and use. Deposits are held at highly liquid and well capitalized financial institutions. Risk of loss is not expected by management.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible assets, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(j) Intangible assets, net</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s intangible assets are stated
at cost less accumulated amortization and impairment, if any, and amortized on a straight-line basis over the estimated useful lives of
the assets.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Category</b></span></td> <td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: justify">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Estimated <br/>
useful lives</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Software</span></td> <td style="white-space: nowrap; text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">3 years</span></td></tr> <tr style="vertical-align: top; "> <td style="width: 88%"><span style="font-size: 10pt">Patents</span></td> <td style="white-space: nowrap; width: 1%; text-align: justify">&#160;</td> <td style="text-align: center; width: 11%"><span style="font-size: 10pt">6 years</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Software represents purchased software and is
amortized straight-line over the Company&#8217;s estimates to generate economic benefits from such software, generally three years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents represent the estimated fair value assigned to finite-lived
intangible assets acquired in a transaction that is accounted for as an acquisition of assets rather than a business combination are initially
recognized in accordance with other application GAAP. Any consideration transferred in excess of the fair value of the assets acquired
is allocated to each asset acquired on a relative fair value basis. Amortization is computed using the straight-line method over the estimated
useful lives of the respective finite-lived intangible assets, generally six years. Intangible assets are reviewed for impairment at least
annually or more frequently if indicators of potential impairment exist. The Company reviews finite-lived intangible assets for impairment
at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be
recoverable. If the carrying value of a finite-lived intangible asset exceeds its fair value, then it is written down to its adjusted
fair value. The Company had previously recognized an impairment loss on certain intangible assets in prior years. The remaining intangible
assets were assessed for impairment as of the balance sheet date, and management concluded that no further impairment was required.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(k) Equipment, net</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment, net are stated at cost less accumulated
depreciation and impairment, if any, and depreciated on a straight-line basis over the estimated useful lives of the assets. Cost represents
the purchase price of the asset and other costs incurred to bring the asset into its intended use. Estimated useful lives are as follows:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 88%"><span style="font-size: 10pt"><b>Category</b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; width: 11%"><span style="font-size: 10pt"><b>Estimated <br/>
useful lives</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Lab equipment</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 to 5 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">Computer equipment</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 to 5 years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Furniture and fixtures</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 to 5 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 years</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenditure for repair and maintenance costs,
which do not materially extend the useful lives of the assets, are charged to expenses as incurred, whereas the expenditure for major
renewals and betterment that substantially extends the useful lives of property and equipment are capitalized as additions to the related
assets. Retirements, sales and disposals of assets are recorded by removing the costs, accumulated depreciation and impairment with any
resulting gain or loss recognized in the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock', window );">Deferred Initial Public Offering (&#8220;IPO&#8221;) costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>(l) Deferred Initial Public Offering (&#8220;IPO&#8221;) costs&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company complies with the requirement of the
ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8212; &#8220;Expenses of Offering&#8221;. Initial public
offering expense directly attributable to offering of securities are deferred and would be charged against the gross proceeds of the offering,
as a reduction in share capital. These deferred expenses mainly consist of underwriting, legal and other expenses incurred through the
balance sheet date that are directly related to the intended IPO. As of June 30, 2024, the Company capitalized US$638,871 of deferred
initial public offering costs. As of June 30, 2025, the Company had completed its Initial Public Offering, and the accumulated deferred
IPO cost was <span style="-sec-ix-hidden: hidden-fact-38">Nil</span>.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(m) Impairment of long-lived assets</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews its long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When
these events occur, the Company measures impairment by comparing the carrying value of the long-lived assets to the estimated undiscounted
future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted
cash flow is less than the carrying amount of the assets, the Company would recognize an impairment loss, which is the excess of carrying
amount over the fair value of the assets, using the expected future discounted cash flows. As of June 30, 2025 and 2024, the Company had
<span style="-sec-ix-hidden: hidden-fact-39"><span style="-sec-ix-hidden: hidden-fact-40">no</span></span> remaining carrying amount of finite-lived intangible related to purchased patents from the acquisition of Shanghai Sglcell Biotech
Co., Ltd. as the assets were fully impaired in 2022.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(n) Commitments and contingencies</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the Company
is subject to commitments and contingencies, including operating lease commitments, legal proceedings and claims arising out of its business
that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes a liability for such
contingency if it determines it is probable that a loss will occur, and a reasonable estimate of the loss can be made. The Company may
consider many factors in making these assessments on liability for contingencies, including historical and the specific facts and circumstances
of each matter.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(o) Research and development expenses</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses include costs
directly attributable to the conduct of research and development programs, including licensing fees, cost of salaries, payroll taxes and
other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing
costs and professional services. All costs associated with research and developments are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has already started the registration
process and plans to start clinical research in November 2025, which are expected to end in May 2026, and we expect to obtain the required
registration certificate by October 2027. As of June 30, 2025, the Company has not commenced sales of the products nor have any revenue-generating
products and do not expect sales of revenue-generating product candidates until the Company has completed clinical development, submitted
regulatory filings, and received applicable regulatory approvals for candidate products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hence, the Company incurred its research and development
cost during the years ended June 30, 2025 and 2024, which is in compliance under ASC 730-10-25.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and administrative expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(p) General and administrative expenses</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses mainly consist
of staff cost, depreciation, office supplies and upkeep expenses, travelling and entertainment, legal and professional fees, property
and related expenses, other miscellaneous administrative expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(q) Operating leases</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Prior to the adoption of ASC 842 on January
1, 2019:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases, mainly leases of factory buildings, offices
and employee dormitories, where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for
as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The
Company had no finance leases for any of the periods stated herein.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Upon and hereafter the adoption of ASC 842
on January 1, 2019:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines if an arrangement is a
lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, operating lease liability,
and operating lease liability, non-current in the Company&#8217;s consolidated balance sheets. ROU assets represent the Company&#8217;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments
arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease
payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is
reasonably certain that it will exercise that option, if any. As the Company&#8217;s leases do not provide an implicit rate, the Company
used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.
The Company has elected to adopt the following lease policies in conjunction with the adoption of ASU 2016-02: (i) for leases that have
lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Company elected not
to apply ASC 842 recognition requirements; and (ii) the Company elected to apply the package of practical expedients for existing arrangements
entered into prior to January 1, 2019 to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification
applied to existing leases, and (c) initial direct costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<i>(r) Income Taxes</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company
is able to realize their benefits, or future deductibility is uncertain.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 740, a tax position is recognized as
a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not
that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical
merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount
of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50
percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition
threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that
no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the
threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense
in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the years ended June 30, 2025
and 2024. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures
and transition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Valuation of Deferred Tax Assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is recorded to reduce the
Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results
in the period such determination was made.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(s) Loss per share</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per share is computed by dividing net loss
attributable to common stockholders&#160;by the weighted average number of common stock outstanding during the year. Diluted earnings
per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted
into common stock.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(t) Segment Reporting</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 280, &#8220;Segment Reporting&#8221;,
establishes standards for reporting information about operating segments on a basis consistent with the Company&#8217;s internal organizational
structure as well as information about geographical areas, business segments and major customers in financial statements for details on
the Company&#8217;s business segments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the management approach to determine
reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#8217;s chief
operating decision maker (&#8220;CODM&#8221;) for making decisions, allocating resources and assessing performance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s CODM has been identified as
the CEO, who reviews results when making decisions about allocating resources and assessing the performance of the Company. For the years
ended June 30, 2025 and 2024, the CODM reviewed the consolidated results when making decisions about allocating resources and assessing
performance of the Company as a whole, and the Company has only one reportable segment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>(u) Recent accounting pronouncements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2023, the FASB issued ASU 2023-06,
&#8220;Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative.&#8221;
This amendment incorporates certain U.S. Securities and Exchange Commission (SEC) disclosure requirements into the FASB Accounting Standards
Codification. The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification
Topics, allow users to more easily compare entities subject to the SEC&#8217;s existing disclosures with those entities that were not
previously subject to the requirements, and align the requirements in the Codification with the SEC&#8217;s regulations. For entities
subject to the SEC&#8217;s existing disclosure requirements and for entities required to file or furnish financial statements with or
to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer,
the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. For all other
entities, the amendments will be effective two years later. However, if by June 30, 2027, the SEC has not removed the related disclosure
from its regulations, the amendments will be removed from the Codification and not become effective for any entity. The Company does not
expect the adoption of ASU 2023-06 to have a material impact on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740)&#160;&#8212;&#160;Improvements to income Tax Disclosures. The amendment in this update are effective for annual
periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods
beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available
for issuance. The Company has adopted ASU 2023-09 on July 1, 2024 and the adoption
of the standard did not have a material impact to the overall financial presentation. See Note 10 for further information.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2024, the FASB issued ASU 2024-01, Compensation
&#8212; Stock Compensation (Topic 718)&#160;&#8212;&#160;Scope Application of Profits Interest and Similar Award. For public business
entities, the amendments in this Update are effective for annual periods beginning after December 15, 2024, and interim periods within
those annual periods. For all other entities, the amendments are effective for annual periods beginning after December 15, 2025, and interim
periods within those annual periods. Early adoption is permitted for both interim and annual financial statements that have not yet been
issued or made available for issuance. If an entity adopts the amendments in an interim period, it should adopt them as of the beginning
of the annual period that includes that interim period. The Company believes the future adoption of this ASU is not expected
to have a material impact on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March&#160;2024, the FASB issued ASU&#160;2024-02,
&#8220;Codification Improvements&#160;&#8212;&#160;Amendments to Remove References to the Concepts Statements&#8221;. This update contains
amendments to the Codification that remove references to various FASB Concepts Statements. These issues to remove references to various
Concepts Statements and the amendments apply to all reporting entities within the scope of the affected accounting guidance. The amendments
in this Update are effective for public business entities for fiscal&#160;years beginning after December&#160;15, 2024. Early application
of the amendments in this Update is permitted for any fiscal year or interim period for which financial statements have not yet been issued
(or made available for issuance). The Company is currently evaluating the impact of adoption on the Company&#8217;s
related disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November&#160;2024, the FASB issued ASU&#160;2024-03,
Income Statement&#160;&#8212;&#160;Reporting Comprehensive Income&#160;&#8212;&#160;Expense Disaggregation Disclosures (Subtopic&#160;220-40):
Disaggregation of Income Statement Expenses and in January&#160;2025, the FASB issued ASU&#160;2025-01, Income Statement&#160;&#8212;&#160;Reporting
Comprehensive Income&#160;&#8212;&#160;Expense Disaggregation Disclosures (Subtopic&#160;220-40): Clarifying the Effective Date (&#8220;ASU&#160;2025-01&#8221;).
The ASU requires a public business entity to provide disaggregated disclosures of certain categories of expenses on an annual and interim
basis including purchases of inventory, employee compensation, depreciation, and intangible asset amortization for each income statement
line item that contains those expenses. ASU&#160;2024-03, as clarified by ASU&#160;2025-01 is effective for annual reporting periods beginning
after December&#160;15, 2026, and interim periods beginning after December&#160;15, 2027, with prospective or retrospective application
permitted. The Company is currently evaluating the impact of adoption on the Company&#8217;s related disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as mentioned above, the Company does not
believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&#8217;s
consolidated balance sheets, statements of operations and comprehensive loss and statements of cash flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policies for deferred initial public offering (&#8220;IPO&#8221;) costs .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_RelatedPartiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_RelatedPartiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_StockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Split and Reverse Share Split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_StockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Principal Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Principal Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock', window );">Schedule of Subsidiaries</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and its subsidiaries are in the table
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="15" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Percentage of effective ownership</b></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date of <br/> Incorporation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold; vertical-align: top">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold; vertical-align: top">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Place of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>incorporation</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Principal <br/> Activities</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left">Advanced Biomed Inc.</td><td>&#160;</td> <td style="vertical-align: top; text-align: center">July 16, 2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="vertical-align: top; text-align: right">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="vertical-align: top; text-align: right">&#160;</td><td>&#160;</td> <td style="vertical-align: top; text-align: center">Nevada</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">Investment holding</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; width: 25%; text-align: left">Advanced Biomed Inc. (Taiwan)</td><td style="width: 1%">&#160;</td> <td style="vertical-align: top; width: 14%; text-align: center">September 1, 2014</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="vertical-align: top; width: 9%; text-align: right">100</td><td style="vertical-align: top; width: 1%; text-align: right">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="vertical-align: top; width: 9%; text-align: right">100</td><td style="vertical-align: top; width: 1%; text-align: right">%</td><td style="width: 1%">&#160;</td> <td style="vertical-align: top; width: 14%; text-align: center">Taiwan</td><td style="width: 1%">&#160;</td> <td style="vertical-align: top; width: 20%; text-align: left">Research and development of various advanced and innovative microfluidic biochip technologies, and provide the leading application of such technologies in precision oncology detection, diagnosis and treatment</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left">Advanced Biomed HK Limited</td><td>&#160;</td> <td style="vertical-align: top; text-align: center">August 10, 2021</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">100</td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">100</td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td> <td style="vertical-align: top; text-align: center">Hong Kong</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">Market development</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left">Shanghai Sglcell Biotech Co., Ltd.</td><td>&#160;</td> <td style="vertical-align: top; text-align: center">April 12, 2019</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">100</td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">100</td><td style="vertical-align: top; text-align: right">%</td><td>&#160;</td> <td style="vertical-align: top; text-align: center">People&#8217;s Republic of China</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">Clinical-related business</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock', window );">Schedule of Currency Exchange Rates used in Preparing Financial Statements</a></td>
<td class="text">The following table outlines
the currency exchange rates that were used in preparing the accompanying consolidated financial statements:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">US$ to NT$ fiscal year end</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29.18</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">32.45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">US$ to NT$ average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.83</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">US$ to CNY fiscal year end</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.27</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">US$ to CNY average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.23</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">US$ to HKD fiscal year end</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.81</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">US$ to HKD average rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.82</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets are stated at Cost less Accumulated Amortization and Impairment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s intangible assets are stated
at cost less accumulated amortization and impairment, if any, and amortized on a straight-line basis over the estimated useful lives of
the assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Category</b></span></td> <td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: justify">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Estimated <br/>
useful lives</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-size: 10pt">Software</span></td> <td style="white-space: nowrap; text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">3 years</span></td></tr> <tr style="vertical-align: top; "> <td style="width: 88%"><span style="font-size: 10pt">Patents</span></td> <td style="white-space: nowrap; width: 1%; text-align: justify">&#160;</td> <td style="text-align: center; width: 11%"><span style="font-size: 10pt">6 years</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock', window );">Schedule of Estimated Useful Lives</a></td>
<td class="text">Estimated useful lives are as follows:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 88%"><span style="font-size: 10pt"><b>Category</b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; width: 11%"><span style="font-size: 10pt"><b>Estimated <br/>
useful lives</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Lab equipment</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 to 5 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">Computer equipment</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 to 5 years</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Furniture and fixtures</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 to 5 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">Leasehold improvements</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 years</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of equipment, net at cost less accumulated depreciation and impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets, Net</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Tax refundable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">221,889</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">161,142</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,548</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,035</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,782</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Prepayment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,894,437</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237,960</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,128,656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">443,137</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: allowance for credit losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total prepaid expenses and other current assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,128,656</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">443,137</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Equipment, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equipment, net, consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,619,480</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,486,392</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,917</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,745</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,332</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">204,430</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">201,516</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,894,332</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,754,985</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,562,986</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,230,457</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Equipment, net</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">331,346</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">524,528</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Company&#8217;s Finite-Lived Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the carrying amount
of the Company&#8217;s finite-lived intangible assets:</p>

<p style="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Acquired technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">372,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">391,016</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(372,197</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(272,018</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">118,998</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties &#8211; Related Corporarions, Non-Current (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties &#8211; Related Corporarions, Non-Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Account Payable, Accrued Expenses and Other Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account Payable, accrued expenses and other liabilities
consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Accounts payable</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">632,697</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">620,476</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Payroll payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,216</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,113</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Amount due to related parties &#8211; major stockholders *</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172,767</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113,812</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Amount due to related parties &#8211; related corporations**</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">916,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">674,262</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other payable#</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,102,601</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,184,586</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">&#160;Total Accounts payable, accruals, and other current liabilities</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,853,317</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,670,249</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Amount due to related parties &#8211; related corporations, non-current***</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">139,772</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in; text-align: right"></td><td style="width: 0.25in">*</td><td style="text-align: justify">The amount due to the Company&#8217;s major stockholders as of June 30, 2025 and 2024 is
non-trade, unsecured, interest-free and repayable on demand.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in; text-align: right"></td><td style="width: 0.25in">**</td><td style="text-align: justify">The amount due to related corporations, which the Company&#8217;s major stockholders have
controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and repayable on demand.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 0pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td> <td style="padding-bottom: 0pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount due to related corporations, which the Company&#8217;s major stockholders have controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and the remaining loan term are over one year. The Company believes the carrying value approximates fair value.</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in; text-align: right"></td><td style="width: 0.25in">#</td><td style="text-align: justify">The amount consists of payables owed to third party creditors, which are unsecured, interest-free
and repayable on demand, and other payables due to operational use.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other Expense, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock', window );">Schedule of Other Expense, Net</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expense), net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(29,040</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">486</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Foreign exchange loss, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(233,808</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(294,687</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Other expense, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(262,848</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(294,201</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the detailed components of other nonoperating expenses. This disclosure may include methodology, assumptions and amounts for : (a) losses on securities (net of profits) and (b) miscellaneous income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciles the Operating Profit</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The income tax provision consists of the following
component:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">The following table reconciles the operating
profit to the Company&#8217;s effective tax rate:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Loss before tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(3,258,969</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,782,278</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Statutory income tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax expense calculated at the statutory tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effect of tax losses carry forwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,890,755</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,019,708</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of subsidiaries foreign income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,890,755</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,019,708</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Effective tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>State of Nevada</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Tax at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Provision for taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Taiwan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Tax at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Different foreign subsidiary tax rate impact</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Provision for taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>China</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Tax at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Different foreign subsidiary tax rate impact</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(25</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Provision for taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Hong Kong</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Tax at federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Different foreign subsidiary tax rate impact</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12.75</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12.75</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.25</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8.25</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Provision for taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Component of Deferred Tax Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The component of deferred tax assets are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating losses carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,890,755</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,019,708</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,890,755</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,019,708</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Parties Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These related parties of the Company with whom
transactions are reported in these financial statements are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 35%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of Related Party</b></span></td> <td style="width: 1%">&#160;</td> <td style="width: 64%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship to Us</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi Lu, Ph.D.</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board and Chief Executive Officer of the Company</span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau, Ph.D.</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder of the Company</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven I-Fang Cheng, Ph.D.</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Chief Technology Officer of the Company</span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chen-Yi Lee</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chen-Yi Lee is the sole director and the controlling person of Advance On Ventures Limited, which owns 10.92% equity interest in the Company and has sole voting and dispositive power over shares beneficially owned by Advance On Ventures Limited. Chen-Yi Lee is also the Stockholder of the Company</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance On Ventures Limited</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder of the Company</span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Fancy Development Ltd</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau is the director and stockholder of the entity</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd.</span></td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau is the legal person and stockholder of the entity</span></td></tr> </table>The following table provides the transactions with these parties for the&#160;years
as presented (for the portion of such period that they were considered related):<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Amount due to related parties &#8211; major stockholders</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"><span style="text-decoration:underline">Name of related party</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi Lu, Ph.D. <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">122,626</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">110,268</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chen-Yi Lee <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,544</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hung To Pau, Ph.D. <sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,705</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">172,767</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">113,812</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Amount due to related parties &#8211; related corporations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Name of related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Fancy Development Ltd <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">211,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd. <sup>(5)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">704,953</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">674,262</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">916,036</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">674,262</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Non-Current:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left">Name of related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well Fancy Development Ltd <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Junfu Electronic Technology Co., Ltd. <sup>(5)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">69,797</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">139,772</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Advanced Biomed Inc.(Taiwan) entered into an unsecured, interest-free loan to Yi Lu amounting to NTD 3,578,212 (approximately US$122,626) for general working capital in January 2023. As of June 30, 2025 and 2024, the loan balance due to Yi Lu amounted to US$122,626 and US$110,268, respectively.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Payments of expenses on behalf of Advanced Biomed Inc. (Taiwan).</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Advanced Biomed Inc.(HK) entered into one unsecured, interest-free loan to Hung To Pau, Ph.D. amounting to US$200,000 for general working capital in July 2024 and the amount was full settled in 2025. And Shanghai Sglcell Biotech Co., Ltd entered into three unsecured, interest-free loans to Hung To Pau, Ph.D. amounting to RMB122,566 (approximately US$17,110), RMB121,681 (approximately US$16,986) and RMB76,000 (approximately US$10,609) for general working capital in October 2024, November 2024 and December 2024. As of June 30, 2025, the loan balance due to Hung To Pau, Ph.D. totally amounted to RMB320,247 (approximately US$44,705) for general working capital.</span></td></tr>
</table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt">4.</span></td> <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Advanced Biomed Inc.(Taiwan) entered into seven unsecured, interest-free
loans to Well Fancy Development Ltd amounting to NTD 5,740,600 (approximately US$196,731), NTD 1,911,944 (approximately US$65,522), NTD
1,906,840 (approximately US$65,347), NTD 3,121,500 (approximately US$106,974), NTD 1,798,060 (approximately US$61,620), NTD 1,291,552
(approximately US$44,262) and NTD 455,992 (approximately US$15,627) for general working capital in July 2024, October 2024, November 2024,
December 2024, January 2025, February 2025 and March 2025. In March 2025, Advanced Biomed Inc.(HK) paid US$550,000 to Well Fancy Development
Ltd for Advanced Biomed Inc.(Taiwan)&#8217;s debt. And Advanced Biomed Inc. entered into two unsecured, interest-free loan to Well Fancy
Development Ltd amounting to US$119,975 and US$205,000 for general working capital in November 2024 and March 2025. In March 2025, Advanced
Biomed Inc. paid US$50,000 to Well Fancy Development Ltd for repayment. As of June 30, 2025, the loan balance due to Well Fancy Development
Ltd totally amounted to NTD 177,488(approximately US$6,083) and US$274,975 for general working capital.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Sglcell Biotech Co., Ltd entered into nine unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. amounting to RMB500,000 (approximately US$69,797) in April 2023, May 2023, June 2023 and September 2023, respectively, and RMB700,000 (approximately US$97,716), RMB1,000,000 (approximately US$139,595), RMB500,000 (approximately US$69,797), RMB700,000 (approximately US$97,716) and RMB650,000 (approximately US$90,738) in January 2024, March 2024, March 2024, June 2024 and October 2024, respectively, for general working capital. As of June 30, 2025 and 2024 the loan balance due to Shanghai Junfu Electronic Technology Co., Ltd totally amounted to RMB5,550,000 (approximately US$774,750) and RMB4,900,000 (approximately to US$674,262), respectively.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Significant Expense Categories in Single Operating Segment</a></td>
<td class="text">The following table presents the
significant expense categories in the Company&#8217;s single operating segment:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/> year ended <br/> June&#160;30, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the <br/> year ended <br/> June&#160;30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">US$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(909,771</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(880,193</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,111,265</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,661,379</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(237,933</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(240,706</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net Loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(3,258,969</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(2,782,278</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Lease ROU Assets and Lease Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recognized operating lease ROU assets and
lease liabilities as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease ROU asset</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">65,399</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">126,740</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current portion</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">35,811</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">62,211</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,879</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,529</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">41,690</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">126,740</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes other supplemental information
about the Company&#8217;s operating lease as of June 30, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Weighted average discount rate</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.40</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted average remaining lease term (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.15</td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2025, future minimum lease payments
under the non-cancellable operating leases are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Future payment</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">36,532</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,929</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total future lease payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,461</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(771</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Present value of operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">41,690</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease liabilities, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,811</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease liabilities, non-current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,879</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Principal Activities (Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 07, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 07, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 09, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 08, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 08, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Oct. 25, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 24, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jun. 08, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 06, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 15, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 16, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 12, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,493,800<span></span>
</td>
<td class="num">$ (85,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 16,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Settle debt of total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,040,000.00<span></span>
</td>
<td class="nump">&#165; 22,200,000<span></span>
</td>
<td class="nump">$ 174,020,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_ShanghaiSglcellBiotechCoLtdMember', window );">Shanghai Sglcell Biotech Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Percentage of equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_BeijingYitanJiaruiTechnologyCoLtdMember', window );">Beijing Yitan Jiarui Technology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Aggregate consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,942<span></span>
</td>
<td class="nump">&#165; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_BusinessCombinationConsiderationNetAssetFairValue', window );">Net asset value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,739<span></span>
</td>
<td class="nump">&#165; 498,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_ShandongSglcellMedicalDevicesCoLtdMember', window );">Shandong Sglcell Medical Devices Co Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_BusinessCombinationConsiderationNetAssetFairValue', window );">Net asset value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_DrHungToPauMember', window );">Dr. Hung To Pau [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Aggregate consideration amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,405,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_SglcellLtdMember', window );">Sglcell Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_DrYiLuMember', window );">Dr. Yi Lu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Percentage of equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.99%<span></span>
</td>
<td class="nump">99.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Aggregate consideration amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_ChenYiLeeMember', window );">Chen-Yi Lee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Percentage of equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01%<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_AdvancedBiomedHKLimitedMember', window );">Advanced Biomed HK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Percentage of equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_AdvanceOnVenturesLimitedMember', window );">Advance On Ventures Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,730,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_YiminJinMember', window );">Yimin Jin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,193,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_XiaoyuanLuoMember', window );">Xiaoyuan Luo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,060,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_NanzhenShenMember', window );">Nanzhen Shen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,511,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_JianWangMember', window );">Jian Wang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,243,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_QiangChenMember', window );">Qiang Chen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_HanyuAssetsCoLtdMember', window );">Hanyu Assets Co. Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=advb_NewlinkTechnologyIncMember', window );">Newlink Technology Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=advb_ShareExchangeMember', window );">Share Exchange [Member] | Dr. Yi Lu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=advb_ShanghaiSglcellBiotechCoLtdMember', window );">Shanghai Sglcell Biotech Co., Ltd. [Member] | Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Aggregate consideration amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_BusinessCombinationConsiderationNetAssetFairValue', window );">Net asset value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=advb_ChenYiLeeMember', window );">Chen-Yi Lee [Member] | Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Organization and Principal Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="nump">$ 6,560,000<span></span>
</td>
<td class="nump">$ 6,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_NetProceedsFromInitialPublicOffering', window );">Net proceeds from IPO (in Dollars) | $</a></td>
<td class="nump">$ 5,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_BusinessCombinationConsiderationNetAssetFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of business combination consideration net assets fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_BusinessCombinationConsiderationNetAssetFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_NetProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds from initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_NetProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interest issued or issuable by acquirer as part of consideration transferred in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-42<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-9<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_ShanghaiSglcellBiotechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_ShanghaiSglcellBiotechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_BeijingYitanJiaruiTechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_BeijingYitanJiaruiTechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_ShandongSglcellMedicalDevicesCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_ShandongSglcellMedicalDevicesCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_DrHungToPauMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_DrHungToPauMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_SglcellLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_SglcellLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_DrYiLuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_DrYiLuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_ChenYiLeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_ChenYiLeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_AdvancedBiomedHKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_AdvancedBiomedHKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_AdvanceOnVenturesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_AdvanceOnVenturesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_YiminJinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_YiminJinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_XiaoyuanLuoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_XiaoyuanLuoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_NanzhenShenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_NanzhenShenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_JianWangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_JianWangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_QiangChenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_QiangChenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_HanyuAssetsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_HanyuAssetsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=advb_NewlinkTechnologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=advb_NewlinkTechnologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=advb_ShareExchangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=advb_ShareExchangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=advb_DrYiLuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=advb_DrYiLuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=advb_ShanghaiSglcellBiotechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=advb_ShanghaiSglcellBiotechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=advb_ChenYiLeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=advb_ChenYiLeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Principal Activities - Schedule of Subsidiaries (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=advb_AdvancedBiomedIncMember', window );">Advanced Biomed Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate', window );">Date of Incorporation</a></td>
<td class="text">Jul. 16,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of effective ownership</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Place of incorporation</a></td>
<td class="text">Nevada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">Investment holding<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=advb_AdvancedBiomedIncTaiwanMember', window );">Advanced Biomed Inc. (Taiwan) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate', window );">Date of Incorporation</a></td>
<td class="text">Sep.  01,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of effective ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Place of incorporation</a></td>
<td class="text">Taiwan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">Research and development of various advanced and innovative microfluidic biochip technologies, and provide the leading application of such technologies in precision oncology detection, diagnosis and treatment<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=advb_AdvancedBiomedHKLimitedMember', window );">Advanced Biomed HK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate', window );">Date of Incorporation</a></td>
<td class="text">Aug. 10,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of effective ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Place of incorporation</a></td>
<td class="text">Hong Kong<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">Market development<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=advb_ShanghaiSglcellBiotechCoLtdMember', window );">Shanghai Sglcell Biotech Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Subsidiaries [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate', window );">Date of Incorporation</a></td>
<td class="text">Apr. 12,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of effective ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState', window );">Place of incorporation</a></td>
<td class="text">People&#8217;s Republic of China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">Clinical-related business<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of business purpose of the subsidiary of the limited liability company or limited partnership, for example, its day-to-day operating functions and whether it acts as a holding or operating company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary of the limited liability company (LLC) or limited partnership (LP) was formed, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>State in which the subsidiary of the limited liability company or limited partnership was organized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=advb_AdvancedBiomedIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=advb_AdvancedBiomedIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=advb_AdvancedBiomedIncTaiwanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=advb_AdvancedBiomedIncTaiwanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=advb_AdvancedBiomedHKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=advb_AdvancedBiomedHKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=advb_ShanghaiSglcellBiotechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=advb_ShanghaiSglcellBiotechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 06, 2025</div></th>
<th class="th"><div>Mar. 07, 2025</div></th>
<th class="th"><div>Mar. 07, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_workingCapital', window );">Working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,820,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,493,800<span></span>
</td>
<td class="num">(85,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,258,969)<span></span>
</td>
<td class="num">(2,782,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash outflows</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,825,055)<span></span>
</td>
<td class="num">(2,126,340)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,560,000<span></span>
</td>
<td class="nump">$ 6,560,000<span></span>
</td>
<td class="nump">$ 6,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Liquidity and Going Concern [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Purchase from common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_workingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of total working capital as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_workingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 15, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 16, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_ForwardShareSplitIssued', window );">Forward share split issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_ForwardShareSplitOutstanding', window );">Forward share split outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Percentage split ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5:1<span></span>
</td>
<td class="text">1-to-4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Tax position, description</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A tax position is measured at the largest amount of benefit that is greater than 50
percent likely of being realized upon ultimate settlement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,197<span></span>
</td>
<td class="nump">$ 391,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_ShanghaiSglcellBiotechCoLtdMember', window );">Shanghai Sglcell Biotech Co., Ltd. [Member] | Patents [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Adjusted share split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Adjusted share split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Capitalized deferred costs (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 638,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_DeferredInitialPublicOfferingCost', window );">Deferred initial public offering cost (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_ForwardShareSplitIssued', window );">Forward share split issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_ForwardShareSplitOutstanding', window );">Forward share split outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_DeferredInitialPublicOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred initial public offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_DeferredInitialPublicOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_ForwardShareSplitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forward share split issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_ForwardShareSplitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_ForwardShareSplitOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forward share split outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_ForwardShareSplitOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_ShanghaiSglcellBiotechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_ShanghaiSglcellBiotechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates used in Preparing Financial Statements (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=advb_FiscalYearEndCurrencyRateMember', window );">Fiscal Year End [Member] | US$ to NT$ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenForwardForeignCurrencyContractLineItems', window );"><strong>Schedule of Currency Exchange Rates used in Preparing Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates</a></td>
<td class="nump">29.18<span></span>
</td>
<td class="nump">32.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=advb_FiscalYearEndCurrencyRateMember', window );">Fiscal Year End [Member] | US$ to CNY [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenForwardForeignCurrencyContractLineItems', window );"><strong>Schedule of Currency Exchange Rates used in Preparing Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates</a></td>
<td class="nump">7.16<span></span>
</td>
<td class="nump">7.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=advb_FiscalYearEndCurrencyRateMember', window );">Fiscal Year End [Member] | US$ to HKD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenForwardForeignCurrencyContractLineItems', window );"><strong>Schedule of Currency Exchange Rates used in Preparing Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates</a></td>
<td class="nump">7.85<span></span>
</td>
<td class="nump">7.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=advb_CurrencyExchangeAverageRateMember', window );">Average Rate [Member] | US$ to NT$ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenForwardForeignCurrencyContractLineItems', window );"><strong>Schedule of Currency Exchange Rates used in Preparing Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates</a></td>
<td class="nump">32.09<span></span>
</td>
<td class="nump">31.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=advb_CurrencyExchangeAverageRateMember', window );">Average Rate [Member] | US$ to CNY [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenForwardForeignCurrencyContractLineItems', window );"><strong>Schedule of Currency Exchange Rates used in Preparing Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates</a></td>
<td class="nump">7.21<span></span>
</td>
<td class="nump">7.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=advb_CurrencyExchangeAverageRateMember', window );">Average Rate [Member] | US$ to HKD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenForwardForeignCurrencyContractLineItems', window );"><strong>Schedule of Currency Exchange Rates used in Preparing Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency exchange rates</a></td>
<td class="nump">7.79<span></span>
</td>
<td class="nump">7.82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenForwardForeignCurrencyContractLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenForwardForeignCurrencyContractLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=advb_FiscalYearEndCurrencyRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=advb_FiscalYearEndCurrencyRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_TWD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_TWD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CNY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CNY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_HKD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_HKD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=advb_CurrencyExchangeAverageRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis=advb_CurrencyExchangeAverageRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Intangible Assets are stated at Cost less Accumulated Amortization and Impairment (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Schedule of Intangible Assets are stated at Cost less Accumulated Amortization and Impairment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Straight-line basis over the estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Schedule of Intangible Assets are stated at Cost less Accumulated Amortization and Impairment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Straight-line basis over the estimated useful lives</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Estimated Useful Lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets, Net - Schedule of Prepaid Expenses and Other Current Assets, Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Schedule of Prepaid Expenses and Other Current Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Tax refundable</a></td>
<td class="nump">$ 221,889<span></span>
</td>
<td class="nump">$ 161,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other receivables</a></td>
<td class="nump">10,548<span></span>
</td>
<td class="nump">44,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">1,782<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepayment</a></td>
<td class="nump">2,894,437<span></span>
</td>
<td class="nump">237,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_PrepaidExpensesAndOtherCurrentAssetGross', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">3,128,656<span></span>
</td>
<td class="nump">443,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent', window );">Less: allowance for credit losses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 3,128,656<span></span>
</td>
<td class="nump">$ 443,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_PrepaidExpensesAndOtherCurrentAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of prepaid expenses and other current asset, gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_PrepaidExpensesAndOtherCurrentAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on receivable, classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 224,832<span></span>
</td>
<td class="nump">$ 268,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equipment, Net - Schedule of Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment, gross</a></td>
<td class="nump">$ 1,894,332<span></span>
</td>
<td class="nump">$ 1,754,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,562,986)<span></span>
</td>
<td class="num">(1,230,457)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment, net</a></td>
<td class="nump">331,346<span></span>
</td>
<td class="nump">524,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=advb_LabEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment, gross</a></td>
<td class="nump">1,619,480<span></span>
</td>
<td class="nump">1,486,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment, gross</a></td>
<td class="nump">33,917<span></span>
</td>
<td class="nump">31,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment, gross</a></td>
<td class="nump">36,505<span></span>
</td>
<td class="nump">35,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment, gross</a></td>
<td class="nump">$ 204,430<span></span>
</td>
<td class="nump">$ 201,516<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=advb_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=advb_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Company&#8217;s Finite-Lived Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Company&#8217;s Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="nump">$ 372,197<span></span>
</td>
<td class="nump">$ 391,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(372,197)<span></span>
</td>
<td class="num">(272,018)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 118,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties &#8211; Related Corporarions, Non-Current (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties &#8211; Related Corporarions, Non-Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Remaining loan term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties &#8211; Related Corporarions, Non-Current - Schedule of Account Payable, Accrued Expenses and Other Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Schedule of Account Payable, Accrued Expenses and Other Liabilities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 632,697<span></span>
</td>
<td class="nump">$ 620,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Payroll payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,216<span></span>
</td>
<td class="nump">77,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Other payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,102,601<span></span>
</td>
<td class="nump">1,184,586<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total Accounts payable, accruals, and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,853,317<span></span>
</td>
<td class="nump">2,670,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Major Stockholders [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Schedule of Account Payable, Accrued Expenses and Other Liabilities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Amount due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">172,767<span></span>
</td>
<td class="nump">113,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Related Corporations [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Schedule of Account Payable, Accrued Expenses and Other Liabilities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Amount due to related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">916,036<span></span>
</td>
<td class="nump">674,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Amount due to related parties &#8211; related corporations, non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 139,772<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The amount consists of payables owed to third party creditors, which are unsecured, interest-free
and repayable on demand, and other payables due to operational use.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The amount due to the Company&#8217;s major stockholders as of June 30, 2025 and 2024 is
non-trade, unsecured, interest-free and repayable on demand.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The amount due to related corporations, which the Company&#8217;s major stockholders have
controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and repayable on demand.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount due to related corporations, which the Company&#8217;s major stockholders have controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and the remaining loan term are over one year. The Company believes the carrying value approximates fair value.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expense, Net - Schedule of Other Expense, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentOfOtherExpenseNonoperatingLineItems', window );"><strong>Schedule of Other Expense, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_OtherNonoperatingIncomeExpenseGross', window );">Other income (expense), net</a></td>
<td class="num">$ (29,040)<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossAfterTax', window );">Foreign exchange loss, net</a></td>
<td class="num">(233,808)<span></span>
</td>
<td class="num">(294,687)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">$ (262,848)<span></span>
</td>
<td class="num">$ (294,201)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_OtherNonoperatingIncomeExpenseGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_OtherNonoperatingIncomeExpenseGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentOfOtherExpenseNonoperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentOfOtherExpenseNonoperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-38<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2025</div></th>
<th class="th"><div>Mar. 07, 2025</div></th>
<th class="th"><div>Oct. 15, 2024</div></th>
<th class="th"><div>May 16, 2023</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">21,640,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">21,640,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock retain a par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,493,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (85,400)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Share split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Share split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,640,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,560,000<span></span>
</td>
<td class="nump">$ 6,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,560,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock retain a par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,640,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>HKD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_NetOperatingLossCarryForwardOffset', window );">Net operating loss carry forward offset</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 13,167,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,767,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Income tax rate</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxable income</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NV', window );">NEVADA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Subject to state income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 4,896,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,817,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_TW', window );">Taiwan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 5,824,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_HK', window );">Hong Kong [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 94,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Income tax rate</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxable income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxable income rate</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 2,352,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744,480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_NetOperatingLossCarryForwardOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net operating loss carry forward offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_NetOperatingLossCarryForwardOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NV">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_NV</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_TW">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_TW</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciles the Operating Profit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before tax (in Dollars)</a></td>
<td class="num">$ (3,258,969)<span></span>
</td>
<td class="num">$ (2,782,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate', window );">Income tax expense calculated at the statutory tax rate (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_EffectOfTaxLossesCarryForwards', window );">Effect of tax losses carry forwards (in Dollars)</a></td>
<td class="num">(2,890,755)<span></span>
</td>
<td class="num">(2,019,708)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Effect of subsidiaries foreign income (in Dollars)</a></td>
<td class="nump">$ 2,890,755<span></span>
</td>
<td class="nump">$ 2,019,708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NV', window );">State of Nevada [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_TW', window );">Taiwan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Different foreign subsidiary tax rate impact</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances</a></td>
<td class="num">(20.00%)<span></span>
</td>
<td class="num">(20.00%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Different foreign subsidiary tax rate impact</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances</a></td>
<td class="num">(25.00%)<span></span>
</td>
<td class="num">(25.00%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">Hong Kong [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Different foreign subsidiary tax rate impact</a></td>
<td class="num">(12.75%)<span></span>
</td>
<td class="num">(12.75%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances</a></td>
<td class="num">(8.25%)<span></span>
</td>
<td class="num">(8.25%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_EffectOfTaxLossesCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of tax losses carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_EffectOfTaxLossesCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NV">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NV</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TW">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TW</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Component of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Schedule of Component of Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses carry forward</a></td>
<td class="nump">$ 2,890,755<span></span>
</td>
<td class="nump">$ 2,019,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(2,890,755)<span></span>
</td>
<td class="num">(2,019,708)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option (Details) - 2023 Plan [Member]<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Stock Option [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Term of option</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advb_TwoThousandTwentyThreePlanMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Stock Option [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock under the plan</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options to purchase any shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=advb_TwoThousandTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=advb_TwoThousandTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3"></th>
<th class="th" colspan="3"></th>
<th class="th" colspan="3"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2025 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>TWD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment to related party</a></td>
<td class="nump">$ 9,040,000.00<span></span>
</td>
<td class="nump">&#165; 22,200,000<span></span>
</td>
<td class="nump">$ 174,020,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=advb_ShanghaiSglcellBiotechCoLtdMember', window );">Shanghai Sglcell Biotech Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Interest-free loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,738<span></span>
</td>
<td class="nump">&#165; 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,716<span></span>
</td>
<td class="nump">&#165; 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=advb_ShanghaiJunfuElectronicTechnologyCoLtdMember', window );">Shanghai Junfu Electronic Technology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_WorkingCapitalLoan', window );">Working capital loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 774,750<span></span>
</td>
<td class="nump">&#165; 5,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_YiLuPhDMember', window );">Yi Lu, Ph.D. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Interest-free loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,626<span></span>
</td>
<td class="nump">$ 3,578,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_WorkingCapitalLoan', window );">Working capital loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_HungToPauPhDMember', window );">Hung To Pau, Ph.D. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Interest-free loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,609<span></span>
</td>
<td class="nump">&#165; 76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,986<span></span>
</td>
<td class="nump">&#165; 121,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,110<span></span>
</td>
<td class="nump">&#165; 122,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_WorkingCapitalLoan', window );">Working capital loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,705<span></span>
</td>
<td class="nump">&#165; 320,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_WellFancyDevelopmentLtdMember', window );">Well Fancy Development Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Interest-free loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 455,992<span></span>
</td>
<td class="nump">$ 44,262<span></span>
</td>
<td class="nump">$ 1,291,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,798,060<span></span>
</td>
<td class="nump">$ 106,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,121,500<span></span>
</td>
<td class="nump">65,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,906,840<span></span>
</td>
<td class="nump">$ 65,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,911,944<span></span>
</td>
<td class="nump">$ 196,731<span></span>
</td>
<td class="nump">$ 5,740,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Payment to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_WellFancyDevelopmentLtdMember', window );">Well Fancy Development Ltd [Member] | Advanced Biomed Inc. (Taiwan) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_WorkingCapitalLoan', window );">Working capital loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_WellFancyDevelopmentLtdMember', window );">Well Fancy Development Ltd [Member] | Shanghai Junfu Electronic Technology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_WorkingCapitalLoan', window );">Working capital loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 674,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Shanghai Sglcell Biotech Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Interest-free loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 700,000<span></span>
</td>
<td class="nump">$ 139,595<span></span>
</td>
<td class="nump">&#165; 1,000,000<span></span>
</td>
<td class="nump">$ 97,716<span></span>
</td>
<td class="nump">&#165; 700,000<span></span>
</td>
<td class="nump">$ 69,797<span></span>
</td>
<td class="nump">&#165; 500,000<span></span>
</td>
<td class="nump">$ 69,797<span></span>
</td>
<td class="nump">&#165; 500,000<span></span>
</td>
<td class="nump">$ 69,797<span></span>
</td>
<td class="nump">&#165; 500,000<span></span>
</td>
<td class="nump">$ 69,797<span></span>
</td>
<td class="nump">&#165; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Well Fancy Development Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Interest-free loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Well Fancy Development Ltd [Member] | Advanced Biomed Inc. (Taiwan) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_WorkingCapitalLoan', window );">Working capital loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_WorkingCapitalLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of working capital loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_WorkingCapitalLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=advb_ShanghaiSglcellBiotechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=advb_ShanghaiSglcellBiotechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=advb_ShanghaiJunfuElectronicTechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=advb_ShanghaiJunfuElectronicTechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_YiLuPhDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_YiLuPhDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_HungToPauPhDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_HungToPauPhDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_WellFancyDevelopmentLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_WellFancyDevelopmentLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=advb_AdvancedBiomedIncTaiwanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=advb_AdvancedBiomedIncTaiwanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Schedule of Related Parties Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_YiLuPhDMember', window );">Yi Lu, Ph.D.[Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship to Us</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Chairman of the Board and Chief Executive Officer of the Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_NameOfRelatedPartyAbstract', window );"><strong>Name of related party</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Amount due to related parties &#8211; major stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 122,626<span></span>
</td>
<td class="nump">$ 110,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_HungToPauPhDMember', window );">Hung To Pau, Ph.D. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship to Us</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Stockholder of the Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_NameOfRelatedPartyAbstract', window );"><strong>Name of related party</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Amount due to related parties &#8211; major stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 44,705<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_StevenIFangChengPhDMember', window );">Steven I-Fang Cheng, Ph.D. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship to Us</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Director and Chief Technology Officer of the Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_ChenYiLeeMember', window );">Chen-Yi Lee [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship to Us</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Chen-Yi Lee is the sole director and the controlling person of Advance On Ventures Limited, which owns 10.92% equity interest in the Company and has sole voting and dispositive power over shares beneficially owned by Advance On Ventures Limited. Chen-Yi Lee is also the Stockholder of the Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_NameOfRelatedPartyAbstract', window );"><strong>Name of related party</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Amount due to related parties &#8211; major stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 5,436<span></span>
</td>
<td class="nump">3,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_AdvanceOnVenturesLimitedMember', window );">Advance On Ventures Limited [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship to Us</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Stockholder of the Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_WellFancyDevelopmentLtdMember', window );">Well Fancy Development Ltd [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship to Us</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Hung To Pau is the director and stockholder of the entity<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_NameOfRelatedPartyAbstract0', window );"><strong>Name of related party</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Amount due to related Amount due to related parties &#8211; related corporations, current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 211,083<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_NameOfRelatedPartyAbstract1', window );"><strong>Name of related party</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Amount due to related Amount due to related parties &#8211; related corporations, non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 69,975<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_ShanghaiJunfuElectronicTechnologyCoLtdMember', window );">Shanghai Junfu Electronic Technology Co., Ltd. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Relationship to Us</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Hung To Pau is the legal person and stockholder of the entity<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_NameOfRelatedPartyAbstract0', window );"><strong>Name of related party</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Amount due to related Amount due to related parties &#8211; related corporations, current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 704,953<span></span>
</td>
<td class="nump">674,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_NameOfRelatedPartyAbstract1', window );"><strong>Name of related party</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Amount due to related Amount due to related parties &#8211; related corporations, non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">69,797<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_MajorStockholdersMember', window );">Major Stockholders [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_NameOfRelatedPartyAbstract', window );"><strong>Name of related party</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Amount due to related parties &#8211; major stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">172,767<span></span>
</td>
<td class="nump">113,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_RelatedCorporationsMember', window );">Related Corporations [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_NameOfRelatedPartyAbstract0', window );"><strong>Name of related party</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Amount due to related Amount due to related parties &#8211; related corporations, current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">916,036<span></span>
</td>
<td class="nump">$ 674,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_NameOfRelatedPartyAbstract1', window );"><strong>Name of related party</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Amount due to related Amount due to related parties &#8211; related corporations, non-current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 139,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Advanced Biomed Inc.(Taiwan) entered into an unsecured, interest-free loan to Yi Lu amounting to NTD 3,578,212 (approximately US$122,626) for general working capital in January 2023. As of June 30, 2025 and 2024, the loan balance due to Yi Lu amounted to US$122,626 and US$110,268, respectively.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Advanced Biomed Inc.(HK) entered into one unsecured, interest-free loan to Hung To Pau, Ph.D. amounting to US$200,000 for general working capital in July 2024 and the amount was full settled in 2025. And Shanghai Sglcell Biotech Co., Ltd entered into three unsecured, interest-free loans to Hung To Pau, Ph.D. amounting to RMB122,566 (approximately US$17,110), RMB121,681 (approximately US$16,986) and RMB76,000 (approximately US$10,609) for general working capital in October 2024, November 2024 and December 2024. As of June 30, 2025, the loan balance due to Hung To Pau, Ph.D. totally amounted to RMB320,247 (approximately US$44,705) for general working capital.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Payments of expenses on behalf of Advanced Biomed Inc. (Taiwan).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Advanced Biomed Inc.(Taiwan) entered into seven unsecured, interest-free
loans to Well Fancy Development Ltd amounting to NTD 5,740,600 (approximately US$196,731), NTD 1,911,944 (approximately US$65,522), NTD
1,906,840 (approximately US$65,347), NTD 3,121,500 (approximately US$106,974), NTD 1,798,060 (approximately US$61,620), NTD 1,291,552
(approximately US$44,262) and NTD 455,992 (approximately US$15,627) for general working capital in July 2024, October 2024, November 2024,
December 2024, January 2025, February 2025 and March 2025. In March 2025, Advanced Biomed Inc.(HK) paid US$550,000 to Well Fancy Development
Ltd for Advanced Biomed Inc.(Taiwan)&#8217;s debt. And Advanced Biomed Inc. entered into two unsecured, interest-free loan to Well Fancy
Development Ltd amounting to US$119,975 and US$205,000 for general working capital in November 2024 and March 2025. In March 2025, Advanced
Biomed Inc. paid US$50,000 to Well Fancy Development Ltd for repayment. As of June 30, 2025, the loan balance due to Well Fancy Development
Ltd totally amounted to NTD 177,488(approximately US$6,083) and US$274,975 for general working capital.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Sglcell Biotech Co., Ltd entered into nine unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. amounting to RMB500,000 (approximately US$69,797) in April 2023, May 2023, June 2023 and September 2023, respectively, and RMB700,000 (approximately US$97,716), RMB1,000,000 (approximately US$139,595), RMB500,000 (approximately US$69,797), RMB700,000 (approximately US$97,716) and RMB650,000 (approximately US$90,738) in January 2024, March 2024, March 2024, June 2024 and October 2024, respectively, for general working capital. As of June 30, 2025 and 2024 the loan balance due to Shanghai Junfu Electronic Technology Co., Ltd totally amounted to RMB5,550,000 (approximately US$774,750) and RMB4,900,000 (approximately to US$674,262), respectively.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_NameOfRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_NameOfRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_NameOfRelatedPartyAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_NameOfRelatedPartyAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_NameOfRelatedPartyAbstract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_NameOfRelatedPartyAbstract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_YiLuPhDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_YiLuPhDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_HungToPauPhDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_HungToPauPhDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_StevenIFangChengPhDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_StevenIFangChengPhDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_ChenYiLeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_ChenYiLeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_AdvanceOnVenturesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_AdvanceOnVenturesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_WellFancyDevelopmentLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_WellFancyDevelopmentLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_ShanghaiJunfuElectronicTechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_ShanghaiJunfuElectronicTechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_MajorStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_MajorStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_RelatedCorporationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advb_RelatedCorporationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Significant Expense Categories in Single Operating Segment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Schedule of Significant Expense Categories in Single Operating Segment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">$ (909,771)<span></span>
</td>
<td class="num">$ (880,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(2,111,265)<span></span>
</td>
<td class="num">(1,661,379)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(237,933)<span></span>
</td>
<td class="num">(240,706)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (3,258,969)<span></span>
</td>
<td class="num">$ (2,782,278)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations and Risks (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract', window );"><strong>Concentrations and Risks [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_advb_NumberOfDaysForOperationalExpenses', window );">Period of operational expenses</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advb_NumberOfDaysForOperationalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent number of days operational expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advb_NumberOfDaysForOperationalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Operating Lease ROU Assets and Lease Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Operating Lease ROU Assets and Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU asset</a></td>
<td class="nump">$ 65,399<span></span>
</td>
<td class="nump">$ 126,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">35,811<span></span>
</td>
<td class="nump">62,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="nump">5,879<span></span>
</td>
<td class="nump">64,529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 41,690<span></span>
</td>
<td class="nump">$ 126,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">1 year 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Future Minimum Lease Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 36,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">5,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payment</a></td>
<td class="nump">42,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">41,690<span></span>
</td>
<td class="nump">$ 126,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">35,811<span></span>
</td>
<td class="nump">62,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current portion</a></td>
<td class="nump">$ 5,879<span></span>
</td>
<td class="nump">$ 64,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>198</ContextCount>
  <ElementCount>246</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Changes in Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Organization and Principal Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/OrganizationandPrincipalActivities</Role>
      <ShortName>Organization and Principal Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/LiquidityandGoingConcern</Role>
      <ShortName>Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Prepaid Expenses and Other Current Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNet</Role>
      <ShortName>Prepaid Expenses and Other Current Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/EquipmentNet</Role>
      <ShortName>Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties ??? Related Corporarions, Non-Current</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrent</Role>
      <ShortName>Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties ??? Related Corporarions, Non-Current</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Other Expense, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/OtherExpenseNet</Role>
      <ShortName>Other Expense, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Stock Option</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/StockOption</Role>
      <ShortName>Stock Option</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Concentrations and Risks</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ConcentrationsandRisks</Role>
      <ShortName>Concentrations and Risks</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Organization and Principal Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesTables</Role>
      <ShortName>Organization and Principal Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/OrganizationandPrincipalActivities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Prepaid Expenses and Other Current Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNetTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/EquipmentNetTables</Role>
      <ShortName>Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/EquipmentNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/IntangibleAssetsNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties ??? Related Corporarions, Non-Current (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentTables</Role>
      <ShortName>Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties ??? Related Corporarions, Non-Current (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrent</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Other Expense, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/OtherExpenseNetTables</Role>
      <ShortName>Other Expense, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/OtherExpenseNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/RelatedPartyTransactions</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/SegmentInformation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/CommitmentsandContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Organization and Principal Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails</Role>
      <ShortName>Organization and Principal Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Organization and Principal Activities - Schedule of Subsidiaries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable</Role>
      <ShortName>Organization and Principal Activities - Schedule of Subsidiaries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Liquidity and Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails</Role>
      <ShortName>Liquidity and Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/LiquidityandGoingConcern</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates used in Preparing Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates used in Preparing Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Summary of Significant Accounting Policies - Schedule of Intangible Assets are stated at Cost less Accumulated Amortization and Impairment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Intangible Assets are stated at Cost less Accumulated Amortization and Impairment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Prepaid Expenses and Other Current Assets, Net - Schedule of Prepaid Expenses and Other Current Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable</Role>
      <ShortName>Prepaid Expenses and Other Current Assets, Net - Schedule of Prepaid Expenses and Other Current Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/EquipmentNetDetails</Role>
      <ShortName>Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/EquipmentNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Equipment, Net - Schedule of Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable</Role>
      <ShortName>Equipment, Net - Schedule of Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Intangible Assets, Net - Schedule of Company???s Finite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable</Role>
      <ShortName>Intangible Assets, Net - Schedule of Company???s Finite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties ??? Related Corporarions, Non-Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentDetails</Role>
      <ShortName>Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties ??? Related Corporarions, Non-Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties ??? Related Corporarions, Non-Current - Schedule of Account Payable, Accrued Expenses and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable</Role>
      <ShortName>Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties ??? Related Corporarions, Non-Current - Schedule of Account Payable, Accrued Expenses and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Other Expense, Net - Schedule of Other Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable</Role>
      <ShortName>Other Expense, Net - Schedule of Other Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/Equity</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/IncomeTaxesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Income Taxes - Schedule of Reconciles the Operating Profit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable</Role>
      <ShortName>Income Taxes - Schedule of Reconciles the Operating Profit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Income Taxes - Schedule of Component of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable</Role>
      <ShortName>Income Taxes - Schedule of Component of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Stock Option (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/StockOptionDetails</Role>
      <ShortName>Stock Option (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/StockOption</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Related Party Transactions - Schedule of Related Parties Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable</Role>
      <ShortName>Related Party Transactions - Schedule of Related Parties Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/SegmentInformationTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Segment Information - Schedule of Significant Expense Categories in Single Operating Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable</Role>
      <ShortName>Segment Information - Schedule of Significant Expense Categories in Single Operating Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Concentrations and Risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ConcentrationsandRisksDetails</Role>
      <ShortName>Concentrations and Risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.advanbiomed.com/role/ConcentrationsandRisks</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease ROU Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable</Role>
      <ShortName>Commitments and Contingencies - Schedule of Operating Lease ROU Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ea0257629-10k_advanced.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>advb-20250630.xsd</File>
    <File>advb-20250630_cal.xml</File>
    <File>advb-20250630_def.xml</File>
    <File>advb-20250630_lab.xml</File>
    <File>advb-20250630_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ea0257629-10k_advanced.htm">ea0257629-10k_advanced.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
    <File>image_015.jpg</File>
    <File>image_016.jpg</File>
    <File>image_017.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="571">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>101
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0257629-10k_advanced.htm": {
   "nsprefix": "advb",
   "nsuri": "http://www.advanbiomed.com/20250630",
   "dts": {
    "schema": {
     "local": [
      "advb-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_def.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_pre.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "advb-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "advb-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "advb-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "advb-20250630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0257629-10k_advanced.htm"
     ]
    }
   },
   "keyStandard": 227,
   "keyCustom": 19,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 25,
   "memberCustom": 30,
   "hidden": {
    "total": 79,
    "http://fasb.org/us-gaap/2025": 66,
    "http://www.advanbiomed.com/20250630": 9,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 198,
   "entityCount": 1,
   "segmentCount": 70,
   "elementCount": 637,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 571,
    "http://xbrl.sec.gov/dei/2025": 41,
    "http://xbrl.sec.gov/cyd/2025": 5,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.advanbiomed.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c9",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c9",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.advanbiomed.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.advanbiomed.com/role/OrganizationandPrincipalActivities",
     "longName": "995306 - Disclosure - Organization and Principal Activities",
     "shortName": "Organization and Principal Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.advanbiomed.com/role/LiquidityandGoingConcern",
     "longName": "995307 - Disclosure - Liquidity and Going Concern",
     "shortName": "Liquidity and Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "995308 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNet",
     "longName": "995309 - Disclosure - Prepaid Expenses and Other Current Assets, Net",
     "shortName": "Prepaid Expenses and Other Current Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.advanbiomed.com/role/EquipmentNet",
     "longName": "995310 - Disclosure - Equipment, Net",
     "shortName": "Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.advanbiomed.com/role/IntangibleAssetsNet",
     "longName": "995311 - Disclosure - Intangible Assets, Net",
     "shortName": "Intangible Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrent",
     "longName": "995312 - Disclosure - Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties \u2013 Related Corporarions, Non-Current",
     "shortName": "Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties \u2013 Related Corporarions, Non-Current",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.advanbiomed.com/role/OtherExpenseNet",
     "longName": "995313 - Disclosure - Other Expense, Net",
     "shortName": "Other Expense, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.advanbiomed.com/role/Equity",
     "longName": "995314 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.advanbiomed.com/role/IncomeTaxes",
     "longName": "995315 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.advanbiomed.com/role/StockOption",
     "longName": "995316 - Disclosure - Stock Option",
     "shortName": "Stock Option",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.advanbiomed.com/role/RelatedPartyTransactions",
     "longName": "995317 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.advanbiomed.com/role/SegmentInformation",
     "longName": "995318 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.advanbiomed.com/role/ConcentrationsandRisks",
     "longName": "995319 - Disclosure - Concentrations and Risks",
     "shortName": "Concentrations and Risks",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.advanbiomed.com/role/CommitmentsandContingencies",
     "longName": "995320 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.advanbiomed.com/role/SubsequentEvents",
     "longName": "995321 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesTables",
     "longName": "996001 - Disclosure - Organization and Principal Activities (Tables)",
     "shortName": "Organization and Principal Activities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996002 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNetTables",
     "longName": "996003 - Disclosure - Prepaid Expenses and Other Current Assets, Net (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.advanbiomed.com/role/EquipmentNetTables",
     "longName": "996004 - Disclosure - Equipment, Net (Tables)",
     "shortName": "Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.advanbiomed.com/role/IntangibleAssetsNetTables",
     "longName": "996005 - Disclosure - Intangible Assets, Net (Tables)",
     "shortName": "Intangible Assets, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentTables",
     "longName": "996006 - Disclosure - Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties \u2013 Related Corporarions, Non-Current (Tables)",
     "shortName": "Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties \u2013 Related Corporarions, Non-Current (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.advanbiomed.com/role/OtherExpenseNetTables",
     "longName": "996007 - Disclosure - Other Expense, Net (Tables)",
     "shortName": "Other Expense, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingExpenseByComponentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingExpenseByComponentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.advanbiomed.com/role/IncomeTaxesTables",
     "longName": "996008 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.advanbiomed.com/role/RelatedPartyTransactionsTables",
     "longName": "996009 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.advanbiomed.com/role/SegmentInformationTables",
     "longName": "996010 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.advanbiomed.com/role/CommitmentsandContingenciesTables",
     "longName": "996011 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
     "longName": "996012 - Disclosure - Organization and Principal Activities (Details)",
     "shortName": "Organization and Principal Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c38",
      "name": "us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable",
     "longName": "996013 - Disclosure - Organization and Principal Activities - Schedule of Subsidiaries (Details)",
     "shortName": "Organization and Principal Activities - Schedule of Subsidiaries (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c67",
      "name": "us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c67",
      "name": "us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails",
     "longName": "996014 - Disclosure - Liquidity and Going Concern (Details)",
     "shortName": "Liquidity and Going Concern (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "advb:workingCapital",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "advb:workingCapital",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996015 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c83",
      "name": "advb:ForwardShareSplitIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c83",
      "name": "advb:ForwardShareSplitIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable",
     "longName": "996016 - Disclosure - Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates used in Preparing Financial Statements (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates used in Preparing Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c91",
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c91",
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.advanbiomed.com/role/ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable",
     "longName": "996017 - Disclosure - Summary of Significant Accounting Policies - Schedule of Intangible Assets are stated at Cost less Accumulated Amortization and Impairment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Intangible Assets are stated at Cost less Accumulated Amortization and Impairment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c86",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable",
     "longName": "996018 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c103",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c103",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable",
     "longName": "996019 - Disclosure - Prepaid Expenses and Other Current Assets, Net - Schedule of Prepaid Expenses and Other Current Assets, Net (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets, Net - Schedule of Prepaid Expenses and Other Current Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PrepaidTaxes",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PrepaidTaxes",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.advanbiomed.com/role/EquipmentNetDetails",
     "longName": "996020 - Disclosure - Equipment, Net (Details)",
     "shortName": "Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable",
     "longName": "996021 - Disclosure - Equipment, Net - Schedule of Equipment, Net (Details)",
     "shortName": "Equipment, Net - Schedule of Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable",
     "longName": "996022 - Disclosure - Intangible Assets, Net - Schedule of Company\u2019s Finite-Lived Intangible Assets (Details)",
     "shortName": "Intangible Assets, Net - Schedule of Company\u2019s Finite-Lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentDetails",
     "longName": "996023 - Disclosure - Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties \u2013 Related Corporarions, Non-Current (Details)",
     "shortName": "Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties \u2013 Related Corporarions, Non-Current (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LongTermDebtTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LongTermDebtTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable",
     "longName": "996024 - Disclosure - Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties \u2013 Related Corporarions, Non-Current - Schedule of Account Payable, Accrued Expenses and Other Liabilities (Details)",
     "shortName": "Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties \u2013 Related Corporarions, Non-Current - Schedule of Account Payable, Accrued Expenses and Other Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable",
     "longName": "996025 - Disclosure - Other Expense, Net - Schedule of Other Expense, Net (Details)",
     "shortName": "Other Expense, Net - Schedule of Other Expense, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "advb:OtherNonoperatingIncomeExpenseGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingExpenseByComponentTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "advb:OtherNonoperatingIncomeExpenseGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingExpenseByComponentTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.advanbiomed.com/role/EquityDetails",
     "longName": "996026 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c83",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c83",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.advanbiomed.com/role/IncomeTaxesDetails",
     "longName": "996027 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable",
     "longName": "996028 - Disclosure - Income Taxes - Schedule of Reconciles the Operating Profit (Details)",
     "shortName": "Income Taxes - Schedule of Reconciles the Operating Profit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "advb:EffectOfTaxLossesCarryForwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable",
     "longName": "996029 - Disclosure - Income Taxes - Schedule of Component of Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of Component of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.advanbiomed.com/role/StockOptionDetails",
     "longName": "996030 - Disclosure - Stock Option (Details)",
     "shortName": "Stock Option (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c141",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c141",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails",
     "longName": "996031 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c63",
      "name": "us-gaap:RepaymentsOfRelatedPartyDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c176",
      "name": "us-gaap:UnsecuredDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable",
     "longName": "996032 - Disclosure - Related Party Transactions - Schedule of Related Parties Transactions (Details)",
     "shortName": "Related Party Transactions - Schedule of Related Parties Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c180",
      "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c180",
      "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.advanbiomed.com/role/SegmentInformationDetails",
     "longName": "996033 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable",
     "longName": "996034 - Disclosure - Segment Information - Schedule of Significant Expense Categories in Single Operating Segment (Details)",
     "shortName": "Segment Information - Schedule of Significant Expense Categories in Single Operating Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://www.advanbiomed.com/role/ConcentrationsandRisksDetails",
     "longName": "996035 - Disclosure - Concentrations and Risks (Details)",
     "shortName": "Concentrations and Risks (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "advb:NumberOfDaysForOperationalExpenses",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "advb:NumberOfDaysForOperationalExpenses",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable",
     "longName": "996036 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease ROU Assets and Lease Liabilities (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Operating Lease ROU Assets and Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable",
     "longName": "996037 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0257629-10k_advanced.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "advb_AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesDetailsTable",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties \u2013 Related Corporarions, Non-Current - Schedule of Account Payable, Accrued Expenses and Other Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Accounts payable, accruals, and other current liabilities",
        "terseLabel": "Accounts payable, accruals, and other current liabilities (including amount due to related parties \u2013 major stockholders as of June 30, 2025 and 2024, with $172,767 and $113,812 due to related parties \u2013 related corporations, and $916,036 and $674,262 due to related corporations, respectively (1))",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accruals and Other Current Liabilities and Amount Due to Related Parties \u2013 Related Corporarions, Non-Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCOUNTS PAYABLE, ACCRUALS AND OTHER CURRENT LIABILITIES AND AMOUNT DUE TO RELATED PARTIES \u2013 RELATED CORPORARIONS, NON-CURRENT",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r36",
      "r39",
      "r1012"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payable",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r765"
     ]
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedPayrollTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll payable",
        "label": "Accrued Payroll Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r101",
      "r525"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r49",
      "r110",
      "r520",
      "r540",
      "r541",
      "r1034"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r12",
      "r410",
      "r413",
      "r454",
      "r536",
      "r537",
      "r938",
      "r939",
      "r940",
      "r952",
      "r953",
      "r954",
      "r955"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r952",
      "r953",
      "r954",
      "r955",
      "r1035",
      "r1089"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Waiver of amount due to related parties \u2013 major stockholders",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for waiver of amount due to related parties \u2013 major stockholders.",
        "label": "Adjustments To Additional Paid In Capital Waiver Of Amount Due To Related Parties Major Stockholders"
       }
      }
     },
     "auth_ref": []
    },
    "advb_AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Waiver of amount due to related parties \u2013 related corporations",
        "documentation": "Amount of increase (decrease) in additional paid-in capital (APIC) waiver of the amount due to related parties \u2013 related corporations.",
        "label": "Adjustments To Additional Paid In Capital Waiver Of Amount Due To Related Parties Related Corporations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "advb_AdvanceOnVenturesLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "AdvanceOnVenturesLimitedMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance On Ventures Limited [Member]",
        "label": "Advance On Ventures Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "advb_AdvancedBiomedHKLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "AdvancedBiomedHKLimitedMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advanced Biomed HK Limited [Member]",
        "label": "Advanced Biomed HKLimited Member"
       }
      }
     },
     "auth_ref": []
    },
    "advb_AdvancedBiomedIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "AdvancedBiomedIncMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advanced Biomed Inc. [Member]",
        "label": "Advanced Biomed Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "advb_AdvancedBiomedIncTaiwanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "AdvancedBiomedIncTaiwanMember",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails",
      "http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advanced Biomed Inc. (Taiwan) [Member]",
        "label": "Advanced Biomed Inc Taiwan Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r841",
      "r876"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r828",
      "r844",
      "r879"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r829",
      "r845",
      "r871",
      "r880",
      "r884",
      "r892"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForDoubtfulOtherReceivablesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: allowance for credit losses",
        "label": "Allowance for Credit Loss, Receivable, Other, Current",
        "documentation": "Amount of allowance for credit loss on receivable, classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r78",
      "r104",
      "r134",
      "r135",
      "r136",
      "r167",
      "r182",
      "r195",
      "r198",
      "r208",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r404",
      "r406",
      "r431",
      "r509",
      "r510",
      "r515",
      "r598",
      "r705",
      "r706",
      "r713",
      "r765",
      "r776",
      "r777",
      "r788",
      "r983",
      "r984",
      "r1046"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r112",
      "r134",
      "r135",
      "r136",
      "r208",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r404",
      "r406",
      "r431",
      "r765",
      "r983",
      "r984",
      "r1046"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r208",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r404",
      "r406",
      "r431",
      "r983",
      "r984",
      "r1046"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r804",
      "r821"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r804",
      "r821"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r804",
      "r821"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "advb_BeijingYitanJiaruiTechnologyCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "BeijingYitanJiaruiTechnologyCoLtdMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beijing Yitan Jiarui Technology Co., Ltd. [Member]",
        "label": "Beijing Yitan Jiarui Technology Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r544",
      "r717",
      "r718",
      "r1022",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r544",
      "r717",
      "r718",
      "r1022",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued shares",
        "label": "Business Combination, Consideration Transferred, Equity Interest, Share Issued, Number of Shares",
        "documentation": "Number of shares of equity interest issued or issuable by acquirer as part of consideration transferred in business combination."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r725",
      "r726",
      "r757",
      "r758"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Principal Activities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r349",
      "r350",
      "r351",
      "r352",
      "r358",
      "r359",
      "r360",
      "r361",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r396",
      "r397",
      "r398",
      "r401",
      "r723",
      "r728",
      "r1022",
      "r1024",
      "r1025"
     ]
    },
    "advb_BusinessCombinationConsiderationNetAssetFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "BusinessCombinationConsiderationNetAssetFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net asset value",
        "documentation": "The amount of business combination consideration net assets fair value.",
        "label": "Business Combination Consideration Net Asset Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate consideration amount",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r398",
      "r723",
      "r725"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of equity interest",
        "label": "Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Percentage",
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r723",
      "r724",
      "r729",
      "r1022",
      "r1023"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r804",
      "r821"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "CN",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails",
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China [Member]",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "currency_CNY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "CNY",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US$ to CNY [Member]",
        "label": "China, Yuan Renminbi"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedComputerSoftwareNet",
     "crdr": "debit",
     "presentation": [
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized deferred costs (in Dollars)",
        "label": "Capitalized Computer Software, Net",
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r518",
      "r570",
      "r593",
      "r765",
      "r776",
      "r777",
      "r788",
      "r924"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Going Concern [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Going Concern [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash at beginning of the year",
        "periodEndLabel": "Cash at year end",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r57",
      "r131"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash",
        "terseLabel": "Net increase (decrease) in cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r57"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r509",
      "r511"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "advb_ChenYiLeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ChenYiLeeMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chen-Yi Lee [Member]",
        "label": "Chen Yi Lee Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/StockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r106",
      "r107",
      "r108",
      "r134",
      "r136",
      "r159",
      "r160",
      "r162",
      "r164",
      "r169",
      "r170",
      "r208",
      "r236",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r247",
      "r248",
      "r250",
      "r251",
      "r253",
      "r255",
      "r258",
      "r259",
      "r262",
      "r265",
      "r272",
      "r431",
      "r549",
      "r550",
      "r551",
      "r552",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r571",
      "r585",
      "r606",
      "r628",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r920",
      "r947",
      "r948",
      "r956"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r169",
      "r250",
      "r258",
      "r259",
      "r260",
      "r262",
      "r265",
      "r270",
      "r272",
      "r408",
      "r549",
      "r550",
      "r551",
      "r552",
      "r714",
      "r920",
      "r945",
      "r947"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r73",
      "r517",
      "r584"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r230",
      "r231",
      "r664",
      "r977",
      "r982"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r665"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails",
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3",
      "http://www.advanbiomed.com/role/StockOptionDetails",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r952",
      "r953",
      "r955",
      "r1035",
      "r1086",
      "r1089"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "verboseLabel": "Common stock par value (in Dollars per share)",
        "netLabel": "Common stock retain a par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r585"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.advanbiomed.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.advanbiomed.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r43",
      "r585",
      "r604",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock $0.001 par value per share; as of June 30, 2025 and 2024; 400,000,000 and 400,000,000 shares authorized; 21,640,000 and 20,000,000 shares issued and outstanding, respectively*",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r248",
      "r254",
      "r519",
      "r765"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_ComponentOfOtherExpenseNonoperatingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentOfOtherExpenseNonoperatingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Expense, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r114",
      "r116",
      "r121",
      "r507",
      "r530",
      "r531"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable",
      "http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment [Member]",
        "verboseLabel": "Computer equipment [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software [Member]",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r753",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r973",
      "r975",
      "r976"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r428"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/ConcentrationsandRisks"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONCENTRATIONS AND RISKS",
        "label": "Concentration Risk Disclosure [Text Block]",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r174",
      "r424",
      "r426",
      "r427",
      "r429",
      "r430",
      "r696",
      "r958"
     ]
    },
    "us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRisksTypesNoConcentrationPercentageAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations and Risks [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r692"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateJointVentureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateJointVentureMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow",
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related corporations",
        "verboseLabel": "Related Corporations",
        "netLabel": "Related Corporations [Member]",
        "label": "Corporate Joint Venture [Member]",
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "advb_CurrencyExchangeAverageRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "CurrencyExchangeAverageRateMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average Rate [Member]",
        "label": "Currency Exchange Average Rate Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]",
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r900"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r901"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r807",
      "r898"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r897"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r897"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r897"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r899"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r899"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred initial public offering (\u201cIPO\u201d) costs",
        "label": "Deferred Costs, Noncurrent",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r925"
     ]
    },
    "advb_DeferredInitialPublicOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "DeferredInitialPublicOfferingCost",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred initial public offering cost (in Dollars)",
        "documentation": "Deferred initial public offering cost.",
        "label": "Deferred Initial Public Offering Cost"
       }
      }
     },
     "auth_ref": []
    },
    "advb_DeferredInitialPublicOfferingIPOCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "DeferredInitialPublicOfferingIPOCostsPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Initial Public Offering (\u201cIPO\u201d) costs",
        "documentation": "The disclosure of accounting policies for deferred initial public offering (\u201cIPO\u201d) costs .",
        "label": "Deferred Initial Public Offering IPOCosts Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Component of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses carry forward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofComponentofDeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r848"
     ]
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable": {
       "parentTag": "advb_PrepaidExpensesAndOtherCurrentAssetGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.advanbiomed.com/role/EquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expenses",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r26",
      "r125",
      "r685",
      "r686",
      "r688",
      "r690"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r26"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/StockOption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK OPTION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r307",
      "r308",
      "r309",
      "r720"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r848"
     ]
    },
    "us-gaap_DividendsPayableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPayableLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Account Payable, Accrued Expenses and Other Liabilities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r804",
      "r821"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r804",
      "r821",
      "r872"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r804",
      "r821",
      "r872"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "advb_DrHungToPauMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "DrHungToPauMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dr. Hung To Pau [Member]",
        "label": "Dr Hung To Pau Member"
       }
      }
     },
     "auth_ref": []
    },
    "advb_DrYiLuMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "DrYiLuMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dr. Yi Lu [Member]",
        "label": "Dr Yi Lu Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r122",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r157",
      "r159",
      "r162",
      "r163",
      "r164",
      "r166",
      "r246",
      "r310",
      "r347",
      "r403",
      "r421",
      "r422",
      "r508",
      "r532",
      "r694"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r122",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r159",
      "r162",
      "r163",
      "r164",
      "r166",
      "r246",
      "r310",
      "r347",
      "r403",
      "r421",
      "r422",
      "r508",
      "r532",
      "r694"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r165"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency effect",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "advb_EffectOfTaxLossesCarryForwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "EffectOfTaxLossesCarryForwards",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of tax losses carry forwards (in Dollars)",
        "documentation": "Effect of tax losses carry forwards.",
        "label": "Effect Of Tax Losses Carry Forwards"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Provision for taxes",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r721"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails",
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax at federal statutory rate",
        "verboseLabel": "Statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r137",
      "r318",
      "r338",
      "r721"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowances",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r721",
      "r945",
      "r950",
      "r1014"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails",
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Different foreign subsidiary tax rate impact",
        "verboseLabel": "Taxable income rate",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r322",
      "r721",
      "r945",
      "r950",
      "r1014"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails",
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "terseLabel": "Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r721"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subject to state income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r721",
      "r945",
      "r950",
      "r1014"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r721"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Date of incorporation",
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Equipment [Member]",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails",
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r89",
      "r90",
      "r91",
      "r118",
      "r119",
      "r120",
      "r140",
      "r141",
      "r142",
      "r144",
      "r151",
      "r153",
      "r155",
      "r168",
      "r209",
      "r210",
      "r229",
      "r245",
      "r273",
      "r310",
      "r336",
      "r337",
      "r344",
      "r345",
      "r346",
      "r348",
      "r402",
      "r403",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r443",
      "r454",
      "r529",
      "r536",
      "r537",
      "r538",
      "r558",
      "r628"
     ]
    },
    "advb_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r841",
      "r876"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r822",
      "r838",
      "r873"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight-line basis over the estimated useful lives",
        "verboseLabel": "Estimated useful lives",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r213",
      "r222",
      "r681"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/IntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Finite-Lived Intangible Assets",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r224",
      "r225",
      "r471",
      "r472",
      "r544",
      "r679",
      "r681",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived intangible assets, gross",
        "verboseLabel": "Finite-lived intangible assets (in Dollars)",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r222",
      "r472",
      "r681"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r222",
      "r224",
      "r225",
      "r227",
      "r471",
      "r679",
      "r681",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r224",
      "r225",
      "r544",
      "r679",
      "r681",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finite-lived intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r973"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "advb_FiscalYearEndCurrencyRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "FiscalYearEndCurrencyRateMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fiscal Year End [Member]",
        "label": "Fiscal Year End Currency Rate Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency exchange rates",
        "label": "Foreign Currency Exchange Rate, Translation",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossAfterTax",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange loss, net",
        "label": "Gain (Loss), Foreign Currency Transaction, after Tax",
        "documentation": "Amount, after tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1088",
      "r1091"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation and transaction and convenience translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r829",
      "r845",
      "r880"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r829",
      "r845",
      "r880"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r829",
      "r845",
      "r880"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r829",
      "r845",
      "r880"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r829",
      "r845",
      "r880"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r832"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "advb_ForwardShareSplitIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ForwardShareSplitIssued",
     "presentation": [
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward share split issued",
        "documentation": "Forward share split issued.",
        "label": "Forward Share Split Issued"
       }
      }
     },
     "auth_ref": []
    },
    "advb_ForwardShareSplitOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ForwardShareSplitOutstanding",
     "presentation": [
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward share split outstanding",
        "documentation": "Forward share split outstanding.",
        "label": "Forward Share Split Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable",
      "http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures [Member]",
        "verboseLabel": "Furniture and fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement",
      "http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative expenses",
        "negatedTerseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r608"
     ]
    },
    "country_HK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "HK",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails",
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hong Kong [Member]",
        "verboseLabel": "HONG KONG",
        "label": "HONG KONG"
       }
      }
     },
     "auth_ref": []
    },
    "currency_HKD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "HKD",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US$ to HKD [Member]",
        "label": "Hong Kong, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "advb_HanyuAssetsCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "HanyuAssetsCoLtdMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hanyu Assets Co. Ltd. [Member]",
        "label": "Hanyu Assets Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "advb_HungToPauPhDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "HungToPauPhDMember",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails",
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hung To Pau, Ph.D. [Member]",
        "label": "Hung To Pau Ph DMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails",
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Public Offering [Member]",
        "verboseLabel": "IPO [Member]",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r804",
      "r821"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r64"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement",
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before tax expense",
        "terseLabel": "Loss before tax (in Dollars)",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r75",
      "r77",
      "r509",
      "r511",
      "r527",
      "r687",
      "r689",
      "r691",
      "r699",
      "r705",
      "r957",
      "r960",
      "r961",
      "r962",
      "r963"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r318",
      "r319",
      "r327",
      "r333",
      "r721",
      "r1020"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r318",
      "r319",
      "r327",
      "r333",
      "r721",
      "r1020"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r137",
      "r314",
      "r318",
      "r324",
      "r325",
      "r326",
      "r328",
      "r332",
      "r339",
      "r341",
      "r342",
      "r343",
      "r514",
      "r543",
      "r554",
      "r721"
     ]
    },
    "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
     "presentation": [
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax position, description",
        "label": "Income Tax Examination, Likelihood of Unfavorable Settlement",
        "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement",
      "http://www.advanbiomed.com/role/IncomeTaxesDetails",
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "terseLabel": "Income tax expense (in Dollars)",
        "verboseLabel": "Taxable income",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r87",
      "r134",
      "r154",
      "r155",
      "r167",
      "r184",
      "r198",
      "r317",
      "r318",
      "r340",
      "r533",
      "r687",
      "r689",
      "r691",
      "r721"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r315",
      "r316",
      "r328",
      "r329",
      "r331",
      "r335",
      "r548"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of subsidiaries foreign income (in Dollars)",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r322",
      "r721",
      "r1014"
     ]
    },
    "advb_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense calculated at the statutory tax rate (in Dollars)",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Income Tax Reconciliation Income Tax Expense Benefit At Calculated Federal Statutory Income Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "advb_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for taxes",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r59",
      "r943",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable, accruals and other current liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease obligations, net cash",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r942"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets are stated at Cost less Accumulated Amortization and Impairment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r223",
      "r227",
      "r681",
      "r730",
      "r731",
      "r732",
      "r741",
      "r742",
      "r756"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r829",
      "r845",
      "r871",
      "r880",
      "r884",
      "r892"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r805",
      "r896"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r805",
      "r896"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r805",
      "r896"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/IntangibleAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSETS, NET",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r226",
      "r228",
      "r677",
      "r679"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r471",
      "r693",
      "r966"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r973",
      "r974"
     ]
    },
    "advb_IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "IntangibleAssetsNetScheduleofCompanysFiniteLivedIntangibleAssetsDetailsTable",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net - Schedule of Company\u2019s Finite-Lived Intangible Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntercompanyForeignCurrencyBalanceByDescriptionAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intra-Entity Foreign Currency Balance by Description [Axis]",
        "documentation": "Information by foreign entity for which intra-entity foreign currency transaction that is considered to be long-term investment with settlement not planned or anticipated in foreseeable future, exists."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r128",
      "r129"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836",
      "r837"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r183",
      "r198",
      "r705",
      "r941"
     ]
    },
    "advb_JianWangMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "JianWangMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jian Wang [Member]",
        "label": "Jian Wang Member"
       }
      }
     },
     "auth_ref": []
    },
    "advb_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment [Member]",
        "label": "Lab Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Lease ROU Assets and Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease ROU Assets and Lease Liabilities",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable",
      "http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r451"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Lease Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future lease payment",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r946",
      "r951",
      "r1055"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r946",
      "r951",
      "r1055"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r946",
      "r951",
      "r1055"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r946",
      "r951",
      "r1055"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r946",
      "r951",
      "r1055"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r946",
      "r951",
      "r1055"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r946",
      "r951",
      "r1055"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r134",
      "r135",
      "r136",
      "r208",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r405",
      "r406",
      "r407",
      "r431",
      "r583",
      "r698",
      "r713",
      "r788",
      "r983",
      "r1046",
      "r1047"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r74",
      "r522",
      "r765",
      "r776",
      "r777",
      "r945",
      "r949",
      "r964",
      "r1039"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r99",
      "r134",
      "r135",
      "r136",
      "r208",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r405",
      "r406",
      "r407",
      "r431",
      "r765",
      "r983",
      "r1046",
      "r1047"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r38",
      "r39",
      "r40",
      "r41",
      "r134",
      "r135",
      "r136",
      "r208",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r405",
      "r406",
      "r407",
      "r431",
      "r983",
      "r1046",
      "r1047"
     ]
    },
    "advb_LiquidityandGoingConcernDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "LiquidityandGoingConcernDetailsTable",
     "presentation": [
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Going Concern (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtTerm",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining loan term",
        "label": "Long-Term Debt, Term",
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r978",
      "r979",
      "r980"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r29",
      "r978",
      "r979",
      "r980"
     ]
    },
    "advb_MajorStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "MajorStockholdersMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow",
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major Stockholders",
        "verboseLabel": "Major Stockholders [Member]",
        "label": "Major Stockholders Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MajorityShareholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MajorityShareholderMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major stockholders",
        "verboseLabel": "Major Stockholders [Member]",
        "label": "Majority Shareholder [Member]",
        "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r232",
      "r233",
      "r234",
      "r235",
      "r277",
      "r303",
      "r304",
      "r305",
      "r311",
      "r423",
      "r466",
      "r534",
      "r535",
      "r542",
      "r575",
      "r576",
      "r636",
      "r638",
      "r640",
      "r641",
      "r651",
      "r659",
      "r660",
      "r662",
      "r663",
      "r675",
      "r676",
      "r711",
      "r714",
      "r719",
      "r723",
      "r727",
      "r728",
      "r760",
      "r761",
      "r762",
      "r763",
      "r774",
      "r985",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r232",
      "r233",
      "r234",
      "r235",
      "r277",
      "r303",
      "r304",
      "r305",
      "r311",
      "r423",
      "r466",
      "r534",
      "r535",
      "r542",
      "r575",
      "r576",
      "r636",
      "r638",
      "r640",
      "r641",
      "r651",
      "r659",
      "r660",
      "r662",
      "r663",
      "r675",
      "r676",
      "r711",
      "r714",
      "r719",
      "r723",
      "r727",
      "r728",
      "r760",
      "r761",
      "r762",
      "r774",
      "r985",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "stpr_NV": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "NV",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails",
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State of Nevada [Member]",
        "verboseLabel": "NEVADA [Member]",
        "label": "NEVADA"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "advb_NameOfRelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "NameOfRelatedPartyAbstract",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of related party",
        "label": "Name Of Related Party Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "advb_NameOfRelatedPartyAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "NameOfRelatedPartyAbstract0",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of related party",
        "label": "Name Of Related Party Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "advb_NameOfRelatedPartyAbstract1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "NameOfRelatedPartyAbstract1",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of related party",
        "label": "Name Of Related Party Abstract1"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "advb_NanzhenShenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "NanzhenShenMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nanzhen Shen [Member]",
        "label": "Nanzhen Shen Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow",
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in operating activities",
        "terseLabel": "Net cash outflows",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r60"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow",
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement",
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails",
      "http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable",
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r60",
      "r76",
      "r91",
      "r97",
      "r113",
      "r115",
      "r120",
      "r134",
      "r135",
      "r136",
      "r139",
      "r143",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r155",
      "r161",
      "r208",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r249",
      "r252",
      "r256",
      "r310",
      "r347",
      "r403",
      "r422",
      "r431",
      "r528",
      "r605",
      "r626",
      "r627",
      "r687",
      "r689",
      "r691",
      "r786",
      "r983"
     ]
    },
    "advb_NetOperatingLossCarryForwardOffset": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "NetOperatingLossCarryForwardOffset",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carry forward offset",
        "documentation": "Represents the percentage of net operating loss carry forward offset.",
        "label": "Net Operating Loss Carry Forward Offset"
       }
      }
     },
     "auth_ref": []
    },
    "advb_NetProceedsFromInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "NetProceedsFromInitialPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from IPO (in Dollars)",
        "documentation": "The amount of net proceeds from initial public offering.",
        "label": "Net Proceeds From Initial Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836",
      "r837"
     ]
    },
    "advb_NewlinkTechnologyIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "NewlinkTechnologyIncMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Newlink Technology Inc. [Member]",
        "label": "Newlink Technology Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r829",
      "r845",
      "r871",
      "r880"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement",
      "http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense, net",
        "terseLabel": "Other expense, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "advb_NumberOfDaysForOperationalExpenses": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "NumberOfDaysForOperationalExpenses",
     "presentation": [
      "http://www.advanbiomed.com/role/ConcentrationsandRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of operational expenses",
        "documentation": "Represent number of days operational expenses.",
        "label": "Number Of Days For Operational Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.advanbiomed.com/role/SegmentInformationDetails",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segment",
        "verboseLabel": "Number of Reportable Segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r710",
      "r959"
     ]
    },
    "us-gaap_OpenForwardForeignCurrencyContractLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OpenForwardForeignCurrencyContractLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Currency Exchange Rates used in Preparing Financial Statements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciles the Operating Profit [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Lease Payments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable",
      "http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Present value of operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable",
      "http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease payable - current",
        "verboseLabel": "Current portion",
        "netLabel": "Operating lease liabilities, current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
      "http://www.advanbiomed.com/role/ScheduleofFutureMinimumLeasePaymentsTable",
      "http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease payable \u2013 non-current",
        "verboseLabel": "Non-current portion",
        "netLabel": "Operating lease liabilities, non-current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
      "http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets, net",
        "verboseLabel": "Operating lease ROU asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r764"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofOperatingLeaseROUAssetsandLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r764"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carry forwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Principal Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND PRINCIPAL ACTIVITIES",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r92",
      "r93",
      "r95",
      "r545",
      "r546"
     ]
    },
    "advb_OrganizationandPrincipalActivitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "OrganizationandPrincipalActivitiesDetailsTable",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Principal Activities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable",
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount due to related parties",
        "verboseLabel": "Amount due to related parties \u2013 major stockholders",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount due to related parties \u2013 related corporations, non-current",
        "label": "Other Accrued Liabilities, Noncurrent",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement",
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation gain, net of taxes",
        "verboseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r529"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS, NET",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expense, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due to related parties (in Dollars)",
        "verboseLabel": "Amount due to related Amount due to related parties \u2013 related corporations, current",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r765"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount due to related parties \u2013 related corporations, non-current",
        "verboseLabel": "Amount due to related Amount due to related parties \u2013 related corporations, non-current",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expense, net",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/OtherExpenseNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER EXPENSE, NET",
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r759"
     ]
    },
    "advb_OtherNonoperatingIncomeExpenseGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "OtherNonoperatingIncomeExpenseGross",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofOtherExpenseNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as gross.",
        "label": "Other Nonoperating Income Expense Gross"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable": {
       "parentTag": "advb_PrepaidExpensesAndOtherCurrentAssetGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r965"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSignificantNoncashTransactionValueOfConsiderationReceived1",
     "crdr": "debit",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received for interest",
        "label": "Other Significant Noncash Transaction, Value of Consideration Received",
        "documentation": "The value of the noncash (or part noncash) consideration received in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r827",
      "r843",
      "r878"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r830",
      "r846",
      "r881"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r830",
      "r846",
      "r881"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents [Member]",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r973",
      "r975",
      "r976"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/StockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid Expenses and Other Current Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets, net",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable": {
       "parentTag": "advb_PrepaidExpensesAndOtherCurrentAssetGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r211",
      "r212",
      "r682"
     ]
    },
    "advb_PrepaidExpensesAndOtherCurrentAssetGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "PrepaidExpensesAndOtherCurrentAssetGross",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Represents the amount of prepaid expenses and other current asset, gross.",
        "label": "Prepaid Expenses And Other Current Asset Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable": {
       "parentTag": "advb_PrepaidExpensesAndOtherCurrentAssetGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax refundable",
        "label": "Prepaid Taxes",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r712",
      "r965"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow",
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails",
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of stock in IPO/(prepayments for IPO costs)",
        "verboseLabel": "Gross proceeds (in Dollars)",
        "netLabel": "Gross proceeds",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from related parties",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable",
      "http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r451"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/EquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r84",
      "r85",
      "r86"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r100",
      "r526"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable",
      "http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Useful Lives [Line Items]",
        "terseLabel": "Schedule of Equipment, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Equipment, net",
        "terseLabel": "Equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r451",
      "r513",
      "r526",
      "r765"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment, net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r84",
      "r85",
      "r524"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/EquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r451"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "advb_QiangChenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "QiangChenMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qiang Chen [Member]",
        "label": "Qiang Chen Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r232",
      "r233",
      "r234",
      "r235",
      "r274",
      "r277",
      "r303",
      "r304",
      "r305",
      "r309",
      "r311",
      "r423",
      "r464",
      "r465",
      "r466",
      "r534",
      "r535",
      "r542",
      "r575",
      "r576",
      "r636",
      "r638",
      "r640",
      "r641",
      "r651",
      "r659",
      "r660",
      "r662",
      "r663",
      "r675",
      "r676",
      "r711",
      "r714",
      "r719",
      "r723",
      "r727",
      "r728",
      "r760",
      "r761",
      "r762",
      "r763",
      "r774",
      "r780",
      "r981",
      "r985",
      "r1037",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r232",
      "r233",
      "r234",
      "r235",
      "r274",
      "r277",
      "r303",
      "r304",
      "r305",
      "r309",
      "r311",
      "r423",
      "r464",
      "r465",
      "r466",
      "r534",
      "r535",
      "r542",
      "r575",
      "r576",
      "r636",
      "r638",
      "r640",
      "r641",
      "r651",
      "r659",
      "r660",
      "r662",
      "r663",
      "r675",
      "r676",
      "r711",
      "r714",
      "r719",
      "r723",
      "r727",
      "r728",
      "r760",
      "r761",
      "r762",
      "r763",
      "r774",
      "r780",
      "r981",
      "r985",
      "r1037",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r822",
      "r838",
      "r873"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "advb_RelatedCorporationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "RelatedCorporationsMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Corporations [Member]",
        "label": "Related Corporations Member"
       }
      }
     },
     "auth_ref": []
    },
    "advb_RelatedPartiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "RelatedPartiesPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "documentation": "Related parties.",
        "label": "Related Parties Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow",
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails",
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r138",
      "r139",
      "r207",
      "r275",
      "r276",
      "r458",
      "r459",
      "r516",
      "r523",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r603",
      "r635",
      "r1087"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to related party",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r138",
      "r139",
      "r458",
      "r459",
      "r1045"
     ]
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Relationship to Us",
        "label": "Related Party Transaction, Description of Transaction",
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r105",
      "r450",
      "r452",
      "r453",
      "r457"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r138",
      "r139",
      "r1045"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails",
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r138",
      "r139",
      "r207",
      "r458",
      "r459",
      "r460",
      "r609",
      "r610",
      "r613"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow",
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails",
      "http://www.advanbiomed.com/role/ScheduleofAccountPayableAccruedExpensesandOtherLiabilitiesTable",
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r138",
      "r139",
      "r207",
      "r275",
      "r276",
      "r458",
      "r459",
      "r516",
      "r523",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r603",
      "r635",
      "r1045",
      "r1087"
     ]
    },
    "advb_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r459",
      "r461",
      "r555",
      "r556",
      "r557",
      "r611",
      "r612",
      "r613",
      "r632",
      "r634"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow",
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments to related parties",
        "terseLabel": "Settle debt of total amount",
        "verboseLabel": "Repayment to related party",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement",
      "http://www.advanbiomed.com/role/ScheduleofSignificantExpenseCategoriesinSingleOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "negatedTerseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r679",
      "r687",
      "r688",
      "r705",
      "r1054"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r823",
      "r839",
      "r874"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r840",
      "r875"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r831",
      "r847",
      "r882"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficits",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r67",
      "r521",
      "r539",
      "r541",
      "r553",
      "r586",
      "r765"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r140",
      "r141",
      "r142",
      "r144",
      "r151",
      "r153",
      "r155",
      "r209",
      "r210",
      "r229",
      "r245",
      "r310",
      "r336",
      "r337",
      "r344",
      "r345",
      "r346",
      "r348",
      "r402",
      "r403",
      "r409",
      "r411",
      "r412",
      "r414",
      "r420",
      "r442",
      "r443",
      "r536",
      "r538",
      "r558",
      "r1089"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase from common stock",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails",
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable"
     ],
     "auth_ref": [
      "r94",
      "r96",
      "r156",
      "r278",
      "r921"
     ]
    },
    "advb_ScheduleOfAccountPayableAccruedExpensesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ScheduleOfAccountPayableAccruedExpensesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Account Payable Accrued Expenses And Other Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountsPayableAccrualsandOtherCurrentLiabilitiesandAmountDuetoRelatedPartiesRelatedCorporarionsNonCurrentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Account Payable, Accrued Expenses and Other Liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "advb_ScheduleOfCompanySFiniteLivedIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ScheduleOfCompanySFiniteLivedIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Company SFinite Lived Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "advb_ScheduleOfCurrencyExchangeRatesUsedInPreparingFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ScheduleOfCurrencyExchangeRatesUsedInPreparingFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Currency Exchange Rates Used In Preparing Financial Statements Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Component of Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciles the Operating Profit",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r721",
      "r1014"
     ]
    },
    "advb_ScheduleOfEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ScheduleOfEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "advb_ScheduleOfEstimatedUsefulLivesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ScheduleOfEstimatedUsefulLivesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Useful Lives Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "advb_ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Useful Lives",
        "documentation": "Schedule of estimated useful lives of equipment, net at cost less accumulated depreciation and impairment.",
        "label": "Schedule Of Estimated Useful Lives Of Equipment Net At Cost Less Accumulated Depreciation And Impairment Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofIntangibleAssetsarestatedatCostlessAccumulatedAmortizationandImpairmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r222",
      "r224",
      "r225",
      "r227",
      "r471",
      "r679",
      "r681",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets are stated at Cost less Accumulated Amortization and Impairment",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r972"
     ]
    },
    "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Currency Exchange Rates used in Preparing Financial Statements",
        "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]",
        "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts."
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "advb_ScheduleOfIntangibleAssetsAreStatedAtCostLessAccumulatedAmortizationAndImpairmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ScheduleOfIntangibleAssetsAreStatedAtCostLessAccumulatedAmortizationAndImpairmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Are Stated At Cost Less Accumulated Amortization And Impairment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/PrepaidExpensesandOtherCurrentAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets, Net",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingExpenseByComponentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherNonoperatingExpenseByComponentTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/OtherExpenseNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Expense, Net",
        "label": "Schedule of Other Nonoperating Expense, by Component [Table Text Block]",
        "documentation": "Tabular disclosure of the detailed components of other nonoperating expenses. This disclosure may include methodology, assumptions and amounts for : (a) losses on securities (net of profits) and (b) miscellaneous income deductions."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r451"
     ]
    },
    "advb_ScheduleOfRelatedPartiesTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ScheduleOfRelatedPartiesTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Related Parties Transactions Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r138",
      "r139",
      "r458",
      "r459",
      "r460",
      "r609",
      "r610",
      "r613"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Parties Transactions",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1044"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Expense Categories in Single Operating Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "advb_ScheduleOfSubsidiariesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ScheduleOfSubsidiariesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Subsidiaries Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Subsidiaries",
        "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]",
        "documentation": "Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary of LLC or LP [Table]",
        "documentation": "Disclosure of information about subsidiary of limited liability company (LLC) or limited partnership (LP)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r173",
      "r204",
      "r205",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r509",
      "r510",
      "r511",
      "r512",
      "r572",
      "r573",
      "r574",
      "r637",
      "r639",
      "r642",
      "r652",
      "r659",
      "r661",
      "r662",
      "r663",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r680",
      "r695",
      "r715",
      "r716",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r775",
      "r780",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r167",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r187",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r206",
      "r700",
      "r703",
      "r704",
      "r705",
      "r707",
      "r709",
      "r710"
     ]
    },
    "us-gaap_SegmentReportingInformationProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationProfitLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Significant Expense Categories in Single Operating Segment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r201",
      "r204",
      "r701",
      "r702",
      "r708"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Member]",
        "label": "Business Combination, Series of Individually Immaterial Business Combinations [Member]",
        "documentation": "Series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r1022",
      "r1024",
      "r1025"
     ]
    },
    "advb_SglcellLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "SglcellLtdMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sglcell Ltd [Member]",
        "label": "Sglcell Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "advb_ShandongSglcellMedicalDevicesCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ShandongSglcellMedicalDevicesCoLtdMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shandong Sglcell Medical Devices Co Ltd [Member]",
        "label": "Shandong Sglcell Medical Devices Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "advb_ShanghaiJunfuElectronicTechnologyCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ShanghaiJunfuElectronicTechnologyCoLtdMember",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails",
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shanghai Junfu Electronic Technology Co., Ltd. [Member]",
        "label": "Shanghai Junfu Electronic Technology Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "advb_ShanghaiSglcellBiotechCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ShanghaiSglcellBiotechCoLtdMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails",
      "http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shanghai Sglcell Biotech Co., Ltd. [Member]",
        "verboseLabel": "Shanghai Sglcell Biotech Co Ltd [Member]",
        "label": "Shanghai Sglcell Biotech Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.advanbiomed.com/role/StockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock under the plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.advanbiomed.com/role/StockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options to purchase any shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/StockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "advb_ShareExchangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "ShareExchangeMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Exchange [Member]",
        "label": "Share Exchange Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.advanbiomed.com/role/StockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of option",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails",
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock price per share (in Dollars per share)",
        "verboseLabel": "Share issued price (in Dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/StockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r106",
      "r107",
      "r108",
      "r134",
      "r136",
      "r159",
      "r160",
      "r162",
      "r164",
      "r169",
      "r170",
      "r208",
      "r236",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r247",
      "r248",
      "r250",
      "r251",
      "r253",
      "r255",
      "r258",
      "r259",
      "r262",
      "r265",
      "r272",
      "r431",
      "r549",
      "r550",
      "r551",
      "r552",
      "r558",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r571",
      "r585",
      "r606",
      "r628",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r920",
      "r947",
      "r948",
      "r956"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails",
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r43",
      "r46",
      "r47",
      "r89",
      "r90",
      "r91",
      "r118",
      "r119",
      "r120",
      "r140",
      "r141",
      "r142",
      "r144",
      "r151",
      "r153",
      "r155",
      "r168",
      "r209",
      "r210",
      "r229",
      "r245",
      "r273",
      "r310",
      "r336",
      "r337",
      "r344",
      "r345",
      "r346",
      "r348",
      "r402",
      "r403",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r443",
      "r454",
      "r529",
      "r536",
      "r537",
      "r538",
      "r558",
      "r628"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r173",
      "r204",
      "r205",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r509",
      "r510",
      "r511",
      "r512",
      "r572",
      "r573",
      "r574",
      "r637",
      "r639",
      "r642",
      "r652",
      "r659",
      "r661",
      "r662",
      "r663",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r680",
      "r695",
      "r715",
      "r716",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r775",
      "r780",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow",
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r168",
      "r247",
      "r248",
      "r250",
      "r253",
      "r443",
      "r470",
      "r547",
      "r559",
      "r571",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r607",
      "r608",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r628",
      "r689",
      "r691",
      "r781",
      "r1087"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCompanysFiniteLivedIntangibleAssetsTable"
     ],
     "auth_ref": [
      "r94",
      "r96",
      "r156",
      "r278",
      "r921",
      "r922"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow",
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r168",
      "r207",
      "r247",
      "r248",
      "r250",
      "r253",
      "r443",
      "r470",
      "r547",
      "r559",
      "r571",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r607",
      "r608",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r628",
      "r689",
      "r691",
      "r781",
      "r1087"
     ]
    },
    "advb_StevenIFangChengPhDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "StevenIFangChengPhDMember",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Steven I-Fang Cheng, Ph.D. [Member]",
        "label": "Steven IFang Cheng Ph DMember"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r826",
      "r842",
      "r877"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails",
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stocks (in Shares)",
        "verboseLabel": "Shares issued",
        "netLabel": "Common stock, shares issued (in Shares)",
        "label": "Shares of common stock issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r42",
      "r43",
      "r67",
      "r549",
      "r628",
      "r654"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockSplits",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted share split",
        "verboseLabel": "Share split",
        "label": "Stock Issued During Period, Shares, Stock Splits",
        "documentation": "Number of shares issued during the period as a result of a stock split."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r42",
      "r43",
      "r67"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stocks",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r42",
      "r43",
      "r67",
      "r558",
      "r628",
      "r654",
      "r787"
     ]
    },
    "advb_StockOptionDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "StockOptionDetailsTable",
     "presentation": [
      "http://www.advanbiomed.com/role/StockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "advb_StockSplitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "StockSplitPolicyTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split and reverse share split",
        "documentation": "Stock Split and Reverse Share Split.",
        "label": "Stock Split Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet",
      "http://www.advanbiomed.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r46",
      "r47",
      "r61",
      "r587",
      "r604",
      "r629",
      "r630",
      "r765",
      "r788",
      "r945",
      "r948",
      "r949",
      "r964",
      "r1039",
      "r1089"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r257",
      "r259",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r273",
      "r408",
      "r419",
      "r631",
      "r633",
      "r658"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage split ratio",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r463"
     ]
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Activities",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Business Purpose",
        "documentation": "Description of business purpose of the subsidiary of the limited liability company or limited partnership, for example, its day-to-day operating functions and whether it acts as a holding or operating company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Date of Incorporation",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Date",
        "documentation": "Date the subsidiary of the limited liability company (LLC) or limited partnership (LP) was formed, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Subsidiaries [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of effective ownership",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest",
        "documentation": "The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofSubsidiariesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Place of incorporation",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, State",
        "documentation": "State in which the subsidiary of the limited liability company or limited partnership was organized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/EquityDetails",
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails",
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails",
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.advanbiomed.com/role/LiquidityandGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIQUIDITY AND GOING CONCERN",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "advb_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.advanbiomed.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "advb_SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsDetailsTable",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies - Schedule of Currency Exchange Rates used in Preparing Financial Statements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "advb_SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofEstimatedUsefulLivesDetailsTable",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofEstimatedUsefulLivesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplementary Cash Flow Information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "country_TW": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "TW",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails",
      "http://www.advanbiomed.com/role/ScheduleofReconcilestheOperatingProfitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taiwan [Member]",
        "label": "TAIWAN"
       }
      }
     },
     "auth_ref": []
    },
    "currency_TWD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "TWD",
     "presentation": [
      "http://www.advanbiomed.com/role/ScheduleofCurrencyExchangeRatesusedinPreparingFinancialStatementsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US$ to NT$ [Member]",
        "label": "Taiwan, New Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransactionDomain",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction [Domain]",
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r1029",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Type [Axis]",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r1030",
      "r1031",
      "r1032",
      "r1033"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "advb_TwoThousandTwentyThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "TwoThousandTwentyThreePlanMember",
     "presentation": [
      "http://www.advanbiomed.com/role/StockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Plan [Member]",
        "label": "Two Thousand Twenty Three Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://www.advanbiomed.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_UnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnsecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest-free loan",
        "label": "Unsecured Debt",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r72",
      "r1056"
     ]
    },
    "us-gaap_UnsecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnsecuredDebtMember",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unsecured Debt [Member]",
        "label": "Unsecured Debt [Member]",
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.advanbiomed.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r172",
      "r175",
      "r176",
      "r177",
      "r509",
      "r511",
      "r697"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r164"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r164"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.advanbiomed.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of shares of common stock in computing net loss per share",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "advb_WellFancyDevelopmentLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "WellFancyDevelopmentLtdMember",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails",
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Well Fancy Development Ltd [Member]",
        "label": "Well Fancy Development Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "advb_WorkingCapitalLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "WorkingCapitalLoan",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital loan",
        "documentation": "The amount of working capital loan.",
        "label": "Working Capital Loan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "advb_XiaoyuanLuoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "XiaoyuanLuoMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Xiaoyuan Luo [Member]",
        "label": "Xiaoyuan Luo Member"
       }
      }
     },
     "auth_ref": []
    },
    "advb_YiLuPhDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "YiLuPhDMember",
     "presentation": [
      "http://www.advanbiomed.com/role/RelatedPartyTransactionsDetails",
      "http://www.advanbiomed.com/role/ScheduleofRelatedPartiesTransactionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Yi Lu, Ph.D.[Member]",
        "verboseLabel": "Yi Lu, Ph.D. [Member]",
        "label": "Yi Lu Ph DMember"
       }
      }
     },
     "auth_ref": []
    },
    "advb_YiminJinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "YiminJinMember",
     "presentation": [
      "http://www.advanbiomed.com/role/OrganizationandPrincipalActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Yimin Jin [Member]",
        "label": "Yimin Jin Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "advb_workingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.advanbiomed.com/20250630",
     "localname": "workingCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.advanbiomed.com/role/LiquidityandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital",
        "documentation": "Amount of total working capital as defined by regulatory framework.",
        "label": "working Capital"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481440/840-10-50-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2A"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-3A"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-9"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-42"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-48"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-38"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>102
<FILENAME>0001213900-25-097465-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-097465-xbrl.zip
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M,5H/T=P0/78].N7]>N>2D6]UZ5R]49"7U[!ESWAP-S-TEC!0B ,%0&H;57X
ME,DDD(R)4B(*HW;/? XX,U#*IC'4'E793 :1ERRZ7T1\/N,VF\A03^[2UCV;
M4B*SZKERA>&??/YMAJZ,P2[%94UE?NO"P,VQ%^X)5X'PY<[,^G[*;8IN]>)E
M?#L7O)7DL62V'R&"Z UB+@J1; 90!*Y@/4*JE@<C,O2OW[K&P=%V+C)=C5R8
MVK<H9_(BUI)CB^2\S 1;*ONWGBR=P98+C5=BL*5M;P0I@X@(W>(DHGK(EARR
MHD0MR8@4%M58?7,!8T%"5YI]4<:7BMB:U]2K'&0;G-4='3.1B^.&(FHFRN;>
MB>@0W-;A)!?*3.??U<:OG/&[(0:S#6H1%PQ.]$YH>]QWV(@J+6%Q/1TRU<F4
M:8NX:A%!DVC9)@H;K3<?:VU/F0V:L]$1&1%P0DSH>+U]J;J>#O>YF*&"^V6+
M_(^X35Y2<^=9LR]XY8OPJ#Q_6X/+5CYK,_'^E]HH/R\M6L1345F=4\%6+AJH
M2HVN79Z2ZVHR2I)+79>NJNI:6K3F0GT*6K-+;'KKJC\"ZGFLRI 76EIIJ>+]
M9"L7+!-FR=>$E4Z]71UH1UOO#DR(,>.9KM2^!6_36CF[49\K4W37EE=XEM/*
MQ;!$8R"3N)LXKX_PH!6@X+LA :2$<QT+K=?P9[R,2C3_U26+#EY;N8B2[,U4
MM1E8(R(8#_\NX1]@Z]U%>5JV&5S0#%^7E5(\Y7/Q*/7#-9F(XG).!\TC +1,
MX8*JX<4ZD/R,87/B>T#+)2@P]:=!?_;QHC 9M:B6EL^7BXJ5&1DA A1!B$9"
M#**.JVB.@R-F^+S'VK9Y#'WM+7+OBE264,[^Z)5<4?WD3Y"%0F%%[XS\BQ'U
MH9'ZW"R_&%Y*?9@VN Q7Z73&' _9PH\&2SYWB\(/'G>9$8A35.%_;<;U-OFE
MS:WMS=;6FR?7C+_=61(%5SK\>&@Y%'&]=5#(OE@L0N#&'R).5AIC/ OJ-(CE
MN4LQP2=5U^L+X6>+97B*:@9_NTL@&J-#_*EE34;B"IR*E?KZ+&0_E*U' ]1*
M4+"4D>9 5W67&&_&;-YPJ:$#(EN<_T@U7*I18V%NXE&9=J%&V&Y8M=RX2TDB
MAEFFX;@X_[&^PKRRZP_7;ACJ9FDNU;Y):-GVH4K8?E17TG[TS?@ P,%&['OT
M4H^PMH<N[%X,F%]\P!YL!)\EWX=KX+:<>V3*K?\&PE&I@PW/\?FGE8-2X-I2
M9@Z">J;O1&NN32V+NU!Q6<#GPDKI\[NG#O-G<2,4Q">\LP)\6IH)'S&Z<WD&
MG^H1HRIVPG-521L<68=E,QO;3OCE6[,=/!33E3\4TTX^%%/%#GQIU1+63-:;
MHD<^JM@U2IQZ R>9!UU)%47X]&Q(F'U[J\C_K:+"96#K4:Q,!&SG$P&KV"MK
MZ[#R(F3=(S\UJF)':*"5&K@[&QJ'2V9U%,M#2GKY!?";%<3?5$[*92+X(),(
M?HF_,R?YV?'J4+0&9H5]OH+_4Z-X41U-%=AD9D3:.>G,_HJ9D[50RR=F_-AC
M9?3+ EIK/%; NJC R>E8/4%2'48$F%1V4J[X5@5T48"3L](VO_MN>*0P8&W3
M#**^V.IC"OY=!\^HAZTO&-P]![P=;9.;[HTILXF'G86H/T;8<@LZ)+PWQ!8/
MQ!YL& X!E,^P,K]&8ZE[\R+M"2S@7[Z/13I+_69.Q>T,O.SPZR4#\N0=6G M
M[B73<_:]^.*:G;2VFRP%)U,GW1$55$D-4+&PQ7F^Y_Q\"4:$/X2JO1%<Y :S
MW^.QDRHJO!9NS5B'(%R2B3"(0DI'9.80@^9#2L$)<Z4Z[]5T545@M-X7]NS7
M247GZE%NP"O[!*:W/X&:CN$/R7F&@O\#]5^0#=&X^:MT=:%NBG[,O/&E+7CC
M"X!V7\)9"(_"O9RO8)+A<UP%;0WD/JS@6R"EWK=0U8'THGI)0P6O]N* ]9\!
MKRI!_^_Z3C8(@DK0&HO3"</'MB*Q+V5!?MEV0P>^RA=;/K4:/XX8>AK+RY&@
M0V*3$>4>2I3C1,P3 IN_< 'T/0;]L90$=W]EESW3ZOXJC>5&^AA\9</KC:!D
M%_@@;@<[SN*$.8_8,7_IZ'IF5Q4 5RS.VJ]JKYQA*XE<9E9@P>H[S"#$=$\<
M-A7NG:IL5[3P2P,_A[Y+;=C'P$H]!$^9-]8!HTY-$L+EFQV^3I_ 7N8SMOPJ
MVXORNDB[I> UZ)6;"UIX93/@D3D/O$H8\OJ%7OASAWH&J#P;I<QKMRO'Y1KH
M%?8]6@-N)]@A07COW'7!&<LHS.^ZZW&\+IDR8"H?*%>GYWL<AIFST970*(E.
MI98R;L<C316>D\7859JGWHQ3N9DH0*?EH5?7ML@@*@\4B;=ZH R<RZ1K"43#
M@IH,W_)V^=/%KQN\U< H7RUR;YZH'&TRB"K:"E[44#D=M?#*7)@O*<^@R[!=
M89,I *N<?_YTR,\@C_#"A2$=C7-^5!E'5-*ZQJ2\]A0LAJE,[^)/MAFD9W^&
M:SZLW5TZA1;,2\+%)BV,R::8"K7[A5D_:G2*<_6@GGD8/+)W]JF*2DG :9 5
MU81%I8H*K6"I,DLR-0:8/F*[HNJDP*GX.23T.UB8>[ O]@7%CD\'Q)C8S&+C
M18=UO8H,0%V8*E4[$V+?TRXAU5 I"T=J&;)GE^TYV,OP"+,BFA0"E$^K(^?,
MM\<#UL=^-93) Y)Y$D<.T%<9U DL,L GU#6P=4^P<VR;,6G5&49%\!2ABS-L
M+_SPE+!"1DN"2D;/<MSU)T<542"/2#Z3P2S;7V#Z5P-Z!HUJ7>CBX3)CIQK@
M!8CD_9[+W:R&#C)8BHQJ;/^$-?$6_E5#A3P@^<G0(W^IP<HGJ8RCJT"FL*?7
M,'O&G<H0D84C=94$.;;5T$ .3!YL&EL&L:S*K&8Y/*I\./ #36:/HSJ7Q*2P
MM!^1.35(E59H;9QREKC'.\'TPK='_K%%#,]A-C4JN8DJA569[!L)BKH-=IT>
MR*B@IG* \F4H.)2)MS*542<'2<F/1^;$/C^)K.:X,@ZE')AT@@T>V6#"?)X+
M-GB$RXO!Q"&D;U4E]%*(3QJ(AH$)'6$LP-P0BP7.7F4FD!J<:NQ]I9@M?&QW
M?58-5?* 9(SP+71EIDH:C-Q<W=,IM2]H169#!HWR*%OQIKGJ/%*IA9(/J.#%
M;N'[B *N_A=02P,$%     @ %8A(6QY<W@PS#@  TZP  !4   !A9'9B+3(P
M,C4P-C,P7V-A;"YX;6SM76USVK@6_KZ_@IO[Y=[I4 AILDFFV1T">2%-"@&2
MIMW9V3&V#$ILB?@%2'_]2K8A&"R_2HBT_;"S@1H]1^<Y.CJ2CXX^_CDSC=($
M6#;$Z&1G]WUUIP20BC6(AB<[=[URO==HM7;^_*-4^NWC?\KET@5 P%(<H)4&
M+Z4&-L<]%9;ZEH)L'5MFZ7^.^?]2N31RG/%QI3*=3M^KY!E;A1:PL6NIP*9?
ME,IETN"\R88%:(/'I2^DU;;JE*J'I5KUN'9XO+=?NNLWR(?:OO^3WSX:$#T-
M%!N4B-S(/ME90IH-+.,]MH:56K6Z5YD_N.,_>3RC7X2>G^YY3^\>'1U5O']=
M/&K#J =)L[N5AYOKGCH"IE*&R'84I%( &Q[;WI?76%4<3Y.)<I683]!/Y?EC
M9?I5>;=6WMM]/[.U'5]OI=)'"QN@"_22)_FQ\S(&)SLV-,<&%<C[;F0!_61'
MT2:#,M5@]6"O2IOX+_WF'^N?!D8V-J!&=7^J&+0KO1$ SDZ)-GW7;84Z07ZD
MH '$)M H@Q7Z3(791.4/$5*VB&&:H.>0OTV \@JZVDI%C$H;BCTZ-_ TIY2+
MG_OB\9&/6J[F&@#K'0N,%:B=S<8 V<!6D-9V1L!JN)9%=%*W;>#8GX'35P:T
M\=0]R G SUQ>!3A[=N&8$ERH&^NM<#275QCJ2!7T8I]#!!UP#2?43(EW&4("
MZ2LK?Q]2-R[&U.JJBEWD=)07"D(^62Y8LXMKJ R@ 1T("G0T'Q+I-><>>S@!
M;B'KBVQ(#$M=H&*D0@/8!+,]IG,\"0$Z%M9A@0XDM\I?^]3<,2)#%NM-H /B
M;[2^,N,QB.);Y=^3'APBJ$-504Y@! TR-0RQ16P7HA[1I/&JU!X84C^5OX?Y
MT82XQ 74-2!A4+=]Y^N:#&/O"RX.(RN&D(Z>NXYK@1OBG$W7]'") Z/*+="Q
MI#9I1V@W5,507<,+6:^)T('HM+$"P5](*6#F *0!+W#]C6KOHX'5T!,&C9FQ
M-?^9H0R <;+CVN6AHHS_\1D)PH:P;JF -I'0BYYUQ1YX(73PPPI5>@48CCW_
MQJ/!HR"Z[5>_FEE(&JQQELUKLK)0VA)1=2LLFF*I<VSRYQIWX;5%\$3%=DW3
M:ZU,0@)S_GO=PF:"ZAV\VFUL:< B2\>=TA3 X<BA?\X#NLR:#(>-]6#.%FD$
M:1 7XWY;F4BEMH"HVAI1!0;F9S*]"QR;2\W[TVL.@\+$R3LO'>*@'**8Y8">
MNR7%0(6\BSP;6N<K;$9QRF(.]'P&M#+YTA;;^IWMKT@X4Q./M0UN-IZ8!%TQ
M1G8>5E97AH3YLYEJN'1#\ )C;0H-@S,YJ2 7W=E6BM(I+F!JC\MD.5^(-+#M
MV)Q)";?])KS7BCH"57_@Y:Y>9U1ADUXTQM:;/D,U 0'[7&S=;UY(D+$-"HY2
M:W3XQIY^MU'Z"'M8CS_SV,/2VES,NB "H(#W"+8F[?G>)-*"[4GA_<B"+-V<
MV-H(F5869;*&3?&0=8[V(H:X!##9:])T5"5IC.^:=$DF87-T-$;.:'OUC838
MR")!=,E6E"+&8#S-=0>*8;'BF$G$VR:OG&69&JD[]H O.N+%C?.M&2)1.L\R
MYVV+%27T0UC0V'.P^C3"!FG2IGM;S@MGHXD */): 9LF1EZ;]XKA L["KC4O
MU<S9W(1>.:RIA/.N9%W3()54,3H*U%JHH8RAHQA+N+SC\V1 N?N3Z8A)HS>N
M8[D+' 4BH)TI%B(SCDV6 *Y)=0.T)M"A"GE/U"D WP)1:?3&=9=R"<!/ </F
MV (C@&PX 7XRWC6VZ7YI6^\K,_[+WTSH2]W<7@XSJY2Q%UHPXB(+;^$S:B*<
M9,+2JH,1ZL3-7WE#!NAXF1Y$G 9&-!H'2.4?'\<AO4%.8A67N&AY*[V,>HKA
M[&EZ4&4E/^@/KDE#:^G<RVI;SALJNI*?IX"*6KDOVB\0S-B <#\B1#;!!!C8
M>^L>M,L]CHG#DAO","D+1S"QRN*YX>N?=C'H#K-F0@1MAXHW 6*824*3NCY+
M14VBOOCN]W[&",_%\KV)&&+8./EE;Z$)L+T)QV^QA1Q@D6^X)U<P8.0.]$3F
MPJD5+%7Q3DFBP?2R:&+,B0GSACAAJVI]B)<+9"/-US+G1%0_*G,)6.",2#!Q
M"G1L!6L>LM0!]MF,^!PB T2*]=(BG?6V$\DOB1X,KV>"QIDX2:7Z_0U0L&Q7
M,488/['_!+J)F()9@RWWC J<UT[QGD5#;4M?/T5V-3SM"&27\\RUD"$PC5,2
MB.G<MT!9*&^%RPC]L =0SNV7U8TX0?N:<4B2MU]2*"'D\</<,09&[G".L3=Z
M3@8N'"+_E:GZXE4P4%1/3TCS/@5:TQY=/_841*0@(:7&#!DM0!1/L8M-P9M;
MK\?_F;M:.>=GVG+'PA-(VCE]N;/I1MHB,J@3U4Q$I$-D ,[M/7^NX",CCYMQ
MF4U !J$*E6" U4UL.?"[]Y$S(7%(DB>P8N3$JI!S^A.Q HNF6C6!__\66L^-
M];SK:V:6L(2I8K)(G:^*$5Z0!.;+=DX6P4C*$\X^"_>'8IJI7/;I(SZL!B=^
MYV>>(D_^"J<XE1"2-S4Y$YY.[^M'GXJL*B/,+MA]59?+*8D?T9&H/Q:_#,T&
MA![P(90AM/^>0T(4'P6<OX3#O-((KJO/+K0 \U0YY\YE -[. #.&_] I_0P*
M7E\:Y'\9PY#Z'"(%J1*L-@JX0.$1K *@>5N]+=MV:3F;%B*-*D;''1A0;>O$
MXQ,PWD:;&G<;XZ88[E?J2J15+M]TN&7@+O 2)CL*&2E-,!!0_8,--5_B>?5.
M__IR<W_P]U]ZX_KIX*)6NVGCBXKN7E]<XETX&S_M'UKC?GUX<VO-#B:XT3W%
M760]G5VAYL-5[>#NV_?JI^F%>^X\=W:G5YU!Y='I/%[U=P\>#_;W*KW+2^.P
MN><.ZT_C_N_CJM.>U>KWSYV',]O=_W#;/AW\?M=3K)JJ]J^&V+ALPN\M\^KI
M4/_FHIIB?H/PKG%4NZCJ]F6W<G S(1%-M=-KJ@?ZIZ]'G<,C2WEX;G[0+AL7
M[Y1!RVC<?QU=3GN?NGAZY R^7E4 VJ_N/WR]?SR\O7B>6MKET^.L-NA][3N6
MYE;@T[>KZ>==YVX/?!KU1^WGJ^_.[UUU_USY<G2)]?O6A][WT:?GZNGCZ,O+
MN]INX_3+_;?#=UBM=C&\&=YJC6^/#T;=U,_-_<JD8_:/W*=;_?/CT:@.INZ#
M?OOABZY>7.X:N#[!WV]/3OXN-7I=OW+L#S!TUBV88^&/+HEK_7FEK0L>*K%0
MV[HUEY*O>#6NK_7+^9/3J)3T/SK=3Q2#8G9)_&!!-=A_)J% ^(NE)SO$WV)M
M/?X-*I:<S=21@H:@2SIP1IRSRML&-BR\[-/2<KA:V3-.O5!*.%#[2X%)07O"
M2:=?"DQRK%Q/(/DBM?5E,=NHD$(X>T,1$DJ?2.5;G!#B8W=V!;Q5SENTG?7>
M.<L(\HK5KL#6(V OK+4WMHS*MZD;*[+H\R"\A"SNB[REIB4Y]%R<1!0+#?0C
M(H4Z+)V@\CAL("D[)85IB=,<WV,333#&-G1LD65UHS'>)C,,??%]<;N),?,C
M#9?XD<+IO>NO<M11@5T&K5#&,E+-M9I3W3#PE&XWGV.KB=V!H[N&!]P%*B Q
M'8F41-7=RX L/53/R&@N[28<51 :.4=<!L0*C_._:=B^.N.<NA 1W8OKQ'KT
M+V= )-.9JG)ZDE,K6E)E.=N0_&V B+3#3;V YR:6Y*VRK.3SHX/I(T4[R/07
MD#']9AY#CH'C[S<3P/(/QYB&1;C.1#C)PR<=J<L#*%F!7(/"&+BEH2PP]SV'
M +(G1*ZD,K4LS?_EO*20X0Q_D@KAA3JXD;Z$Q)98)3\[MS'USI/*O.8DA\I#
M$.A)96]K6!A!+""YUS 4IHBI/\YG?ORE^89\0P*8[%FI(&M)JN2[P\LX%23/
MS:<B]^VRFUW?K,UCT=%'](7!7%=::_5Z1-;+2@#+/H2\+>3X5M._@D[3CFS'
MEHZNQ>YZ*M7P74,QS^5?*!#1<\EUW0$6_WH)&8 E1WWI.<RCU+@4,Z'.*L5-
MX1R715M4V":#JYHG'I$6*6MDBE$LZX70.U4L+9V72FA"MH-*X&7AF9(TP7$-
MLQ!I;J'^-FPPJ%[_57% $](#)V3.APK_VRSS2?$&""VL:+YI++YI+:K%!(A1
M=;J$9&NF BZ8L[J*$59XW3D'&JVW2FLHNZ2ME]##&^EU-HDDS\C9+68]F[0@
M)9S3[=+(U/!R7UMH?F:=/.1OP](;5'RIY^_Q)9A,%NGD'C47;SV9F&(Y4U%F
MM.%YE(M(TK<PQ-M,ZEEW,P7^PZ^4,2)"8'W-GOFO$]8@^+\_CH0HDH6[TMQK
M+1D2*'MALAZY8.#?D1ADZ2,HCMBHV[]3J9-O.L[F)]:TD^6;)"[=9+>A%\,]
MXENA#E5E<<-$@SC8(;8@L"'J$?,R7C=!>F!(\WC$9!A*JH[XEF]DV,I2Q#DJ
MG/^Z5$8H(^DNE(E*7/YUIXQ89M+>)[-64$'X&[M0W;]N^\Z?NA2DA0H!)F8*
MY4X"V$A1QY@2CIP%%Y2]$ \F>ZI((#'%S=HI;GSF2-+/? =Z<:[2W&HMVFV=
MNXYK@1OB24W7],1;%)-+<E-Y[.@:$*\(&/J8(S>Y7VR=&C;_"$D+\9DHL3\%
MQ@3<8.2,N%]2GU<,J=-^5K,(W9V:6_$\[P5,*\57$E?VIU@2ZW-TV=>Q;H#N
MA:*YWC&>"9V0*\N1O>++76EMC&E?U^ST3.%LGV/7DDBV!R\])MH4W;ZR^9[L
MSX1/5IPRR:;P/P_9GK+7"ZAO@FPONTXRXV$9?@K:5]2^7FL]H<#6QPJ%'I#6
MZ>SW+U!+ P04    "  5B$A;;H'WF&TY  !#F , %0   &%D=F(M,C R-3 V
M,S!?9&5F+GAM;.U]ZW/;-K#O]_-7^.1^N7<ZKI.FKW3:>\:V[,2M8[E^Q$W/
MG,G0)"0AH4B%#]O*7W\ /B22(D@ W!7(1!\Z36(3N_@ML-A=["Y^_Z^GN;OW
M0(*0^MX?SUY\__S9'O%LWZ'>](]GM]?[A]?'9V?/_NO_[^W]Q^__N;^_]YIX
M)+ BXNS=+_>._?GBVJ9[-X'EA1,_F._]WVC^__;V]V91M/CMX.#Q\?%[F_U.
M:-. A'X<V"3D_["WO\\&S(<\#@@?\+>].S;JV([VGO^Z]\/SWW[X];>7/^W=
MWARSO_SP4_K)?_SN4N_3O162/<:W%_[QK$#IZ3YPO_>#Z<$/SY^_/,A_\5GZ
MF[\]\7\H_?[CR^2W7[QZ]>H@^>GJ5T-:]XMLV!<'_[P]O[9G9&[M4R^,+,_F
M!$+Z6YC\X[EO6U&"9"M?>\+?X'_;SW]MG__3_HL?]E^^^/XI=%8LLM]QHA69
MX@ _':0_?,;QVMO[/?!=<D4F>\D4?XN6"_+'LY#.%R[G//FW64 F?SRSG(?[
M?0[U\Y]?/N>T_@__EP_!AV/?"WV7.EQ(1Y;+YWP](R1ZML>'OKTZ*\V6?61Y
M]]2?$X>+^H#_SH%PB .^#E"Y_'!I!<2+9B2BMN6& $Q71\29PQG;A7-R';$_
MSQDU3;ZKHQRD^PZ"V>L9@V'FNPY3'B>?8QHM;]@@/_C!2P5>&P8YP%B_QU8X
M.W7]1TTX5Y^G.,+P-PZFED>_)(K#\IS+@'HV75CNH1W1!QI1HK)H)0:#6Z_G
ME(G,84)CE%[[[,A@6-DD\!3X%0X!Q^5U/)];P=*?7-.I1R=LTWK1H6W[L1<Q
M>I=,MK8:QI(#LAF \'\9D(5%G9.G!?%"$C*@QDSY!,=QP-7081B2*+Q04L>R
M(\+)@._M!== :HR6/@/476<>.[JG]-XE.O#5?0T'5;:2PDMK:7$2MAW$[)BI
M".F<6O?4338T^\GAG'\RBDGD7Q&7:RIV1O&?97\[]H.%'U@!4PKAA>]E8RA,
M>8M,@>G]A+-LC:L)N/HEI+9/3SG%/< ^ (,E-0ENK"<EG5?\"HR5Z\BW/XT7
M_*Q24;^%K\!8*:S09>+.6#8GH *1< C HXQ,N38\\[BS9:GBMODQU!&5'-I>
M%"2C\KU_1<-/BK9VW0" *I_YJG,:<0#X\(P>/ZN9JZMV]#>- FE;Q_<A^1PS
M,B</G):2<5+Y%&R+;)HX1\OD3RK:K&$0.,7?:@/?\$,,UJS.AH0\*N3L3.6Y
M* T+I[LDC4[EZ:B-"WV4Y]:I,MLU'T-IXQK[5)D]\1B0"&[/K%0&8.NL 1X?
M%?M57=O5?H]A@6JLR^JW@+B)+#AE+EL& CTD-JPZ]0-!- 1D9%-H-RFSVSX6
ME"+ED7XG=@D[*IE511W*MFY&1 7>AE$@;<85F52OV,N3)WO&E#BY8FLQC$/B
M4"\Y+)GQ,CVES(ZQJ>6N8L,=YM6)(.AF6+%4/;^L@(2<L&-%QWX8L542,I4>
MS^-DHS+%S?3TRKP[FS.+(ICGNED+$U &X#SN%7\G843GG/1M2":Q>TX?NJQL
M\6@XXE4Q^K0FI$0 T,%?(UJU#_7DLC$*CL;QV8+UEB';Y#0B7/I.=?UWT"ZR
M@^,LM<P0+-J!9&-=%.Q _8GJ48(_[.K,/ZT)U0Z$(Z4K8OOL>&%JE=$<+WB.
M G=F W]".TR@?51X]/ER]SVV9?W)B$P(TS<.,W<A-E'SJ/ S*?M &W:PID2:
MQT0X*0MADFPM'S,6ICZWXJAWS1:$NUX;F2W=P4;4IH:BV5>DSHD5DJOQ;6;-
M>$[R#R!Z3Y4&RD1/XR@.R%MVQLSC>4*7Z>&.=G';F%N,>(Y(9%&E]!?Y,<&F
M(4H&4&>^;20X-2$53%6?@-JX6%%-=;[KOA[BW;CZS+?/&]2)G=XPZ\EZ_1U<
M]'H5X5-GJ>9C,+MF?>VLL9TW/X;B2Q1K5&>R;20XI;D1<-1 5#@&I#*LOY=6
MY[9YG)6"M );EF5!^G">_<OSAG]*9N)0AA-/[]YWR,2*W>C97D:FR/EJ#.I%
M!^R3@^QW#C8_SQ8N,J_^W**>-JOIUVM#$8/9&1LBL.-[LK\BK,9OW0"%Q8L"
M< +,_IS,[TF@B&[I4]0E:[FN&F_\@Q5';)WR2!%#\YS1SCC@O]8A3[TT-_(4
M$<\ASK-D(S"*KF^7?L'E90!^D'_E6O?$_>-9'.Y/+6OQ814 9^R1,_;'<!.F
M,)_MQ KODREG7Q]P+75 W"C,_R716PEL#036RTJ?W<P/PF&UY!"5A'@8E+EE
M,L^9R,0OMSZR;R:!/Y>11>2+(? #AP1_/'O.?C=9N;_9OA>Q57'B)K_%5G]Z
M.*U_[OHA<?YX%@5Q<9)J@A =ST?+XD\.GRCT>E(@G&]"< G6*MM&B9:6:U&:
M*CAFDG[Q7"C*KI(<90<=FL1&Q;,013:;IW:=8-27KTAH.62;VQ!%-A^>;T<Z
MR*+)C;]MR(9#EF\=L1+44X.93QR1/WTVVW=LI_,86V;0@,JIB1*:HJM8:&W2
M*JN/HE0:<6K=.IJRL<(9M!#XD&C;HQUL.0LAG;@$JGJXEF^C#[.04AHF7Q5S
M@,(N0[&XAWLJ%RG@6C65CL@PA5,GAG[+H1[Q'Z#/ALO 9V9BM+QT>;C<<\IE
M9\ ;I('4$$32C%4FH9?0$JK<]='I+!I/;L,TCP-81,VT>G^FM$"52>A'\,.F
M)O7[Y,EV8]X3XK7O.X]T[4T#24J*Y$H1]U1><KAE8OL)-C:0YW3PU$)H][\\
M]A!46P6-#/*?P779VI:X\#T;Y:BOI]'WK2! )A/$+[!K'UD"@P-?B/NO&+BC
MH#T0C%?(O@)&MI)*X#E9,F@A>P#)LU"@/(230 G)]F OC-6;TU[BR+"%V "\
M]C:X<D$UQ!9UI(2^NP:ZB9KV2J,+KV]5%4CBFE;UA/I^_#1AE$NFR74'U&%X
MXFFE-X2](X%:+C!X3WX;NVB8&ZAE[S1XYUT%@0?_D$!?0]WDE>M=#ZZJ@P\W
M^KP 7P^**9F\'I2\L6K"*1=.@Z>N+QW?2[)AWUEN#)U.M#%\W[?$)AXY] W.
MNIY/Z3C)]"WWTJ+.F7=L+6ADN04&H%W)=H*]#\'+@)8+3!P#T$M#B=@4B'-B
M!1[;F,5:\1'#RJ;0Y[@$P=Z+2P:T_.H1-FNH0"FM]O#GBX#,>.[- TF+$L[]
MD%\)C"<WUA-\U$:)>O]/)V4\<[&"IQLEN[S4H1A8>#4$AN#8U.&2"P$^*% P
M'9FU@BZ35G+]WT'MB.72:KOC__V@G%&_KE! R+3?:-=>!'27>+]+O-\EWN\2
M[W>)][O$^UWB_;83[]]:'_V 60Z%-SM0TN[%=(Q>7<IEW3> A+)K=M40<-40
M33L&XB83Z;I?0&4(3J00(9E*BH[Q9[9@QD'"II.$7B])D&Q:O)"TD.( 4C*D
M@$,II"A03LB$AW$T8SKV"W'P1+5!J?\.?R-.$@47(+(Y"\,87RX9E2%H."%"
M6 46&P3'<<0?*N19Z-AR*9(:I'!*6,D46&PC/+;Q$J @)*:Y8"K#']Z'4<"\
M$."U(J+2(3YV14+"EL3LT'-&Y(&X?E*]E)7Z@7N.3;0,7HRU2*_L+3;BA5:\
MFCX9Z_+<6V?.T F3-D@/!$=2;=3,900HB*H5LG:/I5.*7]YT&-I5V1C?I%FE
M((\:8) LJC/O@811VMF,LW?F181WC@=7QP(RPU!E8I1DS"I]9_["]_S*4L#P
MYNO(#$,P8I30RE6+U%).<20CIF/4?5<03@-2K56I^I8ES],X92RG*88QHYUI
M4Q[F)A,_((6FG2=/C'O&#/6L8)G8[3P]EWW)X' 3MI'4(1ZG@S X4$757G^K
MO[H8*]DB/F(VTP0\+4Y$Q:Q[JRS9&IC:BW$U]3&)UJL)6@>7QAZ,#"J0M)?C
M=C!1!)ERIVSSTJF7O]14N&MD3D;R-S?9YX?.QSBUK)!R%9&8'(26Q1(03A5R
M#:-(:Z*)TD \Q$:PI J+=424)SKG5S!'5DAM8.'4TQC$?A/ (U$^#"*-$77C
M"/PV1$1E,*>A$":\FN([PKLG$>?P@9FS4W(1\XF,)QM!?XS]HT9[*+ZD(J(2
M1<F <LU6%/;]ERKU@1QERJ!*%3!CW905$JVRS/8;AN,/?O"RX:)LESV^RQ[?
M5O;XBHMT=:X>X@L1$L:;:6&)"3!%O 4L&4-:RW(K4T-)#:^G@65'2V6&2RW-
MDNE6CQ-*9FLM+?"4<*%4C*:%PP@&MPO[*G4&*=NX.KY)ZZE1/P@RBE#3O@6%
MZ2BB:*9E\%Y26BHM:"&E?TO4,./(2YJNN2".O.CD091I*@[2BP%%:@(B@]!Z
M(H!:DS&T[&EDK[Y??KNDIR-TRJ$MY5T[!.5V"&"V5_(FY?K^)[SQ!0?;G<64
M8S">K)Z7O:D\+YM4J159+@M1\!PF$NF^]FA"A1OZ!0PX9LM/#R>Y']M;'77$
M^[S]D6%'.4"_E00-.<5=GYO1%LK>Y68,(C=#H0H5+RT#^*F/Y!Q)J\A&<<!L
MO4L24#^[E[D@C\F/X /+4D2'L.%E\<-Z-41 /RFEW;+X*C0'X.?(82>1VKB-
MPCW^*."IZS^*+R)W]Y"[>\A=%ZM=%ZM=%ZM=%ZNNTMEUL6H/D&P$8NI"^8+X
MANA;LS9O<_>CYDGO&E)]8PVI=I&?]L@/>([^B"P"8E,KBQD<SOT@HE^2OP*+
MH(E2_WV[1IR0-@23?\#?Y1F1]/]G7O9@>/Z":.W#X<!BTV2B]]WX=<%%N\??
M9&CS><"$D_6C36CO]G3CI>\1U8Y(MS=Q@!&_X'$N=%&+Z Y/K$($V^]1@$28
M-9S(GO#:DH*NISI C2R K_WF0M\"Y5'1R\!_H YQCI:W(6]PMEI&A\QQ?,#0
MMPJ$^V\JJ: H<8VA(TBFQ_,+;_MS3 /"F&'DH^6E:[%UY#D\"691[%<')$@%
MPOT7I J*<I<:4#LR[;!D8$?6$>Z_(%50E&C_H+4C ]\FQ$D:N/"+,/ZDRAF'
MRG(OXWN7VN,),[OA\R7EZ?;=O%% $*?C0I&!4A2)W(.KT2920XC>-&.%]Y3[
M%7-A4Z4]GB#+J)'4$&34C)5,&P;0,^V4>FQ+&SC3Z@@/]DRK15&J=8-6%2!3
MN78TGIP\V3/+FY(KQOG8XWSQ_[AY]&"Y?(5=L8,VH':6=L%,I_(_%'X36.88
M' YA<Z-(1N;Q>LV"Q2Z,I6E&F^ZS[<9.TN1R#4$*"_15UW:9'\)[%%L6IT2/
MBZVORCXMLMX;]T"*J2DDIA?13+MD\F(!=N""1R[+HP]@8V\ DB./U3Z4A)P4
M?,BX-/H@@*\ D@/?$''2KH2XIE./3JAM>1&//K/=5L@;2M)YQQ.>2LL,S[08
MYHK8A#X0YP6PH+IR,P1+K3/B^4IH[%B*EE(]#J:6EV4"6)YS&5#F?BPL=].+
MVTBPUEJ?!7+K;.XT*>&2:2:&=O+7\23SA"QW)880Z?44&)ZT=VP7ZB,:\L42
M!^2&">:(4?K4)W#JV#.JK$&77TD+@$NQ/6,*2R6<4V:;.31:,GWPVF<F.YN0
M30(/5!%D1F'%%$3:X2W$.I0;Q?>\*0 /8H_\^#XZO/?CJ(@9UK94(&PR%B8G
MY5(YAP*BLH\JX;1&C.=S*UCZD\+9G^7A\-(II@#LIL-3=\5MDD#:,PV$='N+
M- &%ME'DB)JU--N%6MHBDCB:.T&R5,3\/2<KRT<[+N;!%/QQD .E3+.<]I@3
MQMDI*I2[OI%4@A#-YFN@9/(TT1#Q9B6Z $"YCCXHNV65AM*T)307C3#E!6TO
MM-'KL .$@^.[04JD#:8J2LN[<MNO@*M1J^N,^5'>E/(D9Y13Y)0S1LYY:*:&
M%-*FD23:*3F_/"S^AI&A:#04H";I2A"]'4R9\C^4'5*M!;#M(+;<J@U6J BP
MDG*@M&]2U-@W*>!EIQ=^UJ^EZ:SJX-D4BA@2WHE3X!77D-/A0+?%K 0I_$VJ
MRX71C=MAG51ZG^I)0+*4$2=:S[=P9O\V6HO:#D;NLV'%VFMI:&ZBC?=0TULV
M;L&D%% =)#G")OVE1H$V/BS; *2Q@ZW<$!7HT$D'15KLE<$[]20K=3^]\"."
M?SK(TS7=ZKHQ6B:/GL$80"$_ 'B%KT9>3QEIN3=1ZE)$7AT4SV5I(-6'!^ :
MA5B;;=*W99YLQO&BV)X!:)FO9\HS+>;\U,H2+3(/)HS"I OAO15R]V:)F5'0
MD1GMS2)-]ZA(%VL_=>7&[):#65"E'AQ=I6-PXXJ:4($&WT1$D'9I*SGM?2@:
M&?\,4Z'<G]Y:3<*6Z0[8NV,N;3%YYDW\8&ZUG'::3D%*XHHL>"<?;XJT1X1D
MM)V9RH!;<&,D*)K-(&X19<F;D8'/W,5_DJ/C15F+?<MSKFCXJ3$)1J\+7H%*
M0N&&?15>^*4?7)* _\6:8OD[VFQH-_^KT,/?.U(DS7G_71="N66@#+I&+S_Y
M^W<T?0J#;2W&,-< Q&O+,]-;:RM2AQ52Z'$$-=K=7EELI8.WLY2(F]QC&BNA
M^FJC"LPF[U=X]BGY'#->3QZ*18! 08KJ\%A&FXB,MM%6&1 SJ[F>CED#K45L
MU?QE 53FS++---&C9?(GZ.N4 6<G'UDA#<>3RL 93%@+7I+HD+*397&4V@TZ
M-O*Z]@97=HVDAB2Q9LS:FP/KR.DV)./)21C1N16!-XJI#&XP'5--$%50)'KU
MJF"?]*M/;F"N%RZ-&G>'H$V_^.L^I 2UP-PV?Y3W #?<RN. .#3B?\+VU0N4
M3&:A*"LC,5ZM?6^U4GZ%C]"%Y5?H0MSS1)^/X4BW ]:M77.U9&_1("G/?TLL
M[H9R+W4;=I\\77..OZ)DY9&4>?M/_6 K)R[K'&[-(_3>BI!!0:+-K7ZKI<U"
M7V0#7(KF<)2C)(:M'6XA"D0*U1'E0 %2><@FO2%Y4!+HH?6TK:_<PMUYTF0'
MX!6H0PG?_C91W?G#+;5-D<\NQTE^D,ZYIC5P_]5F!]"DFN-JJ='Y@ME!?-6,
M@Q$-%WYHN>/)N<^?8&'*(-4.N'M3BX7^2[L;PA(==(%O$+%CC]*$AR-:%30E
M6MGJ)>Z%A,V/FV$C\D!</SD!LB(8%$-(AN* 3E$I "7:O>I>L!*7_?/T-?%(
M8+F\IL^9,[C"))[T0/):*-S-J<E$[QW,KB#+='G5DOHY85J?)(]D(8NVB=)P
M%&TC7M@=89&M'Q&9P>PN,5 2+6,UBR"MP&/<\<[=2?T!KHC:J TEXMF*6GMC
M5X@$ZFV$J^5H#D<!2F*8"Q X:'-!'@OL!K['_FBGG4"W(4QE\D.*Q*ECFU^R
MFZ@3:6^^?,-[4S2D(>YZ,(/D-]HSXL0N&4]X^AYUJ!4LQY-SRMS1=3^0):_9
ML[SE.,A^P"]9F D<SNAB1$([H$E=*YH.1N'QZ^S&C"1/<PF<<LUF6Y3%-Y;0
MN5X$6=9!_O(,CRSQ@</58BHLL$L_3$248(F_EP%8&XJ]#"L/V4*<+LM&W"%N
M6ZM#FH,!+@)Y=-M34'7NV]:LY"F7SFU()K'+>0K9OQ;:LAY&_"*)QTW8=.-Y
MG"19C,@B(&R-9B?6^F:B:76($BNWQ4SOXR!;EHU$CJWQ/MD83L!7WRY[O81J
M^CYO1WVW$AYP,VT5>'O26[MM&VDNM&^CQ?;64XEZ<63!MM/N2QUY3;]CC"/F
M*^VEW4#A<,[CR6E (^^<B7G4=&)EH-VWN\'_#;3E;C_F=MVYI6U'&:);LB8U
M6.E#XE#7/MW=9-&C9MVM^_*;Z-E=\1N*3:<S$D=)8-[W$(U.328,&J+2K;QU
M\>U'[V.<LVO@+9 +P;#)A/"K8;*B<\7L@"MB^Y[-%*"UQ8L+#5:,GD:*'92[
M8;Z%RXF\\('QDQF_G@&;1(V+82X 1:1E+RNVVJ87P[W_:KKUKD7="!_^;I(D
M/[R^O>H(]ZIY+T)>Q6#;]ZXS:RI#%_ Z6F8_W$(NE!(7PVGSJPNSR=:_PN:D
M2!<OWT*/TJ1(@]]OHQY!(BIF3YK.G4>%X,E$@36KD,:YMYT07^4:OK6B.&#_
M1Q:C.@<#;BRK!;B,>8YF661:W5^GI>;:$3KDH9GWRJ9$SB(RA^[(UYD=8YG=
M)>GT)94[90K/FK%<5V## "TKT&3M3$2;2IVI%+:33MPDI_2/9V%J+;7L?.DE
M%@;1A_%CQL/A$Y7:,^RCP@IA?UNOCLWQ\ 0\8U\&=GQ/]MF_$B^DZQ=**@('
MW3]<[#6P2354T1;-*#F*((63C8B7O97+9-\I\9Z*1KCN-M#-9PYJ[M10^/ <
M"UUT?,G$BMVH&\!\^I)FA5J&\B$W(FSB'"5VQ)EGORV94XT)Q:)OS9CT#1MR
ME?,KG*WD'6Y';&\L^FAY71 NC6#@KE +Y/*T<3+MRT3?_)6=$MI85T<8!-8;
MTY;-/%>L:N E-3.+7D]=F[@NHQT1>W;LGT<J>+>/TE\](H% :Z?G[7I=(RL"
M=S$Z<&(PS0'%O^@B%)1(D29'JX5_QOR:@(08S\: L&6RK*%'*ZA&7M!F8D<.
MDX++?JRBE!7CS_ST9.ED@FDW$;:X6([BD,TT#"_C8,&XZ,>RJ3*U6T "8;6;
M//A1[[SM?U[XS1.IPIAQ0;VD&HWW;*WI]- 2(-=*FUT0[]0/'JW J3Q)D!>C
M8T7"52AK^P!2W2(ZRV5$(HNZ84V$7.15&.#+0)!<8W&MG1<3HH.(G.MVG2>!
MG6JQ"E1'ELN=YZ-EH16+;)!=*6%7G0.D*]/6F+SIO5WI>*\N.9DX/\XRNK#F
M1/X> '3]%$BC.=:-]P4 FTU-\D6P4?QG%1;D[B8P)6[D#L.@T#&N0WC<+R<(
M=-5:&@YK9PY"IV^"*_4^@I( [6S\#X>NF]'B>3YM*CDD]O=3_^$@_SP5:/ZW
MM4 ;A]_.3:+@IK9NU7+0FP&!OO)JHM:H(<$$8.@>5P=^.06F[)6=TM"VW/?$
M"DX\)^>+;UV%>YFV,<QE\^G88"NOIQ4:\(*JA&Q5CQX^D,!*U:F"3-I',9M&
MVTDR$A#!;I75QKRY&T'J)3Z<B7L)F8.OI)"2><,^CKT:^_CB/22F?+A!8)K,
M&VF=OOD+=)WRX0:!:3)OG N*BI8JFKF%)V)? #MVLE1-=@'0BRPJXVJT.]7:
MSZGV]['X)2HO'[22EH]NN>5CL?N/M='R47Q_H!F"R&98WXGH:/G6^N@'QZX5
MAE@W"5HL !3)MC5NA;X8E">,IC>%H?XNRT"O+>[V\]Q7VD-NG@A!>A7*B+:V
M1M*\[%Z1;'"VB3/\6Z02;*R90(NKJU(WE(O?86](BKP>:Y2PNB(7X)%U+9D;
MC:YO5^P8@?5",>8BCDAP[4\B9EZ2"C]UX1"(&FH)FB:3"35U8.514QE@81W^
MG/@ELXL]QBN&],ICFPUQ <BI I7$/H-5L7E[^PFT_2Q%TF3<&,:"ED/66/O7
MM5-;]Z !0H:;L DUECLJ05#KVD3U<K0.7_1,M5:B!M+0Y%> =O99.]:=G570
MM7^TO&&?(WBH,A0-5G.C;B2IUO=%Y"5\5MBG"]C'*$ZJ#,6M9  U>*8*>T'N
M#8,"F"A>J 1E<,]34I &/4T\,6*E:UTEU\4PN5KKL0:5>ZNB02N0261@:0E$
MWA64$<D6G+_6!*N-=59"4R&!I .>( TPJH@:RIB2P5-*9ZCB^9;-<Q[/P59H
M>3PCA6&";9<C6IDQ=-)?0L)Z@@6U-%XO02W/&"M@NCI)48)KU=&-EC4J&-9%
MVV,#(6 =7(VPXDI$1,5LX%-3-$+(0)7Z*C07!PP4WLS1<T[I$_\33DBZ@9"Y
M *>FB)I D^D<H]UL=N:[/'<F\!_2J@$42351,OLHII:P&H&3:38#ZRFCW27(
M4.SG4=5X=R %I+G.VFN'4N6]8.%U@MY2$S\6:^"9X*Z/4&5C)T\.X;"=#MW7
M]WV;7R\M8H,2XDLX*?.7+6%@8300,FD0Z FF"37POGTYT1%9^"%EC!7?A0:6
M4CV-X0E(@!5XG[]Z/G%D\[5LGN9] V>;)7'BRC%]6'-,OP[\L'+T"*ZBI0<S
M;'BIR441ITQ./X(>0X>NZS_R^K=3/QCY\7W$;+V$@2MB$_J0/%J"LZM4*)L.
M,.CM-R5L,^G^!'T?+&9]&\JRGN*@=JD2E)D4?VZ)2F"G5^6^6ZL?Q*G^_I_[
M^WO_???VW<__\]^??SAY-[*O_O[WZ-UR-)H=O/WQ]9NSDT^+[][^_,_1^:5W
M]_/DK]=_O7FXNPSFGP]^?#Q]/'9?GP1'OTS_'5^\^_L])9]N/C__USG\[B?G
M+_?XE_.?#U_^^N([Z^;^Y_#JQU_>OOU$O3_G[[\<7\Q.1C_]>WE]=G1[]WXV
MGXX7A\>G+\X?3OZ=O_W1>?7Z_/+O3^&K^?3JW>G9S1O_9/EO^.,_Y]_%P9?'
M[Y8?7]H?Z><O[^=W\U>W;V+[+':\5^Z_P2_?W3W2T]M%0+Z;+MT_7\6V>_V/
M2^^(_]WG7^T?Y_.[E^27C_<___CQ_=TR^FMQLO1?3^C'5[_^1%Y\MMUWL3^>
MO1I_NIE\^3C]BRR^.WAY]^.KT47@V\_?3?]VQ_.GHW<_/]PMGW_^[A?G7__+
MZSO[M?,G#<\OSMZ]^?7^]C2\G;W]<_G/XD_[\S_![.)BZBSN?WG\]"E\>!?]
M^<_K&_H_>\?75_O[NF'>KR&A+1]Z72 B#CBAEE*UD.U]MIHZD*:JIG:Y:*U%
M4G)[ "/-#%JFNTRS7:;9+M-LFYEFB1]Y;MTW7OX*/.N:STP[6TJW3\*Y[R[:
M38MF=]$^&!'M+MH')*R>7;371''Q+(1>1'E!K]?+P5W@<I!"9Y@1603$IDEG
M&/9GER20>:6.,4(FH4._4&SU<O<VK@,XB6 E=0I)7A#X6'$#J9[:.GJ[/,%.
M]A(4^P6*M UB*-V7!:06MX$:5O!2BJ2BF9GX&]71F'25X%4NQ04EB&2="J.:
M*I)?N72P$)MX%GG5<_K:)IX54!^H#JQ^7),MG]#V1%[.(( 2/KB9$,MHW'KA
M@AW/$\I.:JC7D\5C&^K=U+I05R(0HX)1LB,D!U)EUB(&8V5GW20!W[);0H-C
M>'^MY'K:#JG1-&S'<-O]S 1M0[<G3!$#1MU[!/D*@<9RX1IX@7?B6HA];<*4
M]N3P';FL[/[26G*CB?V-$=^HB\@?2J2M'98T%]N(/E"'#1)F?&!Y<V(ZFC=F
M&7QA$3_+K1:4%/"SDM@,^V04D\B_(LF.YN]-LI]E?SOV@X4?\./9"R_\K,MT
MI"\R94]Q<)/:MC?:NES73]</#4H(-U=' Q1FNDQZJ%LV%V-XM"S^!"'+1X$P
MFLDHYQT/;RUM'HHJ8L;+.RK20DDSJB%@K+>+_@X3"0XUF6B3$'CND$ Z!G.%
MH&6#V>$XZ2-*H^7US J2*V02H-RXB^D8=0?$NJ,HD@:04'9-IL<C\J?/YO2.
MZ? X4.A1I916)*9D,J8B)Y=&G)!Z%5?.;:1*J'HB)B4B926W@03^8%V!(+=E
M&#TV'S>ITD:3C(B0N1PO5=D(H<(Z9=+"J)1PP;Y$+&\7$S-ZWBA)J@TUB9@3
M@(9;U;5M27S*Y,VFA731BQ+0MF;OP4C8G'"_4KFVBQ2V:ENPCBY\S]ZFDBW0
M&Y#X),!K+<;&#^XG7&;1FO8R7MU2!M]C\QV7B?D>3V*S>#M?K%B^$FFM%Q.2
M88OCG7D,9)(1DN\\(3..41M#1XJK$+<42M#Y':M+MO)+G(78R6LVZ7-&^W 2
MD8#9K- WEO*$3?I@NI+5P1?5%1 N,(Q32DQLD-M4%DBI1XB1CZPK8K,SE+HD
M9,R.<T8O W]"V]M0Z#4@GDP(6]$/)$6#+67^CF_.1YI:CW6&J='NT&19@@Y&
MHP1YNMN^PM62>JDKLSRD6WV[IY0#^)KXT\!:S*AMN="IPQMCF[L>U5[F&\G!
MFX !/[*34$O%7:0%EQTL'+L/V<&B];B2@Q@9A(<GA-1@$H2;)6$^05A;&/"O
M5D2+X,/%NP;00V)_/_4?#OAOIJ#S/Q4 ST8P$T*0VM0)K/E$@5=S$DL*EA]N
M[B0PS'XYA3'[RQK)PE!HE^( 2!9G#+H6\X&/+\"@9$,- 4H^XU870 ?*-W^!
M0<F&&@*4?,8H<?B589,Y;4?$8R! AVI%5,P&:#N;[$+P4%(R4FH\1'+*IG'L
M\[?-8N;+9DXMS^XA$S]8SX:$)T]18#%FJ&<%RV0:/*#,ON3WKHF_'I& ><8H
MXL;AU-P5-]!R01(@VG-*$K,^C$X)HVZYW!2,V5C+TB\;B &T<60RA+J52$&K
M2,";GV<%MSF1$C<"17D8'5NNG18A*:P@83TZ#NU!KA5<:;0W]%%>.>E,QQ-&
M@VM($AY;0; \]8-'*W#DKL5:AC ::N\FR#9P6N_S=;6_8 5EMSBEN8PH8Y+?
M5%/+Q3(?%;D8IL0[8]_>M1W0$J@S8[9RX-<2'J2NU@%8IJ<[FKUW/..O?)YY
M(\)674#XDT1I'>H[RXU3\R-_9<" [:?"G0'??ZMFH)*DLC7U"\RIKL+FEL\3
M$)8&'KN $4NV9'XUF).V2F+P)QNK'*FXO$KF@D1(;^TUDNKT>EAEW%5F!+<O
M$^MR4FMZP\^H@;+A_$T),9=?&5/ %"M_;?M'LNPQ.UPY-IR5L&VBZSC=@D(9
MN'CDFI]L(].L6 ]?K+IM.X8 ^QMLG/FX70W.R[EDW9[<D2M:QGU_1X4'Q.-)
MF&8F*_;ZMWB4$(;H3[EKW:$J>8UG>C3VS:Z%QJZ%1A?9[%IH]**%1G(Y\)Z>
MQY>SD<+[.N4OS'I9S6T6ZB8(NL03 F]B;WKC7UJ*,-9\UGLLZZ8*ZLLD5*XC
M\D"\LU/+FQ[/B#=5PU7\=8\;M;3-&[A2/B'':;#-06H;LPC K7[3=T@WYBCQ
MF(QZUT7NV=ED[&4-7,)S.J>,,05<6X;H.\QM"$C<,"NC?D=<EVT5>SEBN\;U
MTY<L(A70FT<P>+DC@7C+[&&?WDZU$[\,FEGTS]B;Q,R+LZ/ ]ZA]0^R9Y[O^
M='GLJ\&O-&"_I:&&3?OMJ[)PD@9?UY%O?TJ[>]6^.B:0@^C;WELCPDFW7D4J
MXUON3YE8\@H(B[_NNV)OF'?KY1UH^&9$0CN@"_['\:3P[]N)X0BI]Z7%G&PP
M3QE=G$?<=NVT.LA0LN-28YA 7VK;$5?ONBEI"VJ+?<^J]'![)PF;)@U80C4-
MDQH+II#O!*_IU*,3:EM>E"5;'[,I3OV L4J]:^I-W753BJPBK#5I1>N6+1W[
MBBSX6Q^\<&3B!_/\.<<)C9+6*SA)+&JT]7,?KDA(V'*;'7I.P:?":>O23,N@
MKZ,EZ+*!T8@BCCGQFGB\WH!WK7/F###.'D].PQ%>&S5S*K"S]%J!Q*H3VU8_
MI9ZV4NHLN$YME/0D1J)U12*TE$ICFS7\NHNF#%0/S(IU9B%_=OUJ?)MF0EF>
MD_R#RO-*.BLG(7+LAUA9KYOCZUO49:3H=!:-)[=A^FX6M%'=2,N@32"45\F2
M;D8**V&U3#9?N4LDS[29F-$31$-(FVCA10[J">,YJ*WTS!XJ7:15XZ."!Q+J
M*6]'2 ,6#?CU<CV].\+5*W$.']B_3LF(ADFC%UY?<TD"&WL[29 ?G AE( 6^
MQ)9BY(KPV>8_O"'!_,4V95M'?NBRK854KN@9V2X_C9/G?]A \WB><'=I+;GS
M@5("4*_#F-&?$QW%!,E"5R*M&Q0Z)\ST) )-72!TP9"\>23N WGK>]$,VI?5
M9L-<&$EG912WGS[RP'T(51EZ3ZS@YM$WM )RZB;OE+<E^A726 %%)4:8H*$#
MC>KT#7KX6Y5Z"C9H9T<=/D[].# H\X2\65-JFU)/T9;PCO!W^RE],+G9$_+?
MD. 3M-$Z3,FRDCP+8ECZ91Z^C250P5W"S<)=!X9$;S8VO"UA0V<V2]&_]9PL
M6,-?@K?9KZ:/S&]3TD(>ON)-+L:]O1'4+BR]=5FV1:R;TKAW5W-]%%WUUNX5
MK-+=7=EM18HUMWD-[1&P8M#C8&IY]$N2U6)YSF5 /9LN+/>0]WA+9CDBD47=
M=1(M3 SZ* ZIQX\.^W-,PYQWE!8TC:1T&U9+XU;3=D;T.J?:D-M^J$Q&8NNW
M.!7AV>K+9*L$K_@^I ZU@N6UQ?NA) 5E".UAQ'3P3J?6=C =5G&I1Y 80YF>
M+UIB6Q.ZL.:D5+:$T@%&@N 6>HXTM(-I7<@EB4G )Y.TA20[\ XQDM(SVC,&
M6("2+6-4!,A?'AH_>B0(9W0!]()C>;SAZL(:;'+T&^#71A_LB<;JB 8?9JQ=
M6AO8HC2KJJ$ \NQB+;K&'EM4 1BCXU2NO JZZH;].H*U54<!ZWC>EI55BUHN
MHH8<T(X20K&F!,>O.>NI84D*9"!O)H$( -PD$EE )DT@72G(*BNH* 6"QA)1
M013*MA27$,!<9+"O4M:1XW\,"$'19>WTC+<*;5G";<*JH(>C\5H)@VM .<$9
M5(>08D-5D8+F"]OKLFRXK3*0HFR$,1<>?!:-J"L0=B/EOD70)%:Q3#,E5"W9
M2!2UL7(/(V:0 D/1CZ7N@-=3UR:N>T3]B-@SW7:)XE',7) V1*4V^B,V( !=
M(3SL%K<RH(IZVP)V8AX%O'NV GBE#WK8'$\ 97F>\"W"V?H/R,F3G;RGI[;G
M-[XS6"?0#F3M1"7QW/ITI/U$4#VFO'B."/U(O>E[&EG>G]0*8JK?<U=V+(.+
M3%TJT@"U'^]ZS=%X/[;QY,QSF)GOQ);K+L_F<Z9^ FJY-=.I;1T+T"=-DXV!
M;,#N<+=W2] R[1S?FV8*X2UQJ&VY(_) ;1+J6'A2@QE-9]33FG(@873G'P6K
M5RN4#)GJ5R:M&77,:V8-7H23"C<5JN)*KWXT$!TDF+%,6<M@IE=K"\N\%#Z
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MA>_Q"6'TV6JD9;8'A,J:+0<\&_&32#?0D5J%&$HY8#T-K$B,7!\MF<5:E(X
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MA'O%C6"@U\;68R$9$-O0@150@)\ 6HTN?TLH _H6FE2W/C"VL9)*:"JTHNZ
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M0 5\09/87:=^P%9 6BMPO7!I5->"1F!VBKXUG"^LD7DE1 'X0J&>V#B.0K9
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M2>U]T)WT=-9XA5[LO$R-,%V_QTU$EK9*%X7H?4!_(E<G][4K."CU4>9T(3X
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M,-I0_?1LG_UQ> -X.RBLAH6T E7!&G[GK0-OY;D.>2YE21UH2J3+.J0!VEY
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MQ)&S-_V*8ZF8&98A1*O8D P"6$2EF[*OI6QB]VI1X!C9GFUT<Y7 PS,%%D3
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M9CE\\^ G'% _H'9"IF@*T]26@R-/RD3S .7#Q%F9UI)W&ZATF)@I0X$.KWS
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M6[>LS/N22@^!RB,>;;J%N1 2J1$HS?R%CD-1FC++S\@TK>@T$J7L="_=MF;
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M.S@+#!!%Y$M8HPY!0Q$AR/*Y#H.\X'I6G@?]D@ZVRREB>HE*K#-;UN^8 QV
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M.LY-.I013[J4?3VJZ6FIQH;C\8VH4+9!I^KX,*3,?.61Z9;D(>K D],+UE,
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M&U1C,@\GK5@D(GKV35K6R.9C@@66=^CJFS'Y8)NF<8G17;A*GLC[918D!(M
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M]IE$G@M9S6G[@^HOF"^;<]/RQ5(W01@@F.&(_C\J)P+/3[Y$]D4:0E+Y965
M:8E'A2G>;B.< ? K=DP,0$:S#_\/V%L_$% FCX1X:YP'0*>%KIBDIS,G]MPF
MLTT^&<IF0]=%?'@Z(6)F)*H3S,FUYEA@&RU$\!BC T;-DIXJ]7$33=.OQD*E
M*LP\]/-V9:I"51IU[.YSF9"Q (B&AK=E-K"4T_D)HO+Z(!C"?(Q2X\9JKB!%
M5!A]"[0ZF7W*.+L78JMM=Y9H%NB:!3WE+,>4UGI#]&]X_$Q6"8X6SK.(J/ =
M>@%?OBP#S8I#R4Q(%"*8"@QMMM^"ZKOFT;0MSHP:?("Q[@]K;TZB" 0)V&7/
M]N4G-\X>?C6A.9&T"&=>@!,<C0>L>XNAKF+:IX[>#SO'A\J1IT+K$*QS3.N
M(A88Q$ #,:7L=QE$B()TE)50C8\0 ]81JHF1 C3$P(8 .+O2PP(QN 8H6SQA
M5)+-LHICYUF]L5F0&<SS*BJYJS!+<TJ5'4FO@ZQ^V3E;ORQW%F1ST2<>G2TU
M8ELW<NDA@<<T7=!I2F=L4]&L45=/X^#)9&@1(K:,)H2AY#^S,]9#C"QHESHH
MJ"F<^G@TZ,N;W<Q+[9<7#D\^&(<3J8"4>ZZJVS")P-J)KL<<T:-<VK[+T*.6
M<I(;WY4*2L9'4$YO]Y[NA!DUX=D:U88=#/(<;Z&_AU)4&G%DTZ<GWQ37[:.
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ME.] R AE_FV/'G$S'$NA@VUTW)4CA<,I"Q581LF8\=0J**%"8$;:(RUU5&/
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MX^N-9CWE:T#CON4U *I6 #B0,,-]@H-VGTQUJKDF8G[NL]0P.3KHUV<<NG:
MDCBCO0TQN_S5F<54&CN$T)D^MA"(?(3Y.I?EC^QVG%[]1\9N!\3J,9Q$>[X#
M#W$HS,3LG!ZP"9ZMEOGNP4><- ^P-Z5GRII6LV88@+73O3'='7-XPVF@W/?:
M  @^;JHJ28]5"VZ<KX<L)P$YD@VS0;V+;6S'I$$/PB -4*Z)PPF_Y-6JS%Y5
MFNU^)<JLKEQERM(I4N:2&UO,6:JC7%LG+:[K907C!C[1;:(S>3NEP=9F1/18
MR>!C(57;TF&AT,AFSA/'= I)%8;\*,I_Q6)K()!KA^M?&6J_>%S7W>D.#G1,
M&G+D94/J :@53Q&'AC2EQ]@5CR&EF34:@\ $([4(II*'JK4,X2Y=?-D)<F[K
MG;1MF&D4\QQUBX*:Y1'!B;?XH Y9&Z(H*D6&NK'(4(.KM%FAGJ+2]+";J.RP
M,R3VQ0^"%48=OGD%XH*JPVOI7CGUXV;5^NPK498'$0!?"*>DU)Q*PS?P47HD
M'"20QAN'1QYL(4;%)WW]#]GWKNT>Z9U];*<[=SAY?K(,6W^'DER+S5.E@BG.
M6BO]8+]L]Z78?!$MU9:/?9_RRH5N]7%%*&=?2W8K.M#2B;^(?SR+9O U_ =0
M2P,$%     @ %8A(6\C- 67C/   A^8# !4   !A9'9B+3(P,C4P-C,P7W!R
M92YX;6SM?5MSVSB3Z/OW*[QS7LZIK4RN<\G4S&[)DITXXU@>VTDFW]96"B8A
M&0E%*+S(5G[] 7B12(H@ ; AD!D]3$UL2^A&W]!H].7W_WY8>$<K'(2$^G_\
M\/3')S\<8=^A+O'G?_SP[OK1Z'I\=O;#?__7T=&_?O^/1X^.7F$?!RC"[M'M
M^FA,%\MKAQS=!,@/9S18'/W?:/'_CAX=W471\K?'C^_O[W]TV&="AP0XI''@
MX)#_XNC1([9@ON0XP'S!WXX^L%6G3G3TY->C9T]^>_;K;\]_.GIW,V8_//LI
M_<J_?O>(_^46A?B(X>V'?_Q0@/1P&W@_TF#^^-F3)\\?YQ_\(?WD;P_\%Z7/
MWS]//OWTY<N7CY._;CX:DKH/LF6?/O[[[?FU<X<7Z!'QPPCY#@<0DM_"Y)?G
MU$%10LE6O(Z$G^ _/<H_]HC_ZM'39X^>/_WQ(71_2.EV=/1[0#U\A6='">:_
M1>LE_N.'D"R6'D<H^=U=@&=__(#<U>TC3L$G/S]_PI?X/_PWGX)/8^J'U",N
MI_TQ\OA6KN\PCGXXXDN_NSHK;8)]"?FWA"ZPRSGXF'_FL7")Q_]E&LM/ERC
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MN0DZX2B.[MB)^ V[YIBZ ZDGIE26E[N4LAS.WL'M+ QC\QS,H S#O@II!!:
MAF+>-([XT&I>R6::@T50 V5CB5IP]7Y["F+N3)H6!"[UBDM+:QN*5(J@0%0W
MY_WW#:$NAF/9NVCA7&V>YBZMP!Q'O?A0B-F&[T:^.\$K[-&D>#Y#$CQ4U 3+
MZLMYJRB7(T2---/@Y\N4GSZ><V/3^:AZA7VV'8^7S[@+XI,PZ3BZPF;8V@;-
M9@*3$E];R:9Q!1!Q%L3>FK:SEAU^)>;5$$?#VR^SZP;@&?R"^C1'+3TO\NY
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ML)/I+ ND(F]SDIHJ4X#!2?=L[01]0D+'HV$<X!O&FF,&Z4N?B%.'GN5C E0
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MJ7PHY?])+&/UBMF5JTE+&0E2]64@>:E5GHM)"L.E3LRUGBG4:AM%J"A.!AT
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M_IMZ\6*[>:3=*X_]+@/A\A$GU)1L./Z+)Z^WNQM]$%[]N7?<*=DXQ?JGO[R
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MYN;:YLK N9W"?!#"L-VC+XF>D<=II;^E/O5.L*CQ^?HV9A2LXL+=*B5H,DB
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M)I'[Q0RS2DI4T'O!IS).XO\:]6MZ-BNH/I7LE"S1PPK#VH.87H1?#,]"1!<
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M'$]JP@?;$311371>9#!LXE?+M%^.>MV$GZNRY8I%%J"&F+BTAT]#Q&Q$12_
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MUFKE8+JW^WY5(" F&@R;B%L8! PI58. $!U;0$5M$Q]^-6JNID<SUH-6Z*0
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MICK,/#4E\&@],'"E#+8)XC*:R7[9YL[L3"(X\S-,1C0=H7MJKY%"Z,+X)C&
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M.KS5!.ZTN B)<!$]45\@#O10"RIBC$VSC?Q$0!,$S>'NQ*G 1?,8U([._-1
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M0%9T@B"@S]NZJMSLFRUZ?A+DR<]-?4&FYXV(\^J684Y^UQ(/NHUESB[ 1Z"
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M#??1(]_^VU5%Y8K7PTD$$;IRU_Y27.03-\7?,/G)@>-Z.G4-/NM6"\><UO'
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M$BB2HI<#9XP<HM8\9>Y/:Y9G25AV>P[D-A']W^0/YL=%.5Y67D#CMX8M]Z*
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MG07?D?W:6)U)G+N1PNM7$;ZF% 8+W%MD<U;2V>'H2]$"$4>UOB)E$6^,>@V
M1VP" )(*-L3WZ>715?I?MMMQ%Z*_H5&4+)9D+= C#(JOLEK6RQ;6Z9_U!<5]
MS0A8G;47?5;+LFP/,E$;S/*Q_65S%.F1Q09,CZ+(/&(>):F8SFHZC=.8WDT!
M27TQ.R]:BIZ32\5X6]9;@CJ-AAF8N^^)_(6J VJW9.PM5EDY_ V]$'(.9AZ"
M%2FAUZ)L6!=UG7.9L "+8GN[09O@%?#;*F:=!X/HM<^B"581M?CPMM(7_G
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M1VUL)M)9ZW=QU:#<Y+FX0#B60;M[>K';KHI^DL+@R-LL)X+:XD7-I'DS80L
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M2*<B3-@9<R=>4$CZ9S^015LX4'?VWV+)C:Q.-%HES/T% B@L(V[W7E^*CO_
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MO9&8R32_.3SZ9.UA?G*G3=0G?L#W&'+_I"R@WP)O67B@Q%">K@;<"L3!65/
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MO@X?QH/!)'K'%;2=E3Z_<*=MV;E$OK0[-02S:7UI09Z.\.O2E1K.,X2EH\$
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MF(.0@^N:<?[4.:5#/"N1P9#A/8?Z&N(R*EI-9E6QU )^=@7@5>?:'ELNFI8
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M\JY9W=3L^4,V5-JL6!YR+[MZ2T3 :2>^82#.%D]B&*(#K-@R:MH7< 35_!
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M*!0SP.,R>FM$])#!L0B*0I!: *@7E&\;-EV[O]CPK^!'4L5(M,&0"HD[:V'
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M:Q;/%C2RQNDD<'9"XO\BV<)?M:3XI->\";?:K;G;X&4%@CV*Q,FFH\&$E L
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M(>%X.%.<T>JE_]@)V)IZB$NT:[YH6]-9R.O.Z24)1&Y:?C-09Q*S@=,,VI7
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M:SS.&4*8CHWV,IKFW22%^H#.X4P'S[?5ECZC/TUX3V/6493"9S+=D 4S*8/
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M984UG"J-OQ(M/PJ2CPTP\^T/:$,?E*9=$V<L;I,DJS,9(@(1"*I_N]6?[EI
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M;/1?L-%GUK\*<WNJ;:=/M>WT!;6='CXDJ_J%$3>:YK#P,G6]N7/+>M9)AX7
M72X\*!:N7.A*@]J*R]5!;!2*RLEV ZUV&F%8JMIPW' 6)@7W<:64(GKJ(CO7
M7TF^B0G1/5ZFGVN:& 7^W(F?#TXX<JB72Z$TT!3(;!U+:6DW]7EM?7EI9-KU
M^A[=FI[0,$W1;)DP4HA.2 @[3L'V$/CGU>B74OPHNS'"!6390B\D- , \#LU
ML*.6,$GY<!K.#8QK$Q\W< /7@DP-/;WP_Q5<FN$S9%OF5<,1;<U<1>,O:)[D
M"@6>9-2M6357==?2TWARGWAOE&W%;M]4VWK3MJMBT92#G&[],H[LXB/MR3,
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M4+U$.F/V&3,@K(W7+1X+TPO#%+;$[-V8O:0R2W 2F#^9'Q1*?LJUR\7L:(4
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M.WGBN/5[BL3;]7!-[0;ZAQ*C&3!<)2)JS?!M]G%FN)U\A/2.;I1]NQ& UYJ
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M6XE,)%[H("26')(47$>M6%V(TM]R-'K8A&F[W'0^!A=XI8B'HFL=.KH6\]B
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M6B8I/#A]XV..%BGU:.2KQE,!SVXP9^'9[+[C7?'H7L79BA-\2)#_">\%1Q=
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MA/I64+?H>W40+5@PKRK$ZSP^>_1X<1DG$-NUT)6N*N)H$L)2 IA?0T$<5$?
MW>\;=M\4?AQ7:</3\)AMKLC,@WP9<D@)^6YM3@:C#Q_AZYB#A_>__.:[YT\7
M3_0C^N.#+S]FC_NOWWSWS=^>+/[RW?.OGGRW>/:W?WSSZO7WW_SM]>+YBQ?/
M7[[^^]^>O7[VS:O%L\5WK[\^6_BK/I.X3JZ'IY=/7@DWZRN,,P=Z>M,BQ&?M
M]R4S9B8]F[20Q8JLL8#3[\R5L-TJP9C>O)@)=)FZ"_+DTG]1-RGXTA^B3U"<
M>'&M=0RE=:%8['?X^^OK.&:'>]]B)7\ODYKU(BZ^1N(P[A0?_0$[S7TRNH^-
M &NT&IZR"=+0%!J-8@G)2<O=EZ:'PZHLQ,U"E\NG\NR7.73G#ZU_YT'\FT7M
M,;I=,*E>YS!D.H=\KE0F3<C,T=E7IL><<Q!EMIOX!(OANF+YN6;8Q!? D=((
M>U<Z3XQQ5K=^1_AK6HD#*]GV3-3")Z_8)[;8S"<@]!@?^4O9GG@/% :@Q ;,
M5)7F4S,Y,'68\9:=0WE[X9)+6O<$?4U=4?2L19Y<\#ZQ.=7O$GP&3RU\3/J*
M<Q;D.8 /$^Z_G+XYOZ_QX'G1D7&D,*&UE@](71$/">:=&W),EN%0+X1LX+%-
M?Y*4+9D%\-#N>5KUH55D\,XC; &DI-)"7"\9:4%&AGSK!*J&2_(5B5X[C["0
M3B3$O0NUUO&83[HDG@Q<NI@#?^.=X'4^!!O!Z[1O,V=EX,?A.V!=3'Z?,-[!
M.9K56PB.Y"3>"R@9%8Q(MJ9G4M5A\L^61-OV35)68A'IE4K06/^;4%?V0F3C
MUE&FP1.(J1U/)\RTDHG\UZC%YT:I7&YH'R!>;Y:$S_5DBS D_4GS%FG[9;>2
MGC+/_E7, SJB^3;H0?(IZ97[L<U(DHC?KB+'.+T&/\_8JR!)9O9K-;%.GE1<
M$=39OI*F;^""A0S5;<OB+8FTE0VJB/$5BXUR+0Q)X3<DA5_^F3RX!2YFR=I$
M9>_=L.<\Y!2R=WZ[>B_8W./[)]C<"#;W^'<$F_L=%3^G&N,@]*T2U9CW>UG@
M<BXI$P\$4"LL+6&:VJM,=]/QVZ5JTWB3^?4*S;^"RG>2"ECY0RKX/-D-F3#N
MA>/V%,'A"9_/--U&^:"YBU 6[NQSRXAP'N[L@?XA_/1,YNL-@TLXMT,9LI'N
M"E><UON.,FPBZ6+^OAH):_&BFT@IO*4K9_*2Q\=*^CGG0A;W/.>'D49M5H[+
MN2!,/X<^XE.3O,G9@J%R'*R5"(:KZ.S'RNO8=XV\_.YF$'[)DWV"K%J7T?@/
M?[[YAEC&P9::[''H4A@6'[FMCE)-?_@D+2A>8??//DE_F&1UCZ^IU+]_L2\!
M+:Q$(%H3%TQ9RRF R9/E&R]ONHH7N)[CD]8*&72RN30A045>/$O>:KCD,&1<
MT<KL/2E.'0F_IBN!7XX+'G#TXV37S+TV$4WB."&X[  O7EZ 4@&QE :$&8B(
MUJIMVEDH#;@^C93GB*:]U$0,P]@V"L#LD@)TFU9M[]BR_D4=&HG@LDR<!D)3
MPSL+'('*\N( W1G1C$W/!N[O%@0G>AGMRA]!=>XRJ>)TVC1-YT_0ZFTMLB4I
M_,[4UECW+K5&TV:RFA[+5/, 8Q<2OA<D$VQ[%64)J$JWW&]+[I*6!PPS#WAJ
MV#WAL:DO<B7]\;#3LH-B$_Z[([ZB92X\4$N;C!( 'OG^5(GGU+MR,M"?:J 6
M2E&NE$0T.6Q')I7TOY@4DZ D1)TI2=9RU>X\D<XL7[Y@IE9(*&<I9D>[>3+?
MD_G^:X0('L64V>Y4=IXH0TX&=S*XGVIP&E::%RE._"T\JZC0K-L8Y?]RMG=R
M%C\TV]K40@#<59*;L$C3J.P*4X/J*1RME9YQ[NRV7YUVO)-5_O264@$0ETN.
MQXG]79"D%G(#JWZTT=/+08G.T\DB3Q;YTX/JU4@R=K<Y]$3Y.9+X(C@WP2/R
MGC479M,UHC%?=.7)*D]6^=.M4H% C!C=2NB;==XKFO+$\G RM7_%U!2W3%TF
MTF6Q%(3PKQM?_ 8*/T=1IE0@-+P;U0+/RRTI& <F#L^!Q'U<M+VP";L*:"9M
M7>=% <5(^+-%M+.L&E'.9<T4YQE&#(\*B3# X89Z_:VU!E>HKZA^&1^+=&FY
MV29><56=#ZGTZ-J.$^O&"<KW[E"^!R<HWPC*]]GO",IW-U? M[J]C#N,0X8-
M9D+^^2IW-X*W*VUTQFQ/)Y6"_ &1HDY"+U)3)J"A,NH3I"/\_^Q]VW+<1I;M
M>WX%HN/T"2D"8HN294GM.1U!T_:T9EJ60I+',8]@%8J$A0*J@0+I\M>?W-?<
MF0"*I"7+LHL/TV.1Q4(B+SOW9>VUY@KG"=R#:[=139<+N;N$.I[X]2WP_HS:
M$;'-#XPF"R8S@Q?U_$(KITG(^&/<M5=D:$DO%ADX5J,OX#Y'D/+1/V$4FG]1
MP-A8 81(QH]!+;:L#0"XH"%AV@A*X)R@3AX80;G$&<#Y7@Y!,VKZI?GN"*/.
MH5_%8M,$FK;0AE#_ K!)EE4]? I>B,_G) FPY(V?2RPRC/$@L#QU62#.""<(
M\).@&"^4.D3;LXOA"[8O(->=,+4%B#I(T9+"P^6/7@=J)_X<0&OZ".4(6SCF
M*^ 6C$-%F%#KBG>XQJT=3CPMH*9<G_D9$[>-#PNE$&(/BUP]HZ, _>_4"0OP
M,NDNT8,XL77DL2@=5]2E"T\D72V,=9!9,S8T9(;:*Z#; 4ER%%8O"72K6\S0
M.9G>& &Q\5D.7;ADU, MK9C/G_S@0ICER)_<=*5W.N'N%T7Z%%ZKK<+ZZ,E=
M?T!69'H([RZ48J*A%J:P15QDV:5OLX<N;?JH< J,K/F(L$^*_D M\C.R#^Q(
ML<30)06Q%J0VTC]VJG@4-J_>6M FT%Z6T#+6ATH%"KT6T9UF;FZ2^#+?AAL;
M[EUJ*0^_H!?+[?>Y\?=)FAJ("XEG,WOQ6G9?H) *\.Q8.A?V;PH2-QH_$X(^
MX*48+;%#V<%IQTC;P'D/JK[4CQR5H9"1 S_,4B&H_IN5WB_J$*D<U%&D,=]^
MC??!%M7&FSX(L]7+,^:YEX\S-Q,H%L)N8*@S'*>&6.IV;CET@NZ'CH:)AH9'
M!WDMONXJL"VM\OW5)4^>(V(&XO9X30F(5\KM<47])F=EV1!A!V8E%DJ4LKW8
MNS40KUT#9<8YQ&7@S1@O!3+XB,A^U;C_*IH!(./'M$@1XT:N]^<) >^6V==5
MN_;_[Y__K06L)28=Q4S:>_+M1=&<7Q15]O:\A@1G0H+B+TM2!?8G']1V08,3
M]Z@*K$7[]1QN2FP-Q<#)Q_WX+YP*9!&\X6X7CABT;?I[>P:</0-&=!MD::LE
M=BWSO(I.,'8<$:JKZ'M_%4L#UA)*SS6>RZ+>^=\<D$6;'L(/0*HDSC9T3_0]
M7)8QF\U%T<_8M-NL]+Q=N\).!-N>"TJNW'-ME9=N;  I>3SUM*\2JA?_N359
MQPI54!O,4^&6-%W(0+)"71W^P6Z?634;61.F/E)O^H*E[7LC"+[BAI6#WX8O
M0SE=U+66U/&#V^FL#;<JMO60:E>%[$,C#;MD!VY!$!*_6M;#[IHKW"DV2[$L
M*4V^8#)2;V0<]DHPA19\0PTI<%P_Y=#S]JAXKV*+]EO,:.%I30&9$M@(%0QI
M,8"KV@JY%(@W T)&MW1X$>^:@5<'$M[(N(0:H?XIT?X*Y6%J>,)&^2V:Q 7;
MV3-L@*6LCQ\-]J1FW[7:]:1O9.:IC[F?,*@BJ^NNM;IF>'F05F":4RPDAG?T
M;FG5(T\O? W\0V@HO GYV7X2'>@^8@ 3_>>@IP-*YA*\"4W6]"V3Q;=,1&-H
MWWS9ECTS91CV%@QH36^K6?VNO>&V.0CR4=J!WR#!W]<R]7YEWA755='\>=U1
MB2=2SXW>.^PJ;F3T=QT()<*&4P%<K(>AKM]!NN[?MU-3@1+MZ)8+ R2I+,[,
MLX_U5T47-MQ1]F)+*0#P!)I6I2SWB!=BEW=7+*A"JM:,HO'<H;5#M5ADQ^*?
MPX-Z;NG<!:-3]?.P'6\FA/:GD+=!=%K3M)=43%A7BZY=U5"\761G5;N W)AM
MN3EXQ^)V5=!'=U70I KZ[*X*^@<_ 5\7[%^> )+#QV%/P;*0^1/N)O>:C.G)
M DB;,1HKJ 65:9DZB/+\I8U)1LZ+HRZLR13.&;(T=\\QHI)K0OR(/?*N4"%B
M3M'S/^FC,YX^*QG UV)*=M:>]A<%50*@[$>1 SVCHWAQ/8"QAR@3J"V7I+&%
M[>Z!TM3_^?8*;AN_5R^$US8G4P_/ICSLS).@X-@@7^BPI3SKNEUZ?Q 5ZUN\
M,$@S$N5Z.?+I)5=.^69EW0QY$&*6L6NES\=@N":?R[OG=>LC#OP>&@HZY/%8
M= Q'>H6ZY J% 2[).V:-A*Y%.8N 6AV(@1AO25JI=V_?O, 5P6B'B,#ZTM]?
MM'F0^JP95@6$+E*T-0A8'Z]40)#@\,9[X./R5H0TXT\COW-T"^[V[ A.X2.)
M\6:+U'#^YZ$85OC?O_F_Q7KSU3?RN)Q5KOH%U*\@+@&NB=+$78QZPLGMBDT%
M41_X UMT]^UO-0: QBW,,]+&Q_Q@O3:?/<J^-AN.M@$LZONRW&"J!B7DEL6V
MR&6@7$JE)^ [KB@0!?KC&?<(OY?+!+AB4$/\]^##*:Z8\4,D]6-D,H"S&*4>
M*+/:].S"3#]):'-XBZ 'QMM7JFS-C*B\+;4U<GS["RQJ8)8>H -^DSF)/F'0
M9SMVT)C7#@V',6,T[S=YK#]?R,%,E+_R_5QDK-OP];S1RN[(16N''_T);"DP
M>UR%N'_.W:Q6D"A@P@90LJJI=]JF%2Z29WK'DJ;8FETWEGFWE2-K;)6PH3WK
M%P/"!^FT;&"]@( 0.WFPSKNL^LT ',1@E=.!]!G26/^8,(8Z8@SER%E%UZ\:
M I/@"/<Z\CB+*GNC<CHZ%F2W3FZY+-QR!^07FTJ6-Z_^3O"GKO5FE-:\!?X>
MZ"WH,$;WJ],N(-6_=&BVEQBHGXT"]=P 0X%M4MG;L_.R#5^Z+8G61FY-,3/^
MR:?>RA6V(#D2@8E*C_@W%R6QTY2, _$F($'R'&1D?"HY ^;M(,:@F>L;+LC]
M82-9PS2SCYRD? MG_ONJA5\7);8#?YLL\@*_PM\P6!/RNP>&95?REI2IZ@M.
MTI\&%( 0S#"M#)B.!12\*/%WWGI7J8$=4M0.]N>"0"7%SP5=Q>==>^7W.T#J
M(*I?,7LU M';+M31.F1;1_8F($'"MP!]*ZF<HXM1>4\+&L+HC/&G+"D N'=@
MYE3L2+,1,>(:WGMH*A]TF9,*Q8BA#TZ\+A<.$OLI];-K_]Z452\&)/KI =T
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M),T5NL^+!=##5F1",2:BX;=1@QB:,@WD_2>G?6UQDRD'-R?D[8P"B(D($2X
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MAEX)5;0!,HELXJS5Q '!\K=N-\AI0JT<2V2+5DT4!%V8$T!0N4E?P=@F_R*
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M>:V(-7-F.#D^:>E_WV9<.0MUM+E7@(E#C1 @=3ER:25IFRY(6 ^S%G@=R'I
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M*OU_^\?"?I2O_<GOP7Y)@L#,,J0=ON1*08^9#,96!RBVER1+T75P/Q+;E\S
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MQY<0MO& DXE&P/':*,J%K$B,(RX:@D%32NL1D\%\>RIH7+_?X.Z2T)"I%WT
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M+0$6X#:"$?2(-FP[(O4&^7/,PY< ,9.60O4."?ZW8MQY<F:4YY@,I,'&^TG
MHO)VI]A"\UN,7+T7(J24,LAVV*+R*UA^T!M#0<AQNT1:8!0@GR,H$MW8,9!N
MTP+O5*5<Y3PE@#D"#];;EK?0HX$\$@!S](->@;.[*.5CHU<D,"$XIY"'$6$-
M[M6@3DTQ$3(5TC:A'U;PREV5X=6@8+7LQQ^]Z_7ZZ/2(K@SX)'EGV^O=0XG/
MD!<!*VQ1J(='%BC>ZKXD(4V\@$+CCO#3\U P&R=%/-V06$26$=0*O?VAP1[5
MMU0-0^00C6F*!9XQA[$L.<)4)[]M$Q3J'.6.PE'@PR_DM%UD!;8M%][P0DTQ
MRSA#@5H 6A9*#.=H=[(XL5F</*P.0*9'E^;; HSOMFSS[!10):UWLA@F5?3(
M29M-@PNI)B]O( I>VE5=]-:XR2OC,UW(:D" F+U0B$1B.!+3&YR0=!RC $NL
M^G[OU-%E\S;@#Y@_N?4^:L+J_Z'^:SMRI0-CGYN'>V@ -G2CDY,H/8^,(_>=
M+$O&$I'H>C=JS^:*JHM!%@:5H7B+0S=ZMRNM/KDKK2:EU>.[TNH?_ 1@HI=P
M^A&J'$N>;A95KL!/[E0=D_))88,1IJ%=!6RQS=50<?4&\$IGX95#S[2H+*-;
M&+3O>==>03L0ETVPI!NPSO"8NA9?T#8642..7FL6ZYPD\=RUA24E0TIB9F#3
M0/)P#E1#=)RBZ&;<*^5@UQHB:>\&(F>Z:17MOY*+!"?#7!?2I\#XFREW?+*E
M:7RKN7VW6L$\Z?PET"-T)"0>N:G8\\1!4@'J:=VH4LR#N:;:G$<U73_75;N,
M:#>L''T$W>+(%]PLJ<N. 8^6^P+7 %X!.3']0T6- =[1/GJ^0HP(8%H R6C
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M%J).G!2:5*?X4*+F\NNJ:%@" B^#/CRIH=BAB9#ALET,C!WK5#HH2I&:]YP
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M6H0!G87R6G(X7A\F%)/[U,K((HE4UR(%B_=]P3->P&B;\@JAWKH'<NSN;1_
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MRA+./G&TD)7O\)_88TX;C"E=WV$" KY*(0J<*YQ(0^G-M77C/"=6N4=Y3K)
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M+UEU>K&BR! " 7;5X#P!#!D8S9T$&>O\HKW3LMQ!B%WSYP,)8&B-GIY#\J<
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M=O<.Z;0%5P!#P]>PBZ7"\N,2.:F+N/-*L:XRFON_TJ]:';;A+VV<_G<%<\$
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MI8TB+AC1K$KL2X3V):PYP6QIK?[@N;"*9#M#BO,!<PG M(T+\>3CU[MV$R-
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MHT&+E-1PGH>CY;WB\E*MBX^8O[M#N+RP47-B577:;] -/6%5-!&K)XF-Z$@
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MQL$EP0-8()E&<U)IND3=4>F]9T+2#[$JW8RD66'H=5087B-1$'S0$H@=0[Y
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MAX=Z.8.]HV#_8+=FW]6A8L;-C?56V-B6U[105CTL_$L\QSPN*#2!?9Q+1!9
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M640WG\/*(W).!-ZXRE/J3RNE/U]MKUKJAX.54"AQ\^R*2Y5^I-]@6!@W',%
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MMA Q_8[]4?.0D)-Y(8@?B1#: D2*7S/GX$)'(NT6:F3!6>$Z</O.#LC/X9Q
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MM334@L/S0,2E$IK*+>L/_*[$2 <=B*Z#(P\"G:).:%]A,B\8DHAE^C5P3[;
MM(/%LS5^@8G868RQ ":9$YC!K +"'@G(&<_6P1^SJ%/\'')L,TEG>I1=#-H"
M_H$O&R9UR3Q!\U"<6*0_ZDH%$X#LWA.^Z"!*07N(9$:ZKFND,T\+%-)4B:_S
MAVJIP+3]=O$['M;V_YK!4@>[QM%4CSP2OE>-)_0W<*-B])R!<)ZE:(MPBCF*
MI',F%ZS![_,0-I'NNHTB\@#/,H1B8V>M01=RU'X4C7R\E--.%16<?,Z :RGH
M]:*NMG+K(C4E("5%);8^Y:^SXNK5]>NXK&RY K,BJXP4._[/:&X8'48,+ZWX
MQZF B9%&/(DO)WK&J"6@>'<_(8I29C#;/-'(+1"D4X+$&#LY[ UPR1AX70>:
MQ-+"V&'WS.&-[_9V3GTXSD02\CWXPY'^0^" CR% IJJO%&W-[@T$Z>3 4Q)*
M8. LR>I*,&IS!OB'(Z]S!@&I70[ZE$,3F (:4\&PWA2P5))87>GD0)$5"TZ<
MTU ZCBWP8L&?PFRW&/$T[#D4VI#E5ZY!O9L0&@XG#4Q#6&4U13.8\PT:9"S%
M;PU]N3!D3?@Z>'3ZQ#S)PK3)LC5?0%&KO[%+U436R[&-XO$LQ]YI1$ZOEUR;
M2FGVC-Q[2_\V:!A:5%$2N,;\%,#*J5*,+6COI&-4=J#1UM*IC22C;&D0) 4:
MG53NI4SN^80X(^+1Q0;4U/VR:QKKXD/WBX%XO88@^+1_GL(U);"<@CQHUJI
M&9=5Z+5"@Q595Y6" :]F'$!DTQR-6]PB N\*I^&EMH3;]0YJ5I5B3)SY7V!>
M4KG&W)SRA UNK:X85I>8D96-/>O9FAL/J:G& TE#?C&&M1QW 'D@ZT<# .OZ
M]$@LGAVL7)[.**=LY9Z-;A3#L:!*(P)4>IN.&9"PYZ6;2&[H*RGG,^WIE[-"
M<$A4;CB1D[-"R#^LHAIW139G"W&U=X,Q>!2ZYQDT%0/5V<Q4J<)T0#<:C_T"
M%"F-C>[IM[G*P-)-E_KJH)HSRIIQ8 LB.$-):BBC>B49XP/!)W[)KA'8B?!W
M$!Q5"GV\-"._2$Y.1\9E4@9M%5BK_A H_:BB(CZ-F2Q'3;JF#/SW,LF&--<:
ML';/P#;JEC,#N^ Z(R2?Q\^X>$EN2Y-UK^:^B>YWY9G6)YSA0M5X\UI^2R%G
MBLU!"/ 5@< Y40V-1S%0C0Z)):[(9=!"9NSEPA*%N#F%ZUC,@@C6F\\]T['
M%#D6#@>*UV;[/8W\@+N_"Y^1 KRWUF_^^"_Y4]1.J/V11T@JH2E20L3WI%#7
M?$/3.D@S2&J-QQY>BQ^)7):Y$I1Z)_ >B#<2HQO9=!J7TGXC,V"/)B'6UIUZ
M2?P%/66@Y32A7A7'T*6A0TT'":S]0N/K#DN@C,"S(\5?966#HO.<!&*235Q/
MF2%:#Y>IT<MCTBL(%1+S#C)C7;4T'T) ,N,92[+70^YK3;?+ ]SK\P ;>8 G
M?1[@\[U3=RS\_[O".H22F"2%>?Z;(@O,-%\YY8N<]_6>4S_8&=RK!P^MM_W_
M[+UK4^-(LC_\7I]"#[MS DX(QO(5=^\2X>8RPVXW<(#>^<]Y,R';,FC'EGPD
M&YK]]$]>JDHE6;9EXQN@B-UI;.M2E965M\K\Y:5L('>+^1%%B'Y7!07X8](,
MH^,VC@HE\/,YC/M,QX1QYTH]BQ2[;F%Q,I@NA6VR\W.:G8DX_<P[Q_ES]@FX
M-?,(W-!/E#/[.W1=/D%848<'<^L='MXQ\ZXA88GS5@L5LJML)A9(/^)5>4F:
M^TK8J<F33.'G)I#2>H[7%^@FCMF!&<"^I)Z+CMY95_0G'8WZ;O* F"Q%ZLXJ
M\)/U ^/DVRWJ_^!WM7/=GM/O\SER$G#,5,!7V"&)XA14C@FC<?J60-I,)JT8
M^9-6)G*F9!(VP8=)J+ #*[.N(9;5,Y-<C+E)+A-(9*#C>63QQ8Z.\DQ32<1M
MIR3L%&)UIV200*(2W?+.9=/L0L#N*L-=CT.#XXO4!5FV-Q02Y3NVQQ$@TI%Y
MAF(I3&YF48'T,'9"V*6NWHI&U$VHSNED[],):N@.N(NHZW1QAJJ@R5 G+MBV
M,XH\V34XG='#Q4O#0& *1\Y [S/*05?.)7].]"[A$CK1)B]98]?KCU&J$^IM
M<LPL[;&/(KY/G/8B_ $!S(N7==VA2UX*]8!.W \ON+K_*[T3VV!R8TQQ1O[]
M[J^F1#9$8<K4E?<; DD:)RO'YR9?I;4APEPD@<:"V$KPGF#@=4S7?_+"P&?Y
M+-*$4-]X".^LCK]UZC+8H.RY[1@SK>;$7!>WEM7M"!'],RKR0J3OE-0#D7X:
M,E]91BN&#/O'N"N!+)'=_@DFSAV?8B##GW/Y(#IPW^-DL$+^[QIWWJ/ %6$:
ML*N$_/BW6ELP9-$FEC9T0'L>RU>IQUJ\R/N1BQ7)(!(/8FFM)7ZCT3?@*BJ!
M71O@B97P_0E(F1!Q?T%X?96%J"'4B41++CAR^('T#I3)"4-1G;^-5.<"O3&4
MRKM1EF=LOA:B9Y$YT7_+C:-*#8].YL_O4%R[>H,3A(\1Q<)'X\NQ+GS6;(#N
M CW>J8PR, ,Y6;V."ZN@L,4I=UPEA-?/Y0C9*8A0QGNRF8:PA=E4M#08:\?0
MY0QYWE06(GN/*.N&0?)([HFP0)9K/@6<2S2*QKM\(*LFI[ ;-K4=-.(D"!*Y
MFX*Y+!*))L2/EWP8O:Z+'7R(V3YQFP#/=_=2+68GNAXJ&GB%A;1STB>.*6+#
MGTCTC17]C"8;6*::QZJ6]WPRP.AX@P"+'$)*8Z!N[[T\O66G=WS-Z#D*%A=U
MK<CJ^MK*POX5V+NB@$5 SXQC=+ZX4,.8V7&5XJG)>A+1.S713HOBH\(?5:<E
M,/7P =<CT4(K%LUPGYRIH69JQ6UN-;H/@$'DQ'/8?N1YQT$$[4$T.]FF%KN'
M.?W.F!/5VV!XC-L4$5:Z:*+YE>@0(L/0$Q.)+Z+@<"S=$3<&"^/K2H_HM859
MLS!D 3TJ"VPQ@-A&LY!!TMRK)_ ['>*'KHF]T'S1R1<9SN.&4L\(63YZ!)/]
M0;2&P!M$]2Q,ZP[9^-'QS+N'/B(8@IWNB\ZV.+R,T94+"WSGYZ0+Q'2ZM.ZQ
M202A!$>E]RB%^@00C'(_,QXB>]R)H-TG<]\^,+C[2S2.J$>1*.P3X23:;0(Q
M"]MK\%\RYH>G!Q+V7H@JW5N5K7=TBY-3@80,C)R^*Q#"P/]$7N=OXD8X7D_M
M;/!UN^-.5NL>M:_D1MOGWMA4<^_]X$U\\)E>M%\^T*$VB.)2*I%EZ1MZPW(*
MO9'9*CUAU>:(A8](4$V E>&IU3-N5">B'Q'LAQMQT^/:KK)QC\QOBERZD)?D
M,C+()0!J"<U'__XIZ(\';*<O2"ZIL'2[7(%EB;4VQ&'=Q!CD:XE(*KJJ=,30
M$?!DZ?;EHNB<F*T;@)>ATX+B$BC QR* ZNJ53W2"&!'6F>HKCOID!N,S> &M
M5(#B%NZ)JQ4D_ K_]$@-L$4#^TS8!979QH56I+$":J(D,JB_G?V7,QA^;A&"
MC'2:< FT]:+\:@J<CT/6VUA.T<:0$6K1W]2,>=3\?0RS%C=>I*<9H,L<LIA\
M]UFMO868$#ZF<\#%%.GNZ;^;?0?<N$<<BSK&U9*W=8D#=_5?Y(@()9G?4"B:
M=<UIL43G2I'HG$IT;A:)SKN]I[8QJV0"!8HQ$/3!..J_&'HGOT3C;]+<>$0H
M>J1-.JIX:$A]Q\C08 ^(#V>Y0BU]/>7:J=/!I)MK.$J#)VV*+K7)8S =I28Q
M?L? JV3(^ &HF) B=[H1XRB?M'NT5:&F;8%M#>%^\D!%K@17&E) 4M-\'):4
M;=Q'26,6[1H$A/N/*X$0L0OTR'N2J(=L12NM#<8<9C%JQ5!=%P;2S:Z)"CJ=
M<2C,8[G.=&S/3TV?"^M%VS'" R<?I2JDXC:$V<WKG1D)J!H+O4>Q]%:"A'QD
M<^MV2&AH)WQAX =CT?2R:#F\0MX#6_X:'(8V2%?8!Q4._%RT[KX8'L@$ZAK\
MG7XY+-4MZ8W'93#FY0!1$7A=/H$:ZL8-)%OP95=":9NW;C0$\:)09>[.3Y7S
MH3WO^Y!:FN*^O*-NJO)QQB4UF\34[B/I\=\3>*5\#653A\. DTVD9OM^='<$
M1)*0DO1DE7QVBHY!%-$I-0SHP)S6;8SZ<,*P#22-'B&]4Q%2?>XR8*@3 ">-
MQ)SP&1'CHL=M49B8^B@8[I,R+)V)7J0&9:LB5J<+0A%!%77ZWP=#KX.G](C'
MBUY92*FH%%T&R8SUH)S^A*=<(Z:.AM:67B35!%3OX4:X?'SVKYXA$#%$>4=L
MC:0?KL^$C0!BV(G?)/$2DU.R7ANBP<A[(J/_ JMTEYM7\O44E- ?)NT.?%H/
MRU.P7G8<^M@&+\X(UC)?V4\/M;>S>>5B[AE-1X9FT>^EW-R0OAJ.0RR.8? 5
MV(\4DX]Y62E<)+0.M!<G(AL8.0\]QE2B>$_H^%%/IG5Q1@26MM&VHVDZ",NB
M-I7$-:%P!:6L22Q;.16@4Z!P^Z21H1$38S0&9DN'8P)FQ(7!A&<^C954M41.
MAMHR\L7Q$#%ACV/7E *M9:AY/01;T55[PU+CDU@P/,ZNP?R5.4Q*ZM:X:.J@
MQ+/B^%.".9%C^&2%\+KB&?0(%_B%)_UR9.BFN\KU9N' ;Y[HITR".*NV7,+L
M^C2'N8<!F[*9=\(^!B5W!C;%((^6:UKF)57EF/?.#\R))S%J-JJE YX)"8[R
M9_Z@JS^N8).WZK6B*76@0FICH>Q"UTCS"-4)R934M@O3)K_+Z<%RQY.Q:Q:;
MKTEI)X&9$;.(4:/;:/'CD=G4[49J0 ["6&(0M2/SG%!/%=/"#(?8>6 T$AZA
M>&(6/VJY%+@'7ES</:XOUP=/10EW7F%:DX<)/Z(W.5E$0&-(KBMN#:V!=E5%
M2/5-1C)8=MSM>K$G8DQN-2'-Z>"TK\]*U]=H>R0AK)4SJX%R?[#-^(V@O^*#
M1C*JDCNQ>EB"=<(E!>>3I:K8>&!R!9T_C<1/<I/:QUF;]*X3#,'VPG[F0D##
M2M]0;G9DRHIA:7)2<[P6'E_RIIJY@8RTB0<L_UUMZ@G!O]BFEIWWD.L&ZC:5
M X0V%S_2$+_E5JVO'ELM<VQ&QMA,-;9YPH&@+.43.0BQJ+00/&3,DQ:7B/DB
ME#"/*$J3B(HU4Q.T\#@D>J0(!=V%-PU,+;BER,9?& D:B-P)#GI$\I/^@J0<
MTP"1XRRVA*P"&N)V\72[@<W2E'5@+&\=%"[US/$O=J)1+4XTDB<:=JE4'&E\
MW,VR!;.#IYZT/30O(/[YL%16 :^$=Z?;_!G6AA;V D%\2XXB_$.1=HQ2JVI@
M'U-3(JZ@$P^CL!:ZA;%S@+Z\X_F1KIS4([11">^;WA8FWB9[N9"5E?%:V:*,
MB!!Q1AL^QLA^3,838E-:LS&P=(/R>JBJ3Z9.*Q]%RV6.R#Z3N6XRXA^'?XV'
M,>@J9><O8G--L][8$@</S>GSJG%<89K=P]> \6.PMR5LF:1%.6E!Z&/+<(9>
MQ @XXRT(4]8 7<6AELQTOFGFC[D_V_XY2)H9F&3"]9@P)=&<2.%5JMX]L>$A
M@W&)_!%C,J#RX4(,5R@4%+,H"6.DO!M=PE14L$%MI@R)<JMV#U(]=!_Q/ [6
MGF_-N.'\![I&!%?E/#Q@WR:*H.OH5?MWX_8(G28QG'+IL%HZ^)2ZQ22 [N0
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M%JU[>E['#05]Y>]:LUKQ.YY_N6&$)=?P+PZ*@E8BQZDW]CLBR=6)&&4='D8
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M/Y*/9'.T$DX5JG:D*@^L6JH:0HK?.6';@>4]O/[1=U^DMB^72F7A.K#E+9P
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M50.9=,II-$)^?/ Z>J_9(Q/(S4L/!-<[]"AZZV.\@E7K/'K#Y$ -R>V4)^7
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M9-H,T\[."LXK.&]!C<OY %+2I0^>.D&7))YJ$"&Z,A0QHH+9\CPUU7=$ZM7
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MP1ZP]()PQ#XYO=^(,;WHU7@\[7&G2=[IGO)I,?V=ZOP1]!;,6QQ3;XS^Y\3
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M9AO\+'EGP?3,:A-T7\5JE-ZG+3.S5.U8C&K9&1RN<(^]1J&G*JS6NSE)8IG
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MT.BUK7H3#K.U&,XDFG_YX\/^["#5J=5MX&BXIM4LV,69GR-)[J0D+%BAK>2
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M;!T?B</EF*]TQQSC]1R>/6G/9AZ02^8LPCFL0/\F1AIG =POSD]+6"5,V8E
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M1I2=$E=8(PI;F$BM>>A,YAXL&7Q2\F>0J-3O;C""3 26)>5)>(-6@IAST6>
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M$]3,&#M/I/T<FC5ASD!,BG!,*L'@1G.!Z\1.*4%<^H$+BX)//*&1SDX SK;
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ML^ %4_N!(!]4IWIHOCPZV+(M>LZ?L*K3<_]$Y-WH$>%"_8AGEH:8+,%I,RA
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M#C_/?#JQ@9458P@+F<;07<F&CQC YV1'09![P(:"+:/]<.+VB0"FQ4N:=H@
ML6P4#WV@Y9%)#9.U<BDP6:S(UL WL]W8,?X5[TDKN"?''6V/WSH7UNC@94/%
M%_5O6W?9'@YR-?8^#"N?7ZW4-WO\O$QH+!L=S^:^L]'Q)Q80" 7E( -HO>OC
M B*X#V!$?::' ]Q5:E,]XI',A\"-H-T-@5^X*[$IFHX3W+.8/GWKB1YW@/F8
MR*9 0$"KWA_F!KP+ASCA?3, [6P,?%3X)@O(T"GFFR-_]YO;Y9CH9] 2+##F
MF@'3BBJ_R\CB678T9_B734WR]05K+@":NCI3^77CGCY2)*.!V=4B]H<+7OA9
M"KTPN/S*!:RWR%PG &M0U77P9,3&^E$646"=["SGCUZ@F'G9*OB7E-FLX)L'
MV"FEYK6IL8EW-,!<<^Y@L9 GG5Y*!5$4"U)UD_:_O^X4>%O0?2+ 8[=LJE6Q
M4*H%&T%$!EY.YB^SEIP^4Q30:^2^VVQJK/=@Z!,7K,U<ZQ"Z00_OWZ=GJP@(
MZVI+M4*CE. 4H(#*VC.T;<'T2:$->V"5BX5:,?YPEW5H2WAJPGKN9QUM'XCM
MQ=MBNV5;=\2--')VPR:Y:YZ=NI@@MDMF"-N8-%;%V[)2I5YH5-?KEM!&OY$
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M +1,>JOWF*J!3ZBAHA):8ZHMU@"ICJG*X[DZ2;_XYQJ(Z=8P'Z>K>G$!:]Y
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MWH4=X15M01!,6#_/HH0@UYAO-1?#,Q%'JG6B^%BQY\(1"U%6YK IFDR'&'5
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M7GPHS10?WLF6?2PU7"PU+&]2:IA^M=]J2I[0P$D0A2JU1IH\1ICK!*!"WS^
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M("%212SF\R0;$)<H)G\4[UW+,$>&V\4\:>$11EVBQ.5)PLBKQ.5)PJ@KH.[
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MQR0W[PI&?HX7W7PZXS*JQXE6KI^)4BK"88_#7KO7RJEAC<O8U;( >G0\'7+
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MG+<>'E4NPTV1L=R5Z9N\,P\E;RQ=XS+4Q FR\\;9-2[#3-&0';E8[& XF\M
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M$%EEBAV^"OB[]/_[8JCC2_C;P!YJE_\/4$L#!!0    ( !6(2%M=7UE,5S<
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M?"Y"UNPV\GL?+BJR3/;"M<)ENR63=$J6I0S8M('W"]-S+8<W;LA!#Y41Q?S
M;G00UE9R0\K88ALRK4HSKUK!G063Q)=@L0 ;*"UW\JR'&%*;3@Z3_HG@WFY(
MH/&\M^P0"6"6MR!.@)+^E6\;)C(]4@(DC88,N:J@S9\ V27*H^M*9OCAE#*R
MI>LEZ_;OPR9N/JID_1S&(SD($7J&7X'^U2F<G<Y;A1L5J/(FXE._B?;&H]^X
M* M[R[A:+DT0%5@FMK>WULP']#C1!GC4\6CC5C]]OWM!E$&*(J</P2=!>V6M
M>C0:SXR'PJ1/^(9;_+*RA: 1U2\BO<2ISYE?[S;Q$(_<5,5MA]\ B';M=CC_
M"</$"6K:NF)HD=$$*I9=(SX@(4B#](9%O@JZ^);M9:Q!*?MW?C(<<:RB.4D@
M8+P6:ID(=X;7]'DQL'\18ENU@1?'?-9>2:V 0XAKH$1CP@X2N['&^9Q^W-Y\
M20^N%^:)=Q9I'ZZY[L*';1^//OB^OP"PC!N-M+*3W@X+,M!!5=O\N=JZM0#B
MLO:[PP /A"LI[@QW-)E#%33KQ^, A#>IX9PR$+!VA5]Q_MV/58NUP*Z4;)+H
M@'N'FU@4OHWRB,9+*R@QM^<@-!/W4%SLHJ9(,#LB[C(>]1&1AS(%C1KLOB1K
M7T*3E.U3SLVZ:\!*M\D1_'J?(WC+',&O]SF"GZ=O4?IO,,D=O22=Y!4SC9WQ
M#SYZ\I@(=-TG#3'7=Y)9]<8[[6#&F:)@F>3[V#B_2"1H/!>F^7%F&$FGXX</
M'JC5.BRZ-0:/OR;IF)()46:Z9C!\)Z +&'I+VI6%2R>?D9)%LO.73M>V#I(G
M(-YY-D;9*^,PE0OC8D(V P@(33'VO@K@[>*C9,E#PANHZ&Q4V0RW1AI_S=B<
M31=K$ZG=)F"6-FW)#M%TI."4TCM#=H>4PR)VNB4(MUCM1\QON^WLAQJ/I#4E
M(SC1-TUG:P3L?I/1W9H!U"[I;VF=3R7[R3F8SLX&'8_R@?]U5G5UN[8VI&PI
M1.#^WI'-_N4#URFI%L^0@&OB1D')MRMT"/=S&.374@"_]/CKT)K@%FXD#@#\
M&WXDNS* =O7GW6QU*@V]OM>:,'N'$F<A6V7>H:C[S?:ZFE6@G:?=V:Y5B9/I
M^Z.O4_S7E'N&:'.FQ.QZ4Y?+=3ZIE95L,E1BRWQM/29LY:R72/ QI@X[PXV0
M;+EEASM&R\^';""Q)986HQ+9"9LC03T:#BV+.&D!?-O\.\&BA*\.DB:6B%*Q
M+;BQKT(2-PJH'<:F"*8LH'Y>$V$SJ>Z$&'OIW-;ZO!"/T)6Q)JA=J&V*%R3K
M1+WII\Y$E$TO@.V)7!J)_C&)H@^*=@:M=8#Z#G'7S?ARD1=B!@;YRV'VW%G(
M2>Q4Q3O=K"-,55X?JQB2<\0;9K(0Y3\AR;1!T',&06V00!#U+4)"$SZ^J-YB
M:ZYW:=R%*W:C*BP]4EY537MTSNY8,?>C^M*=T<W/++*NAU806ETQ=JA0[VT\
M)9?HJ!B%[QI37^3<E$>VUW ,%/T'PTC._W'CI6("MJE8\: "3PW_C%.A!>6D
MK!1 BFD:=ZG7Y2V!Y^-6AZ^CAB_8W/]HHN9_?@LO1'^T;^%L.*:UGST^\9E^
MT2X(_ONGF,3O&$;U"]]T4Y%GLBDL$F,U;&FRX^U0CLY6W+NGB>.C$6K#C=V"
M?.J--#$KC<F.VNKH;5E=JJEN\F;036^M_"&2FM,X ].VW+5Y!%W+S<1X(,D;
MX.@+^@,N)3>)9N+R)'+IQE*+[<=*=&\K6(D%$ZK-G/0L[W"H26](G9-8=Z0R
MU/FO- ^ -',J<:1UN55'2Q%@I I12YZTC6?XS2GC3@(;-NH.\+/WPR;I-XGP
M5#X>;6\-L=:ERBEX-S6UXNA$B[: J98>@?0="1L@+W"$V-B.07$%!0)81GL4
M[#7:Y<8 V<*V%1TF(WLRLTVR0&L<OMM2HW$7".#>XR^8:Y]Q<S\LG@V><^[G
M\4K7D/T?E'G_OB3L%FFK:US3$J0=CD<.E<8#$&OB(5=(2R$RZ_?F<LU* Q^/
MV+&0M.\;X5L$!X-;N3Z)\M4=;9/X@6-0W^QC4+>,07VSCT%]GM:!].=XX9/E
MX%Q706]\*I7QR%^*-.?_8'/A0U1K:.[R+4D_6:\*+9;+B$D->UMN5*>1WF;[
M%XHZX#M8[AC+/=FNA@5\TL:)-=;$H+DUK5G)SJUJ8QL%D[5O0,-:N@/3$;1U
MCJ8ECK*3T!W4)#<[,J97MO./"TU*ZY\]9,F=*YQV=]F9=,,K;8V&(]:<!I'.
M/53#+E&*;81D"26O(R 1L!9N 1:W(VXX<=:V9Z[SYJV*BY_ZCH&^"=F#G7MM
M+G):Q>!'*JO23L(@\-,*!UN1)AD8)OM&>,J(7E2V/;LK&;2<<8JBBLAQ82-Z
M>\K>)<IVXE(JGITN&"@,]#W+D082%5X@Q:5#B@9_<\AYS9:/WMR%CR$;0T'2
M%D=@/%S,IVU1/K?O8Z:=H7E3/O5-Q/I3SVH]$_0G__GAGL!WB<!)F5^NT">O
M-LOJ0C*E,DZ*+R5MBQ7++?PUX DXNK;>&_S>.O+JJEHV@*=UYH-5)8AZ&TN3
MC+5@#"[9GKWN%/79PE!!JKL5H:WTBFTBGQQ(6D(OH@EB"O:D3:H8CUS76%_-
M#Y[J$T5(,:#/,FG7BA+-  ^T)\A=(LC-\E[71J,W[UL4V$G08<W)$5%K5=\H
MY_=4M4M4U>B9F7<V.EKH%7JU.B617KRLIDB* AY3RGD@@'I %'E),AF]%FG=
M;^G/I\]B3IBW9MDXU$ZF1W0AV!P-VZ/>[1K)<;JV4[=@47>-4[=N[K%>.GLY
M-$GJ]5IV1C2LC(4ANN:D.9^^Z")URA3F0DNB(S-6J(*)0@7#I;ZR'^H.E820
MZ'E-HY:2"MGJ=T \N>NH>N_AZY0:O=(4OI9:?.HW1OJ3D-3)[I49R3) __LD
M%=?&>H/K)O+9( ^$Q6"#9M8H$0]]X6VUQYWRUG-5SD\3=6*S;8BA.G!#VOHX
M$_+NH'+YC-JH"M\57"/2@P9IBJADOB!*HN]8J18''E'+?5<IL@&"2'*F\S)2
MK#W=V9)4ES$_S)*WD#/<AQU\B*2<Q9$"=(($_:/3X%+VFB.D&^ %AH7XFW+#
M;\Y_X2(L2%OZY"H4%D0ALD&VB@][^:EO@%"*,CH_AVC*)P(4>[.HZE:]02G5
MKH139<E2/3; VNKU;S* /, UXL(9D)#(7UM)A^284$-7%)(-U[J:.I]QCYQW
ME+8!VH5([0)Y&K[IC-P41HFGJVPEA0",V(3BZ/52S^[-GM0G)?/E;MF_7K='
MX!TA&7*8LQ@M7LHDB F8:)0(UA)I'0R/ :?HDF_N("M,NN5(4QQ;J=8 *@8]
MD9K^8-M1S2R:@F?NS!L\Y^G/?SP*N% 'Z1IZ*Z.QDMY2%1VCL;BW-C&<5&T8
M/L WJ&Q<3\JH,,0Q"H]4BO/J4\KQ@S\*Z-2B*N"Z..P!F%ZW=/A VJL>KMNC
ML\>8 ]+)DO"4 +P$LG)HBAZBJKHL&?R'2_=1B(.'&'8&%9F#U[B>!Y>+/%UL
M?E]FBMRYKNU3-O/SBP<"7Q&J0O'ZNZ!I?.!4K#_O4[%NF8KUYWTJUN>A&=QD
M>T48 2]7GZ#ZZ%;S^3TQX0:@:0Y_*T>F;%Q(1T9ZZ]2%2#8O29"Z/.R^3&0,
MP[YJD')SXV:HV@L,D1=0/=0"KRJSR>#J\*:ZX2IBR_4'+>0&"K%=4A*@FJ1K
MB.3^&RMN$_G;E?97TE\2>$@"D8;9E-S4&:Z*(_K1$8-R<\0*OX@Z3\ZJM&NB
M%;E-"2OSVQ2MT'^&/HNE4\]B/2BH*$JW4I$*9:YLS-KV(X0A3U5L Y$H)/7I
MA,LO: >+JV3-<%AU\)VD9(]$\&O$N $'AZK%2,L1O\&PEF4\VJ -;-AE-M]N
ML]=J^U9?JV:-1]=!#3B!+]D>RR4VF8F5"U@*QH3O WTZA*K;%-[$^ WCT29=
M";8>G9DHX/!3A;ZLVY=T!Y236Y:*?F^R.8Y@%RM$7PDJR!#,OFEKB0=%U0LK
M4OUUGI$-5N>,YTRLX1(>",[;T%PZYJ[CI5[A9E=%H7TC)6=ES#KNU^0N/+LV
MV$%BZ\77<7T7=$"&017H,C2XC2C+\FC+<D_X1RKZC0!\0 (TQJ$?V.O.9N1M
M+ OP5JE2CZ3%>!2P#")NBDF$4*ZT8>6+#\O"LT3L9&]4"SH9V4(]+Q"GQN($
M!LS3LL/-%SY>@I-!_)+8M(9WW/$9W?29A-W?<$ +4N(<!R+3T"(/RU^)I%+O
M-BN1^MP?^!F6>IV+_;\J0)D9C&B[][O"7,**F7ZD Z"\C QOV2,AO0)9N&CQ
MC<([]QNZ2KIT2"YDMWG'YY0["'N,8$[*H7E4R\@!0TRIX1X*L][W:J;S0FII
M#3$"/1[9L:"%3-2;G"PX78.FHZNRLB>X::IK<\P9'L:X+% [/EFD=77)ZLU,
M=T7;.,T6ST_4$\'" $Z*G8_H"W7O7?P9QJI2FAO*O+0X+CCO@]UJF*G4R:\!
M(2)BMAD&,5QSSD81,!T' 57=6,*?*#"NM3KCGO86#M6=>V]<GO>Z=A>[N;;L
M/0/;F)Q97,J PGFSXUJ-% .AQK(D:0(,GF=1(N7.<)\?*Z[N$-$?P?\W,#-;
MB[E228V[J.X6CA[I7 K9U RJHU=Y2Q2WBK8S0$4+NQ"4)!M,$0=AP#OBNSA#
MER17RN[36LU >O>1I^%X=:,FH4QT.+9UPT[468NAL) !O#XCSF%.'L0U[AO3
M,LY^F*"L);$M-P#LI'M--_(:CE/$T8G!%NH "% A,':8"%*Q#<$YWZK+DH-*
M%M-B$@QKCDK5''5'H!?ZI*1SQJ7]$MC=VE+D+EQO_\(U]V+L,OQ+Y.7[/$.W
M$H,^FZC7Z']R_&#Z]=&Q[P7UBHW0SSOV?,L8X,L+H.&8RUUAJ_%QDDG8V!Q7
M5:T0&.I*[AP@K4DX/L*\S+?#(E.AAA5HH;XJ00 ]B/ I#S=Y]6)5SZ<YVH8L
MSD5W21.M;%NA-0SGQO8O<9J29-Z2)>I0Q8*:U"_3B5;+P4B+#1*'NWIAKN"6
MX8"6W00!0.<,NESWNI[$ S"L8&SF68 3KN[)JZXARRMJ+.8-[X2=.F*4P7)/
M?1NZ39H;J56\IQSK8#1/+MM0\ZK*H!YS@[]L$W8*,W-B[+SM\<0/0JL@NM%G
MC^-K+B /3T*G(-<-#6#L  )?$@&ZIJ3^,'N'3.8\]J9=#&0YH#]AU,*RC8<4
MAP-#G;N^$,LJ"UT1L,T!&8S=FK5!TU2'7,[=15J//,,EJ4=Q^L4&&,D> CLC
M907 +-]:X !K[&W5B2W28EO>/CW<LD0ZOY+BGR^Q'%DQ4E!<6R+1_O.E;5^I
M/2B)+TIVP=YXG[AVC#Z+YA @+#.#%,U0?PMU(;O(&\C=B?J>C)D+>,XYCR2/
MNZ/T1K!!^8U4XWIR>##X83J,]VQZR+_^[&UZ'[=*6-=Y0EX.D4V.MB(NI;!/
M*W"#NCR +;MQ%_2*#QRI_<L^4GO+2.U?]I':WY/@U^'*^TIH5C$'L()H0S\U
M9C[7-U1SA6-(J?/-<#<FS50DN^?:=QSBYR3@UCA\BAF9H])5F'[@U06$F("D
M38R4_<+]13"\L6_36#H1 [..51FTLC$SQ.VL3'$.<:D:]@J1=@'. #4.NZK+
M6[8OD>J"5-W6UQLWU=( XHP7,@5:.5>?^*<^J(K_N?')DPC4N J"/P20(;*9
M48F2I?ORBP]-L#4%#'_A''!]D,[;Y+V+RL-O=*#Q[@31YQ":L<-1=Q!ZH4M6
M@%L_"KCE:-P#I7L^"#WX5C!..>VMB75DZ?_'M6IJ)D0[[/XV2+MR$S$2MNFU
M$0O%POC5+] '(.%%+:,]/U1K*/;#C89#9]-U9.O -]&:&ON-Z'VL$_@24ZMB
MV4X"[$\1[1K%]^PM'>#>2UOLM.+P-PH)>&+<0=5=/HZHU3KTE;</\7Q]L=]S
M].[Z*E*Y\&A7T-8A$;FO]P@9>*8A/2*QR6@#+B\7!.$F:MA]S<9,9!=@YM47
M-H^BYG[9ZRCV,.8$S#B17M[H#=N9@:/7]4@?'O,U[N7QB$VW_@%')I%7S/MZ
MG?6\;U#GG*:W*8&:Y@''6^B\E01O5F.S2B64YI&9X^7V?>I^N;9=D#WWJ6$:
M@/G5M#[#48"?>X0;[!!V>/,ZR<@ M^;;1Z:<E$&8=W")Y2!4NL5E=<D1B_Z.
MRKDQ5H0]@UOVPIVHYSHO.@%+C$_6MY00ZI64263@.YPZ:?@!-R)=6>E/Y[L#
M^VOO3 ,V[!PQ_G1FF[>[KNSP]C>A%0-+:T8-];8A=B6_$]B)[S'RRYMA62&$
M=%9A#CV=@1F A-)LG)V8/R=:2U,P["S[%:Q;(K.L:=T]$T/-VM/QG65M1@NI
M+Z<!@A-,%*)JZ[2TB_'Y5F2, 3^L@!";^]SHY<3V\;Y.#,Q-B>!1<25[$H)H
M8$5T&@,6VWN6!83KDJD5<8-\V2V=GD5<'KSUB)0 *SV=FC4U[:6QP3GONK'I
M:XCV]0U:N+L9=S_U*6X#/NE\0LR"W.E\#A47^Q+(#UH">6W&/5\*KHC+?",4
MCHR"8+[MY9KS#;,BJ>\#FR'XW5>3:NZ V^^X**^QN@,&8G7D^,'1?^/W[H__
M(;JEW0ZM 7O=?M#BUZ?-]]5%1(\P1?0N\%,$N(&$E6R<)P&6!U_HI7['%X^F
M?VRSZC]!??"^//ASNAOK?9A@<%Q[8YP_V&IE\FD2PW"[WBOA9K'=_^7M;U./
MLC]R[>]_3NGO6>10<3TA>!M)"$M33;:$AZY=G]IBD=Q%ZC&CLYCT_;AP2%@A
MU6#H9!ZT>_=ZM&@1X]'>XXOL9?2/8YM1@FQL?7*8SC8"[VGGDQ/G. .7OK((
M_?U#[ 68IE?B7 (L->LV\$R]7R:%U/#Z3(5;9#Q8G/8M8_Z[F0[,(.(ZVNV)
M"7:,TNZ?_'JP7W>!Y&Z,6TLAS&MS446<$]6!:#;E@L)]O61G$I;ZN]+; F_H
MB]'"QA.15%=V#9KM]'CA1)VZ[E""(R5&1!V]G229V^]UT24^O*GI%[,;:=Z,
M%!T&KK2).,)(JZVN%@:Z=./FL?<0/34O:_#L$GPDE[X)(;WS+ER']_(E6U>D
M%@"G7D!>#%;6.*[8.D<;[;ZG2!+/E;88)K%V(M4>["2-?+\Z:EFYS0<LI]Q+
M,Y4BH-[8W.@@S5>PNGTQK'5?W^BXGJ@?>E-=-]L'C39C">[[G6UR\F'N_6U8
M)W5!()(X#J< +I&;FHACF;/[0_(:WX&X=ZVMZ&$5HM?0RA?U;+I8;9W/&>M-
ME41#ZYX#EC,;>ZVRU.5F=KO6*_$?K/VYLO(>MTO6O"B/SA[#6X,D"G'I<VL\
M%%7DHH(Z-TY?@W1E+DP&94ET$#EAU-+4\^ X9BXL$)&V-2B"8=8[+'UJI6JD
M'72%MXG*1,;B!S76=K^4CD%2-0*:!Z PZF*873*8/WN(S[<[M'4&IU1#H[&J
MM+DZ4HJ_H$8%;& N6\'>Q[GUR$#G))/>7DN@<(HM)'4I)%2XF&$OJ$@S"#)G
MQPCV-AD4W^XS*&Z90?'M/H/B\]3FGUIMWKE;#O(9Z7L2MSS<%;7];.9CM0B_
MJC>G3ZU?]*NO$'L799JLUL)P\-WC;OLP1D@ZN2_L%^3#MNJ6)$SSCA@]!W,Y
M3R1TKW/C6H<M"K#I"E8M&N'ZH+M0N5-I_"/6PL!D4I%,+D@OD1674U*;3=/:
MJ%AQ;J!#DHJ\,A(OC)R_D'#_C_XW<7$3."2N\^@E-BP>P^+;/97*?]ZF,@L8
M0TB7[/FV ^25Z+19;]%R$ C^ZD($+$=;>E+6ZK'-X! MO$!/\&.MDN<(*K&9
M.@&@C =GH<U2E^5Q'JPF*-3BX&=W&1\*]QC;O)YP:OQ>41MDOUP@:\,9N[D2
MS>KFIIR*NR#/7='FQX#E^#T9TJD-OS91_%5U+7$$R3).=;-P)8N.)OMQ4'O5
MG](/&8/.!73=[;1><.,'<E#4/FX[,-H&.?HATBH54#:U7M)HN& :]"SY!.+Y
M[7E#[@;Q29F>#5N_C WS?OK\':'*9S8M#94BIAQ01"(%$@:Y(V3R\"\YPZ@G
M5*+J!AL$!9GI@C2\[,HCO]H/B15*R:[SBZSY+5P>"SL=I@X"D4S%.T%>SZ4*
M5!PNSWQ;FCM#3]L2T^ ^%C=3<>7:\7!:H9CT[-21< &;OOFP=:=MP3EH">PB
M?TG/I90,2DEZUW<\\DD=<'W%02E'_'$Q5.*<"]O+(5@F;TJ[O!L4^S>AV,U
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M;>U:86\:.Q;]CL1_L)#ZU$I# LEF=Y7PD(#0+;ML$I'IZO6CF?& -S-C:L]
MV%^_Y]HS0 )IZ+[RTI7H!^AXKNU[[7///79H??+_.6Q7*ZU/_<XUOAG]:_D#
M?]AOMT[=-]Z>%J];W=OK+^S>_S+L_UJ+5)I=LF9CEC%?)L*P&[%@(Y7PU',-
M'KL76D8U=$37N^_M=\42KB<RO61DVKABF7C,ZCR6$S1I.9EFM7:KV^X_3N58
M9NR\>=)LG7;;OZ1C,[MJG=X=8MI I)G0=MYRGF[[\'/U^B-_\''0Z_B#VQMV
M^Y'=C08WO<%=9\CZO_5[G_W!O_IHAD5_],=X=/=Y=/^Y<^,S_Y;=]WO6K_/&
M&?GF?^K_,3[<=T;=SDW_OG[[V[#_A75Z/DU_UFB<_=#Y:S\:4K7VP&-?)!OF
M'L+1F8R6+)OR[/*'S> ^3RYD6BR>3$-!(]4;)V=HW0K)[W2'?=;K#X=WG>OK
MP<W??JTU:O;Y_J[3*Y\+IQ8RS*;D5>/=%?M>#^N9FEDO5PUCE64JL6W85G]4
M3C.GI0EX7.X\.A*5M/SK9XXTWM6(K*[;.UX5X39/GAML8NK?N:%-P+ZP*9\+
MIL5<BH4(L2O2,)ZF.8_1.%,Z8RIE'Y5.$'']'TQ%K!/.>1K MBM5@J]!&IQ@
M433Z"C9#Y"ID JL?LK_GJ4".>-7*6>/LXLHY=.J/Z(.6_T!;_S3&(QYLN&?[
MX:'+#38.6YXLV4.J%K$()\+;!8M0(=1492Q _%RF>+UD>9KI7#"3\4PD6&_"
M"T>8(#")KA$/T*2K%96@?F7*&6Y9I"(0QG"])).$/P@+K=6@!FTAG,*<,15%
MFH0, JF#/($9T&G@2B@T6TQE,&4FIX]U_X70P@U2K5 (B32QX*%,)VPALRE"
M-#,16 \W0!TH; A69[S<L1Y'=+\ENL]_)[H%BV0*W! $USCQL,4PQVN]\5ZF
M(#L 5F(<F09Q3E0'+&Y@HEIQH/" 9ZGC)9L!490.E"9QO(9[ 33SS 6D5"AI
M H\L\A@&P+@"#NVTQOH5<#-E4:P6IDP +2;29)IC(DZ-0#<9PEUO \>F]&;+
M[2.4?P(H_VD_*/M/]OL7;;[FZLH48"TT%O&9BB*)1XN8 >-:6,P!0W(<"UNV
M!0 _CJ69DCF9)6!S8G0\5RNA-$&L3(Z.1/1:Q0Y],ZV@ =!LV'N +11 KP-4
M_S&8\G0B6 <,.LIC6#3/>;UY\5Y\L%V;%Z%[<H^2Y&WJ4._&)Y[=R :'2NO-
MWE-%3Z:*,%6I4#:3!!8D?RZ/@#\8X(N87@$]WP_TH3!HP-[;@OXZ-#V(#?!D
M;O;O@E"JE;%@JZF<CE"YQ@@@T+DTEI<A#41J!Z*#S)K1-ZN#%C$GW)8Z8@T]
MKZ@<]%*"W>&,4;$,>68]'1L92JXE(JA6I-,[MF"E-%1N2(+83#=6KU@65T;
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MA,J9#O$Q_L_IR9?Z]X-GMK[%>PI[)[8%'_V!ECLRE%>R;_/5(J8<'B\QQ7\
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M*C0U<WIZRM9\:*3LWSG1W=+]OP!02P,$%     @ %8A(6YC/\052;0  <&X
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MY<:KV[@A4Z['#H:N#N?((.K'3+P,FP0)&HG!=U.Q:S=]>[B5J(B<3,K*(XK
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MF!-1H"L-841G(=[2G3:+4'[,H\>E[/1T:3,F,%XS8"Y"'MRW9^X2]&J4K9P
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MSF.)K7P(MZ*J=Q1-Z!]Q*T^*;:Q2AKT6K? .FGK+OG9ROS)2?.(!5ZE'J$;
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MI+!0H[U<&"!CZV6"@<J@U;AY>:T7\!7&?>[QU 7.EMZ):,V-H?.+!];.VIM
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M(5'O0?.IMQJ3L_44NC;6$>>2S1]!:BZ#IM'C>;'Q<#2)!$9(EX:N[.Y@78K
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M2=52585+%6?EATF^=M4O_5$-^O:BOKXM# ]W @G%X[TZK5']-\_^@VUME)>
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M:6: ;?5C+=[I\;O9*;QLFIFV.I^^1WS;R99]O6C[4V3(GG"B_Y:L$P)*[O]
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M=G![TJ;VQ!%#Z[5!^&2VV$)Q[@5'\#-7$SLN4NTW$:3?D:E:F1>.MP7/33:
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M77^(SX. /'K(%JM[ *S_[DFPTDG9)ZB3$"E&\F0;1D;>4X2&P"_C95G\*LW
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MY'YEE4K\0GA<A$S6@>XW\C-9A,B>5T.O'LC%@<3G2D[&;'C0G@F^OAC!TR1
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MYA3JN[$%_3J&DP$F"_A6W"=EAQX(+9%3Q&"O/.#F93,Z=FN_;[&FH_)4\)6
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M7]H2"[.BWFGW]T'N/[-T2Y&E2)8Q2"P\."VNWT>""5@7H_!C]NCX=^'?AO\
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MZN&]BJE"I]1C'FITY4JCG)\S;J1U453;4E<_.J'X&?$B7X5^(/C7<^'[W2_
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MLO\ P]G_ &JMQPN_X: 'RR0K?\*[T$%G;NJ@8XQU[G-?D,91'*&558.NT\[
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M@"L64E&1HB0W"A\D8!/!!Z=NF:^R(O@_9J-BW<8\Q) JE&**JG@%2""0 <$
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M!G*CR\M/*\:K727-[&S5NEI/1]]GU/_94$L#!!0    ( !6(2%M$G_&"ZG4
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MJY,FYJWA7V)/OK]_Y4KY*;;BVV?MV'@&O,0W%!KO*0$:2K_+B01Q=+!3/P,
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M76,.:[4$T;542V,F*>!]^N?R)_./40>L;T$>P. =S^<2:R%CZF=1\V'Z&/4
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M!,PS:CZ"E^TEK<@:WWTU2_C15ESYQ,LQYO80K; 65W6\@NY,:/A[GR>TG[.
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M*@MTI=^LLX3(B6/'NX3>>XQ? )\2QF*N.@_X/ M:&IX1D[JJV;5 $^51V#P
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MDW@J14W!;"$ C5AX$NC3'#PW]/*HE=)T+>PS'O?2;H#OK@LRP"Y&D?6W2+,
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MJQ3_=2$<IQ8>H#;700O-9BJX&@E0?4="!]W3.D^>;?9SIT-U'>T4SOS(FMT
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M7"FE!>808%:@:]>G/QDTJN*6%@K^^.*AG<>\&XLIL<LW$3\8:+^K&FBO]@S
M0UQTMI*]MFO,;E-J!#LO7#P#WH6]$!E$SS^$PVFOU'372YD (A1_:+"EG^H3
M_U;)1(W4E?Z1B+^8"H,W*M#^>F0G:Z(V-TE)::;M#,-X(TU@7TS:L=L".CY\
M:+B_)SG:*K<K23NN 6D+^29="W66#^'84C93,&UT#K_?]@"CT[83!K4\V1/U
MPO<WNXC&)7BJZAS\O\.RL#WV:I:8\?;8UOG8!E8A6AQW-KE8UV8MR6&D417@
MJK T%0J#L$%W,6^ID+.' ]D*XP/]K*.AVA3:IHJBH5\,'YM2,";-E&@"+KK7
MX7%9<U#LF?"CFK&Y;"5[<,#BFKJ\IT9^H?V-74"')TB:>VX3%NVTG4BEEZZ(
MT314QD?4@<O=RI@\03)PY"G])?;1%AF1F/T+I=V-7#(U/A"#[:;8<#T>3.+M
MS"AFV;<Q';_!?"G+@$]NGNMZ2Z^_*=T'C%GHI#F+^OY 5[)$HVT(]](+,K=@
MV[85LUY0=.'^F;+3T3<6AXO^@8<ZI$/:_8%@(]R4HT>?S<4&38PUV\_-N8(.
MH11)M)WYMG'(5):-0?;#ILP_#L[JU\5^ H6"V+)9$Q\.]$]GU5HO]5J\;$=(
M,SA3ZIM4GF@^M'5"!Q"@XP2".[WZK;7(8"ZD>MCE:6P9\G\^\XR2CNI:*^8^
MLCJ[JK(#;]XZ$R/$\A#F-LX[]MKN=8M]/)R^3K*S!X[ 0*L-%V)#A4U1\!_$
MJXW,#3(<PB7@_DT1I/%$/J@V(9)T^!A"@4J^ISK,,%*(O53'#C1OF9) WZSR
M!L920L+:E390@FU!W":Q5RZTHY_A#&X!)#D7(5^LC!31T[%"7CQ0H= X@ZEG
MR ;TLH*2HB\?O3=W_^R/[]K!TWG'.9;,<!;>71R31?2.45-\^YNO*&)TY[B9
M]Z*8\UV^S?OS>UN1"M$R#J#J;?!.23;%!JL>7]6Q,0I8[P,B,%ZK>@8(!?EM
MK46 <-MU-^*HG'S^!)//9=T8-,"$]19<EX#T' QII X?BV5#I*PQN,E)SI\!
M$<^ ]1P@CI0(BKMOE7GZP6:3.[+U.GO35$%AMK"Q/LYP:KMIEC%Y,_::;F64
M.G:X:4)+7I%K"CY+:1/!@GPPHIG(!P5Q#2]4+U %B&>RUHOY)#/$[NK\/!$N
M7<1 "_E%K3\M_?+T,KJ3P+?)8(:+2FW6HO,L$;JC*HR@F8 4KV2W#2;7D91D
M\7.G%KVT^"$I4=YB9IQ0OA'3;<[LJZ:953PJYB03J%J\,*FP)FOP[<Q5(T$,
MQCBNQ;[?9F0R<XK@\IXW+GO8<[B&/Y'-! H)] =]VE)&SJ^FD/0INK%>F\'*
M#(8]=H+^&>UL\@MSNGZ<6(9SW(OZ@O1176=QBDB2Q!B0QQ8=A8-0JUHNQN_Z
M_FL7'L'^L417>E@,J7',SC<AXW[^I!:@?$D6Q'SJ:]Z[4[>-RSF#KVVO8'&'
M;1L-A&J[ALTTV*Z8!(+W_TM4GGU,$^".6J7*V&ILRU^$Q@?:V"Z8D6:I^(Y/
M)&]865#?\+3@6F0;9;XB'!@!JD?RWWSX2;?;23D,(78KL4B?+7SJ5: SZQ1^
M.Y+CBJ+&_* 3E&JDIS6@D_0[W+EF;'LNC8TN*,_:;5@D "_&H_-#![DL-A64
MU:Q*9,0]_29"9#1+;Y_*5)3Q4GA]LJ<#:[VK-PGW01+YH!GG1#@@V-&FN" \
M+VB7JE1F[_%2]_;D)#XQ5N'DU]M/4@;]_@G$^E<=E *_+\LT\M6(2Z>AKW7*
M>MAYH/\I X97_4RI%N1%8&"<TQ.!Z$31GE91#E1+*V=[9;E85%2I::5Q[0$C
M-/9]%?;_DV6_TZZR#L+R'4$8JY/X6LC"US._*9'IS#HY+U?R^?V.R%(<.[O5
M"MS?&2HV /.FY)7$JK)Q"&0%E*2H;\\"0V;M5H0@G@B0O]T3Z[A_TE'7NALG
M7.K-0J#ANDI<@L+Q17^! ^'*OE;%9\8 [J,$$Z!AOZ6AE@S>[W#&R%>?6M#'
MO-1#@10"!N_NN9X!80\@7#>@NO<N3M*K0W"[7%[/S*R%/:5EG5JX F<3YDM#
M-'HG\Z83=HX\7PF)9\ .(NQ4]5RZQ0Y%D^J!:TK#J)_I9%<L*>XA..YR[P?)
MO,MV,*/CJXD-I-F<?"U82>G8I&UF5U/QK^P#E"&2W&)!P,.-9*[3_>?.J^0B
M_-'=(STMZ]!=Q+'E/=X*;#%2AGAS=5,TBPT+CW@JGW!IO'EKV+6RZ$UOJ/J^
M;(%B,9-<,E6D@L9(KVBW'@;M1XG$0L%=Q$WW,R!*ZAWDV.>);':S4[BJ%/:4
MDU!B)GG8LW#JQGFMBJ/**+_&FRIEJ#NT^FN! ,WZEGUDLJCZV,G3[M;HV&D5
M<4=\T2)R#B\>+V\H:\@R!7*FMSJV=*T'2I<-3?V38A?7426(]*K32==#:UB\
M[J2*#YO%_;,5ANA*.(U?HZKNQ$LB4B\Y*)=0K;1O_3GMF;3"MR+1Q,\P9T-X
M<NYYSQEI]PI/<N3G%+$$R [4$-53\=]/A/[$[GO1 WI3P^DDP8P<'&A-SX?Z
MUJLWG.&*=?V]C*NH\#762#XZ=7)F><]): F6S4S_&/G1!X0^C=+71&5O'2OT
MK3(TU7;-59_LY+9OO+.[\VK]LC<</J*<^P&C+X0@RR%_I]'AO%IJ,$B%+&.#
MG4V[)KHXNHK 1E.@3-NU>)R52I!"IUUWSFL7=@Q==86]IBAF_YMG7;9Q*)^F
MV*J=TO[K0*ZI2'=KV@QA>J2/"O+;K)*#GD%C(G;+-D=_"#H8[]?(I3:^-3,E
MX#?H_/B:-P<=,Q/Z]J)ZN:":LLM:BC1XC6!#E92+3@?YO:4^:V !VUF0R(WI
M>F;I'>>DN6 %F/"K\% !@._O)$7-:,4P+9>N!.^&2)7W_BAM(:ATI<?4F07P
MN2D#\ RHNI=%>YF6/*8WE#V'G@*4_]<DU 1!QBN4HEAHC T[&AQXJ>_"]HWD
M2Y!$NPUQN [7\N8W.4I@3#_RFH11_D#CU T%X<+O->.T!@O9%6-@;R<VV8QA
M\=,NV4->0V=2#2_F[[FV_8;*),2B+A7.'[C:EE0$YAM,U1>XL9]6@ 1>;33N
MW'7+"!.Y7V,[W(W+!AC-62*+A3%C^FB%>JP,[D)(;(#^%(0@T&.C*R8+%'4E
MSE;)V-CL7=?45#=GON8G6?OJHMJ,;<O&6YM)"[<,G:*FYYAC8PNU"XQV]97N
M%>HD7A P):4*J*"04"(M+I#CFK_\QD":[\.D'KF!_25: ZPP&FLJW=TI.GT9
MQ,9P1EKVZ^".JW\R$ZK@\SX1<+I#"LLTE9I)XO.;6O[LQF2NMBY:$]Q$9NWW
MN52=CE/*7*[#P;Q\X*V[E@I8J0PFJK :ZZ);<K0>*1<Z^,FM5U2CRH;.1BNG
MV'(V\&&_7R OW4YX3?N.%A5>MI% )CN?>T5<FW?8Q_)*B]?#R\\+/XWE7=./
M;4>\N4@T>6.)S89@<@>Q <@])2I#-[LW10$C#Q>5"W(3\'G;,8;M8^&'JZU"
MN;5KNO5>=)"\)N-_Z[2KGF[@-"D+&.-5$_V?B&^W*WP001[G/B5OQ"4)NIC=
M]U/&*]<KV6&6I/QQ<JPR&2X/ G]F43H^FK&UNH@'%8.#1X$T@63(T3X(MB?5
M?TL%M=>=-0$!;=Q3)< IL6(K!<;=,'R:9G%V4U1;\J:&&2MM-%@^4R4;R>FX
MS/ M.W/P_P$Y:';K>KH9&$H(LBEI5VD*.P<K$&^1,3-CSE[_,!F5KT&*M/XU
MP>>K?E'-+O'7J"+++;R8[/V 4L]^0U'+X[_&9;.,%>YQZ<6HZ\",+9<^$+KM
M[NHN#9TJLBG".5#3C?.SG$NA76M09<9[Z$N]@/QWADMEXA$KR^XYE6I8ES!S
M<YOBOXO[64'M>NF4054=:6F5[(14#BH&8!S?=YH]@\2*R;^.RE_ZJA_=(%D5
M40P;(@)_LZB._0]ZOS3."\HX)W\Q_]T0^[XR<-Z/TC(6).7'O%PA<%[/Y#90
M6_"(;H!4P.Z-Y#%8G-?9R[3^>R0O3J'':]>3JSQO;^Z:X:QO8*N;(9&BF6N?
MDJ6GV93<9[A<'R]/(3-N[BIB)&+_)J4U=>-5^=6MEDEUPV9E[K+YJY*3OYIR
M)->#DR^)-3_^_YJ:KN\9$/E$C.I"WO>OX;:[6;$4;DA3_LMHQ6^QP^M+3QFV
M"J"0#PCXJ0C&B09:7I\G=+,D4*3-D4@/*QRK_'>1#:C!>VE4^3E=5![50C!#
M(+^WTF4-^3[EEXR,42?1M,BTZK]V3X'I/HUCX>/OEN(HED;SR'1</D@?J<7>
M?F!?/ZJ/_:>=R.[E^G-9PHI:R")RY_HRG\UC)'Y#J R>SX9PSCG:$A_)6=_Y
MX%*P\<0R)N)?I1"Y7159O7E&+C9>KFN%QRCX'BKFQ4BZ-4FURIWN!M;<>09(
M7B*CKEF*2U6WG"CO>]U5H;)%LMS7CM-+M:$> L+"6I_BWV5IC>&>Z'Y<?D6^
MI;P0Y*.=Z0DB6+/U/P[)Z7<BZ>_3BZ/07;XHGA49T,7W3FX^B]_M:B7X[^77
M@_ZLQ0FE(% 7&Y (+VC>XK'4LL 0)TSDFP]?"F;AM\8;344F:Z\?B@;\1'F*
MTMG/ #+I]3A@W6"<D\MI.Y'/)B@2$1TR^@*A0A?MF=JBMWP^;A7$E0=]IQQ2
MV(O98MO"W(T'_&$M]=:-E%*YQ##3JB65D<QW\_TH6LR-XWQVKC]_*LRI]8=2
ML=-*UY<>WXP4/67R]B:B[RD[:CI0:E/:C!0EK5*P_Q)8O1/Q#!!MRB.;:JB)
MHH3&N0AR">T^ PPS5'^WSW+IV7Z;V0Q%QC#>JV>=E@.7&ZR.TU_%LN$TAP_7
M5$E;)(4&<ST6M]ML +%_S['4 QZ[C-LB19=Z:=\TY$ADU E)1%F&677D>*3[
MP<3C?%\(.'V8Y$3MWXOMKV$$^FT2A)-*,3?/'UVVK;!\7K"8@2MG?:Q$R=4'
M*>CQQ+L:<JL(^0D^LC\#ND6"L7TM-IK^!.$,(#RX%KK.N-5@<U=4)?61\"/*
MH%2XT(*_8&W"CA^]$CA@*69E]IA,&".:0;%09@\)P=X5;7H+LMY[$\&)J9?.
M3R-/DJ^/6"@TXRF6$QE5G%"2UXH2S!^?+_$Y8R6<&JV3B_NC<_TS?D)J%$NZ
M8B2I#BK2Q)[0X9=/-DX^+'^^HW:=?(,5*D&RT1453#(M0;9!P[>F^!]C11U]
M^SU[5#6MPR[/SW3! QCW\F +B*N(&DM95F*J5N&M+H_EN+/GC6<D_\0;SD!"
M+L\FSQNO%?\_81FOI<0$5F)*1C$5LXUHY^04LXDJ:SEKI18M_5=.C?^WB#7E
M-!GDB#70_FNLY\7_ U!+ P04    "  5B$A;+_ -+2J9  !7F@  #0   &EM
M86=E7S P-2YJ<&>DNV507%T0+3H$"QX<@B98@KO#$ @>W#TX9'!W" 1W")#@
M"1XLZ.#.X!#<W7T&'6 8+M]]K^[[\W[<NG?_.[7[[-VKNGOUZE-UGA:>-@"O
ME.04Y0 H*"B _[F>E@$R_SW]7ZW_#OF_/0/EJ0M ^!)PB8*!BO(6\((0!940
MY:D/0 < H*#_/P: _W>AO$!%0\? ?(F%C?-LT/ *\ (%%?4%&BHZ.AK:\V[@
M\SX C1"=Z W/!PQB#7/,MZXDO%^3?[UDD*[I)M6<A#+R6;B%8F&3D5-0OF9B
M9GGWGI5?0%!(6$14YJ.LG+R"HI*6MHZNGKZ!H:65M8VMG?T7=P]/+V\?7[^P
M;^$1D5'1,2FIW]/2,W[\S/Q=4%A47%):]J>VKKZA$=S4W-+3V]</&1@<&IZ:
MGIF=FU]87-K<VM[9W=L_.#R"75Q>7=_<PN_N_\.% D#]7]#_?W$1/N-Z@8:&
MBH;Y'RZ4%][_&1"BH;_AP2#ZH(%I[DK\EO?K2Q+IY%\UW5@,?)I04@NW26PR
M1OY-)MA_T/XGLO\]8*'_1\C^%[#_#]<2 !<5Y3EXJ(0 ( #Y>('!ZY<=))GM
M752=A0#!B/LR,://ZRM%E<W1V*@(!-^."H6(7J:H?F!(\+:,V0-N.L)'&#P:
M/]+R[ H!BUS%C2T+7-5 0+CE;V%%E??RZ8KE8,OC@+!_8;(!>73]SF3@]?2Q
M#Q >K'W)-H]RU*W@F!\AM@U#.T$[VPLW>XF55;"')\ &WL8>6.,:C."YEB6]
MQ Z0AXFH&_H;9^_?JBPD 96"$>S!Q,$3_;^NJ?#5P,8[VR2YO&Q>&6/!28&J
M:E9YA<[W>2J39KQ/@)Y!&!?BJO$)T$$U+]G1]FA/T)='_/5"\0M!FU6<^[)D
MYUQF?__)]NT3H LS+&4]X^P)$!HHJ$"C0&?(2R"-%P"19(+_M25:S+X>96E
MW=*+N77B,ZC^&Y(\76TYH3;W[.V!F7;&;=#VH?QR.MZ_O(G4[$>>=<J)35,^
MF 7RK/=3C:/DGI&>D!*C3V@-J^\2#N*/*C?*F0_I,%VT*8L(QM:TJUCD&;[(
M[<#A,F8Q*!'F'--@$K1$TF%'/<"21=1+*,?>;*4UA*V,AIF PKA/BBBZ^C=V
M2=UZL+NE$I!%*(YAKL?I\7[[UQCEA^$.&N21BZKI%+>JJ[V)FPG(<G$3P85@
MWYC9IG0K$Z)TM*U-N]ES-%PR*.BCNLF$!SX!<-2,X+SKI!X^DBP^SCWKT"Q0
M+G%32\32$T !6OI-A;DZ<(\\GOW4XJT!HD]ZLB5I& ,TQ [<^&56UUBT.>8,
MX0EPF]Z$WD9>EP/Q5K_,NZPO'H(-JVI\;_#>\P^QU!CY/X".B^PJSQU?*Z3%
MI+B^G=\C3PS>R 361\9WL".DX$N2G#[!:C"6?@[_+>](<=G?]DN:'&>IT(P!
M4^J\7M' \.J8HK&U$L\"N4:_BM<!1T1880.4^"A5#Q!@'?EI^%;U0@=P,>)V
M,['+:A[!5@1GZ.X@@EDG%$.K"G[!)<]6.S??M7 XU1UF7N^VQQ<BE09WG0N;
MTQ(HL)\ KPZLL^EKQVG[N K-R"SXV#_6BG.]\L=GZ+/^7CLTW]ORL]_/I?P;
MB"KROO>7'/6DTS?[F3)#'7)&O</X^2> G1K+KR_&XVEEQ?LD)RFW::O5QX'L
M$U,TH)L5^/O-";HQZ( A?/K7X1IWW:216>NT<_%/AU/^G;\FBK_;9\::P(%R
M(&9RGL4,H\0WOUWISLG%>9[S+B5H5 -N :0<@NU_4F$V>S6VF?(:9[*4N01-
MT9UUK #'K,'('FHX1'U:KA"*WFCU\T=8$](8H??\IG70))#2TXSTP'"M;",1
M!RX/,3Q+ALEM]PN2WY)+LD\A;(OAV 0X YL4"STLS="'+V3)*VJ>5']&B,MY
MS76;C1+AS)&G.D\ K*!J6!65V3=-^&U_)D8!M%H;'BPQ-H!X<Z\6SM6&Y;RQ
MN:TLEO:-?8W)^]L7%90XQ^\1[%+5O[NM:2D@\4QFAW3]9]6S]NZ*^PL_W/1V
M^Y2\L@J$2[Q_NP8-0:B1L_.)S *TG+_K>?U>@=O.T?\HS:V"YE:##)\ '[WR
M",.1B27P"#J*;K+P\F7]E</,HO$BD'/QEU='=F9J(*.AU;=)IF]HU=)'S^2D
MS]#TT@[,&IQ# N0WG<E]1C["H#,>9B] 0D@:V(=0\:/,H++B3V]:PQYHA4 _
M?R7(2X$W/SHW :44X-[;\B<%,!9MN.<#C0]?-^AW@-3T$\!6.5YR>D 2#^8$
M_G/00I>P$2FMPG]T86:@3!58(-^I!C8P&%7[T6?EJ(NYDS4!9R:'M*HX&\/T
MP@)4\GW,C&!>E3"G[7XW^_NS&D=0Z:$D;_IP,+914>TGRW@$<&<,.RG7=KC2
MI9]1X&Y.)F2HCIU_]V<@8U,/Q8H<&R5U"]W2CP-E/'F"Q&KI[SP:H$PNTLAX
MUBN;E/#BJL+OS5[?_\BGR3#]SFF_':%TE]0^)UM>4BDI;IPV,KLM480G")3R
M'UX] <BZO99RLT#ER]TTU[5'0/.V.&,C9<_BG[@W\,@(9IYNE!HS%017>WL[
M%.%-GJ)P67\1>BFH^$(&?-#JTN5QN+#Q!. &UN2=1#_('0+KCQ$FL.(\\O"V
M-]#+ :3$W_:Y!HY@O6885Y\_U>K; =7I>JM)3A9'P?7>)>L^&^3PA?"W^'?H
M:FEM= >@WC6!.7XCNAI]?K87PN;[O](U1_-SSKA+T#Z_X@GQ@R6> ']QTO%O
M3A1>4X<AWQ9[;C%K:(6YBA0D<!8YF%)A_E 9TNR>[1]3RCY2BONE\6XBDR>U
M1("R1\.4@&32TTU1Y?-F>#4K-$8C3M,US/1":<S@O';=T_*XSP&?VWWE>F>_
M9F!7>8_:-H[.%%@9T"K4UTG6LD?I^-RLQ7/RMVFPQ%T'YFJJ.Y@#/J@7B]1O
M\.0Z+EQ#>/V(1-#"AL[-SMZ.ON]V&\8_EC^Y#O6OS[-:;7<*<K^6GRU^*,Q9
MRT3:SO]4E=2:4 NX&A#?BROY]02XOCHW(^F$Y$4)3HFNT/!LG&AB<*4>N%]D
M[[,DB>QD8S=@#M 1*X;;ULLC82&G5Q!WB/O$=;_,:%E1L!7R_/B*;M8:,7)_
MEV=C Y2Y>S[N4$@^^_/^M&3S[4UU<@&\=6M(STWM<]=E(OM^GG/OU;WF$,P6
M<B#$.,<V(!=U.9,B,;CA/K^>F7>J9'9Y^-PX@3MT.GERG=59DLW#P1ZP[AO)
M'+MA]^[M:O!\GNO=?#]Y)T706SF#C;:IV>@A+8<[3 J(/ U?:J+3=>^7)P!5
M$._E8U[EP<V).UC40C&=<CE[9UMX=;W:CQ;TP5FE6O\)8);?42YY\/AJV(_N
M$C[YXT(.7Y[1FZ9YKU. ?'M_ ,=GD5/ D<Q CONX,)QVG_X6\"CJ/3C_][%
M\GU@3OC)DI9*'*81RW+. B6-A.N ZV$FF;WLJ4H#D@[^^;Y!%?8P,<D]F1MR
M[WU[>\/?K':6=PF?W__\F(_DH,3@XK>-BQ_NM&#M0YV,I@_+?4P #%9:P1]@
M[%P3@@F5XQ\:V5T"'R'OD+/YG;O+#V%'=4?S0WGY]"&8YE_C)LT8 @3A==M
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MLQ^G6^>?@Z5-^G98C?&49@@SL7K$K,L6(6OY8#U 58>@A#.Q>:J4_P'\$8W
MWD@=W$>EWJ?86NU$T 0^F'XDW(&30W5W/I.9W/]N5-/I#A[T9.@0G6^,S,TU
M@WY:2?&:/WO&( ;OQ66A>/LIB1?E(=N6&BK/P+B=GJ[';GQ&'?Y&WW$ L/OO
MW8"J N49&USH68^&U09_L8FK'#B9A?JNQ$4FZLPD<=,HO[%9"%ZDP1JDUFU/
M1-!$/WR4^^/4:6,6+DOSM\,LRI-C8[_9;I#&AP4UVY9T>[]94J6?4I6%<0NW
M(\(V;3MXS84BT[4\LLQZA-9.17B(_W%G#FS-_NE@1J=4Z/4?P8ZYVE4CH\-'
M,[6SFH+PC'W'D:0@FSC<A#S/NESXU?'4;UYY?!3N)K'&Q S48F_KQ,V$R",V
M>.'4,ZD<341K?4PL#YK(?1$]O+/<7VU:.H1\\RXRI$E8<^5R#6SY#.@/0BGN
MM_/B?G?*&9($)@#]_&$'=SDY=6#[JGKXUY4S]"W_BEF$.,OH_*<LM/NU>8_T
MI6"%SM/L:=N$RN*E$;4^Y,2+C\U+I+V-B(!P&6HW28>(+IJ:Z9B?6G2B39?Z
MCA:;%.@'/I14D5(?-C[KP=J=GP"8FD=B4XI/ )MS_.2DZKI^<H#CN#?7/?<^
M8\*'[4/3KX7!W5,MD@5[C$^ NK'OQ-2^_N)6T?@^F&Y#SFWXG:L'BN-NKGF3
MG5WE;'"S'K61!SIT:_"C*"?EN'5P,(U!N7T%^'DL2#R.GOP1,$9I^LT9E>U?
M_!^ A;RL"-JC?2()NXZT0V):LHXZC]P127*(PD8*067P>R\@U-TKS:/;ZC'W
MZH0,^V.08*0[W@*]#2^*>4[SMO"!2-7X!!)?$;H[B-YI:Y0OPBB_->+;!$B1
M8;6,\YX *PT]4HOCQ;1SX3:I$K=\46;N-C%";E[Y!WD)(!<'/"&S3X"A/.1*
ML+JU]\6"ES#GZ(N4=6]Z7$[L;ZO)3;6A^*(B@@/= -M_85WCKBFB?H%^WDC'
M*S6X<,%F1"'JD1FZIPH/J=MH@ S:@)?4&[WA3[BVF"S3U'-@Q$<Q:*Y1?V,=
M_,V66"D8<,MSG!XJ*#-O<X7)$N<YCA?HC ?7VYQ_:<,S+FS[K38[4:!(44-_
MM!-'!H^U?JG^%Y,286W,M.XYG!J>/4 8'2^LTZ]3_G+X(NY[L[<)=<-#XL$A
MRQLI39YQOD2S2CR7D@AKX1.].&10064PYQ. ]#G']B;"Z+ TQ>+=;YSA:?[V
MKJ\RV=KY#*:*0M[1<R>)Z&DE[* D0WPFOAL&=Z\":T:CBF\W,"'^!A3ONU(_
MIKGY;8:/FW6\1/4N^?+(&4XY%^NQ[='!F7NI!QJ[7MCUB='S:J^Z:J@(-B0G
M$[S$6,E.\LO]>3PNC#218,MK_;<%T?#/:UEKEFCU>Y0(#^867(=Z59^\$27T
MA99OZWR+_$HYS7XFEH"5(,LBLI&0PY-Y?+4.%[U$8DU[4P56]P13U#>_"N=9
M\?%[GW.+KQ2U2V%:N)]/[U'"+N&D]U!VND#V-LO>Y.CT,=A$XY&F,8__(T6A
M!ZLB"R-J'.$\C0BFA.)M$:J&!<'2+VR,U5I)ZB2_2\1S3[TTFQ H0=!(/ '0
MAEO,:5;,2$_!EAQ"WTR2/QS'IU GB P=?IVAOLD,1E //=N4SWHYP[P3/.Z$
M6/^V0PMAI7H,]@2MU$3>5M0HN;Q\$ZP"OZL.9ANSI-6"6AWLCJ2!]A*:M;/'
MN_Y70%]:+..42VG%XXB)(UY1RV*1/U.'\)TT-UZ]YA61;0FU$O']&#C!AAJ"
M-/:&^+' F?^8*R+XU59'JD9[I%J$,MQP"'T5@J9[<>[X=U#Q#DQ3,->I3+LV
MI9T LIO=2B:RRR9(5\@.2>FGMT@H<7&X^HQ",?9N6JM3(*U%67Z^P%2V4N>>
M+RREEW5@:$6ZYJ%I@E("]L^U__/*8>U;HLD0:FN7IN7EW%5YC02%O795?1]6
MKS_)(X0IP#<S5]0N:F:?E$MU0N2M/W^(EYM20Q6A#PL;P.Q4,Z01LZ<R.IO?
MP\RBPOKQ7F\Y' * 2+9E9P<"M>07.0<H5Q.WZ%."J;T.X7J*[O:,^-HT73ME
M4BX80<>>8LWC4B_RWVJK:8KM),]<=2/; ]5(O_WBM 6O'V 6!9 ;A<][6J>E
M=4TFL7YCL"-/"L%W3\&0\Z']KIO8S:S8)E_!&/+^-1]Q+I959P,U\4S :6Y[
M\[&LG[!^@S2Y'KSE"> GX]]Y_%N4+@;T%GZL]WD A[29&A42Z'K>36^E1]V%
MCH:O"DPS@X^4&1L$2,\3^F*LX?UQD]ZQ]D&[D'LY2.V&L72I@) )KB<&4]QT
M[5Q+\/HE^'EL_5%>LC@6*$I-R\M008_P*LZ[U=OQ_M#6N4;8;#G"^]Q2T=R(
M2\7_FF;##C.1EL"-[?/E/ 4X'U2F%UA7'7F-I07I)!X!9:Y^)U*HQ @O#@AG
M7G*S:,FNO0S%WJ#.1,8T!%,$V^JOK!T)>=T(ZG(K!WNZLY<3R:#76^>LQ'VE
MD+.88&90YU6CI-NS?@*@%S]66SP^JQZ'B2A)KBGGMQD]09BYEUT=)/J[Q('%
MZ[(M_J#RI*XDAJ9F^Q6'.T9912%N$4J5RTO-Q?KK53OM(TZ3W..R.XVM:I(C
M4^89\4?IW5S]*9T8)N$(E*9$#BE41DNT#M632W4C.V_")0.S,2IEQ_>!:PH<
M/.+)WXU#^>91,3&K12J+Y6TR=:LKC3^.GGND>[&XCJSP.;5]IDR0BCK3E' 3
MW6M_@:>YA".F[[!:4I?.1S>:A>W+MM>L1X].@2YTM@]('1 6>"G-7T"6;>26
MV@AN3%]7OGUTS+;V+S=<L_EH^':PJ]_:YY\R[6G/&+2D2G%Y'4#$D^0>%I,)
MQ!^YY#ML"9%)TS72&V+)']18L,USV*[T:RCIIV*,ME AV\1KBN"G'[CT=?GI
M@R[E^!"HNCDA4.8,*UYC1+\"M=<V:5;2-#)LBX?F,[LV6:&&*@R6OO7TI6EV
MO@0?^/S[YV2N2,3&H8*[D@YZ7RBL3E+*9(2*F0+8EXPH%XQZJVT; ;NM5ZQ?
M&"_D:>*15"H5L=YP[[K:F&_MA"R[-Y/+M>%1FKXPBNA]L?:3/L'OE5S@4?@^
M!,= E]F$67W-P](V%6,7._Q"NJQKD"M/+2N7EZ(EP_'B?/\) ("-F!!_,>9*
M%6<EGTC1K<V)"54EC0U+P !R^^DT72T+8--P8:_T#6,UNC4SA+H5 H0W03.G
M'<P#KB31M#EO[ N__A@B^9BVW%3NI&G@)C4@Y7<Y&[O=9*/LRUAK([W!;:0?
MI8UD -MU48=*:DPGQZC9*.=,ZZY*=D()^!TYQ\A>%&^[L16V5JX[[0/D%"#_
M1D+) :CC7P2F'"F_R?CDB<7ERNR\1?2Y=Z&K*E(_S%<0D"TV5,ROFQM8)N[&
MOQZF6U-2&W8A&-?#+'8==TVP2.R_]["GRROJWUOAW#.W*['KNON 1AB_$I?0
M%>>N-2(9+[G$2\#>/EV_T.>,-U*?,!R7(OM&5F.FQF$[115#PGW,7L89]&+H
M9=/+,BH:&&.6\N<:MK!LW(V-ZR&!11.?9:D8S/1 5IJ:42WGA8*==YB,GD?Z
MN;X[85,5]KDBT,;\/PQ3#*P8O.S?0WCEJ)RD#ORN,44DEK34UI:+$X.;\)5>
M?K28$Z[FU-C[S.B9=J$1M8^>(*F5'4=XO5>_/>.)(Y_F*#"F\)%"+HN31EM0
M;CN^*SN^-Q=#K<C['SRUQ]W84%$PGOMK=#RN;K(3^TMCR)]%>EIYXWG-6TD4
M/3N,O-*^C_9BR98HGZM<%J3]MK\B#+K'7;4QT_NKCQ5=\H_!#V_E7$FF^3 _
M<Y-LXZHQQN6N*TV"8<'1?7-E!%%,^F>,[F\'52WU!UX*;RJ@/X\Q ZB4I\4S
M"#*6E\D?"^PNR,Y&1M)^#V+ZRK*X"&,*]UPN_>J@I<QE!"[.G42^8ZZA3.,[
MP*FBFK<3N<8(D;AB"4=R!U#,>?S<\Z\,5@8G&_H4!R!/E;]+&XNF=/%17X\+
M4]"E3/O([>V;MDSR+QLM+Q]CV1@5)96DXO*(L=9QWWU]HSC$F+NS+W"O ?7;
MEX%VQJ@F.F-4+#E'<10F''+F\_12U\:Q16B$ZS(&]'>8Y\H&',*.NR49X(XP
M<L-6Z!6/OGT0.Z$A#B*"L'*94GQP7OP=WJ7HU9D/<SMU8X6YR'M)[66_D]6*
MMO.BSM&Q[L;5AUM)6>18#);3VV;<2B<(;W+;)_'1!&7JO^*TD=33#7CTA\?.
M;H>,S"=8'*MS(A^6$WQUQ10V]A- ^3#,""=^$T7ZQO9(3;LN_Q)9/(=;;&\Z
M@7&# N$W/ZCW::\E9MZ7VU\<OQ[_Q536H .><G!,5A+[C"%#BX+2L\-C;.ZW
M3WK:,@6R.P[*$?5"X([%QCJC@M;HOEHV!6+VW<!./3WU&MH!G(>\;?G"0VB6
M^U12>TWUT* "=NM3VJ43,N&+V #X1AI:DI^+BP@PW*!=U$J4'PM49.Q[\<IZ
MKJK 9W6UI1O-7TZ7L)=G(U(CX1T4V>Y?8F98LL02+]O'(Q?^*O*RZ*/781Q*
M?%E<@BJ&7;@!Y-3M$,MN.RAOMI/P4I%_N:/\&F@#W,@5G MZ!0=Y,':0F;*T
MS*M<?DSA-3%Z*W3//BR#2MPSTF[@E3Z(E_S5;-$90<R%Q#9BB;EN9[OQ@N_^
M62JN=]13@1+$V":AE,LZ$ N"J[I16JV7291#=Z-VJ/4N5#;60UN<$:P25'U(
M]-:FJ380^C?#_M5EL2= WX+\RY^55F!&.:$=>BH%^A<2B,M-EE.\[1R9+5RA
M1HQS!9ASB*?=685-C""OK+\]J[&\N#(%44!*?WM/X"ZZ&:NKV9MH]_*8[ (-
M^;0U>PZFZFK5QPDY <TX<K;Y,3^Z(P%V5!>7P>$=5E];/T<K7O9O.WD_,3]=
MJ*$*_.3H9#PU%27*?R"&7\Z'^IZ;9:U#/P4OK_?F-0)[8E78^LAU[VTA!!C+
MO=9;[7A%T38SDD.829F5M9'XQXR@#@_9SW&J)X*@:PQEGYO:/X@'-QG4G))?
M]"$*XSS'5U6E(S]90 8&U0*52&]12WRKG-.@=%MR5^N]R)5N.8IMN^,XU&PK
MUP0,GOM<^Y.?KZI.NZ-?/D\M(@,[/N+^G_6"F1I-.DP?(<!/U(%\][-8%6F]
M220ONQCR3PAH\/VNZ,P<K&% LPNF<L%6*KJ7E;D$KXZ^Q77><%-%R'FO=1GE
MGVGXNR:(31K1X=#[(&3_U.#*V.,DR5 3^Q,.L"Z<)WS7^Q6)Q)6@VQM=53%K
MA5=?B-#%I[ @V,?\LS?TK3Y?H&<P)&$>FRJLBPXU(&K[2(UY=OY"5+DQ7%.S
M4>8!-NVHV[GEUHXP^3Y"9>9%@H7OG"B,L>RP<:"XNZG0'Y_0\7&(<LC#C[)E
MBL]5O6X1@+ 0KY0N6S34P<+'I316#N-4%8^&>\?J48^L>.'E"BWO)P#6'=.S
M'"E\K-I\_ &TG*!9MP='8\8%.#L@,:&CA"M9_F5,LZ^Z??F5O.ZBT3Z2,893
M"EMFZ]U5'HL6ML0_SN[N9)TY[S<UMZ8MNRNZNZ$JW3D%V4[0GQY/B#\!I(!0
ME^K30""D<RF"+DR2=@85+K.Q6O8W8\2=G?SU]1#OV+N[)2$?N3YOQUJV""JO
M^(&[Z\GZD3%_;?!496-ZFM (C\DX0P+/OD+?OM,>KC9 :EMXB%0ISN%H]=)P
M;FKXYJ[=$>3DIM.GJ"B?+MAR[O_EX0G02[NY<8X'9^DS):JIF_/,JA3=ZAOQ
M^KUZ.LG89./!NB6O]P30!0S1A."9=*1"+[MNO<;LK<M]8K7(_@WQ%17^5=)]
M035F2?UEM*9T-44OA%>1.O?M\B9Y.&-M8U-&OU]:6UVTS !Z"[=N_$]C$:(+
M+$V2RZ$!ZGGK32"F'9*H)??9@PZ!^1/.LQ/3X</P;"T(=+2(1:7VDU=&] H]
M*GV2OTVSK2J;WGN3U:4ELZIV(%6[Z,JDMFM,BM+9L4E+N^1I+!]<:[.OCK6J
MN5RFD2FI?'6)M4">$HR]0UWNZ. @_-F''G?N"?"U'ABQ1-N,45;V2>! O#51
M2'6V <>KSFO)(CP;HAQQL? #EHW?-I_9V1.,UI8Z]AQHF[:IX0M%UH86$E]3
MZ>49W][4G%8% $^7Q-%1 "VT)M1"7+G22)R(_U/MLER<TI\\'D 34S(8U\/9
MZ;V;IM&PVEFB(X=WW=1CD*V$4JVC8-KIU!-@7J:F$^K=>[RJ>7(HFG;:IL8W
M3E_77@_RUV)MOOB=8DNDD+QOX00!=*$1@;+,7L"5A,P?FRM:HW8_!RU:CV[1
MO==*/W(/']=;IZA ARMO;&1E]06]Y>7['<W0 %Z\3,DG9AQ=&*?8IG8/_1)'
MA]M&*5X8W".[]6(H-[VQ::G*DD6$4MQ-7D:[M/NHB$VBD6\_R"SQ+C<F%Q>J
M&15ZO%1O:FQ7 ;D82<=&Q74:5T;-!=YO0JO#W\2'S%Y#!9.\QIQS WFY>9"3
MV%*WE#O+F\ (!ILP))&$]YM!-.FF.W4E*1S6Q.9%;4 O#>M] !]TPZ43FGH<
M[B;$)]4?"CMVK0\5=9^@W*N[^7+3NK8JMC!U;S;\! @?_QK L=D<$.LK\&@V
M#&9*TU[Z1A4BDJR'UB3236V5VZ>U#?6.^&FE4?6EU#LEL7')&+7+ ?-.$?4X
MMYV-"DFJ^VU>DP*A5O']#<"Y+J#$_9TFP9(O6K8M3>)4576/":60;?_KYIY6
M<W-/8*M;''#^0G''WU*8\6N]O1ROZNER04->97*>V$DG44<!]*'WUH5BWFA6
M,*P^CWE^3[@[@'R?/D0T*)#F=P#?OWIXT<4S1Y5^OXQRA L?WG9^VJ#U.=94
M@V;(OCP)T*H,U^9T);Y15QC(N_W;]00P!%M""Q1>00KZ[N=,8D,L4NG1U]RC
M8=F$H<+7_$<03C9E4,M58&_.C5ETL^U&):M(I4;#XIR8K195< '&W0^G'9$W
M$:JJF(S)F:<L4*=0+$^8SDQK&L[XU#)A=M6;'3:BP@37KPE8I-W]T$AY;TUQ
M^3^Y,K4.O:R!)]G&.<\CX(3$G_L EG\['EI;)C;".:^E%U=(OV_J.?_ V.KB
MTA2]$":-K#-9WS"VVO5?EE$-?F&GN>Y;N:4<F<0 ^-DX@D^PQO6U)W6$8*(R
MBR["3V#U1RZ0XF7;2 VU*V6E[/ P2L_'7!N>..N?WS$')'_^1;!,DM0"8Z[-
MW^E<S/S!^#Q*C)ZIL0BF]K.E+,>"IO8F >1CG"WU%Y,*Q,T7ZU+?"F5RKZ]"
M>+E5Q?:9;";E"WULE2(_-C?[B >[.@K\".5BT4P8UW(A3<OA,/A86H@;/_$6
MGY>@I## $V[]W% V<XH;+"L_\!W&U*ZM]$U*',G%B,_W$(GWAC40L]*A4KQM
MP^8*SR7A]=6$5R%^DM)87&I*2:$R%5Y^8']4VM\]G$Z^ O:JX1WRZ'^1)*R=
MPUL12J]NQ!DI @<,\A:Y3-E24FR+0(3+-:9X54H*)J]5GP N=*EKC/70B(S2
M$7OSX*WR<KL%9B='_ID.K=3;%'$>H-IX#>=)=77]814_C9!ZVW1]DRRDP-\E
M*=FFPBL_8R1I2X[]Q>\7^YC8<BJ!I##4S;']"''[+2H:4S&J:#*8S11&P\Y=
M(0\'5;]'(OD2MQREM;8T%N6IL4I>+$8J:&N,VLCNKS'HWB=ADSW?"&1G.!-0
M6^ [)<^0\F'\7U\NIJ8$7'$\3:17>TFS$V3X!/#J*-T7Y_1N\OELE/4S^V-?
M%)9C\AFV?II3F)WI8A<UM46[[49G3_D3(#J8L(WIMP'X!]=UZWONI,'C&P7K
M^'U?277B8>H:!R=,;*ID4RX0^ZU[K0I#G0+E8D^5PHH6P$-,&Q>=\3+5K-CL
M+U-Q#DN?F*_'<K"0=BUXX3Y\\.<GD(BLLKX%Y@BOM<GW&G5OZFR O5X>$VM*
M:ZQ&6N:YC?;;(L;<-5/Y4\?.GJQU3!_-18Q?#I\;I^<PHTU(@_1U7K':NJS\
M$>ZBWX<A>M1PU^#.6\7M6Q*D5HWM1&.^L=I$1(N.H\,E^*UR!D''[R$\9I7!
MK\25-ZIQ[ 94FF;UM#H$)[,:&>^\P$RD.XUQY\ VZ66%(74W(:_JZ&MG4A]5
ML8; ]Y812*FCU*CO/_N^A>$-L>QBNFJ.- %4 T$[W(C+<L/"^_JTQEKG\Z#@
MJ:O5EZ7=:WI&CGL/K_/JO$^%ML\7Y[?Q8V&VW1E@7;_BK%+?EOB&.OY77^:*
M-VG]02/:RR3)*WU3<IN7#:I;**2/#\B!)T"#=T@P*/B;(7E?)YJ9#.,M(6,0
MT^3HL<!-=$4MU[)CE;IY"JKD7I@=#ZNYMVT8TD62"9PR=:,BW;]\0E[); +0
MB=B]8 )8X<6H#?(U0$FRJ?,Z@!LY0# P 6A)$&LH'WW*_#JQ=YW(6-YQNQKG
M[L&A^FHOF<%W:I7Q/2B0L+]'B5*9E\0-4V"5LJE#.RVW(Y#P3ZHB$XCA$:<P
MUIT(Y4T'E#[T)4MHX0N4HQ+JL"2%4L/9RPN'Y66WN(=KVF:(^X#??M KA#I4
M#>(<V4$!3]O TYTW@()CZD?$3B6/WA/9-/K2:PGF> R/C[C;,U#D!=.]ZR4<
M\_O:H.DVG'\+B/.W!"3\.#=4PM'S#KSW^I2^W'K\!$!%HOR"[@W8U)0UF71?
MP6M]4+US*(5W7/!=O\;1N8:V %%[:HZ\^UWX+"F$GP!5-0\$:I=S,6>]U2N]
M.O/>5>>#E]:Z 1,Z!2#KR;K-)\"2M%[LME#TK"HAL9K%2[2<FT 4ZM)!P&<B
M]*#/R)6\>MVT!Q$$ !X/H]-LBR:(%!<(NE%B%,O3::I-/?G[D<K>/EW/I%7U
M)&Y; J@"_,+VK0[>OM6,=!S!^($@;$JK'2>F!PSDBYR'LL&_/P'"HH._H#GR
M=3\!ZI"I?SJ7/)6C V2V0"#[.*M?9IQS<WO"@Y11[RRHQ'=KYD7&SXD.90_.
M*O?6 \=_#FOT:J4X*A[<+-K7F;3D#6?T.4>]GNA+?.U3,!#$D+NU;P#3K2D%
M@5-'3QE:S50O>ZGX:MX4?"U 5_N4(#J-('=9T@W;<B9JXC$6:'LM^&/S[TB@
M7[\V%S6T*S7.LJS?Y?, 8T5,&(]\A .BFOE?J8$O5<A_'Y( ##$G5R6)6M-7
M$_B8VDE?B+^X?RS 4'P3P_4N8?U]7!J-C)]-ZSJCY<G244ZEM]5UJ_^5<$8[
MTUC5N>FNLOW957EYN?]#;+.STA)9V*EFQ9?1(TX:M^X/$".[+I&AC7E94+ S
M^JCUM<CW(]$RD"?HIU3$2XMNEOWNI57M$-&XK49VKGK_>$VRV5/'N,8,[O:I
M(T)$,:^F .[(;=K-SGY<7J4_:6<4DEH\?Z 8+CY&,F'_*@7B]?$[=39!Z^!F
ME+!(OWN3M-Y>C#>R_B!]V>/(V=NJA2.1-%9[DH6 =*\2N*0Y+J0<M9\DOZ\<
MA((OWI7/J-"O(&+A"E&L?&;5UXQ^:<5EU:N*@>:@LE45B>_>4W<9/ -D@^9T
MPF;KI%K-'>=2^.A^M3YYFW_HZF5+X/PO9Q=[[*=I.3[&P*D46''J/B?@$YAG
MF4%3$8(^-$5@: PC4BMJ7CD5;=25;(,X7 (VLRV '\[2YF<D-X7 M>T<N;9-
M!V4B,_Y\$3(LRI),*S$Q.>RTF4)?KM/O&3Y9WL'OL*0I0/OS]=\V]06WB?W)
M14_&9=^4 5'*@,>XC%KIJS;?$"L655^69ZY><R;RH5W]'5<=/FO<',,_G?./
M0O_]<!K%DCYK@L]V3 %M]8;^#F'O8^@$170B0GGG90S%V&L^"JAW#6/<U;%V
M60_KD %'@Q7MYWF8PI[&GV$T[]>QNU4KE&ADRPRZM+:T=FC93DL^@*^9\\H'
MKP9<[IM\JF0+E;%7%?<8F#I_OO^,K\<NG2?U8=R%[=^T 50[.8XY),:Z*5U;
M-"!NT/(#R8;@>--&0G@S1+&D&+S1P#T*K,,_)/SZ0)0"V?VHV"6EL !01Z'?
MB8.RD5.L'LY>!SXJ[:7/7QRXW.CI#@S7(1<R]B)&VR*VI#X0D0<D<J.$Y-/Z
MCOMMZ"R<%UAE;EXKHFG( U\<Z:Y5\W%_]K9%+7'SJ?Y0/R]./\U\?M+G2^3M
M)1HTN3L@E-IEU=63/,T"Y*Y\"#3KZK']:\^_&[/ZD>AO#3Z3;Y"GNHZP]9)[
MGD;"MW3%G7DA5XZRU;)!70LCWY;O)(IOXRR=3EPP_*XD,$4:BD""1"NC!9JI
MPW6QOL$-2LI"Z5&6;*T U^Q0OWN]VB< ""'Z0)?',9X]>8&-@TG'FL=&=P3O
M?;^#DNUZJ,?O_ZQIH227M/\:#FU0^,L2UCG<NG]:O(&,4@?1?!A5LSZ^YQ;_
M,WS?9;BV&EAKZ<Y4P4;KQ-3S50@]*"!E&Q"'4G\]SN:EG$4:*U>7X&4KDK)G
M5J_T6DXD62-BBX0!)12+T8_8M)D\IN/UD*M 4;V7V.]0H0Q1ZVY:19>_&[YF
M[SF&)+H&J'6$8!EA^B8KK/H#>+7U%K+3+&O29;B6-HDX20IX"1C^<;J<Q!D]
M)^DWKQT=3GQ-&I"YG)Z*5@0NCK,S3KGJZG\7Q/,ISJV W <*U-N9T<X.LD4%
M!-PB3;K+#W>OK5'1B[&-AN@1?_)SNE"7VGG$C39!^F^Q+)U=.(U>'MIL:3++
M^5@E_6@6"Z&*&AKGB9D"PU03V0(SYQ4466)0W-_&XJV_<WX?*_*AH6W4W*<'
M-EW10DHUVXKH')SC:/#>\R4=N\G,_)GTR]I'"/,1;F>E38'"FQ_?6P:1EU(<
M\^C @Z$GA)<:^<0<76Q:QZB4X2:K;BF$X?WF2?X&$;SNHLYV\W^)4+:_46ZM
MGX+^,^9G3SW,SQ.0V\-JX=4GI4;)3LC]OA4@L:4L)H3LR7SOO!?=][?L<NOR
MGTCR;[&/K'UG^J%?:;VN2!4-#*XFO]L'3:>_%HH59ROVN5A7>IV8BLO%]K'#
M*#Q>\=UH97)*T*4EQ0[M$^ 5G*4G,[(?ZSK+A&RI5ZIFZFK;X[:ED(NI.K>"
MAV3ZS26#)DYXT@M>7CE7L])@@JMSS*,@JAEQJFKF9M\OND<,N#?04[>H$2(4
M0B_(62M?TS98+31 =B,K#^LXE_D??Z!,?Z;=?)5N#P[;RPJ.4ZM&^ZAH1D6"
MK-UPRSUNR,D+/]S[)A$!=+3'@>F2.R2C<#^+-;CLDFFL82^YS'CI+IVOH:$/
M2GE*HNR@T,6\6KBP9F">Y)J^\XJ;[X'I"8!V U<I/URCG ]B_I(A>',H9M00
MQUM^GOR;U2*=)QS=;2S.LWOB4][7(&[D^!)=*+LX&UEBQ9!D<T7OE_ND3-NL
M$T=Q>X:V'\R,UC;TX4X4MX/5"XD+J5V9*0'<T,?<YJU F0=F"-&\US%VOO;X
M&TTC B&IQ6[U"K[<Q3V51].1BC3$_&"%J.KOEHZX R27F6+MN]>+V)_&W*P2
MN+A5W-8%^ZU',BS4T&PE%S#W8N-%1>A\?,W32.M(OOX&<C-%<?[Y0+UMMR]\
M6UT>X+CU!(@T)8"9W/ST+1VJ!OWMYS-8Z&>TM_Z,-4K^^NN;KF;C,FO4M"6>
MS#N9_M>0@HHO\;XNO.-WC0F35+R .^SD/ZRM35UQ/(!LJ^W,._A#S.2DUR$\
M-]6Q,&O2$?X$R.*W2*[:2A]V)\;:?,7:C$(80JL=\DJ:MTG3ZG URCCY8>B!
M/;B;\PE@]2Q';&^,_DD*(H"P<P@.UZN/2XF1DNP&!H;=5<L(7A@DC5LG0Q_Z
M6%]6NG*P]%WE)DOD5",,\H$-O%_=:X;F0V \9R7:D5]M6[A4DWL\OHQ-Q4_7
MJ7RQ0[')DTX4-<1HA4O$=A6&Q.I^<#H(?N:D4RK730F0WDSBR3'L]U@ .LQE
MQ%U<L,4CXUUC)F;\%:213<21")9O[[3-)M!GQEBAH2#A\_K['.\WMJF;^G)%
MS2QOI11'TX*&1K5SDS@>PHJ#F5PZP^];NR/M4RJG^S:)\^<+J4:/OX(WLFGY
M([LZ7YTZ(5F0([3<LY93A?#$C0DQHREQ'E_/M\N+9D>B6FQ?#$FZPDTTQWW,
MR<H[K+TA;/=>4YXY0-.:VIFK\A&C4R'UQHCM3QWU%C?><RF06B-E1T[!VA$L
M7*%7NW7-'S ZL3D]Z5X%O((ABTI\8KO!?L^<>CU4Z?2[==HSZU'^(ZPXK+3Z
M9_&18#J$K=RHOF-Z+_&42(YT2I<I86<LD.U!/, X:P,<?;4>@>1L[VR$"\!H
MST#KWSJ8YZW][0+8MLB;DE80P/84N-R\(LVTBK,YZYVO;-P[>MR'@ _IXEFD
MLE,9<W^%B[#4RZ=<ONN<S%^T#IA.U&SO&HSR_&FDK3 1UR';9KR-5:FLKSW\
MX_ 8!C7O?US>/C=$2?BQS&^YGF?(RH6N0FRR<DKQ=AK-EIZ0UPO3Y69(W%MD
MC+072X"B]*#2 ]QP=G\\<]7^G;92K-VT.JAD3_ZT=ZM47 )&!0'K\;[< M?6
MYAI0(,JI#5V3;X-KO4(&:B:8.\?*D=B!6[&=L7F4;=[;$5S>WL4@;_4(7.-X
M"2:[[27]%"+N9IT-SQ->('@"SGD+*4,2&R$T,\?/'"6/M:?K*WFG]JB=&OB,
M:M>47!%N$&^6VZ^#VS'(EPBS+06!ACF,_'/VEK(FXI4.W-VSU:BT5,:[V"9N
MBO.IYGVM#(HC%G^Q5;%[ILDG0!>K\HKW<D;5LOU.D!^DR?>GDJ^;Y#6VI#7C
MB^6.PML!D?(Y/3<#DV[QSSO C":702?NK]W4H8+78R!X>8]>!^G,;D,N%R]E
MY%)EU2\]CY0U327?.!2<=_MN4"F(K%O?7Y/AA#YA8S0WH5<EF*A5HOC%[5&E
MX]B5LU>ZCJ83(_,U/=ZYCB'MD@YQNA?(N<5"\?0$'*\4'1N184HY%Y_5L+B-
MF3FPGP>F ABW$Y1[JS[C5.6"&V0H^RY4\ E@]RPQY-P3TO8W.<\8G5G7[A:>
M.5!W6I(GQ/4;"P.%Y$9"FK7#-9E;F759VW!(WI58G*5=#_5 -P/.-3"<C7,$
M2K/N?=MY*8:C'"^YQI:EDSD]9D+@9ZP4DM;2V>(JB86Y?V$P0Z=>2)M6S )N
M2H<:\:LO+ZXM+#?"=3)!RD;6::,2@F<_N#[DJE6ZU-IGCJ+O!3)HR+Z+9I!(
MZ]*V896N(X$HB%!,&'^=I^@]Y1F$_CA[%<$4.L ,[8VO:/U 38MXP'TML<[!
M[V_W(#DQ=,1\K8A0L[I]R"WQ]RQ=F+!V+B77=Z+_.W.&1D"AFVY0+"FCN+J\
MBUOA:XR:V4FZ(KTF'#?)TS;C0>%$93<<'A7XFU?JH?!QPP6?6\[=U$K3^_,+
MD[K2\75FZ65YK9#"4QJL ][ HZ[T"ZE<]=;/+YETUZ2UXW"3B$OI+^,2VMPC
MG<J"Z* H!R=7((\)#>58^JU5IU@Y1X'R:*8SY?'E0*A8$$6E_OXT<IJ:J2OB
M_55:?!-5QX0#S0#@%4V'3??.Y0#ISF1@TZLQY\ (MZ]C]0\&W=WJ2I:,%U+C
M/H/C;$I+O=HY.+%X.B%'DOV>"3PK_5__X>Z3 O743 3F@YX T$=9S]7 8\2$
M>J(6V(>IR;+F=_V,I90"XUG[)]J<1B1-/*BJQ/Y5@N)+#<$RM-21KYU6NFY$
M6! %&^OCY.^DN\F']\>HG:HSLV\H[>8@!X/DE$,OWBK=W^SXZQR;B/5I)7%X
M<+CY9*%@WE@?XZT.;]&Z3Y>HN\Y]_PO;]7^^MN>XY6'^+C<3[.<N@U>6ZN&V
MB"64A,4^S\9\7DI$JR:>!SE++3>0N-Z6?V/G:'IJ,<1@1XCF@BGUDD+X2.2F
M"I\ !]YR)!>QW!M$?]FSN>AQ/(OB>_?B3L(_S_+4L!%(@&208TP6I]P:*><8
MY13/H=V3*I+;UUQ3W1C&/Q&RG"=-G$T]07H_ZI^U5K<'_SP0#2HS)VW?1:2$
MMSRPJRL1#W&Q.W.^E:/?;=QQ,&LCH!AG,_$,%%P;'^>W]FQ)1HPHFK_P6(D<
M!46P_-B1>X,BO"+OGKD7( $U>IZCSRVF$!+098A>W6K)DJZ( U/]MZZXESY+
M^CI&J!1,:>ZSW]W-Y)XKIUOR">!@(J.4:$SWLBIHP)60D#]S+0UO]$N,DOC<
MJ1\U=0@ @@*1!9:77H,+*^_XV:J.S\WV?!E F3*K@=D?1)C?28ZYE!!^8"1B
MNY TIO_&BS(X$(";X\AF5@=NF#G;2["WYE$]@([LDD47T>K?)HAPPZDQ3$5(
MCSL).C=RGP -P?$!\D4^]N)XUIO1 D:STWMS")TM%=9>97#*I]*FYN2J;"J%
MC@<^=%F<%(1%:QY1</<S!WQ)Q#JZ+XDXKVQ#]7>U=W/8"N2#+#G,>1\[OXM;
M6ZYLJRA#AWC+*?;%7G+*BF@^KGX_N5XRO#T/E \&#B"Q+E/A<STJ@HLL%V?.
MX7V8EN,*N@SVV5^_[G\3]F9@W)^KDMGF(!3P87?4<#375JCF3(>V,B2WO$_C
M%6]<$BS%W-&*N?WQ!-CXF=<@!KGU2^OL/17LW\7!ZX77KAW)X4LEO:0/KJ?Y
MEMS5Q?"B/;8G#RH/3%QCF[K&,P[0AU-N=I?(U0X5'TN^]_'$.1@.C6"SM^ E
M9Z PKM$]ZHN;^_*-O9IQM:%5SWD,"#Q6W[M$!&_DFD%CM^@B$5SE0Z5?]& X
MBN?$)R.>W %DGU]J?EAN%1X\/0)UPA>W@.'>KRNKVH%I:/,*5C$7_=N7YM92
M,BX_"5%'<D66C998$$09V_&SZ:T, ;9P&9!O/C^?@;WFES6'UUD!5<=HN5ZO
MMQFHR']U38A;P"=N7L";JWV^;*L$TP0(.9HN4IJ:G99Q%(;NNE$R1&>G#*-0
M\0S1QR6QO5/JH%7B2M=P-(',*R%S*HO+1W\J7K0J-TY,S,#W->80J%MYK_07
MBN:*^(R_Z.:O'@GA;OFD:.Q5%.Y[MH79?=R4FI!@N]Z7@IE]$Q?:.%;P> +4
M0>BG--\ARG_FZ\>IHW8(1*%C^W$&689E)^11(EX_ 4(U$2I/@&]Y\LWS2,$
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MG[ME:$^_5\5Z34E?>*WO5N;>(KM'P'B4VC#5J4%\!&#"-<ZC^KE">5(3UQ2
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MQ(H+*?0[>PQE5R<4)0Z ^2KBKSXI+I"D#F.5007;974UK@@"7MOL1'+A_GD
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MB0:O6U4.T4(?DS# T'<:I[]&[S)5SW0?\A^(I]X1N;7H[Y-L!#30DQR$K_D
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M+*,;?96R=3J=Z6&GO8-O9E2[4ZUC)TO!2M/I,2RKIE>8; >#+?O>KU:*.\6
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M:A/W(E0E*(:8<\>,#-PM#;9S(BOK=SNETZP/7=IR*$KC_Q@W6E[ ^Q97W1D
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M#'_L1@%T=*9R.M[,DL=A[/5QL]/(I9Z14,"\K^<,&B;+Z/+WC9S\-'2Z>/U
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MD*8%6%L(O*-5R6^5REKW(6UV@0H0JE.U;2Z"A@SGKL0%S)]B.Q# 7J+I '#
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M'L-H9!N'"D+W!1J!O<E_S4G4^%0=9*9D $F^D<^"#?G[?<X49$19IRL^[3=
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M52O&]3_X)>^*$U_X>OX6\;^$=+\/:%HGPXM=:OI[+59_%/A_5? M[-J6I3^
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MEZB<E=3?U"\T^JDY)]4.%>NL/2M6JKWY;5*G=_WRVW[>?[66"1\7+H'V\(^
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M[NL[O^Q\KN]'O_PGZ_,Y?;5?^?M3_P &3_\ DA\/[>G[6;L"WQ=NF.<<^$?
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M'<A33JV:R7*KJ^,J7M_PG=;*_<3K5;_Q:G_@R?=?WBN_[>_[6H=@/B_>  X
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M.%J_O67<"EUE7F#F(KI%\-*7[5:O,]>=O&UYHF7AE3E_]EZQZ*LU7T0D'B-
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M[U,C">\1<X5;U7^7AOZ>IQD(F3,'DZ<XR$^ >'0$?!J#Y@3P^^K3G!YQ9(5
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M;\5Z_3T($VA:\P\+D$E,@V<S9BX#U9#^CMT"</)2+V8<Y&8&W)(PL.,U.FC
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M">-"_V[7NGC;AE;U^(8R/U'W83_]!QRIVS]!V\(CFG.*S@S!9"^TO0'M>V_
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M@<C?^C;&@'+QBQHV$F]IP DD0PJ1>8,I&"!QW)"X3EN(T'3Q:&.\[N3/7<#
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M'9 W UF=>EW)4X$[461AV3'GS)WLG\$WG6*:!IJB9Z_27N\W2.T5L_Q+2S
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M%V'M8+$^T\XQAQ<]E68O1BMFDF?H.1C/HE'1=HQ/DHC: $3OS)9K$TS!FJ/
M:5*";IF#D2T4=LO:+''^A"S0N2/'.M%@7_NHM=,,@_EC>#VVR0[6&1:VQ_P_
M>X0[>1X^1.X'C8G2/\-V+*Y7X$RF)#OO@(-NG=32 >[,U5\@>PZU'3^YK<H<
M%.#?SIXR_]P9<7226CW^&SQ'[J7/)/CUB]I6XZL/81[;*T_"MOVO1R(+"L[0
MX+ F&R)"O/$>]!0!5AG2?B/VO-F.PAD1,"9?8F+S3]AQ1FUDN\D7>YNX5&5D
M6\N*L; POMP70E@S\C\GKP_C\P;D?U%("EQT&AXQ2Y)@DN:(=+&D\&N2@[N
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MSFRQ5>"B@X$+&HL1/WF:@QJ3<AR>PTST<"J4N&?20IGZ%!M,]]84TL5BK1I
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M[##?ROM) JP/:PSB"F&HLWK4%8B,>M/"0Z)F5QX2#$E$!WX" 1U187.ZW&J
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M4/_$E$6-UH9( VUO!X=9*[\ZN6H@M^)"P3XR=K@/KS6$%\,*5GL*IUY/DY]
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M[V%BF='D8B4[-2V5<U>S]_+B?^N]!9MHW^O9<31RCWYBT6/(#-"^71Z*5/T
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M+>5A+G(7S&JY50?C7(@(4!%?_2SLA],I\^HX'7-& /"0G9RB]+^(ZQ</@WY
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M39U&&*^?(G!BA7ML4E"N?5/HJV'E_G)6DU;IHIC4%?M^X-W(-T7D5N1>WI\
M<,C[L%[C\Z A4]H1W3@2]BU"+'H1RKA -7GQ<6@(R?DF()-'/NYX-F%U\J1I
M:YU<UIM:-?GSZ);':<WL\8IQ;Q;4S'35[&E-OED*)VS ['O.P,GD%H[+QU0T
MOATQ/;;;1SA_K]*MI#A/[X<A8G*7CIZOCHO%3#JJR3N?IW"WZP&Y\+4W0*X#
M0+ 1B)<6[GPHDM^DU\]U8C US/[Y9,X),8/+R(;GZCMK>._S"V*%5X%O@A-V
M1=)G&-'(JG(04-E7J57[5?E\%8#W)R%+R91:8!W95P-83<:F_Y8G9U9A#$0
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M \6;&(C./^J^M^KWNWTLUBZ.O.<+U.E]^QGH0>:D_(L\S/5DB)"AB\H=T<7
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MG[=C]!Y"I#FB?LKM9#S#:N_U#Y3D.0?B]Q!_5Y+X5D90^^1]VPM?*F*RF,)
M&/"F3M"I9$#ZKM4MH*)N[:1I,6EZC_*7HJ, <U]3T%LCDG3U;)G/Z"98^U!<
MD28U^RC=A!_2ZKO_?7%#ED.4KWQ^3K(BP36RV$%]530LZA>0Z_6FMTVTRNK
M2Q7O#^\K^WN;)\W#[P&[OWSR?*3E9FMK9G$KZTAO1%PL,>D YM1X<@W/A 8(
M:J*KMTK=];M5W0>^PFD$BYXNJDU!>"4A4ZH!%V<JN=2&>#N=6$VN>1Z>;GW9
M5?>:..7@9/O=@TN/S\WF($,BP7T#9*]39495T\OF! &>XB-1@&&=11O/-'W=
M'XUH\Q #A286I4NXU9T[I S=9$:!@ ]+!'( !&9NDJP<2S571>PW^A11NVF6
MCD@3PJQ]1%2R+X]UH!PDH,Y<#.JQP;,6M70K_KQQS@ND!"KYCT(=_,H1=,0
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MSP)>_O?M_^KZ[Y#_VS.(KEL!-&0 !%$*,=%#P"T:(F(:HNM.  < 0$3Z_VP
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M*/HWZC#C%2T#\<Q^F3>]>7+_LW%5@LEKQ"9U^9 W]T'X[SGY@7M@]VIZ2EP
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MZ?S$)I9O/_/\95D&DQ'[,Q)I8^Q$C]MT65>!5,$Z?N:-5=4T"/97/WS[Q6!
ME<[>-?I,UBK;%V+BA/W'T;,7"F>Z>D+H[EE!=ID]NXU_AEQ&4MFB%04\JL_-
MJB/RGB-F%M1)[&A[Q(Z/-[@7A?;=S+X-P:7\?)>%"4J-RC,!^ESK/_HYEEAF
MB(F#J5D.VV1]_9$8X=F$[H4'8Q^YZLNC,6]KJDQ>-R3;9S_6^I%M_?;V"^1\
M&XG'$3)$QFA%7:TS9;"[HJ#?JK$^1>6#Q1>*VG@: "<I*"B8K'4/G1R#^_F,
MZ1N#$%T7BBD!)=2A6_BU:$\\.O\%595DWFB55'R\V;8W1-RT7T9+V[">SVJ<
M-XU'D-\@#\%BKC4M03_6\G('%=%2JM2%_+)(VLQQ82$5_64%?A=V_DK=;7*L
M PV?N1\=Y_2B6EP:5N/]&/CW.=@6*'LW8.JFE.?L5US-<K!9QKYKPSGQR#SJ
M4"KL)),$O0L9(L+$/H4.?D@X?^YG,GS((L.32]@RC5!(&=ENJ>"M]XTP++96
M1Y*(#)E91&:UT7SN5L:*7SZ"M^7\A,]",1UUMY4(,E]^6&+=BU[]]1=5@?0@
MV:M68)YJ7TL)F]\/MCTIK1@?YN 2LC1TYUQ&OZ?Q>]H-::N^C?J]6I0S<5QV
MUO(-$@-<AWPPTPFS->BPS [5/6#6N!?%HAOY/B&WO^0L;[YD^NKKVZ"U+);S
M0'>4'_;@G[^(]K@6\1KGQKZ0R-#MD9[EL5/=JO.!Q*.(Q,9XA]4 J@ R4PV$
MT23GFI&X_TO!N ..2GE.JK13+H G.-4->K]JBTUX>5QGGF@5[KCQZ<1IB/XE
MR0'9C %D3;<4R **A@PZ.=25X:FJ'EI0V"=G!0$*:9Y6:VH->?=@4M%#S7*U
M,3W/SE!?CHRXHV=6%DP\/,!63,38FC3Z]++^K%,LX%*)8OI,OO>?O 3<'AHZ
MF9)\W)R5YSWVA-V_\D]@UAV); & Q"VR#C>3\>-3BK9TF9KAR@&*\^>2>/G/
MS1.N <F <K5;$M_+%4+6G7E%7]5A4_'1\OH]TQ<O<S5Q)V85RHT6N<9-X8/<
M'\OLC\MN">XYKOKQQ1N&)[UU(UNE@2;"&61(K@%4 3Q3O[YH6>>;J]AXT5EK
M):U=U"C]*RF.JW63W'41""V",#4%*$W8V8Q>RO=.,B1S9PL:M-=/>[6H?=K)
MQX?U+%*B\#U+R.X8"EMCCT5<PF!!%YZN(\GE@U;^X'OKE/U'7-J&O2.,[R)"
M0=A4R],\O,07<7\3K48'-=9O0B4?]DL$/UNIV^0K=$O_ 1O,O+>VLOP)X+:Z
M10W=02L1>')AGD[B*$K529_RGN,&.NX;/1=Q]]P2+/>1UF8@GE&["+$%Y?3S
MN&D&2@0OC!S2%<_5ROXH8ED^_&A5XDIH)+=:E&"^N>["?J!7[<%WS%O+LZ"L
M/%WW"[@[.65<(#.B]4D#[S3H<]'"E>XK#!W)&%K<?KZ,I(<Y8%2W7 VKQF/_
MI:2')QT7LW6.;09P?JF,8)-]2\N^;K2KE\(]4*0ZI$B$W#,X9I#C(4!7#.6(
MS:<<FA^-;OL]^&V?LAC^\!LO#A56%?6BU50M9Q;ZX-%!Z]\'2:)=(]]O$2'_
M(J><K\B?+B&#FR5PV$YJ!MBRC.<?8S79M<^Q+Y*D[D:U"RB)[Q0]=G4->'H>
M\=.+[-L\,R41\A]J>3&DD6-)D]J^H_W8S=C.(%XNMT##:%?()D6RS<[<A665
MGY[A.3J3)'PF6X\[9\]J8C'%V*1A\8IY2+3"?E8<W7>C"_$].P(Y]E[-G/&C
M*T9B@TPJIY@?C#H>'+Y_.X4D'IEE4F)3#P8#V"_<"4>_+QAQUX#H@ =M>9OF
M0I,/QGEQZ"_FP^)=T=\*YEX_B=$91_,\J*FB2>+IWW4!D*1<9E\6!@@1H%T!
M]YLK</,=YJ8O+;V</-5,2_H";:N?+)V.>%C+!#=MG780HFYPH]EO$[*667N1
MB#*\5UB5[Q3)H'#Z3&Y#U;C49[X!"R9^0S>:BIZ'I2G9*,:59@&H>34ZNQGQ
MRO)9KMC<>\R^X_'A>;,-UGG;&U_1R2YWF7FAO+5R/NO\]7[C67,-G"G\2,F?
MN#NIVIEG?B'1!I03<5?%0O^^861!Q4-.Z:\])X@;B79RF9E%.,$]583M#JYG
M+=M11?UY&A6O!'JL+]H:;ZBHES4?\P,!HHDYD+Q,/]S:(3Z.QF%GUE+Z&@7R
MYS?OY\Y*!PMZ',:K?6/KIDY^&)6=\>N!M_AEZTTI9;NP*/G'<;?XXE6*_^(Q
M.,K9TZ!6EU=,C>Z/LJ!0JY\U9F9(836KQTWIM;=.UB/NT<CXED'NC MB2;[^
M'0?FO8#DK1LM O4ZG%T:.(HQ;"KE>?-TZO$V'>F7K@9+]W=+P)?11$ 2FY3#
M2L_$EV$SY. Q=P\0R ^!1FC4=L'V0BJSWY?;KU8T_RX3$U7N+ T:E^0DCI3S
M1H$C\5T^AS9D/]ZN)<BX$.W4K#/+GKZGKA(;,S 1'3I9]A;$[(!2+_K<6[?]
MDGI)O$Z.>FZU#"1?4;@FW Q!:I<ENM&:,5R<(9'Y8X_WJ:C(,/ANV 9T4Q;7
M8',!3I%;>GGJ9=@C>3EPMS":^J2BA]O@U 7>YFP-)?AX[7SHI.'$SUD$25+*
M5P@^ ;K Y+42@D8;4S<DDF7E^)--Y%K"+%=AU7N"Y0UN?RHW4S9J3#[)\V=0
M!))S<N2Y[O4=]D@>;MM75/R4O%O#%L9&I<+IYB\KGY;$,T0V0_WF4X]YII/,
ML216+))<LG7))I(R6CJ >1?^'$I'[B:]AYAO3BDYSTCNVF_2.W0P3]ZJT7S^
MY)7M7Y?!>$7W2!=R&:(X%,=88",,A:>BEF&'\2N!@_IZS)^JQRE'-:0K$J',
MFQL34'!3O;M+(1,J\]%A7#4ZP^YC:)F3/VVJ^QO^#=[3TM< D_LO0!L-E<CR
M6:C0O%2*PV-K%\28;3?U>Y^@]-M/,RQV?G'=CCMH(\%F:@W=%LGH] )S1=M]
M^4&5DS[O<^[>>]0&Z:FBM;$/=E, 6$;2*K$3VK!EW+2P8@L29"'Z=4"U5WU5
M44MA2CO5W<T=062+[XYCPU;M3VT(YT'/&YL63/A_H1>L1,]1L7?!P$P)[RNR
MMZDF&E@]0)<L/"50HI?7)[EY SYF)$=+I6?'="RTN+0LQ?5G'_O>_"HGWCUF
M&JJKLS6!CUQE;U[%CC9%YBI*_K1'[R+RCL?R:M 7J+*E//2])6U3U$Q[7\M>
MF^>A_.U,DNX<6J*=R^7TEIB5YWL:;F3\ !*;,;9K@$A&"?S.Q.BAXTOM\O25
M_AF[I;*PO^G*(S^Y-%1L.*V5D)S1_D^>AKKVMH%H4,R8%G&DC+6VJX:05D*]
M<>6OT2W/ !3:\GPF[<YP^[+ITK)J%;.DADIMWZ,7@J^;!S>O ;WA#_VI ,3<
M1/'RFL6J(#=9#0@0U\;>?/5]A6R3["Q2FSV,S3= ";<5;JTH^IE>M[I%?6+/
MHLC4+4WI9=Q%M-39\?&>V<_9;_0)?2C(A3<6X7ZV4A2Y9(/TB:R>Y(RL%D&!
M?)8\=HYZ9-83DZU/N*2^#?)BQ;T"],<BJB=-YE!^H;+/,5,88K9+Z4]_YM9,
MN"\G3W9V'9[_IE)[(JW)Q>8>C9A%+D?;I\8MD[/649)O DE\/P&#VK;2)UR\
M7-%J><V._CT)W[*UGQ2<.J7:.,S+ZE95(POD'6XD2TXX]HK<X*8^I5GK/_ 0
M#L=P@JRV)J\!L,B@(26=>->C"]+30-8@D&OJX=Y40.(ET4W%4>)] F_COY$S
M9%R"K+901@"0.]3,9PZ+(([.>'.,.C@;'?!\6)#)>EN:"K#71H(C9X: WK<X
M]_*-9">^]=A"YW_M[%+:+$4\*YDL%BOFL?$7*JJ2_W&@>PVH+.O74E&BT9]!
M^ X9F$.E688^)63H7"I?;"IGT]Z&S# \9S_])[GD>Z:3!Y3DC&27Q$3_D'^#
M96^^>-F$_O+/YR 2!Q<2Z"W*^M*CZ[G,URZ:7.>DGS,V<E1I=;1H4S; N,9@
M8[/O S>&]IKNZWHNT4KOPT >7.P9JI2?B69E*"GI9ELT1U.(4/D0,#CKOU>5
MD);ABH?\*FPN0$QDR,8<7!7CB:?1]D"220A[\DGSSJKB-:TFFU37-- 3N1;$
M(>G4Q&#$'XX8J+VV:&, 5Y;\7TKVIDL"0HFU5T&K-BZ)Q*-'(ZW>\Q*2:[MF
M].S>\XV;- (=RM -ZZI1_-#/!;TJ/4*HYKY69-"#G$-T/]G?\4LML=]26\P-
M@Q4+E22A#=3VFHIJY!7DE[Y_SOCOGWJ;=/C*)8&:3?Z?,#4B"[O0HM6R5+JO
MQG1!OW=<8Y8[?/'R V=(2/T0R,6?J'=;$A,$_0''J3H80 F/%K>M=LF!F,7
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M326K1_W^V:I[0+)*YT[LD4>?^-ASI;KQ=EOA6+.B_;UUVOG__(RW.*.S0->
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MM<FG/+_EF65IY-!(>> C_>36 KN3NI1Q:9>@?_ZZ!,8,(N75FO(<]VI&S#7
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M)8.MEL:&6G1[9G+#NG7B'"92RH4#&%+-=>;E)9$O,MP6&,\0?6H'K-@@AD8
M#F6TX0T(.2]"(->^ZQ[$X=]$)N%?!EF]$]$*[7(J/9!5H#U=^SKJ/Q9PT9M!
M 3#F C&HK_IN<%IX3)YPI$9227\:&+0L@F[G=(-YXC,/XC]#0RQJJ"'6AT;S
MK74E C=8?*L1YW9680/[_OM%6],D["ID_,3]JBK4B4;EZF>(""@9K20Q]4R^
M\I>&N"TK63#MVZQ$XFQH73@@85X8#1R,Z/%#&9%X1E H^?($K*9 W<F=MNKU
MS8O)('F1B0&WGIUR4:/_P%]#J:&N9)M: <'B,Z?HB?(/+-/EIT,EDC70@XM=
MPA 1]5LH'YLV8[VN;7G9&-I9WS]A?]9S5181K3LOCB:5YJU!:YO(+*ISGW?0
M1\(M,*H.G\]ZKWZI JY^$H7I$V6P%64-;H?(L7,T7%='R1F0O WF MW2\1\5
MG2DJ*M*)9 B3^FRLXA%&.6R_R#G&>@GQ?/[;HTSWUU2RZ\Q9<EN[TJ=0QRWY
MIY:!$N=E\I)'Z;#@A+R%_T58ND<[+[V.XTFJQ:$,ATF:X:<K5HT'*1T(9+L=
M[7SD62)6N&MEP>6T/9Z347(XCNW,J[E]0J=H/4YS?^>\V[+F95,=H^9SW<IJ
M-[V<_'C/+$)\ L4+QF/RSKOQJI1<-C[LES2>.]8_E*NT[N&,\#Z+C^\5[<_X
M=+,,"B#>I([)*$0FJRG<\AL)-.409W[J9= SE:R7EB>77'=AK7K0A&J\-(EZ
MTX1KIY-QHHWIF2J++LE<>VO, "U@!AI3:71I%WF'[,#I-? FQ,DS/#U1/DC[
M:QA9+I9]>RC?+GR@ Q1X)-KG2'Z%"'6D,PU="P[2 B:SX+[M*:"+1N)S1("%
M,@@^)/9VMKG&V8($;-UKGN73T%N*VYY04.*S71&*,W3!P\Q86X%DD_!84MAB
M:/CA(KX6VS"4#'7$J\MH%$B#'7;/CI3GH/;4F#/.NU$P!I97FN7/H07:>II>
M[;YW'R=K('T6S X6+QF)#]!G!0H)"=8,F55AH6O<#4".QH%1M;4Q=_[-]@-O
MO 'E?4/<*5:.58U0&]-S7CD A/!\2GX&6Y6N6H421M^$A\F, 8(/0RYV15&H
M^+IWE%T1H-7X3"#4:SN)&*SQL[9T.K)(:K=/H^\UO)7UY3_H>[_:RR7E%S&W
M4S=JG8I.^246VMMR[]69/TZ;7CH<G[V<YIQ'GV6U5GY?(HZO,/6,)VTNC*P?
MZ'_<Z.?>3/]@$#FF*#O(G=8#/ZN\*KHOLZ&;T,Y@[LDTV\;=1%/@<0RBCX=Z
MI*%3OEW\&OH517ILRY6PKBAU@@9A BYA8K,KK$*J<A!E&M&99,6VND$U&@PF
MU>&)7B&JE<(@ZB'/H1>:HD_H<GEOLTQQ_R4UK%5.HB#C;6/)BV29J 6HZ_E4
MLR2RV?6*-F_L(!AO,"CFW\Y)Y!M-JG^DE7#?D?$G#?R1%C?_^2I MF/5!*&&
MMR'X*=%[M^$ZL:+>7K%769?"]$O\<M"W!:,F=V:I25?B!=:'LV6,1Y>W9%\H
MY/VS)Q-;I?/O1R4&'_E,IB/-XD8:4(]<!N;F8PTC^L/$=( Z:)8Q8#ED4A_Z
M1#5V^4'.@PSW OSW=G]9(3-'RF-%JZSZTV;G<XBSD&E*2_"#1IT[G JNMPKD
ME%"T6O?0_+6;@SR;K W:X#R=W?Y]Y@-&_.N0B4LU J/ F2Y6+9HH&Z0YX;UD
MLM[>RQ9L8%2)U<EU"0YV<:.)=UF#O2E039;1:OP/[/C/F48[1'4$[QDR_SJG
M_RP+-RIW*W1->EJ6&T% GAZ,[8I?WL7KF%D]NS']C5?Q!V?^GL*]A]\Z4Z6I
M?]YERQVEH6 '*)SL)/0=Z&\^6'*9OZVF%X'K9I A#1,]/%QI#2T)H?(+3;17
MHGGKET!/N88]R=6'.@VEY"A8_$0\</2P&/<9/VZ6NH1OPK\:E$2A%Z\!=QYX
M%-S^;F(UQ/=,/^C(5:'>HL3%14HI@A/Y^0#J=PV(AN+&XHN( G$VJR37 ,M+
M@)Q7N1/M0N#9G^;E0;Q.T/LNPD@":/=_YX ^;*? P@.I3Q )K_2?/&5DV9N!
M;B.?)2!L@AW5A7C"8J5(/6?J_3="9!3[U-@%4 /55JS#QT$2#9$\T=QD&YM/
M-&-M'V?K&<26JBW'G?HT.55A3_F-TF3Y#6KKC5TN3V?QR;0+]F?#ZBHWJTK'
M]4JM:H#[FJH\!H%PA<2;#0NW5Y@.N@8@E0\^,Y;"YYW03^TXOX=VN93%0IAE
MCD<U_HG&%Y4'%;E4_)?(S\'J&:'[VE_18U35;_6D7U)7KPW9S#_.9W)G+"AE
M%"(S9B.*(O/N(&:,?<1I$7^M\6^8AF@H].7P*^]+8FKY#1WFANA3'3P#5??K
M6B\YM*7CC H.[/54373T4I/'=YJK#W&<AI8A-]M;+VO#=544(LX($T>[6-B%
M,*+W8.([V@EG&U>UZ1]_M]>.]>D7 3DQV8ZK=.(SYTL8/VZR,T0*%R_/"R%#
MU[LK4/I^]FC:7(4C$2>=LQ/EE$VI_YPZ.X"*QQ%^P/!(W+;D11MMM(P J,IT
M2UR@<TWTC?-+2KWAXC4'80<'M:P3>VU-S1FW)8<3>; U$_,#/>CF_?P"??T
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M11_;'DVWB&+)%W3;&]M0M7OEUD1Z:\:=;WJ_*G[6QILR3/ME)O'<J25-)NE
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MOR+N-)1VOO_C67U*78_CBH/0-8 ;:L.T2B<[P*U8*8Z*%:@3HQRE=08=_]F
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MI?MAN.PLA*IX6ZD! ()=T<BALMV-^"'DI![]5NA)+(I;J97?* %(0S&JP3K
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M%\MULNK7<_D*DBP&$A).TE",8SQ@#VSU/'!]:D5XXT!PR\#(3().!SQV]?\
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M(X\^FG[21@G(9>0>/;/5O4;K_@WO_:\<2K#\0?A!Y3'$:R7VIGY?4D6@!)_
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M>DKOEBG>23^@R7*J.94L35K8GZO"@X)OEO=SE9*U[W;MM<YB;PKKY88T/4R
MQ.!9R'(S@9XZG/!& #[5!%X5U\2R#^Q-3!;(YLIN P&2/E[=,9!SSTQ2_$']
MLWXF^#;^PT'3_@-<W&L^//'6D^"O@_=:QXAM[+0_&:ZC:2ZC/K=U=*))=/L[
M2PC2<J49Y#,J 94BO,/BU_P5(\'> ;+QEX4T+P[_ &W\9_AX=&@\5>'XI2_A
M6#59]2TW3M>TNTUD(K32Z2;])$9D3SB %[@?S+E_T[?&#,I86. \',)B?K-:
MK3;H9Q2JJA"A+DJU:\J:DJ=*%1.FW*2M44H-*49)>W4X:P%-2<\Q<5%1;YJ<
MDFY*Z4;[NSO:S_$]@B\*:Z$XT/4BP."#:2A@.^3MP 1T'Y[>AJGP]KL;N!H&
MJ@#+%OL<A.  0,!0#^7I7SYX<_X*FZI+XR\':3XY^&VF>#O!'B*ZU2*_^(FJ
M:M-!H"7&FV3WG_"/Z7(D$D=QXBFA#2P6=S)%YP39$7;BOH7Q3_P4@^#'@KX>
M>%OBCXH\.^-]%\&^*]3AL+#4+_3HK>:.TNKQ+.RUA[1V%S)I]X\L<D+Q(S>6
M?F (%3G/TY_&[*,3A,/'P*EF$L:YQPSP&9QK1J3BY7IW@G[Z46W%OF25VE="
MI<,9;4C*:S6*45>3G!JT=^:S=ET\GI;L6U\&:EK_ );77ABYBMK6,9EGT\I-
M=E =JO\ *6=01QN) !X SQQ<WP_\2:?->1Q>&+FXCU?_ $0P-8,]O'$[=-AC
M**"I&3@!<D@\\>A>!/\ @H?\ O'VJ_$?3[";Q-IEG\,_#^M^)M8UK5]&N+72
MM3TGP[,MMJLVBS/$#>-;7$D43!02TDJJ!SBO-/B)_P %)?#7@?6O@5J%U\/O
M%T?P[^,&D:WK,^J3Z5,VN:)8Z?=0V]AK$UG&&5='NQ.DS7#X98G1B WRGS,!
M]/?QKS#,<1E<O 3$83&4%><,3F$:*<I4W5C3C*5E*HZ:<U%2YG:UKM)Z/A7+
MHQ4WFD9PFVERPNK;<U]6E>VK6YZ?X'_9QT3PWKND^+++1+G3-5MH)!J%K9VW
ME6%^\S>9&;B$IAVA8_(>N0!V%?2$.D:M,[-%IMW)A1N5(')4$Y!(53@# P#C
MGTZU\::)_P %*_A2NO\ A[PQXJLM<34?$_BK4-#T_5=#TZ[N_#VF67_"377A
MO1+K7;^2-$M9]0N8-C19^21C@LH!K]@OA*J27>J%U\PO# RLZJP9' 92N<]0
M>HZ@_B?O?#+Z;?'?$WBYPMX9\9>%=7A7_6?V\<'F53%\\)JBDYNDE&TU%M1?
M9NYR8WAS#8; 8C&4,=&O[!Q<H*.NKLD];6WV/FBVT#6F7C2;_ 4')M9L,V.O
M"GKCOUQU&35Z'2=9V,#I-^N ?F^S2C'!ZX4\>_7D]<<_H?':Q,JCRU&0  (U
M'RXQZ<D'J<=,9P35EK&W P5&#D8")TQWX&../RK_ $RITE.',FXW5DK;:+KN
M_4^*<F]/R_'O]]]5T/@?PSI>I0ZL\MSIU[%"EC>EYIK:1(ES"1R[* "21U.2
M?I7QEXM^-OB/2_C'XTT9_$.@^$?"7PK\.VFN76F:]"PO/&[:A%-)(]E<&1!!
M:6K1QQ&2*.=U<G*J<!?VC\0:/)J6EW]A T4)N('AC<IG:S# +8/*\D$=>G&:
M^7=6_9?T+Q'?IJGB#2?#FL:E%9R6"7M_I4=S<"SF)\RV,KKO>%@6'EN2HR2H
M'?\ RF^G1X(>('B1XA<,9IPWP1C.*LHPN0XG XF>%KQINA7JUXS;M*4%S2IJ
M24EK%RO'56/N>&,SP>"P]>%;$1H3E54E%QOS)1>B=NC:=M-K,_(VR_X*5:3J
M=K?)9_#&_FU72-3OK;5D_M18;.?3]/:,37FA-/$MQJ4\RRHUM;)$#)C&<XKM
M-*_;ZL=,\,:AJOCSP++I6J6]Q?M8:9I-^MV;^RM]<?2+<?O41TU QA+FYME4
M^6K $XY7]#YOV(OAK+K6AZ^WA/PLNI>'?._LDQZ7'%;6[7!1I9C;J!'+/E%*
M22*67'!&2:Z2[_9+\&WTT5S>>&/"-U-%<3WD4DNB6TACN;A]]Q.A:/Y7E<!Y
M,#F0;B<BOXFQWT/.,ZN#CAZ'@9Q#&4YPJUJW]L356,X/^'%NO;DG+67NZ)V6
MVOTT.(L(I.4LQHRDM$O8IIQ=]=MX^NY^8=Q^W+>SQZ%KMA\--:DB\22Z]8^%
M]$>\CC;4%TJ_CL7O]6N"H2P4R^8\:*LK/%ABP8XK2\%?MX)\0/B=X/\ AYH'
MPXNA%K=G]H\0:G>ZJD$OANX6U-S.CVK1A;B$;=D<@<-*4)VC(S^G:_LT:2@M
M432_#82R\W["O]D0XM#.YDF,("@1^9)\SE,;VY//->3I^P#\,(?'L?Q(ATRW
MMO$D5W'>1_9IIH-/%PD8C5Q91ND(RB@&,@QMR2O)SA0^A[QSB<)C*6-\$<^P
MV*IX>K#+ZM/-*E2*J/W:?M+5XMN*M/F;:<WJFM"WQ)A(R@X9E1Y>9<T73UMU
M5FFONZ'PEJ?[?UC!XM\5>"M$^'EWXHU;PSX@LK&2\TO42ND2:->VNIW37YNI
MHE9KRU72KJ.:TC5P)3$%<ALTW0OVOO$WQ#^+7P]T/P_X431_ FMW7B.WNK^Z
MU2.7Q!/-I&GS2NMUHHQ)8VYN(@+>:0XD4 \9P?TZMOV5_#%A<7=U:>'_  K:
M7-],+B[GAT:WBDN9BLBAY9%C!D8K+*N23\LC8!R<OLOV6/"VF:O)XBT[1/#%
MCK[H5;5;728([O#IL8"95W*&3Y6P06Y!&.3$?HA^(N&PDX8#P+SOZXL#[&6(
MQ&;2J1EB)Q49UE3=9*+3O*"UM?6Y*XBP3E[^:4I1=2_*J=E&*V5[.[OOZ=C\
M>]?_ &\M4TGQ)X&BMO#.JW/A31_%_BFS\>7CHQU^^M=(TG4KZ*WTK2$#/+;D
MVT:K=;BI;Y  1BN[TW_@H*=9T71/$.E_!_7WTO5Y;R_DGN;DVRVOAJUDMP]^
M$FB$DM^@N%62S50 ZLH8YK]2'_97\-2:A%J[:!X3;48$FCCO3HUN9U2X#K.H
MD,9 $HD<2'&Y@Y!)4D4^V_9<\-6,#VUMHGAJ"%GF<01Z5 L*F=P\P6,KM19F
M16D50%+*N0< CKQGT4/$"M@\KP\_ '.7B,)3BJV(AFTJ:KR;3FYJ-1.4G.Z3
M;LHZ6ZE?ZPX)NHY9G2C%O1*DFTEL]K:Z'XM_$K]N+XHOX,O9O"W@JSMO%.M>
M([KPS9V8U*4V5AI<>M2Z='JCSK&DD.HR0QAS"5PH<DD@"O63^VY9VD&EV5MX
M/\2WNI^%[B3PWXCM6DC87'BV"R=TTV:Y."J7 1;I;ME/[J1,@D@5^I"?LK^&
M5,I30/"@\VZ%[)NT:W8FZ#^8TXS'Q*7&XN,$M\W<U0TG]DKPIH\NLSV&E:$T
MVOZP^O:I)<V*W#W&JM$D)N\R[BCK$BQJ%X"@#MBNNM]%;Q#Q&$AAJO@-F]*%
M"K*I0C1S)QG4C448SIUJGMN:4815X=5)MW=U;*&?8&+?_"G"7,MY0NDUJFE;
M2[T:V/S+TW_@H)8ZMXA\#>#+7X;7D/BWQ1J,]GJ6GWFJQPV^F_9-4DTRZ>SN
M#$K7;))&9H]PC5TS@Y( [#X@_MJ6?@+6O&5M=^"R^E>#O%FG>%I)9-29-5UV
MYN+"TO\ 49]$T^.!A<)80WT0.]U1R&^88%?87B7_ ()]?"OQ7XSTSQ_JNCVD
M/B;21'';7.G//96Y2*Y^V('@@>.(L;G][(X4.[ AC@UZK?\ [+WAS5I%EU'1
M?#%_(+E;T27>E03R-=K$D NF9T+><8HXXRY+,515).T8\7'?0WXXCBJ%7 >"
MO$56A5PK6+PU3-JD)4,1[3FER3]LU.+@N2.BY;WU:1I'B'!N$U/,J,9<WNN,
M'M9J[5M^I^7]U^WW&/$FC:1I_P )?$,UCXCUEM,T"Z>5S/?VUE;V]SJ=S+%%
M"T5O-']JC2T@EDW3LLCMM5=Q] \3_M87'@GXNZUX)\6>#DL/"MAI_A6XT[Q"
MNHJEX\OB.&69SJ5O)&L=M;VC1- S"1ANQC.\8_06;]F/0[E+9)]*\/.ME=B_
MLE&F1+]DO H7[3 R*K1RA0%+H0=H&3@<LUS]F#0O$LL]QK^C^&]7N+JVALKF
M?4-*BGDN+2W8M!!*SJ2Z0D[H@20F[Y0 3GA7T0/$J6.A%>!.=4\#+!UJ%:G_
M &Q4E5=24TZ=>$G62A.$4U9\T7=NVUJAQ#@8P2>:4Y2334N3HD_=:ZZ]?(_,
M.X_;P>]UR33O!WPFU;Q#IJWM]I@UI]4MK6U>[LX;^[$L>5;S+)K33YY#<#+&
M1XD53N(&%?\ _!1;1=/EMKP?"_7[[1M6M-072#:W2-JO]K:9"DUU;:EIS1EK
M.QEFD6*UO,L)%WR$%17ZK6/[+OA_2X8;73]'\,V<$&?*A@TFWB5/D>,[56,
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M;;O3:7I9+5;7/S!MO^"AFEW>K/)'\+=?B\(6:K'?>)I[R$-'>3Z9=:E9B"S
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M/^<<8XSSCU)HHIU*<)6O%/5+9;?< WRDSR 0<\;0!CICCL,]#FI-J^@_S_\
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M.&#'5.A8I7K1R(#I&_:">&H=T!PQCDLHI;X1FL=3EC<@%V7=D/ Z[+<O25,
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M?S1ZG_.TG%/$K/T]B!D3?S#TEU3U$$E5KPG#Z&P5-0[S.LGRJ#LGU6N0=EE
MGI=C=!/]@33C!'\FTKX/JBCP_*/O2S74L@&:Y)P+4H3D,I! Y\/0Y96;2X]E
M9Y>LUN&N?@Q5$O-9YC*?*]P<NBFZ1AT0IS73@&!TJD.S%-K]5%^5A B< T\0
M,J+F X;:#JH5&,OGW-^(J6(@CML;L;ZSCG8V5FN^G3T3J[<8/G,'*]F<)[K
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M!TP=3BGEU-$LCTQ%W5%R[2K$7&LF7<;(]ER7M/[=":+]<\5L,OW&$-&$1<,
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M(\M!$<&<W>YD M/&>.5?00,P[HI/W$\@FSX#726%+@]/W:HH<UV&>83Y);/
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MS]BR+GW!+,V5-Q>A8U^'C_#R1SB?QX.BNE=CH?%M.7&3W#;<'FM\UA\H)IQ
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MG[$;-==>\9+^)\)S2)L8-^WH0=9;P4P&I7Z<<:[M=OM>OR#8'4/X486@GW
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M#EP\769\+O.T=K6]?,^!=,>Z8)+%"CET*] W>6T9,.OH&)ZB-8,-%39UG#3
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M.;(NMV;"6WU7CT,P$T&=T(5]]!IKDJCLM',\G@_ >]&EY%N5VWRP$B4>%4<
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M0]:JT7')Y$\@'T?(4D+&MA8][AO*E9.7^,UVS*4(AE'@/:\#DXM _:XM92I
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MZL#X<CIFY(O-2NK[T=!=K,0W3.?&I^5]M>:22K>9%EV1(,2^KU21YN\$>=W
MJ'*@GFR.1"KP\"'DD+QM,?)[+_/04[QJD*:-].L@OZR;G&S=MD>Q:V9L]ZL
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M"'7IEG-Z'+4DN.(3=X;I$HW&1NN,KRW&<E8C6:<-.ZK'<80H6_<J/U!<>#0
MF>8Y;I=)BC8.#7S@202?-+GIBX9.P3YZW#(?[8\7S'3'.DG28CV.][*BHHT
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M'0K;(Y2%#,D!T%<24I1/RUY&>U'#LH9^6W*@ZO.;]#LOQ\V7+MI![,]"5O+
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M'SA9\ER/<_A&!7_C#HC](',VLM]%G1Q&3ICB8,[V^WVN ;+RZ2C?KH<8*A7
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M+3X+C,'E^L1[^($E'&RL1DY]D+;_R$XPA!?BB$+R$$FEGO*R?^1Q-L#1U&-
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MX!W"WQD:2%G4ZBB;DT]^RD#$^D.38CO^+L9L^7+[\9 \?\2?%3\_1A^:F;-
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M#J1_%SH]54<-XJ,3%N<5L^@#G%?F>@=VGHM<.OC"VCJ_06:O[L2.'GI5*5/
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M4I-5>$33%2\T:'-L. Y^]#ASI\@ ZD&KHJS$5UB0COA$][.@#6)7'B+>P"1
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MT(H6Q#B./LU2XJ!6[[NKG>98""]O0-9 _!ORH,<7LWY^-M&[N3F2M/SCP/=
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MDX L"0YR9'"/,)?!S'J$T+:0DS9X562Y9)/)*A3F&HV<9-7M'<1+0FVT&@M
M[&YP,K**^S44VTNI9\^#$_)_FYBUTYP'&$DF*G"A3)]V"A8]?B3(X*X/^P6R
M$B<WZ^34;&P9&-N^ET8=;/SXVGI6@JS4DQZ*-NGD F!A<$&;-5^3MA7,N7^;
M1H:P,@).0Z[=7?$]2G0]70_1=CE()?D(PB)&[[K<R^13=AH?O+J6A"KD2]Q(
M#ICIV8;?/X"+R[37?24R]J\_Q4^XG"U6;7A_>*BZ*D:^O$2^$;Q<JN<#G?_
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MP#X2=+SK5TG4B\:!))N@X-" A!-9)#NOM(KO.+?J@/R0;:_5/]35'Y@';QC
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M($O#&(B+%'?OI!(3GP:C\.1T6(FI.X22TX=^[CCKHQ<0-B:8DG/R0Y<I,0+
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MY,DR% HMR3>&OZ0O(AKA+O[VRGQ6%4G'$=L*[FV^G'FBZ_X8\)[I_7OV9;8
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M>\7CDE[9WH9-#4G19$<> 3KPJ);FH$O^37!\L5-"%WB6VCOADL):I2*,]LD
MSWB!9Z(-<2[\1WD%%,8_,$E=0PKPE\]EIT6&+FKR.>I[)_++*N**$)_J.S[]
MYY=DNF_Y_=^/ALQ"4@@/_X$[ET1KR#.7T1KQLZ"HIL&YLM]A"UEFDC45&Z2B
ME/.Y"=+BTAH'W2?!':P:=J-NZ>__,G"NZ<M,*A[_-O!CLN#1^<Y[J>&+%_]
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MHE?#[06'C@<6!Q^-R!FZQK7^/A!%G(!]W^<\S+QZ31)E2LQ@=RQB+T2ZPL&
M^I?P'MG#0K2=-"_UB>[:W2B+;;!5Z%HB'\");>?"E;'>AZ/YS+2=,?Y43880
MKZMYQCFA)B99P/O1_PP*< ,F?Y.V10];#1^D@XF:*RJ:Z)C#P0)NL+^1?%Y&
M(6&-[5_=UG%'/K&]U7A%9B_PRP:AQ#LL/)'LP)2<ZJGJ>?@=%1JF^5] @(4L
MH!;\\O$J"PESRG@Y$$PXCVH"-[9DJ\8*5@I+3HR?%K&KIR:GX&V[AJW^'4F>
MD-YBZDZQ$_K]\PN#:WXFE6A>3DB8(9UDVP(2$3G-G+),_ZZ:4M"/9&L.JK!#
MI_ G1&'NU1=*HF+])M]?4YXP?L]$2>,C'A=?@9=0;] ,K9T*CD'>PE8+8-2-
MH_R!&%-.CB!DO,SC_<>?FHJ939,.6LQ3?#^1APY]:]<>,8)+[&1V,%M6@?U.
MQO(Y^(DI?IU7JSA-7[DX5K$+%?IV(&0ZBC^KJ07.QYDA-\ JG0:U):C<W*]#
M)TY\B?GN1,CO2!@9UV(&/*>N/TDVNSZ\<-.3Z_]]X)G2.-FS3)N!A$^[2=CC
M3KF1;T!Z]12]_R6,1OZ;#[68C\<AHA9S%GTHU=]N>_#9%%>F&-5MQ?C_W9S]
M\[_WQ@$:HK+%2JE23\'Q.64Z($MU^(>R\QMVGP8P<;VOID^DTTY-2E47DD48
MS30JW7ZQ4-K9%]RT36GR+PV/E&[;I9K&Y3X?!V,?M>V"4;&7BA^/Z4U$2"AQ
MER#1_TKVK.ZGJ@HFD4KX%EA_::M<?3Q$3XMA<QO!6>D:H"Q&B\D)H'N8J62U
MFL\GD-,B@":$-&9*6[0;W2@&K;8- V -V59670:,XT=UAN"Z:"WFYPZIXVP9
MOGZ'IZ:\J)<&3>/3P]G\-L^N$C &+W,!E5;21?54:%(NHKK8!P(RZEVT[V)I
M,SAW$*O%W'W2^ LH 4F S"6Z3+WZHE(TRESN$/U!8:\S,L*1B_T,TBQ#;0<\
M1!Z;*^/?Q/A>IEUCB?=?;$2>QF''7Q%W(]FH\:D%2<_B/TG9PBZ.,;857Q@-
MY3&!KQ,E?2NV_M1B]K]%1QN?U\?")RK9=KL.@'&*5#4%QWC7%J="3JHN<8>K
MUX#"B:()8>XW= CLV\LE6LQOKXY'^_<C@$BU!O^?@L7="-1B<#U,4>6)ESW@
M+VH[:.6S30E3\)E:#%WJ'<;^?HW;RBFCX*<:?X&Y$=MFQ&K 22WF)> ,-U_Z
M+PM>)(@98&LQE^UU#<"OU'SD..6_Y/E7$#C"%%(YNU A'U=\X?^4A/WS_]0U
MQM(=[+:5:^Y13-R_$R.]5D^9Y5O^>37L7SK+LE]/H*]XX*7R5AVO9!)8M)^Q
M-,\&IJ^/(,2RMUA0T:<L85;ND>;HSE'%MX0HQZ$7=(*[8#?)%*4^U6I].Q'S
MZ(AJ<I<-A$\%QG=^&D!!R\AGF/ZY/YE),)>V:V@-7P?Q-K&#(;Z.$J.(+N>(
M-0>4#%?XO2J2?3E&@Q41W.!M\N.LA*E<)]5\0,BA.[8YVIG0V -%_ZH<6D+>
M@VOC7@KA/,!CQX!CC": ES;[8Z7Z6C'05R+Q5!%YL> 4:XK^6?8/+3)(X35X
MT(()L#R*Q+ONV+FT67SQ/5%=U],S\6X,V2GWR@BTR!=2(65U#:NW9)?A/]T
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M7V K/D/5L?JT  $=<VI@ L7_Y33=F<*7Z$!Z-@E72[/40AZQR7(E:8+?1A4
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M$%*U&-D1IG(+L 08W=?-G)PFE*^<R7.::Z;%W"N0"9$F1U35>4;,4C)_:*2
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MNO">W.O/E\>*[WH^.M?WX_=?QUYX;PE_\+/(8/.A$ZO;O![X-!YD/;P+-T,
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M<Q-L9$6TI,(IX*\@8? [T[OX97R**4;W[AV)ZW89WU%KJ?AT]6%T>-43"7!
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M[NA)D,4K%T2/[\%!F5,V\''AY,3_+/D=]^_GU_]M'$]Q&3 H.=%+.00_B0E
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MNM1J/5H_BH!.JFO[X^$OA@7K=^\/O?+?FG5[K;:VW\EM3_%:FQG4LK8< "+
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MOZYXU$JO:^C+B:H#]\YW7DEU@ON[G>ZY\[UX^O5"M\-+V%2CMO9,)54SO5<
M(N@<^4W[>G=\<T9,6/T"O2H]Q_]B_K%-[8Y^84<1$WG22]ZR7$]^#')"/_QE
M]@+VQ93LTR+UL7V3[\,-XCSD4Z&*:&5,A\8&-@XB$S[U#&W.JUZQU 2$^34.
M("[]:('&T!%2!1(=I!Y1JX*&QJP35)1;$.W%0N*GPSL,$"T\:\X^E .OC*^
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M-3,T\>:(T)9,/W_9K7+LPL4ALDJ9=^"_O$2A(<4E;T<NM]*%I;";>$\O#4(
M=\+DT!2?(P">]C62G03 H23\\UR)-,/$H2F^AJTWLSQ6"0Y6T+A[$7E1WZG/
M:U=A3)"4])<%"TI.5E6-D]&Q$CT_O:A,KV<3)=&NSS(/S/A5-]RQ5.W^YOZ[
MH?]3S-P[G$'2IM=#(C&\OJU\_2:=(O,3"2<5'F%9OH;2O6FI>BXC^,LZ:_7Q
MR6_L*K]^;O\L_?&Z%&_79[S0:0G7BTB U$]U8/:AP@ O!%T9(0[DSKD2AJ99
MKOG;-JW-%W^4#GK/#.UQ^-TUU/D[?29G1NR2S1K@)30QRU1,$'0L9QJ:# V
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M:P(M=XVT.'"F]AF1GMU4"3SE>JYJ[I;^YHH"NF/$YQ2OF'A[:LS<#2BB-PM
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MKOE1E5X[9+=</#A5[LN*O2X,NS72P)F7(P#=77EL!NN!J0$N=/FEZLH%M2.
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M0]P6]A\)_# N%'/U_JF.!7W*6T6N#09"JG[@]G5-Y7)(YGC*U1F)>SWZ3O_
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M0YS[SGD.4#Q6I JAR[%Z_"\GIIBO%OR*AF&\9J( ) _/%-*8VS*F@BL'1 A
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M])25QZ@L34VIS$Q-R<Q$179E:CE165IJ4IF9F9(YCY03E14.*0XI ID#(N"
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M[[=0N<8;5:17H;,C4^RIWTPEL56A3 E5H"6*J_R_.T5]IR$%!\K![[1*M)#
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M,C5FQ0I:SC^V,T9=(DWY[2[P/0S@YQI/R/Z^F3/FQAH#I]28-Z'HL\Z BKK
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MGYFGG2Q>N]+93#]/=^N1;45N?EL/;YE(=0URB(K(7J"\#'&:C:Q4,01]2"3
MW9I%,[>US.8NP4!DM F*#KN6D9+#=_8.,O&.L#SA\X=>Q_]\+V^_7Q6S.NPJ
MN'3'[!V[[ BTC$CQ'* */@ >8DB/2^)=J(=4V4%4"W+1&<H5W)WZ-?4VU\O]
MCIU[%TB]O&XY8^?*-C,,O@(7QY"RYWK5F ?)H:$B5-JHLD[<R-@L$M5\3ICT
M,&_-UH,N#X4+Y!NW?3E^*WBRW?F MSBW:.3W=+.Q7671J6W?7O-\MUFGJ58Z
M_:),TO,-6IE.49[ >0?ES1G@:,BQ@'\6,<4CT]-MU^=@D-%=?Z,-O/@$WAZF
M)X%/A1:! 2@_G?]O\;2<W+-'C4GMO^^N2)\01?\68)<K0W/D\/R<!"[('"]7
M FC""C@L4#P:46AF R/24 8'-\)-8/I%(#=#".#PM J+DFWJ#))=-K$2_J,^
MPP2%XQ7[Y<FNTPCA6S;M Z$V^JI#U*EDIZ'L1SECD=;QT4)ED,VQCHGBB/!P
M5"%P:HS,7JQ HHL=NVI96 A#56-^??0S9=\G$+J0J&A0=<KG=.T4>7)=-JUQ
M+8W!F9T9\Z+#ZPDZG;G3DEHP*-]3C6D=SGU%?SNM0,,5)&J.I/)*BF)EBQV
M,QVUH#P0G(@V8Z]. _L.HH _\^NFP@WHHOZ?0_&TBS53(</I+%"A\)EJ/HU2
M9>H<202-(5'7Q*)^JQD ME#15:NBB6H,AJ68>8>P[5W!7V"W@C%#+!X=  DJ
MB\ZD;E1L6(,P./14<Y0'K]AX$FD'4\[.5! 6D-CZ\\A9I9^(,Z;9R(M-']2
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M:\?+C!M!#9C\/'!P'1D[SEH2QN=7ODAL6OW[:C$EL_'W:L*NB^<[#Y5\ 4\
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M]:;M1I'0[4/X^)MU74&SI@'M5:W^D;^K"D4>A\[UST6^OTD_:S(:*:Q=RR\
M%T'[&[)7O_\8WS"XMJ/4<Z>]SX$.%T<<\9$;_0S7AV2\)_3(]Q-G.(]:W:W"
M_6S"(\K\C,,C[/;4#*BR='>LQPW?]E%C;C2;MVU]D7#KO_=T8#. 2Y]IF]%I
M,1GB2]\%.J(N$LN14BDWH"B C(Z;+K+2:Q4T6DXC3>SG"Y"0,RO^&3%-4NUJ
M^C45F3W277].E8,/$1(Q%)>/U14WQ,?&(T=:&#'96EV'.CQ/8?F@'M2_OYUZ
MZ?2N?*+Y/K]KLD4[3/O_B-"9-0D#7&#1S,038#9\1X>-O$=4*3)6=LDB-@=[
M167[@D*G847Z&'8=_9C_)>;S![47:IJ9=9;NB+\:4\YJDA0C76I,:3.=H<88
ML8P(6\%Q?R9"0+.^$.,V358>VL__AD,C>8(E4YL$^H\J2'*O1T\'L0H0/NPX
MTLF=&:(]!#_^@S\7C157*2^=]N2=&:NP9I7&L^DS-2SE6BLU9MP^-.FZ@*57
M&_&6Y$U)$2A1CJ,G%CV-#N7Q9OZN7<I:^JZG:H]I?V]XT$QQ.RAWF)WEOJ[(
M>+BLQ_/T!P=S,CB&&F%:A%!SFGFE,TQB_+$Z7'6376$W,\+KSY@G*8DJQO2\
MVSOO &]B/)X.T"<N:XA;KH3,*"+=NGPIS-="5ZO-E.^[CC^,;FTY7.0;E.D:
M&13ZO?GCJ1,Q=7EZ^RI%FU[EKA;^?EA4*RY6Z/"Q_>%#%;>NX99\]!EZ&NC<
M?6TM[M_W=5VEB0X;G7](%&#P_7N[M'?M&3*\Z<Y: ?BWJC%W/'R;<-.:U27*
M($:_=MB.P-X9->9)XJPD 69,4_F_Y*-V*H=B.E4A2YA-MCD=KS0;!,5>N_HG
MRL'SM4JO$0U<*ZP*G*PL:=&VY*Q/8V\MB/L\_+!#'NR^9?5M/_>K5P^<9+Q+
MROM:FGDU;8H0WV"V9BC8\%N)GA\EH.KK9O-+::#WV_Q_ID=HWW<5;,W5-;[P
MZ.U]Q3Y9H/Q%?0=><TAE<HIQO*H";4>T#1>VT",N[44^=%FU?R_C5LAQTE^_
MWQ,6(0.DE32C,44S'=X$]I$":I6Z\HH>-:8D#)BHG8-9&B0&L!SV_+N$+]9O
M5+HY=S-+/[[J3?0RC7NV9GLY[?K\X74Z+82+>W97)HQ<NQ/F[+3S]-Y_D9>A
M*9'3=&]5X#1MX[>2E.V?KMA2%8\ \9DBE^"7_IV)K[->=F;>7IGZ('WW444Y
M+2:6?:7\@(!P[HDO1:_5^-L/M_?R(O?->PYLV_J/2TAB>^ZEPJ!QV@15"V7D
MVU3']S)<@F65I)3_:L##P%!%IT_4A?ZER$JZY?C<T(@'-LJ.-0:2?Q$?FUZC
M]BI\%-EH/+9'?.&5SV#G]EGQ?F2;%QG!LSJ!MNF4QTC56I5H]@6'G8H.L%T.
MQZZJO!)ALX%?(2F!4SW#1W>EI,UUEKVMWR1WFG'X3FB63EK;T<RW7IO*/[)K
MY%A(0*15X);)S#IF;@;P(TI.JM.G3_0K >_I1-8MQI+)*L,'5)UG(X;REMV2
MC\Q(9@;HDX]PE9N1KS; -$\>#5G_O(Z.V,J]J@A8-!:@,E^8Y=_@L&I#8>>A
M9M #%^<D2*L=G"F3%'!'6%]1P1%MVNF _CA3/%'_2]-<4/N?Z ANCCT3&4OM
MS["0:C7&6L29U\.C&NQCG@#.S 2J-M2&[4S\F&U1B5=E-B ;\(KD#>%L%-Q(
M=> #FP16(,MP_QM(T,)N*.=:JS'2!Y07GP8&!OU<U)A[W:P6XI0B)6K>+@Z7
MZ>4U,:,*MVFL"1"_GYJ@ .)<_F?$'&IML2]Z)'#6_;>]7IL2Z-1==E^PDB[^
MHTCD\P^NA[)IV1J-&*[>4!+]>P1SQ^7)VT!?=1"G%QR>ZF05.40K&*\H/5"9
M$+L&ZF_6U6?>F7 N:SF0WC/#F/];R%WG\PQ%5Z(-\@V5#7#&X/Y/-89!#>E1
MGN7^E'X/2^;#V[,7$:YU'NT;L.PNKQ?5T3?N;G34#;-^$'ZBQC,@6]7%.8O*
M[X-%A4&E#.A(J=B:AS#LA;+96444%_?JVYO&M]"M:&VPM!^%V5V3G?W962@I
MUS6'X;0MM=Q.M,/GGO= 5_M=?EA))FI,<6)PBJ_&6/"Y! 8C^-&,9BS+[ULH
M?S)&+DG(WMA.T!U%\"5JS'XE"4ZJCD/I[RPPG_[)87>67];Y^OADZB'!49,/
MPQ1#@4O6M@,'+1[F;6T^^-G]R(GCUYTNI)PIV?SQ[,_<F.&DO+=]P_3= P,%
M-B-1C Y->*4FLA@UE+]@52SHJT5H8>^'V*C!LA, 09BLI F0WE1C_/U!:3;8
MIKN?:S<1:8A8R0^,P*NGY::J-V8LOCLEE)_.EMS5Q4WIH]6(:O"PZRQS4F,F
MS!LK-=280M)-.0TK_0N0'J*GX*3QE )DQ0#P 2P=B478!=%TI8W^JYH7JKUP
MRL(Q]#RDP20TM&*-I;-)T_W1C).0@VP_77E+_NL"EKU6Q3)L]JT\0Y2GF'G8
MPMN);R88>0?F&:'Q7RU<6Z_<-<OO&XR:9^U6G):YP:OV?%!C5I:A5Z24_Z-Z
M&1QL68AKUM_\-'>0KLK,3S;Q:@<%46()7>1],Y\V0%H.GPL;4KD@:P=D7,\?
M>$TD<TCEZ?H]4Z[=,S>#5V.2:?>\*03VZ>Z@$8;J0.'O@BCD+@>.O[;_V327
M/F526=KIG.5!_3N*,>,)%$=31(SI9FKSN_N] ;7,"MAB0D5:-=SIEBON4N"R
MY&"%FSCJK5.0ZA%:]TD98LN15R19!MED17(;5X-2$FY%@+=-%_Q'+L(A&)9U
M6YKZ* V:+LZQ;_MGK'ZES9L((B.O#.-.1 :[<#3)$H2.O;N^^^RMA:8I='FC
MO*:FA@,]0:)K%#.29G 5LA/*'Q)Q[O ,+0MPL2!67+MO"*#KY_43/K?D"7C0
MT\#_@B"7<%NIQNR0Q"8TC^;T=<].$5],32\E=DLSR^;F/)"EJL=<UM [GN&&
M+NIQOB<V%M2TY*VB>$\[*7'RBKM63YW^974HZ. 8Q)WZJ'2B.D#)0T]=V#@=
M*TX*HM\)\/V@QF8CRQ*I/#5'C?GJXO7?1S^SBDMW-MV_$<(^WI_*R$%VT]H]
M7J/]<PO$4$(;(S<W%X[(NWX7R@'H"1UZH,9\TNT)%:DLYHG*0U2:+)UM/@%"
M1\U3<D.>@<_=50\X2AL9P&'514*7ZP'WD.N'"]S[I\$</-5[B[.W1"+)FYT"
MS@-#J179&&[].AA;+\/16>7()G_0 &^NQJS(K"$JDE=*>G!%(2V!JC/K-;YH
M:M@Z1!? :"</9=5;<?$KE7XT5"AZ783$+@*>:OZ^MI2#BMBB5S?I:';.XBK]
M&I$WV+Q9'?$YJ1ISJK/[\V5F75D%'[I$63'W=+!ZELM\VFIY_$"X^W72E5NI
M&FVTDZ4N&K\X_5O(QOP_''8+S9?2X3NHO8\D(3KSOB-@)SBMQE#=QO+$S;]1
M'7Y"_Z3&/&]M7&NOQA1TEW"S_/0X_$'6E@EX/E>EFNNM0L6+,]U"T9-XLGV'
MYW.RVF0G;7B]USM[>-$90J4/>B'HU[WT2C5&=!T)&U;,P69/?4Y6W%HT,[#2
M4>FG7Y;[.SD_1/*<WCDCGR!L0H>QV> U\;DHC6L?EZY*CY([.0VR>FPE(C;$
M_3;'6%GKN+1<>GJ<Y5_!@:.]>L-$6;@B3<.4/2G>&UB^<^93)(>]BOTM;3V-
MYW*@@F2;8](Z!GS43&P._')X(^]&K:098.O]NA#)_818R^+B!<Y^IV]%B3(#
MHT]PG)272D>8EVE>]KA0QR3\X=S CC&Y_>\"85!@@QIS68VYV_PJU2\'].>-
M4<%/6#6F._#>>\A'4T&HRJ6$-E=XV'BV.G@F$_.$/#@%H19K<Z(9X+2]-N\#
M;9L4N%%*7N;O:@WTN1&V?OO_Z'K[>*C2_X]_NA72)'<ASI:DDF:%;!ES*EMJ
MK6:[5<1LV4+2;$FF.LU)8MS/=FM3F4IE2TPE;&$&,\QV.VYB0IF["B'GA'&8
M,V=^Q^?W_?WY^^,\YO$8'EPW[_?[]7Q=YYSKNO+X_UT/&=\)?R(]_W )JQZT
MH3W]N+5+5B<^T!+W[6']8+N'USTB_QG.*7&62_Z,^)IW#FB/\'A62\H&\[&1
M(N,5SH,W\_+7GYI^#0'VO"L3#+#ZB\*M)/]K:H!#!7YN:.PTN&+:7I[4K]K9
ML.V;8H?A^*1C@ U'\YVFE-\_22UA,N7-U:S *G1>^U#WL^%1><N[2%2X"U$D
M#_M/IRW P@Z&PT(MGQ#%/LJ+,YLK/A(9AX_UOD]T_J#@Y,N;B,#.B1-3:!5S
M18O-^_A/YT TN<CG6T$A4ZAFK8?<6X@%[?A60X$;FAEKH;9@RB*L*['0A*!2
MN!"N^XGKR#GAH^Q?8_J^4%I4S.-_<9D6YK=1:&,X%U5Q"=KT?<%[,1KT2:?B
M)+LM3'@A[Z$*G^)>J!N_C)\A>+J3K_EW.3.5[J45F,>P9CD,KG?8"\^*!2SH
MJXK["C>TUM"$?&R3XZX#/U#=#Z;NIX3PKW?LCMA7\GQY_B\-5$/?))35)?XP
M"-.V]9JY#T76@A57'FMI\_;@M!82,H#.*3^CH:$<K51D+4(3)4YNDJ[)*)Q4
M1;5+N[A1L0^5YKM?E'39,U:@&[+R'1!V*K37-Z4J=N')41X]FFXW\5#YF^,"
M#XQ)F#W3PFEBBI%R0&S'<=2Q6UP,=\"#[(Y36G'_"V1(!62*EJ\OY,2N16G]
M?45X*,NIC^&-W54/6F!%AY/5 BJ^I/77)QB[5G$'JPA%<,N%L>ZK"?;,"AN?
M;Q6N^Y\\WU34QUY(:-^#1WN$W0X*POPU?8MJMV@)QURWO[H-7X*$J05)A#NW
MX_AXKE2[5\,\,\[,)E9@@ZJL#KNSQXZH=YO4WXB7Y/^ V&5#P7^^IEM?X 0$
M9+FX2A]U?V X&2FU>URQI!)\+6++1]9M9"R@.O5&4+$EZH\A,K@]N"1F$VFG
MYD4[^[8Q? Z.*U,NX0M)--]!0L44FG3080E97>MY9R$8:9TMS(:V_U5T8I''
MHHYF1>=+%5<SEMR"DV4,SB^\.C"QH%?TG4>8D9DU;1)*[6=I6.W7:@A;A$JF
MGWT?\'09^4$#(C Q^I5V)F(RTG89":KI",Q)>/<O.G'PF:V) @]U(VJ0/^+F
M4)^N6/$T3>Q;QYI-UE*1J>HJ8]97'5CJ4U:2@E)UNS%[_=98YYE8+JI<A\7I
MUWYU1\6:G&JD: ,6B02I#XO59P1SB1\XT3V%TGYJ)@2015>0;,HYMW6V9"9C
M=Z:THFB3WZ&R<I+=#=,[>HJ'GAFFXS\C*84YN)U&;*+\Y=  %'3S:VC AT=;
M/:8^_B7SGSD_;I#]<2G_SM+NL\'<0S'*&3[\=-*J^J8P%L6"UF#T-=@ZECL'
MZ98,9ADIDQ,\6"$MX &Y62]@GB#16$35CSN?@;Q*B3FL#.[\IF..'%_.RP!:
M<H+8,I?Q1];2[E3Q87D6: M'BS/S33 7_<J8"%?##?$!9N;)J%IQA[FV,%OD
MT\N:-6+PDYG?CF:L0FNQ<*2^RDL[MRJQ %J*#*8=B]0&HLPLNKGKRU+:&6G?
MX7#N;6RM?A\T#?N(\*4 0*=JPH]WJN2IWJ=#I(EB*RA&Q7* 5B)E1DK2L?#9
M?4\X?>O:&/.QR+HB#8WB9.+LRK+D'-QT.V?A3,_<P)%'-J5T?A^VQT>IN^,Z
MS9UU8<7.2_LZC@=[7 SZ+^1Y^(7.)\.#/:?W.NRC_ZZ=-R3S/R)S<<83W^SJ
M@I_#<G4_O!3?C"62P7'=<$/T W08:[_;J?RZ$YA$.$*V$U_U,%95(7;28IK&
M-P=*T/^,*60,$R1$DFVB/E"M[L%#-/90Z',[W@@YOK[G< ]W3*@_:3KY2>#B
MW,XJ4GFF'3,D5]FH 5..8C=66IQ)M8\&YE0%WNT9#ZE3IN?_@%Z^<A4)D@)(
M"AX6'E_K#"#5LG1H-=>VKRL:_0_]>;9OJOW"H6L6\QZ=8+7_W:"4)9[POCW^
MM:N37=+6IG-2[(#]2D<<,O"SB!RW\5/UD[,>([# OGQI WA*<ZX+]RUA@MD\
MQ#V;JJ)0H($,CF4"9^ZD:('3L0-(R!G<]R9'(&6XGL?!1>(?R+PZL*3 V;JQ
M2I._+WD70?+$60GWS1!6M)M,F+#BH(;14?%C7@8I!^ T:%L;W0==_4IUNCNU
MBDY?MZ\19VF#IZ@5&0F#,WVJ.IQ+B!47@@*=J9[ M*I(C97 -'OG[BQ%R/ZB
M4183FPQN%BW'-FMEK%DX4UTY?9=/YBO7:F3DP^N_'Z&,E,5MN&/18_;89TVP
MR\:+)C'LJQ2+O[@F"$W"ML/7&@J7$VXLZ  VHJ%.X]Q3U' 7H+S^7G2RO!^<
M(3+!"M1;DV[UBJANDO->G(OU+$LK8D[B:SG!5RL][_X&.5O%2UC(-GG[.J8U
M1,,BM<STXRL%LZL28I&CDIW/D-%D8@%V40VF<!=#?R(E%[7,%.6L,F&&A_H/
M1);J,VB;?< >IZJ5MA^P;?6*\N9HRW*!^;]4!2$GI6LK^+Y/=QV[9E?+/VND
M6 ]"0=JKN*^&9=F[,I$[G?RSU32I RL)VD<WT5Y!(JHU;#/LE(18>+$V_X>W
MR9H1I&IHDSKH2KUD[MM/@S4[7G^O6AZ9(EFW?-7#""1X_>[[NU_2SI>=SGO>
M$O[;-[RU0ED)KEG@O#V<%/Y&(R4?3RBRWA(QO3JQKT^!SOZ_3<LF#<D')J$A
MV[$@M7AZ7][FB_>^^CHOQ,H02<W4KR&<('^P@?!NHO\T_F3.VH^6K1OW7K^Y
M=+46V!B7B?.)!M$Q[#-JLAZ+),OOC*_CRM2;Z/J2"C1(G7MFX%#4QLGM7T4_
MH269MWK&FY3S;O(M*M-W93\YO&-,]EHXS+Z4+[AII)@96*EY5[:M/;U[ZR_;
M^L>NE7V\UMSY,7145'@YO?GITR^=G\6YK,9GZ[G;N.\F]FZ5IXI+J0/A^A^Y
M+PK5BBR&"Z;0I6,I*MH4+%/:Y2AJ]OXX1?4K;#-R@QV A3WD? U/F'F6Z1 T
M\<"X[SFZ+R5GMRPUP5"?]8M[JYC-[ P=U"U%A+79(>LP_W_P8R1TP]E=M@9!
MU115L9<L?R86,@/=^4RE!+!!?=@>5,S?SY><M$TVX>%3BNU.;#",68H23W!?
MW!]K0J,(BUMD5AS&]V,"%- HLY<;*=%J+9#!\$+94JIE^7DT_>E'%[*D.GP=
M%,8V1X^OP&*N?* 7F-V]NW_=JJA9]]4G>;B#!VF8KK:69(_TB\N"/LS;SY/]
ME(;[XN R?S19YJ-_=H=H[@@\!T8YN>@R#/>?%EOI=K78_=J20$U;'9A#1F>@
M=#4H.>%S([HG=,%7DOJ'367G1@JK8KPO6N<[/[OPDS+TYTAW N'(4DBE>J!$
M-L,.L5UFB/@<? @^P_@!I4K!M*/0$B3G\EZ4&A@7&('V;SN;-S5FV>.%1Y73
M023-[^F?6'/(+MS.1S.I<AHOYJ.[__'P\4,F)(>N,R<;_Q=AI R$&"F\-AJ1
M6%;JBSOXD-]>OT);_$:_X_<H <9:%H\!YDDO1@9D-OHH_7QN6P<X<,1DP [D
MX8"&.C6,^U90QFI@MK-VK6[5G><2RU&W6HNP 'XHFI]BR+HU/5D37W(K8]7:
MRY-M7$X]9M\01].PI4P)ZPQ<P:P!WB?OQ-A:YIR#@#VHGMJ"AZ.9FRJ;Q.KI
MF*<&R R5YSRE)N69Y.R0IGJ<TLC3JJ8]#%3UY)J[;'#ZRW9I9=+8:2-E-GG5
MNH#=6MU](T726@ /5?XCUE %V,*H4_R.(M*\[_P+'+V>1^3<Q5ZH;+!7=C61
M)4NP^[Z2)/2@LBYV[X-XE:6F'F'IQEIWL *,E//9*?^>X3\]7/O]JMEK> %,
MTCCF(3LK<L?$JGZ6-1A%2Q.7=M<*.MQW&@J/L<ZRG*$PK3@UX@?$-\V'V;Z!
MZ12$;@6=HKN<%<P,AK-!((DP0=W2MG/N63Q\OBQ#*!@^2TM4M[0P7]8F'A\L
M^J@,&?HP))\$USX1([_"O(AYY8B0YPUGKWOYCK_BJUZS(?<T?+J21*=8/T[P
MU!KGZ:UK0JX+?_D&:YR8F%LBKH<.DQW/O@L/T5AQ3%*KUI"1#0LE>C#SN)%2
M!M>^8:JK!W-&6+R\P*RG3)OU&B>7W6A#\NU.#H_5="SI]OJ%'4.<(,GS1ZA=
MUH7W07;G-(Z#,W]=\,>H,DWPU$CI'T6*5+H;:*>,98O;WX0<%(>J/!+4\K0I
MNX.W2?(7,9V\36K-5?H;-M^8:8+ZOUZ98\'02L6<KB+3FUD#<06CPM/LZI%G
M>YK+GMVX\O+;JZ8(V>?M(')8@5MU.5_ $W#NPMZ ,<ZNX>Z6X:(5<&VE$F&>
MT'Q??@#3Q\?Q,=TSK/C9";<I HMD_F%XJ5[2 "!;Y._9-:.@>1P]3A^,>R 7
MH9AFNIN&F5I<$LLL]$V#?+3A!SP<)7F]5S1M:V]'1[BB5@'JGL/0#K+X?5HP
M<'C^"9<+<W:*^61:W8$?@77,# =^+4RZW3)Y#7\J]%M+F7[0HB_"#*7RC_G[
MA332?\EW3&YX<Z>O1[I>/<9,'5DK?(Z=O[5V9NKZCPO^^J#<(6&_<NPR@/]M
MWGKYTMTEKD\NW6D>KCP^MFN\5%UQQIN6 E,A"T1>]P7AG%(KSU7YJ.2SC)28
M+L:M^TZ 9'QU=.BZK]\OAUR^,N/\;L6D?+K&.SB]9V0,%R/;J.]-N598E/:N
M8B .":6>8_BT5NU0"V=@7P<;?HSIV"S6\"?+#,5:IFG,_,M.Y(^*XHK=4JY,
M1W\YM_BOTL6)ZD#<^IH:3!/Y$R\BIF)1Q9BCAEHC[LA5^0YXH-\D.EXSE'B
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M-J>P /Y?:S;M^$PJ?CPG/0E$G@[O.5*+M)6VD+]KZB:DM]F&YW[(25:G5^T
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MV(FIHA67!LSVMG$&,I[\TK;I;EGQ@R>=E:PO)BVB1215V$!+*QE128QE![N
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M,TBBPYGZP-B0<7%MC*QA$%M2T1^G/["[O'1_\4&'=&RM?C5IAVBI>(PJ;E^
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M^)LU0.6[$&T@;M6G^_X4J]5[<E_"%H0+MYE!04<':M%,%15?].8!!I.*FI7
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M_]D?/9"0N *J1R0Z2\/?#&O(&_N(5-1U35$L/P9T!/O,$#'ZB.7HJ%3H"&W
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M(=;/=8V@7$/+43IREH3HO=D!@ ^?U/V)=1D%7CU7"Z6%>UIS(,E/8.WW2R3
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M=/:#TP=S?N!UB[ZG2=!.*,UO81HS N"C4RD!8-U, /RIJ!^[JD3C[9ID4@D
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MS-19A%K<WY3ZIB> X3XATH=,EV5U7W :NO9H^>!/YI@"\XEJ18],GJ6ZS=R
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MT@FL[]9 K#IT?DEY;1$R+GZ8TP#;[U(J_RLF6JS$9+OC)BB71Z7L<1 "_4$
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M29,18_:VZI)CY)046W2!)&BI]/[&D 4?J6T/-OQJ'Q&>$Q>")C]80Q( C 2
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M.[$P!PR0$>XUABU%;T>B($H*1-%-2&R@^5OO;/4A^3E!EBG/SM#U@IJ-U2N
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M8,3UG@2U650\@KA+7-/6/EV$GZ7XB;7%ZBQ5KCHT K><.M)-3VR(]W[W>D5
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M3"Z0S?=E,OD76F5LJZ6P 4:G2Q:4 0_L)R+DM3Z6D;_/32GP+?N=K*6V<L7
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MX41%]5,%6 $$,HR,+"^WK3(AC02)@["N'1^^]%*GOD SG@_!]J-[68/L51=
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MPZ^OB<7!;&G%!,\I#:*Z3]\+3S"ENE4><"XJ=?:T)KH7%MF!B)\.Z#:MKGL
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M\JGR+#+5<*A'B@AK%8JMI@H4:R-&_I%"U1Z3VQQ@?&(I\[6>#?."')0+>'3
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M>;;G^3KA_E8V=,Q>V0Z<'7&\C8M/5T6'Z3+9/:*)W40LA@9C#SJMB8,9'>\
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M4@_;/E.M6/Z167IZR;!#M;]K >*EA].3,'BAC0Q/6("]QK*-WC7A?=_&B0[
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MDC'BJ-N"4S/6@.8[D?YE03E?Q64=3UO;<N42R+Y G#50WF-C?!ET>(W$\$E
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M=N;SI_\@U%^O8M0A83,2X$W!;FB]X'(:?.66)T#K0*8@C^+$_/@X$FG-5K<
M3'?47K(+&==J'V0K70#AK$-:!;IQ5]F/C]YQM:ETD7B[L#7'$[Z<8O4(5C5
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MZ>O@\$?B.NJV!(D[P;<\NWZH9JI7'-1HZ'_Z>FU7FSUU70)V:,ABKL9&F70
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MJHT=K>4&%V#OL<[W// #E\JQNM5G[C<AMSE2!">UQMU,/Y&'W"4RG$:.T^V
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ML\B62)R[<C FG&060+9HK+0)L#(6A.71&4@Y$H.M; AS4;JB!^$1/+@O6E8
M+)3?H<"*?+EI!F 2UD%<C"VA8N^(N.@0_3VR>X.DV@ 8J=R$EZ"IJ+.(.]D
MG AN?Q GV0UMQ9]OPEV6D%37B5.!!(J.@$FW<A _^WQ%L)JCSRV$/C)V(RD/
MKD"343/DI<3-V9NW<&QC:0K_2A'E&XC6 RJ=!$X@?B$N'ON.'H'- ?O)V$RB
M(OG,B[N$GJ_HX($[VLQ?78@,*GD2^*K38J6E9%Z\!")\HF\^@,1$BN3>-5!;
MFLUCY98Q!I'/(/#1_1A>=>.E5FFW=#>P;%2Z":UP+F4=F6?[TQA:>.H%FHZ#
M/>DO1O60MGFQ">&1+U3[1?+"F<VUJHC&^9J?[AB-\ME3>SO#!%T:54L<T1B
M5G0SRW7QBCP&A0IC'\/2E KBO@NTJS NG?H9BL?HY"+X,YQG$LH;.4IMX#XG
M:58+QV[]/<XES/5+]\;VXJRD8\])]\'WU#_W;C/OF4^,YRH.0)J5U!E0_[96
M<$1#O4W^NCW71$5^>)MNFE3+O;2Y%#8.ZOYMHXFWA R_3D;O8VUQ6#0K#@VN
MPQ5"!<YCW@S6R(?TL__=1\4!*)^0.9RN.T:D2#UOCK(XPX[_[AAD-SC<PB"X
M.+0C%P_PCEE:R)&CS\3X&O3A;)5)E:9\<'K?K"AZ(DY?9%)PCSXZ2O#W;L(
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M)=B)/:!3>)T95.7)#;GC-JK E?R\>@'&)%OV?-JLQ5%,!=#U^TV[7!<>._9
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M,VJ:8"H2A)PAES>&^QZ>YE'/_%';%K"CI-3JR/4]66JB1 \I_"''E3J8#DA
M"O3*>XGT!R9A7K7*2%%K,H.O[70#O-(S(W:E4*/-37*FIW2:]PIZ4PS>K+KH
M[X48OQJ>@8_*CF2U")ZS%C:8EH_#.]OGDV(7B(Y=PA":G<K\R++HD_;=G'<B
MZ6 EYX(XCU_!/I=ADR$RF/F5-88ZQKSVKKP@C=WXG&V%85,=-\P/LIT[?]^R
M!<Q9;Z=."L&[2J,RI94;^P$'^L$*G@/HRYQHEE_(&]J,R$H^.0,+D:;;NZN\
M+S"=0X\[YK36>ME51=> N;S\=_/Q-<?>![I>_LTK!MHE9#T5>T8S2'/WS(EG
MK]D5BV/=PD^(-?!QI",+T(X(?#[RN.R,[3P *PGX4NIXQ2K6U!E(<W%&7%:G
MCQBG(U*/I$Z;2#P'  UV2>5=%4V[)YWX6ZW[6TT9O%XI/G_HP4"Z716G'WH[
MX* ;%>NV7'><VV^DN/R/G*]*J=3)G[TM6/*=J"K#LJQIZ6<0T_U#._P4:#WK
MAK?^'/,'95MRGN2U^^["O"*ROD#9?D^[/$J"]BYQ(.W0=U"_-<!"6F-]U+L'
M#HW'O$&J[M!QTLA%;PL8%P!< +;5RY@4F^:A/)*7U:Z8D?HTSTB91N\IBRA'
M5&XU9P%W3F&%?$"P>=0JARE=(H9R&]4<^XW_BV$=<=_)*\2#?%E*OGYK^IHV
M2WXE.9^52<Y'<FGHH8/%&?]C[E?MC9FYE/5:"X]O]O=K P S!2WL1MZ5@CM0
M@RH52^/X8! YQOM.EP^?C73DS' 6$CD>(B3(RX%PZ$%:=ALI>W$_/9EQ(ZGI
M[=</^BQ8_O=.[&B;Z5RB0>X93JE"I$TY3@]Y5P/V2^F]U*<'63-+2TKR&Y /
MWQ+@]N9RWY).."B!Y3Z.S0/BT_#$OE*/^XH(VFH1;[Y\YQ/51#GNM1A^],0+
M20H09P<(4\F[M&7NDEIX.L;XB<<3LAI"5'$_D?PG)4U.Z<Y;4;*B(8JLM$TO
MWA=X)T27 "JY[F!^>R>-&B<H@E7A,!W[CF"CT0]*IEG;'DX)F+Z]*/5:JIM_
M\LLES#KFCMF*R(W<OWJ:]!I1-K>3-1ZC!;DJV.*D"+V*= U[SX)V,MW>GEEQ
M4/U)U#NCD'-8@(9RYZ&F)2ZW 2BA4'29E!D\C10SET"Q6]1+?4!7MQ5<?EWR
M/_JQV'O0S^W'A/-T$7V=(8,9-JH PVA0]VY\M-F:S^H7'?;7][['6U=V4'M_
M7'M@E2)0Z*OIO2V^99@;:/",O"\PN!OL*S.F"I$"QV.98#J_"/C%$#5(%FES
M(.6;]F6 :5?JN5KOLV2#) 8>6+LRZN'$E>0ZSCM8Y=H)7UM=S:)7*G,A?>()
M>6^ZH$N8?<_FOI&"+WH&RPL$Y.A@,+<9VP%;%RRY(DHXT-JF=M,3N?*+@(]S
MIA@I[HN"B</CN6[%00*1C;.V1D5>S(QD5%YS@<#OYI4Z/ A.;6(?O!A ?I?:
M!T@#U!J71[X7_/2Q#PYVL ;JR%+<['.XH$R4Z(A.:S^X*J)8H-U/WC,]A@*9
M7&>D<"0B"UTHP.)K#GX@>N8NIN-4\3^:$]_#RI6[C!2K!-F!75P\P+,O1<<F
MYRZT)\_/1#J6&2GS-)G^1%[I,2Y2L>5+TD)YM0 ]?XBLCM)ZNA)Q5M_4QX#Z
M\C##WE:M?8Y=C%F:YZIG@ AQ@V0;0'K_I0/R3\Y=C8?T\T+CCX89B% N,=HI
MXTPX3C439JT'UY,K)F.Z$6Q-$UKSS/OB+@C(A*3??)RTV>]-ZM;W7%?5HL&#
M2S?P:GLTL(>$N.7J<:<M2K_CZNV#V89YAJE:86^J0(^ W_FZ-+-<2;_'7*\$
M4<?](J_T%B:(.UU8K!H>8 _Q>\#-NVD@?&)3C@)JGN;!J40F'^XYA'R  "9"
M'"#"$U-0V_>V=,FN QF.DF/O)@C-XR4\_^!?SJ=%YP:M]ELKWF!?<L+-.J?2
M>B-UEO4!^Q5Q'_\W/S.+L_BVMG!;24B8QNSGA#J9>,#D<;8ZMZ)NYES]<;VZ
M9KE(J*05< *IH4!E[9;KDI"?WOUG'R49<&]IU+;THJB/OYSH%7S[DWAI")/=
M+"T*F-E7.Y,/Z/%YQBU-0H^S,WX@M(?+T2_),%.\E/GT8FQ^]T88/0]^K>]=
M&$E?J04#^EBM+#%2Z%^C]:.?/C^\5:0)I-E'=#F\^N;V^8&?J1_RR4ESC93+
M!L-:(Z5YCLI#(0.UTH=DH1]3=&0OBT3*JP)A" U$0N-(.R@EZ0T*5/+0>TQ>
M #F 5L5@+M;OG!:T'523I4DZT^[*?%!Y=[,R=4U)IKU\NX1#&QD5-P9^6%2V
M\W8<9UI3.T"H6P;[3C 1+[->M$_BY>49=MRZV8QO;@B_Z-,')..9WW<>] !U
MK8L!,$JYC5OHSWJ)//D2:O:Y6L9+ 2ER1/NJ6Y3JK-UOVN^*?G"Z'10+3Y#U
MR_@XF$]?+<8N&K[I=$EX;H#.^D\! N"4IL\<R_8Q^#]\$.(_6[6*0X"83+6)
MV #4" )=H\H8%Z "RUZ)*E-[Z2QUG"+;7>EQJCHC97^$Q&'<OH/%)^L?'W?H
M+0MC3)0R)H]*_JV2^]?L&S&FC>_U:O6$E9';]PM50OT[4D9:=#V*Y&I=B>MX
MP/Z T(?=EHQ\5HJVMLS7HRD<ZJ'09G;:ELKA@57AMHTX*%?E>Q[($\JAL9I=
M/>%+G T.?,X[-*1$,'1?6Q"U6;T!@ XU.S=&/AO.[\-GM*@E?3TY@(3%\;[!
MEMP/N8*O4=9C3*9'!_><K-+E2(GDRNV)X[^W^A1OI(Q14+$?/!(*%SW]K</^
M\'<_L?]"6MVU#2I^[[P[D;._"YW8Q9NJ=#Z[Q&GYGY$GZ@P[53.R[P:GSK*%
M7)J*N,OLN4J6^@OS7\98'\\ZD1+&YZ;LY=WG>$&U'H5>3C"*Q/O/Q\)D@@2:
M):>&9H$=EGJ>4GIVM/5>%9]S=<I$*KP0HN0VN'A+/]%O<#:ZV[N.7*0Z RFO
M=9*3E">N=E#'M"I::K)OF[* O4O>J[\#+GGN^YA^M]C59O.RB3\N:K,-2UBO
MR?D9,6EIL3$=<'EMJ]M"D0?Y1@@73)>1[DPCI8*V&E]G?FFSUQWQKBYD!ES
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M3F"M[FW59[27;:!KK]F%Q/#*)E'OZUB0DMK$G@IBX6U7VKC4R;?O)#S5R2V
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MVBLYN\#1 <LX?7[ZY\647V04F^?7-G@Q),X].F6^7QX6KMI:#4_)92+A![,
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M[==H;TXZ_<#;C<@S.;<B*2"#4@RL2M)TR"3Z_[C&<\@&@"L98M-4SB-,2W6
M'Z:'G<K; !*I1<M0BW4-D\H"G$3O?H6[H #+[/<!N Q?]]S\#91/QU-,Q]6T
M,QOA@==<T><-+$OR5=@L'HVY%-+,;#1_9J0D+N4AM@GO3<@U;MC"[?7Y-KVG
MVN0G_^,I#$R KW[\HU+*CB/U\'DJPR^DTDA)1O1M*L;5D38*FFGDN#SG2]*^
M.$3K@&6_ V-=V4ZH! ]9/XX\!;"<1FK4H%X-@]J6H20=;KQ14#O\)YG#*;]W
M:YL>??79,<;-N^K2;OHMW_?=C/VE!@MY,_P)ND^ZCF+3F4F:9E-7@AIXP Q
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M D@ XN5_ZD\P5Z8J-G&ZRZB#J2=A!WQ/)")9H4I@Z*Q=M["WFDA[)93P\77
M2,G,5LGQ9-+DLHZ:7-:C+4X-$< U]<?_+3L[_J%QRG]>\YEN_6D8<;MY6<ZM
MCF4;^4EM0?HL-HN'X2J%(&OZCG&#.PH^/T2VF7>-3F42]O0N3M[! ';_2HUL
M3K3:'Y:%7@2,W)R+5*R1NGD;G#<#&/#KE>LA/-(&!*]1S,VVCN:E.5_)# +@
M8?Y&IP]"B2.X]RMH)FUJ).0O8K/Q[3*;T IO2^_4'1<"(PX2%P0$Y0F#7Q7
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MT[Y,THZCO(#-Z6!;34BE$'FW_UGH4;*@UE9M+G;O(4L 36!-12H*A<QC,IN
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MKKUI@'0O=[2Q^-Q?C&;2%T [SD/<B855@11,<UECU(_D1HK>\+<M Y^X/0P
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M23*.[^)K[D5(Y.Z&W6:2XBV$? <8GI,K0O-):N!/9[K>&_PCD;.= */(V:8
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ML. ))0:>9%DG,U 6U'JH+U:K+PSB]$29/;</.I(Z'FEEQN%9/B!):.LD-%"
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M$J3;>S#T2 3#%==VCW[:;_>$QI@K&FL/(]\]E)O365N?L)DW]E]<2(#2X76
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MD[-\]B[-HE&]A@I/]T&\&,<ZH,Z#,9DA-"_=:0]KF\-U'-Y=!\SW]+#]79(
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ML[W4!2YTFA-:Y(&?V#VA@>]Q-T --@;RM;B[8?/(_-L8_KZV>3,>':V.%_%
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M;#K*RL:C66EZRZ3F*<9:7BF.I'_K\@6K*!F-@!+6VYT85TTU;XR;@E?\8@&
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MJ!N HW"HY3VXXJ4Q>22MY1+H*0:47XPO(W^ YU"I:<72AMUZ37UL=9S$"^$
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MA]3) ?"IC:3&I%CO64T6\H%@_ OR07*Z;=I.)DS'2E??Z/,U];HIX<,&*8<
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MPY^+Z92KO9[TVOE3KEY@8*]<8:6;MP^BA9YFXS62MICE4O_*V'J'CASWYPB
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M;AI $X2Q5#)CT 3@[Z-'Y]6/W [O@@G\T=5I^.#4#S7??M<P5 6;O0IGH\E
M8_ 17PM>6UMI=:CK;W=M"Q?,31K%!#B/X6,X!_YFLW33:U$AEP=CL02SQ _U
M9(=11R,1@OH*32) P0B4:4;:W?C@'"TH4&Z\G@%=ME[J;ZY8H"OMQ$V]2:!"
MCM,$S0918U2^P.G64_'L&*D>;-]C'(S4%\2%#\,9T)XI@.-GY:!.)^T3U^D^
M+$N@8<]/Z-$T@R]J5Q08MKU^S#$2EV%7^"^3IJP'\C0A(%'@:+@]H_//B)A
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M9^1:;B_-7>/A,A"4):GCHL55!5W3V:<YD38URC;Z3)8?'PCY1T](?H^1FYY
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M[L=VIDLE<IP%](]$</\J/.]^93_"M"OLE+^<*!JE_RE!1-29_VL,?54,4HI
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MA.X-*?_&=*-23DY51<[F]4SG,=O(XXU.+34PO0RZ,EA0 6,ZJC* 1N=%/,.
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MJ+"C'Y+M%\/;84H&\O "/@3JJ?<MM5?A-P#P^?6= )Y9H:*X3J&=--)" ;]
M0KA1:PN^'*VAH0IL.F9%%F! R>R4=*I58&NIH(3KD2Z,8]?74T&/.=1M'CU<
M*K9Z_P[:/RML6D*!"$]N,.,U_@0XMNJ%\^M*D!C(ZY<M%-K[+>['5?7ER9VG
M8_\@%X3&NL::^J8IKTLS307-NJ@/=5,5@OEU-?5A /WPV;%9Z<I*M-(= _8X
M:H ([Z9 MDUN-ZMV"UM$<]#I7*:=[X"OT>+F>9H8&^=Y@5:'0R H3T.W3\\+
M@]'X.$/'S^7;,496_6+(PU0]7B\-*4*QH:Y7H"R_^'-GQYJ[!%2T6IU95%W-
M-[E&#>7!R>'9+GD(3[%Y(5W6MUBX1BX/V#V"FNDV_PG01@8_,@9!HU]953*^
MD'#6,^O4B+,SA;_SC3V;.RKX'?4Q#D?C&AF\GM75R-9_ Z @N.&C+D4)('Q&
M>0!X5ER3V!SK%,0Q"Y<HM?>;^^KBI6D[K)7UKB/W0GKM_41C>: R4YRDWJ9@
MXW[E?@.5QE/SH '(M3!F/&S=MS%'=W'-NO:(M#!9\H'[1FC/*X"'V-2#3@X\
M[/(=@1>O6 )M1WEW9JR[1J3ME^QA>1":CH_9E*:](<[<) >5)T@/719%T]9X
M!8F3*SX*X#C']<XS-?=_8)DJ\OLI6ZVV_#Q]-CNV+<93/39\*H\?+;B(4O7)
MT@]!HY".:.N:H;3GA2)X 2W*-+YBT4K@;^N:;P5:8=9'>R!^ME1TZ29-30I&
MHK56VFM75GI/SN"JDD3' !GA6<F7PLZ'SY2.^E,27@*DZD-QZ7H'G4Q[6X@I
M-T,JM7"+0]3F]>//\SE@BX6'+A$_!EF4/N#)$50!IEBEN3#X0QO5ADN5CID
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M:[K/0IDKS(R?YI9K7I_R%)/+H;Q(B4&[I/#,+</OGV<B/,!4\_8]Q7UKG!I
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M[?Z->RF848:M]QZGYH7!]&$:4W@Z[&3/,JHI:XCYKU^&$X^JJ_,OPBG-^:T
M5<>23@H-[A?959HF'NF80V3B]&,7:S!1-2H'6L);&:)&=B5\[EE\*8G)R621
MUN,AM9FZ]Q@5+!F=6H9SJX3CUCLMO7Q,4OH<9<T">79C86ZR/7@Y*S6V(GVZ
M+,>OAS?_D/OQ8CVX?-'5FJ;NW/+DOMY$,QJ*&4P2!/UDN4@6(8&=2SR GH]-
M\/Q]#!K*,:;$J,74)CLZC/'-V[7U$VLNM2WHNHR]+AV;:U9 '7 +HH8_:J)K
MY1)9]&/E"8?P_&]LP&!@D$(6!\MH,)Y!>\/#!6D>(N26:BXT%^?3,?5]"_%M
M)>J(3CU,G#?"'=\8]TDK12]>0>ON3?CG:4*ED]!5[8\W6N, /#>/&E^1^:&K
M$'H/"F=-$S37^UYUCBA2EENFI25G*[+PY[JU4[.4OK-(#B7QE"J<L^,=DH&T
MC[6UPP<#5E4LH@+!3+\7JT/J^41PB2>R(TU97'E^&R),#O)6YB[)?;]-NU=E
MT>9%A@IR<!23(9*.*AHS\126LI;"1_; K=P,N.L" HNK$ADY5(>@DYU.HANJ
MRW+)++PQY;FNLV23<K4,5*PI(<0'6$*/$NO60]*)=^((1T)BYU'/8%7>_-V4
M._K'<T[SU[XVHB)?SBOE!TAQT]+Q?LU2>0KAN0RK.BWZ8EE:7NJI]KS2^)YV
M[T&O#BWG)[N%?I\]5D*/^<.'2$89F"(%O59NV$#-JYVE7%\5V3M6-BC$%:8W
M"[(3@]=DM?Y3Z_ZZ2+^46T]OG_U.,>\V5/@&LZY-+Z2UK%2T&N'GN0UAB2E7
MQ>@<=K.NJ[B?DS ZM11Q#77*'/HKNL?FA&1&O 4W(P67D"72[,9 #,3:IP3'
MW&X+"R3+6%W8<*#VA/.X=+T#R[)DPP>$\\OITY@8[_&=.QG[/UETZBDO$;%%
MN*C&6+(6P01_%<P'Y\(A&!9A"]9-I!#O\IU:2UCH^(G)-\NR<2EO?$?CI)3K
M.,I^8(:)=RD/$NZS[\P]4C#F&W<!6'V+J($D2H.TRF'QW8,6DVW6%+?8ZL,C
M_8J4?1IE2W4#WF;B]?J)@U)O:4,.BYSG2L'!_G,/V";'L:U,HJL(TJV3;LC;
M0R*[P]L+ "?9;'6*5":99R\SGA)=MV^!.<D1SOHH':V 8+39M@#F0:$E6Z>B
M3?4UOTHYA%"^KL@0ER97?KRAYI$ 45/HN\?Z!X>8-F?@B\+7023G!-)O3-M)
M5""]N2#+*V1X0N$'1W\Y_),W-^,"1XB$TX)IN?GL^5EIMU?=W; 2IC_*;R(R
MVI@PV?%SBDPW"%,J8!8'4'K B#C.4&BT2',W;>B;I<3#JM<#A.S$>[I.N\]V
MG60F/^,)017F0YYX#93J1)4) 8&#D%G!CXC'W[Y8R<-2--64XE:7/'%!P_?J
M=J&Y#MS;%FH=Z0J;<H^SG#@KRZ*/@RXO^614K>8$\E1VE%52QD]1B4!OY:XO
MTM)77/7C[HC[>E4R*C^1N?(\*392Q[F[B,?BX%X?^<;FL0.:4%^=!IX[<F"Q
M@2$P2*ZT7C[&']=>!R-*8-KC&X.8L1U@V,[)=):D(]7^QK)%X.+ D*X@\ )
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M&)OPE.^&<>JBIB#=(S^=S!'EQL738#)SS,/PT+4>/BG2#![,"<VR2+-7F*$
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MU27.]$;V]]^L6K!LL 8^<>5K4,N4$N<R3^)18D3:W,5M&XW*55Y.%F"/]L_
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MXKL!PM\H6DZN = #&U%L"RRG*9%=+IG_'^4*"FBS]2@W/5V'2W'31><_'I:
M3,L087%?X,L^^JL.C'B50Y55\H0BODU1C'+3A7+KY_O>GTWT97%-@7(C\M74
MG7U7^O+ %EQJ,"%,LWU(_F;S,C^= YWH\XJ[PSLZHMVC''M@'X/UCTH[/E5O
M[(KZW4MAM2_>?\Q87O09^O[^Z_OY>UU/8^Z(7JNUP")YPW(3%&;J+%KK)J)1
MP9XM)0FV\]L2-';&^$NJF;PJKQZWOS>??>4OS49J7X4D7P 8-"3(CA> 2'MW
M!X8V7^B:^ 6 !DY#&A9)OCTFU-;Z!F,=>UY 5BR6BL+_-7ND!HDOFJQ$34,8
MH0R,C=['^KD?) 53O%"_1;H<YHIP&F4$30J-*FH'R9"ZV\//UB&XJR;=<WAS
MT=:S#,M_$R[NO\H4%TJF,))>?^;JF8D%\0J=1,/!/AV\TT [ 7'QZQ*XAF15
M5^;?D*0OT_DU0]>8N TUND9:AXK+=2W@HKJ]_XS?]HF(<:9(O"-MW&"FPJ^]
MA]Y.8MT93,$,1PZ=Z[-!&LKXCCNX/&_$OJ5C31/!@&N#M2Q3LX_<JT@DV6[>
MZ_?GA/.IWR%PL,5VZ>53VW>()P9X=$%$_Y'FYK*C*/;F3Y#BI% &9_U<3:5#
MF.+G>CI=A33WW,8E!BUAJ+Q/K@T<[ROZLL'RV?C"KK7B1H%WA;7GO,MT1NB-
MN9V7)\>UVR=.VG>CYW^)6L_['51^=GI_(I?!]2^4#*J&WULMN$(:M2;YK^VK
M09@HF(CK_U8]$ZXYWH; /68_G<&-1DO\\7T5P3<3P;G=(5H;FR"IC*,O8%=4
M1=5#U5'2W2]/IY8+CK?P45/B+/C@:#@UOIWI^#W!M\NA(66.#HMN0.]QX="7
MM59SJ\PG<$NC<8J0&PN6$6-*#O2^+[:=&E,PP#>#'V>A,WQ<^0I,^U9_7"=*
M1K.A2'A(;)1:38@]N]GG+Y-";ZV2'N._.'U^VF.6*98A^FP1_77)5KQ; KZV
M7Q1;P6F8DR[TL P5?2J\KE+I2ANYUO8KV2%[4&+8W9^>)$]C<[O[IRK2X_TS
MC^<J>^%\=Z)$\!D2C.$0,%PPNKKF]*_VM?90SD;-FSKRW0C=E\#D@B_SFHB2
M%:L=<XY+.<O'W1O<@[I3O$6!#,.M_?2%SW6T[^ZQ3:7CTE\'-*%CT(QM#(2"
M;B#XE08WS$:'X/9&X?J!P!A<^>-\%3*CM&1I\>1$'.I3'(L]R;+@D,M+_6T@
MF):I.&^QE9YOH9>+ OI7;W=-)W$9OG"VR C3T@MRIDTK+0FB,7TK<G=N0-:[
MA S-UKG$\U))U<S6VZM&I?)1P,Y<!KT4MTS%:S/7KQFRLW VN#ECM-R+>WG?
M%/RR\[2!&6XJ3U'F><ZJK$9:[@%4_T_6\?^OA.CT@M^>,O7\(RXK)*AE8Z.R
M)%77^*%(E+!-6%RA^_-HO+(YR_;)-]F&24E+5B2UJO% _<Z126()C:A6TX"D
M2MV\1VG.?Z-XPD"]Q#7'0#@]S4#XWY4T X6)_X;2/SW70&$>T7D!Z!N-!O^7
M;)7F4%\+-R1T)'P>/@.3-:==QMK<<"I/4J E7 =\.R</KKYGACBW&$"[. [?
M(B>&)YYD,]H<+^!2]G7.5$@QG3_@FA,1<J1+(%FAF(7-E@XB7[YSB"-?UYW,
MG.0/_FJ>[#F)=[*+:\(0=2$?/U7X7#W_C^G$CW4 MBX -2/UQ"O'KP@;%2$$
M/.0F3/_?:]V ZQ=YE!Z#KY*">W(^CWMU",#BW3.J%:JXNZPG3X.&9V)QNOQ:
MT?O54CK'H;:L%&\*[P6@ZT8;! ]AVP[^!R'$U0)6N,0,GZ3.(^*UN-*E77N!
MR1<V-37S[4D=N1*G[(4*#:.<!@\EC;R6OF<O1&F8(;1_JF;%= @]^QK4IHVW
MM;A.5'H051:)W83!J6=F6-<YW:6_2#RZE^1+LNDV2?P:W[8/TE+6KLR'FB:!
M-X?6+N%%HIL6PZ49FAQH>D'*2+SGVM=F1A$9*\1I19[3\V51W([:D?%W_Z#2
M;ZF%?.Z.GF)'^')I-S'D!>!,"]%E<Z#(8 R)0=2 WZ) )BB'D7GOLN0@;^&=
M_<V6]SD2,$BWD>#2RH!E=&/;Y'NS#BOV_AC% ?+E?R!A1IE U*,3)2.$(J8U
M)(AV7W9\>==(/OJ%Y;"=XQ%MY@1H9OB\].NZQ1MH-U/EIT4\U@MZ3>"."\"W
M33+SX&K?WEJ9]?\I[#NCFMJZM6.C1Q3I+0H"TJ4+1G(\2&^"TIN@E( 8:1(D
M!!7I[4B5+@:(U$A'"$0(19I(AX! $BST! 2V$L+'^=X[OG&_^^?^V&/LL7^L
MO>;:<S[S>=9:<^U%^()P"N2<,0=8K^?IXNRNF[AO#N@3@:0LU$S;*$DN^@66
MON9P4VYYVW*U+):\(4+,@KN_7=G;XU]E(7.<N%S% NW_IIT&Y[8>4Q-_?/6J
MO/-TKW-4%*TE*;4S_X4VK]R=+!&AW@_M.M<V%8<O3BO\,*CVL<%F6KT;SY<=
MLWB,=_:QSKB+&<Y&:G6+>B<2?W1H!8A0=!I6#2^\6#)+*T417@3F+!:>.]:P
MULD/5]OEMRVJX089\Y[#<=7L+8.4R-F\/59 \4 '>#2N3QN)^N4BS#;&WU([
M[K&CI,%.O0WNBVN<O3G1N%9V,7NGS,G&XY;5RZ[IK[9335.W]?W@"'!U@QS/
M%46J47$RZPEK=8X*UC<GL6\)A4%<?9!<RAJU7L%+1BRI>R+3$<AW>3J3L%MA
MO'"GW+;1I%%&IO&;UH,,ZR3KI,@W[Z^)\CN\+'XV^![IS,+)::'^>,9,7#Q%
M /QWA@W&(IF#=\4:>X9TU<Y_P,(Z,#_ARMN6E-KJ2=C"L2AU8AS>H/_WHJHW
M)Q.N_+^+F_[[^#M35[9O'L>,U6%+3?7-5V7 ;\JL,TY"2WJ"]YXJ[S]M*6&D
M0$.-W[NT(JI=(O04;F;M*4L-"8WSJB6IY.0T?/7H=%,L\?O"PO)]M$Z_O5^:
MTCF'LGR?SVP^#IM[&\'^EO\>^8MPG.^4R5V$0&W.CB7TRVLW<@W-BMS\P8I
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MP%H?Y_M*(PXJQ]>6&X$Z)Z^+WI>YAE.A6\:_;4VY96M]-O!QV*G3^?^P,4Y
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M&Y >S?YLU2SR4&\#RYC5CO,UUQ1XN_OY>]0X&]D[ZO$XQ:C*=9#%0Y_-SI_
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M=W6P=@).KGM85R)K*/2<^/W<;]Q'6%U1%RZF4!7PH[JQX^+?3*#Y4&*3'6R
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M7O:F1&I3]Y/<5X0V >O9ZOT?G--]\PJ6J\NAGL&,])3XEOFIM9;EJ8W?MD;
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M.JN\XB7EFP;(O$*'13N\^W#31"ZHR..^-/?L/Y@0LWB\+UH&84:3:LQ#Z-%
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M^A-R:&43Y<4TY,/@D$\9Z ?KQ<)XS=<<KI(]ZPX/T ]IAC+_'>-#Q$>?\B(
M%6PA;7>N1B7;KE0B>1(GFSM>387"4LZ-6E;-9C02??=VQ\!MG"K46.S,C>I4
MAA:MK]7'$Y8#/';3MW_B 0+,J7]!/I5WSN(KLI53&ZA94)4*<A?+S) ,:R*.
M"JO#?3"DB"GBH7<-Q_]Y+9/]>L+G]:&3,G<D#TK>4]MGJD\4VJS_GW%R58&S
M1!17YZ5E04'5E_GMD;&>;M1IESR-20YD\7?,/.)LL8MWDQ1MJA)^RF(2>FT
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MA>1'Q* 1-9ODT+S\M(K:'NCEE@?;7R@[V-2^>1RXEJ^*!&W_4]\I!Q@SG'3
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M4"+$XG#MP=SA+N=!I3)O)1@FW+ADM;'*N@IFL*@X?^&*^I7MFR.*->JW"_B
MZR[2? !,@!<[TWS VT.%A2P^@  Z%6[EOH&?$:8CJJ :Q=^H?\G2S4Y94CY'
M#\VZHG,LK0X?D3-YE,D92;XA^U^?5E_3R[C'BN)G-<U1AFMCM9)?\3;NB%J0
MQ+37RMN-)$G"(":Q]6%G&,4QX6/(7-FN31,V2/;QR#P6^0<DQ+D[%*Y\XS_M
M+/,4N 8?8);Z3AGT8)02 &0H\7!;N9'L^XLIMBNAR-AU)35IB&+XN--M4SZ
M]M.@/]4C"!KTO\%T%6F!V-BH<WXMNM MD9$-24VIT-RC#,.<9G966*W.J\Q?
M T.WV,JC9;3[&EDFWY_DU= JB( <^2U)@@9/FD$ 8]HRI"AOPEVAZ [9'%_%
M03JDP,F9FQHO/<.4I["V2-L(<P[8/YP/^.F6.=<U%S)L:8B$/[ETQOB>,O#
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MV@A[4QO_Y.<G6A]!E4L8J?D]XL2W&:K!A7;.ZV+K6N-A$"@W?_LD$@HZ/.7
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M(HPWB!S SQ(L+K.3,@/1$PF0<)M>/J FR@9_G _P (I-4 @ET%#4.T48YU)
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M8D1FXG6[DO +A:LG=@#7A?U5#<*^/X(3G;H-XK>I_49RK\ATQ-,Y3P1O]4@
M.&%@=4YX6.N07X2CDCP%YE/0.^X.3V=E1'C%)FG6*_/ /,<_:WB$C,(G!7]3
MY#K,*6&NF_5O_Q9I[&RA:Y_^B$;0#F"1T\7!HEKN>[WXQKM3C]:__I'6/1SB
MCOK4T+A23;K/\&<H+RGW)&'5;0*=3"]G591L.6!<2U9*.WI!1YM 7/%O)"69
M5M ^$T7N7O[5J<8;EDW/W$V[>0X\:^)^S3"W10YAMJ0\['#88T+!V<&W8>;Y
MUVZ-IB^I"DQ(DV/8I%%P.Y*K>O EHUNZ^D8TDBW3KI!5AG+J]89I5#+7HPT-
MH<5?BJN)-)2[/#EK*[7@J-4[L;$M4*?1##S %+SG )MN;.8FC"=1<H52H.IX
MJE"B"-T7&.Q=L-F:51=AK38&J_GB?JI\:%"0OFH&&!X=A>R*E<N_"J4TZ_[3
M89TQD2IW>*8,^$HM? R9%$6;V/9E>C9C;.QS9QUJ"Z)'^P*Y82';:1]>J87L
MG@./5L[=Q0D*$:KCBY=K)GPYVP<N^0\YT!>7UZ<^^2$?U=6"H)];%&TFO>V.
MJ:9_Q2 >=DUC]XQU_>J9EI9L ;V%1<QT8?W"=P"_-[-(_U.U/6UE*W%XPL7_
MI$Z?Y5N>1;GOM@>IU/UW#B53(?4=4M*5YC*NGJQJ<_'9/AKU37#YP6L=GAY>
M.X #6ZS$=586:-F0$<3?( R\]7#TP_2'PS3H$00/E^>.%L8Y=1,B]\JXP56<
M/I]ASSZ(FC*^ P6M0VIW ,V>OR)!CPA$XN7B)9<Y0>P"B M<?-YB%L;3@)M,
M3:48:05OOA[KUAI5UULY<5UZVWZF$ 2K8JL.8QL3!%=\@&RUHSST_]>' Z*G
MJ79@.2LO>2)!Z9^)Z"O<EP9BO9PS(:R(U-U6^ 4,47<'D' 3ZXBMW &\2_[[
M=],MTGC 4!UI[@O7NAPQ: )(MP"+...+:*>A]3*3GON<I"0+K26#]L+(L$@?
MS.P AR<T2DT\6"0"%-\=0*<CDS2B\'5@35 >2>)"W^P _N4BI]R06UE8>A_7
MI^\%9/V\-!\(+]X!9(<B6TQB3N\ BFXA)WEM0'Y#N47:W VA I8A+=C%E]\!
M/-L!'$*NKN*(&CQ3_C]L\10CM=)Q= (31_-L+0 .+)<OK7=CN1PB@5C3L .X
MV]@TB)?>2G)!*!BG"6Z"\*"HA"483^MA&M>FZ<#T"4'66AXOMF:;VK,#P.LO
M;?+4X?K-""![+I5_O-S/0YZ5G.%++9MDFKGEV@G;#4X*AM)*YZ/N>."RO;M=
MJFMJ!G!,$^U/==1/B:Y6KX\JA& -0L^C+VP,?JZX&:+/7(DX&CI6_9L*Q;S$
M9<!*TF&U PX>CP0 5CS:!#\%.; H?_';B>WVI\4+=1)B=R_VQ*)=:)V? TZT
M5RCO6?CK8_LRNKGI'-^30I1GF*=):N 4I-"<:X,:?+-?A4<6<E[H=SYBNEYG
M;34-+*FO+.D5AW4DXH%+M61<[KQ3@$%X?AE?DD5N]]!@)R2K\\5CV9(,^3B^
M&F8T!I36;"(Q8 2=5IX&[H>+K;E?=HBJ2S3Y^S?AR>?_*==U6640*!V@4)M%
MN*[0X%\XZE($1(V"OO8E1(%?:A"#0HK!#"VE$=.A(:$>^W)1& :>RJ"YX=_B
M9T8SJZ(MKIS%<NP@(U./E'K)UG-V#O7&3DNUSA915UPHRGH;EEX;SJ;^&K\S
M<S+3TQ_CT@-Z%U;*K5IM6VW#SN,HH\NY%J7DD8WE8/I^($/06_%QP86"GTEX
MKJ>V ZA5!)[\4W[EV T=%]JHAV:F^B,<I:K&W7M@)*O%>F"=>=GX?)UO?^<9
M87_V;W.&W.@OSN';!>.PJTKCB+P<X@X@5 C\82\I(@/K#7U@%;=I =E#Q9L^
M>'%EHF[P$S.45@:&QF+;YRSV1@V2%IEZ.X",5J&(,?K'@K\B#X4BC[5 ]?)W
M (FD*66VU% <D-\T3WA";>K N- $B2*?3?L<BR7S[)S#L"U8<?AS.Y9J.V@_
M/,MP&->:W<X9RGE32]!N^>"O8#%3@4[4->_^X*0U]HW ]GXK>"]OXUZ'9)\G
M0UI^@!>,ML&),=?9:FT&]N]JS*%I0'CW][6K!8'<PD7Y[ =+.X"^;#[B(;+3
M42"#C]'B/8*K?@.)\>_#&!9*BTYLE>=!8>CQQ='8QOXU'%)V9#XB"SE:FXU<
ME6YL$K;@*#B!$[*UW)_TZ#-H]1CY9K! @G^OI?_/#GO?4D^U"@)WM_UW8(2U
M^N.L/UQ]XX;BAKKJRL,B8/D@)]0VX#+,<#YD&?&?<)=7C/E4WP%VI5E<*]BD
M4_O8HXX357<.AA197G$I:\G21'S[KA!"PW_X*?P92A^+_C9:]\SH8NDP-W6?
M[A;Q+-HO^Z?_]]5K%F\;:145M(I\2CI]]*^;%5L'%.V^A2E[Q>=)QW%S.>^Y
MBE/<E17^;;9A,T<"77A9:)[4X*2:P,QVXMG3T/P7XGR$3QH*^3<5R;)!OFS2
MK/H9<Y@%GNQ%1V#4S=\W-7X,+.@#RT5)U Q8=%4WJG&8-\IXN[4N%Y[S?&VT
MUDJ7%L$3_>50,!1YS,@GLFS!45P@/R4?MTRJ+@_42ZN>)0N/]+C>;-H!_%,U
M^"@LD)LK968KI @I'?P[81;'1'Y1V%U5OP.0JP>#>K6;SC^H!\9=&E<*?)GJ
M&(=*0^?X#!-WMS,^]B-:)&U"M3=1EIE,9YIJ>252Y['C,?C+5MU+R1E2Z5-5
M^FC+!,ICV3E-7W**PD5XAZ7F!O5T=>7 *D5GNX;=P9>=YJARD47CW 0G+KEX
MPJ\6Z9NU8*'98E>_"EMB!JQH+I/(CT+I6T&X'<!KQ$',? D;\J00M_('+AD[
M@':I0 >N#V]OS&52MA#$-$O5N^X?.-<WIF%"+4$>W,M$<U+?"O)&*+B&L8T]
M2.]TTE$X4B@Q5L:WRKB5RUAYJ6>L9G9IK$6^)6T?Z(VG/A^A:.[:T!2FV+U2
MMTOXY"KEYCL*";]A ;$5#H**@ =(#_JD^>JL7PX@:2.% OG:S[47%PA9Q5#4
MB+]\.]F\?VE%<T4KK(%I:',F7V4P'<FPLR@RAO[6T2J)B!N7SXP^(+,#<.;6
MWEZ=#K*P_LZRB9C!R60/G7A(;?"QG%?F.3YK2AN'OK-J\3YAMJ%>_7S&/SV]
M93I;7\W*NL(:MV$^Y:[@4+75!VQ&CMZ81LT4)H-\@4I ICF=;G[V&Z&)\HBY
MHMN@;=)=(FC@F70+#)=R$!4BB4?BKH'8Y_66FZ0%N4)YN,D"E!L:J=?X#\,U
MTJN>>A;?])P)])(S$\@L@>9)J_-I3)E/R([\A*.;@?$(Q5K4A1NE\XX*M%_(
MQ8 S(H)P+ B:MMZ$K%GZ4Y0.- J9*DAH+9186M]'MAJ:)0\(US9)PYR(35MZ
M[ >1%NV@T-[W#9<C^[5 C/MHI+](/ R1<NJ[Y^7;C.Z_@KL%1%RP0X4=(*EG
MLC*WW <@CJANN70__;$JP>$,+C#K86VF29'Z -$VN'WU0=5^"95?N9:'R=X5
M/E#_&++"A]-G_*I."P:M.ZC\:>#4 *D"Q#VU'MXO_#YQ!J[DV%C/3<%TAQ^[
M_JME5QU.3D1S5/F-&,4W*L%&-7X9R7-;MFPQC-2OE_=]#CR>WPZM$].J21NW
M"*$RW9#JP%;JQOT=P)XKJ6/"XY!6G;:C*Z,01D!C8)!>\]YJK]HZO'9L84'@
M,\N^LEV=/ NT$?4G5]\#C]#\1L6>O]TM_BHS;RPSE^;^?7E[(Z)1B,R"]\<U
M>_&-727^P4&))B )^<YT1XH>JC+#AFQ7CIWAV36*_T1><#F'79+9NO;_SRUH
MB__O4HT23Z*>(/=K&XO_.N_[?L_7=>!KU)^+OLX][8,@*V2M_KH7)=UITW\3
M(&O]?V]!P"-76.*I?=CG(F5/O=$$G%N$3$VS=T\[8-!N7$QS+3B:@XEU;3,P
MX^2Y/,7)O48VW\9L0;SKJN_2+@[$56M,>W1>G<H_Z@'>E&/C4V:QDRM'_1P.
MO5O9 $M!MV-?*$XE@J,C4;0Q5]<=0,FALB_#?_4E-L=[=W8"9XXR^KAZ=.'^
MS4IN<:M+#_H;1 )54,.0"K3%ITZWH_OB)S9M&AIJY95YTKMJQY^T_LJ[> %P
MK-X^#Q2_V3\Z6N&P ]#):CH8?WX@+%NG!7^F<MH;;S&"P:Q'N+KK(O4:4F_O
M2;T-?+D^[TJ(W6CPF >-F2YLFE=]J;NM$3,TH=L/#PA@:CR_NQ>;VS3GYW L
MW3MS*A6Z+2L*>X[(R<_(==.8HSN .!'4\(N*A:=$2O?9MQU _W&6HU".O -8
MC:_4FY,=1.L#9T*RM<9G BUT#<X>/0LC#@GJ0">(QKQ;\"RM8S<B*KIVL=X*
M>O IO9E5\0JFA9SWID5^P1HW!31A7ASJ#7;T?IG(,JTV*G+2:,3S>:&V(/61
M'DD&JLU=;--&O_SUF4!(I3IQ0Z26QS0N#9&7ZB*R"4,HSLP.X(:(+5\S\,[2
MEN:W=7 J8L][[@#$L*+@YN9%3 D#OT#(UWP^\VY9=T4FQ7+UU"\YH'=-0S59
M;FT/;#_AU1,S\=.-$68[@.<NI,GW!C%9M@N%NS>8_K[*;4S<A,Y/=5W,6(:_
M&PQ?76V0@LH>,Q0% 9U'?5<Z*R^L>WILG,A9@1HN1NO2+0Q\H:8V1>*66=EK
M-;R)7@ZE<0DNWUR8A!032L O<[HG00D;^9;N#KX*$W-M=%8RE*!N8#%/U"\=
M'J'[/ZP-6-Z04E.NF#.HXYN'$GAFC#FF1#F4+KT./,[%.-83B8-&^FC:[U'G
M["43,*>M(G^&AGK?#ZH)V0$ WPE_BL0GA!\Y[./P9Y>6J/S=0JE5T3AE<3WO
M?A[0A8S,PW "[:-5M?7L,-1*NL(B,YXN7S>:W9V1G,J=*XWJ\13N$XWK7F=J
M3"$3_,S6H\4[96\%L>#\0$S2%4>1O7!S0J.$XR>O+XCKS3!6L>7?DVS#DRO'
M,BS4)M;5UZ.@B(J"2FEME()HJJB; B>M4U/'C"S"V*%^9S63J"Q73CQ;K(:A
M)=7-2'%T&I2:??IQGCH:UD)S]^@[()<=D05ZR+M_I8]OL;RRS:8WQD#+^="A
M2EW7QB.Q=Z:=Z@I&%;6,FFMSDN6^#\TR32O\W]!^!/8?Z04S93Z6I>[Y>ORJ
M\/T&G:M?+-QOSX"*D?7Z1GKIUE61_*D]PO,#W_8<NKX'XG7K2KMV2)\'M"\
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M3_U)>5H_%;VEZ!SW?TAW(G=&_A=02P,$%     @ %8A(6Q,-(L=)#P  )!
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MJ(I^DN"Q\WD5K_!"J@;N-.D;$:/"(#5#JCK]%]I_DOW?P)+_7V3_ OL?KFE
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MO\W(9V66OGO[D -[SM1_ %!+ P04    "  5B$A;;;@7A$A-  #V5P  #0
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M9/)$X/)0TVNP!-G0O%1>/_"4\A=T-%VRF1A,RH(!'L1$,N"% DVE?7XW0<)
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M?B*G\39A%QM'4)A#JH$I@BAP<5L&IF:T)5<$#0VM[9WLN;ET#A!0PR_5DX(
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M_E&'OAZUAOP'2.W D0G[Z^A;$4KCE*^&/ZBT3!H&>P]&1761,XIUQ;?A5OA
MH'Q!%>@6!+8P?^%W\T,$0<"B:!?!"'"\AP\.X9EMP3&&N6:,6ME9$E%JJ#N&
M;N9K=Z5$MT0YT ("/E*J"C^$I/0*[05VH ^O-PFQ->:-9.],DVDBKS<-I=9J
M*L+P->_@3:J4B'0R- ::$71\"!_>"NFS&*[O_W=8-B5X@$L=C'D1+;:D^_*E
M5%I^&:-4],V@['E$<J?; 4:-M6?1WE(M*FINQQK12W SLK[4(4NO<6A72Y%C
MQ(7KYU7R+WL\"C'%?3J?XV82Q<2=W1>:>J//W;/6HP96U;-$+\S^/4 ?R@%3
MVE" !YE5WHG::H) !Y!  W;ZI/@)D:,Y1-@3'G3\*RT<>;=I'9)ITJH-QIDX
MK'KS+8N 3X(Q>F-30TE$*3K6_PE!,R(>.6@:0IJ_]H[=%("8R:=#L\B*K8?I
MW$)22M,*HZ%8GDR_V;J/_72N"2M(Z,W R_YW<VS3.7A%F5]7I9C6%F0&3+TV
MZ/L^8/),^Z%?KWDL<,&_\X^+\#^WNQ>NB%Z'U,>VVYD)'@#L!3E#4E>*J2:7
MU Y3)HS"*(06@, [_VYPQ25C7,8#M.>PL_Q)[\?MVWT.(]52VBWAL#? O;S^
M?4]8G@R#1KWAA%BAA^0S31>!UH+K2!C%AN*25CT\D=]U%R\58^HB<[ 1<'Q_
M$RY;Z @>!82<H!(.,DU;MA.U V?HVQ<]?M0=V&N=5U@#JKKQYV/U8 /W0QP;
M!BB4N@'3\OI[QAX^N6%?*VQM,@3I,9SD-F=S(Z\+C\+CPU>NFVXS!^I(=15R
M7A>^IFO?>/%#(U<]]5H!85IHP^#]6\F\]V36<32X(OC)G\KA&UX<#[4?Z,8Y
MMC)Q\CG[M54[&_3.!DLZUR'*M;5P4W C*CU(AFF[66@CZ2.JK10AWY^;]5ZS
M+=X[0,$F(^2; RO!OWLL;-YAS,PZ-0HLNI'75;ID%K>T(#B]"[G"8WB?1([M
MQ 8P->8MW&)NPA:HO7W5 "C/7';]FZ@N.M+W<F4= L/Y=$IIV/9X&4:J5%PX
M$::,*9[7U]9=:(G6X--LC5&3O6^+=UP218!+PKV2(;@FOW<^IPH7(IU"B=QN
M1 JJ+ABTXBL$B!-I88NWB9NH\; T,QYI&RZ==XJ_>;6K5A-GRNML54QG=9W+
M.?.F_RI^9%$_>6KJ&+P_. 7%Z6W#CAE.GB;-=_*#V )/<)1?X@[ %JR$;OC3
M0W 8!J5#"S4A"IZDO*=IP17L.4K0#O;.5@.IR[2Z2U %I[DR8'^$VP0*/&7K
M7J6DSQ$WWJ,XOJ4U]T5>><B3WSEX?.I/B/_Y@7^9WK[5;GH'_,T>.Q=9>X5X
MG72_]F*VXN3]1XR<1P<LGD\G9J)/4$O1%P=C=3Y.P+_4_BIU??-E<?3=8#^B
M:6(W6#.)E!?9@_% [85A5U*6Q&@$9'H >JG1/4&<&&D6&OR]2WAR7THQ(9;9
M99E[F ']WR\-UE;O;;9*SU.(-;_QG+C?4*0V+#A0R)!2Z]U14=! C$O>L&,2
MD^%OUDZ\+_49,R)GUB<P)EH!E<5"T,?8B9IQ;X>UHN]<QO!&2[6SA7+K$&<]
M5_P,EZ@HZ2,W.$J;)+%U-Y\\W\6/%2"!Z7NMNH01A)P(687C=9%E1*[<0'6X
MI<@8T$CAP+1_VG.L.J1*TO="N8!:7!<:JO2RW+(TI"*,.^W=V%_]Z^JOR/C%
MNQ-P\9O6G3A/3N_\^#I$T?#?F7SB-CR"@X"L0]J7F83C>#,F\8KQHB+H=Q /
MQWM)58723&,^3&]YK,7^5'U$4#?G1V_[CMU,"SFF?2$C:G1L'1+9N[T<-A[O
M9'K+.;9$<T=%_]KPWM"5E ,>SS@IUU]P+'JM/%F_FZ*-OD99/?_CG7XXJ&]<
M>%P<Y*4=75WNY=8D"#^W&ORIHG'!N+\&QLSH[@Y0""B<F_O'Y&!UQ%3SNW=-
MN1<;J-2&S/(W36^*'7RY=[>Z?\]#:WF8^]R\^.]P%[&N=B&CA##,DNV(\&>^
MU]L#2O<,M LVJC&Q@Q\ASIVJXV*36_?V7[7U H@\B_O>AT\=%.GS4]IB!9)]
M0$_1B*3_59;-@K&7;TR@I8!U@!@)2Z%IP"WQZH6"!- /D8H_0M:+J4(E$U4E
MQF#X='MV.$VV%1HNR&^$*=L&EH[B*F,;ABP6 NQ?Y[R?T*MK[,.?VC6(]]E2
M5X'VF/'WFJPEV1X70@E]Q(V(,*B<R*&?B$9DLBG#200ST>&!=<AE8N;-"2.@
M=WX0X"YRK.@!NIH=+&DU$.D2Y13IL91NAU@UBW245E X7/LA8VJXLV ^3K9#
MH;!(Y<N.:+^GA=:QA/$W%<<]JUP4-(^UN:B[)9T]N^^ ";J=&A=]XX?WZRQM
M8W5;Q__N5CW\\>/YHQK3N)@JM_Y\ YVQDTEG]O^L/'^^'*4[/S/17*Q2M+5+
M7&FUAO*17K6 T*EME5DKDHOBQWNT-O?'5)&59B?,@%5I.T\8@:=+<7E=[A%Z
MJW066=KSBB*[P=9M(YB;UJ^EF"9F&HN/I\_VNA\(CMEIE56GU\WS6?@A-!%M
MX#_#'P=3^ K^Y*Z/EY_/%I0G$G;B3<&W_/*.((U^"[;MS[7>K&A2(F$S?WSZ
M]G*"NTFD 7,%H77ZZ6C0&'U?)X5Y\FE7#T(&CQ1>P\N#1&!1<)Y)#&Y1]7D#
M!G "93A3B<*3/]<A.JT:(%9P=5ADQ_FG)EH'IAM.V*&Y)(H#!"U5,PU='=:K
M=P["U3#9]C7? F>&6BUI#8\MFOJ83$&Y. =^0!23^)[X^DJ5\#P.REMEZ*Q#
M[A>8=2"2UR'JK<HX38:>RK"MW].?UI:UD[49!68,F I.=]'6:G*FV4:)EHB_
M/-D2P+ B TG?T 5*O8GF<S1HR6SC?J9;7T6OVJS0>N++N35F1LD\9_Z2N Q:
MY%;C%OYKANGKAJUFE*+;;]1'[GQ](?W\6YY9B*;1IYC 2X\.[TPW]TA2&\CU
M274^%J-M/$/4EHRQ7_?2%Y-:9<"/7%2&]0T0QJUX0^+$AQ%@?%(&/I"OQQV:
MF)K]W?N>J-1LS!D/Y5IEQ"C8!+BD+<Z;(^390;[V.PH$.Y3[BLOO$2-[1T.Z
M4/)P?=$5H+=3)F:R-W$H+9[OWWL.""6)[/BRG)YF05K"55LTD-]!T.@G&.%N
M!G0;"J^0MU1,CJ%C%,Z4OZW+XNJ@BQ%;P41.+^M=.UD-KB(99L6^AVZ5^LH?
MY#:4N@@&E@ *[]EJT29'.XIE*<.V(:&\(N,.U.;F>#Z\JZU5D0^O/3*31]
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MT)/9\XFEUE%B*R81C;T;U[B@P$6->G=U:2SR%]M14'-L^MHT_0\ED] _!8.
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MTY'2_9UVFHWE;L;C.=FK?B>30W-XKZUS]>67&@RW3,V7!CTINKR#6O-LLN2
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M$HK>YB[BCP*T$ZV!/NW:)AW9M=E*75G-[F5=M^R:'R:\UE6E2V(?YK&JS:R
MI$G2#I#9#M_%M%B';)@K-@+(:<%OY)[/Z4&'5EQE._;$YIZF>%NMV?64KD.*
MF1&^O*PS@E^GDF%O?0=JYK_G_'#O_YV#/FTSX;J<[KRP['AZITTE!5N S%-.
M=WT;N+<F8>QFX$2*$'5WV[43;6T">'(>C4P"=VLNR G]\"Z@RRV *<CBF[;P
MKV W@)@3 [\(1F##[PFL^DQ<:\M42_GM&.,/_SK9.NDFDQ44$CS6G"Q2M3]A
M%XP+>RGMTIGVUTH6BE3R.+@DG;X4?]R-:M&KY_WC)-59%1,].>WZQLFR5*,X
M:\;VBLI+665;"X*7A_PV9U/!]+TK.0$,)Z<H!R<GNZ&VT_A,H5.;,-*E"G=.
M\G&87#_X,K7I9H749!2(PC,8K\.AE3J%B/FH?XGMAFH/%"PH5FRL9N+GH^+"
MCW\4<Y=0HXC)UXAE=7$B H#QH.N0/<.)_USW[.;G IBD-[UZ+YP/KTWY/+#7
MNEW;XZ9^_!687\0)].TB/XS@S-P82#KC]SO*I:_].]N?SJP5UST(;GF&'0DY
MZFBOZM;_*,+[87?5?J??2_L60G'.1YJF7HM=G]$.MGZ4*MOL=<B_M?-:ZY#;
MZY =Q#\:I-?$MDO$G\;"+<1)! ,F.?W2;(6%6CX-)JU#4BF(-7VK=8@/;9;8
MO@X!;^6O0ZR1 RSCW]WS9, /MB8O:2.#4'[*.B0[3&@HTG"4W*6]"I7(B(+7
M(=_]$<-H8I\F5U.RY^LZY.=]Q.#B&AF@2?0NKT.^Y*Q8IO\O[9SG5Y-Y%L=S
M9G50&(U2!48S@@B(@")%,8:U !M8B("$)D1$%(P!:4( B>/0I$HS&DH&"3 8
M@@X)A!XA%!E J:$3$D2*E(3Z0-IF7^Z9>;.O]L7Z!WR?<[^?>^\YWWM^YSS"
MRC]K8']9XW]6!-Z,$I<*#26@A%>X==)_8:U(] @O.AQS',?5!XL3F2(O"4C:
M+SD)B/,%)5RP<$*W0\\*H,+#O,!VBV<0FG9\DRJ @ ,<?CB<]_%GOCHWV_Q^
MUXR% H!K9OG[<"C?K;K7^:]@C(\:')G)O*1BA]8WY:X9#QKJ!P3VWAQF6MR1
M@)Y^D(!Z7;:D9\U[7(J%,-GZ3VWO$]?;BA,9AQA\92G':][BM[A!"4CJE;=N
M* XEEM%<9O%_%FTA@-/IHKVX6Y^$,H T='R@X2KZ):#7AJV&0LM"":CO"([,
MWK3@X(30+@DH7WL1H[3C^V?1XRRQG*8$=!DU<DZZR.(S$M":/N0KC3&?S)=B
M.>R'V[""+&Z+$ !* @(;24!S\-U<RQBWOY3]E=O=9<-=#>$5:=ARAX@.)^PV
M2D!.8A4)B-G-V.F/*>E#O4!]@_0-TC=(WR!]@_1_"BEJ#-?L:VJ!)\<T>]UE
MC;B/SQSL 7;";[//3S+#-U91I>9'6%:I)/"A7.7A=OPM$U9_+/.?F#ON;:*2
MT%4:=V[I^_6/ @A1P*;N> 7VU#66$R]A6_F'L!!Y:84N<1?6[XW>"!YQV<K*
MPS[L3[OW,LI_8/8+647M9D;>T;D>/Y[/VNR35-W3';H=46[VT-J "]Q9VPS+
M=21")NYSR@Y%!KMN8X1,K=B<?YVTG6ZLI^G52R,JS!,ZXC=%L %D;Y7(0&J,
MM4$&'+\PG?LV/>#E)I>,=J<L=2_EB[+7W2>O,!\\[_[JOG%=9L<'UXQF3&<7
M2!5/'XK[ZG*V$XR_IMIN>0.-Y6B8!J#-C=!?-=!O,*WTL@O#\M(]ZP)SH%<Y
MKB?B,6=)K_#NO-U15,LRU#SV$3N3(0O3C:!/#R>7"_VG&^V6#<M)'A@;N7BL
M\>0].[_F7)NA!X,XTOA-S.1:92?Z9.>O!)51+=R[N64[@7ZTDJBR23:",:W2
MP=[G#C YVRGZC^P"!+>&:/JW)^^8(Y*@9]\\P-(0"G[AX"V*MC-]IS K6D&K
M+;^GA\;^@I&&+>E</36(Z47Q[ Q5O= 6OD,PO9CNR$U1'P_5GF]H4Y=YZ=CD
MA!8]H4G7PW5<E-PL/F59$W\D@/2JP8(+UE\));<&A7BCVY);^M[:E^L-I-YW
M_HESRC%IEFKG.2]69]]9R;*[:#)_ZW?[V!F=S@'*_A"G-P5O>F">H=L$^"1M
M@)J2T[>ELN0CK60O8:YU%Y4"4XQ@.P%._!#+-*W:WKUC'?JBQ*CP>GJ:JKSG
MQ3:8:OU+S(MVSIU<'\V>!VF)FZ(CTCV2413J 6=Y;Z1C#JDR8U("!MI8[@&%
M*O'CG(9J)S>A%?] (ZE_H4[_13(9);<*]KQO=$W^JX-_E:>VW0_;9N#O'E1;
M?)D\,"0F]-GZZ/?D3+@*E-K*2]1?9A[?E^:WDI%3^/) BTD</L7<HM,3D=IT
M'&!R]TYE1<T$RJ-C3C8.G/;NI]P=K.CI&O?_\)YDRG^>E+(&,5IYU#HL?TIZ
MU>I]YKDIG]/KN(*]ZPN%W9@]E5.YT^)\_&C @F,P_H2/XXH]R3'?M,HIFKX+
M]?*-[>91L6ER1,C>(U=5;2>"^]?R7?;2;A-F,X,:JQ+.P2:D'4O'-<,E(#\&
MH(MH]X_1%-X=MLKA')6W_6H8CY*E>223>"@FY7ON+.$B6L_M3I8 T4I'OM81
M7N8F%YO'TX/4K-7'7:\&>F,H@F,QP]LQ<KEV@ /?VB$S\/LN8V2,,E])F()B
M&EU43+ >+'YT @CPASPP^D?WV,U^:;CO%4<%9L2 H_<"Z?R652<JSQ0OUUSH
MVA4>3EY,-7F1N:VW/\(X8M5Q+/2QS0YNL+VP@5*_4J XM3EKWO2L;*&N>(I(
M'K$K7HST'631(P.* K:V38>5^S$%<A^TK^5HISE/_+YT(\/&/#HM3?S"-ZYK
M_4U$7EW#PD?*OG9X>U"!IHSCZ^!2Q_SQAYD#!-UFLS](%0,7WCGS:Z\M^#SD
M461-,$JJVK+G"4'4[*/X!H)=B%O-A1!MY4WI<H.!DT2A8MKZ-.5C,@\Q8_76
MM(AW#TE0Q^T#ZES0M3"UR2GOPJ=W4[JT/OV\ZE;D3*^*8[Q;,8"-8II:_#-@
M]5+PE=+K.TP"NF<!:-.?;A+_)KPX+#S'+]KZG46+A\D#_H7WSZ+=P3^/.U;F
M;!"/1",'-^HS,"5^?8RL$#0G-^HSW[11_>KG<3=_*HP,V:E98-,Z.@Z WV\Q
MP!NX1+6/KSA=<N'5-%L9NB>2U9QXN;2C0AUKHA,Z[C>,:6PX9_6.V:2(._%:
M^\D$(BPL+ @;IFD;!8W'KA1GS-74X.\'$N EZUK!7[=)F&YU8$T/!FGY,AJ@
M''$ZQBC>($>W\Y8OV(\/:PZ!7R&59%^XX5*K.AA<JL<<<TZ9T;$*.TT_T]K?
M-LW;?)A%/OC@CG:GVD%J<F:>IBH,;J;:3HW.6QW]--JV7KM+;'^;BE.P\#=,
M]H(" WQB&W[J+)#%5V@EE"9"[=ZR$3^A<\=?C=ZJJHS+EX"HH8VF0\<'0O./
M32(_(?J7,>7+1==B%7;5): ]?:+T:!3_%ZY+'-0'G! 01BXS(3_6YMR+GT&R
MN>DJ]CU[(O$9IIIJ=Q->E7ATOO(6W!85LWUC6QH4MFQ%Z="K_ Z/@09K[N.+
M#OWB8VV_:1P^4-]!!MH7GG8>Q/_:<?K@L/*VBOZ/9BK2DY*2%DAUQ6X;KN&*
M7(3R1/'^.6_!^7^_3M%G5G\8FV<?JDK]CM7Q7@SVN!9O$3<%KJU.*2:/]<C"
M?;D]]AI]BTF5-J$"^1=1X@$3 4LU7J/D7E*!-1Z92\CSR?7Y20(*^Z7%S;PF
M,DRSNT!30:;3;S D=3PIY4;QL21%OUG7L)=<?R8!RG!@,M(5GL5BBPR0>"TU
MHZ R\[SJ3!L]@I,#3"!*L[@["=YR!Q0XB/A('#Z\ GO5D]]$4]8TH,X<0.Z[
M,U2L<(K<Y>.M48$OWNGNKC:]/C<7+K/X1N<MF>F]X.WGR.Q]&J=F/&.?Y^A^
M15<KW/?19G8NRS&;-(ZAK^60;[2RR(D4;?.JTE,Y)R;'LS^/"VA)2T5*E9<M
M%9%?O/_7?VQRA9WD=21 _3DBGY:",[W&*$7 I]548<%].P%J7>*&=E>FEGCJ
MIGU%#!E3K-23U05ZB9UP3,6OF:J*PGET9!)(?!,7  %,B%N7 %$8!6!OW>);
M50GTHJV&-O=7Z>7+CDTA5(5JC?YC;K[4*AYF:.@%91HHX%[OE8!:S"HD(-_1
M*PS?ZMX]TA&!;4N3#3I<J(AB0I0U>%MEOM-@]>A35.\@LU9$@OA\/U04T*[[
MO)J(YK"5<-X1"?\8JM#,P#^>3>U)K1X.;6A8RS@I <'OHW4")2 WB'UL:+E>
MW];@&Z<X^/5L+I?LF'*)<E(\:7:^IAT=T=E^LY*6[8%\K'A6OM!1Z4<?]S.9
M1"JYFW,R?]@HY?588V[JTE:D'TZ#48D3'KXZ WM%B;CW/N8,SSF]&1$[IK'?
MI-&+[=P;9A?E6!TWLWY\ +-![EHP$,+)T6P_UN:M:M[;_',[:<_'X:M25T@<
M8%8Z/;P,YWG8\A%+>,ZD B=\69=7RI0KG3]#[L"\%C[L"_U048'CJ &_/#[^
MY--,\FB>]:_"OP_.9=HBLP1ZSM9]4Z,;Q(72KN8/T$B?2^N#F;A/I4I:6#>K
MRT_^.'H_V]EF)&E9<-/^I$TQMJTK-Z/S8G 9W<2OA#1)2'+P'(T/3^N>-'&_
M7FR35&6NJ%'69\\*NZ"0%9+]F#51C9SU8*S1 2<)Z/M=7#-2K/,IZD=4Y50M
M3P)"4!L8]/K!&.T(?(M8[EE;;M<>IGUE$^LS*\QU[%K64K#;2 _Z-ZL/O1,[
MAG,N\XBE=>E'9J7Q#)(<.@@D\)*]^"Z)W":XY>JSTCYC2+R:^96%ZJ@G8\4"
MM$[L?IDQM052^HJ_/9?1*R Z[$#XI#$C\-'@\Q<^7@H9_EL9A?H#9:90-JC#
MYV%HQ:2?M[9-'KFM*L*^?,&>I,'ID5E:VKD[.9CM_FD_ 2$[JQ7'1.;23_Q^
M.$^4G?DHVUM5!UX6_,> O5E:CVEZ)WLD7;S?@U>_=1L#:9\R-W=I#4PBA&+[
M2<D(V\ ]P$^QS[S3F>:GW_T<\MOH/F%-6!=0%/%W=LG(PNHZD:5U4S[J^;D5
M*ZS(?]#%"O5BNK(!^K!&[7"AE?E:R:PNO'IB\49NCDU6%J;6/C@\8*)LY$O;
MS-DCBVNMM]_4Y:C->EB=>3JFR%&W.I1NJ;0X/J3H8!G^8_/_>/ME)*/_ E!+
M P04    "  5B$A;A!R C@ G  "W+@  #0   &EM86=E7S Q-RYJ<&>E>'E<
M4OG[+V7EE!F9J84I4U;6F%(IVK@Q965&1LOD @DM4XI$3*,F*D)E;IDQDY.4
MCI*Y92YD@J:BIKA\RXP$ <5<P')'(;>3(ESF+K][[^L[KW[=^SN\SA_G.9_S
MX;R?Y?V\GZ/MU/:#UAX]['48M&3)$M YW0^D[09Y_'WU7SK^WN2_NL<2[2N0
MT7>@34M7Z2W9 EIJM$3/:(FV$00%@98L_Q\+0/_S6+)4;]GR%?K?K5QEH%O
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M2'H9>B20C!I?K:]6M]&47W1KI]Z[<W":+"U(&:^G!;UM>?!/R?'/&=.'HW9
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MP02])EV5["T\=J[B8-R6P7T/+I[1&SYJ<S3";LV#+\&7[1:F!K]P-1-7FGW
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M3)]U _K9H1_Z>KUSO8G+/\9AKCD^V-9H]\<;QA:YP\-H(SEN52?EY&*V.P)
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MNLWN5I0S*G"]PJD??->AE>C21-4-9K&GY:3U)64#*SE==JA$!U)R9,]$1E&
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M!Z:<'-""UHZ85:%NL#@LZ'#5&W*AEP1NTW?'?:N &-9*WT@VD,W6K8G/[_Q
M2'./ERUL=*@V=#JI,ND9?&"?RTR &KKKD1>:>JU2FFB;V&VXYMY][3-]:\AE
MF!19KKCTB7]OYXB8NK66(<.RC,^2";*^1B880.X7=&*TH(;] V CKT!9SW8M
MZ%3[)!SSX\>7,@[-@CS4WU<_V172[*ZONIJ+E_.EX'K+[Y3YC="UP3Y8J&CR
MDXBRO_@#T#PE7Y/&F'<0GR1WP2<3+>VJ$T9-TYBW+T'N[HR6V?#'%U943,!)
MFX#)ACISS5;J.[3G7?@.C440= W5EN)/0QQ7OIV?K2P Z USM58=%'A1,.GQ
MEXL-?<H4@/FS:K5!CO^(^U;D /&R9EO*P8J K3>B]ZALY(A7S#O05:>FL"I%
M33ROSX"@!:VD7))7ZYSEU'C2T/>G"E7JS6? -3L'J G>V;&@($@#[YA>B#:5
MX,J$8>8(CO>ORMRVMHRW.P=I$(VI>KLRKSKP61_%7V76T,5FKB2C>?WA,5R+
M/'+>W $@^I(RNU%%[L:IK-4V=<N]=VGVOK<63ZAAX#L?)46Z=$<<+6UW=97,
MOA^MJWE5"MCT)Q^J^X49+T:R !+/W06(EH,W  *8(<#P?RYR]7Y&1LD"XQWH
M:]#!SFI)>.3'2-,_H(TP8QQZ&$+-NI1KB!XT]%)@![LVJ%L**:% MG).AHU7
MV?,TUG^H<4\"R(39:Q4=G"1#>W\":P78 $!BA3,]7AR#'X=J524/BLX&^RJ#
MIXZ'*@X3T2J*QY.QDQYY+?DWHD_+C)7=KS(WBQT08,W[>;VSE%//=6WE#G4'
MNH<"CPE0\N_6;J,<%[ <QE")59JR*RT\=]!+H)3XC+Q7RG]5-5B\AOXL2+-!
MV1870UQ%D#BE)?,A@$L_H\4VI!^6&,I,[#41P=2'B<:R,\4MMS^*IL$;R,+^
MJRDJIR-B\="K"C,(E1$ERW#A89V Q(MRTNI1^Z#7CX/+J1OJ!!R;:)QWF1>W
MKZ5VLRHP%A%$7ZUI^YU<>%I$T5\XT$7VQ &)3T=G+<U))LAG'_QXLK[U'T8@
M]QX]'DDCQJNM(>$QXYX)ZP(@"H>1R;"=%--:XYYSY48:ON4Z82C=3-.F@7'2
MOK#49^2&P?+1-Q%/4HX*[>#TVW7K\U2[I!:/;^)0-)-@R(J80L( _Y$=QVV+
M6-YCZX/\U\0-MW)8Y^F&/"^K6O$5V)4PW92@RS:W-Q2$;E@>P# !3QB'>-C0
MJJ'.R"%AG(N405<&>!7UX.^3L7*4,7J$"N'_3079 #4JW6QFT;C_> V43K$8
M()D ,N[)\'XMJ-2#N$,Y0X_O)2)XO18JZDU9DAXQ#_?AU=P/&C>58ZG<^P3[
MUU'?]N%9Z65Z]HAXSI0_W;-^B?)ZRL)Z/_*)T>> 39,XTJ1(2#D6#55DZK6[
M[G]JCDJB[B:9 M4'@)AGP>C'E4"6[+83)/6F3 'S#=@^=>#]#/3#:%EPVO5T
M6F!RQ((>^;H:YQDV8!!B64TPS:#^#H ]./'UD%!+6*WJ[C7UJGL62,1*.P2;
MLW'K_;'PN]M?5E:4=Y1 %<-3WO,FAT"4B %<UUY>DQ26Q%V6Z:QR?Z 4-E7=
M*Y83DE>LA<.,I4"KS_O<]CSQ!> F*QB=5QF1MTN@!5U!9H^F5C!\(?<7&0M$
M5]?))QU8D\4_A3Q3ZDZA@GLHMW.$ZJ[RO<%AF@.$AM[5I4K&K1D:&%CS^LH%
M95-\7'%8\9&@@::3F$Z/@6C,@L?):)KW"V^+\<W/TWYAO=CQ&/R[J]O"#KPS
MN-F%E'1RK '9BDN@_@C\7I2Y26C+#8@J +2@PQVA;J=Y:5K0O8%:0AOA%?I,
M7GXU3[,18G%7;'U8^<')N?@CY' KGS7\?W^__E\G0MOUWP!02P$"% ,4
M"  5B$A;2"03KZ@2   ^QP  $0              @ $     861V8BTR,#(U
M,#8S,"YX<V102P$"% ,4    "  5B$A;'ES>##,.  #3K   %0
M    @ '7$@  861V8BTR,#(U,#8S,%]C86PN>&UL4$L! A0#%     @ %8A(
M6VZ!]YAM.0  0Y@# !4              ( !/2$  &%D=F(M,C R-3 V,S!?
M9&5F+GAM;%!+ 0(4 Q0    ( !6(2%MAQ_$]%'\  %44!@ 5
M  "  =U:  !A9'9B+3(P,C4P-C,P7VQA8BYX;6Q02P$"% ,4    "  5B$A;
MR,T!9>,\  "'Y@, %0              @ $DV@  861V8BTR,#(U,#8S,%]P
M<F4N>&UL4$L! A0#%     @ %8A(6VGW^+A09P, $B 9 !H
M ( !.A<! &5A,#(U-S8R.2TQ,&M?861V86YC960N:'1M4$L! A0#%     @
M%8A(6UU?64Q7-P  ^E<! !X              ( !PGX$ &5A,#(U-S8R.3 Q
M97@Q.2TQ7V%D=F%N8V5D+FAT;5!+ 0(4 Q0    ( !6(2%L9NHC,8P<   4G
M   >              "  56V! !E83 R-3<V,CDP,65X,S$M,5]A9'9A;F-E
M9"YH=&U02P$"% ,4    "  5B$A;&FRWF&T'  #!*0  '@
M@ 'TO00 96$P,C4W-C(Y,#%E>#,Q+3)?861V86YC960N:'1M4$L! A0#%
M  @ %8A(6T(,&,,:!   -P\  !X              ( !G<4$ &5A,#(U-S8R
M.3 Q97@S,BTQ7V%D=F%N8V5D+FAT;5!+ 0(4 Q0    ( !6(2%L(^<%'"P0
M %8/   >              "  ?/)! !E83 R-3<V,CDP,65X,S(M,E]A9'9A
M;F-E9"YH=&U02P$"% ,4    "  5B$A;R4Q>B1@)  !;)0  '0
M    @ $ZS@0 96$P,C4W-C(Y,#%E>#0M,E]A9'9A;F-E9"YH=&U02P$"% ,4
M    "  5B$A;FI)><WE@  "V?@  #0              @ &-UP0 :6UA9V5?
M,# Q+FIP9U!+ 0(4 Q0    ( !6(2%N8S_$%4FT  '!N   -
M  "  3$X!0!I;6%G95\P,#(N:G!G4$L! A0#%     @ %8A(6\,[T'O&@0
MYH(   T              ( !KJ4% &EM86=E7S P,RYJ<&=02P$"% ,4
M"  5B$A;1)_Q@NIU   J=P  #0              @ &?)P8 :6UA9V5?,# T
M+FIP9U!+ 0(4 Q0    ( !6(2%LO\ TM*ID  %>:   -              "
M ;2=!@!I;6%G95\P,#4N:G!G4$L! A0#%     @ %8A(6W:N2+:)XP  \.\
M  T              ( !"3<' &EM86=E7S P-BYJ<&=02P$"% ,4    "  5
MB$A;.#^3+1\V   X/   #0              @ &]&@@ :6UA9V5?,# W+FIP
M9U!+ 0(4 Q0    ( !6(2%L]O<5FW[$  /BR   -              "  0=1
M" !I;6%G95\P,#@N:G!G4$L! A0#%     @ %8A(6_PZ X:^7P$ LFL!  T
M             ( !$0,) &EM86=E7S P.2YJ<&=02P$"% ,4    "  5B$A;
MW [#$%'=  " Y0  #0              @ 'Z8@H :6UA9V5?,#$P+FIP9U!+
M 0(4 Q0    ( !6(2%N?535334\! &Q? 0 -              "  79 "P!I
M;6%G95\P,3$N:G!G4$L! A0#%     @ %8A(6\W%?!V_N   "\H   T
M         ( ![H\, &EM86=E7S Q,BYJ<&=02P$"% ,4    "  5B$A;']TV
MU2$H 0"[*@$ #0              @ '82 T :6UA9V5?,#$S+FIP9U!+ 0(4
M Q0    ( !6(2%M+'K$I$:P  '>R   -              "  21Q#@!I;6%G
M95\P,30N:G!G4$L! A0#%     @ %8A(6Q,-(L=)#P  )!    T
M     ( !8!T/ &EM86=E7S Q-2YJ<&=02P$"% ,4    "  5B$A;;;@7A$A-
M  #V5P  #0              @ '4+ \ :6UA9V5?,#$V+FIP9U!+ 0(4 Q0
M   ( !6(2%N$'(". "<  +<N   -              "  4=Z#P!I;6%G95\P
<,3<N:G!G4$L%!@     = !T 10<  '*A#P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>ea0257629-10k_advanced_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:advb="http://www.advanbiomed.com/20250630"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:currency="http://xbrl.sec.gov/currency/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="advb-20250630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <instant>2025-10-08</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-07</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-07</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-07</startDate>
            <endDate>2025-03-07</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:BeijingYitanJiaruiTechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-08</startDate>
            <endDate>2023-06-08</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:BeijingYitanJiaruiTechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-31</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-09</startDate>
            <endDate>2023-06-09</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:ShandongSglcellMedicalDevicesCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-31</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-15</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrHungToPauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:SglcellLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-15</startDate>
            <endDate>2022-03-15</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrHungToPauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-15</startDate>
            <endDate>2022-03-15</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:SglcellLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrYiLuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrYiLuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:ChenYiLeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:AdvancedBiomedHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:DrYiLuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">advb:ShareExchangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrYiLuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-12</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:ChenYiLeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-12</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:ChenYiLeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-24</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:AdvanceOnVenturesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-24</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrHungToPauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-24</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:YiminJinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-24</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:XiaoyuanLuoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-24</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:NanzhenShenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-24</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:JianWangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-24</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:QiangChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-24</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:HanyuAssetsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-25</startDate>
            <endDate>2022-10-25</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:NewlinkTechnologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-06</startDate>
            <endDate>2022-06-06</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">advb:DrYiLuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-25</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:AdvancedBiomedHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-06</startDate>
            <endDate>2025-06-06</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <instant>2024-10-15</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <startDate>2024-10-15</startDate>
            <endDate>2024-10-15</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-15</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:TWD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:FiscalYearEndCurrencyRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:TWD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:FiscalYearEndCurrencyRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:TWD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:CurrencyExchangeAverageRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:TWD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:CurrencyExchangeAverageRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:FiscalYearEndCurrencyRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:FiscalYearEndCurrencyRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:CurrencyExchangeAverageRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:CurrencyExchangeAverageRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:FiscalYearEndCurrencyRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:FiscalYearEndCurrencyRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:CurrencyExchangeAverageRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:HKD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IntercompanyForeignCurrencyBalanceByDescriptionAxis">advb:CurrencyExchangeAverageRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">advb:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">advb:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-15</startDate>
            <endDate>2024-10-15</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-15</startDate>
            <endDate>2024-10-15</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NV</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:TW</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:TW</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:TW</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NV</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NV</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TW</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TW</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advb:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advb:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advb:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:YiLuPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:YiLuPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:YiLuPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:AdvancedBiomedIncTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-29</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiSglcellBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiJunfuElectronicTechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiJunfuElectronicTechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">advb:ShanghaiJunfuElectronicTechnologyCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:YiLuPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:StevenIFangChengPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ChenYiLeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:AdvanceOnVenturesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ShanghaiJunfuElectronicTechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ChenYiLeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ChenYiLeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:HungToPauPhDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:MajorStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:WellFancyDevelopmentLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ShanghaiJunfuElectronicTechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:ShanghaiJunfuElectronicTechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:RelatedCorporationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001941029</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advb:RelatedCorporationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="twd">
        <measure>iso4217:TWD</measure>
    </unit>
    <unit id="hkd">
        <measure>iso4217:HKD</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-16389">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-34">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-16390">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-16391">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-16392">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-49">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-60">001-42548</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-66">Advanced Biomed Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-76">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-81">87-2177170</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-16393">No. 689-85 Xiaodong Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-16394">Yongkang District</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-16395">Tainan City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-16396">TW</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c0" id="ixv-16397">+ 886</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-16398">6-3121716</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-132">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-136">ADVB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-16399">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-16400">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-16401">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-16402">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-16403">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-192">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-199">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-207">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0" id="ixv-213">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-219">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-225">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-237">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="-4" id="ixv-16404" unitRef="usd">4430000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-16405"
      unitRef="shares">21640000</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-6795">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We recognize the importance
of identifying, assessing, and managing material risks from cybersecurity threats, as defined in Item 106(a) of Regulation S-K. Our risk
management program is designed to detect, evaluate, and mitigate cybersecurity risks, and is informed by applicable laws, regulations,
and industry best practices.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our Chief Executive Officer
oversees our cybersecurity program and leads our incident response efforts. The incident response team is cross-functional, drawing members
from cybersecurity, IT support, mining operations, software engineering, compliance, legal, contractors, and partners.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;When a potential incident
is detected, the cybersecurity team validates it before escalating to the incident response team for triage. Significant incidents are
escalated to executive management. Response actions such as allocating resources, setting priorities, creating action plans, and notifying
external parties are directed by the Chief Executive Officer in coordination with the cross-functional working group. We also consult
outside counsel on materiality assessments and disclosure decisions, with executive management making the final determinations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In 2025, we did not identify
any cybersecurity threats that materially affected, or are reasonably likely to materially affect, our strategy, operations, or financial
condition. However, no program can eliminate all risks, and we cannot guarantee that undetected incidents have not occurred. See Part
I, Item 1A. &#x201c;Risk Factors&#x201d; of this Annual Report for further details.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c0" id="ixv-6801">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our Chief Executive Officer
oversees our cybersecurity program and leads our incident response efforts. The incident response team is cross-functional, drawing members
from cybersecurity, IT support, mining operations, software engineering, compliance, legal, contractors, and partners.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c0" id="ixv-16406">The incident response team is cross-functional, drawing members
from cybersecurity, IT support, mining operations, software engineering, compliance, legal, contractors, and partners.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="c0" id="ixv-16407">In 2025, we did not identify
any cybersecurity threats that materially affected, or are reasonably likely to materially affect, our strategy, operations, or financial
condition.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c0" id="ixv-16408">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c0" id="ixv-16409">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c0" id="ixv-16410">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c0" id="ixv-16411">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c0" id="ixv-16412">false</ecd:Rule10b51ArrAdoptedFlag>
    <dei:AuditorOpinionTextBlock contextRef="c0" id="ixv-11135">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Opinion on the Financial Statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We have audited the accompanying consolidated
balance sheets of Advanced Biomed Inc. and its subsidiaries (collectively the &#x201c;Company&#x201d;) as of June 30, 2025 and 2024, and
the related consolidated statements of operations and comprehensive loss, changes in stockholders&#x2019; equity, and cash flows in each
of the years for the two-year period ended June 30, 2025, and the related notes (collectively referred to as the consolidated financial
statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of
the Company as of June 30, 2025, and 2024, and the results of its operations and its cash flows in each of the years for the two-year
period ended June 30, 2025, in conformity with accounting principles generally accepted in the United States of America.&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="c0" id="ixv-16413">WWC, P.C.</dei:AuditorName>
    <dei:AuditorFirmId contextRef="c0" id="ixv-16414">1171</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="c0" id="ixv-16415">San Mateo, California</dei:AuditorLocation>
    <us-gaap:Cash contextRef="c1" decimals="0" id="ixv-16416" unitRef="usd">2903915</us-gaap:Cash>
    <us-gaap:Cash contextRef="c3" decimals="0" id="ixv-16417" unitRef="usd">2607973</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="0" id="ixv-16418" unitRef="usd">3128656</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-16419" unitRef="usd">443137</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="0" id="ixv-16420" unitRef="usd">6032571</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" id="ixv-16421" unitRef="usd">3051110</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" id="ixv-16422" unitRef="usd">331346</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-16423" unitRef="usd">524528</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="0" id="ixv-16424" unitRef="usd">65399</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-16425" unitRef="usd">126740</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c3" decimals="0" id="ixv-16426" unitRef="usd">118998</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredCosts contextRef="c3" decimals="0" id="ixv-16427" unitRef="usd">638871</us-gaap:DeferredCosts>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="0" id="ixv-16428" unitRef="usd">83027</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c1" decimals="0" id="ixv-16429" unitRef="usd">479772</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="0" id="ixv-16430" unitRef="usd">1409137</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c1" decimals="0" id="ixv-16431" unitRef="usd">6512343</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-16432" unitRef="usd">4460247</us-gaap:Assets>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="0" id="ix_1_fact" unitRef="usd">172767</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c5" decimals="0" id="ix_0_fact" unitRef="usd">113812</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c6" decimals="0" id="ix_3_fact" unitRef="usd">916036</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c7" decimals="0" id="ix_2_fact" unitRef="usd">674262</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-16437" unitRef="usd">2853317</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-16438" unitRef="usd">2670249</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="0" id="ixv-16439" unitRef="usd">35811</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ixv-16440" unitRef="usd">62211</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-16441" unitRef="usd">2889128</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-16442" unitRef="usd">2732460</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c6" decimals="0" id="ixv-16443" unitRef="usd">139772</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="0" id="ixv-16444" unitRef="usd">5879</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" id="ixv-16445" unitRef="usd">64529</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c1" decimals="0" id="ixv-16446" unitRef="usd">145651</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="0" id="ixv-16447" unitRef="usd">64529</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c1" decimals="0" id="ixv-16448" unitRef="usd">3034779</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="0" id="ixv-16449" unitRef="usd">2796989</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="3"
      id="ix_12_fact"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ix_13_fact"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ix_6_fact"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="INF"
      id="ix_7_fact"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ix_10_fact"
      unitRef="shares">21640000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ix_11_fact"
      unitRef="shares">21640000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ix_8_fact"
      unitRef="shares">20000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ix_9_fact"
      unitRef="shares">20000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c1" decimals="0" id="ix_4_fact" unitRef="usd">21640</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" id="ix_5_fact" unitRef="usd">20000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c1" decimals="0" id="ixv-16460" unitRef="usd">21347278</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c3" decimals="0" id="ixv-16461" unitRef="usd">16493989</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="0" id="ixv-16462" unitRef="usd">-19233044</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" id="ixv-16463" unitRef="usd">-15974075</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c1" decimals="0" id="ixv-16464" unitRef="usd">1341690</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="0" id="ixv-16465" unitRef="usd">1123344</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" id="ixv-16466" unitRef="usd">3477564</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-16467" unitRef="usd">1663258</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="0" id="ixv-16468" unitRef="usd">6512343</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" id="ixv-16469" unitRef="usd">4460247</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="INF" id="ixv-16471" unitRef="usd">909771</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c8" decimals="INF" id="ixv-16472" unitRef="usd">880193</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="INF" id="ixv-16473" unitRef="usd">2111265</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c8" decimals="INF" id="ixv-16474" unitRef="usd">1661379</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="INF" id="ixv-16475" unitRef="usd">3021036</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c8" decimals="INF" id="ixv-16476" unitRef="usd">2541572</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="INF" id="ixv-16477" unitRef="usd">24915</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c8" decimals="INF" id="ixv-16478" unitRef="usd">53495</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingExpense contextRef="c0" decimals="INF" id="ixv-16479" unitRef="usd">262848</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c8" decimals="INF" id="ixv-16480" unitRef="usd">294201</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="INF" id="ixv-16481" unitRef="usd">-237933</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c8" decimals="INF" id="ixv-16482" unitRef="usd">-240706</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="INF" id="ixv-16483" unitRef="usd">-3258969</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c8" decimals="INF" id="ixv-16484" unitRef="usd">-2782278</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="INF" id="ixv-16485" unitRef="usd">-3258969</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="INF" id="ixv-16486" unitRef="usd">-2782278</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="INF" id="ixv-16487" unitRef="usd">218346</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c8" decimals="INF" id="ixv-16488" unitRef="usd">319324</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="INF" id="ixv-16489" unitRef="usd">-3040623</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c8" decimals="INF" id="ixv-16490" unitRef="usd">-2462954</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="INF"
      id="ix_14_fact"
      unitRef="usdPershares">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="INF"
      id="ix_15_fact"
      unitRef="usdPershares">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c8"
      decimals="INF"
      id="ix_16_fact"
      unitRef="usdPershares">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c8"
      decimals="INF"
      id="ix_17_fact"
      unitRef="usdPershares">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ix_18_fact"
      unitRef="shares">20525699</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ix_19_fact"
      unitRef="shares">20525699</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ix_20_fact"
      unitRef="shares">20000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c8"
      decimals="INF"
      id="ix_21_fact"
      unitRef="shares">20000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c9"
      decimals="INF"
      id="ix_22_fact"
      unitRef="shares">20000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" id="ix_23_fact" unitRef="usd">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="0" id="ix_24_fact" unitRef="usd">13673365</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="0" id="ixv-16503" unitRef="usd">804020</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c12" decimals="0" id="ixv-16504" unitRef="usd">-13191797</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="0" id="ixv-16505" unitRef="usd">1305588</us-gaap:StockholdersEquity>
    <advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders contextRef="c15" decimals="0" id="ix_25_fact" unitRef="usd">1233764</advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders>
    <advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders contextRef="c8" decimals="0" id="ixv-16507" unitRef="usd">1233764</advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders>
    <advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations contextRef="c15" decimals="0" id="ix_26_fact" unitRef="usd">1586860</advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations>
    <advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations contextRef="c8" decimals="0" id="ixv-16509" unitRef="usd">1586860</advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations>
    <us-gaap:NetIncomeLoss contextRef="c17" decimals="0" id="ixv-16510" unitRef="usd">-2782278</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="0" id="ixv-16511" unitRef="usd">-2782278</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c16" decimals="0" id="ixv-16512" unitRef="usd">319324</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c8" decimals="0" id="ixv-16513" unitRef="usd">319324</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c18"
      decimals="INF"
      id="ix_27_fact"
      unitRef="shares">20000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" id="ix_28_fact" unitRef="usd">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" id="ix_29_fact" unitRef="usd">16493989</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" id="ixv-16517" unitRef="usd">1123344</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="0" id="ixv-16518" unitRef="usd">-15974075</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-16519" unitRef="usd">1663258</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c18"
      decimals="INF"
      id="ix_30_fact"
      unitRef="shares">20000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" id="ix_31_fact" unitRef="usd">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" id="ix_32_fact" unitRef="usd">16493989</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" id="ixv-16523" unitRef="usd">1123344</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="0" id="ixv-16524" unitRef="usd">-15974075</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-16525" unitRef="usd">1663258</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c25" decimals="0" id="ixv-16526" unitRef="usd">-3258969</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-16527" unitRef="usd">-3258969</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c22"
      decimals="INF"
      id="ix_33_fact"
      unitRef="shares">1640000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c22" decimals="0" id="ix_34_fact" unitRef="usd">1640</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c23" decimals="0" id="ix_35_fact" unitRef="usd">4853289</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="0" id="ixv-16531" unitRef="usd">4854929</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c24" decimals="0" id="ixv-16532" unitRef="usd">218346</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="0" id="ixv-16533" unitRef="usd">218346</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c26"
      decimals="INF"
      id="ix_36_fact"
      unitRef="shares">21640000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="0" id="ix_37_fact" unitRef="usd">21640</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="0" id="ix_38_fact" unitRef="usd">21347278</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="0" id="ixv-16537" unitRef="usd">1341690</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="0" id="ixv-16538" unitRef="usd">-19233044</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" id="ixv-16539" unitRef="usd">3477564</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-16541" unitRef="usd">-3258969</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="0" id="ixv-16542" unitRef="usd">-2782278</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="0" id="ixv-16543" unitRef="usd">343830</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c8" decimals="0" id="ixv-16544" unitRef="usd">399602</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" id="ixv-16545" unitRef="usd">2685519</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c8" decimals="0" id="ixv-16546" unitRef="usd">279425</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="c0" decimals="0" id="ixv-16547" unitRef="usd">-117661</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="c8" decimals="0" id="ixv-16548" unitRef="usd">479634</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-16549" unitRef="usd">-23709</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c0" decimals="0" id="ixv-16550" unitRef="usd">83027</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c8" decimals="0" id="ixv-16551" unitRef="usd">-56127</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-16552" unitRef="usd">-5825055</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c8" decimals="0" id="ixv-16553" unitRef="usd">-2126340</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-16554" unitRef="usd">31650</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c8" decimals="0" id="ixv-16555" unitRef="usd">74110</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-16556" unitRef="usd">-31650</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c8" decimals="0" id="ixv-16557" unitRef="usd">-74110</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c0" decimals="0" id="ixv-16558" unitRef="usd">5493800</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c8" decimals="0" id="ixv-16559" unitRef="usd">-85400</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c30" decimals="0" id="ixv-16560" unitRef="usd">296507</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c31" decimals="0" id="ixv-16561" unitRef="usd">294900</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c30" decimals="0" id="ixv-16562" unitRef="usd">237552</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c32" decimals="0" id="ixv-16563" unitRef="usd">981546</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c33" decimals="0" id="ixv-16564" unitRef="usd">1657320</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c32" decimals="0" id="ixv-16565" unitRef="usd">600000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-16566" unitRef="usd">5934301</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c8" decimals="0" id="ixv-16567" unitRef="usd">1866820</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="0" id="ixv-16568" unitRef="usd">218346</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c8" decimals="0" id="ixv-16569" unitRef="usd">319324</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-16570" unitRef="usd">295942</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c8" decimals="0" id="ixv-16571" unitRef="usd">-14306</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-16572" unitRef="usd">2607973</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c13" decimals="0" id="ixv-16573" unitRef="usd">2622279</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="0" id="ixv-16574" unitRef="usd">2903915</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-16575" unitRef="usd">2607973</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-16576" unitRef="usd">295942</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c8" decimals="0" id="ixv-16577" unitRef="usd">-14306</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 contextRef="c0" decimals="0" id="ixv-16578" unitRef="usd">24915</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-12902">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;1. ORGANIZATION AND PRINCIPAL ACTIVITIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 16, 2021, Advanced Biomed Inc. (the &#x201c;Company&#x201d;)
was incorporated in the State of Nevada, as an investment holding company. The Company&#x2019;s principal executive offices are located
in Tainan City, Taiwan. The Company has no substantive operations and assets. It is holding Company that holds all of the issued and outstanding
shares of Advanced Biomed HK Limited and Advanced Biomed Inc. (Taiwan).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 7, 2025, the Company announced the closing of its initial
public offering (the "Offering") of 1,640,000 shares of common stock (the &#x201c;Shares&#x201d;), at a public offering price
of US$4.00 per share for total gross proceeds of US$6.56 million. The Company raised total net proceeds of approximately US$5.49 million,
which was reflected in the statement of cash flows, after deducting underwriting discounts and commissions and outstanding offering expenses
upon the completion of listing. The common stock of the Company began trading on the Nasdaq Capital Market under the ticker symbol &#x201c;ADVB&#x201d;
from March 6, 2025&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;(1)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Establishment of Advanced Biomed HK Limited &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 10, 2021, the Company incorporated a
wholly owned subsidiary, Advanced Biomed HK Limited, in Hong Kong to facilitate market development and commercialization of the Company&#x2019;s
oncology products for sale and distribution in the People&#x2019;s Republic of China (the &#x201c;PRC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;(2)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Acquisition of Shanghai Sglcell Biotech Co., Ltd. and its subsidiaries&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 1, 2022, Advanced Biomed HK Limited
acquired 100% equity interest of Shanghai Sglcell Biotech Co., Ltd. Shanghai Sglcell Biotech Co., Ltd. was established in the PRC on April
12, 2019. It is engaged in the establishment and operation of medical clinics in the PRC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Shanghai Sglcell Biotech Co., Ltd. owns 100% equity
interest of two subsidiaries namely 1.) Shandong Sglcell Medical Devices Co., Ltd. and 2.) Nanjing Yitian Biotech Co., Ltd. Shandong Sglcell
Medical Devices Co., Ltd. was incorporated in the PRC on July 8, 2021 to carry out the establishment of medical clinics, and the supply
of medical products and services to clinics in the PRC. Nanjing Yitian Biotech Co., Ltd. was established in the PRC on January 6, 2017.
Nanjing Yitian Biotech Co., Ltd. wholly owns a subsidiary, Beijing Yitan Jiarui Technology Co. Ltd., which was established in the PRC
on October 20, 2017. Both were established to carry out marketing and clinical services in the PRC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 8, 2023, Shanghai Sglcell Biotech Co.,
Ltd. transferred its wholly owned subsidiary, Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co.,
Ltd., to independent third-party individuals at aggregate consideration of CNY500,000 (approximately US$71,942) without any other obligations
arising from the transfer. Nanjing Yitian Biotech Co., Ltd. and its subsidiary, Beijing Yitan Jiarui Technology Co., Ltd. have not commenced
business activity since it was acquired on January 1, 2022 and the Company believed the transfer will improve in operational efficiency.
The consideration is determined by the Company according to the net assets appraisal report issued by an independent third-party appraisal
company on May 31, 2023, as of the date of May 31, 2023, the net assets value of Nanjing Yitian Biotech Co., Ltd. and its subsidiary,
Beijing Yitan Jiarui Technology Co., Ltd., was CNY498,587 (approximately US$71,739).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 9, 2023, Shandong Sglcell Biotech Co.,
Ltd., the wholly owned subsidiary of Shanghai Sglcell Biotech Co., Ltd., was transferred to independent third-party individuals at zero
consideration without any other obligations arising from the transfer. Shandong Sglcell Biotech Co., Ltd. has been inactive since it was
incorporated on July 8, 2022 and the Company believed the transfer will improve in operational efficiency. The consideration is determined
by the Company according to the net assets appraisal report issued by an independent third-party appraisal company on May 31, 2023, as
of the date of May 31, 2023, the net assets value of Shandong Sglcell Medical Devices Co., Ltd., was zero.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;(3)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Subsidiary established under Advanced Biomed HK Limited&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advanced Biomed HK Limited incorporated a wholly
owned subsidiary, Sglcell (Huangshan) Biotech Co., Ltd., in the PRC on March 4, 2022; it was established for the expected future manufacturing
of medical devices in the PRC.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 15, 2023, Sglcell (Huangshan) Biotech
Co., Ltd., the wholly owned subsidiary of Advanced Biomed HK Limited, was transferred to an independent third-party corporation at zero
consideration without any other obligations arising from the transfers. Sglcell (Huangshan) Biotech Co., Ltd. has been dormant since its
incorporation date from March 4, 2022 and the Company believed the transfer will improve in operational efficiency. The consideration
is determined by the Company according to the net assets appraisal report issued by an independent third-party appraisal company on May
31, 2023, as of the date of May 31, 2023, the net assets value of Shandong Sglcell Medical Devices Co., Ltd., was zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;(4)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Reorganization of Advanced Biomed Inc. (Taiwan) &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Advanced Biomed Inc. (Taiwan) was established
in Taiwan on September 1, 2014. It is primarily focused on mainly operates as a research and development of new center for technologies
in the field of oncology to help efficiently and cost-effectively identify and diagnose cancer cells.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On date of incorporation, July 16, 2021, the Company
issued 8,000,000 shares to Dr. Hung To Pau. On March 15, 2022, Dr. Hung To Pau transferred all of his 8,000,000 shares to Sglcell Ltd,
an exempted company incorporated under the law of Cayman Islands, the sole stockholder of which is Dr. Hung To Pau for a total consideration
of $8,000. The Company was dormant and has no substantive assets. On June 8, 2022, Sglcell Ltd transferred all of its 8,000,000 shares
to Dr. Yi Lu for a total consideration of $8,000. In July 2022, the Company consummated a reorganization of Advanced Biomed Inc. (Taiwan)
under share exchange arrangement of its then existing stockholders, who collectively owned all the equity interests of Advanced Biomed
Inc. (Taiwan) prior to the reorganization, transferred their respective shares in Advanced Biomed Inc. (Taiwan) to the Company. Prior
to the re-organization, Advanced Biomed Inc. (Taiwan) was directly owned and controlled by Dr. Yi Lu and Chen-Yi Lee with 99.93% and 0.07%
beneficial ownership interest, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;The Share Exchange&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to a share exchange agreement (the &#x201c;Agreement&#x201d;)
dated July 11, 2022, Dr. Yi Lu and Chen-Yi Lee transferred their respective shares in Advanced Biomed Inc. (Taiwan) at the time of the
Agreement, representing in aggregate 100% of the issued share capital of Advanced Biomed Inc. (Taiwan), to the Company. The consideration
for the share transfers was satisfied by the allotment and issuance of an aggregate of 385,257 fully paid up shares of common stock to
Dr. Yi Lu and Chen-Yi Lee. Following the completion of the share exchange and related issuances by and among the Company, Dr. Yi Lu and
Chen-Yi Lee, Advanced Biomed Inc. (Taiwan) ultimately became a wholly-owned subsidiary of the Company, and Dr. Yi Lu and Chen-Yi Lee became
the beneficial owners of the Company with percentage ownerships of 99.99% and 0.01% as of August 12, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Subsequently, on October 24, 2022, the Company
issued 365,368 shares to Chen-Yi Lee, and on October 24, 2022, the Company also issued 2,730,000 shares to Advance On Ventures Limited,
a company incorporated under the law of British Virgin Islands (the &#x201c;Ventures Limited&#x201d;), the beneficial owners of which are
employees of Advanced Biomed Taiwan. The Company issued 4,405,625 shares, 2,193,750 shares, 2,060,000 shares, 1,511,250 shares, 1,243,750
shares, 1,230,000 shares respectively to Dr. Hung To Pau, Yimin Jin, Xiaoyuan Luo, Nanzhen Shen, Jian Wang and Qiang Chen pursuant to
the Debt-For-Equity Exchange Agreement the Company entered into with the abovementioned stockholders on June 30, 2022 to settle debt of
a total amount of NTD 174,020,033 and RMB22,200,000 (approximately $9.04 million). On October 25, 2022, the Company issued 625,000 shares
to Hanyu Assets Co. Ltd. pursuant to the Investment Agreement the Company entered into with Hanyu Assets Co. Ltd. on June 6, 2022, and
the Company issued 250,000 shares to Newlink Technology Inc. pursuant to the Investment Agreement the Company entered into with Newlink
Technology Inc. on June 6, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon completion of the reorganization, Dr. Yi
Lu&#x2019;s percentage of ownerships of the Company became 33.54% as of October 25, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 7, 2022, the Company obtained the
approval of the Investment Commission of the Ministry of Economic Affairs (&#x201c;Taiwan Investment Commission&#x201d;) for the reorganization,
and the issuance number of which is &#x201c;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x7d93;&#x5be9;&#x4e00;&#x5b57;&#x7b2c;&lt;/span&gt;11100116890&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x865f;&lt;/span&gt;&#x201d;.
Additionally, the Bureau of Economic Development of Tainan City Government has also approved the reorganization in accordance with the
Taiwan Company Act on December 26, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to this reorganization, the Company
determined that Advanced Biomed Inc. (Taiwan) is the predecessor entity as the Company is an investment holding company with no business
activities carried out and all of the business of Advanced Biomed Inc. (Taiwan) acquired formed substantially all of the business of
the Company under Rule 405 of Regulation C. To reflect the real economic substance of the Company&#x2019;s business under the reorganization,
the accompanying consolidated financial statements were prepared assuming that the share exchange transaction, as disclosed above has
been completed, and the Company exercises control of Advanced Biomed Inc. (Taiwan). The transaction detailed above has been accounted
for as reverse takeover and recapitalization of the Company; whereby the Company (the legal acquirer) is considered the accounting acquiree,
and Advanced Biomed Inc. (Taiwan)(the legal acquiree) is considered as the accounting acquirer. This transaction is deemed to be a continuation
of the business of Advanced Biomed Inc. (Taiwan); therefore, no goodwill has been recorded for this transaction, and the Company&#x2019;s
historical financial information prior to the date of the recapitalization transaction is that of Advanced Biomed Inc. (Taiwan) and historical
changes in stockholders&#x2019; deficit and its results of operations have been presented from the beginning of the first period presented.
The above-mentioned equity is before the stock split on May 16, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company and its subsidiaries are in the table
as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="15" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Percentage of effective ownership&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Date of &lt;br/&gt; Incorporation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Place of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Principal &lt;br/&gt; Activities&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left"&gt;Advanced Biomed Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;July 16, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;Nevada&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: left"&gt;Investment holding&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; width: 25%; text-align: left"&gt;Advanced Biomed Inc. (Taiwan)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; width: 14%; text-align: center"&gt;September 1, 2014&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: 9%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="vertical-align: top; width: 1%; text-align: right"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: 9%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="vertical-align: top; width: 1%; text-align: right"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; width: 14%; text-align: center"&gt;Taiwan&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; width: 20%; text-align: left"&gt;Research and development of various advanced and innovative microfluidic biochip technologies, and provide the leading application of such technologies in precision oncology detection, diagnosis and treatment&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left"&gt;Advanced Biomed HK Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;August 10, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;100&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;100&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: left"&gt;Market development&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left"&gt;Shanghai Sglcell Biotech Co., Ltd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;April 12, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;100&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;100&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;People&#x2019;s Republic of China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: left"&gt;Clinical-related business&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
are presented assuming that the Company was in existence at the beginning of the first period presented.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c34"
      decimals="0"
      id="ixv-16579"
      unitRef="shares">1640000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c35"
      decimals="2"
      id="ixv-16580"
      unitRef="usdPershares">4</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c36" decimals="-4" id="ixv-16581" unitRef="usd">6560000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <advb:NetProceedsFromInitialPublicOffering contextRef="c36" decimals="-4" id="ixv-16582" unitRef="usd">5490000</advb:NetProceedsFromInitialPublicOffering>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="c37" decimals="2" id="ixv-16583" unitRef="pure">1</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="c38" decimals="2" id="ixv-16584" unitRef="pure">1</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c39" decimals="0" id="ixv-16585" unitRef="cny">500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c39" decimals="0" id="ixv-16586" unitRef="usd">71942</us-gaap:BusinessCombinationConsiderationTransferred1>
    <advb:BusinessCombinationConsiderationNetAssetFairValue contextRef="c40" decimals="0" id="ixv-16587" unitRef="cny">498587</advb:BusinessCombinationConsiderationNetAssetFairValue>
    <advb:BusinessCombinationConsiderationNetAssetFairValue contextRef="c40" decimals="0" id="ixv-16588" unitRef="usd">71739</advb:BusinessCombinationConsiderationNetAssetFairValue>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c41" decimals="0" id="ixv-16589" unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <advb:BusinessCombinationConsiderationNetAssetFairValue contextRef="c42" decimals="0" id="ixv-16590" unitRef="usd">0</advb:BusinessCombinationConsiderationNetAssetFairValue>
    <advb:BusinessCombinationConsiderationNetAssetFairValue contextRef="c43" decimals="0" id="ixv-16591" unitRef="usd">0</advb:BusinessCombinationConsiderationNetAssetFairValue>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c0" id="ixv-16592">2021-07-16</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c44"
      decimals="0"
      id="ixv-16593"
      unitRef="shares">8000000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c45"
      decimals="0"
      id="ixv-16594"
      unitRef="shares">8000000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c46" decimals="0" id="ixv-16595" unitRef="usd">8000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c47"
      decimals="0"
      id="ixv-16596"
      unitRef="shares">8000000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c48" decimals="0" id="ixv-16597" unitRef="usd">8000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="c49" decimals="4" id="ixv-16598" unitRef="pure">0.9993</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="c50" decimals="4" id="ixv-16599" unitRef="pure">0.0007</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="c51" decimals="2" id="ixv-16600" unitRef="pure">1</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c52"
      decimals="0"
      id="ixv-16601"
      unitRef="shares">385257</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="c53" decimals="4" id="ixv-16602" unitRef="pure">0.9999</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="c54" decimals="4" id="ixv-16603" unitRef="pure">0.0001</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c55"
      decimals="0"
      id="ixv-16604"
      unitRef="shares">365368</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c56"
      decimals="0"
      id="ixv-16605"
      unitRef="shares">2730000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c57"
      decimals="0"
      id="ixv-16606"
      unitRef="shares">4405625</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c58"
      decimals="0"
      id="ixv-16607"
      unitRef="shares">2193750</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c59"
      decimals="0"
      id="ixv-16608"
      unitRef="shares">2060000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c60"
      decimals="0"
      id="ixv-16609"
      unitRef="shares">1511250</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c61"
      decimals="0"
      id="ixv-16610"
      unitRef="shares">1243750</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c62"
      decimals="0"
      id="ixv-16611"
      unitRef="shares">1230000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c63" decimals="0" id="ixv-16612" unitRef="twd">174020033</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c63" decimals="0" id="ixv-16613" unitRef="cny">22200000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c63" decimals="-4" id="ixv-16614" unitRef="usd">9040000.00</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c64"
      decimals="0"
      id="ixv-16615"
      unitRef="shares">625000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c65"
      decimals="0"
      id="ixv-16616"
      unitRef="shares">250000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="c66" decimals="4" id="ixv-16617" unitRef="pure">0.3354</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock contextRef="c0" id="ixv-13015">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company and its subsidiaries are in the table
as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="15" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Percentage of effective ownership&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Date of &lt;br/&gt; Incorporation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Place of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Principal &lt;br/&gt; Activities&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left"&gt;Advanced Biomed Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;July 16, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-36"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-37"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;Nevada&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: left"&gt;Investment holding&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; width: 25%; text-align: left"&gt;Advanced Biomed Inc. (Taiwan)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; width: 14%; text-align: center"&gt;September 1, 2014&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: 9%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="vertical-align: top; width: 1%; text-align: right"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; width: 9%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="vertical-align: top; width: 1%; text-align: right"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; width: 14%; text-align: center"&gt;Taiwan&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; width: 20%; text-align: left"&gt;Research and development of various advanced and innovative microfluidic biochip technologies, and provide the leading application of such technologies in precision oncology detection, diagnosis and treatment&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left"&gt;Advanced Biomed HK Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;August 10, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;100&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;100&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;Hong Kong&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: left"&gt;Market development&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-indent: -10pt; padding-left: 10pt; vertical-align: top; text-align: left"&gt;Shanghai Sglcell Biotech Co., Ltd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;April 12, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;100&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;100&lt;/td&gt;&lt;td style="vertical-align: top; text-align: right"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;People&#x2019;s Republic of China&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: left"&gt;Clinical-related business&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate contextRef="c67" id="ixv-16618">2021-07-16</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c67" id="ixv-16619">Nevada</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c67" id="ixv-16620">Investment holding</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate contextRef="c69" id="ixv-16621">2014-09-01</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c69" decimals="2" id="ixv-16622" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c70" decimals="2" id="ixv-16623" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c69" id="ixv-16624">Taiwan</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c69" id="ixv-16625">Research and development of various advanced and innovative microfluidic biochip technologies, and provide the leading application of such technologies in precision oncology detection, diagnosis and treatment</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate contextRef="c71" id="ixv-16626">2021-08-10</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c71" decimals="2" id="ixv-16627" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c72" decimals="2" id="ixv-16628" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c71" id="ixv-16629">Hong Kong</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c71" id="ixv-16630">Market development</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate contextRef="c73" id="ixv-16631">2019-04-12</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDate>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c73" decimals="2" id="ixv-16632" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest contextRef="c74" decimals="2" id="ixv-16633" unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState contextRef="c73" id="ixv-16634">People&#x2019;s Republic of China</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c73" id="ixv-16635">Clinical-related business</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c0" id="ixv-13128">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;2. LIQUIDITY AND GOING CONCERN&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared in conformity with U.S. GAAP which contemplates continuation of the Company on a going concern basis. The going concern
basis assumes that assets are realized, and liabilities are settled in the ordinary course of business at amounts disclosed in the consolidated
financial statements. The Company&#x2019;s ability to continue as a going concern depends upon its ability to develop, register and obtain
regulatory approval for commercial sell of its products to generate positive operating cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To sustain its ability to support the Company&#x2019;s
operating activities, the Company may have to consider supplementing its available sources of funds through the following sources:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;raise additional capital; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;cash generated from upcoming operations; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;financial support from the Company&#x2019;s related party and stockholders as well as third parties.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company certain related parties have waived
off the amount due to them as of June 30, 2024, which amounted to $2,820,624 in order to improve the Company&#x2019;s working capital.
The Company completed its initial public offering. In the initial public offering, the Company issued 1,640,000 shares of common stock
at a price of US$4.00 per share. The Company received gross proceeds in the amount of US$6.56 million before deducting any underwriting
discounts or expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 6, 2025, the Company entered into a purchase
agreement (the &#x201c;ELOC Agreement&#x201d;) with HELENA GLOBAL INVESTMENT OPPORTUNITIES I LTD. (the &#x201c;Investor&#x201d; or &#x201c;Selling
Stockholder&#x201d;), pursuant to which the Company have the right to issue and sell to the Investor, from time to time as provided therein,
and the Investor is obligated to purchase from us, up to Twenty-Five Million United States Dollars ($25,000,000) of the Company&#x2019;s
Common Stock, subject to terms and conditions set forth in the ELOC Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;However, for the financial year ended June 30,
2025, the Company reported net loss of $3,258,969. In addition, the Company had net cash outflows of $5,825,055 from operating activities
for the financial year ended June 30, 2025. These conditions give rise to substantial doubt as to whether the Company will be able to
continue as a going concern. The consolidated financial statements for the financial years ended June 30, 2025 and 2024 have been prepared
on a going concern basis and do not include any adjustments to reflect the possible future effects on the recoverability and classifications
of assets or the amounts and classifications of liabilities that may result from the inability of the Company to continue as a going concern.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <advb:workingCapital contextRef="c3" decimals="0" id="ixv-16636" unitRef="usd">2820624</advb:workingCapital>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c75"
      decimals="0"
      id="ixv-16637"
      unitRef="shares">1640000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c76"
      decimals="2"
      id="ixv-16638"
      unitRef="usdPershares">4</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c75" decimals="-4" id="ixv-16639" unitRef="usd">6560000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c77" decimals="0" id="ixv-16640" unitRef="usd">25000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-16641" unitRef="usd">-3258969</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-16642" unitRef="usd">-5825055</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-13172">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(a) Basis of presentation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;)
and pursuant to the regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(b) Consolidation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements include
the financial statements of the Company and its subsidiaries. All inter-company transactions, if any, and balances due to, due from, long-term
investment subsidiary, and registered paid in capital have been eliminated upon consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Business combinations are accounted for using
the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective
fair values as of the acquisition date in the Company&#x2019;s consolidated financial statements. Any excess fair value of consideration
transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection
with the business combination are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent
reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in the consolidated statements
of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;When the Company determines that assets acquired
do not meet the definition of a business under the acquisition method of accounting, acquired assets is expensed, no goodwill is recorded,
and any contingent consideration is recognized only when it becomes payable or is paid.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(c) Use of estimates&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to useful lives for equipment
and intangible assets, assumptions used in assessing right of use assets, impairment of long-lived assets and uncertain tax position.
Actual results could vary from the estimates and assumptions that were used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(d) Stock split and reverse share
split&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 16, 2023, the Company effected a forward
share split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, the Company
now have 100,000,000 common stock issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the
above transactions on a retroactive basis similar to share split or dividend pursuant to ASC 260. All references made to share or per
share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect
the 4 for 1 share split. The shares of common stock retain a par value of $0.001 per share. Accordingly, an amount equal to the par value
of the increased shares resulting from the share split was reclassified from &#x201c;Additional paid-in capital&#x201d; to &#x201c;Common
stock&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 15, 2024, the Company effected the
reverse share split of all issued and outstanding shares of 100,000,000 shares at a ratio of 5:1. As a result of the reverse share split,
the Company now have 20,000,000 common stock issued and outstanding as of the date hereof. Unless indicated or the context otherwise requires,
all number of common stock in this report has been retrospectively adjusted for the reverse share split, as if such reverse share split
occurred on the first day of the years presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(e) Risks and uncertainties&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The main operations of the Company are located
in Taiwan and mainland China. Accordingly, the Company&#x2019;s business, financial condition, and results of operations may be influenced
by political, economic, and legal environments in Taiwan and mainland China, as well as by the general state of the economy in these two
countries. The Company&#x2019;s results may be adversely affected by changes in the political, regulatory and social conditions in these
two countries.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&#x2019;s operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(f) Foreign currency translation and transaction
and convenience translation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
are presented in the US Dollar (&#x201c;US$&#x201d;), which is the reporting currency of the Company. The functional currency of the Company
is the US$. Advanced Biomed Inc. (Taiwan) uses New Taiwan dollar (&#x201c;NT$&#x201d;) as its functional currency. Advanced Biomed HK Limited
uses Hong Kong dollars (&#x201c;HKD&#x201d;) and Shanghai Sglcell Biotech Co., Ltd. uses Chinese Yuan (&#x201c;CNY&#x201d;) as their functional
currencies, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Assets and liabilities denominated in currencies
other than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the balance sheet
date. Translation gains and losses are recognized in the consolidated statements of income and comprehensive income as other comprehensive
income or loss. Transactions in currencies other than the reporting currency are measured and recorded in the reporting currency at the
exchange rate prevailing on the transaction date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated
statements of income and comprehensive income as other income (other expense).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The value of foreign currencies including, the
NT$, CNY and HKD, may fluctuate against the US Dollar. Any significant variations of the aforementioned currencies relative to the US
Dollar may materially affect the Company&#x2019;s financial condition in terms of reporting in US Dollar. The following table outlines
the currency exchange rates that were used in preparing the accompanying consolidated financial statements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;US$ to NT$ fiscal year end&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29.18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;US$ to NT$ average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;US$ to CNY fiscal year end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;US$ to CNY average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;US$ to HKD fiscal year end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;US$ to HKD average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(g) Fair value measurement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting guidance defines fair value as the
price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded
at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions
that market participants would use when pricing the asset or liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting guidance establishes a fair value hierarchy
that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
A financial instrument&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant
to the fair value measurement. Accounting guidance establishes three levels of inputs that may be used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1 applies to assets or liabilities for which there are quoted prices, in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical asset or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3 applies to asset or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash, other current assets, leases payable, accounts
payables, accruals and other current liabilities are financial assets and liabilities. Cash, other current assets, accounts payable, accruals
and other current liabilities are subject to fair value measurement; however, because of their being short term in nature management believes
their carrying values approximate their fair value. Financial instruments are fair value financial assets that are marked to fair value
and are accounted for under as Level 3 under the above hierarchy. The Company accounts for lease payables at amortized cost and has elected
NOT to account for them under the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(h) Related parties&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We adopted ASC 850, Related Party Disclosures,
for the identification of related parties and disclosure of related party transactions for the years ended June 30, 2025 and 2024.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(i) Cash &lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash consists of cash on hand, the Company&#x2019;s
demand deposit placed with financial institutions, which have original maturities of less than three months and unrestricted as to withdrawal
and use. Deposits are held at highly liquid and well capitalized financial institutions. Risk of loss is not expected by management.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(j) Intangible assets, net&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s intangible assets are stated
at cost less accumulated amortization and impairment, if any, and amortized on a straight-line basis over the estimated useful lives of
the assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Category&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Estimated &lt;br/&gt;
useful lives&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Software&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="width: 88%"&gt;&lt;span style="font-size: 10pt"&gt;Patents&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; width: 11%"&gt;&lt;span style="font-size: 10pt"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Software represents purchased software and is
amortized straight-line over the Company&#x2019;s estimates to generate economic benefits from such software, generally three years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Patents represent the estimated fair value assigned to finite-lived
intangible assets acquired in a transaction that is accounted for as an acquisition of assets rather than a business combination are initially
recognized in accordance with other application GAAP. Any consideration transferred in excess of the fair value of the assets acquired
is allocated to each asset acquired on a relative fair value basis. Amortization is computed using the straight-line method over the estimated
useful lives of the respective finite-lived intangible assets, generally six years. Intangible assets are reviewed for impairment at least
annually or more frequently if indicators of potential impairment exist. The Company reviews finite-lived intangible assets for impairment
at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be
recoverable. If the carrying value of a finite-lived intangible asset exceeds its fair value, then it is written down to its adjusted
fair value. The Company had previously recognized an impairment loss on certain intangible assets in prior years. The remaining intangible
assets were assessed for impairment as of the balance sheet date, and management concluded that no further impairment was required.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(k) Equipment, net&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equipment, net are stated at cost less accumulated
depreciation and impairment, if any, and depreciated on a straight-line basis over the estimated useful lives of the assets. Cost represents
the purchase price of the asset and other costs incurred to bring the asset into its intended use. Estimated useful lives are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 88%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Category&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid; width: 11%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Estimated &lt;br/&gt;
useful lives&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Expenditure for repair and maintenance costs,
which do not materially extend the useful lives of the assets, are charged to expenses as incurred, whereas the expenditure for major
renewals and betterment that substantially extends the useful lives of property and equipment are capitalized as additions to the related
assets. Retirements, sales and disposals of assets are recorded by removing the costs, accumulated depreciation and impairment with any
resulting gain or loss recognized in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;(l) Deferred Initial Public Offering (&#x201c;IPO&#x201d;) costs&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company complies with the requirement of the
ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses of Offering&#x201d;. Initial public
offering expense directly attributable to offering of securities are deferred and would be charged against the gross proceeds of the offering,
as a reduction in share capital. These deferred expenses mainly consist of underwriting, legal and other expenses incurred through the
balance sheet date that are directly related to the intended IPO. As of June 30, 2024, the Company capitalized US$638,871 of deferred
initial public offering costs. As of June 30, 2025, the Company had completed its Initial Public Offering, and the accumulated deferred
IPO cost was &lt;span style="-sec-ix-hidden: hidden-fact-38"&gt;Nil&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(m) Impairment of long-lived assets&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company reviews its long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When
these events occur, the Company measures impairment by comparing the carrying value of the long-lived assets to the estimated undiscounted
future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted
cash flow is less than the carrying amount of the assets, the Company would recognize an impairment loss, which is the excess of carrying
amount over the fair value of the assets, using the expected future discounted cash flows. As of June 30, 2025 and 2024, the Company had
&lt;span style="-sec-ix-hidden: hidden-fact-39"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-40"&gt;no&lt;/span&gt;&lt;/span&gt; remaining carrying amount of finite-lived intangible related to purchased patents from the acquisition of Shanghai Sglcell Biotech
Co., Ltd. as the assets were fully impaired in 2022.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(n) Commitments and contingencies&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the normal course of business, the Company
is subject to commitments and contingencies, including operating lease commitments, legal proceedings and claims arising out of its business
that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes a liability for such
contingency if it determines it is probable that a loss will occur, and a reasonable estimate of the loss can be made. The Company may
consider many factors in making these assessments on liability for contingencies, including historical and the specific facts and circumstances
of each matter.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(o) Research and development expenses&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development expenses include costs
directly attributable to the conduct of research and development programs, including licensing fees, cost of salaries, payroll taxes and
other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing
costs and professional services. All costs associated with research and developments are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has already started the registration
process and plans to start clinical research in November 2025, which are expected to end in May 2026, and we expect to obtain the required
registration certificate by October 2027. As of June 30, 2025, the Company has not commenced sales of the products nor have any revenue-generating
products and do not expect sales of revenue-generating product candidates until the Company has completed clinical development, submitted
regulatory filings, and received applicable regulatory approvals for candidate products.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Hence, the Company incurred its research and development
cost during the years ended June 30, 2025 and 2024, which is in compliance under ASC 730-10-25.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(p) General and administrative expenses&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;General and administrative expenses mainly consist
of staff cost, depreciation, office supplies and upkeep expenses, travelling and entertainment, legal and professional fees, property
and related expenses, other miscellaneous administrative expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(q) Operating leases&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Prior to the adoption of ASC 842 on January
1, 2019:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Leases, mainly leases of factory buildings, offices
and employee dormitories, where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for
as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The
Company had no finance leases for any of the periods stated herein.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Upon and hereafter the adoption of ASC 842
on January 1, 2019:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company determines if an arrangement is a
lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, operating lease liability,
and operating lease liability, non-current in the Company&#x2019;s consolidated balance sheets. ROU assets represent the Company&#x2019;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments
arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease
payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is
reasonably certain that it will exercise that option, if any. As the Company&#x2019;s leases do not provide an implicit rate, the Company
used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.
The Company has elected to adopt the following lease policies in conjunction with the adoption of ASU 2016-02: (i) for leases that have
lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Company elected not
to apply ASC 842 recognition requirements; and (ii) the Company elected to apply the package of practical expedients for existing arrangements
entered into prior to January 1, 2019 to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification
applied to existing leases, and (c) initial direct costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;i&gt;(r) Income Taxes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company
is able to realize their benefits, or future deductibility is uncertain.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under ASC 740, a tax position is recognized as
a benefit only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not
that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical
merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount
of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50
percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition
threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that
no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the
threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense
in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the years ended June 30, 2025
and 2024. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures
and transition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Valuation of Deferred Tax Assets&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A valuation allowance is recorded to reduce the
Company&#x2019;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#x2019;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results
in the period such determination was made.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(s) Loss per share&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Loss per share is computed by dividing net loss
attributable to common stockholders&#160;by the weighted average number of common stock outstanding during the year. Diluted earnings
per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted
into common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(t) Segment Reporting&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;FASB ASC 280, &#x201c;Segment Reporting&#x201d;,
establishes standards for reporting information about operating segments on a basis consistent with the Company&#x2019;s internal organizational
structure as well as information about geographical areas, business segments and major customers in financial statements for details on
the Company&#x2019;s business segments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the management approach to determine
reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#x2019;s chief
operating decision maker (&#x201c;CODM&#x201d;) for making decisions, allocating resources and assessing performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s CODM has been identified as
the CEO, who reviews results when making decisions about allocating resources and assessing the performance of the Company. For the years
ended June 30, 2025 and 2024, the CODM reviewed the consolidated results when making decisions about allocating resources and assessing
performance of the Company as a whole, and the Company has only one reportable segment.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(u) Recent accounting pronouncements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In October 2023, the FASB issued ASU 2023-06,
&#x201c;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative.&#x201d;
This amendment incorporates certain U.S. Securities and Exchange Commission (SEC) disclosure requirements into the FASB Accounting Standards
Codification. The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification
Topics, allow users to more easily compare entities subject to the SEC&#x2019;s existing disclosures with those entities that were not
previously subject to the requirements, and align the requirements in the Codification with the SEC&#x2019;s regulations. For entities
subject to the SEC&#x2019;s existing disclosure requirements and for entities required to file or furnish financial statements with or
to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer,
the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. For all other
entities, the amendments will be effective two years later. However, if by June 30, 2027, the SEC has not removed the related disclosure
from its regulations, the amendments will be removed from the Codification and not become effective for any entity. The Company does not
expect the adoption of ASU 2023-06 to have a material impact on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740)&#160;&#x2014;&#160;Improvements to income Tax Disclosures. The amendment in this update are effective for annual
periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods
beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available
for issuance. The Company has adopted ASU 2023-09 on July 1, 2024 and the adoption
of the standard did not have a material impact to the overall financial presentation. See Note 10 for further information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March 2024, the FASB issued ASU 2024-01, Compensation
&#x2014; Stock Compensation (Topic 718)&#160;&#x2014;&#160;Scope Application of Profits Interest and Similar Award. For public business
entities, the amendments in this Update are effective for annual periods beginning after December 15, 2024, and interim periods within
those annual periods. For all other entities, the amendments are effective for annual periods beginning after December 15, 2025, and interim
periods within those annual periods. Early adoption is permitted for both interim and annual financial statements that have not yet been
issued or made available for issuance. If an entity adopts the amendments in an interim period, it should adopt them as of the beginning
of the annual period that includes that interim period. The Company believes the future adoption of this ASU is not expected
to have a material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March&#160;2024, the FASB issued ASU&#160;2024-02,
&#x201c;Codification Improvements&#160;&#x2014;&#160;Amendments to Remove References to the Concepts Statements&#x201d;. This update contains
amendments to the Codification that remove references to various FASB Concepts Statements. These issues to remove references to various
Concepts Statements and the amendments apply to all reporting entities within the scope of the affected accounting guidance. The amendments
in this Update are effective for public business entities for fiscal&#160;years beginning after December&#160;15, 2024. Early application
of the amendments in this Update is permitted for any fiscal year or interim period for which financial statements have not yet been issued
(or made available for issuance). The Company is currently evaluating the impact of adoption on the Company&#x2019;s
related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November&#160;2024, the FASB issued ASU&#160;2024-03,
Income Statement&#160;&#x2014;&#160;Reporting Comprehensive Income&#160;&#x2014;&#160;Expense Disaggregation Disclosures (Subtopic&#160;220-40):
Disaggregation of Income Statement Expenses and in January&#160;2025, the FASB issued ASU&#160;2025-01, Income Statement&#160;&#x2014;&#160;Reporting
Comprehensive Income&#160;&#x2014;&#160;Expense Disaggregation Disclosures (Subtopic&#160;220-40): Clarifying the Effective Date (&#x201c;ASU&#160;2025-01&#x201d;).
The ASU requires a public business entity to provide disaggregated disclosures of certain categories of expenses on an annual and interim
basis including purchases of inventory, employee compensation, depreciation, and intangible asset amortization for each income statement
line item that contains those expenses. ASU&#160;2024-03, as clarified by ASU&#160;2025-01 is effective for annual reporting periods beginning
after December&#160;15, 2026, and interim periods beginning after December&#160;15, 2027, with prospective or retrospective application
permitted. The Company is currently evaluating the impact of adoption on the Company&#x2019;s related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Except as mentioned above, the Company does not
believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s
consolidated balance sheets, statements of operations and comprehensive loss and statements of cash flows.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-13177">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(a) Basis of presentation&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;)
and pursuant to the regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-13186">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(b) Consolidation&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements include
the financial statements of the Company and its subsidiaries. All inter-company transactions, if any, and balances due to, due from, long-term
investment subsidiary, and registered paid in capital have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Business combinations are accounted for using
the acquisition method of accounting. Under the acquisition method, assets acquired, and liabilities assumed are recorded at their respective
fair values as of the acquisition date in the Company&#x2019;s consolidated financial statements. Any excess fair value of consideration
transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection
with the business combination are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent
reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in the consolidated statements
of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;When the Company determines that assets acquired
do not meet the definition of a business under the acquisition method of accounting, acquired assets is expensed, no goodwill is recorded,
and any contingent consideration is recognized only when it becomes payable or is paid.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-13214">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(c) Use of estimates&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to useful lives for equipment
and intangible assets, assumptions used in assessing right of use assets, impairment of long-lived assets and uncertain tax position.
Actual results could vary from the estimates and assumptions that were used.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <advb:StockSplitPolicyTextBlock contextRef="c0" id="ixv-13222">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(d) Stock split and reverse share
split&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 16, 2023, the Company effected a forward
share split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, the Company
now have 100,000,000 common stock issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the
above transactions on a retroactive basis similar to share split or dividend pursuant to ASC 260. All references made to share or per
share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect
the 4 for 1 share split. The shares of common stock retain a par value of $0.001 per share. Accordingly, an amount equal to the par value
of the increased shares resulting from the share split was reclassified from &#x201c;Additional paid-in capital&#x201d; to &#x201c;Common
stock&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 15, 2024, the Company effected the
reverse share split of all issued and outstanding shares of 100,000,000 shares at a ratio of 5:1. As a result of the reverse share split,
the Company now have 20,000,000 common stock issued and outstanding as of the date hereof. Unless indicated or the context otherwise requires,
all number of common stock in this report has been retrospectively adjusted for the reverse share split, as if such reverse share split
occurred on the first day of the years presented.&lt;/p&gt;</advb:StockSplitPolicyTextBlock>
    <advb:ForwardShareSplitIssued
      contextRef="c78"
      decimals="0"
      id="ixv-16643"
      unitRef="shares">25000000</advb:ForwardShareSplitIssued>
    <advb:ForwardShareSplitOutstanding
      contextRef="c78"
      decimals="0"
      id="ixv-16644"
      unitRef="shares">25000000</advb:ForwardShareSplitOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c79" id="ixv-16645">1-to-4</us-gaap:StockholdersEquityReverseStockSplit>
    <advb:ForwardShareSplitIssued
      contextRef="c1"
      decimals="0"
      id="ixv-16646"
      unitRef="shares">100000000</advb:ForwardShareSplitIssued>
    <advb:ForwardShareSplitOutstanding
      contextRef="c1"
      decimals="0"
      id="ixv-16647"
      unitRef="shares">100000000</advb:ForwardShareSplitOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c80"
      decimals="0"
      id="ixv-16648"
      unitRef="shares">4</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c81"
      decimals="0"
      id="ixv-16649"
      unitRef="shares">1</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c82"
      decimals="3"
      id="ixv-16650"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <advb:ForwardShareSplitIssued
      contextRef="c83"
      decimals="0"
      id="ixv-16651"
      unitRef="shares">100000000</advb:ForwardShareSplitIssued>
    <advb:ForwardShareSplitOutstanding
      contextRef="c83"
      decimals="0"
      id="ixv-16652"
      unitRef="shares">100000000</advb:ForwardShareSplitOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c84" id="ixv-16653">5:1</us-gaap:StockholdersEquityReverseStockSplit>
    <advb:ForwardShareSplitIssued
      contextRef="c85"
      decimals="0"
      id="ixv-16654"
      unitRef="shares">20000000</advb:ForwardShareSplitIssued>
    <advb:ForwardShareSplitOutstanding
      contextRef="c85"
      decimals="0"
      id="ixv-16655"
      unitRef="shares">20000000</advb:ForwardShareSplitOutstanding>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-13233">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(e) Risks and uncertainties&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The main operations of the Company are located
in Taiwan and mainland China. Accordingly, the Company&#x2019;s business, financial condition, and results of operations may be influenced
by political, economic, and legal environments in Taiwan and mainland China, as well as by the general state of the economy in these two
countries. The Company&#x2019;s results may be adversely affected by changes in the political, regulatory and social conditions in these
two countries.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s business, financial condition
and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics
and other catastrophic incidents, which could significantly disrupt the Company&#x2019;s operations.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0" id="ixv-13243">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(f) Foreign currency translation and transaction
and convenience translation&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
are presented in the US Dollar (&#x201c;US$&#x201d;), which is the reporting currency of the Company. The functional currency of the Company
is the US$. Advanced Biomed Inc. (Taiwan) uses New Taiwan dollar (&#x201c;NT$&#x201d;) as its functional currency. Advanced Biomed HK Limited
uses Hong Kong dollars (&#x201c;HKD&#x201d;) and Shanghai Sglcell Biotech Co., Ltd. uses Chinese Yuan (&#x201c;CNY&#x201d;) as their functional
currencies, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Assets and liabilities denominated in currencies
other than the reporting currency are translated into the reporting currency at the rates of exchange prevailing at the balance sheet
date. Translation gains and losses are recognized in the consolidated statements of income and comprehensive income as other comprehensive
income or loss. Transactions in currencies other than the reporting currency are measured and recorded in the reporting currency at the
exchange rate prevailing on the transaction date. The cumulative gain or loss from foreign currency transactions is reflected in the consolidated
statements of income and comprehensive income as other income (other expense).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The value of foreign currencies including, the
NT$, CNY and HKD, may fluctuate against the US Dollar. Any significant variations of the aforementioned currencies relative to the US
Dollar may materially affect the Company&#x2019;s financial condition in terms of reporting in US Dollar. The following table outlines
the currency exchange rates that were used in preparing the accompanying consolidated financial statements:&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;US$ to NT$ fiscal year end&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29.18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;US$ to NT$ average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;US$ to CNY fiscal year end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;US$ to CNY average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;US$ to HKD fiscal year end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;US$ to HKD average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock contextRef="c0" id="ixv-16656">The following table outlines
the currency exchange rates that were used in preparing the accompanying consolidated financial statements:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;US$ to NT$ fiscal year end&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29.18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;US$ to NT$ average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31.83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;US$ to CNY fiscal year end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;US$ to CNY average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;US$ to HKD fiscal year end&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;US$ to HKD average rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1 contextRef="c91" decimals="2" id="ixv-16657" unitRef="pure">29.18</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1 contextRef="c92" decimals="2" id="ixv-16658" unitRef="pure">32.45</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1 contextRef="c93" decimals="2" id="ixv-16659" unitRef="pure">32.09</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1 contextRef="c94" decimals="2" id="ixv-16660" unitRef="pure">31.83</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1 contextRef="c95" decimals="2" id="ixv-16661" unitRef="pure">7.16</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1 contextRef="c96" decimals="2" id="ixv-16662" unitRef="pure">7.27</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1 contextRef="c97" decimals="2" id="ixv-16663" unitRef="pure">7.21</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1 contextRef="c98" decimals="2" id="ixv-16664" unitRef="pure">7.23</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1 contextRef="c99" decimals="2" id="ixv-16665" unitRef="pure">7.85</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c100"
      decimals="2"
      id="ixv-16666"
      unitRef="pure">7.81</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c101"
      decimals="2"
      id="ixv-16667"
      unitRef="pure">7.79</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c102"
      decimals="2"
      id="ixv-16668"
      unitRef="pure">7.82</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-13354">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(g) Fair value measurement&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting guidance defines fair value as the
price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded
at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions
that market participants would use when pricing the asset or liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting guidance establishes a fair value hierarchy
that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
A financial instrument&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant
to the fair value measurement. Accounting guidance establishes three levels of inputs that may be used to measure fair value:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1 applies to assets or liabilities for which there are quoted prices, in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical asset or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3 applies to asset or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash, other current assets, leases payable, accounts
payables, accruals and other current liabilities are financial assets and liabilities. Cash, other current assets, accounts payable, accruals
and other current liabilities are subject to fair value measurement; however, because of their being short term in nature management believes
their carrying values approximate their fair value. Financial instruments are fair value financial assets that are marked to fair value
and are accounted for under as Level 3 under the above hierarchy. The Company accounts for lease payables at amortized cost and has elected
NOT to account for them under the fair value hierarchy.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <advb:RelatedPartiesPolicyTextBlock contextRef="c0" id="ixv-13395">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(h) Related parties&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We adopted ASC 850, Related Party Disclosures,
for the identification of related parties and disclosure of related party transactions for the years ended June 30, 2025 and 2024.&lt;/p&gt;</advb:RelatedPartiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-13417">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(i) Cash &lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash consists of cash on hand, the Company&#x2019;s
demand deposit placed with financial institutions, which have original maturities of less than three months and unrestricted as to withdrawal
and use. Deposits are held at highly liquid and well capitalized financial institutions. Risk of loss is not expected by management.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c0" id="ixv-13424">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(j) Intangible assets, net&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s intangible assets are stated
at cost less accumulated amortization and impairment, if any, and amortized on a straight-line basis over the estimated useful lives of
the assets.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Category&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Estimated &lt;br/&gt;
useful lives&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Software&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="width: 88%"&gt;&lt;span style="font-size: 10pt"&gt;Patents&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; width: 11%"&gt;&lt;span style="font-size: 10pt"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Software represents purchased software and is
amortized straight-line over the Company&#x2019;s estimates to generate economic benefits from such software, generally three years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Patents represent the estimated fair value assigned to finite-lived
intangible assets acquired in a transaction that is accounted for as an acquisition of assets rather than a business combination are initially
recognized in accordance with other application GAAP. Any consideration transferred in excess of the fair value of the assets acquired
is allocated to each asset acquired on a relative fair value basis. Amortization is computed using the straight-line method over the estimated
useful lives of the respective finite-lived intangible assets, generally six years. Intangible assets are reviewed for impairment at least
annually or more frequently if indicators of potential impairment exist. The Company reviews finite-lived intangible assets for impairment
at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be
recoverable. If the carrying value of a finite-lived intangible asset exceeds its fair value, then it is written down to its adjusted
fair value. The Company had previously recognized an impairment loss on certain intangible assets in prior years. The remaining intangible
assets were assessed for impairment as of the balance sheet date, and management concluded that no further impairment was required.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0" id="ixv-13428">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s intangible assets are stated
at cost less accumulated amortization and impairment, if any, and amortized on a straight-line basis over the estimated useful lives of
the assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Category&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Estimated &lt;br/&gt;
useful lives&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Software&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td style="width: 88%"&gt;&lt;span style="font-size: 10pt"&gt;Patents&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; width: 11%"&gt;&lt;span style="font-size: 10pt"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c86" id="ixv-16669">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c87" id="ixv-16670">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c86" id="ixv-16671">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c87" id="ixv-16672">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-13462">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(k) Equipment, net&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equipment, net are stated at cost less accumulated
depreciation and impairment, if any, and depreciated on a straight-line basis over the estimated useful lives of the assets. Cost represents
the purchase price of the asset and other costs incurred to bring the asset into its intended use. Estimated useful lives are as follows:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 88%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Category&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid; width: 11%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Estimated &lt;br/&gt;
useful lives&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Expenditure for repair and maintenance costs,
which do not materially extend the useful lives of the assets, are charged to expenses as incurred, whereas the expenditure for major
renewals and betterment that substantially extends the useful lives of property and equipment are capitalized as additions to the related
assets. Retirements, sales and disposals of assets are recorded by removing the costs, accumulated depreciation and impairment with any
resulting gain or loss recognized in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <advb:ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock contextRef="c0" id="ixv-16673">Estimated useful lives are as follows:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 88%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Category&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid; width: 11%"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Estimated &lt;br/&gt;
useful lives&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</advb:ScheduleOfEstimatedUsefulLivesOfEquipmentNetAtCostLessAccumulatedDepreciationAndImpairmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c103" id="ixv-16674">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c104" id="ixv-16675">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c105" id="ixv-16676">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c106" id="ixv-16677">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c107" id="ixv-16678">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c108" id="ixv-16679">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c109" id="ixv-16680">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <advb:DeferredInitialPublicOfferingIPOCostsPolicyTextBlock contextRef="c0" id="ixv-13524">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;(l) Deferred Initial Public Offering (&#x201c;IPO&#x201d;) costs&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company complies with the requirement of the
ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A &#x2014; &#x201c;Expenses of Offering&#x201d;. Initial public
offering expense directly attributable to offering of securities are deferred and would be charged against the gross proceeds of the offering,
as a reduction in share capital. These deferred expenses mainly consist of underwriting, legal and other expenses incurred through the
balance sheet date that are directly related to the intended IPO. As of June 30, 2024, the Company capitalized US$638,871 of deferred
initial public offering costs. As of June 30, 2025, the Company had completed its Initial Public Offering, and the accumulated deferred
IPO cost was &lt;span style="-sec-ix-hidden: hidden-fact-38"&gt;Nil&lt;/span&gt;.&lt;/p&gt;</advb:DeferredInitialPublicOfferingIPOCostsPolicyTextBlock>
    <us-gaap:CapitalizedComputerSoftwareNet contextRef="c88" decimals="0" id="ixv-16681" unitRef="usd">638871</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-13534">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(m) Impairment of long-lived assets&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company reviews its long-lived assets for
impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When
these events occur, the Company measures impairment by comparing the carrying value of the long-lived assets to the estimated undiscounted
future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted
cash flow is less than the carrying amount of the assets, the Company would recognize an impairment loss, which is the excess of carrying
amount over the fair value of the assets, using the expected future discounted cash flows. As of June 30, 2025 and 2024, the Company had
&lt;span style="-sec-ix-hidden: hidden-fact-39"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-40"&gt;no&lt;/span&gt;&lt;/span&gt; remaining carrying amount of finite-lived intangible related to purchased patents from the acquisition of Shanghai Sglcell Biotech
Co., Ltd. as the assets were fully impaired in 2022.&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0" id="ixv-13543">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(n) Commitments and contingencies&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the normal course of business, the Company
is subject to commitments and contingencies, including operating lease commitments, legal proceedings and claims arising out of its business
that relate to a wide range of matters, such as government investigations and tax matters. The Company recognizes a liability for such
contingency if it determines it is probable that a loss will occur, and a reasonable estimate of the loss can be made. The Company may
consider many factors in making these assessments on liability for contingencies, including historical and the specific facts and circumstances
of each matter.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-13551">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(o) Research and development expenses&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development expenses include costs
directly attributable to the conduct of research and development programs, including licensing fees, cost of salaries, payroll taxes and
other employee benefits, subcontractors and materials used for research and development activities, including clinical trials, manufacturing
costs and professional services. All costs associated with research and developments are expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has already started the registration
process and plans to start clinical research in November 2025, which are expected to end in May 2026, and we expect to obtain the required
registration certificate by October 2027. As of June 30, 2025, the Company has not commenced sales of the products nor have any revenue-generating
products and do not expect sales of revenue-generating product candidates until the Company has completed clinical development, submitted
regulatory filings, and received applicable regulatory approvals for candidate products.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Hence, the Company incurred its research and development
cost during the years ended June 30, 2025 and 2024, which is in compliance under ASC 730-10-25.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c0" id="ixv-13566">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(p) General and administrative expenses&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;General and administrative expenses mainly consist
of staff cost, depreciation, office supplies and upkeep expenses, travelling and entertainment, legal and professional fees, property
and related expenses, other miscellaneous administrative expenses.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-13588">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(q) Operating leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Prior to the adoption of ASC 842 on January
1, 2019:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Leases, mainly leases of factory buildings, offices
and employee dormitories, where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for
as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The
Company had no finance leases for any of the periods stated herein.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Upon and hereafter the adoption of ASC 842
on January 1, 2019:&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company determines if an arrangement is a
lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, operating lease liability,
and operating lease liability, non-current in the Company&#x2019;s consolidated balance sheets. ROU assets represent the Company&#x2019;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments
arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease
payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is
reasonably certain that it will exercise that option, if any. As the Company&#x2019;s leases do not provide an implicit rate, the Company
used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.
The Company has elected to adopt the following lease policies in conjunction with the adoption of ASU 2016-02: (i) for leases that have
lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Company elected not
to apply ASC 842 recognition requirements; and (ii) the Company elected to apply the package of practical expedients for existing arrangements
entered into prior to January 1, 2019 to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification
applied to existing leases, and (c) initial direct costs.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-13606">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;i&gt;(r) Income Taxes&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company
is able to realize their benefits, or future deductibility is uncertain.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under ASC 740, a tax position is recognized as
a benefit only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not
that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical
merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount
of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50
percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition
threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that
no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the
threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense
in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the years ended June 30, 2025
and 2024. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures
and transition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Valuation of Deferred Tax Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A valuation allowance is recorded to reduce the
Company&#x2019;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#x2019;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results
in the period such determination was made.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement contextRef="c0" id="ixv-16682">A tax position is measured at the largest amount of benefit that is greater than 50
percent likely of being realized upon ultimate settlement.</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-13638">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(s) Loss per share&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Loss per share is computed by dividing net loss
attributable to common stockholders&#160;by the weighted average number of common stock outstanding during the year. Diluted earnings
per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted
into common stock.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-13646">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(t) Segment Reporting&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;FASB ASC 280, &#x201c;Segment Reporting&#x201d;,
establishes standards for reporting information about operating segments on a basis consistent with the Company&#x2019;s internal organizational
structure as well as information about geographical areas, business segments and major customers in financial statements for details on
the Company&#x2019;s business segments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the management approach to determine
reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#x2019;s chief
operating decision maker (&#x201c;CODM&#x201d;) for making decisions, allocating resources and assessing performance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s CODM has been identified as
the CEO, who reviews results when making decisions about allocating resources and assessing the performance of the Company. For the years
ended June 30, 2025 and 2024, the CODM reviewed the consolidated results when making decisions about allocating resources and assessing
performance of the Company as a whole, and the Company has only one reportable segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c0" decimals="0" id="ixv-16683" unitRef="pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-13661">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;(u) Recent accounting pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In October 2023, the FASB issued ASU 2023-06,
&#x201c;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative.&#x201d;
This amendment incorporates certain U.S. Securities and Exchange Commission (SEC) disclosure requirements into the FASB Accounting Standards
Codification. The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification
Topics, allow users to more easily compare entities subject to the SEC&#x2019;s existing disclosures with those entities that were not
previously subject to the requirements, and align the requirements in the Codification with the SEC&#x2019;s regulations. For entities
subject to the SEC&#x2019;s existing disclosure requirements and for entities required to file or furnish financial statements with or
to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer,
the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. For all other
entities, the amendments will be effective two years later. However, if by June 30, 2027, the SEC has not removed the related disclosure
from its regulations, the amendments will be removed from the Codification and not become effective for any entity. The Company does not
expect the adoption of ASU 2023-06 to have a material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740)&#160;&#x2014;&#160;Improvements to income Tax Disclosures. The amendment in this update are effective for annual
periods beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods
beginning after December 15, 2025. Early adoption is permitted for annual financial statements that have not yet been issued or made available
for issuance. The Company has adopted ASU 2023-09 on July 1, 2024 and the adoption
of the standard did not have a material impact to the overall financial presentation. See Note 10 for further information.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March 2024, the FASB issued ASU 2024-01, Compensation
&#x2014; Stock Compensation (Topic 718)&#160;&#x2014;&#160;Scope Application of Profits Interest and Similar Award. For public business
entities, the amendments in this Update are effective for annual periods beginning after December 15, 2024, and interim periods within
those annual periods. For all other entities, the amendments are effective for annual periods beginning after December 15, 2025, and interim
periods within those annual periods. Early adoption is permitted for both interim and annual financial statements that have not yet been
issued or made available for issuance. If an entity adopts the amendments in an interim period, it should adopt them as of the beginning
of the annual period that includes that interim period. The Company believes the future adoption of this ASU is not expected
to have a material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March&#160;2024, the FASB issued ASU&#160;2024-02,
&#x201c;Codification Improvements&#160;&#x2014;&#160;Amendments to Remove References to the Concepts Statements&#x201d;. This update contains
amendments to the Codification that remove references to various FASB Concepts Statements. These issues to remove references to various
Concepts Statements and the amendments apply to all reporting entities within the scope of the affected accounting guidance. The amendments
in this Update are effective for public business entities for fiscal&#160;years beginning after December&#160;15, 2024. Early application
of the amendments in this Update is permitted for any fiscal year or interim period for which financial statements have not yet been issued
(or made available for issuance). The Company is currently evaluating the impact of adoption on the Company&#x2019;s
related disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November&#160;2024, the FASB issued ASU&#160;2024-03,
Income Statement&#160;&#x2014;&#160;Reporting Comprehensive Income&#160;&#x2014;&#160;Expense Disaggregation Disclosures (Subtopic&#160;220-40):
Disaggregation of Income Statement Expenses and in January&#160;2025, the FASB issued ASU&#160;2025-01, Income Statement&#160;&#x2014;&#160;Reporting
Comprehensive Income&#160;&#x2014;&#160;Expense Disaggregation Disclosures (Subtopic&#160;220-40): Clarifying the Effective Date (&#x201c;ASU&#160;2025-01&#x201d;).
The ASU requires a public business entity to provide disaggregated disclosures of certain categories of expenses on an annual and interim
basis including purchases of inventory, employee compensation, depreciation, and intangible asset amortization for each income statement
line item that contains those expenses. ASU&#160;2024-03, as clarified by ASU&#160;2025-01 is effective for annual reporting periods beginning
after December&#160;15, 2026, and interim periods beginning after December&#160;15, 2027, with prospective or retrospective application
permitted. The Company is currently evaluating the impact of adoption on the Company&#x2019;s related disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Except as mentioned above, the Company does not
believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s
consolidated balance sheets, statements of operations and comprehensive loss and statements of cash flows.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-13702">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;4. PREPAID EXPENSES AND OTHER CURRENT ASSETS,
NET&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Tax refundable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;221,889&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;161,142&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,548&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Prepayment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,894,437&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237,960&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,128,656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;443,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Less: allowance for credit losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3,128,656&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;443,137&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;*&lt;/td&gt;&lt;td style="text-align: justify"&gt;The amount due from a related corporation, which the Company&#x2019;s major stockholders
have controlling equity interest in, as of June 30, 2025 are non-trade, unsecured, interest-free and repayable on demand.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0" id="ixv-13707">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Tax refundable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;221,889&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;161,142&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Other receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,548&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Prepayment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,894,437&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237,960&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,128,656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;443,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Less: allowance for credit losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3,128,656&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;443,137&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidTaxes contextRef="c1" decimals="0" id="ixv-16684" unitRef="usd">221889</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes contextRef="c3" decimals="0" id="ixv-16685" unitRef="usd">161142</us-gaap:PrepaidTaxes>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c1" decimals="0" id="ixv-16686" unitRef="usd">10548</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c3" decimals="0" id="ixv-16687" unitRef="usd">44035</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c1" decimals="0" id="ixv-16688" unitRef="usd">1782</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c1" decimals="0" id="ixv-16689" unitRef="usd">2894437</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="0" id="ixv-16690" unitRef="usd">237960</us-gaap:PrepaidExpenseCurrent>
    <advb:PrepaidExpensesAndOtherCurrentAssetGross contextRef="c1" decimals="0" id="ixv-16691" unitRef="usd">3128656</advb:PrepaidExpensesAndOtherCurrentAssetGross>
    <advb:PrepaidExpensesAndOtherCurrentAssetGross contextRef="c3" decimals="0" id="ixv-16692" unitRef="usd">443137</advb:PrepaidExpensesAndOtherCurrentAssetGross>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="0" id="ixv-16693" unitRef="usd">3128656</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-16694" unitRef="usd">443137</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-13809">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;5. EQUIPMENT, NET&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equipment, net, consists of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,619,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,486,392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,917&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;204,430&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;201,516&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,894,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,754,985&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,562,986&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,230,457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Equipment, net&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;331,346&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;524,528&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation expenses were approximately US$224,832
and US$268,279 for the years ended June 30, 2025 and 2024, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-13814">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equipment, net, consists of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,619,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,486,392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,917&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;204,430&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;201,516&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,894,332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,754,985&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,562,986&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,230,457&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Equipment, net&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;331,346&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;524,528&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c110" decimals="0" id="ixv-16695" unitRef="usd">1619480</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c111" decimals="0" id="ixv-16696" unitRef="usd">1486392</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c112" decimals="0" id="ixv-16697" unitRef="usd">33917</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c113" decimals="0" id="ixv-16698" unitRef="usd">31745</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c114" decimals="0" id="ixv-16699" unitRef="usd">36505</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c115" decimals="0" id="ixv-16700" unitRef="usd">35332</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c109" decimals="0" id="ixv-16701" unitRef="usd">204430</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c116" decimals="0" id="ixv-16702" unitRef="usd">201516</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="0" id="ixv-16703" unitRef="usd">1894332</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" id="ixv-16704" unitRef="usd">1754985</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c1" decimals="0" id="ixv-16705" unitRef="usd">1562986</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" id="ixv-16706" unitRef="usd">1230457</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" id="ixv-16707" unitRef="usd">331346</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-16708" unitRef="usd">524528</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-16709" unitRef="usd">224832</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c8" decimals="0" id="ixv-16710" unitRef="usd">268279</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0" id="ixv-13923">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;6. INTANGIBLE ASSETS, NET&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the carrying amount
of the Company&#x2019;s finite-lived intangible assets:&lt;/p&gt;

&lt;p style="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt;
 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt;
 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Acquired technology&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;372,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;391,016&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(372,197&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(272,018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;118,998&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of June 30, 2025 and 2024, the Company had
no remaining carrying amount of finite-lived intangible related to purchased patents from the acquisition of Shanghai Sglcell Biotech
Co., Ltd. as the assets were fully impaired in 2022.&#160;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c0" id="ixv-13928">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the carrying amount
of the Company&#x2019;s finite-lived intangible assets:&lt;/p&gt;

&lt;p style="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt;
 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt;
 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Acquired technology&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;372,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;391,016&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(372,197&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(272,018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;118,998&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c1" decimals="0" id="ixv-16711" unitRef="usd">372197</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c3" decimals="0" id="ixv-16712" unitRef="usd">391016</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c1" decimals="0" id="ixv-16713" unitRef="usd">372197</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="0" id="ixv-16714" unitRef="usd">272018</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-16715" unitRef="usd">118998</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-13987">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;7. ACCOUNTS PAYABLE, ACCRUALS AND OTHER CURRENT
LIABILITIES AND AMOUNT DUE TO RELATED PARTIES &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;
RELATED CORPORARIONS, NON-CURRENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Account Payable, accrued expenses and other liabilities
consists of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Accounts payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;632,697&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;620,476&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Payroll payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,216&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Amount due to related parties &#x2013; major stockholders *&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;172,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113,812&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Amount due to related parties &#x2013; related corporations**&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;916,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;674,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Other payable#&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,102,601&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,184,586&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&#160;Total Accounts payable, accruals, and other current liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,853,317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,670,249&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Amount due to related parties &#x2013; related corporations, non-current***&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;139,772&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;*&lt;/td&gt;&lt;td style="text-align: justify"&gt;The amount due to the Company&#x2019;s major stockholders as of June 30, 2025 and 2024 is
non-trade, unsecured, interest-free and repayable on demand.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;**&lt;/td&gt;&lt;td style="text-align: justify"&gt;The amount due to related corporations, which the Company&#x2019;s major stockholders have
controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and repayable on demand.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; padding-bottom: 0pt; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;***&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 0pt; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The amount due to related corporations, which the Company&#x2019;s major stockholders have controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and the remaining loan term are over one year. The Company believes the carrying value approximates fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;#&lt;/td&gt;&lt;td style="text-align: justify"&gt;The amount consists of payables owed to third party creditors, which are unsecured, interest-free
and repayable on demand, and other payables due to operational use.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-13993">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Account Payable, accrued expenses and other liabilities
consists of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Accounts payable&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;632,697&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;620,476&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Payroll payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,216&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Amount due to related parties &#x2013; major stockholders *&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;172,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113,812&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Amount due to related parties &#x2013; related corporations**&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;916,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;674,262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Other payable#&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,102,601&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,184,586&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&#160;Total Accounts payable, accruals, and other current liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,853,317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,670,249&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Amount due to related parties &#x2013; related corporations, non-current***&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;139,772&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;*&lt;/td&gt;&lt;td style="text-align: justify"&gt;The amount due to the Company&#x2019;s major stockholders as of June 30, 2025 and 2024 is
non-trade, unsecured, interest-free and repayable on demand.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;**&lt;/td&gt;&lt;td style="text-align: justify"&gt;The amount due to related corporations, which the Company&#x2019;s major stockholders have
controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and repayable on demand.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; padding-bottom: 0pt; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;***&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 0pt; text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The amount due to related corporations, which the Company&#x2019;s major stockholders have controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and the remaining loan term are over one year. The Company believes the carrying value approximates fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;#&lt;/td&gt;&lt;td style="text-align: justify"&gt;The amount consists of payables owed to third party creditors, which are unsecured, interest-free
and repayable on demand, and other payables due to operational use.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent contextRef="c1" decimals="0" id="ixv-16716" unitRef="usd">632697</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" id="ixv-16717" unitRef="usd">620476</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c1" decimals="0" id="ixv-16718" unitRef="usd">29216</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c3" decimals="0" id="ixv-16719" unitRef="usd">77113</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c4" decimals="0" id="ix_41_fact" unitRef="usd">172767</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c5" decimals="0" id="ix_42_fact" unitRef="usd">113812</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c6" decimals="0" id="ix_43_fact" unitRef="usd">916036</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c7" decimals="0" id="ix_44_fact" unitRef="usd">674262</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c1" decimals="0" id="ix_39_fact" unitRef="usd">1102601</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ix_40_fact" unitRef="usd">1184586</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-16726" unitRef="usd">2853317</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-16727" unitRef="usd">2670249</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="c6" decimals="0" id="ix_45_fact" unitRef="usd">139772</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:LongTermDebtTerm contextRef="c1" id="ixv-16731">P1Y</us-gaap:LongTermDebtTerm>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="c0" id="ixv-14148">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;8.
OTHER EXPENSE, NET&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Other income (expense), net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(29,040&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;486&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Foreign exchange loss, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(233,808&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(294,687&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Other expense, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(262,848&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(294,201&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingExpenseByComponentTextBlock contextRef="c0" id="ixv-14152">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Other income (expense), net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(29,040&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;486&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Foreign exchange loss, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(233,808&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(294,687&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Other expense, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(262,848&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(294,201&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingExpenseByComponentTextBlock>
    <advb:OtherNonoperatingIncomeExpenseGross contextRef="c0" decimals="0" id="ixv-16733" unitRef="usd">-29040</advb:OtherNonoperatingIncomeExpenseGross>
    <advb:OtherNonoperatingIncomeExpenseGross contextRef="c8" decimals="0" id="ixv-16734" unitRef="usd">486</advb:OtherNonoperatingIncomeExpenseGross>
    <us-gaap:ForeignCurrencyTransactionGainLossAfterTax contextRef="c0" decimals="0" id="ixv-16735" unitRef="usd">-233808</us-gaap:ForeignCurrencyTransactionGainLossAfterTax>
    <us-gaap:ForeignCurrencyTransactionGainLossAfterTax contextRef="c8" decimals="0" id="ixv-16736" unitRef="usd">-294687</us-gaap:ForeignCurrencyTransactionGainLossAfterTax>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-16737" unitRef="usd">-262848</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c8" decimals="0" id="ixv-16738" unitRef="usd">-294201</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-14209">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;9. EQUITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the sake of undertaking a public offering
of the Company&#x2019;s common stock, the Company has performed a series of re-organizing transactions resulting in 20,000,000 of common
stock and 20,000,000 of common stock outstanding as of December 31, 2024 and June 30, 2024 giving the retroactive effects to the 4 for
1 share split effected on May 16, 2023 and 5 for 1 reverse share split effected on October 15, 2024. The Company has accounted for these
shares had they been issued and outstanding at the beginning of the first period presented. The Company only has one single class of common
stock that is accounted for as permanent equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 16, 2023, the Company effected a forward
share split of all issued and outstanding shares of 25,000,000 shares at a ratio of 1-to-4. As a result of the forward split, the Company
now have 100,000,000 common stock issued and outstanding as of the date hereof. The Company believed it is appropriate to reflect the
above transactions on a retroactive basis similar to share split or dividend pursuant to ASC 260. All references made to share or per
share amounts in the accompanying consolidated financial statements and applicable disclosures have been retroactively adjusted to reflect
the 4 for 1 share split. The shares of common stock retain a par value of $0.001&#160;per share. Accordingly, an amount equal to the par
value of the increased shares resulting from the stock split was reclassified from &#x201c;Additional paid-in capital&#x201d; to &#x201c;Common
stock&#x201d;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 15, 2024, the Company effected the
reverse share split of all issued and outstanding shares of 100,000,000 shares at a ratio of 5:1. As a result of the reverse share split,
the Company now have 20,000,000 common stock issued and outstanding as of the date hereof. Unless indicated or the context otherwise requires,
all number of common stock&#160;in this report has been retrospectively adjusted for the reverse share split, as if such reverse share
split occurred on the first day of the years presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 7, 2025, the Company completed its initial
public offering. In the initial public offering, the Company issued 1,640,000 shares of common stock at a price of US$4.00 per share.
The Company received gross proceeds in the amount of US$6.56 million before deducting any underwriting discounts or expenses. The Shares
began trading on the Nasdaq Capital Market on March 6, 2025 under the ticker symbol &#x201c;ADVB.&#x201d;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="c117"
      decimals="0"
      id="ixv-16739"
      unitRef="shares">20000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c117"
      decimals="0"
      id="ixv-16740"
      unitRef="shares">20000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-16741"
      unitRef="shares">20000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c80"
      decimals="0"
      id="ixv-16742"
      unitRef="shares">4</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c81"
      decimals="0"
      id="ixv-16743"
      unitRef="shares">1</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c118"
      decimals="0"
      id="ixv-16744"
      unitRef="shares">5</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c119"
      decimals="0"
      id="ixv-16745"
      unitRef="shares">1</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:CommonStockSharesIssued
      contextRef="c82"
      decimals="0"
      id="ixv-16746"
      unitRef="shares">25000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c82"
      decimals="0"
      id="ixv-16747"
      unitRef="shares">25000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c78"
      decimals="0"
      id="ixv-16748"
      unitRef="shares">100000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c78"
      decimals="0"
      id="ixv-16749"
      unitRef="shares">100000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c80"
      decimals="0"
      id="ixv-16750"
      unitRef="shares">4</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c81"
      decimals="0"
      id="ixv-16751"
      unitRef="shares">1</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c82"
      decimals="3"
      id="ixv-16752"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c83"
      decimals="0"
      id="ixv-16753"
      unitRef="shares">100000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c83"
      decimals="0"
      id="ixv-16754"
      unitRef="shares">100000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c85"
      decimals="0"
      id="ixv-16755"
      unitRef="shares">20000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c85"
      decimals="0"
      id="ixv-16756"
      unitRef="shares">20000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c34"
      decimals="0"
      id="ixv-16757"
      unitRef="shares">1640000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c35"
      decimals="2"
      id="ixv-16758"
      unitRef="usdPershares">4</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c34" decimals="-4" id="ixv-16759" unitRef="usd">6560000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-14225">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;10. INCOME TAXES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is not an operating company but a
holding company incorporated in the State of Nevada and is considered U.S. tax resident under U.S. tax laws; accordingly, it is subject
to U.S. tax laws at a statutory tax rate of 21%. The Company is subject to the State of Nevada tax laws at a tax rate of&#160;0%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s net deferred income tax assets
as of June 30, 2025and 2024 consist of net operating loss carry forwards. The net operating loss carry forwards for U.S. federal tax and
Taiwan, China, Hong Kong tax purposes are available for carry forward indefinitely for use in offsetting taxable income. The U.S. federal
net operating loss carry forward offset is limited to up to 80% of the taxable income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of June 30, 2025 and 2024, the Company had
total net operating loss carry forwards of approximately $13,167,716 and $8,767,393, respectively, which consists of China net operating
loss carry forwards of $4,896,250&#160;and $3,817,009, respectively, Taiwan net operating losses of $5,824,336&#160;and $4,200,888, respectively,
Hong Kong net operating loss carry forwards of $94,686 and $5,014, respectively, and US net operating loss carry forwards of $2,352,444
and $744,480, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;&lt;i&gt;Taiwan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The Company&#x2019;s operating
subsidiary, Advanced Biomed Inc. (Taiwan) is considered Taiwan tax resident enterprises under Taiwan tax laws; accordingly, it is subject
to enterprise income tax on its taxable income as determined under Taiwan tax laws at a statutory tax rate of 20%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;&lt;i&gt;China&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The Company&#x2019;s operating
subsidiary, Shanghai Sglcell Biotech Co., Ltd. is considered PRC resident enterprises under Enterprise Income Tax Law of the PRC; accordingly,
it is subject to enterprise income tax on their taxable income as determined under Enterprise Income Tax Law of the PRC at a statutory
tax rate of 25%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;&lt;i&gt;Hong Kong&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Under the current Hong&#160;Kong
Inland Revenue Ordinance, a two-tier&#160;corporate income tax system was implemented in Hong&#160;Kong, which is 8.25% for the first
HK$2.0&#160;million taxable income, and 16.5% for the subsequent taxable income generated from operations in Hong&#160;Kong. The Company&#x2019;s
subsidiary, Advanced Biomed HK Limited is considered Hong Kong tax resident under Hong Kong Tax Law; accordingly, it is subject to corporate
income tax on its taxable income at 8.25% with &lt;span style="-sec-ix-hidden: hidden-fact-64"&gt;nil&lt;/span&gt; and &lt;span style="-sec-ix-hidden: hidden-fact-65"&gt;nil&lt;/span&gt; for the years ended June 30, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The income tax provision consists of the following
component:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;The following table reconciles the operating
profit to the Company&#x2019;s effective tax rate:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Loss before tax&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3,258,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,782,278&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Statutory income tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Income tax expense calculated at the statutory tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Effect of tax losses carry forwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,890,755&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,019,708&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of subsidiaries foreign income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,890,755&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,019,708&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Effective tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The component of deferred tax assets are as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating losses carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,890,755&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,019,708&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,890,755&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,019,708&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In assessing
the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred
tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income
during the periods in which those temporary differences become deductible. Management considers the cumulative earnings and projected
future taxable income in making this assessment. Recovery of substantially all of the Company&#x2019;s deferred tax assets is dependent
upon the generation of future income, exclusive of reversing taxable temporary differences.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A reconciliation of the differences between the
federal income tax rate and the effective tax rate is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;State of Nevada&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Tax at federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Changes in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Provision for taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;&lt;i&gt;Taiwan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Tax at federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Different foreign subsidiary tax rate impact&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Changes in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Provision for taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;China&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Tax at federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Different foreign subsidiary tax rate impact&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Changes in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Provision for taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Hong Kong&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Tax at federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Different foreign subsidiary tax rate impact&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12.75&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12.75&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Changes in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.25&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.25&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Provision for taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c120"
      decimals="2"
      id="ixv-16760"
      unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c120"
      decimals="2"
      id="ixv-16761"
      unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <advb:NetOperatingLossCarryForwardOffset contextRef="c0" decimals="2" id="ixv-16762" unitRef="pure">0.80</advb:NetOperatingLossCarryForwardOffset>
    <us-gaap:OperatingLossCarryforwards contextRef="c1" decimals="0" id="ixv-16763" unitRef="usd">13167716</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c3" decimals="0" id="ixv-16764" unitRef="usd">8767393</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c121" decimals="0" id="ixv-16765" unitRef="usd">4896250</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c122" decimals="0" id="ixv-16766" unitRef="usd">3817009</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c123" decimals="0" id="ixv-16767" unitRef="usd">5824336</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c124" decimals="0" id="ixv-16768" unitRef="usd">4200888</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c125" decimals="0" id="ixv-16769" unitRef="usd">94686</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c126" decimals="0" id="ixv-16770" unitRef="usd">5014</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c127" decimals="0" id="ixv-16771" unitRef="usd">2352444</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c128" decimals="0" id="ixv-16772" unitRef="usd">744480</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c129"
      decimals="2"
      id="ixv-16773"
      unitRef="pure">0.20</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c130"
      decimals="2"
      id="ixv-16774"
      unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="c131"
      decimals="4"
      id="ixv-16775"
      unitRef="pure">0.0825</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c131"
      decimals="-5"
      id="ixv-16776"
      unitRef="hkd">2000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c131"
      decimals="3"
      id="ixv-16777"
      unitRef="pure">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c0" decimals="4" id="ixv-16778" unitRef="pure">0.0825</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-14271">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The income tax provision consists of the following
component:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 2.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;The following table reconciles the operating
profit to the Company&#x2019;s effective tax rate:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Loss before tax&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3,258,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,782,278&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Statutory income tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Income tax expense calculated at the statutory tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Effect of tax losses carry forwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,890,755&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,019,708&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effect of subsidiaries foreign income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,890,755&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,019,708&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Effective tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;State of Nevada&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Tax at federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Changes in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Provision for taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;&lt;i&gt;Taiwan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Tax at federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Different foreign subsidiary tax rate impact&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Changes in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Provision for taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;China&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Tax at federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Different foreign subsidiary tax rate impact&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Changes in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(25&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Provision for taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Hong Kong&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the years ended &lt;br/&gt; June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Tax at federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Different foreign subsidiary tax rate impact&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12.75&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12.75&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Changes in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.25&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8.25&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Provision for taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-16779" unitRef="usd">-3258969</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c8" decimals="0" id="ixv-16780" unitRef="usd">-2782278</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" id="ixv-16781" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c8" decimals="2" id="ixv-16782" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <advb:EffectOfTaxLossesCarryForwards contextRef="c0" decimals="0" id="ixv-16783" unitRef="usd">-2890755</advb:EffectOfTaxLossesCarryForwards>
    <advb:EffectOfTaxLossesCarryForwards contextRef="c8" decimals="0" id="ixv-16784" unitRef="usd">-2019708</advb:EffectOfTaxLossesCarryForwards>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c0" decimals="0" id="ixv-16785" unitRef="usd">2890755</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c8" decimals="0" id="ixv-16786" unitRef="usd">2019708</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-14416">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The component of deferred tax assets are as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;June 30,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating losses carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,890,755&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,019,708&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,890,755&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,019,708&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c1" decimals="0" id="ixv-16787" unitRef="usd">2890755</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="0" id="ixv-16788" unitRef="usd">2019708</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c1" decimals="0" id="ixv-16789" unitRef="usd">2890755</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="0" id="ixv-16790" unitRef="usd">2019708</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c133"
      decimals="2"
      id="ixv-16791"
      unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c134"
      decimals="2"
      id="ixv-16792"
      unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c133"
      decimals="2"
      id="ixv-16793"
      unitRef="pure">-0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c134"
      decimals="2"
      id="ixv-16794"
      unitRef="pure">-0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c135"
      decimals="2"
      id="ixv-16795"
      unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c136"
      decimals="2"
      id="ixv-16796"
      unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c135"
      decimals="2"
      id="ixv-16797"
      unitRef="pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c136"
      decimals="2"
      id="ixv-16798"
      unitRef="pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c135"
      decimals="2"
      id="ixv-16799"
      unitRef="pure">-0.20</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c136"
      decimals="2"
      id="ixv-16800"
      unitRef="pure">-0.20</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c137"
      decimals="2"
      id="ixv-16801"
      unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c138"
      decimals="2"
      id="ixv-16802"
      unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c137"
      decimals="2"
      id="ixv-16803"
      unitRef="pure">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c138"
      decimals="2"
      id="ixv-16804"
      unitRef="pure">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c137"
      decimals="2"
      id="ixv-16805"
      unitRef="pure">-0.25</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c138"
      decimals="2"
      id="ixv-16806"
      unitRef="pure">-0.25</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c139"
      decimals="2"
      id="ixv-16807"
      unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c140"
      decimals="2"
      id="ixv-16808"
      unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c139"
      decimals="4"
      id="ixv-16809"
      unitRef="pure">-0.1275</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c140"
      decimals="4"
      id="ixv-16810"
      unitRef="pure">-0.1275</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c139"
      decimals="4"
      id="ixv-16811"
      unitRef="pure">-0.0825</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c140"
      decimals="4"
      id="ixv-16812"
      unitRef="pure">-0.0825</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-14798">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;11. STOCK OPTION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective from March 30, 2023, the Stock Incentive
Plan (the &#x201c;2023 Plan&#x201d;) was approved by the Company's Board of Directors. Under the 2023 Plan, the Board of Directors may grant
options or purchase rights to purchase common stock to officers, employees, and other persons who provide services to the Company or any
related company. The participants to whom awards are granted, the type of awards granted, the number of shares covered for each award,
and the purchase or exercise price, conditions and other terms of each award are determined by the Board of Directors, except that the
term of the options shall not exceed 10 years. A total of 15 million shares of our common stock are subject to the 2023 Plan and maybe
either a qualified or non-qualified stock option. The shares issued for the 2023 Plan may be either treasury or authorized and unissued
shares. As of the date of this report, the Company has granted &lt;span style="-sec-ix-hidden: hidden-fact-66"&gt;no&lt;/span&gt; stock options to purchase any shares of the common stock under the 2023
Plan.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c141" id="ixv-16813">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c142"
      decimals="-6"
      id="ixv-16814"
      unitRef="shares">15000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-14808">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;12. RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These related parties of the Company with whom
transactions are reported in these financial statements are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 35%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of Related Party&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 64%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship to Us&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Yi Lu, Ph.D.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman of the Board and Chief Executive Officer of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hung To Pau, Ph.D.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stockholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Steven I-Fang Cheng, Ph.D.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director and Chief Technology Officer of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chen-Yi Lee&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chen-Yi Lee is the sole director and the controlling person of Advance On Ventures Limited, which owns 10.92% equity interest in the Company and has sole voting and dispositive power over shares beneficially owned by Advance On Ventures Limited. Chen-Yi Lee is also the Stockholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advance On Ventures Limited&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stockholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Well Fancy Development Ltd&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hung To Pau is the director and stockholder of the entity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shanghai Junfu Electronic Technology Co., Ltd.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hung To Pau is the legal person and stockholder of the entity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the ordinary course of business, during the&#160;fiscal
years ended June&#160;30, 2025 and 2024, the Company was involved in certain transactions, either at cost or current market prices, and
on the normal commercial terms with related parties. The following table provides the transactions with these parties for the&#160;years
as presented (for the portion of such period that they were considered related):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Amount due to related parties &#x2013; major stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Name of related party&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Yi Lu, Ph.D. &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;122,626&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;110,268&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chen-Yi Lee &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hung To Pau, Ph.D. &lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;44,705&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;172,767&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;113,812&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Amount due to related parties &#x2013; related corporations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left"&gt;Name of related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Well Fancy Development Ltd &lt;sup&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;211,083&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shanghai Junfu Electronic Technology Co., Ltd. &lt;sup&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;704,953&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;674,262&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;916,036&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;674,262&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Non-Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left"&gt;Name of related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Well Fancy Development Ltd &lt;sup&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shanghai Junfu Electronic Technology Co., Ltd. &lt;sup&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;69,797&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;139,772&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Advanced Biomed Inc.(Taiwan) entered into an unsecured, interest-free loan to Yi Lu amounting to NTD 3,578,212 (approximately US$122,626) for general working capital in January 2023. As of June 30, 2025 and 2024, the loan balance due to Yi Lu amounted to US$122,626 and US$110,268, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Payments of expenses on behalf of Advanced Biomed Inc. (Taiwan).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Advanced Biomed Inc.(HK) entered into one unsecured, interest-free loan to Hung To Pau, Ph.D. amounting to US$200,000 for general working capital in July 2024 and the amount was full settled in 2025. And Shanghai Sglcell Biotech Co., Ltd entered into three unsecured, interest-free loans to Hung To Pau, Ph.D. amounting to RMB122,566 (approximately US$17,110), RMB121,681 (approximately US$16,986) and RMB76,000 (approximately US$10,609) for general working capital in October 2024, November 2024 and December 2024. As of June 30, 2025, the loan balance due to Hung To Pau, Ph.D. totally amounted to RMB320,247 (approximately US$44,705) for general working capital.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Advanced Biomed Inc.(Taiwan) entered into seven unsecured, interest-free
loans to Well Fancy Development Ltd amounting to NTD 5,740,600 (approximately US$196,731), NTD 1,911,944 (approximately US$65,522), NTD
1,906,840 (approximately US$65,347), NTD 3,121,500 (approximately US$106,974), NTD 1,798,060 (approximately US$61,620), NTD 1,291,552
(approximately US$44,262) and NTD 455,992 (approximately US$15,627) for general working capital in July 2024, October 2024, November 2024,
December 2024, January 2025, February 2025 and March 2025. In March 2025, Advanced Biomed Inc.(HK) paid US$550,000 to Well Fancy Development
Ltd for Advanced Biomed Inc.(Taiwan)&#x2019;s debt. And Advanced Biomed Inc. entered into two unsecured, interest-free loan to Well Fancy
Development Ltd amounting to US$119,975 and US$205,000 for general working capital in November 2024 and March 2025. In March 2025, Advanced
Biomed Inc. paid US$50,000 to Well Fancy Development Ltd for repayment. As of June 30, 2025, the loan balance due to Well Fancy Development
Ltd totally amounted to NTD 177,488(approximately US$6,083) and US$274,975 for general working capital.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shanghai Sglcell Biotech Co., Ltd entered into nine unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. amounting to RMB500,000 (approximately US$69,797) in April 2023, May 2023, June 2023 and September 2023, respectively, and RMB700,000 (approximately US$97,716), RMB1,000,000 (approximately US$139,595), RMB500,000 (approximately US$69,797), RMB700,000 (approximately US$97,716) and RMB650,000 (approximately US$90,738) in January 2024, March 2024, March 2024, June 2024 and October 2024, respectively, for general working capital. As of June 30, 2025 and 2024 the loan balance due to Shanghai Junfu Electronic Technology Co., Ltd totally amounted to RMB5,550,000 (approximately US$774,750) and RMB4,900,000 (approximately to US$674,262), respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0" id="ixv-14813">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These related parties of the Company with whom
transactions are reported in these financial statements are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 35%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of Related Party&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 64%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship to Us&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Yi Lu, Ph.D.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman of the Board and Chief Executive Officer of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hung To Pau, Ph.D.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stockholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Steven I-Fang Cheng, Ph.D.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director and Chief Technology Officer of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chen-Yi Lee&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chen-Yi Lee is the sole director and the controlling person of Advance On Ventures Limited, which owns 10.92% equity interest in the Company and has sole voting and dispositive power over shares beneficially owned by Advance On Ventures Limited. Chen-Yi Lee is also the Stockholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advance On Ventures Limited&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stockholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Well Fancy Development Ltd&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hung To Pau is the director and stockholder of the entity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shanghai Junfu Electronic Technology Co., Ltd.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hung To Pau is the legal person and stockholder of the entity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;The following table provides the transactions with these parties for the&#160;years
as presented (for the portion of such period that they were considered related):&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Amount due to related parties &#x2013; major stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"&gt;&lt;span style="text-decoration:underline"&gt;Name of related party&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Yi Lu, Ph.D. &lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;122,626&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;110,268&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chen-Yi Lee &lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Hung To Pau, Ph.D. &lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;44,705&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;172,767&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;113,812&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Amount due to related parties &#x2013; related corporations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left"&gt;Name of related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Well Fancy Development Ltd &lt;sup&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;211,083&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shanghai Junfu Electronic Technology Co., Ltd. &lt;sup&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;704,953&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;674,262&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;916,036&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;674,262&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Non-Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; font-style: italic; text-decoration: underline; text-align: left"&gt;Name of related party&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Well Fancy Development Ltd &lt;sup&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shanghai Junfu Electronic Technology Co., Ltd. &lt;sup&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;69,797&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;139,772&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Advanced Biomed Inc.(Taiwan) entered into an unsecured, interest-free loan to Yi Lu amounting to NTD 3,578,212 (approximately US$122,626) for general working capital in January 2023. As of June 30, 2025 and 2024, the loan balance due to Yi Lu amounted to US$122,626 and US$110,268, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Payments of expenses on behalf of Advanced Biomed Inc. (Taiwan).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Advanced Biomed Inc.(HK) entered into one unsecured, interest-free loan to Hung To Pau, Ph.D. amounting to US$200,000 for general working capital in July 2024 and the amount was full settled in 2025. And Shanghai Sglcell Biotech Co., Ltd entered into three unsecured, interest-free loans to Hung To Pau, Ph.D. amounting to RMB122,566 (approximately US$17,110), RMB121,681 (approximately US$16,986) and RMB76,000 (approximately US$10,609) for general working capital in October 2024, November 2024 and December 2024. As of June 30, 2025, the loan balance due to Hung To Pau, Ph.D. totally amounted to RMB320,247 (approximately US$44,705) for general working capital.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Advanced Biomed Inc.(Taiwan) entered into seven unsecured, interest-free
loans to Well Fancy Development Ltd amounting to NTD 5,740,600 (approximately US$196,731), NTD 1,911,944 (approximately US$65,522), NTD
1,906,840 (approximately US$65,347), NTD 3,121,500 (approximately US$106,974), NTD 1,798,060 (approximately US$61,620), NTD 1,291,552
(approximately US$44,262) and NTD 455,992 (approximately US$15,627) for general working capital in July 2024, October 2024, November 2024,
December 2024, January 2025, February 2025 and March 2025. In March 2025, Advanced Biomed Inc.(HK) paid US$550,000 to Well Fancy Development
Ltd for Advanced Biomed Inc.(Taiwan)&#x2019;s debt. And Advanced Biomed Inc. entered into two unsecured, interest-free loan to Well Fancy
Development Ltd amounting to US$119,975 and US$205,000 for general working capital in November 2024 and March 2025. In March 2025, Advanced
Biomed Inc. paid US$50,000 to Well Fancy Development Ltd for repayment. As of June 30, 2025, the loan balance due to Well Fancy Development
Ltd totally amounted to NTD 177,488(approximately US$6,083) and US$274,975 for general working capital.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shanghai Sglcell Biotech Co., Ltd entered into nine unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. amounting to RMB500,000 (approximately US$69,797) in April 2023, May 2023, June 2023 and September 2023, respectively, and RMB700,000 (approximately US$97,716), RMB1,000,000 (approximately US$139,595), RMB500,000 (approximately US$69,797), RMB700,000 (approximately US$97,716) and RMB650,000 (approximately US$90,738) in January 2024, March 2024, March 2024, June 2024 and October 2024, respectively, for general working capital. As of June 30, 2025 and 2024 the loan balance due to Shanghai Junfu Electronic Technology Co., Ltd totally amounted to RMB5,550,000 (approximately US$774,750) and RMB4,900,000 (approximately to US$674,262), respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c180" id="ixv-14830">Chairman of the Board and Chief Executive Officer of the Company</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c181" id="ixv-14837">Stockholder of the Company</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c182" id="ixv-14844">Director and Chief Technology Officer of the Company</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c183" id="ixv-14851">Chen-Yi Lee is the sole director and the controlling person of Advance On Ventures Limited, which owns 10.92% equity interest in the Company and has sole voting and dispositive power over shares beneficially owned by Advance On Ventures Limited. Chen-Yi Lee is also the Stockholder of the Company</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c184" id="ixv-14858">Stockholder of the Company</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c185" id="ixv-14865">Hung To Pau is the director and stockholder of the entity</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c186" id="ixv-14872">Hung To Pau is the legal person and stockholder of the entity</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c145"
      decimals="0"
      id="ix_46_fact"
      unitRef="usd">122626</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c146"
      decimals="0"
      id="ix_47_fact"
      unitRef="usd">110268</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c187"
      decimals="0"
      id="ix_48_fact"
      unitRef="usd">5436</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c188"
      decimals="0"
      id="ix_49_fact"
      unitRef="usd">3544</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c151"
      decimals="0"
      id="ix_50_fact"
      unitRef="usd">44705</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c190" decimals="0" id="ixv-16821" unitRef="usd">172767</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c191" decimals="0" id="ixv-16822" unitRef="usd">113812</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c192"
      decimals="0"
      id="ix_51_fact"
      unitRef="usd">211083</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c194"
      decimals="0"
      id="ix_53_fact"
      unitRef="usd">704953</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c195"
      decimals="0"
      id="ix_54_fact"
      unitRef="usd">674262</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c196" decimals="0" id="ixv-16826" unitRef="usd">916036</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c197" decimals="0" id="ixv-16827" unitRef="usd">674262</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c192"
      decimals="0"
      id="ix_52_fact"
      unitRef="usd">69975</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c194"
      decimals="0"
      id="ix_55_fact"
      unitRef="usd">69797</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c196" decimals="0" id="ixv-16830" unitRef="usd">139772</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:UnsecuredDebt contextRef="c144" decimals="0" id="ixv-16831" unitRef="twd">3578212</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c144" decimals="0" id="ixv-16832" unitRef="usd">122626</us-gaap:UnsecuredDebt>
    <advb:WorkingCapitalLoan contextRef="c145" decimals="0" id="ixv-16833" unitRef="usd">122626</advb:WorkingCapitalLoan>
    <advb:WorkingCapitalLoan contextRef="c146" decimals="0" id="ixv-16834" unitRef="usd">110268</advb:WorkingCapitalLoan>
    <us-gaap:UnsecuredDebt contextRef="c147" decimals="0" id="ixv-16835" unitRef="usd">200000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c148" decimals="0" id="ixv-16836" unitRef="cny">122566</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c148" decimals="0" id="ixv-16837" unitRef="usd">17110</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c149" decimals="0" id="ixv-16838" unitRef="cny">121681</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c149" decimals="0" id="ixv-16839" unitRef="usd">16986</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c150" decimals="0" id="ixv-16840" unitRef="cny">76000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c150" decimals="0" id="ixv-16841" unitRef="usd">10609</us-gaap:UnsecuredDebt>
    <advb:WorkingCapitalLoan contextRef="c151" decimals="0" id="ixv-16842" unitRef="cny">320247</advb:WorkingCapitalLoan>
    <advb:WorkingCapitalLoan contextRef="c151" decimals="0" id="ixv-16843" unitRef="usd">44705</advb:WorkingCapitalLoan>
    <us-gaap:UnsecuredDebt contextRef="c152" decimals="0" id="ixv-16845" unitRef="twd">5740600</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c152" decimals="0" id="ixv-16846" unitRef="usd">196731</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c153" decimals="0" id="ixv-16847" unitRef="twd">1911944</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c153" decimals="0" id="ixv-16848" unitRef="usd">65522</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c154" decimals="0" id="ixv-16849" unitRef="twd">1906840</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c154" decimals="0" id="ixv-16850" unitRef="usd">65347</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c155" decimals="0" id="ixv-16851" unitRef="twd">3121500</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c155" decimals="0" id="ixv-16852" unitRef="usd">106974</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c156" decimals="0" id="ixv-16853" unitRef="twd">1798060</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c157" decimals="0" id="ixv-16854" unitRef="usd">61620</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c158" decimals="0" id="ixv-16855" unitRef="twd">1291552</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c158" decimals="0" id="ixv-16856" unitRef="usd">44262</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c159" decimals="0" id="ixv-16857" unitRef="twd">455992</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c159" decimals="0" id="ixv-16858" unitRef="usd">15627</us-gaap:UnsecuredDebt>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c160" decimals="0" id="ixv-16859" unitRef="usd">550000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <advb:WorkingCapitalLoan contextRef="c161" decimals="0" id="ixv-16860" unitRef="usd">119975</advb:WorkingCapitalLoan>
    <advb:WorkingCapitalLoan contextRef="c162" decimals="0" id="ixv-16861" unitRef="usd">205000</advb:WorkingCapitalLoan>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c163" decimals="0" id="ixv-16862" unitRef="usd">50000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <advb:WorkingCapitalLoan contextRef="c164" decimals="0" id="ixv-16863" unitRef="usd">6083</advb:WorkingCapitalLoan>
    <advb:WorkingCapitalLoan contextRef="c164" decimals="0" id="ixv-16864" unitRef="twd">274975</advb:WorkingCapitalLoan>
    <us-gaap:UnsecuredDebt contextRef="c165" decimals="0" id="ixv-16865" unitRef="cny">500000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c166" decimals="0" id="ixv-16866" unitRef="cny">500000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c165" decimals="0" id="ixv-16867" unitRef="usd">69797</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c167" decimals="0" id="ixv-16868" unitRef="usd">69797</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c168" decimals="0" id="ixv-16869" unitRef="cny">700000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c168" decimals="0" id="ixv-16870" unitRef="usd">97716</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c169" decimals="0" id="ixv-16871" unitRef="cny">1000000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c169" decimals="0" id="ixv-16872" unitRef="usd">139595</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c170" decimals="0" id="ixv-16873" unitRef="cny">500000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c171" decimals="0" id="ixv-16874" unitRef="cny">500000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c170" decimals="0" id="ixv-16875" unitRef="usd">69797</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c171" decimals="0" id="ixv-16876" unitRef="usd">69797</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c172" decimals="0" id="ixv-16877" unitRef="cny">700000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c173" decimals="0" id="ixv-16878" unitRef="usd">97716</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c174" decimals="0" id="ixv-16879" unitRef="cny">650000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c175" decimals="0" id="ixv-16880" unitRef="cny">650000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c173" decimals="0" id="ixv-16881" unitRef="cny">650000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c176" decimals="0" id="ixv-16882" unitRef="cny">650000</us-gaap:UnsecuredDebt>
    <us-gaap:UnsecuredDebt contextRef="c176" decimals="0" id="ixv-16883" unitRef="usd">90738</us-gaap:UnsecuredDebt>
    <advb:WorkingCapitalLoan contextRef="c177" decimals="0" id="ixv-16884" unitRef="cny">5550000</advb:WorkingCapitalLoan>
    <advb:WorkingCapitalLoan contextRef="c177" decimals="0" id="ixv-16885" unitRef="usd">774750</advb:WorkingCapitalLoan>
    <advb:WorkingCapitalLoan contextRef="c178" decimals="0" id="ixv-16886" unitRef="cny">4900000</advb:WorkingCapitalLoan>
    <advb:WorkingCapitalLoan contextRef="c179" decimals="0" id="ixv-16887" unitRef="usd">674262</advb:WorkingCapitalLoan>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-15160">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;13. SEGMENT INFORMATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company operates and manages its business
as a single reportable segment, which is consistent with how the Chief Operating Decision Maker (&#x201c;CODM&#x201d;), the Chief Executive
Officer, makes operating decisions and allocates resources. The CODM assesses performance and results of operations at the Company level.
The Company&#x2019;s operations are centralized and integrated, with financial results reviewed and managed on a consolidated basis. Accordingly,
management has determined that the Company has one reportable segment under ASC Topic 280, Segment Reporting.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Measure of Segment Profit or Loss&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The CODM assesses performance for the segment
and decides how to allocate resources by regularly reviewing the consolidated net income from the statement of operations, after taking
into account the Company&#x2019;s strategic priorities, its cash balance, and its expected use of cash. The following table presents the
significant expense categories in the Company&#x2019;s single operating segment:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the &lt;br/&gt; year ended &lt;br/&gt; June&#160;30, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the &lt;br/&gt; year ended &lt;br/&gt; June&#160;30, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(909,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(880,193&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,111,265&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,661,379&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expense, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(237,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(240,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Net Loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(3,258,969&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(2,782,278&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c0" decimals="0" id="ixv-16888" unitRef="pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0" id="ixv-16889">The following table presents the
significant expense categories in the Company&#x2019;s single operating segment:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the &lt;br/&gt; year ended &lt;br/&gt; June&#160;30, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the &lt;br/&gt; year ended &lt;br/&gt; June&#160;30, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;US$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(909,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(880,193&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,111,265&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,661,379&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expense, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(237,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(240,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Net Loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(3,258,969&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(2,782,278&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-16890" unitRef="usd">909771</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c8" decimals="0" id="ixv-16891" unitRef="usd">880193</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-16892" unitRef="usd">2111265</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c8" decimals="0" id="ixv-16893" unitRef="usd">1661379</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-16894" unitRef="usd">-237933</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c8" decimals="0" id="ixv-16895" unitRef="usd">-240706</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-16896" unitRef="usd">-3258969</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c8" decimals="0" id="ixv-16897" unitRef="usd">-2782278</us-gaap:NetIncomeLoss>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0" id="ixv-15240">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;14. CONCENTRATIONS AND RISKS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Credit risk is the potential financial loss to
the Company resulting from the failure of a customer or a counterparty to settle its financial and contractual obligations to the Company,
as and when they fall due. As the Company does not hold any collateral, the maximum exposure to credit risk is the carrying amounts of
other receivables (exclude prepayments) and cash and bank deposits presented on the consolidated balance sheets. The Company has no other
financial assets which carry significant exposure to credit risk.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Liquidity Risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Liquidity risk is the risk that the Company will
encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another
financial asset. The Company&#x2019;s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient
liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking
damage to the Company&#x2019;s reputation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Typically, the Company ensures that it has sufficient
cash on demand to meet expected operational expenses for a period of 60 days, including the servicing of financial obligations; this excludes
the potential impact of extreme circumstances that cannot reasonably be predicted, such as natural disasters.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Foreign currency risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Foreign currency risk is the risk that the fair
value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The company&#x2019;s exposure to
the risk of changes in foreign exchange rates relates primarily to the Company&#x2019;s operating activities (when expense is denominated
in a foreign currency) and the Company&#x2019;s net investments in foreign subsidiaries.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Impact of Inflation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inflation in Taiwan and PRC has not materially
affected the Company&#x2019;s profitability and operating results. However, the Company can provide no assurance that we will be unaffected
by higher inflation rates in Taiwan and PRC or globally in the future.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <advb:NumberOfDaysForOperationalExpenses contextRef="c0" id="ixv-16898">P60D</advb:NumberOfDaysForOperationalExpenses>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-15287">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;15. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the ordinary course of business, the Company
may be subject to legal proceedings regarding contractual and employment relationships and a variety of other matters. The Company records
contingent liabilities resulting from such claims, when a loss is assessed to be probable, and the amount of the loss is reasonably estimable.
In the opinion of management, there were no pending or threatened claims and litigation as of June 30, 2025 and up through October 8,
2025, the issuance date of these consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Lease commitment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company determines if a contract contains
a lease at inception. US GAAP requires that the Company&#x2019;s leases be evaluated and classified as operating or finance leases for
financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation
includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods
when the exercise of the renewal option is reasonably certain and failure to exercise such option which results in an economic penalty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The right-of-use assets relate to leases of office
premises and a dormitory for employees in the PRC and the laboratory in Taiwan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The recognized operating lease ROU assets and
lease liabilities as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating lease ROU asset&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;65,399&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;126,740&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt;
 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt;
 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Current portion&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35,811&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Non-current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,879&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64,529&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;41,690&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;126,740&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of June 30, 2025, future minimum lease payments
under the non-cancellable operating leases are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Future payment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;2026&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,532&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,929&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Total future lease payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(771&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;41,690&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Operating lease liabilities, current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,811&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Operating lease liabilities, non-current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following summarizes other supplemental information
about the Company&#x2019;s operating lease as of June 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%"&gt;Weighted average discount rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Weighted average remaining lease term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-15307">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The recognized operating lease ROU assets and
lease liabilities as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating lease ROU asset&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;65,399&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;126,740&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt;
 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt;
 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Current portion&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35,811&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Non-current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,879&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64,529&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;41,690&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;126,740&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following summarizes other supplemental information
about the Company&#x2019;s operating lease as of June 30, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%"&gt;Weighted average discount rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Weighted average remaining lease term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="0" id="ixv-16899" unitRef="usd">65399</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-16900" unitRef="usd">126740</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="0" id="ixv-16901" unitRef="usd">35811</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ixv-16902" unitRef="usd">62211</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="0" id="ixv-16903" unitRef="usd">5879</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" id="ixv-16904" unitRef="usd">64529</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c1" decimals="0" id="ixv-16905" unitRef="usd">41690</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" id="ixv-16906" unitRef="usd">126740</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-15398">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of June 30, 2025, future minimum lease payments
under the non-cancellable operating leases are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Future payment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;US$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;2026&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,532&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,929&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Total future lease payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(771&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;41,690&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Operating lease liabilities, current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,811&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Operating lease liabilities, non-current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c1" decimals="0" id="ixv-16907" unitRef="usd">36532</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c1" decimals="0" id="ixv-16908" unitRef="usd">5929</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c1" decimals="0" id="ixv-16909" unitRef="usd">42461</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c1" decimals="0" id="ixv-16910" unitRef="usd">771</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c1" decimals="0" id="ixv-16911" unitRef="usd">41690</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="0" id="ixv-16912" unitRef="usd">35811</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="0" id="ixv-16913" unitRef="usd">5879</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c1" decimals="4" id="ixv-16914" unitRef="pure">0.034</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c1" id="ixv-16915">P1Y1M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-15498">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;16. SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has assessed all events from June
30, 2025 through October 8, 2025, which is the date that these consolidated financial statements are available to be issued, unless as
disclosed below, there are not any material subsequent events that require disclosure in these consolidated financial statements.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c1"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredCosts
      contextRef="c1"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c7"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c8"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders
      contextRef="c14"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders
      contextRef="c16"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesMajorStockholders
      contextRef="c17"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations
      contextRef="c14"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations
      contextRef="c16"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <advb:AdjustmentsToAdditionalPaidInCapitalWaiverOfAmountDueToRelatedPartiesRelatedCorporations
      contextRef="c17"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c14"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c15"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c16"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c14"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c15"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c17"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c22"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c23"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c24"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c24"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c25"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c22"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c23"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="c25"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="c8"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c31"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c33"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c8"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c8"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1
      contextRef="c8"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c67"
      id="hidden-fact-36"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c68"
      id="hidden-fact-37"
      unitRef="pure"
      xsi:nil="true"/>
    <advb:DeferredInitialPublicOfferingCost
      contextRef="c76"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c89"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c90"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsCurrent
      contextRef="c3"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent
      contextRef="c1"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent
      contextRef="c3"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c1"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="c7"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c8"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <advb:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate
      contextRef="c0"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <advb:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtCalculatedFederalStatutoryIncomeTaxRate
      contextRef="c8"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c8"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c0"
      id="hidden-fact-52"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c8"
      id="hidden-fact-53"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c133"
      id="hidden-fact-54"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c134"
      id="hidden-fact-55"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c135"
      id="hidden-fact-56"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c136"
      id="hidden-fact-57"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c137"
      id="hidden-fact-58"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c138"
      id="hidden-fact-59"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c139"
      id="hidden-fact-60"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c140"
      id="hidden-fact-61"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c1"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c3"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c131"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c132"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c143"
      id="hidden-fact-66"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c189"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c193"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c193"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c195"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="c1"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="c1"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="c1"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="c1"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-16993">0001941029</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-16994">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-16995">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-16996">00000</dei:EntityAddressPostalZipCode>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">See Note 12 for disclosure of related parties amounts.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_26_fact"
          xlink:label="ix_26_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-14"
          xlink:label="hidden-fact-14"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_25_fact"
          xlink:label="ix_25_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_28_fact"
          xlink:label="ix_28_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-15"
          xlink:label="hidden-fact-15"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_34_fact"
          xlink:label="ix_34_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_32_fact"
          xlink:label="ix_32_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_38_fact"
          xlink:label="ix_38_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_24_fact"
          xlink:label="ix_24_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_22_fact"
          xlink:label="ix_22_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-11"
          xlink:label="hidden-fact-11"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-25"
          xlink:label="hidden-fact-25"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-8"
          xlink:label="hidden-fact-8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_23_fact"
          xlink:label="ix_23_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-21"
          xlink:label="hidden-fact-21"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-26"
          xlink:label="hidden-fact-26"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-20"
          xlink:label="hidden-fact-20"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_35_fact"
          xlink:label="ix_35_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_37_fact"
          xlink:label="ix_37_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_30_fact"
          xlink:label="ix_30_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_33_fact"
          xlink:label="ix_33_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-18"
          xlink:label="hidden-fact-18"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-17"
          xlink:label="hidden-fact-17"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_27_fact"
          xlink:label="ix_27_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_36_fact"
          xlink:label="ix_36_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_29_fact"
          xlink:label="ix_29_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_31_fact"
          xlink:label="ix_31_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Giving retroactive effect to the 5 for 1 reverse share split effected on October 15, 2024.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_26_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-14"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_25_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_28_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-15"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_34_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_32_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_38_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_24_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-11"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-25"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-8"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-21"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-26"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-20"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_35_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_37_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_30_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_33_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-18"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-17"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_27_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_36_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_29_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_31_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_39_fact"
          xlink:label="ix_39_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_40_fact"
          xlink:label="ix_40_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The amount consists of payables owed to third party creditors, which are unsecured, interest-free
and repayable on demand, and other payables due to operational use.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_39_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_40_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_41_fact"
          xlink:label="ix_41_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_42_fact"
          xlink:label="ix_42_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The amount due to the Company&#x2019;s major stockholders as of June 30, 2025 and 2024 is
non-trade, unsecured, interest-free and repayable on demand.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_41_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_42_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_44_fact"
          xlink:label="ix_44_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_43_fact"
          xlink:label="ix_43_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The amount due to related corporations, which the Company&#x2019;s major stockholders have
controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and repayable on demand.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_44_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_43_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-45"
          xlink:label="hidden-fact-45"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_45_fact"
          xlink:label="ix_45_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_7_footnote" xlink:label="ix_7_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount due to related corporations, which the Company&#x2019;s major stockholders have controlling equity interest in, as of June 30, 2025 and 2024 are non-trade, unsecured, interest-free and the remaining loan term are over one year. The Company believes the carrying value approximates fair value.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-45"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_45_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_47_fact"
          xlink:label="ix_47_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_46_fact"
          xlink:label="ix_46_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_8_footnote" xlink:label="ix_8_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Advanced Biomed Inc.(Taiwan) entered into an unsecured, interest-free loan to Yi Lu amounting to NTD 3,578,212 (approximately US$122,626) for general working capital in January 2023. As of June 30, 2025 and 2024, the loan balance due to Yi Lu amounted to US$122,626 and US$110,268, respectively.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_47_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_46_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_48_fact"
          xlink:label="ix_48_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_49_fact"
          xlink:label="ix_49_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_9_footnote" xlink:label="ix_9_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Payments of expenses on behalf of Advanced Biomed Inc. (Taiwan).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_48_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_49_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-67"
          xlink:label="hidden-fact-67"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_50_fact"
          xlink:label="ix_50_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_10_footnote" xlink:label="ix_10_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Advanced Biomed Inc.(HK) entered into one unsecured, interest-free loan to Hung To Pau, Ph.D. amounting to US$200,000 for general working capital in July 2024 and the amount was full settled in 2025. And Shanghai Sglcell Biotech Co., Ltd entered into three unsecured, interest-free loans to Hung To Pau, Ph.D. amounting to RMB122,566 (approximately US$17,110), RMB121,681 (approximately US$16,986) and RMB76,000 (approximately US$10,609) for general working capital in October 2024, November 2024 and December 2024. As of June 30, 2025, the loan balance due to Hung To Pau, Ph.D. totally amounted to RMB320,247 (approximately US$44,705) for general working capital.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-67"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_50_fact"
          xlink:to="ix_10_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-69"
          xlink:label="hidden-fact-69"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_52_fact"
          xlink:label="ix_52_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_51_fact"
          xlink:label="ix_51_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-68"
          xlink:label="hidden-fact-68"
          xlink:type="locator"/>
        <link:footnote id="ix_11_footnote" xlink:label="ix_11_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Advanced Biomed Inc.(Taiwan) entered into seven unsecured, interest-free
loans to Well Fancy Development Ltd amounting to NTD 5,740,600 (approximately US$196,731), NTD 1,911,944 (approximately US$65,522), NTD
1,906,840 (approximately US$65,347), NTD 3,121,500 (approximately US$106,974), NTD 1,798,060 (approximately US$61,620), NTD 1,291,552
(approximately US$44,262) and NTD 455,992 (approximately US$15,627) for general working capital in July 2024, October 2024, November 2024,
December 2024, January 2025, February 2025 and March 2025. In March 2025, Advanced Biomed Inc.(HK) paid US$550,000 to Well Fancy Development
Ltd for Advanced Biomed Inc.(Taiwan)&#x2019;s debt. And Advanced Biomed Inc. entered into two unsecured, interest-free loan to Well Fancy
Development Ltd amounting to US$119,975 and US$205,000 for general working capital in November 2024 and March 2025. In March 2025, Advanced
Biomed Inc. paid US$50,000 to Well Fancy Development Ltd for repayment. As of June 30, 2025, the loan balance due to Well Fancy Development
Ltd totally amounted to NTD 177,488(approximately US$6,083) and US$274,975 for general working capital.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-69"
          xlink:to="ix_11_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_52_fact"
          xlink:to="ix_11_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_51_fact"
          xlink:to="ix_11_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-68"
          xlink:to="ix_11_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_55_fact"
          xlink:label="ix_55_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_54_fact"
          xlink:label="ix_54_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_53_fact"
          xlink:label="ix_53_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-70"
          xlink:label="hidden-fact-70"
          xlink:type="locator"/>
        <link:footnote id="ix_12_footnote" xlink:label="ix_12_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai Sglcell Biotech Co., Ltd entered into nine unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. amounting to RMB500,000 (approximately US$69,797) in April 2023, May 2023, June 2023 and September 2023, respectively, and RMB700,000 (approximately US$97,716), RMB1,000,000 (approximately US$139,595), RMB500,000 (approximately US$69,797), RMB700,000 (approximately US$97,716) and RMB650,000 (approximately US$90,738) in January 2024, March 2024, March 2024, June 2024 and October 2024, respectively, for general working capital. As of June 30, 2025 and 2024 the loan balance due to Shanghai Junfu Electronic Technology Co., Ltd totally amounted to RMB5,550,000 (approximately US$774,750) and RMB4,900,000 (approximately to US$674,262), respectively.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_55_fact"
          xlink:to="ix_12_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_54_fact"
          xlink:to="ix_12_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_53_fact"
          xlink:to="ix_12_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-70"
          xlink:to="ix_12_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
